<SEC-DOCUMENT>0000059478-21-000122.txt : 20210430
<SEC-HEADER>0000059478-21-000122.hdr.sgml : 20210430
<ACCEPTANCE-DATETIME>20210430092335
ACCESSION NUMBER:		0000059478-21-000122
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		71
CONFORMED PERIOD OF REPORT:	20210331
FILED AS OF DATE:		20210430
DATE AS OF CHANGE:		20210430

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ELI LILLY & Co
		CENTRAL INDEX KEY:			0000059478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				350470950
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-06351
		FILM NUMBER:		21874199

	BUSINESS ADDRESS:	
		STREET 1:		LILLY CORPORATE CTR
		STREET 2:		DROP CODE 1094
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285
		BUSINESS PHONE:		3172762000

	MAIL ADDRESS:	
		STREET 1:		LILLY CORPORATE CENTER
		STREET 2:		DROP CODE 1094
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LILLY ELI & CO
		DATE OF NAME CHANGE:	19941024
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>lly-20210331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:e048f7a3-28f3-4092-a916-bde5dfced0f0,g:3190a302-79f3-4ce3-a4d9-ac703a7bb0fb,d:3cd151b5d83246a98b0e0ef4a9feb269--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:lly="http://www.lilly.com/20210331" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lly-20210331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80L2ZyYWc6ZjRiODc0YWZjODYyNDM4NmE1YWUzNWM2ZmY0NzAzMzgvdGFibGU6YWMzNjM5ZGQ5MDljNGM1ZTllMzFlNTI3ZTNlYmY3YjQvdGFibGVyYW5nZTphYzM2MzlkZDkwOWM0YzVlOWUzMWU1MjdlM2ViZjdiNF81LTEtMS0xLTA_25bd029b-d269-4078-ade8-49a8fde5e6ab">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80L2ZyYWc6ZjRiODc0YWZjODYyNDM4NmE1YWUzNWM2ZmY0NzAzMzgvdGFibGU6YWMzNjM5ZGQ5MDljNGM1ZTllMzFlNTI3ZTNlYmY3YjQvdGFibGVyYW5nZTphYzM2MzlkZDkwOWM0YzVlOWUzMWU1MjdlM2ViZjdiNF82LTEtMS0xLTA_470931e9-72e7-4323-abab-91652d95fd9d">2021</ix:nonNumeric><ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80L2ZyYWc6ZjRiODc0YWZjODYyNDM4NmE1YWUzNWM2ZmY0NzAzMzgvdGFibGU6YWMzNjM5ZGQ5MDljNGM1ZTllMzFlNTI3ZTNlYmY3YjQvdGFibGVyYW5nZTphYzM2MzlkZDkwOWM0YzVlOWUzMWU1MjdlM2ViZjdiNF83LTEtMS0xLTA_dce5736d-1265-4056-b3ef-e0c487ee4dd8">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80L2ZyYWc6ZjRiODc0YWZjODYyNDM4NmE1YWUzNWM2ZmY0NzAzMzgvdGFibGU6YWMzNjM5ZGQ5MDljNGM1ZTllMzFlNTI3ZTNlYmY3YjQvdGFibGVyYW5nZTphYzM2MzlkZDkwOWM0YzVlOWUzMWU1MjdlM2ViZjdiNF84LTEtMS0xLTA_189acf29-f303-4b2d-952f-fafdaaf432ca">0000059478</ix:nonNumeric><ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80L2ZyYWc6ZjRiODc0YWZjODYyNDM4NmE1YWUzNWM2ZmY0NzAzMzgvdGFibGU6YWMzNjM5ZGQ5MDljNGM1ZTllMzFlNTI3ZTNlYmY3YjQvdGFibGVyYW5nZTphYzM2MzlkZDkwOWM0YzVlOWUzMWU1MjdlM2ViZjdiNF85LTEtMS0xLTA_4fd04c6a-744f-4599-a012-ab066e0193a6">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i08bd92534c0942898d7deffdcc7f9938_D20191201-20191231" format="ixt-sec:durday" name="lly:LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83My9mcmFnOmZjYWU3NTY3YWMyYTQ0NDliN2YxYjJiNjQ1YzI3Zjg3L3RleHRyZWdpb246ZmNhZTc1NjdhYzJhNDQ0OWI3ZjFiMmI2NDVjMjdmODdfNTA3_7b495efd-4927-4cb8-a7c3-719b42e6dcac">21</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lly-20210331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6bc00b2d2b24b739475df069c617a03_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3e378dfd41341fb9e60b25e358c23ef_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.000NotesDueJune22022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44103ce383994d74a3ab84ed4f5b4a46_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A718NotesDueJune12025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i086dc0b8a28b43438b0ec2d949452e3e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.625NotesDueJune22026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ffb83ec38e84898b6c89250d5c39070_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A2.125NotesDueJune32030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8ceb4ed9fcd4e6e8a65b6d5a85314e7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A625Notesdue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i996950b9da7c4950a18ada582b1fc257_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A6.77NotesDueJanuary12036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8debecbe586414a933f775ea52cd38e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.700Notesdue2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i8777fbeb1d88449d8d60f606fd5c2c77_I20210427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-04-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bce3a2756434f739e7c3845a02a47cf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ffc5bab7133436682aff62ddec1e376_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i957ad33ccc1240e3948e9f141963844f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f3109e398cb4ebe87fb955a863b8ede_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46e5e55c87bf4c9285d8bfe7ce6fd6d3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i932abea342a94c46a25f33f1c8acc500_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdecec535fa14d78b9ef123144efa368_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7db1dc190e2453aba10749ea47cfdb0_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2eee151cb0194a7c9d3cdf6eaece9015_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcf85b46974c4de78d45cca588cdb257_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f89a4953ed54302a07fe2fd0dc4e36b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i610527f799c444f999e77fc61f00e502_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86f7f5436d51421a8501779a09dd82ab_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id525ea543ffc4ac699696ae6133c1a3f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie25f9462d4864ec48a45f240362e710e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e1e492a833a4874b74b3fb0b7f96fa5_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id163dac405614d4ab0aab11d9539c9a8_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife78f2b5881b4ab594c089c77d07dfdd_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a5e6fba402d49eda6d65097c72bd64e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a2504bfe86b4fe3905a4c1dd6e8a31a_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib44d59353e664823911abf62eca2a0ec_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc56172f5f014bb48f88ac5499c1c0c8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60d84be3db5c4d85abc4b594cd075e4e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcdf0da7a8b34a378831b2abf856ab11_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0582a765e6944e928d84c3bf2f09767c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaaf707b56bb5401397f3d1be8be7a6da_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia85d98868ecb4c1d9f33581b32035094_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i002f042f1d494e298177c727853e4883_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0d38013f7a5421cab5b95d3ca766cc6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6e502d3f77649d3b4966205297947db_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5aa2dbcea11b45b1bc31588610d72e1a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2c1d39a9337457d82ae76c6cc3e027a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2d8de6d89ca4b36831a2fad2f21e997_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i717123173f4f4d45a26fc171fcef135f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19ffbb6496914f979518c442d56ddfdc_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia95ec94014ed412d9ddf912309b31906_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i336e60271cdd431887ad40e2953cb881_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf8fa9dfe55240c8904822bb89d5d580_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia54f7cb622be43a6a63855f304e93c8a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b0151dc1fa445c680975efcbdc26506_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice5b008047fc4f969d378bc0e8f5337b_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea0fcbeedbfb4018b173fba695dd9fc7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9dd152b8ae7b497f800f65a679736686_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b961987b212484fba2e55e3f8599292_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00e2ad623e9f4f09a525954c7be34a38_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib696b72b79fd4a64a05a14552524fd57_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9bcfbde64cf4e6885eff068fd1c0181_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a64fdc1a7fc44278f9cf486b1d6c7cf_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38bd7b2a836c4d14abc0e95512ba56c5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i0b2a402409bd47ceb3efc76f535f0984_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec6120b958de4ece8b0bb1b2c92eb827_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14a1f7c9c8094a24b89b05adbfa13722_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1da1bf79aee54038ab5fb824f0b5459c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7879b1c8e8154d82951f06d7277606ca_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib22403656ba044288e3a7c9bd076149a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie60de7ffff384040bda8a7073de65757_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35e2453e887841ba845624286f429037_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac9fe39efa6e493c8fc3b5a5cb61875a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12fc66e4003b4a108dafd95f3f948eae_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf36848406364477a5b09c68263549c0_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cec2d3e8980474dba0ccd4ba2f4be53_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ac183bd15654d9ea8bfb79ecfdabc21_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d5411d889ea4b0c92badda1ff003164_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80b19d05555b462299ff41542279ba37_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8ce72672e984dc38dbee5c4872a819f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bd74f7f91ca4076b9bc23d4ac7407c8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6cacb66e50b43a29e19d4cc6a18b475_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82b9a6cc26eb4896a200c5b2d5ee6aa5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23a99b86356248b7a363e089040850b1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c94039dc776423e982d5e1215b9f0e7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if95072ac7b3c4004b82c2aac605e5d70_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57d3bc0a03b5400f848a8a445a06af73_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c9abc35851840cd80b9598eb84e59be_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65808f9c08a34e2fbb20de15f09d6663_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68c425bf807b4ecfb4bfc4e63113b9a5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i991e0184719242bb9681a766c00e183e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6308d09ed16f45708083f216e5eb9053_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ad3a54cc6da48c7aabdfbd4ce0fd7d8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97e8d103205d4d8a8ddce47720e2b0df_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b572a7d820847f2b77197f14a7598e9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37a9f92fe3be4a59bd100214c32741d5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab3763aca7de40e3bd3755d4afdf8ddd_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08fa42e2b3004f2c8d8c3d2949a77b62_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if05b79fd4afb4b3b85e0170d60701765_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53e1ac90f1794867bdc0e1208a22454d_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5488586d175451ea3762d3e3427d7fb_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6655e736bfc145ae9b61bcbd43ca3775_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95a511f3e56540efaf67326c58f115f8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a8600a4d0ae48ac8eb847f76d72fb39_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d683e3edb3b47769c30eadb5fc443db_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia92a87d280ea46c88caa7e96c7a0c2c6_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dc1168de1ac4bd892f4336105fe8d34_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1eb5c54ee4f4ffd849c70b74454938b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99351a29767e4c33b139db7c60592e0c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c035a4a36d1475c87f42c50e4fe5b66_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica6ff26a8f5c493bb678f8b8bdd2f5d0_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a84f264bd5f43d18f95d6449dbfd211_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ad5e6e9c6b04e0ca3a23762ff4389d4_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3895e84ece4456f9fd7475f8330b5e2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bf54072320b4a95bcc03ebf93fd790b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a64b17a7372474b936176a48e73353e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1ca44d898d14b6ba06c659cc8685067_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaec1b41e2f1c429990d5463381ccb5b2_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic305b0216fae4bc4be68a9c14511b14b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc30d8c3304846bf98d3aff4faa90db6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i301b5063b45f4c778fa6be355225f1d2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ac8015a990a47ac84766a6b061f5c80_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice0f65e55bc14fb4a8b9c74295879c9f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabd56efbd9ee475196495211900a4916_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4990ade4fb749c5becfec40f273af6a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc1ec2db8e1b4baa971e09c08d4342fd_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i699a1a79461d4373af3cf037c5ca77a1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbf8577a767f4b6fa45fbea9fc0008e8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a65c960be0f46ebaab122d5eb8f5e3c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib410c05551594d84936a917166832ea9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d36ff64df614dd2a64ea2e3cb167f9b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if30239ae11764340af612d6d0acb2802_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55a39c6d0d9146729c9cbfd483622222_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10cbac4f340148c58e34434fbbf2a27f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a346e0ad24144caac752ea7f4355d34_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37c6a808e0e24c1f8e75607e3a823271_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3156015f19b4add93eceadb6f839944_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16d7bf43c3214967ae1523ebc568940c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a1925d8bba04bf5a88ae7c5a2c5a30e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65134b9feaf3468bae4f56eb446cc39b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b08818da51f405ab315d6a7b99fcdb8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f8df345856f4facb882054634c50249_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b44fc5413ea4394a3af4e9ae8cc9357_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6c1690f2a1044549cd196b5d0d49bad_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f2094304a9b41efa6498348dc920bd5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccb5bb5fcf05439eafdaafbbf45b94dc_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if46aa3d35d9f4f9e9f98c940d7063f27_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27ef923c97994ad09a5131b38a10eff2_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22ac5026b0df4c01a41cbb9fd7bf0ed4_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e7b860d15e24b6d8a4c42caa07a07e9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9d2acfb73014f21b93868d591ba0055_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic86716e51463478c9178d57dbc0df5e9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1eca7f391c9c4eb4bf1be4d2f78c64f1_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23a06e4fd12547b68a8c1fa847a573cd_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cdd8652ee714626a6ac6694e023589f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe710610bc2745d6b62b94d3e5a59c49_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5195f2602fa4de78f56cde487a199e9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id181bab5e80145f7b4aac52329fa68c0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e4a642cedfe46019dbf6bdbe6fbe49e_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82c451df337849a9aa0ebbd6efa659e5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c5697fd7da74cdbb6d77c6a62017381_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5d69a9f098946b99fd0dc8d1e98e66a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d569029e59948f09619b73bf0efdca2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ec2c9c0bb35428e84cb57a3987f75e0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida0989eec65245df9b1682cf38ed4bd2_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bc0464b0bdb43f5a8e902cdb4b263da_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8cb347768764c2b955eac4a8f4a17ad_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98c884b95b7b4a8493c13f83a7b6caa7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c53c31a3a5c43e680ca9bf03cd18bab_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f23306ae00143a6a4003c6797529b59_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6964e815afd40a1a706fd094d27e141_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ff073cd832f489a918e71ed9f2bc601_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icaab0628ba61471db8a691d30a7a5ae6_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6540e5cb4f94023bd8a1a99cae7dd50_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0244d48c6684b1d90aaffa07334e12c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a035aacb6aa496e9aacfa82670a5f77_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2126f23f1b6c45da8eda485ea4fb0ffd_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i476ff2f62e6e4dcd89e4d0e6f6e2e23a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd995ff940774cf9958d9496ccefdd49_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91bb5aef62c64ba6b7374026ad6cb167_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc1a4bfd08874c51bd52ae124d146ed1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d060a91a83540adba28a86e89f8a0a9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ead156d8e30415e96ef9f5d2ae30817_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1019c9ffdc464664a457a1558f80f5c1_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d28979d157949e8beda765ff3ebba18_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59a5e3ece3b2457d9dc9503670f62a19_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcb95436aea141439b320a672d06798b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbdb540b92834be9a1952a6988efe111_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5ec8f6c1a2745b6aef8220c52179da0_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdac2859144646f497bdee29d8f1077c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ecf74960c9f4004bfb28db9ceeee105_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe3a395375b74608adcd0dcb2511ccb6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e845118c19743509f235e3de1249c91_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i956b8eaf8bcc48e18a6392d104e3f82f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f802e7b0b4c462498edd33fe1a08df8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41bf8c2f57c2453187f38f71658035fd_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccd1e7bf99a04464a2be5ae2844e93c3_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a96f967a3e14ccfbf1709108752b15a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e1de888a7434a7d8901d5d91e9a5662_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i805e06baf0334dd2a9272620abb71ef1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bf6f39de92a477295091f337c5f246d_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87c3683c282e4dcab93976f033317191_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib781ea03fa4343ea9f43fe30bf85eaff_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9004a4576d54acdab802ba18e5954b5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b813d4b7f6a4ba8ab05eb62fa8c0d7e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e2d53c2e70b4fa7b373f89ff566d337_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6e00607e2514771bb461112b624c3c8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i678860fa552c43d4b4fcb6cefb64112a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i009fa3f9194b481097ec59ef54e9398c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic91d06961c624604bf888bc77f143328_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a70d046e3e04fe8814a35c37222c987_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a1a9bda61764661a686cd2e6cdf4353_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f37eacef6da488b9411e64b1e6f9bf8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46371b039efc4855ab60d1a0cfdee9ef_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae0c3902df5443afaa207966c3c336ae_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01ed93e108f540d895209d6cd63a4196_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02826dfbba6c48f19cdc43d704001dbe_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0da8ce69328d41578d3e52a25ef5c637_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf3afa843ed74fd3a1dccd7d9a340f73_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdbb2ee92d984ead82d0bfe89b0b7e67_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b635789ef4a4a3ea608c5ece8aad1d5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0503e2189e0437c94e4365e2f5e1a42_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7a3d52cbc5f4c36913820afde8b5ce0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29a85ee0346840baa3213980b51c8392_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48278fe6c84a480c993daadca8e14bec_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2da738de9a9496d82ebcd1ed1dfc349_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72d5f436073e4013afbbcd703dec4745_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f47b5c8b6e647f7a98ae58501327a48_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ba01d74fb2f4bc0a8c1b64e3b1eef96_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91fdfa6c20d94c5db431e71629735e62_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bdeb0b05ca8485aae2687a910e899e8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf27f4b868ff4ca6852de83fc00626db_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i725c25318b374568a7f6a1c522f751f5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddbce9adb77b4313a6ec25296cfc82c6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8f05f60f5234be3b895a985508995c8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35174116703c48a1ba3d71d19b34d188_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecc41b1e93894363b921a691b8c9ad5f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a8c46f072984025becf4f91f04a0ad4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53a4c1fd0f0e411bbd983b92368c6662_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8476fa283c5420a8c1cb44bf1886c3e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a141f4168094f93bc307eb5ebbf7392_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf7492d96a0b4f29b67c7ffc8e4fc10e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d6aaabb8fc4471fb4d955cbdc949682_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d1b2d8fe9744bfb992ea8ca03c8de17_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fb432a8a93945a68250848e46684f98_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3e93321ddf644359c1906deaf4915d8_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrevailTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8e0d422156841d5ad8a9105568a5622_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrevailTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="right"><xbrli:measure>lly:right</xbrli:measure></xbrli:unit><xbrli:context id="icbcb632a5c694ec29deb85ebe3a2a2e9_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:DermiraInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i532d485d20654594a8b1a96d44626d00_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:DermiraInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a359ced678146c9b9d8f9eb94adc1f8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:DermiraInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0a60d23094d4089a16f414a2eb40222_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrecisionBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib490931de5a249db92647a2ab94af9ad_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:MerusNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1c5831cc7174801a03a8b0a2fd91a4b_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:AsahiKaseiPharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6460ea51b114fd5952c6937cbc22e89_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:RigelPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if871b5e2a0ea46059a74abfa4e82d02d_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:SitryxTherapeuticsLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c7fcc42f3b34de0bb6bf706fa7541fa_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:AbCelleraBiologicsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cfe3973fd10441580375afacb0b0090_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:AbCelleraBiologicsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i787debb10db9449ebf355978b2cac4c9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d95635b39cc445ebd68b8eaacc4cf49_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8356c279b93c42829023f67b564fd0f1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7898c22d6db548ba8e625e7b4cb51b1c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie49f3b9fa84949058c66e2ccc6f1bafe_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecf3e061ab6a44e0b3e95b09ceec5863_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabb0222b012c480fa8a4b4033fb1c3b4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50e1340911c44726ba35205e9879816a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i661524a58a1c40ec97906a968e6f6aca_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9bf6a3d44b2458aabd053d1804a3283_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsCapitalizedAsIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64aadc652c4343c1bcd2bfc5b72d6158_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3343c905d8554be69ab7b345fa893082_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ec641d1b0e0486dba0286bc54d9f28f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsCapitalizedAsIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:JunshiBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cadf4d9d0bd4bf6b1d1bd9d0dc96dee_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSuccessBasedRegulatoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:JunshiBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44a54fd999064e8484fd5ca2af4dcc17_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:JunshiBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied018ff88f6646e88340a81a87e88722_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:InnoventBiologicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:NonCHINAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d761f2cc36e4a03b6ad57e5ab13c540_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:InnoventBiologicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia32a56f35ba84943ac17a6ae53d314e0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OutsideUSAndJapanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TanezumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24615d347773426cb44faa02b5f3a282_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TanezumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b6de8f942f44cf0aced4adc5181105e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TanezumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ee311292e604c2ba36873038aa0d41a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e55c79531a045a4849418d1e780b569_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bd3d506e737426ca9f7d5071e2fe975_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6017620bc984fc3b23178c68fc11436_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c39357db5cc4a9cbcfd00adcb81f908_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fea589edc3e4ab08f9ed7052aad2e59_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8fd6ec70f034998b9025e47bf69042a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyUsDollarSellEuroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="iacc428f5b7444f79a59f33bd449c5b64_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyEuroSellUsDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53cacc69bc7f436e8384c8ab4a5a9044_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyUSdollarSellJapaneseYenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="jpy"><xbrli:measure>iso4217:JPY</xbrli:measure></xbrli:unit><xbrli:unit id="gbp"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:context id="i196a382db4dd474f9215758c00592480_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyBritishPoundandSellUSDollarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i790e81260a954cde9599960f6c59fcd6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee91d9656eb3472e8cf1ac38a3807882_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifca25d1668f0447a8c0fb8e92c444a46_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:SwapU.S.DollarsToEuroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd062c4f7c644c92a3bd0c5fc8d3cd2c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:SwapSwissFrancsToU.S.DollarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08261dc843c546e282dc7746c9935f3a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40ae6e16034149ffab19351331c55b6a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bc95e47cf6e4f3da137f20ede5e2282_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02b03c88c1f84031a54577f36537d1bb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5492a540a4eb4396826f07e4a6429720_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e9ced055f4647d1b7ac5f1b13d3dcdb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0675cae41ecf4fad80226860b67627c8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cc6b325c96343679b6ae5ded2b4017a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ebf8484d97442a79f3fb0056a0a0636_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48597227bfbf4037b23b06218e7f576b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i733a2380e7734f87b92e3f8aed9fe6ac_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4ed115b785a4ad9a93f7287cb139b8e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d351595dea941808d14c80b2e44c3b3_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie02bf6e1811a43e7a3d115fc98ca56c9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8a0cc4c13104fccbd1c69dcb601af62_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0468ac52ec0a40758c116186c956d819_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i259ea4a4728c4829bf5a1d53b88fe316_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i379b7bdd53b04924a6915f7b6f539ae9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i502fd03d8e8b42f384a0637943ac9227_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i110e7dd739b14882b203dd13e31a425d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b1fc639100545e8b40e4cfd5886def1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50db401e52d34c6bbb22d8b87c712ee3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d9b74593ec94447a6448aee79dc1a4f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11210e6bf5044a31804dbf8297477c5b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f4fe1622f184cf9a797fcf2b732d7fe_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c35346f0f3b44448000e57b1d0d71cf_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e2ffab98d7f45a0a3b806e73e461745_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab695d20c84c457e96ce06476d8e182f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c6474daeefd44828fcb9effa40e0c54_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e03a9ef9cef4a99bcd45329382a4b01_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6f572bcda8c4de4b675b9afeb36f32c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5321b80fe49f4dc4a8096c02973ab7ab_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b5fc37a695a4b88b864b0b0f8a57e93_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94d22e93a3ad41848489c4810cedd352_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8aef2fe7df7413a99dc9b367490fdba_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21ff33225cde42d38dd508e225243ffe_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i094cfa08457b4639b53077e02b7b579b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39943827be2c4f9ea50a2cdfca84df2b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idaeb507e6d804976ad515b86786c2663_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd103e4954f440de8adec2b901b7d26f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2765888bb9a44e86856eb0e40a7a95a1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i937ee9f927b84aafaa8fd46c3071e390_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5623a1b5a79348899d40b0b51b54335e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i273c3175cdf54c6d9bd6414b446f3ab2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib521cd4c99774b97881a80a2a1c9c35d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49b67199341a409fb3c610a89020e4e4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d997ddd2afa4e4aa435ed61a0039a79_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i162abcddb00540a6b88917d1b8c94bc8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70666e8c06ae4150b3d53ba8f358e55b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b8e28324e994e5a9e7af4dd5abbfa4b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cef5c921b4d4a13aa14e51caae1e54c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45eb28a2afb843b5a7599d09796ba47a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c96a7e6ebdb4b5894e42f4f674afc2f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35a6dbafa15745eabd7e346fc0404f3c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie03e1c230dbe49b5b1a23948beb4fdf8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4814dc5f3094945b14b09c32634e414_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5428a6a7e77a4afc87dbec371aa0e81b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b460fcffdff4102b1a5f350e775eb50_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68b41c9f5b24461e99ffaf90ae7df35e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07692a7baeb34e989f264a119af0c6a3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cc36d48d552416e883d9009bfca5133_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id251b7aadbd741c38319af027dda2015_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie57e8b8550a94ed3a3001f7258f40509_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie22efb639d76469d92d9d05b55c13b2e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:EquityMethodAndOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5244871105b411bba98a34bdca3bb0f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7364db11b9f4acc956a7d2db362e700_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc89d6e873484ce2a724580ab1fb0293_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib227796e6d934483a3898110d9a529dd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic99278c5824b4d0d9f4dabbc783d760a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i173d02bf976949bb9c2fff706b29e7c8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaca67a3e336f480dbf5c62f2d4887602_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2385ee7845f44db9928643d251ba010f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2a7caef4a994ecfa2504a1f8fab161d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i674d272a65ea4e939a918cbd40640fad_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5ba42bd6f784aae8d55cfe3e64aaebb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea8e950975814a17bb0570d6ed036339_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab6a22cd5a3647489cfa1868842fce27_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id94556bfa50648c6896a229ad967ebdb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ba9c3716f03494583ac46573df6d898_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3f1ae733c62431ea7747e533857a063_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e05c6e58a3e45f9bbc6bfe65eb5fb24_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15f60e22ff78453692beb5eecfca6ffc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd7549721eee45bb8a3527258d461fd4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f9525a450be44ef9048544d4294da74_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65bf701b377c4beda33939db2d2f21ff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55aec24c88d44f4fa43277cc7538aab2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34a3b14dc8874f0c86a0d3eb37f253a0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i853e5949474b4d67b1db52061559bac8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb0f7206c077458c83a576a665d51173_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb18caa1f88e42d389a9b17c85b0d9bd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43215dcd05be459096efcec752179430_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54c52e457bd4422ca65d6e22cb0ade48_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1389fc9ec68d4b2db27d6a8e3bbd4bf1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3c4f4f185ab4ad881bcc56455b80c21_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79853a9b5da14a6fac53703381e9a418_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33320e06f4274ef9845c5efab8d73bb1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b2eb8a9c98a498ca9bf40a99de8f49a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib04cc817383740faa1e617ece927631a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id384954fa3fa4e6095584ab30e130a4e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8955bee463a4261b77faca6da120420_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e8796c582de405f85453b6be2e3dc09_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if57b6463cf5a4132bbba6db81c527ec0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65887bb8147d4233b2936ee964d36760_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45624739b2404896b6fe384552b5797f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18bd77315f3640e2b75151bd1a403bd6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i095078139e5147baa3f7c5a93913c9f2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41723e47817543c98de3be1e9ac4e77b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide25b210128b49279f9dcc009920c562_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ed173a5c7554ed8a6efa974dce7de56_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8841002a34004d4d894ac4dd47bba8cf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd5d2cfe7b1c4e6293342168871eb584_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1862e16eb5894cbb872c6ebca5ff8dda_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a8f781677394edcb970a7db2a230211_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:EquityMethodAndOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0320b4ac23843468622fdd30e513355_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id725308cf9eb4e51afe628b2f6dd2bfa_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9df56ec982804883a504fffec19bec2b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i818be88d8b754d358fa8f0f48530989d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4605596f0c549af8b2aa8ac2b0821f7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff50ed7383624a5dabf03016acb58cb4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic22a911ebb564c3e8e5e11aebe36daf2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3791d236011c495c9a6bc09f31e0e651_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1eef9a676fef442f8cc0df6224b88661_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f4f985dfc4c4913b6b477e42c5b7abf_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97f888ed727b47c4969964bbc26cee74_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb9cad6e8ee145a28421160b0fd93ac8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc00ea5651d44a68866912b87e772f32_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9728137c063040fdb217c0c575d24e90_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5691e9a962e48b9bab39a38eebafc58_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8f794d05abe4bb88fcbc982b4151ef0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i083270152267493cab8ef4a98752605d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb4db963049a418ebc24c7b6962c9c42_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2df54907b9c740578baa39b1f16db346_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9868066d4bf64c67b21b80f50a543d09_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3477ea907754af1b237c11ecd845a8c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5579461ee30641f5866f90f7f973fc2d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c522dc4d3644e6b89e1c04ae748b784_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4028304ed5344f378d4d8453889c1244_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c3b7e0e20ce4aa79064e5c448631a6e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i835b04928dc34e3d9eb5b6a882d6a434_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59341bae0f284bb79a7771c86ff861f4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i253bfddb6f414fe3a582437856252d99_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd815ed694bb4b1da50025622caa47df_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie39cd3b104234bdfbcbaedb52a41b15c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94f25e4c5e4b42cca659ef04248013aa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1893ad6b0e8c4f9d9ce45848acc79e12_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i541afb2da75d43639f7fec2ae5748d7f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i014bd38c39aa4b1895340e1de5390e79_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79425d230e734042bd4df00c16901373_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2553d800f08240b1b782fd37f8f03377_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdf6391061294c348287bce4418a7767_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i326c763bfd9e49bdb908141c5104c4c6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if72250a4fe7543458ef88e49f913f39a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53ee22718d2249e6932918034d9479f7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11784cd0180b4240bfe628b8a935091b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2b7165b4f9f4b159f2f118447ef21b2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c9d21e349b44826bb9ff73def0b0f9b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i492cf935c87d44ea908c1584da4f932b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86f5f0213b924cf4a2443b1755e0e558_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie913be1662fb496dadd88c102ecc6d7f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5133f4445b424b37b5a24aee0f8c8ad5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb9d49fc86e54fa4aef040dc305765cc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34c34c5498af462390f43272c1214aad_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80e1536360e0467e919e75a282b9c273_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d9dae1aca8e45a9bd0624944e8a56ca_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e38511a533b4a35afcd45b88276b271_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4b0ceabb1674432983305cc3a962999_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf4e9376f20b4a76a67b9874281b82b7_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="patent"><xbrli:measure>lly:patent</xbrli:measure></xbrli:unit><xbrli:context id="i9472948bb7f947afa49886afa824b300_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7408050434b1433f9057403b967bc044_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dfd4b4b1d2a4b459b67e2e9c72eac8d_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6e455b81cdd4b63a8577a6c3f916221_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>lly:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="i19d9bfc8635f470e9a7adb121100256d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fbb93a5eb8140d2b2faeef2de2e7c59_I20111231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2011-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9877de074e3b4cd68f3e14e738b53b96_I20120731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:WhyteEtAlVEliLillyEtAlMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idac89cba080843258ae570efc0620a18_I20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:WeilerVTakedaCanadaIncEtAlMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad757e1928624ece99a2023c2b06db4a_I20130131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EppVTakedaCanadaIncEtAlMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic92b96cca8ef435288a260a7692a4296_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="plaintiff"><xbrli:measure>lly:plaintiff</xbrli:measure></xbrli:unit><xbrli:context id="i87320df79b3f461da082a107fa7a8e57_D20090301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15f9ce4e2e9f47789b45d86896781f54_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:LosAngelesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6776f7310a5341a3b3f6bfdef846dfea_D20090301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:LosAngelesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib44052b397dc4098a69265e6060b79a8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:SouthernDistrictOfCaliforniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i121dcf9b52ce46eead9ac16494dd1642_D20090301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:SouthernDistrictOfCaliforniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib73e27481f2e44bcb74fda4f3cecf682_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:VariousStateDomicilesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fa2b0f3392543f2b160709e35c124d7_D20090301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:VariousStateDomicilesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b029559694b48b08c94d12ad381445e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="lly:PlaintiffAllegationsAxis">lly:PancreaticCancerOrThyroidCancerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if02307f1292e42dd8aa0a8c7f88d014f_D20090301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="lly:PlaintiffAllegationsAxis">lly:PancreaticCancerOrThyroidCancerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ccdd965fb0d44ed8eaa51cd4f6af3a8_D20090301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lly:PlaintiffAllegationsAxis">lly:PancreatitisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5a9904ee8fe4ee9900bba9f1c855eb9_D20090301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lly:PlaintiffAllegationsAxis">lly:AmpullaryCancerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="claimant"><xbrli:measure>lly:claimant</xbrli:measure></xbrli:unit><xbrli:context id="i0ac86530d3c243cca63aa23529e06624_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f7430fd06b947ef84b255b6fb8aee26_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="site"><xbrli:measure>lly:site</xbrli:measure></xbrli:unit><xbrli:context id="ida0a952118b340e6ba680f7df96d7075_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="brl"><xbrli:measure>iso4217:BRL</xbrli:measure></xbrli:unit><xbrli:context id="ib5001859aff84e2dbe43c4543f7e5dbc_D20180701-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb85b610e8d84b4788f9a42c2d175b66_D20210331-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i877919e055e34b8eb3844514babacc6f_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa67ffc334f74fdd88aeff3e17eb06fd_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69f451428d3e45a3a75cd744529fea05_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogHumulinAndForteoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="request"><xbrli:measure>lly:request</xbrli:measure></xbrli:unit><xbrli:context id="i08bd92534c0942898d7deffdcc7f9938_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:DrReddysLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b10da171de74c8882000a2f696152fd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5614d38977b64c168c1b9fc251c757ca_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffd75cb32c5543a891d689e8933d4949_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icaa91bb6c1a24ffcb202a27011d73dd0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2845560a0ba2491a904c84ba82f35819_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i743947277250425485ee1e0a26d90120_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i205a56c975a443f7b7c7708eb29b679c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ebbc7661fa041f1ba2dd368ac1ee896_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c5b25a00f1643c98078aba97cc80b62_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9655bade5b00400dba7752533cb6743c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i577b7fef6c2c49bf87fe8cb8121248ce_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie23fc76e1a5a432a8db78dd624ef5cc1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7caab5ff3a4d4ca8a64128cbbeb05cdd_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b8b459cd1fc47f6baa6f11b48145ac4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1eeb66393264479aecf1f1d2fcd51b1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cc74d110d0145598aeabdd970d87f17_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa58ad2146314403b3eff9eaf3e10324_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ebe01e7039a44a4888856db6e4a7d39_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffabc6d5c4614780a93ce1b21d701159_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96ce660d25654b37a7243b236eca576b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55b8fd6090834514913a2977fd43623e_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17796a268f3742fda454ebd20b70ba1d_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bc687d07e3f4ff4bcb96e53bc8d83ec_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd5fe3b1199247e6a91eb8d01efc2392_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41d912b5241343a9b988106cef8e0215_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33afbb7d73484c0a83d56114c6756d5c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i194e7735259d438eb363e7d9f3ae1523_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i986fb3e559c0490ca09848e9ac9bf901_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf742f7aff334b05a91842e894677604_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02045ea33c7d43d4a34c42a37721b125_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if48b9be7413d42df903afc9bf15c3c13_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i492583e2c9b044f29ac4a51092ddfbe8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfdc30c8362d4397a4020c9b938662fa_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2917edad81e5463e9d61cceea8f62ea4_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if82cce099c354dd78182619455a05af1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25e6d224ac334db98fbf37d17ced616d_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i191727da20c34eae98d4dbc93f0337fe_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9638221883d14af2935d735e8cc9a360_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37bfd76d6ecb46708142e81e2d19a33c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c0ff30fbf7f474f9b43c59d3bc7e538_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Form <ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl8yMDMx_c2b9ed78-63cc-4402-9b93-0d368b9aa5bf">10-Q</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" format="ixt:booleanfalse" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl80OTQ3ODAyMzI3MDg3_50524f91-7466-4ed1-8a0e-4ce3dec76b0b"><ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl80OTQ3ODAyMzI3MDg3_ed6a6b1d-7d90-4454-9a97-2f44f6fac31d">Quarterly</ix:nonNumeric></ix:nonNumeric> Report Pursuant to Section&#160;13 or 15(d) of the</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Exchange Act of 1934</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl8yMDU_54d3768c-fcb0-4dfe-a940-17fc80e0a257">March&#160;31, 2021</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMMISSION FILE NUMBER <ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl8yMDM3_941c6df3-644e-4aee-a032-e86c79125d81">001-6351</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl8yMDMy_eafa7129-abe9-4396-85ac-0509a8a791db">ELI LILLY AND COMPANY</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of Registrant as specified in its charter)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:47.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6MTMzMGExNWNjZmMwNDI3NmE0NjU5NzBiMzgxZDlmMmEvdGFibGVyYW5nZToxMzMwYTE1Y2NmYzA0Mjc2YTQ2NTk3MGIzODFkOWYyYV8wLTAtMS0xLTA_5ba4d629-ef82-4d8c-9fcf-ff68042ea2ae">Indiana</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6MTMzMGExNWNjZmMwNDI3NmE0NjU5NzBiMzgxZDlmMmEvdGFibGVyYW5nZToxMzMwYTE1Y2NmYzA0Mjc2YTQ2NTk3MGIzODFkOWYyYV8wLTItMS0xLTA_d4bbb31a-df75-48cd-b8b9-306cf3d83247">35-0470950</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(State or other jurisdiction of</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identification No.)</span></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl8yMDMz_27dbb615-7f0c-415d-99ef-cb4d12b161b0">Lilly Corporate Center</ix:nonNumeric>, <ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl8yMDM4_477fb1e2-e68e-4a77-8667-f1aaeb4f6608">Indianapolis</ix:nonNumeric>, <ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl8yMDM0_1d8d3687-6efb-46f3-a252-33f8569fffb0">Indiana</ix:nonNumeric> <ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl8yMDI5_67048238-f05e-46fa-94fb-89c7384b062a">46285</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Address and zip code of principal executive offices)</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code (<ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl8yMDM5_0f54f8d1-891a-4573-93cf-0745c6d91461">317</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl8yMDMw_73cce34b-600d-420a-9c6b-b59b8b5171a1">276-2000</ix:nonNumeric> </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Exchange Act:</span></div><div style="margin-bottom:5pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.313%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Trading Symbols</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Each Exchange On Which Registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib6bc00b2d2b24b739475df069c617a03_D20210101-20210331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl8xLTAtMS0xLTA_5852ea3e-abe5-46df-8885-e1ff73dd97c9">Common Stock (no par value)</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib6bc00b2d2b24b739475df069c617a03_D20210101-20210331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl8xLTEtMS0xLTA_32af1ca8-ec20-4bb1-b2a7-3b7a3b6ec007">LLY</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib6bc00b2d2b24b739475df069c617a03_D20210101-20210331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl8xLTItMS0xLTA_a6e4c6d9-81fc-4c24-8399-e83077bae5fd">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic3e378dfd41341fb9e60b25e358c23ef_D20210101-20210331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl8yLTAtMS0xLTA_02a9f67b-f920-46ba-bedd-a609ff4ba425">1.000% Notes due 2022</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic3e378dfd41341fb9e60b25e358c23ef_D20210101-20210331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl8yLTEtMS0xLTA_55876694-6a66-457e-8c0c-11de8b5f3b9d">LLY22</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic3e378dfd41341fb9e60b25e358c23ef_D20210101-20210331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl8yLTItMS0xLTA_eb74693f-0c5a-446c-b927-bc5be1003f72">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i44103ce383994d74a3ab84ed4f5b4a46_D20210101-20210331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl8zLTAtMS0xLTA_d8b50eae-ed90-4d86-a091-ff0573a57d9a">7 1/8% Notes due 2025</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i44103ce383994d74a3ab84ed4f5b4a46_D20210101-20210331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl8zLTEtMS0xLTA_01faa47f-63d7-46ec-ad8d-321e3e04bada">LLY25</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i44103ce383994d74a3ab84ed4f5b4a46_D20210101-20210331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl8zLTItMS0xLTA_5be754f0-9d9d-404c-8baf-9f91d7df91f8">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i086dc0b8a28b43438b0ec2d949452e3e_D20210101-20210331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl80LTAtMS0xLTA_62ccd249-293e-4394-a1ee-2ff65d4a3668">1.625% Notes due 2026</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i086dc0b8a28b43438b0ec2d949452e3e_D20210101-20210331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl80LTEtMS0xLTA_d649d9e3-810f-4f88-b11c-5af5437046c5">LLY26</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i086dc0b8a28b43438b0ec2d949452e3e_D20210101-20210331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl80LTItMS0xLTA_31e4cd36-ac40-4fbe-b189-c65c92f1feeb">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1ffb83ec38e84898b6c89250d5c39070_D20210101-20210331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl81LTAtMS0xLTA_0d331ad7-b4c1-48a5-81e0-23cd986ebe3c">2.125% Notes due 2030</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1ffb83ec38e84898b6c89250d5c39070_D20210101-20210331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl81LTEtMS0xLTA_647c3c2d-dd00-4092-b7ba-12447200608b">LLY30</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1ffb83ec38e84898b6c89250d5c39070_D20210101-20210331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl81LTItMS0xLTA_f67af9d2-a1a2-45b9-99c8-68565551dddc">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if8ceb4ed9fcd4e6e8a65b6d5a85314e7_D20210101-20210331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl82LTAtMS0xLTA_1af55436-1efb-4d22-add3-749d55e1acd1">0.625% Notes due 2031</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if8ceb4ed9fcd4e6e8a65b6d5a85314e7_D20210101-20210331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl82LTEtMS0xLTA_8c5d9633-0fbc-44ba-95ea-bfd8bec2c49d">LLY31</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if8ceb4ed9fcd4e6e8a65b6d5a85314e7_D20210101-20210331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl82LTItMS0xLTA_6906eeb0-ca8f-46e1-8a49-0e2b75ab686f">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i996950b9da7c4950a18ada582b1fc257_D20210101-20210331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl83LTAtMS0xLTA_bfd3ae83-1f34-4d48-b4c7-3ceff96c5453">6.77%&#160;Notes due 2036</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i996950b9da7c4950a18ada582b1fc257_D20210101-20210331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl83LTEtMS0xLTA_ac233df6-c8ae-4368-9082-b9bd752f8f97">LLY36</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i996950b9da7c4950a18ada582b1fc257_D20210101-20210331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl83LTItMS0xLTA_d3dc6bff-572e-4d8a-9f9b-203d8eb0d68f">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if8debecbe586414a933f775ea52cd38e_D20210101-20210331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl84LTAtMS0xLTA_cc65f1d5-af80-44f1-b7d9-7c97935d37cd">1.700% Notes due 2049</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if8debecbe586414a933f775ea52cd38e_D20210101-20210331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl84LTEtMS0xLTA_994a0125-366c-4068-abb3-25aba8111495">LLY49A</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if8debecbe586414a933f775ea52cd38e_D20210101-20210331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl84LTItMS0xLTA_03a472e8-842f-426c-99e2-543f449c964e">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2)&#160;has been subject to such filing requirements for the past 90 days.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl8yMDQw_8316d960-0856-4a7e-8b1d-ee51109c64fb">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl8yMDM1_c638c031-3805-48a3-9c9f-ad1df8425815">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:5pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6Yzk4ZGM0MmNmMjBiNGQyODhiYTJkMzUzYTRjZDljZWUvdGFibGVyYW5nZTpjOThkYzQyY2YyMGI0ZDI4OGJhMmQzNTNhNGNkOWNlZV8wLTAtMS0xLTA_6fcdb110-1ea5-4f3f-9769-81e29600c2ad">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6Yzk4ZGM0MmNmMjBiNGQyODhiYTJkMzUzYTRjZDljZWUvdGFibGVyYW5nZTpjOThkYzQyY2YyMGI0ZDI4OGJhMmQzNTNhNGNkOWNlZV8xLTctMS0xLTA_26fe7f6e-5b13-4a6e-aa31-43601438e047">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6Yzk4ZGM0MmNmMjBiNGQyODhiYTJkMzUzYTRjZDljZWUvdGFibGVyYW5nZTpjOThkYzQyY2YyMGI0ZDI4OGJhMmQzNTNhNGNkOWNlZV8yLTctMS0xLTA_5943a540-b02b-47db-ae6c-851d80537700">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl8yMDM2_55615946-59d6-4dae-b2f9-bc6a2db335fc">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of shares of common stock outstanding as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">April&#160;27, 2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:47.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of Shares Outstanding</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8777fbeb1d88449d8d60f606fd5c2c77_I20210427" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6ZGQ4N2E0ZWZkOWUyNDA4Y2I3ZTM2YTgzOTYxZGUxMmIvdGFibGVyYW5nZTpkZDg3YTRlZmQ5ZTI0MDhjYjdlMzZhODM5NjFkZTEyYl8xLTItMS0xLTA_2e4c175a-d277-48bd-9ae6-fd9d9db41429">959,025,446</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eli Lilly and Company</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Form 10-Q</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Quarter Ended March&#160;31, 2021 </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.750%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_13">PART I. Financial Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_13">5</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_16">Item 1.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_16">Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_16">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_19">Consolidated Condensed Statements of Operations</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_19">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_22">Consolidated Condensed Statements of Comprehensive Income (Loss)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_22">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_25">Consolidated Condensed Balance Sheets</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_25">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_28">Consolidated Condensed Statements of Equity</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_28">8</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_31">Consolidated Condensed Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_31">9</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_34">Notes to Consolidated Condensed Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_34">10</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_85">Item 2.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_85">Management's Discussion and Analysis of Results of Operations and Financial Condition</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_85">34</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_88">Executive Overview</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_88">34</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_91">Revenue</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_91">44</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_97">Gross Margin, Costs, and Expenses</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_97">47</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_103">Financial Condition and Liquidity</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_103">48</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_106">Financial Expectations</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_106">49</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_109">Available Information on our Website</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_109">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_112">Item 4.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_112">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_112">50</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_115">PART II. Other Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_115">51</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_118">Item 1.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_118">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_118">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_121">Item 1A.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_121">Risk Factors</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_121">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_124">Item 2.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_124">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_124">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_130">Item 6.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_130">Exhibits</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_130">52</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_136">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3cd151b5d83246a98b0e0ef4a9feb269_136">52</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-style:italic;font-weight:400;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. In particular, information appearing under &#8220;Management's Discussion and Analysis of Results of Operations and Financial Condition&#8221; includes forward-looking statements. Forward-looking statements include all statements that do not relate solely to historical or current facts, and generally can be identified by the use of words such as &#8220;may,&#8221; &#8220;believe,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;project,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;anticipate,&#8221; &#8220;plan,&#8221; &#8220;continue,&#8221; or similar expressions or future or conditional verbs. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">Forward-looking statements inherently involve many risks and uncertainties that could cause actual results to differ materially from those expressed in forward-looking statements. Where, in any forward-looking statement, we express an expectation or belief as to future results or events, it is based on management's current plans and expectations, expressed in good faith and believed to have a reasonable basis. However, we can give no assurance that any such expectation or belief will result or will be achieved or accomplished. Investors therefore should not place undue reliance on forward-looking statements. The following include some but not all of the factors that could cause actual results or events to differ materially from those anticipated:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">the impact of the evolving COVID-19 pandemic and the global response thereto;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">uncertainties related to our efforts to develop potential treatments for COVID-19;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">the impact of acquisitions and business development transactions and related integration costs;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">the expiration of intellectual property protection for certain of our products and competition from generic and/or biosimilar products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">our ability to protect and enforce patents and other intellectual property;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">changes in patent law or regulations related to data package exclusivity;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">competitive developments affecting current products and our pipeline;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">market uptake of recently launched products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">information technology system inadequacies, breaches, or operating failures;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">unauthorized access, disclosure, misappropriation, or compromise of confidential information or other data stored in our IT systems, networks, and facilities, or those of third parties with whom we share our data;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">unexpected safety or efficacy concerns associated with our products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">litigation, investigations, or other similar proceedings involving past, current, or future products or commercial activities as we are largely self-insured;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">issues with product supply and regulatory approvals stemming from manufacturing difficulties or disruptions, including as a result of regulatory actions relating to our facilities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">reliance on third-party relationships and outsourcing arrangements;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">regulatory changes or other developments;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">regulatory actions regarding currently marketed products; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">continued pricing pressures and the impact of actions of governmental and private payers affecting pricing of, reimbursement for, and access to pharmaceuticals;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">devaluations in foreign currency exchange rates or changes in interest rates, and inflation;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">changes in tax law, tax rates, or events that differ from our assumptions related to tax positions; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">asset impairments and restructuring charges;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">the impact of global macroeconomic conditions and trade disruptions or disputes; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">changes in accounting and reporting standards promulgated by the Financial Accounting Standards Board and the Securities and Exchange Commission (SEC); and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">regulatory compliance problems or government investigations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">More information on factors that could cause actual results or events to differ materially from those anticipated is included from time to time in our reports filed with the SEC, including in our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2020, particularly under the caption &#8220;Risk Factors&#8221;.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">All forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are expressly qualified in their entirety by the cautionary statements included in or incorporated by reference into this Quarterly Report on Form 10-Q. Except as is required by law, we expressly disclaim any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this Quarterly Report on Form 10-Q. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:400;line-height:120%;text-decoration:underline">PART I. Financial Information</span></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_16"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&#160;1. Financial Statements</span></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Condensed Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELI LILLY AND COMPANY AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars and shares in millions, except per-share data)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue (Note 2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMi0xLTEtMS0w_cdc049d5-2d49-4700-9596-113c5a6bdda8">6,805.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMi0zLTEtMS0w_dacb8a1f-5e19-46c6-9a11-2a2c57bae91d">5,859.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs, expenses, and other:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfNC0xLTEtMS0w_9ba2fceb-ee49-4a8b-8346-76e081a31a3f">1,878.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfNC0zLTEtMS0w_87ad829e-e05d-41bd-ae98-2f91a74a2b62">1,215.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfNS0xLTEtMS0w_f8b4cd4a-2076-4e6b-8580-772d97f02af6">1,684.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfNS0zLTEtMS0w_025feed4-c178-4e39-ab60-2494910cdcd0">1,392.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing, selling, and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfNi0xLTEtMS0w_e9da96b3-fff1-4c26-be72-dc12179ab88b">1,576.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfNi0zLTEtMS0w_da1c1dee-53f6-481d-bfa1-65b9d3399c1f">1,549.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development (Note 3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfNy0xLTEtMS0w_f22b0665-a414-427f-a392-d550ff6a24db">299.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfNy0zLTEtMS0w_e596da16-5335-4bd7-a836-7c3abf06b559">52.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring, and other special charges (Note 5)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfOC0xLTEtMS0w_867dc0f3-4934-4403-bb1c-95f003c7ea49">211.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfOC0zLTEtMS0w_61e9d0f7-00f1-4631-bc7a-178c42842cd9">59.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense (Note 11)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfOS0xLTEtMS0w_49172d7c-4713-4a2f-973b-380bc431025b">321.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfOS0zLTEtMS0w_db66b2b8-dfdf-4080-ba6b-e3e254491d0a">89.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="lly:CostOfSalesOperatingExpensesAndOtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMTAtMS0xLTEtMA_d0032acc-81f7-437b-ba30-aedbaaa5b406">5,329.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="lly:CostOfSalesOperatingExpensesAndOtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMTAtMy0xLTEtMA_070ba26f-5648-4913-b04c-09e4be48ac68">4,179.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMTEtMS0xLTEtMA_dd4bee67-0886-4a2a-9b4a-487c6a1d8f0c">1,476.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMTEtMy0xLTEtMA_2a049c13-51fa-4014-b603-b30c60c21d65">1,679.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes (Note 7)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMTItMS0xLTEtMA_939aec93-1f5e-428f-84e7-ca213f434238">121.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMTItMy0xLTEtMA_f7a2b37d-1475-4fc4-9d8c-34d43b09a8fe">223.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMTMtMS0xLTEtMA_cc339fb1-a3d8-40fe-bd5a-d7d496f2ee0b">1,355.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMTMtMy0xLTEtMA_be444e07-fef8-45e6-aa2a-4663cf497616">1,456.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMTgtMS0xLTEtMA_6dae2d9a-054e-4ba3-a878-91126bff5d82">1.49</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMTgtMy0xLTEtMA_a412d89f-0c49-4153-b210-3917b8f07278">1.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMjItMS0xLTEtMA_abf07fd6-089c-478d-86a2-347b71efc313">1.49</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMjItMy0xLTEtMA_03a4aa9a-eba9-4fea-8fbb-7fe5d08add7a">1.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in calculation of earnings per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMjctMS0xLTEtMA_3c35c5a9-73e4-4f0c-ac6d-e930b74dc741">908.8</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMjctMy0xLTEtMA_895ee77e-373c-4d4b-a6e4-f46c3819ee3f">908.2</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMjgtMS0xLTEtMA_da1d0de4-5bcc-447d-8960-719067847d15">912.4</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMjgtMy0xLTEtMA_4c301199-0d52-4f7f-b99d-f82add56f70d">911.7</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated condensed financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Condensed Statements of Comprehensive Income (Loss)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELI LILLY AND COMPANY AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yMi9mcmFnOmE1NTQ0ZjAwNjk4NDQ0Njg4MjYzMzE3YWVkNzYwNzdjL3RhYmxlOjI1MjFlNjExZTdhMDQ0NmU5ZGY4NjNiMDI5NzJmZTM0L3RhYmxlcmFuZ2U6MjUyMWU2MTFlN2EwNDQ2ZTlkZjg2M2IwMjk3MmZlMzRfMi0xLTEtMS0w_cc339fb1-a3d8-40fe-bd5a-d7d496f2ee0b">1,355.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yMi9mcmFnOmE1NTQ0ZjAwNjk4NDQ0Njg4MjYzMzE3YWVkNzYwNzdjL3RhYmxlOjI1MjFlNjExZTdhMDQ0NmU5ZGY4NjNiMDI5NzJmZTM0L3RhYmxlcmFuZ2U6MjUyMWU2MTFlN2EwNDQ2ZTlkZjg2M2IwMjk3MmZlMzRfMi0zLTEtMS0w_be444e07-fef8-45e6-aa2a-4663cf497616">1,456.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax (Note 10)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yMi9mcmFnOmE1NTQ0ZjAwNjk4NDQ0Njg4MjYzMzE3YWVkNzYwNzdjL3RhYmxlOjI1MjFlNjExZTdhMDQ0NmU5ZGY4NjNiMDI5NzJmZTM0L3RhYmxlcmFuZ2U6MjUyMWU2MTFlN2EwNDQ2ZTlkZjg2M2IwMjk3MmZlMzRfNS0xLTEtMS0w_a79a99fe-4b1e-44a8-a984-c93057b5c890">100.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yMi9mcmFnOmE1NTQ0ZjAwNjk4NDQ0Njg4MjYzMzE3YWVkNzYwNzdjL3RhYmxlOjI1MjFlNjExZTdhMDQ0NmU5ZGY4NjNiMDI5NzJmZTM0L3RhYmxlcmFuZ2U6MjUyMWU2MTFlN2EwNDQ2ZTlkZjg2M2IwMjk3MmZlMzRfNS0zLTEtMS0w_82ff9c03-fc22-4abb-93c4-d85c797465a2">362.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yMi9mcmFnOmE1NTQ0ZjAwNjk4NDQ0Njg4MjYzMzE3YWVkNzYwNzdjL3RhYmxlOjI1MjFlNjExZTdhMDQ0NmU5ZGY4NjNiMDI5NzJmZTM0L3RhYmxlcmFuZ2U6MjUyMWU2MTFlN2EwNDQ2ZTlkZjg2M2IwMjk3MmZlMzRfNi0xLTEtMS0w_897f99ac-b4ae-4368-95aa-9a941897260c">1,456.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yMi9mcmFnOmE1NTQ0ZjAwNjk4NDQ0Njg4MjYzMzE3YWVkNzYwNzdjL3RhYmxlOjI1MjFlNjExZTdhMDQ0NmU5ZGY4NjNiMDI5NzJmZTM0L3RhYmxlcmFuZ2U6MjUyMWU2MTFlN2EwNDQ2ZTlkZjg2M2IwMjk3MmZlMzRfNi0zLTEtMS0w_09eecf62-c95e-4973-9cf2-1ac3c1956e81">1,094.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated condensed financial statements.</span></div><div style="margin-top:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_25"></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Condensed Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELI LILLY AND COMPANY AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Current Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents (Note 6)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMy0xLTEtMS0w_034f9e93-900e-4fb4-8ad3-cdd9bf5ecf03">3,002.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMy0zLTEtMS0w_69ace194-1e38-44a0-b337-1996cc5d86d1">3,657.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments (Note 6)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" name="us-gaap:ShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNC0xLTEtMS0w_442e9d67-69bf-4e3f-b9b1-29d1fded794e">49.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" name="us-gaap:ShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNC0zLTEtMS0w_34125e58-651a-4c6a-a066-f4d405257885">24.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net of allowances of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNS0wLTEtMS0wL3RleHRyZWdpb246NDZjNmI0Y2EzOTJhNGRmZTlmNzdkNDhkY2ZmMDA1ZmRfNDc_1d325f81-0281-4300-a333-ff1fee095d03">23.9</ix:nonFraction> (2021)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and $<ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNS0wLTEtMS0wL3RleHRyZWdpb246NDZjNmI0Y2EzOTJhNGRmZTlmNzdkNDhkY2ZmMDA1ZmRfNjE_d50d661c-f008-4799-96a3-ec599f5664ad">25.9</ix:nonFraction> (2020)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNS0xLTEtMS0w_8346b42f-e329-40c0-9f85-47311fed5b74">5,592.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNS0zLTEtMS0w_a524cd36-3168-4ddd-8cd1-0c45e977037a">5,875.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNi0xLTEtMS0w_24df703d-80b8-4e64-8cd0-0061c234dcf7">1,065.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNi0zLTEtMS0w_9201bac2-3ffc-4783-9889-ed9d7c50d6dc">1,053.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNy0xLTEtMS0w_cec099a5-ce58-44a8-9836-a02f318df379">3,660.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNy0zLTEtMS0w_a92ddf93-bb71-42ea-a458-397c3cf21504">3,980.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfOC0xLTEtMS0w_7bb5cdcc-af37-403a-be67-49a7c67fa27a">3,233.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfOC0zLTEtMS0w_2e14d297-3829-42da-b5e0-6b89a044d785">2,871.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfOS0xLTEtMS0w_ff560519-b78c-4506-b7a1-6cd75bcae2af">16,604.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfOS0zLTEtMS0w_3b9e257c-b4f0-4a4a-bec1-01e6d8166461">17,462.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments (Note 6)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTAtMS0xLTEtMA_5f709141-2822-4a7b-a241-db41dd0c099e">3,232.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTAtMy0xLTEtMA_a767f40c-70db-4008-ae4b-88d702843af9">2,966.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTEtMS0xLTEtMA_c58376a8-4d20-456d-9a96-b1e3957cd079">3,877.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTEtMy0xLTEtMA_313289d1-34ef-44cd-978b-7bf1803a0e60">3,766.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangibles, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTItMS0xLTEtMA_67c308b5-6d09-4964-b9f7-964f3c398e1e">8,087.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTItMy0xLTEtMA_1cfc3905-b15c-4fb3-a57d-c193a31ee036">7,450.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTMtMS0xLTEtMA_8a0dc432-cf32-41f7-8eb6-b34f6d40d71d">2,649.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTMtMy0xLTEtMA_1283a6f0-fec8-4a79-a915-738152bf6282">2,830.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTQtMC0xLTEtMC90ZXh0cmVnaW9uOjQyMjA2NmYwNDMyMjRhZDVhOWM3Mjc3NDAzMzdkYjdjXzYz_05ccbfcf-5761-451b-b76d-3d7b3f4f7208">9,643.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2021) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and $<ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTQtMC0xLTEtMC90ZXh0cmVnaW9uOjQyMjA2NmYwNDMyMjRhZDVhOWM3Mjc3NDAzMzdkYjdjXzc3_d952a318-4574-4d1b-b8d7-88ede913ff9e">9,570.7</ix:nonFraction> (2020)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTQtMS0xLTEtMA_dc5ec02b-146f-455d-914c-ab68f74ce807">8,630.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTQtMy0xLTEtMA_490bad88-3732-458b-8c7e-c6e65c4a5008">8,681.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTUtMS0xLTEtMA_75703814-703c-468f-8d09-98d359c7c032">3,756.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTUtMy0xLTEtMA_d89b4823-f88e-49cd-93d5-c8a9b8d12ded">3,475.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTYtMS0xLTEtMA_0415647e-435e-4299-b5e2-0d4829261b63">46,838.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTYtMy0xLTEtMA_d6978284-b968-4dc4-86fc-9b1b71a4db78">46,633.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Current Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings and current maturities of long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTktMS0xLTEtMA_23f4c3fe-b9f1-4774-a007-033a7e650e04">4.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTktMy0xLTEtMA_a6a294f9-36eb-461a-ab90-21ea90d5c4f0">8.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjAtMS0xLTEtMA_1e429c67-bd7e-4ccc-a1d2-d28302ce40fa">1,639.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjAtMy0xLTEtMA_12ae1353-3677-49be-9afa-862ba08f4f67">1,606.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjEtMS0xLTEtMA_2ebde5b6-8fef-47d4-b426-b626cf00e0e2">649.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjEtMy0xLTEtMA_67faf49b-20c0-422c-837d-a608fd8e6372">997.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales rebates and discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="lly:SalesRebatesAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjItMS0xLTEtMA_d9ca682d-9455-4e50-aa36-c0693e6fb6d5">5,821.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="lly:SalesRebatesAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjItMy0xLTEtMA_57d73291-4974-4d25-a5bd-bf6a59492e91">5,853.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DividendsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjMtMS0xLTEtMA_78b8a931-1340-4301-b518-97e4aff9487d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" name="us-gaap:DividendsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjMtMy0xLTEtMA_89812fa7-98c8-4285-a6e3-db0a3caeeed5">770.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjQtMS0xLTEtMA_8bd63a24-fe57-4d97-97e0-8207844b9a1a">791.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjQtMy0xLTEtMA_770468c6-042d-45d4-be29-cb09bf822891">495.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjUtMS0xLTEtMA_d0b1c191-bbed-4c21-a776-bed48a1ad5df">2,806.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjUtMy0xLTEtMA_766a78e7-cc0e-492f-8039-ceabf5bf8511">2,750.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjYtMS0xLTEtMA_e8d21695-899b-4c59-aee6-c79d52de7d6f">11,714.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjYtMy0xLTEtMA_b1eb52d3-b3d5-41f3-82fe-054caa817bfa">12,481.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjgtMS0xLTEtMA_71fb1798-e563-4adc-88f4-30795d1922db">16,199.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjgtMy0xLTEtMA_3c04221c-244c-4a10-b24b-169f3b87da89">16,586.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued retirement benefits (Note 8)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjktMS0xLTEtMA_fcb2b670-6441-4559-a93a-6d562cc2d101">3,969.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjktMy0xLTEtMA_fad1d723-a179-43d5-88a2-b43d1d27d780">4,094.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzAtMS0xLTEtMA_0a5a8745-70ba-4e14-9918-027ef227844e">3,917.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzAtMy0xLTEtMA_27ab968b-a764-46a9-84ea-7ba8970b5da1">3,837.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzEtMS0xLTEtMA_b9915539-b00c-4b33-8344-1677059b5e1e">2,200.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzEtMy0xLTEtMA_d4d13d47-c4bf-40ac-9893-703717bdc702">2,099.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzItMS0xLTEtMA_79aa0d32-c818-4dcd-bfb8-a4a0cc7972b8">1,737.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzItMy0xLTEtMA_bfa0f893-cffa-4109-b416-2724a56acf68">1,707.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzMtMS0xLTEtMA_0de7255c-da6a-4975-95e5-55546a09e56e">28,024.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzMtMy0xLTEtMA_ce3d877d-8429-4ba7-8393-9248fa26e178">28,326.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Commitments and Contingencies (Note 9)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzQtMS0xLTEtMA_1430d540-ea80-491d-af71-87513bb9824a"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzQtMy0xLTEtMA_cff7caa8-a783-4578-a425-3a848eece547"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Eli Lilly and Company Shareholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzYtMS0xLTEtMA_7f7c3cad-f765-439b-9b92-3ae56712ddfc">599.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzYtMy0xLTEtMA_d1dedd7b-9125-43e6-9ce7-608d90369ecf">598.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzctMS0xLTEtMA_1afeeafb-607b-4647-b92f-ea8716703329">6,579.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzctMy0xLTEtMA_a5015b02-4133-489e-98ae-1d2672f0b72c">6,778.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzgtMS0xLTEtMA_f281b49e-e72a-4036-b9fe-592174303a44">9,181.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzgtMy0xLTEtMA_c961505c-154a-4637-a02b-f51dac7f9cf5">7,830.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefit trust</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesHeldInEmployeeTrust" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzktMS0xLTEtMA_5dd4d647-217d-4ab7-90f0-28a13d698817">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesHeldInEmployeeTrust" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzktMy0xLTEtMA_51734cc1-6ea5-4bf0-8e2a-398e9ea3e162">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss (Note 10)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNDAtMS0xLTEtMA_639e9003-c830-4c07-883f-c0597984374d">6,395.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNDAtMy0xLTEtMA_1e77ebaa-a100-4485-9488-6819d91787fd">6,496.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of common stock in treasury</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNDEtMS0xLTEtMA_0f1a838d-bd9d-48a6-b7a1-9e46b3cdd4cd">52.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNDEtMy0xLTEtMA_8589a315-f65e-405a-909b-10c9fad292f9">55.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Eli Lilly and Company shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNDItMS0xLTEtMA_0f8ec0ee-a6bf-4170-a295-ea85a65cb488">6,898.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNDItMy0xLTEtMA_d4ec8dd4-0412-45cf-8201-dd528b951a6d">5,641.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNDMtMS0xLTEtMA_dc16b1c7-7859-4e91-a67f-e58e294a4258">200.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNDMtMy0xLTEtMA_cbdaf687-1576-471b-958f-67f5516ee4dc">183.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNDQtMS0xLTEtMA_c5cec4f2-e4e6-46f5-beae-1a937d9b975d">7,099.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNDQtMy0xLTEtMA_a6649690-4901-4147-a160-beffc79b0ae0">5,825.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNDUtMS0xLTEtMA_30ec29c8-6ed0-4486-9a97-10ec81476ee2">46,838.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNDUtMy0xLTEtMA_8391f9c8-ea95-4c2b-8afc-3442797380ac">46,633.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated condensed financial statements.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Condensed Statements of Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELI LILLY AND COMPANY AND SUBSIDIARIES</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:23.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.517%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.760%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Equity of Eli Lilly and Company Shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(Dollars in millions and shares in thousands)</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Employee Benefit Trust</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common Stock in Treasury</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Noncontrolling Interests</span></td></tr><tr style="height:11pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5bce3a2756434f739e7c3845a02a47cf_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMy0xLTEtMS0w_9c1b04ea-872d-4a06-afe7-fc4e379fe744">958,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bce3a2756434f739e7c3845a02a47cf_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMy0zLTEtMS0w_5ce40ca3-4adf-41de-ba30-eff791195989">598.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ffc5bab7133436682aff62ddec1e376_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMy01LTEtMS0w_8b4ed52b-d8a9-4996-bce0-f6f74f0c4b93">6,685.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i957ad33ccc1240e3948e9f141963844f_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMy03LTEtMS0w_e445cf97-c62d-41ac-9b33-3826bbed0dc9">4,920.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f3109e398cb4ebe87fb955a863b8ede_I20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMy05LTEtMS0w_fb52eddc-d19f-499d-a27e-fe55841bf227">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46e5e55c87bf4c9285d8bfe7ce6fd6d3_I20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMy0xMS0xLTEtMA_c9b95bb8-785b-4ce8-85b2-2e7ef11d1695">6,523.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i932abea342a94c46a25f33f1c8acc500_I20191231" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMy0xMy0xLTEtMA_7e73863e-9cb2-4626-b057-57e3085d9eb7">530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i932abea342a94c46a25f33f1c8acc500_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMy0xNS0xLTEtMA_896c20ea-1137-46b1-b06d-3cfc73c9a19c">60.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdecec535fa14d78b9ef123144efa368_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMy0xNy0xLTEtMA_4020e14d-dd44-48ad-a24c-18016e40e376">92.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7db1dc190e2453aba10749ea47cfdb0_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfNC03LTEtMS0w_061c9e8d-e6f4-4340-af12-8f82b634b072">1,456.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eee151cb0194a7c9d3cdf6eaece9015_D20200101-20200331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfNC0xNy0xLTEtMA_f6557702-9e71-4c8e-9da5-1296046877ca">26.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcf85b46974c4de78d45cca588cdb257_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfNS0xMS0xLTEtMA_98ca8388-f71b-4f97-8a7a-32a63cd7130c">362.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Retirement of treasury shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4f89a4953ed54302a07fe2fd0dc4e36b_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesRetired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfNy0xLTEtMS0w_8bab93fd-bc14-4b2f-8243-0d9167876dd8">3,627</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f89a4953ed54302a07fe2fd0dc4e36b_D20200101-20200331" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfNy0zLTEtMS0w_6bb74d66-56d6-4e79-83ed-019a0b014199">2.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7db1dc190e2453aba10749ea47cfdb0_D20200101-20200331" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfNy03LTEtMS0w_145a0233-bcbf-4f90-baaa-f63a1c879372">497.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i610527f799c444f999e77fc61f00e502_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesRetired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfNy0xMy0xLTEtMA_fa34a8c6-acd0-4dd6-b1f0-f8bf46aa4b63">3,627</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i610527f799c444f999e77fc61f00e502_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfNy0xNS0xLTEtMA_588282b7-d96e-49e6-b9b3-6a61a0e391a6">500.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchase of treasury shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i610527f799c444f999e77fc61f00e502_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfOC0xMy0xLTEtMA_76263621-d7db-43c7-9a4b-2c8ce236b352">3,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i610527f799c444f999e77fc61f00e502_D20200101-20200331" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfOC0xNS0xLTEtMA_cb394133-c64f-4a76-8f37-d79b3621fe3c">500.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of stock under employee stock plans, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4f89a4953ed54302a07fe2fd0dc4e36b_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfOS0xLTEtMS0w_f1ee94fa-5aa6-4b96-b149-edd2ede0336e">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f89a4953ed54302a07fe2fd0dc4e36b_D20200101-20200331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfOS0zLTEtMS0w_ccf810f7-601c-4236-8d4c-f9e538d5295e">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86f7f5436d51421a8501779a09dd82ab_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfOS01LTEtMS0w_d3f2ec52-6485-44cd-94ad-82147ff606fd">201.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i610527f799c444f999e77fc61f00e502_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfOS0xMy0xLTEtMA_c510d9f3-bc28-4070-8865-f7a0fe2dbd73">43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i610527f799c444f999e77fc61f00e502_D20200101-20200331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfOS0xNS0xLTEtMA_062c3330-5553-4be1-aa49-20efe7e43411">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86f7f5436d51421a8501779a09dd82ab_D20200101-20200331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTAtNS0xLTEtMA_7c1614b3-2d10-46d8-91e3-2c010e71c751">71.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7db1dc190e2453aba10749ea47cfdb0_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTMtNy0xLTEtMA_2c25eb19-bad4-4277-b227-e28d5d92621e">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i2eee151cb0194a7c9d3cdf6eaece9015_D20200101-20200331" sign="-" xsi:nil="true" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTMtMTctMS0xLTA_e7d28129-b3a8-47dc-8c13-25ab5d8ee729"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at March 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id525ea543ffc4ac699696ae6133c1a3f_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTQtMS0xLTEtMA_a1efb309-54ae-4022-9d60-41ba30c599be">956,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525ea543ffc4ac699696ae6133c1a3f_I20200331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTQtMy0xLTEtMA_6aefc5f1-297a-4155-978b-c3f81077f45e">598.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie25f9462d4864ec48a45f240362e710e_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTQtNS0xLTEtMA_1fc861ef-e719-4608-a8e6-5d9b97a44c4a">6,556.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e1e492a833a4874b74b3fb0b7f96fa5_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTQtNy0xLTEtMA_98830ab4-71fb-407f-8cde-864d345bb8cf">5,879.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id163dac405614d4ab0aab11d9539c9a8_I20200331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTQtOS0xLTEtMA_a167bd24-69ba-41ba-afda-bbf93b82b7c1">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife78f2b5881b4ab594c089c77d07dfdd_I20200331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTQtMTEtMS0xLTA_e882d840-3e3b-4741-99e8-066e76382c23">6,885.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4a5e6fba402d49eda6d65097c72bd64e_I20200331" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTQtMTMtMS0xLTA_60b33594-c5f1-4c72-8b2c-f2c91e7eae87">487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a5e6fba402d49eda6d65097c72bd64e_I20200331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTQtMTUtMS0xLTA_02e5eef2-b0a6-47ee-8ec3-455237f458df">55.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a2504bfe86b4fe3905a4c1dd6e8a31a_I20200331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTQtMTctMS0xLTA_264fb1be-6682-4895-850f-737d7443e544">118.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib44d59353e664823911abf62eca2a0ec_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTYtMS0xLTEtMA_6364214a-064b-4e14-8ea5-e4ab5d6cbeca">957,077</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib44d59353e664823911abf62eca2a0ec_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTYtMy0xLTEtMA_43ea76a6-364f-4f91-809d-4562c757f477">598.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc56172f5f014bb48f88ac5499c1c0c8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTYtNS0xLTEtMA_336e9203-62f3-4643-bbf0-064f47f20caf">6,778.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60d84be3db5c4d85abc4b594cd075e4e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTYtNy0xLTEtMA_7abb21c8-7bf3-4214-ac06-b9f071dac6ce">7,830.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idcdf0da7a8b34a378831b2abf856ab11_I20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTYtOS0xLTEtMA_0fde597f-1d4e-459a-9cc4-bf63677962e4">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0582a765e6944e928d84c3bf2f09767c_I20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTYtMTEtMS0xLTA_eaf3c92a-ed87-4dac-a63f-6b53a6e6d2a2">6,496.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaaf707b56bb5401397f3d1be8be7a6da_I20201231" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTYtMTMtMS0xLTA_75b3c8b2-21ed-4ad7-aabc-e741d28250b3">487</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaaf707b56bb5401397f3d1be8be7a6da_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTYtMTUtMS0xLTA_ff57fea3-796e-44c4-89ea-0f44504b2776">55.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia85d98868ecb4c1d9f33581b32035094_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTYtMTctMS0xLTA_d30ea7f3-281c-4efb-9ba2-b0809b98bdd1">183.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i002f042f1d494e298177c727853e4883_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTctNy0xLTEtMA_883c9ba3-03f2-4b07-9836-0f25eff17743">1,355.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0d38013f7a5421cab5b95d3ca766cc6_D20210101-20210331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTctMTctMS0xLTA_9349dda0-e39a-4217-b527-76e1dc5b4888">16.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6e502d3f77649d3b4966205297947db_D20210101-20210331" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTgtMTEtMS0xLTA_6acfa60a-464f-4735-8c2b-559ac2392fd9">100.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of stock under employee stock plans, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5aa2dbcea11b45b1bc31588610d72e1a_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjItMS0xLTEtMA_6b4a8131-b98e-4717-be4d-30549319d681">2,405</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aa2dbcea11b45b1bc31588610d72e1a_D20210101-20210331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjItMy0xLTEtMA_a5b62b9c-0d44-4684-aa93-f61bc6c852af">1.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2c1d39a9337457d82ae76c6cc3e027a_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjItNS0xLTEtMA_fe592fd7-c0d6-4ac8-bac4-daecc8749730">283.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic2d8de6d89ca4b36831a2fad2f21e997_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjItMTMtMS0xLTA_ed2669e1-f56f-4a0f-90c2-8b8e603ce075">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2d8de6d89ca4b36831a2fad2f21e997_D20210101-20210331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjItMTUtMS0xLTA_750ec208-8831-46fe-ab4b-fd9f77971ab1">3.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2c1d39a9337457d82ae76c6cc3e027a_D20210101-20210331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjMtNS0xLTEtMA_a9ae4bd5-d1d0-4fcf-b7d4-7d1732ea9fc4">85.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2c1d39a9337457d82ae76c6cc3e027a_D20210101-20210331" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjQtNS0xLTEtMA_eff4418b-9f6e-4bea-97c2-66bc61fbb52c">0.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i002f042f1d494e298177c727853e4883_D20210101-20210331" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjQtNy0xLTEtMA_153cde31-f440-455a-9b6e-dd4598b71513">4.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0d38013f7a5421cab5b95d3ca766cc6_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjQtMTctMS0xLTA_146a58fe-01e5-40bd-9725-d358cf6e8aa6">0.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i717123173f4f4d45a26fc171fcef135f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjUtMS0xLTEtMA_0519d9a4-9de4-43ca-b1e8-17e424dc890c">959,482</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i717123173f4f4d45a26fc171fcef135f_I20210331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjUtMy0xLTEtMA_9e192271-604d-4b0f-bcd8-5fee2a23d64b">599.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19ffbb6496914f979518c442d56ddfdc_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjUtNS0xLTEtMA_a5912e6a-35a9-44fc-b9e9-96d1b1b8ce8c">6,579.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95ec94014ed412d9ddf912309b31906_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjUtNy0xLTEtMA_e098123b-d178-4987-bbdc-250e984fa2de">9,181.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i336e60271cdd431887ad40e2953cb881_I20210331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjUtOS0xLTEtMA_c9d9f0ed-8cbc-4642-92a2-33f72e9abcd3">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fa9dfe55240c8904822bb89d5d580_I20210331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjUtMTEtMS0xLTA_62f91c8d-d804-4763-890d-d11c3067fc2b">6,395.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia54f7cb622be43a6a63855f304e93c8a_I20210331" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjUtMTMtMS0xLTA_85488785-e26b-45f8-b3c8-8d6b78d135e6">463</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia54f7cb622be43a6a63855f304e93c8a_I20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjUtMTUtMS0xLTA_e46dcc18-cf01-4074-9b97-4f814d5cf7f1">52.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b0151dc1fa445c680975efcbdc26506_I20210331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjUtMTctMS0xLTA_b204493d-1f36-497c-9d6b-8cfe503871da">200.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> <ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RleHRyZWdpb246YTMwNDZiY2ZiZjAyNDg5N2FmN2ViMWVmZmE2NzMzMmZfNDIz_c5e5909a-8548-407b-aee5-ee9ea5f20454" footnoteRole="http://www.xbrl.org/2003/role/footnote">As of March&#160;31, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RleHRyZWdpb246YTMwNDZiY2ZiZjAyNDg5N2FmN2ViMWVmZmE2NzMzMmZfMTI3_f031e19e-8127-4a8f-8d2a-c700b0d97016">1.00</ix:nonFraction> billion remaining under our $<ix:nonFraction unitRef="usd" contextRef="ice5b008047fc4f969d378bc0e8f5337b_I20180630" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RleHRyZWdpb246YTMwNDZiY2ZiZjAyNDg5N2FmN2ViMWVmZmE2NzMzMmZfMTUw_d403757c-0ecd-4915-a9d9-f760002d89a4">8.00</ix:nonFraction> billion share repurchase program authorized in June 2018.</ix:footnote> </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated condensed financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Condensed Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELI LILLY AND COMPANY AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Operating Activities</span></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMy0xLTEtMS0w_ae7ee78c-bc2a-4a56-8162-6b0384fdf98f">1,355.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMy0zLTEtMS0w_f158bb6a-1289-4b50-9341-e6fd06c0b0c5">1,456.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfNi0xLTEtMS0w_899d8243-13d3-49a8-baab-59805438dc16">350.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfNi0zLTEtMS0w_45fb5017-a964-4749-b022-4336855051c5">273.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfNy0xLTEtMS0w_c5a37435-e612-4242-a7d3-6fda0e8ea615">119.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfNy0zLTEtMS0w_44d0fa7a-9262-4e7a-8b74-2c1d160feb2e">11.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfOS0xLTEtMS0w_289e0aec-9861-46d1-854a-c93c7a316019">85.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfOS0zLTEtMS0w_3928ef4b-17e2-4e5d-a12c-2653d5e524a7">71.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:GainLossOnInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTEtMS0xLTEtMA_6c502d6e-b3e4-45a6-93c5-b341df7383e2">302.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:GainLossOnInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTEtMy0xLTEtMA_27208db8-e473-4ff6-9fad-e29823183e0b">186.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development (Note 3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTItMS0xLTEtMA_d69046f9-685d-4939-9370-816b77c86a76">299.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTItMy0xLTEtMA_5da87cc2-3e07-4dac-8cb3-0ca427a092cf">52.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other changes in operating assets and liabilities, net of acquisitions and divestitures</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTMtMS0xLTEtMA_edd17af3-f84f-4e30-8c38-95163872eeeb">102.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTMtMy0xLTEtMA_353f55d6-c299-4b0e-b96c-7ae59d5fc2df">1,408.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-cash operating activities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTQtMS0xLTEtMA_2206b6ad-6444-4caf-b752-c62fcac9b413">131.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTQtMy0xLTEtMA_f015a202-6238-41b2-90ac-d8cf5a56bf5e">111.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Cash Provided by Operating Activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTUtMS0xLTEtMA_9871c9fb-7ff5-4e79-9516-056db5f18943">1,697.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTUtMy0xLTEtMA_02557f3b-a2d5-4f74-967a-7cda6a90d707">382.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Investing Activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTctMS0xLTEtMA_ea76a953-9d1b-4e58-9ab4-894286ac61cf">300.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTctMy0xLTEtMA_862e91fe-247d-4537-ac49-1f418013ad0a">258.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTgtMS0xLTEtMA_0c2b1814-56c6-49a6-bb3a-b300096af45f">4.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTgtMy0xLTEtMA_f50132f9-410a-4b26-bac0-6925aea9f013">36.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTktMS0xLTEtMA_d4860695-0b8e-4d98-821b-0da7602614c4">19.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTktMy0xLTEtMA_fd3db003-2441-4469-8ee0-aa4025160ec0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales of noncurrent investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:ProceedsFromSaleOfLongtermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjAtMS0xLTEtMA_a2daba93-2536-49c9-8501-8081497c690e">284.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:ProceedsFromSaleOfLongtermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjAtMy0xLTEtMA_9656bcf8-0fed-41e7-9d33-192783cb3f99">54.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of noncurrent investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsToAcquireLongtermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjEtMS0xLTEtMA_ad1fdbe8-fdf7-48fa-bbb0-b37192a6622d">291.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:PaymentsToAcquireLongtermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjEtMy0xLTEtMA_ad5b0792-48d0-4aa0-bb2a-9a58065a35d0">83.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for acquisitions, net of cash acquired (Note 3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjItMS0xLTEtMA_71e42b07-63bf-494b-a7b6-8b25546e0d90">747.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjItMy0xLTEtMA_35952610-324c-45b7-9ca4-89e51ef4a9ab">849.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of in-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="lly:PurchasedInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjQtMS0xLTEtMA_dd3195b0-1a74-4524-a625-ce8f9e25d894">191.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="lly:PurchasedInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjQtMy0xLTEtMA_87988fb2-237a-459a-9868-912b8de8e45c">13.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investing activities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjUtMS0xLTEtMA_d577ec7a-7cd0-4309-8d48-15dcc3ea5846">21.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjUtMy0xLTEtMA_9f7f2452-e907-4ea4-974b-1cc804a04046">51.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Cash Used for Investing Activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjYtMS0xLTEtMA_db111105-b95e-4418-a567-252f99a4f5ae">1,283.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjYtMy0xLTEtMA_e8baff8e-15f8-470c-b669-fab0965698e1">1,060.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsOfDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjgtMS0xLTEtMA_d3e8f006-e6c5-439e-a21c-6a2f1dbf2f41">774.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:PaymentsOfDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjgtMy0xLTEtMA_7eac4258-65f4-477c-b3d2-5e9c0ad9d66e">671.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in short-term borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:RepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjktMS0xLTEtMA_ff8f3835-9afd-4747-abdf-43eb11be0a69">3.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjktMy0xLTEtMA_980128f1-cb67-42c3-8f93-236c77fce4d6">1,748.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayments of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMzEtMS0xLTEtMA_252516be-9ad6-4b33-a9a3-6115af6854be">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMzEtMy0xLTEtMA_715cab77-5188-4b46-b3d5-2254e2ccccca">276.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMzItMS0xLTEtMA_0bcaec84-4534-4129-a36d-8248dbd3df6e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMzItMy0xLTEtMA_75c398ce-1ad4-4696-9a32-dd934c3f96cc">500.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other financing activities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMzQtMS0xLTEtMA_b265bb6b-3b03-4af4-ab0f-15918d9f82d9">279.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMzQtMy0xLTEtMA_d2fb53c3-da61-44ef-bc78-e7ae3b2216ce">194.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Cash (Used for) Provided by Financing Activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMzUtMS0xLTEtMA_768671b4-a1cf-4af2-9214-71dfa20f6d83">1,058.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMzUtMy0xLTEtMA_c5fa09a2-23af-4249-93b2-899c00bbfdc0">106.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMzYtMS0xLTEtMA_3d063542-ea23-41b9-89b3-79d7274c33bb">10.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMzYtMy0xLTEtMA_204c10d1-cb08-417a-a74d-f1229c65e219">66.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMzgtMS0xLTEtMA_0804902c-2f69-4417-a853-8139e4858909">654.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMzgtMy0xLTEtMA_1d836a92-775c-47fe-820f-039a1cfacaa7">638.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at January&#160;1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMzktMS0xLTEtMA_aee31920-0162-4fa0-aed1-d404307d4974">3,657.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea0fcbeedbfb4018b173fba695dd9fc7_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMzktMy0xLTEtMA_10ae2936-d0bb-453f-861d-9b269eaf4005">2,337.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and Cash Equivalents at March 31</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfNDAtMS0xLTEtMA_3b4ae334-c242-4ec8-a83a-e7d10052e40b">3,002.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dd152b8ae7b497f800f65a679736686_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfNDAtMy0xLTEtMA_d7f7f66a-9b33-44ab-9a42-55af35b3a70c">1,699.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated condensed financial statements.</span></div><div style="margin-top:9pt"><span><br/></span></div><div style="margin-top:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Condensed Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Tables present dollars in millions, except per-share data)</span></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_37"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1: <ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zNy9mcmFnOmViNDAyMmNkMGRiMTQ3MGY4MDYyMThhNzc2ODBmMjBlL3RleHRyZWdpb246ZWI0MDIyY2QwZGIxNDcwZjgwNjIxOGE3NzY4MGYyMGVfMjc1Mw_3fb1f345-b9e4-4a93-9eba-3c4a64f1819f" continuedAt="ia466a7485e494f25bde27141d8733768" escape="true">Basis of Presentation </ix:nonNumeric></span></div><ix:continuation id="ia466a7485e494f25bde27141d8733768"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have prepared the accompanying unaudited consolidated condensed financial statements in accordance with the requirements of Form 10-Q and, therefore, they do not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). In our opinion, the consolidated condensed financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for a fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our consolidated financial statements and accompanying notes included in our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2020. We issue our financial statements by filing them with the Securities and Exchange Commission and have evaluated subsequent events up to the time of the filing of this Quarterly Report on Form 10-Q.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis, that is, based on the weighted-average number of common shares outstanding plus the effect of incremental shares from our stock-based compensation programs.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide. A global research and development organization and a supply chain organization are responsible for the discovery, development, manufacturing, and supply of our products. Regional commercial organizations market, distribute, and sell the products. The business is also supported by global corporate staff functions. Our determination that we operate as a single segment is consistent with the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods.</span></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2: <ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RleHRyZWdpb246ZTYyZjZlZTEwMTg1NGZhN2IxN2NjNWZjNDU1ZjVhNGRfMzM4MA_cc163449-fa82-412a-bdac-5ea120741e96" continuedAt="id6d2f14c7b96409c963ae83958d9ec09" escape="true">Revenue</ix:nonNumeric></span></div><ix:continuation id="id6d2f14c7b96409c963ae83958d9ec09" continuedAt="i5ddc236a48f34365b503b4aceff610fc"><ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RleHRyZWdpb246ZTYyZjZlZTEwMTg1NGZhN2IxN2NjNWZjNDU1ZjVhNGRfMzM3OA_298eb2a7-7132-4b14-92b7-0934812fbef6" continuedAt="i8080887e51394ba18b07f4e0f5622673" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue recognized in our consolidated condensed statements of operations:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b961987b212484fba2e55e3f8599292_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjRmMmJmMTRjYjNkMTRmYzlhOTMyMTdkYjIzMWFhNzk5L3RhYmxlcmFuZ2U6NGYyYmYxNGNiM2QxNGZjOWE5MzIxN2RiMjMxYWE3OTlfMi0xLTEtMS0w_03785b25-56a0-4de7-9429-0c09b0fe5ab5">6,320.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00e2ad623e9f4f09a525954c7be34a38_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjRmMmJmMTRjYjNkMTRmYzlhOTMyMTdkYjIzMWFhNzk5L3RhYmxlcmFuZ2U6NGYyYmYxNGNiM2QxNGZjOWE5MzIxN2RiMjMxYWE3OTlfMi0zLTEtMS0w_933928b0-4b7d-46c5-8150-d6ada1d5d9e1">5,403.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration and other revenue </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib696b72b79fd4a64a05a14552524fd57_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjRmMmJmMTRjYjNkMTRmYzlhOTMyMTdkYjIzMWFhNzk5L3RhYmxlcmFuZ2U6NGYyYmYxNGNiM2QxNGZjOWE5MzIxN2RiMjMxYWE3OTlfMy0xLTEtMS0w_abeffc77-ed9f-49a2-921b-99f934035343">485.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9bcfbde64cf4e6885eff068fd1c0181_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjRmMmJmMTRjYjNkMTRmYzlhOTMyMTdkYjIzMWFhNzk5L3RhYmxlcmFuZ2U6NGYyYmYxNGNiM2QxNGZjOWE5MzIxN2RiMjMxYWE3OTlfMy0zLTEtMS0w_b5f92ba6-f837-44bb-af82-4c369008a91e">456.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjRmMmJmMTRjYjNkMTRmYzlhOTMyMTdkYjIzMWFhNzk5L3RhYmxlcmFuZ2U6NGYyYmYxNGNiM2QxNGZjOWE5MzIxN2RiMjMxYWE3OTlfNC0xLTEtMS0w_e2466254-4b1c-42d5-84e3-adb2cd00661d">6,805.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjRmMmJmMTRjYjNkMTRmYzlhOTMyMTdkYjIzMWFhNzk5L3RhYmxlcmFuZ2U6NGYyYmYxNGNiM2QxNGZjOWE5MzIxN2RiMjMxYWE3OTlfNC0zLTEtMS0w_346c0333-f621-411c-8941-80d8dc8eb8a3">5,859.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Collaboration and other revenue associated with prior period transfers of intellectual property was $<ix:nonFraction unitRef="usd" contextRef="i3a64fdc1a7fc44278f9cf486b1d6c7cf_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RleHRyZWdpb246ZTYyZjZlZTEwMTg1NGZhN2IxN2NjNWZjNDU1ZjVhNGRfMjM4_5b90024e-dd78-49cb-b2a9-0cdd52c79720">43.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i38bd7b2a836c4d14abc0e95512ba56c5_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RleHRyZWdpb246ZTYyZjZlZTEwMTg1NGZhN2IxN2NjNWZjNDU1ZjVhNGRfMjQ1_a2540f76-d446-46f1-bec0-a2e20ace801d">35.4</ix:nonFraction> million during the three months ended March&#160;31, 2021 and 2020, respectively.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements includes our share of profits from the collaboration, as well as royalties, upfront and milestone payments we receive under these types of contracts. See Note 4 for additional information related to certain of our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue from the Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trajenta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> families of products resulting from our collaboration with Boehringer Ingelheim discussed in Note 4. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Adjustments to Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to increase revenue recognized as a result of changes in estimates for our most significant United States (U.S.) sales returns, rebates, and discounts liability balances for products shipped in previous periods were less than <ix:nonFraction unitRef="number" contextRef="i0b2a402409bd47ceb3efc76f535f0984_D20200101-20200331" decimals="2" format="ixt:numdotdecimal" name="lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RleHRyZWdpb246ZTYyZjZlZTEwMTg1NGZhN2IxN2NjNWZjNDU1ZjVhNGRfMTA5OTUxMTYzMjUyNQ_64f45f88-44e1-419f-b95c-9b78b4662655">2</ix:nonFraction> percent of U.S. revenue during the three months ended March&#160;31, 2021 and 2020. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contract Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract liabilities result from arrangements where we have received payment in advance of performance under the contract and do not include sales returns, rebates, and discounts. Changes in contract liabilities are generally due to either receipt of additional advance payments or our performance under the contract. </span></div><ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RleHRyZWdpb246ZTYyZjZlZTEwMTg1NGZhN2IxN2NjNWZjNDU1ZjVhNGRfMzM5Mg_a20590c0-f11a-4876-b466-d92fce9f433f" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract liability balances:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.276%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjI0ZTcwNzA2YTA0MjQxM2E4YTE4Njc5ZjI2NGU4M2ExL3RhYmxlcmFuZ2U6MjRlNzA3MDZhMDQyNDEzYThhMTg2NzlmMjY0ZTgzYTFfMS0xLTEtMS0w_98e0a090-0409-41a6-9ae9-98b31c749fcc">346.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjI0ZTcwNzA2YTA0MjQxM2E4YTE4Njc5ZjI2NGU4M2ExL3RhYmxlcmFuZ2U6MjRlNzA3MDZhMDQyNDEzYThhMTg2NzlmMjY0ZTgzYTFfMS0zLTEtMS0w_52b8aa3b-2191-40f4-9407-b94416773d3a">276.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021 and 2020, revenue recognized from contract liabilities as of the beginning of the respective year was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.</span></div></ix:continuation><div style="margin-bottom:12pt;margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i5ddc236a48f34365b503b4aceff610fc" continuedAt="i960f332faeab45d386014048a8eb364c"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Disaggregation of Revenue</span></div><ix:continuation id="i8080887e51394ba18b07f4e0f5622673" continuedAt="i824163b5c1774b82bd45421d3163d1fb"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by product for the three months ended March 31, 2021 and 2020:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trulicity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec6120b958de4ece8b0bb1b2c92eb827_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNS0xLTEtMS0w_4f66f567-9c0a-4c9f-8128-b5251d29f0a3">1,116.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14a1f7c9c8094a24b89b05adbfa13722_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNS0yLTEtMS0w_7955e0e6-4e9f-4dd0-bb80-8c03f038c307">335.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1da1bf79aee54038ab5fb824f0b5459c_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNS0zLTEtMS0w_8319a666-4a1c-4502-ad7e-5a9199b95737">1,452.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7879b1c8e8154d82951f06d7277606ca_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNS01LTEtMS0w_86ab1026-90ea-489b-ab46-db48ee563ba7">929.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib22403656ba044288e3a7c9bd076149a_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNS02LTEtMS0w_c26c050d-7c65-480c-8c0e-573b699cc69c">299.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie60de7ffff384040bda8a7073de65757_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNS03LTEtMS0w_04113082-064a-4a2a-ba83-375e8581eb8a">1,229.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35e2453e887841ba845624286f429037_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNi0xLTEtMS0w_f5e08274-e4f7-4510-a9ef-38d7e3057cf0">332.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac9fe39efa6e493c8fc3b5a5cb61875a_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNi0yLTEtMS0w_b6bf08c3-968a-49da-8052-b0501f0f2d42">284.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12fc66e4003b4a108dafd95f3f948eae_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNi0zLTEtMS0w_020d842b-3727-431f-b1f6-39468a0b167f">617.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf36848406364477a5b09c68263549c0_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNi01LTEtMS0w_90d63d05-c14a-456f-a582-b94fc4e7c615">398.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cec2d3e8980474dba0ccd4ba2f4be53_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNi02LTEtMS0w_bb8211b0-a021-49bc-b488-f459ea381b90">297.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ac183bd15654d9ea8bfb79ecfdabc21_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNi03LTEtMS0w_17472488-fa01-4361-8d8d-547d412c09d4">695.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humulin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d5411d889ea4b0c92badda1ff003164_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNy0xLTEtMS0zNjMx_65f93c6d-1cca-49e3-9f59-332ada8a4fd7">219.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80b19d05555b462299ff41542279ba37_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNy0yLTEtMS0zNjMx_03770a81-b3dc-4328-9a11-75daa539f75d">102.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8ce72672e984dc38dbee5c4872a819f_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNy0zLTEtMS0zNjMx_eeffdfe7-4d39-4737-bf1e-abd17ef8ff56">321.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd74f7f91ca4076b9bc23d4ac7407c8_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNy01LTEtMS0zNjMx_75182754-2b34-4afa-ac3b-d49eec86db1b">214.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6cacb66e50b43a29e19d4cc6a18b475_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNy02LTEtMS0zNjMx_0d67ab58-520f-4f65-b075-84220d858c05">101.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82b9a6cc26eb4896a200c5b2d5ee6aa5_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNy03LTEtMS0zNjMx_14e7bcee-661d-4c56-bb6e-36f9a1c31d5d">315.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Jardiance </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23a99b86356248b7a363e089040850b1_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNy0xLTEtMS0w_96876aeb-d36d-454b-b8bc-814dcc1ed10f">151.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c94039dc776423e982d5e1215b9f0e7_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNy0yLTEtMS0w_07a03a6f-447b-4c2b-95b8-6761e349e362">160.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95072ac7b3c4004b82c2aac605e5d70_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNy0zLTEtMS0w_aafa8472-ae8a-4bc6-80be-9b15648fda23">312.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d3bc0a03b5400f848a8a445a06af73_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNy01LTEtMS0w_d8e2c058-6d7d-4c3c-b864-5ea1a7228f6a">144.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c9abc35851840cd80b9598eb84e59be_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNy02LTEtMS0w_4cae0cc0-9247-471f-8a9d-4804c0607ac4">122.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65808f9c08a34e2fbb20de15f09d6663_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNy03LTEtMS0w_5bd7fdb7-0e99-4719-bc21-00d331b9d6a9">267.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Basaglar</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c425bf807b4ecfb4bfc4e63113b9a5_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfOS0xLTEtMS0w_33595673-891d-46f9-a7c4-70bd0b328ad7">175.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i991e0184719242bb9681a766c00e183e_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfOS0yLTEtMS0w_f47ed12a-e32e-4385-a129-f72d431ed912">71.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6308d09ed16f45708083f216e5eb9053_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfOS0zLTEtMS0w_dbc0725d-fc85-44cd-9fd8-4b1bfe2430d3">246.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ad3a54cc6da48c7aabdfbd4ce0fd7d8_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfOS01LTEtMS0w_52650033-a694-4c97-aa1b-ef47a2b5083c">230.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97e8d103205d4d8a8ddce47720e2b0df_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfOS02LTEtMS0w_32b5f669-6b71-4b03-bec4-11314720cbfb">73.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b572a7d820847f2b77197f14a7598e9_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfOS03LTEtMS0w_5b2e845f-3e4b-4b3a-86bc-2680bbf4e4bd">303.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Diabetes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a9f92fe3be4a59bd100214c32741d5_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTEtMS0xLTEtMA_926932e5-593e-4b7f-b823-28104204d1bd">66.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab3763aca7de40e3bd3755d4afdf8ddd_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTEtMi0xLTEtMA_57fb056b-d37f-459c-8d2f-448d9d609137">94.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08fa42e2b3004f2c8d8c3d2949a77b62_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTEtMy0xLTEtMA_6f77ea1f-35a9-42dd-aafa-c90a65001536">161.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if05b79fd4afb4b3b85e0170d60701765_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTEtNS0xLTEtMA_12938704-05e5-4c98-9b39-5e62117d230b">74.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53e1ac90f1794867bdc0e1208a22454d_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTEtNi0xLTEtMA_d2cfea7b-68a1-43ab-b710-c91e566eb514">82.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5488586d175451ea3762d3e3427d7fb_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTEtNy0xLTEtMA_d64b51de-c125-4335-afca-9fc26f294da5">156.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Diabetes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6655e736bfc145ae9b61bcbd43ca3775_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTItMS0xLTEtMA_a02eec77-6333-40c3-86c9-18c580b355f8">2,061.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a511f3e56540efaf67326c58f115f8_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTItMi0xLTEtMA_0cbab2a4-4c15-4df7-a6fa-de79571bfb40">1,049.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a8600a4d0ae48ac8eb847f76d72fb39_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTItMy0xLTEtMA_c9234a1f-32e5-46f7-ae41-27f7c3d56ef9">3,111.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d683e3edb3b47769c30eadb5fc443db_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTItNS0xLTEtMA_cfe347ee-828c-4227-839b-c1b12f726954">1,991.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92a87d280ea46c88caa7e96c7a0c2c6_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTItNi0xLTEtMA_bc717e06-5720-43cf-9d94-671003e27840">977.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dc1168de1ac4bd892f4336105fe8d34_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTItNy0xLTEtMA_c51ffb0f-c259-462a-897b-e047713186c8">2,968.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Alimta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1eb5c54ee4f4ffd849c70b74454938b_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTUtMS0xLTEtMA_4b9d1937-f406-4ef4-8362-b4ad3878c888">261.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99351a29767e4c33b139db7c60592e0c_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTUtMi0xLTEtMA_b041014b-b937-4571-9868-935fd56a1d3b">297.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c035a4a36d1475c87f42c50e4fe5b66_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTUtMy0xLTEtMA_a19d5740-7f55-4a7e-bc3f-fa40b87c9d93">559.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6ff26a8f5c493bb678f8b8bdd2f5d0_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTUtNS0xLTEtMA_f47b8149-c703-46a3-97e1-7fdb4d02eb89">324.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a84f264bd5f43d18f95d6449dbfd211_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTUtNi0xLTEtMA_caf6095c-800d-4aa0-a54e-53f03654fec4">235.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ad5e6e9c6b04e0ca3a23762ff4389d4_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTUtNy0xLTEtMA_53dc05fd-0e58-4197-968b-174390ecfd61">560.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Verzenio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3895e84ece4456f9fd7475f8330b5e2_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTUtMS0xLTEtMzYzOQ_6fb149a7-b32e-4029-b23c-d8c65860c785">172.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf54072320b4a95bcc03ebf93fd790b_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTUtMi0xLTEtMzYzOQ_fe82de4d-d533-424e-ac03-4488aa9147dd">96.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a64b17a7372474b936176a48e73353e_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTUtMy0xLTEtMzYzOQ_2fe831bf-95a2-4b0c-874e-ee25f4ee2298">269.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ca44d898d14b6ba06c659cc8685067_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTUtNS0xLTEtMzYzOQ_586f8119-f23d-411e-bab7-3690733e6087">129.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec1b41e2f1c429990d5463381ccb5b2_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTUtNi0xLTEtMzYzOQ_07bd4b8c-c15d-47f9-8ee8-c3829c8fd847">58.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic305b0216fae4bc4be68a9c14511b14b_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTUtNy0xLTEtMzYzOQ_25753e2f-fb7f-44d6-9469-a4a5740f2c55">188.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cyramza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc30d8c3304846bf98d3aff4faa90db6_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTYtMS0xLTEtMA_a1e43dcf-daab-480b-933e-b8858367c67f">80.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i301b5063b45f4c778fa6be355225f1d2_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTYtMi0xLTEtMA_44f909dc-bded-4dc4-90af-62e00831ff0f">160.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ac8015a990a47ac84766a6b061f5c80_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTYtMy0xLTEtMA_124c656e-0fa3-46fd-9d3e-eb02c58aaa83">240.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice0f65e55bc14fb4a8b9c74295879c9f_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTYtNS0xLTEtMA_b08dd4d2-5cfa-4138-ac24-923a056cdf49">89.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd56efbd9ee475196495211900a4916_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTYtNi0xLTEtMA_25477350-7944-4a5f-9201-dab4b3849e69">149.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4990ade4fb749c5becfec40f273af6a_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTYtNy0xLTEtMA_f0514538-f30a-4f4f-9e66-d9386fe75291">239.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Erbitux</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc1ec2db8e1b4baa971e09c08d4342fd_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTgtMS0xLTEtMA_e892bae4-aaab-4387-b900-f69a86cfd6ad">107.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i699a1a79461d4373af3cf037c5ca77a1_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTgtMi0xLTEtMA_ec723406-69a8-450e-8401-daca49d88901">14.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbf8577a767f4b6fa45fbea9fc0008e8_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTgtMy0xLTEtMA_5a2d0784-2491-4bd5-99e3-5f2db37cda1f">122.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a65c960be0f46ebaab122d5eb8f5e3c_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTgtNS0xLTEtMA_8c37255d-902f-4885-9e28-ea339b8abaa1">117.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib410c05551594d84936a917166832ea9_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTgtNi0xLTEtMA_c758f8ee-e6a5-4cec-81cf-4977fdd964fa">13.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d36ff64df614dd2a64ea2e3cb167f9b_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTgtNy0xLTEtMA_80b4b6c3-fc00-479b-8587-88f6ed1636ed">130.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Tyvyt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if30239ae11764340af612d6d0acb2802_D20210101-20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTgtMS0xLTEtNTkwOQ_dd13c573-a839-4cdf-be82-18ed024672d9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55a39c6d0d9146729c9cbfd483622222_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTgtMi0xLTEtNTkwOQ_b1fa3217-3b4b-4488-be3c-9a95a7c78d93">109.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10cbac4f340148c58e34434fbbf2a27f_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTgtMy0xLTEtNTkwOQ_1494f895-e1dc-4797-a905-5c54a4bd2f9a">109.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a346e0ad24144caac752ea7f4355d34_D20200101-20200331" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTgtNS0xLTEtNTkxMg_730ab310-6c00-4dda-a369-75dc317202d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37c6a808e0e24c1f8e75607e3a823271_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTgtNi0xLTEtNTkxMg_0f70f948-9ad1-4927-a458-413ccdf9f113">57.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3156015f19b4add93eceadb6f839944_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTgtNy0xLTEtNTkxMg_c2095b64-e688-40c2-a2c4-425ccf0506cd">57.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Oncology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16d7bf43c3214967ae1523ebc568940c_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTktMS0xLTEtMA_e3821a8e-0522-4d9c-ae02-c470701ee86e">20.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a1925d8bba04bf5a88ae7c5a2c5a30e_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTktMi0xLTEtMA_4a13c13b-011a-4f81-9958-3b706f8fa620">51.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65134b9feaf3468bae4f56eb446cc39b_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTktMy0xLTEtMA_6d72189b-6ae0-4552-b604-9c3ac0ade6dd">71.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b08818da51f405ab315d6a7b99fcdb8_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTktNS0xLTEtMA_021d56da-a8f7-4857-853c-7f4c7b0b1cf6">2.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f8df345856f4facb882054634c50249_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTktNi0xLTEtMA_3ca7b4cd-f2dd-4e26-bc4c-ff99aa9515b4">28.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b44fc5413ea4394a3af4e9ae8cc9357_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTktNy0xLTEtMA_45bd42f8-67c4-4009-8b9b-79362f426b07">26.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Oncology</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6c1690f2a1044549cd196b5d0d49bad_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjAtMS0xLTEtMA_d62dbc9b-63d6-40ef-bd33-d5d6b43d7120">642.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f2094304a9b41efa6498348dc920bd5_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjAtMi0xLTEtMA_f39017a6-86f6-4f77-96b8-54b72a79a22e">729.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb5bb5fcf05439eafdaafbbf45b94dc_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjAtMy0xLTEtMA_3efabe92-683f-4d77-9f06-5ece818aca4c">1,372.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if46aa3d35d9f4f9e9f98c940d7063f27_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjAtNS0xLTEtMA_207a841e-6a29-493c-a10c-a6be02b90d7d">657.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27ef923c97994ad09a5131b38a10eff2_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjAtNi0xLTEtMA_48fb196d-b7f8-4e0b-921a-7be87b6aba7b">543.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22ac5026b0df4c01a41cbb9fd7bf0ed4_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjAtNy0xLTEtMA_556d4b96-7732-49d7-9eb3-9eb503c906a7">1,201.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunology:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Taltz</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e7b860d15e24b6d8a4c42caa07a07e9_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjMtMS0xLTEtMA_821a1405-f33e-438a-875c-db72c58fbc51">249.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9d2acfb73014f21b93868d591ba0055_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjMtMi0xLTEtMA_9a1ade00-ee6a-4490-b4ff-cc840a222285">153.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic86716e51463478c9178d57dbc0df5e9_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjMtMy0xLTEtMA_7b833611-ad34-40b6-8565-e2cc8bcc0cea">403.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eca7f391c9c4eb4bf1be4d2f78c64f1_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjMtNS0xLTEtMA_e245bfb9-d929-4354-9bd7-1d42774957d0">327.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23a06e4fd12547b68a8c1fa847a573cd_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjMtNi0xLTEtMA_b28c6d9c-c21c-41dc-b5d0-47a2ba434d18">116.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cdd8652ee714626a6ac6694e023589f_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjMtNy0xLTEtMA_ab1185d0-0961-41f9-8a95-52888c0756cc">443.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Olumiant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe710610bc2745d6b62b94d3e5a59c49_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjQtMS0xLTEtMA_9e543814-3451-44fb-973b-c0ed60e63dd6">24.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5195f2602fa4de78f56cde487a199e9_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjQtMi0xLTEtMA_4d810de1-2f5f-42f5-bcb4-a82d890e20a8">169.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id181bab5e80145f7b4aac52329fa68c0_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjQtMy0xLTEtMA_43dfdcb5-e735-4121-ad47-147da4f5a662"><ix:nonFraction unitRef="usd" contextRef="id181bab5e80145f7b4aac52329fa68c0_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjQtMy0xLTEtMA_ba60441b-b236-48e2-9d7f-ff80305eb163">193.8</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e4a642cedfe46019dbf6bdbe6fbe49e_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjQtNS0xLTEtMA_1f7cad31-7de3-4f61-b43b-386a96321e7a">11.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c451df337849a9aa0ebbd6efa659e5_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjQtNi0xLTEtMA_5f9beb2b-cffd-4dae-996d-bcb53c4c5b86">128.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c5697fd7da74cdbb6d77c6a62017381_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjQtNy0xLTEtMA_72d5363b-b180-417d-b6c7-91b3343689d9"><ix:nonFraction unitRef="usd" contextRef="i6c5697fd7da74cdbb6d77c6a62017381_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjQtNy0xLTEtMA_eff31ee2-fe9a-417e-9b48-e79b1e0348ce">139.7</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Immunology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5d69a9f098946b99fd0dc8d1e98e66a_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjUtMS0xLTEtMA_8daf5991-22ef-48a0-8471-ffc68d24bec8">10.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d569029e59948f09619b73bf0efdca2_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjUtMi0xLTEtMA_0e64a3b5-21ed-4a2f-91d5-028001e680d8">6.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ec2c9c0bb35428e84cb57a3987f75e0_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjUtMy0xLTEtMA_d88ee19d-b17a-440c-8274-0c2591d1119e">16.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida0989eec65245df9b1682cf38ed4bd2_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjUtNS0xLTEtMA_eb9d6fc3-bed2-4a79-aa4e-e45e895a4220">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bc0464b0bdb43f5a8e902cdb4b263da_D20200101-20200331" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjUtNi0xLTEtMA_92a84263-a5df-46e5-b0d4-a8947cea3aaf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8cb347768764c2b955eac4a8f4a17ad_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjUtNy0xLTEtMA_2eff3293-2a61-4971-b25a-9166f6b56ee3">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Immunology</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98c884b95b7b4a8493c13f83a7b6caa7_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjYtMS0xLTEtMA_6d5b2d5f-8334-4484-bc00-1cb47c3576b1">284.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c53c31a3a5c43e680ca9bf03cd18bab_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjYtMi0xLTEtMA_2bb5d873-800b-403d-972c-86c6d680cbb5">329.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f23306ae00143a6a4003c6797529b59_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjYtMy0xLTEtMA_a395506b-e34e-4b22-9107-01577b0a6eca">613.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6964e815afd40a1a706fd094d27e141_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjYtNS0xLTEtMA_c96d7e64-4aff-40cb-9424-c6a24499364f">341.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ff073cd832f489a918e71ed9f2bc601_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjYtNi0xLTEtMA_92e8db33-91f8-4811-80dc-660bcc762e95">244.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaab0628ba61471db8a691d30a7a5ae6_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjYtNy0xLTEtMA_03583474-a9e5-4836-9303-3471aeae8d96">585.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cymbalta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6540e5cb4f94023bd8a1a99cae7dd50_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjktMS0xLTEtMA_1709741e-a5c7-437c-8cbf-9812972e95e5">11.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0244d48c6684b1d90aaffa07334e12c_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjktMi0xLTEtMA_377c945d-0c51-402b-b471-64631d0eb054">165.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a035aacb6aa496e9aacfa82670a5f77_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjktMy0xLTEtMA_aa7d3802-acbb-4c50-a36d-8ff9f7c90599">176.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2126f23f1b6c45da8eda485ea4fb0ffd_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjktNS0xLTEtMA_9e1e9b22-fda7-475e-8582-e40580488905">11.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i476ff2f62e6e4dcd89e4d0e6f6e2e23a_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjktNi0xLTEtMA_e81f2805-12ac-457f-9502-c33d3bd09114">198.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd995ff940774cf9958d9496ccefdd49_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjktNy0xLTEtMA_1c33885e-dfd8-4327-b85a-47194c584e1c">210.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Emgality</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91bb5aef62c64ba6b7374026ad6cb167_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjktMS0xLTEtMzY0Nw_a7e20e58-02e0-478e-8040-b75b11d1b42d">101.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc1a4bfd08874c51bd52ae124d146ed1_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjktMi0xLTEtMzY0Nw_fdc60b3a-825d-416c-a68c-2e28976a2af1">18.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d060a91a83540adba28a86e89f8a0a9_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjktMy0xLTEtMzY0Nw_87d3660d-5c73-4ab8-af0c-4b9e97561451">119.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ead156d8e30415e96ef9f5d2ae30817_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjktNS0xLTEtMzY0Nw_468e6097-73e2-485f-962f-e485d6fc19a4"><ix:nonFraction unitRef="usd" contextRef="i7ead156d8e30415e96ef9f5d2ae30817_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjktNS0xLTEtMzY0Nw_ec2bdabf-07de-46f0-9126-e195a820151c">67.3</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1019c9ffdc464664a457a1558f80f5c1_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjktNi0xLTEtMzY0Nw_68cc054c-472c-4e86-ba72-7d30c5262036"><ix:nonFraction unitRef="usd" contextRef="i1019c9ffdc464664a457a1558f80f5c1_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjktNi0xLTEtMzY0Nw_de70a077-08ed-49c6-9944-08a28e4fbe48">6.7</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d28979d157949e8beda765ff3ebba18_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjktNy0xLTEtMzY0Nw_5cb3666b-706e-4437-b613-183f14e15ba5">74.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Zyprexa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59a5e3ece3b2457d9dc9503670f62a19_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzAtMS0xLTEtMA_14b3a014-62b6-4f30-824c-3281b096a49b">6.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcb95436aea141439b320a672d06798b_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzAtMi0xLTEtMA_6556d913-23e3-4039-a647-94131b19b45b">88.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbdb540b92834be9a1952a6988efe111_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzAtMy0xLTEtMA_537d2206-f07a-4fd0-b455-5b4712c4a9fe">95.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5ec8f6c1a2745b6aef8220c52179da0_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzAtNS0xLTEtMA_2a898070-554b-49a4-90a7-8834f3abfb70">11.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdac2859144646f497bdee29d8f1077c_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzAtNi0xLTEtMA_5965c6b7-a80d-49f5-8169-b104d98022f3">87.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ecf74960c9f4004bfb28db9ceeee105_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzAtNy0xLTEtMA_d1286232-001d-496d-9ea9-184f578d75e9">98.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Neuroscience</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe3a395375b74608adcd0dcb2511ccb6_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzMtMS0xLTEtMA_cabd0fa4-bc12-40c0-8aad-b0de68273fde">22.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e845118c19743509f235e3de1249c91_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzMtMi0xLTEtMA_2507100c-1886-4840-b16d-183d3cbc4541">51.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i956b8eaf8bcc48e18a6392d104e3f82f_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzMtMy0xLTEtMA_fc8b4dd9-aaba-4637-b01d-dc14a57f26fe">73.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f802e7b0b4c462498edd33fe1a08df8_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzMtNS0xLTEtMA_d5c8f589-9d63-468f-93bd-a9f31322c4dc">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41bf8c2f57c2453187f38f71658035fd_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzMtNi0xLTEtMA_ecec1dcc-bca2-4e5b-9fdc-44e0c771ae8d">60.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccd1e7bf99a04464a2be5ae2844e93c3_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzMtNy0xLTEtMA_57a1733f-5d72-416c-90bc-68dee9467df1">80.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Neuroscience</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a96f967a3e14ccfbf1709108752b15a_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzQtMS0xLTEtMA_58db5dec-c3f2-4bad-8685-0ea3321bfae2">141.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1de888a7434a7d8901d5d91e9a5662_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzQtMi0xLTEtMA_4d506696-6955-48af-915e-59f46f157a3d">323.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i805e06baf0334dd2a9272620abb71ef1_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzQtMy0xLTEtMA_9f3ccbbb-3813-44ba-8bee-2d93c852fce5">465.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bf6f39de92a477295091f337c5f246d_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzQtNS0xLTEtMA_cf22b358-6e57-40ed-ae3f-80ca874dcfc7">110.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87c3683c282e4dcab93976f033317191_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzQtNi0xLTEtMA_6fc5e62a-736f-4ac8-8130-e838a28f1eae">353.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib781ea03fa4343ea9f43fe30bf85eaff_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzQtNy0xLTEtMA_d950276b-5811-44d1-b69a-755d4eac702f">463.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">COVID-19 Antibodies </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9004a4576d54acdab802ba18e5954b5_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzgtMS0xLTEtMzYwOA_60affd60-a097-4595-a747-dca3ae7397ff">650.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b813d4b7f6a4ba8ab05eb62fa8c0d7e_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzgtMi0xLTEtMzYwOA_0b8eaeaf-9a60-4300-a57f-19f1e07bf504">159.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e2d53c2e70b4fa7b373f89ff566d337_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzgtMy0xLTEtMzYwOA_287208df-52a7-4065-8892-5d3b6e35705c">810.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6e00607e2514771bb461112b624c3c8_D20200101-20200331" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzgtNS0xLTEtMzYwOA_0e2cae64-98d9-4c66-9bb1-587c5733f421">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i678860fa552c43d4b4fcb6cefb64112a_D20200101-20200331" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzgtNi0xLTEtMzYwOA_0bbff655-0788-4ea7-aeff-9125460078e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i009fa3f9194b481097ec59ef54e9398c_D20200101-20200331" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzgtNy0xLTEtMzYwOA_fb8da522-d627-4243-b500-71cfb89b670e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Forteo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91d06961c624604bf888bc77f143328_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzgtMS0xLTEtMA_cb3102df-a6bc-41e5-9ce5-708bc2e1baca">97.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a70d046e3e04fe8814a35c37222c987_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzgtMi0xLTEtMA_1de89ddf-6d15-49b9-b555-98ad2189865c">100.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a1a9bda61764661a686cd2e6cdf4353_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzgtMy0xLTEtMA_25e677b0-e5e0-4d99-8fcf-71b705d40801">198.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f37eacef6da488b9411e64b1e6f9bf8_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzgtNS0xLTEtMA_71290bb5-bbc1-4c1f-a640-45a4f20217fd">122.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46371b039efc4855ab60d1a0cfdee9ef_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzgtNi0xLTEtMA_8dbcb534-f565-4a67-9347-d19780bcb521">149.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae0c3902df5443afaa207966c3c336ae_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzgtNy0xLTEtMA_f3925561-5ba8-440f-af56-e8792f167a71">272.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cialis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01ed93e108f540d895209d6cd63a4196_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzktMS0xLTEtMA_8c8f637a-c30a-4af6-b994-a67ea3fbec43">8.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02826dfbba6c48f19cdc43d704001dbe_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzktMi0xLTEtMA_a78c5581-be87-4fde-9d0f-5a606d50cfc3">118.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0da8ce69328d41578d3e52a25ef5c637_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzktMy0xLTEtMA_0755f358-1bb3-4252-bffc-88acdde89d9b">126.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf3afa843ed74fd3a1dccd7d9a340f73_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzktNS0xLTEtMA_96ed555a-4c5e-4106-b682-d783869558c4">26.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdbb2ee92d984ead82d0bfe89b0b7e67_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzktNi0xLTEtMA_aa6ed3e0-ada1-4fe7-865a-183e48ce5e3c">167.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b635789ef4a4a3ea608c5ece8aad1d5_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzktNy0xLTEtMA_5bf6594a-65ef-47d8-b9c7-2c89179a8b68">193.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0503e2189e0437c94e4365e2f5e1a42_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDAtMS0xLTEtMA_897b229e-37a9-4f90-a795-2c16677de794">54.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7a3d52cbc5f4c36913820afde8b5ce0_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDAtMi0xLTEtMA_dec1123b-9fb4-46f3-ada1-71582f018212">53.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a85ee0346840baa3213980b51c8392_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDAtMy0xLTEtMA_33338d0c-7c8e-44b5-9399-dca215404a26">107.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48278fe6c84a480c993daadca8e14bec_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDAtNS0xLTEtMA_830f38e5-eeb1-4afe-9399-d429ef2187bc">79.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2da738de9a9496d82ebcd1ed1dfc349_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDAtNi0xLTEtMA_c2893e08-2554-4cc8-b63d-a99cc13b006a">95.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72d5f436073e4013afbbcd703dec4745_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDAtNy0xLTEtMA_62f00c01-f336-45d3-943c-79ee36be5b52">174.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Other</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f47b5c8b6e647f7a98ae58501327a48_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDEtMS0xLTEtMA_d12c39f3-2f9b-4c52-ad42-8c3411ea8d51">811.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ba01d74fb2f4bc0a8c1b64e3b1eef96_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDEtMi0xLTEtMA_88f090ca-62a0-45f3-924a-f8e7d8e9c86c">431.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91fdfa6c20d94c5db431e71629735e62_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDEtMy0xLTEtMA_944790e6-c38b-470e-97fb-b50bfa9b7ebe">1,242.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bdeb0b05ca8485aae2687a910e899e8_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDEtNS0xLTEtMA_1b32ac05-2480-4752-9b92-d3e2ac19eb5f">228.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf27f4b868ff4ca6852de83fc00626db_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDEtNi0xLTEtMA_92b1a8b2-2227-40d8-8085-82c004008439">412.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i725c25318b374568a7f6a1c522f751f5_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDEtNy0xLTEtMA_bd1638e2-761f-4aea-9948-a760e4bddf72">640.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddbce9adb77b4313a6ec25296cfc82c6_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDItMS0xLTEtMA_a1d0804d-182d-4dbf-8f9c-6e154fa32ebd">3,941.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8f05f60f5234be3b895a985508995c8_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDItMi0xLTEtMA_adc413f7-cec7-400f-8bf3-e5dc03a65a66">2,864.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDItMy0xLTEtMA_4b6e8fa4-7d70-4f2a-a5d4-22aff23211dc">6,805.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35174116703c48a1ba3d71d19b34d188_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDItNS0xLTEtMA_0d977cc7-613d-4854-ba8d-997ae56f3841">3,328.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc41b1e93894363b921a691b8c9ad5f_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDItNi0xLTEtMA_0cb0ffd8-9857-458f-91c2-2c0c8b2646b5">2,531.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDItNy0xLTEtMA_63f76030-5ba4-4b9c-8f25-fa75b15dd0b4">5,859.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Humalog revenue includes insulin lispro.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Jardiance revenue includes Glyxambi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Synjardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and Trijardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> XR.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)   </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to Emergency Use Authorizations (EUAs). </span></div></ix:continuation></ix:continuation><div style="margin-top:3pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i960f332faeab45d386014048a8eb364c"><ix:continuation id="i824163b5c1774b82bd45421d3163d1fb"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by geographical area:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddbce9adb77b4313a6ec25296cfc82c6_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjljY2I1MjY1NWJlMjQ5YjA4MmJhZjMwYzQ2NzAwMGY3L3RhYmxlcmFuZ2U6OWNjYjUyNjU1YmUyNDliMDgyYmFmMzBjNDY3MDAwZjdfMy0xLTEtMS0w_69d784ca-1c74-435b-be92-ca91c961dd02">3,941.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35174116703c48a1ba3d71d19b34d188_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjljY2I1MjY1NWJlMjQ5YjA4MmJhZjMwYzQ2NzAwMGY3L3RhYmxlcmFuZ2U6OWNjYjUyNjU1YmUyNDliMDgyYmFmMzBjNDY3MDAwZjdfMy0zLTEtMS0w_9c7065da-483f-4a4e-8fb6-5b4c4b4435d3">3,328.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a8c46f072984025becf4f91f04a0ad4_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjljY2I1MjY1NWJlMjQ5YjA4MmJhZjMwYzQ2NzAwMGY3L3RhYmxlcmFuZ2U6OWNjYjUyNjU1YmUyNDliMDgyYmFmMzBjNDY3MDAwZjdfNC0xLTEtMS0w_10d6e43d-1d95-492a-bf90-8939490e3bc5">1,321.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a4c1fd0f0e411bbd983b92368c6662_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjljY2I1MjY1NWJlMjQ5YjA4MmJhZjMwYzQ2NzAwMGY3L3RhYmxlcmFuZ2U6OWNjYjUyNjU1YmUyNDliMDgyYmFmMzBjNDY3MDAwZjdfNC0zLTEtMS0w_b23a1060-ce44-49f1-bd3c-1e9e1f9894d0">1,061.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8476fa283c5420a8c1cb44bf1886c3e_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjljY2I1MjY1NWJlMjQ5YjA4MmJhZjMwYzQ2NzAwMGY3L3RhYmxlcmFuZ2U6OWNjYjUyNjU1YmUyNDliMDgyYmFmMzBjNDY3MDAwZjdfNS0xLTEtMS0w_f038800b-140c-4413-b5e0-80017bbf49c4">571.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a141f4168094f93bc307eb5ebbf7392_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjljY2I1MjY1NWJlMjQ5YjA4MmJhZjMwYzQ2NzAwMGY3L3RhYmxlcmFuZ2U6OWNjYjUyNjU1YmUyNDliMDgyYmFmMzBjNDY3MDAwZjdfNS0zLTEtMS0w_67bb26be-6ac7-4e3a-89b1-6557422ddefe">592.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf7492d96a0b4f29b67c7ffc8e4fc10e_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjljY2I1MjY1NWJlMjQ5YjA4MmJhZjMwYzQ2NzAwMGY3L3RhYmxlcmFuZ2U6OWNjYjUyNjU1YmUyNDliMDgyYmFmMzBjNDY3MDAwZjdfNi0xLTEtMS0w_5309b16d-74d1-4958-85e6-5d89bef7fff1">362.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d6aaabb8fc4471fb4d955cbdc949682_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjljY2I1MjY1NWJlMjQ5YjA4MmJhZjMwYzQ2NzAwMGY3L3RhYmxlcmFuZ2U6OWNjYjUyNjU1YmUyNDliMDgyYmFmMzBjNDY3MDAwZjdfNi0zLTEtMS0w_76331d3d-5faa-4c9e-baf4-2981aa689a53">267.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other foreign countries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d1b2d8fe9744bfb992ea8ca03c8de17_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjljY2I1MjY1NWJlMjQ5YjA4MmJhZjMwYzQ2NzAwMGY3L3RhYmxlcmFuZ2U6OWNjYjUyNjU1YmUyNDliMDgyYmFmMzBjNDY3MDAwZjdfNy0xLTEtMS0w_69443a3e-aac5-40d3-b5a6-025df928ff3e">609.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fb432a8a93945a68250848e46684f98_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjljY2I1MjY1NWJlMjQ5YjA4MmJhZjMwYzQ2NzAwMGY3L3RhYmxlcmFuZ2U6OWNjYjUyNjU1YmUyNDliMDgyYmFmMzBjNDY3MDAwZjdfNy0zLTEtMS0w_3c591930-d0c1-4d95-95b1-67a6d9a848b2">610.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjljY2I1MjY1NWJlMjQ5YjA4MmJhZjMwYzQ2NzAwMGY3L3RhYmxlcmFuZ2U6OWNjYjUyNjU1YmUyNDliMDgyYmFmMzBjNDY3MDAwZjdfOC0xLTEtMS0w_8090a2ef-b28f-4707-a0ab-9ca08a41ba3a">6,805.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjljY2I1MjY1NWJlMjQ5YjA4MmJhZjMwYzQ2NzAwMGY3L3RhYmxlcmFuZ2U6OWNjYjUyNjU1YmUyNDliMDgyYmFmMzBjNDY3MDAwZjdfOC0zLTEtMS0w_8d0e9611-a5e6-4efb-8ef5-5fba0c98e408">5,859.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenue is attributed to the countries based on the location of the customer.</span></div></ix:continuation></ix:continuation><div style="margin-bottom:12pt;margin-top:3pt"><span><br/></span></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_46"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;3:&#160;<ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfNzI5Mw_65c4c3c3-765a-4151-ac9a-b89405a6752d" continuedAt="ia371c93e293f4dd087767565e289ef31" escape="true">Acquisitions</ix:nonNumeric></span></div><ix:continuation id="ia371c93e293f4dd087767565e289ef31" continuedAt="i44ee3174d18344e1a646c1b677b5bd26"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021 and February 2020, we completed the acquisitions of Prevail Therapeutics Inc. (Prevail) and Dermira, Inc. (Dermira), respectively. These transactions, as further discussed in this note below in Acquisitions of Businesses, were accounted for as business combinations under the acquisition method of accounting. <ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfNzI5NQ_660d065c-49eb-43df-b468-9119d86187ab" continuedAt="ib7ba92052bc6492e86c635684b6d0d7a" escape="true">Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions are included in our consolidated condensed financial statements from the date of acquisition.</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also acquired assets in development which are further discussed in this note below in Asset Acquisitions. <ix:continuation id="ib7ba92052bc6492e86c635684b6d0d7a">Upon each acquisition, the cost allocated to acquired in-process research and development (IPR&amp;D) was immediately expensed because the compound had no alternative future use.</ix:continuation> We recognized $<ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfMTA5OTUxMTYzNTI5Nw_c1726182-6323-41a7-ab12-320e1c94ecf2">299.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfMTM4Mg_9587bc0b-3486-4772-9d87-da9a861caf6c">52.3</ix:nonFraction> </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of acquired IPR&amp;D charges for the three months ended March&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions of Businesses</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Prevail Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Transaction</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we acquired all shares of Prevail for a purchase price that included $<ix:nonFraction unitRef="usdPerShare" contextRef="ia3e93321ddf644359c1906deaf4915d8_I20210131" decimals="INF" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfNDk0NzgwMjM1ODc0MQ_adf8230b-a63f-438d-b5ac-4ebef0d49e25">22.50</ix:nonFraction> per share in cash (or an aggregate of $<ix:nonFraction unitRef="usd" contextRef="if8e0d422156841d5ad8a9105568a5622_D20210101-20210131" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfMTA5OTUxMTY2MDY3NQ_e1639a03-a0de-40c9-a68a-914a2f8fc235">747.4</ix:nonFraction> million, net of cash acquired) plus <ix:nonFraction unitRef="right" contextRef="if8e0d422156841d5ad8a9105568a5622_D20210101-20210131" decimals="INF" format="ixt-sec:numwordsen" name="lly:BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfNDk0NzgwMjM1MDQ1Mw_99f2580c-5b75-4669-ae75-fe6a66c34996">one</ix:nonFraction> non-tradable contingent value right (CVR) per share. The CVR entitles Prevail stockholders to up to an additional $<ix:nonFraction unitRef="usdPerShare" contextRef="ia3e93321ddf644359c1906deaf4915d8_I20210131" decimals="INF" name="lly:BusinessAcquisitionContingentValueRightAdditionalPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfNDk0NzgwMjM1ODc1NQ_ef6771c6-8094-469d-8e1f-805780b3eff2">4.00</ix:nonFraction> per share in cash (or an aggregate of approximately $<ix:nonFraction unitRef="usd" contextRef="ia3e93321ddf644359c1906deaf4915d8_I20210131" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfNDk0NzgwMjM1ODc2Mg_2c276e04-a8b7-48f7-83a8-98f44af3801e">160</ix:nonFraction>&#160;million) payable, subject to certain terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom, Germany, France, Italy or Spain. To achieve the full value of the CVR, such regulatory approval must occur by December 31, 2024. If such regulatory approval occurs after December 31, 2024, the value of the CVR will be reduced by approximately <ix:nonFraction unitRef="usdPerShare" contextRef="ia3e93321ddf644359c1906deaf4915d8_I20210131" decimals="3" name="lly:BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfNDk0NzgwMjM2MDkwMQ_6bb9b1e9-c864-4b6b-937f-92d3fda3b645">8.3</ix:nonFraction> cents per month until December 1, 2028, at which point the CVR will expire.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prevail is a biotechnology company developing potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The acquisition establishes a new modality for drug discovery and development, extending our research efforts through the creation of a gene therapy program that will be anchored by Prevail&#8217;s portfolio of assets. Prevail&#8217;s lead gene therapies in clinical development are PR001 for patients with Parkinson&#8217;s disease with GBA1 mutations and neuronopathic Gaucher disease and PR006 for patients with frontotemporal dementia with GRN mutations. Both PR001 and PR006 were granted Fast Track designation from the U.S. Food and Drug Administration (FDA). </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i44ee3174d18344e1a646c1b677b5bd26" continuedAt="i861bda280f1544cc9df0970276b5df6e"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our access to Prevail information was limited prior to the acquisition. As a consequence, we are in the process of determining fair values and tax bases of a significant portion of the assets acquired and liabilities assumed, including the identification and valuation of intangible assets and tax exposures. The final determination of these amounts will be completed as soon as possible but no later than one year from the acquisition date. The final determination may result in asset and liability fair values and tax bases that differ from the preliminary estimates and require changes to the preliminary amounts recognized.</span></div><ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfNDk0NzgwMjM2MDkwMg_12b29c0d-c796-4cad-ac1e-0b6dc66c5370" continuedAt="ie5eff5dcf6de431ba284955ac134a7cc" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at January 22, 2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3e93321ddf644359c1906deaf4915d8_I20210131" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOjVlYTMzNGZkODY1ZDRlOGJhNDY0OGFhNzJjNTViOGI1L3RhYmxlcmFuZ2U6NWVhMzM0ZmQ4NjVkNGU4YmE0NjQ4YWE3MmM1NWI4YjVfMS0xLTEtMS03OTc2_86525dbf-0f39-4901-98f3-0e12836ff32e">90.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3e93321ddf644359c1906deaf4915d8_I20210131" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOjVlYTMzNGZkODY1ZDRlOGJhNDY0OGFhNzJjNTViOGI1L3RhYmxlcmFuZ2U6NWVhMzM0ZmQ4NjVkNGU4YmE0NjQ4YWE3MmM1NWI4YjVfMi0xLTEtMS03OTk1_701e81f5-27d8-4080-8673-4f3ee872dc74">834.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3e93321ddf644359c1906deaf4915d8_I20210131" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOjVlYTMzNGZkODY1ZDRlOGJhNDY0OGFhNzJjNTViOGI1L3RhYmxlcmFuZ2U6NWVhMzM0ZmQ4NjVkNGU4YmE0NjQ4YWE3MmM1NWI4YjVfMy0xLTEtMS04MDAx_90f88061-c9e8-41e1-913f-e84fd79313d7">111.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3e93321ddf644359c1906deaf4915d8_I20210131" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOjVlYTMzNGZkODY1ZDRlOGJhNDY0OGFhNzJjNTViOGI1L3RhYmxlcmFuZ2U6NWVhMzM0ZmQ4NjVkNGU4YmE0NjQ4YWE3MmM1NWI4YjVfNC0xLTEtMS04MDEw_81132a22-3980-4ff0-8605-f81c8cf743d2">100.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3e93321ddf644359c1906deaf4915d8_I20210131" decimals="-5" sign="-" name="lly:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOjVlYTMzNGZkODY1ZDRlOGJhNDY0OGFhNzJjNTViOGI1L3RhYmxlcmFuZ2U6NWVhMzM0ZmQ4NjVkNGU4YmE0NjQ4YWE3MmM1NWI4YjVfNS0xLTEtMS04MDE3_7e868679-3ce8-4652-9c4a-7882cec79228">31.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition date fair value of consideration transferred </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3e93321ddf644359c1906deaf4915d8_I20210131" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOjVlYTMzNGZkODY1ZDRlOGJhNDY0OGFhNzJjNTViOGI1L3RhYmxlcmFuZ2U6NWVhMzM0ZmQ4NjVkNGU4YmE0NjQ4YWE3MmM1NWI4YjVfNi0xLTEtMS04NTc4_c951eb16-7415-40e3-aa4d-1ad3581787b0">903.8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8e0d422156841d5ad8a9105568a5622_D20210101-20210131" decimals="-5" name="us-gaap:CashAcquiredFromAcquisition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOjVlYTMzNGZkODY1ZDRlOGJhNDY0OGFhNzJjNTViOGI1L3RhYmxlcmFuZ2U6NWVhMzM0ZmQ4NjVkNGU4YmE0NjQ4YWE3MmM1NWI4YjVfOC0xLTEtMS04MDQw_fc9e256c-cb16-4390-a5d1-60ae62329edf">90.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Fair value of CVR liability</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3e93321ddf644359c1906deaf4915d8_I20210131" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOjVlYTMzNGZkODY1ZDRlOGJhNDY0OGFhNzJjNTViOGI1L3RhYmxlcmFuZ2U6NWVhMzM0ZmQ4NjVkNGU4YmE0NjQ4YWE3MmM1NWI4YjVfOS0xLTEtMS04MDM1_96c4f215-44a6-4c2d-bf12-5dfff74a99ef">65.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid, net of cash acquired</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e0d422156841d5ad8a9105568a5622_D20210101-20210131" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOjVlYTMzNGZkODY1ZDRlOGJhNDY0OGFhNzJjNTViOGI1L3RhYmxlcmFuZ2U6NWVhMzM0ZmQ4NjVkNGU4YmE0NjQ4YWE3MmM1NWI4YjVfMTAtMS0xLTEtODU4MQ_4a3f43de-e613-4b73-9f48-465c4eabae38">747.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquired IPR&amp;D intangibles primarily relate to PR001.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The goodwill recognized from this acquisition is not deductible for tax purposes. </span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"><ix:continuation id="ie5eff5dcf6de431ba284955ac134a7cc" continuedAt="ibd85c98b37994a01aa4355a7566d62a7">(3) </ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="ibd85c98b37994a01aa4355a7566d62a7">See Note 6 for a discussion on the estimation of the CVR liability.</ix:continuation> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma information has not been included as this acquisition did not have a material impact on our consolidated condensed statements of operations for the three months ended March 31, 2021 and 2020.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Dermira Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Transaction</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we acquired all shares of Dermira for a purchase price of approximately $<ix:nonFraction unitRef="usd" contextRef="icbcb632a5c694ec29deb85ebe3a2a2e9_D20200201-20200229" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfMTY1NQ_6ff5a115-2354-408c-aebb-1be9fe7fb083">849.3</ix:nonFraction> million, net of cash acquired. Under the terms of the agreement, we acquired lebrikizumab, a novel, investigational, monoclonal antibody being evaluated for the treatment of moderate-to-severe atopic dermatitis. Lebrikizumab was granted Fast Track designation from the FDA. We also acquired Qbrexza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (glycopyrronium) cloth, a medicated cloth approved by the FDA for the topical treatment of primary axillary hyperhidrosis (uncontrolled excessive underarm sweating). During the three months ended March&#160;31, 2021, we decided to sell the rights to Qbrexza. See Note 5 for additional information. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values recognized related to the assets acquired and liabilities assumed in this acquisition included goodwill of $<ix:nonFraction unitRef="usd" contextRef="i532d485d20654594a8b1a96d44626d00_I20200229" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfMjkwNg_f7a3f23a-fc30-42eb-a690-c30dba993546">86.8</ix:nonFraction> million, other intangibles of $<ix:nonFraction unitRef="usd" contextRef="i532d485d20654594a8b1a96d44626d00_I20200229" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfMjkzMQ_5a6fb229-69c3-4faa-bdf9-212dc068ac1d">1.20</ix:nonFraction> billion primarily related to lebrikizumab, deferred income tax liabilities of $<ix:nonFraction unitRef="usd" contextRef="i532d485d20654594a8b1a96d44626d00_I20200229" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfMzAwNA_b5d48ad5-ba9f-4645-b4fa-f9fba4a6e252">49.5</ix:nonFraction> million, and long-term debt of $<ix:nonFraction unitRef="usd" contextRef="i532d485d20654594a8b1a96d44626d00_I20200229" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfMzAzMA_1f0fda30-5c03-42dd-bac4-4d3bf04004a7">375.5</ix:nonFraction> million. After the acquisition, we repaid $<ix:nonFraction unitRef="usd" contextRef="i1a359ced678146c9b9d8f9eb94adc1f8_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfMzA2Nw_bdb3a1e3-da09-4039-80d6-6775cc221b40">276.2</ix:nonFraction> million of long-term debt assumed as part of our acquisition of Dermira.</span></div></ix:continuation><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i861bda280f1544cc9df0970276b5df6e"><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Acquisitions</span></div><ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfNzI4NA_696c362c-47d4-4f87-a851-b553d2a25903" continuedAt="icb7c243339b24baca288f603996b9df9" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our asset acquisitions during the three months ended March&#160;31, 2021 and 2020:</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.916%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Counterparty</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compound(s) or Therapy</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition Month</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase of Development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired IPR&amp;D Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Precision Biosciences, Inc. </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development of potential in vivo therapies for genetic disorders</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0a60d23094d4089a16f414a2eb40222_D20210101-20210131" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOmExNWQ0NmZiOGFhZDQwMTBiNWQ2ZDMyNjQ2MTFkM2Y5L3RhYmxlcmFuZ2U6YTE1ZDQ2ZmI4YWFkNDAxMGI1ZDZkMzI2NDYxMWQzZjlfMS02LTEtMS0xNzg0_23bcdc46-58f6-4403-9f71-8c36c4ce8bda">107.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merus N.V. </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CD3-engaging T-cell re-directing bispecific antibodies for the potential treatment of cancer</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib490931de5a249db92647a2ab94af9ad_D20210101-20210131" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOmExNWQ0NmZiOGFhZDQwMTBiNWQ2ZDMyNjQ2MTFkM2Y5L3RhYmxlcmFuZ2U6YTE1ZDQ2ZmI4YWFkNDAxMGI1ZDZkMzI2NDYxMWQzZjlfMi02LTEtMS0xNzcz_8a893286-42d6-4b00-bd50-3e730c38bb2c">46.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asahi Kasei Pharma Corporation</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AK1780, an orally bioavailable P2X7 receptor antagonist for the potential treatment of chronic pain conditions</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1c5831cc7174801a03a8b0a2fd91a4b_D20210101-20210131" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOmExNWQ0NmZiOGFhZDQwMTBiNWQ2ZDMyNjQ2MTFkM2Y5L3RhYmxlcmFuZ2U6YTE1ZDQ2ZmI4YWFkNDAxMGI1ZDZkMzI2NDYxMWQzZjlfMy02LTEtMS0xNzY4_c441e7e6-126d-45cd-af5b-57d921f6a5a4">20.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rigel Pharmaceuticals, Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the potential treatment of autoimmune and inflammatory diseases</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6460ea51b114fd5952c6937cbc22e89_D20210301-20210331" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOmExNWQ0NmZiOGFhZDQwMTBiNWQ2ZDMyNjQ2MTFkM2Y5L3RhYmxlcmFuZ2U6YTE1ZDQ2ZmI4YWFkNDAxMGI1ZDZkMzI2NDYxMWQzZjlfNC02LTEtMS0xNzk4_ef3cb04d-7268-4d7a-b416-4422385a8966">125.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sitryx Therapeutics Limited</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new medicines for autoimmune diseases</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if871b5e2a0ea46059a74abfa4e82d02d_D20200301-20200331" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOmExNWQ0NmZiOGFhZDQwMTBiNWQ2ZDMyNjQ2MTFkM2Y5L3RhYmxlcmFuZ2U6YTE1ZDQ2ZmI4YWFkNDAxMGI1ZDZkMzI2NDYxMWQzZjlfMS02LTEtMS0w_4717fb67-fdcd-4428-af0d-f26f1e352184">52.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbCellera Biologics Inc. (AbCellera)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neutralizing antibodies for the treatment and prevention of COVID-19</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2020</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c7fcc42f3b34de0bb6bf706fa7541fa_D20200301-20200331" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOmExNWQ0NmZiOGFhZDQwMTBiNWQ2ZDMyNjQ2MTFkM2Y5L3RhYmxlcmFuZ2U6YTE1ZDQ2ZmI4YWFkNDAxMGI1ZDZkMzI2NDYxMWQzZjlfMi02LTEtMS0w_20723a11-eb11-4077-85b0-91f946b85d1c">25.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable. </span></div></ix:nonNumeric><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"><ix:continuation id="icb7c243339b24baca288f603996b9df9" continuedAt="i32d3acfdedf941e0b4989dc25664605a">(2)</ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i32d3acfdedf941e0b4989dc25664605a"> We recognized an acquired IPR&amp;D expense of $<ix:nonFraction unitRef="usd" contextRef="i7cfe3973fd10441580375afacb0b0090_D20200501-20200531" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfNTI2MA_6fa1f3b0-daa4-4b87-88af-0fef5b91a60e">25.0</ix:nonFraction> million in May 2020 upon closing of the transaction.</ix:continuation> </span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with these arrangements, our partners may be entitled to future royalties and/or commercial milestones based on sales should products be approved for commercialization and/or milestones based on the successful progress of compounds through the development process.</span></div></ix:continuation><div id="i3cd151b5d83246a98b0e0ef4a9feb269_49"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4: <ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfMTAwODk_99ca6efb-3712-4f6c-b910-5f4d58db5b43" continuedAt="i2d615b4acd384fd0ba9122c932d07a45" escape="true">Collaborations and Other Arrangements</ix:nonNumeric></span></div><ix:continuation id="i2d615b4acd384fd0ba9122c932d07a45" continuedAt="ic541bc53cb314ea1aa5120c8988d7f41"><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We often enter into collaborative and other similar arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These arrangements often require milestone as well as royalty or profit-share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements from or payments to the collaboration partner. See Note 2 for amounts of collaboration and other revenue recognized from these types of arrangements. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Each collaboration is unique in nature, and our more significant arrangements are discussed below. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Boehringer Ingelheim Diabetes Collaboration</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Boehringer Ingelheim have a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Currently included in the collaboration are Boehringer Ingelheim&#8217;s oral diabetes products: Jardiance,  Glyxambi, Synjardy, Trijardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> XR, Trajenta, and Jentadueto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as our basal insulin, Basaglar. Glyxambi, Synjardy, and Trijardy XR are included in the Jardiance product family. Jentadueto is included in the Trajenta product family. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic541bc53cb314ea1aa5120c8988d7f41" continuedAt="i686abc669804468e921aee8abff5a888"><ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfMTAwOTM_5e29e693-ec19-4791-803c-fad41b8c15bc" continuedAt="i74e546f17e8a4e0ba9af4687d825859c" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the net amount of significant milestones (deferred) capitalized at March 31, 2021 and December 31, 2020 for the compounds included in this collaboration: </span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Milestones (Deferred) Capitalized </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">as of:</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product Family</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i787debb10db9449ebf355978b2cac4c9_I20210331" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOjY1NDkzNjUxYTQ5ZDQ3Njc4ZDZkM2Q3ZDhhNDUwMmI1L3RhYmxlcmFuZ2U6NjU0OTM2NTFhNDlkNDc2NzhkNmQzZDdkOGE0NTAyYjVfMi0xLTEtMS04MzEx_0361397f-01c7-4de2-997a-88e0ac9ad3ab">151.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d95635b39cc445ebd68b8eaacc4cf49_I20201231" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOjY1NDkzNjUxYTQ5ZDQ3Njc4ZDZkM2Q3ZDhhNDUwMmI1L3RhYmxlcmFuZ2U6NjU0OTM2NTFhNDlkNDc2NzhkNmQzZDdkOGE0NTAyYjVfMi0yLTEtMS04MzEx_aa18fde8-72f4-43c2-9573-2aae2451a8a8">156.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8356c279b93c42829023f67b564fd0f1_I20210331" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOjY1NDkzNjUxYTQ5ZDQ3Njc4ZDZkM2Q3ZDhhNDUwMmI1L3RhYmxlcmFuZ2U6NjU0OTM2NTFhNDlkNDc2NzhkNmQzZDdkOGE0NTAyYjVfMi0xLTEtMS01MDM3_ca961c16-e81e-499a-b1c0-581a629f4d8a">108.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7898c22d6db548ba8e625e7b4cb51b1c_I20201231" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOjY1NDkzNjUxYTQ5ZDQ3Njc4ZDZkM2Q3ZDhhNDUwMmI1L3RhYmxlcmFuZ2U6NjU0OTM2NTFhNDlkNDc2NzhkNmQzZDdkOGE0NTAyYjVfMS0yLTEtMS0w_4fb1a185-7395-46e9-9cd4-35d8b9a2d5b2">114.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie49f3b9fa84949058c66e2ccc6f1bafe_I20210331" decimals="-5" sign="-" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOjY1NDkzNjUxYTQ5ZDQ3Njc4ZDZkM2Q3ZDhhNDUwMmI1L3RhYmxlcmFuZ2U6NjU0OTM2NTFhNDlkNDc2NzhkNmQzZDdkOGE0NTAyYjVfNC0xLTEtMS01MDM3_f2921045-378c-4d32-90a1-ff887f74aac6">163.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecf3e061ab6a44e0b3e95b09ceec5863_I20201231" decimals="-5" sign="-" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOjY1NDkzNjUxYTQ5ZDQ3Njc4ZDZkM2Q3ZDhhNDUwMmI1L3RhYmxlcmFuZ2U6NjU0OTM2NTFhNDlkNDc2NzhkNmQzZDdkOGE0NTAyYjVfMy0yLTEtMS0w_f32badb5-5d80-47b8-8642-20f7ef2b9441">168.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In connection with the regulatory approvals of Basaglar in the U.S., Europe, and Japan, milestone payments received were recorded as contract liabilities and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. In connection with the regulatory approvals of Jardiance and Trajenta, milestone payments made were capitalized as intangible assets and are being amortized to cost of sales through the term of the collaboration. This represents the amounts that have been (deferred) or capitalized from the start of this collaboration through the end of the reporting period, net of amount amortized. </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The collaboration agreement with Boehringer Ingelheim for Jardiance ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The collaboration agreement with Boehringer Ingelheim for Trajenta ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Jardiance product family, we and Boehringer Ingelheim share equally the ongoing development and commercialization costs in the most significant markets, and we record our portion of the development and commercialization costs as research and development expense and marketing, selling, and administrative expense, respectively. We receive a royalty on net sales of Boehringer Ingelheim's products in the most significant markets and recognize the royalty as collaboration and other revenue.  Boehringer Ingelheim is entitled to potential performance payments depending on the net sales of the Jardiance product family; therefore, our reported revenue for Jardiance may be reduced by any potential performance payments we make related to this product family. Beginning January 1, 2021, the royalty received by us related to the Jardiance product family may also be increased or decreased depending on whether net sales for this product family exceed or fall below certain thresholds. We pay to Boehringer Ingelheim a royalty on net sales for Basaglar in the U.S. We record our sales of Basaglar to third parties as net product revenue with the royalty payments made to Boehringer Ingelheim recorded as cost of sales.</span></div><ix:continuation id="i74e546f17e8a4e0ba9af4687d825859c" continuedAt="i026dfac012d64444bba0d47947deb0b9"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our net product revenue recognized with respect to Basaglar and collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product Family</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95072ac7b3c4004b82c2aac605e5d70_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOjBmOTdhOTVjZTgyMTRlNzQ5Nzg0MjdhZGUzNGExZDcxL3RhYmxlcmFuZ2U6MGY5N2E5NWNlODIxNGU3NDk3ODQyN2FkZTM0YTFkNzFfMi0xLTEtMS04MzMz_aafa8472-ae8a-4bc6-80be-9b15648fda23">312.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65808f9c08a34e2fbb20de15f09d6663_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOjBmOTdhOTVjZTgyMTRlNzQ5Nzg0MjdhZGUzNGExZDcxL3RhYmxlcmFuZ2U6MGY5N2E5NWNlODIxNGU3NDk3ODQyN2FkZTM0YTFkNzFfMi0zLTEtMS04MzMz_5bd7fdb7-0e99-4719-bc21-00d331b9d6a9">267.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6308d09ed16f45708083f216e5eb9053_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOjBmOTdhOTVjZTgyMTRlNzQ5Nzg0MjdhZGUzNGExZDcxL3RhYmxlcmFuZ2U6MGY5N2E5NWNlODIxNGU3NDk3ODQyN2FkZTM0YTFkNzFfMi0xLTEtMS0w_dbc0725d-fc85-44cd-9fd8-4b1bfe2430d3">246.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b572a7d820847f2b77197f14a7598e9_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOjBmOTdhOTVjZTgyMTRlNzQ5Nzg0MjdhZGUzNGExZDcxL3RhYmxlcmFuZ2U6MGY5N2E5NWNlODIxNGU3NDk3ODQyN2FkZTM0YTFkNzFfMi0zLTEtMS0w_5b2e845f-3e4b-4b3a-86bc-2680bbf4e4bd">303.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabb0222b012c480fa8a4b4033fb1c3b4_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOjBmOTdhOTVjZTgyMTRlNzQ5Nzg0MjdhZGUzNGExZDcxL3RhYmxlcmFuZ2U6MGY5N2E5NWNlODIxNGU3NDk3ODQyN2FkZTM0YTFkNzFfNC0xLTEtMS0w_7ef61ed1-ad75-442b-b0da-806f8d9af6df">94.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50e1340911c44726ba35205e9879816a_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOjBmOTdhOTVjZTgyMTRlNzQ5Nzg0MjdhZGUzNGExZDcxL3RhYmxlcmFuZ2U6MGY5N2E5NWNlODIxNGU3NDk3ODQyN2FkZTM0YTFkNzFfNC0zLTEtMS0w_60603f4f-6ee6-4292-a88f-0de106a7fe4d">93.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Olumiant</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a worldwide license and collaboration agreement with Incyte Corporation (Incyte), which provides us the development and commercialization rights to its Janus tyrosine kinase (JAK) inhibitor compound, now known as Olumiant (baricitinib), and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases. Incyte has the right to receive tiered, double digit royalty payments on global net sales with rates ranging up to <ix:nonFraction unitRef="number" contextRef="i661524a58a1c40ec97906a968e6f6aca_D20210101-20210331" decimals="2" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNjI1Mw_971163d5-a212-4916-9914-af3cd3cf4e56">20</ix:nonFraction> percent. The agreement calls for payments by us to Incyte associated with certain development, success-based regulatory, and sales-based milestones. In 2020, the agreement was amended to include the treatment of COVID-19, with Incyte obtaining the right to receive an additional royalty ranging up to the low teens on global net sales for the treatment of COVID-19 that exceed a specified aggregate global net sales threshold. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the regulatory approvals of Olumiant in the U.S., Europe, and Japan, milestone payments of $<ix:nonFraction unitRef="usd" contextRef="id9bf6a3d44b2458aabd053d1804a3283_I20210331" decimals="-5" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNjUwOA_75191053-25b1-4459-ad43-6db8ad11885e">210.0</ix:nonFraction> million were capitalized as intangible assets as of March 31, 2021 and December 31, 2020 and are being amortized to cost of sales through the term of the collaboration. This represents the cumulative amounts that have been capitalized from the start of this collaboration through the end of each reporting period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, Incyte is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i64aadc652c4343c1bcd2bfc5b72d6158_I20210331" decimals="-5" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNjgxOQ_0dcae872-c3af-42fb-a209-7c7c28c86e6b">100.0</ix:nonFraction> million of additional payments from us contingent upon certain success-based regulatory milestones. Incyte is also eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i3343c905d8554be69ab7b345fa893082_I20210331" decimals="-5" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNjk3MQ_19489ce0-3fb9-4522-910f-6b707b34fd61">150.0</ix:nonFraction> million of potential sales-based milestones.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i686abc669804468e921aee8abff5a888" continuedAt="i5673fc1096ea41a6a58f1af382a310ac"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record our sales of Olumiant to third parties as net product revenue with the royalty payments made to Incyte recorded as cost of sales. <ix:continuation id="i026dfac012d64444bba0d47947deb0b9" continuedAt="i7579c930bf4a4fcd86f20810dee6e07f">The following table summarizes our net product revenue recognized with respect to Olumiant:</ix:continuation></span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><ix:continuation id="i7579c930bf4a4fcd86f20810dee6e07f"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olumiant</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id181bab5e80145f7b4aac52329fa68c0_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOmRjNDUxOWUxYjhlYzRjZDE5YThiZDc0OTM5NjAzNGU4L3RhYmxlcmFuZ2U6ZGM0NTE5ZTFiOGVjNGNkMTlhOGJkNzQ5Mzk2MDM0ZThfMi0xLTEtMS0w_43dfdcb5-e735-4121-ad47-147da4f5a662"><ix:nonFraction unitRef="usd" contextRef="id181bab5e80145f7b4aac52329fa68c0_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOmRjNDUxOWUxYjhlYzRjZDE5YThiZDc0OTM5NjAzNGU4L3RhYmxlcmFuZ2U6ZGM0NTE5ZTFiOGVjNGNkMTlhOGJkNzQ5Mzk2MDM0ZThfMi0xLTEtMS0w_ba60441b-b236-48e2-9d7f-ff80305eb163">193.8</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c5697fd7da74cdbb6d77c6a62017381_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOmRjNDUxOWUxYjhlYzRjZDE5YThiZDc0OTM5NjAzNGU4L3RhYmxlcmFuZ2U6ZGM0NTE5ZTFiOGVjNGNkMTlhOGJkNzQ5Mzk2MDM0ZThfMi0zLTEtMS0w_72d5363b-b180-417d-b6c7-91b3343689d9"><ix:nonFraction unitRef="usd" contextRef="i6c5697fd7da74cdbb6d77c6a62017381_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOmRjNDUxOWUxYjhlYzRjZDE5YThiZDc0OTM5NjAzNGU4L3RhYmxlcmFuZ2U6ZGM0NTE5ZTFiOGVjNGNkMTlhOGJkNzQ5Mzk2MDM0ZThfMi0zLTEtMS0w_eff31ee2-fe9a-417e-9b48-e79b1e0348ce">139.7</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 antibodies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we entered into a worldwide license and collaboration agreement with AbCellera to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including bamlanivimab, for which we hold development and commercialization rights. AbCellera has the right to receive tiered royalty payments on global net sales of bamlanivimab with percentages ranging in the mid-teens to mid-twenties. Royalty payments made to AbCellera are recorded as cost of sales.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we entered into a license and collaboration agreement with Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences) to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including etesevimab, for which we hold development and commercialization rights outside of Greater China (which includes mainland China, Hong Kong and Macau Special Administrative Regions and Taiwan) and for which Junshi Biosciences maintains all rights in Greater China. Junshi Biosciences has the right to receive royalty payments in the mid-teens on our net sales of etesevimab. Junshi Biosciences also has the right to receive certain development, success-based regulatory and sales-based milestones. In connection with the regulatory authorizations of etesevimab (for administration with bamlanivimab) in the U.S. and Europe, milestone payments of $<ix:nonFraction unitRef="usd" contextRef="i3ec641d1b0e0486dba0286bc54d9f28f_I20210331" decimals="-5" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNTQ5NzU1ODE1NDg3OA_e328a81f-6023-4d4c-bb97-f9359f674143">60.0</ix:nonFraction> million were capitalized as intangible assets as of March&#160;31, 2021 and are being amortized to cost of sales over the estimated useful life of etesevimab. As of March&#160;31, 2021, Junshi Biosciences is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i9cadf4d9d0bd4bf6b1d1bd9d0dc96dee_I20210331" decimals="-5" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNTQ5NzU1ODE1NDg2NA_71ed43c5-b39e-42f9-bb9e-f1dd1d8becd4">15.0</ix:nonFraction> million of additional payments contingent upon certain success-based regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i44a54fd999064e8484fd5ca2af4dcc17_I20210331" decimals="-5" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNTQ5NzU1ODE1NDg2OQ_6bfe2c41-a48d-4c7b-a34a-dae460326a01">120.0</ix:nonFraction> million of potential sales-based milestones. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to EUAs, we recognized $<ix:nonFraction unitRef="usd" contextRef="i1e2d53c2e70b4fa7b373f89ff566d337_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNTQ5NzU1ODE1OTk2NQ_287208df-52a7-4065-8892-5d3b6e35705c">810.1</ix:nonFraction> million of net product revenue associated with our sales of our COVID-19 antibodies during the three months ended March&#160;31, 2021. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tyvyt</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Innovent Biologics, Inc. (Innovent) to jointly develop and commercialize Tyvyt (sintilimab injection) in China. In 2019, we and Innovent began co-commercializing Tyvyt in China. We record our sales of Tyvyt to third parties as revenue, with payments made to Innovent for its portion of the gross margin reported as cost of sales. We also report as revenue our portion of the gross margin for Tyvyt sales made by Innovent to third parties. Our Tyvyt revenue in China, which is primarily recorded as net product revenue, was $<ix:nonFraction unitRef="usd" contextRef="i55a39c6d0d9146729c9cbfd483622222_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNTQ5NzU1ODE1OTY4Nw_b1fa3217-3b4b-4488-be3c-9a95a7c78d93">109.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i37c6a808e0e24c1f8e75607e3a823271_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNTQ5NzU1ODE1OTY3MQ_f9954cb6-a22d-425c-a088-134ad2d685fd">57.4</ix:nonFraction> million during the three months ended March 31, 2021 and 2020, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we obtained an exclusive license for Tyvyt from Innovent for geographies outside of China. Innovent, with collaboration from us, will pursue the initial registration of Tyvyt in the U.S., and we will pursue initial registration of Tyvyt in other markets and all other subsequent registrations of Tyvyt. We have exclusive commercialization rights outside of China.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, Innovent is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="ied018ff88f6646e88340a81a87e88722_I20210331" decimals="-5" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNTQ5NzU1ODE1NDg4OA_ad2281d6-a9e6-4001-a984-47b8469128ee">825.0</ix:nonFraction> million for geographies outside of China and up to $<ix:nonFraction unitRef="usd" contextRef="i2d761f2cc36e4a03b6ad57e5ab13c540_I20210331" decimals="-5" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNTQ5NzU1ODE1NDg5Mw_a1337b91-4c92-4b78-ad4f-890665ad5b1f">235.0</ix:nonFraction> million in China in success-based regulatory and sales-based milestones. Innovent is also eligible to receive tiered double digit royalties on net sales for geographies outside of China. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tanezumab</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Pfizer Inc. (Pfizer) to jointly develop and globally commercialize tanezumab for the treatment of osteoarthritis pain and cancer pain. The companies equally share the ongoing development costs and, if successful, in the U.S. will co-commercialize and equally share in gross margin and certain commercialization expenses. As a result of an amendment to the agreement in 2020, Pfizer will be responsible for commercialization activities and costs outside the U.S., and we have the right to receive tiered royalties in percentages from the high teens to mid-twenties for net sales in Japan as well as low double digit royalties on annual net sales greater than $<ix:nonFraction unitRef="usd" contextRef="ia32a56f35ba84943ac17a6ae53d314e0_I20210331" decimals="-5" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNDk0NzgwMjM0NTYzOQ_8a0e07cc-289f-43d3-ab41-e429dd02c103">150.0</ix:nonFraction>&#160;million in all other territories outside of the U.S. and Japan. As of March&#160;31, 2021, Pfizer is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i24615d347773426cb44faa02b5f3a282_I20210331" decimals="-5" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfODA5Mw_7a5b96ac-6595-439e-885b-4f61c456cfdb">147.5</ix:nonFraction> million in success-based regulatory milestones based on current development plans and up to $<ix:nonFraction unitRef="usd" contextRef="i3b6de8f942f44cf0aced4adc5181105e_I20210331" decimals="-7" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfODE4MA_4992ab14-7f3e-4803-8581-3143b6bf1ec9">1.23</ix:nonFraction> billion in a series of sales-based milestones, contingent upon the commercial success of tanezumab.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i5673fc1096ea41a6a58f1af382a310ac" continuedAt="i8520b90efb954b96a309bdd9f66cf802"><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lebrikizumab</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Dermira, we have a worldwide licensing agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. (collectively Roche), which provides us the global development and commercialization rights to lebrikizumab. Roche has the right to receive tiered royalty payments on future global net sales ranging in percentages from high single digits to high teens if the product is successfully commercialized. As of March&#160;31, 2021, Roche is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i4ee311292e604c2ba36873038aa0d41a_I20210331" decimals="-5" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfODc2NQ_2197898d-1c35-48a0-86c8-40da352577c1">180.0</ix:nonFraction> million of payments from us contingent upon the achievement of success-based regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i2e55c79531a045a4849418d1e780b569_I20210331" decimals="-7" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfODg3MA_77e1fb01-e28e-493e-9d42-c474a09ec427">1.03</ix:nonFraction> billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Dermira, we have a license agreement with Almirall, S.A. (Almirall), under which Almirall licensed the rights to develop and commercialize lebrikizumab for the treatment or prevention of dermatology indications, including, but not limited to, atopic dermatitis in Europe. We have the right to receive tiered royalty payments on future net sales in Europe ranging in percentages from low double digits to low twenties if the product is successfully commercialized. As of March&#160;31, 2021, we are eligible to receive additional payments of $<ix:nonFraction unitRef="usd" contextRef="i1bd3d506e737426ca9f7d5071e2fe975_I20210331" decimals="-5" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfOTUyNg_db3476fb-d847-445a-8fc5-f48a832c7a6d">85.0</ix:nonFraction> million from Almirall contingent upon the achievement of success-based regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="ia6017620bc984fc3b23178c68fc11436_I20210331" decimals="-7" format="ixt:numdotdecimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfOTYyNA_4372d029-f890-4b0d-a4d3-7784585ca72a">1.25</ix:nonFraction> billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8520b90efb954b96a309bdd9f66cf802">As of March&#160;31, 2021 and December 31, 2020, $<ix:nonFraction unitRef="usd" contextRef="i5c39357db5cc4a9cbcfd00adcb81f908_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNTQ5NzU1ODE1NDkwMw_46e412e0-d89f-4983-86aa-a650444a5dae">23.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6fea589edc3e4ab08f9ed7052aad2e59_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNTQ5NzU1ODE1ODY3NA_820362df-11ab-42bc-915e-58e9962906ba">29.7</ix:nonFraction> million, respectively, were recorded as contract liabilities on the consolidated condensed balance sheet and are expected to be recognized as collaboration and other revenue over the remaining Phase III development period. During the three months ended March&#160;31, 2021 and 2020, milestones received and collaboration and other revenue recognized were not material.</ix:continuation> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_58"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5: <ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV81OC9mcmFnOmFmMzJlNjhkYWFlMTQ3NTliYjY1ZjRhZjVlZWFhMmY4L3RleHRyZWdpb246YWYzMmU2OGRhYWUxNDc1OWJiNjVmNGFmNWVlYWEyZjhfNzc4_36abbb79-574f-414e-b791-2864374b5292" continuedAt="i5bec616772c74dee9962071bd9a87384" escape="true">Asset Impairment, Restructuring, and Other Special Charges</ix:nonNumeric></span></div><ix:continuation id="i5bec616772c74dee9962071bd9a87384" continuedAt="i40676bd2921a49fe82c7ec5fd2df15cf"><ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV81OC9mcmFnOmFmMzJlNjhkYWFlMTQ3NTliYjY1ZjRhZjVlZWFhMmY4L3RleHRyZWdpb246YWYzMmU2OGRhYWUxNDc1OWJiNjVmNGFmNWVlYWEyZjhfNzg1_d9ee5252-7669-466e-beb3-eda60f33990a" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated condensed statements of operations are described below. </span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.036%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV81OC9mcmFnOmFmMzJlNjhkYWFlMTQ3NTliYjY1ZjRhZjVlZWFhMmY4L3RhYmxlOjRlMzhjNTNiNWY1NjQ0N2ViNWIzM2RhODFhZTFlZmZjL3RhYmxlcmFuZ2U6NGUzOGM1M2I1ZjU2NDQ3ZWI1YjMzZGE4MWFlMWVmZmNfMi0xLTEtMS0w_6d174d88-bd85-4952-b4cc-f3df9bff93b9">11.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV81OC9mcmFnOmFmMzJlNjhkYWFlMTQ3NTliYjY1ZjRhZjVlZWFhMmY4L3RhYmxlOjRlMzhjNTNiNWY1NjQ0N2ViNWIzM2RhODFhZTFlZmZjL3RhYmxlcmFuZ2U6NGUzOGM1M2I1ZjU2NDQ3ZWI1YjMzZGE4MWFlMWVmZmNfMi0zLTEtMS0w_b4e78399-dba1-4aae-8ccc-3528e952767e">9.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment and other special charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV81OC9mcmFnOmFmMzJlNjhkYWFlMTQ3NTliYjY1ZjRhZjVlZWFhMmY4L3RhYmxlOjRlMzhjNTNiNWY1NjQ0N2ViNWIzM2RhODFhZTFlZmZjL3RhYmxlcmFuZ2U6NGUzOGM1M2I1ZjU2NDQ3ZWI1YjMzZGE4MWFlMWVmZmNfMy0xLTEtMS0w_0987e5e5-2fc3-494a-8f25-22f0cd050e33">200.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV81OC9mcmFnOmFmMzJlNjhkYWFlMTQ3NTliYjY1ZjRhZjVlZWFhMmY4L3RhYmxlOjRlMzhjNTNiNWY1NjQ0N2ViNWIzM2RhODFhZTFlZmZjL3RhYmxlcmFuZ2U6NGUzOGM1M2I1ZjU2NDQ3ZWI1YjMzZGE4MWFlMWVmZmNfMy0zLTEtMS0w_26bb8512-cc99-4be1-aa04-8de2e2d65491">50.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total asset impairment, restructuring, and other special charges</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV81OC9mcmFnOmFmMzJlNjhkYWFlMTQ3NTliYjY1ZjRhZjVlZWFhMmY4L3RhYmxlOjRlMzhjNTNiNWY1NjQ0N2ViNWIzM2RhODFhZTFlZmZjL3RhYmxlcmFuZ2U6NGUzOGM1M2I1ZjU2NDQ3ZWI1YjMzZGE4MWFlMWVmZmNfNC0xLTEtMS0w_867dc0f3-4934-4403-bb1c-95f003c7ea49">211.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV81OC9mcmFnOmFmMzJlNjhkYWFlMTQ3NTliYjY1ZjRhZjVlZWFhMmY4L3RhYmxlOjRlMzhjNTNiNWY1NjQ0N2ViNWIzM2RhODFhZTFlZmZjL3RhYmxlcmFuZ2U6NGUzOGM1M2I1ZjU2NDQ3ZWI1YjMzZGE4MWFlMWVmZmNfNC0zLTEtMS0w_61e9d0f7-00f1-4631-bc7a-178c42842cd9">59.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairment, restructuring, and other special charges recognized during the three months ended March&#160;31, 2021 were primarily related to an intangible asset impairment of $<ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV81OC9mcmFnOmFmMzJlNjhkYWFlMTQ3NTliYjY1ZjRhZjVlZWFhMmY4L3RleHRyZWdpb246YWYzMmU2OGRhYWUxNDc1OWJiNjVmNGFmNWVlYWEyZjhfNDk0NzgwMjMzMTA1NQ_ab77e7a4-3bae-4da2-9fc0-bb1eeb0c06f9">108.1</ix:nonFraction>&#160;million resulting from the decision to sell the rights to Qbrexza, as well as acquisition and integration costs associated with the acquisition of Prevail. During the three months ended March&#160;31, 2021, we entered into an agreement to sell our rights to Qbrexza, subject to closing conditions which are expected to be completed in the second quarter of 2021. The assets associated with Qbrexza were written down to fair value less cost to sell, which were determined based upon a discounted cash flow valuation. The remaining book value of assets associated with Qbrexza subsequent to the impairment charge is not material.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i40676bd2921a49fe82c7ec5fd2df15cf">Asset impairment, restructuring, and other special charges recognized during the three months ended March&#160;31, 2020 were primarily related to acquisition and integration costs associated with the acquisition of Dermira.</ix:continuation> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_61"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6: <ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTQ4OTg_77a10609-7cb8-4d05-9dde-2c32f7d2eea0" continuedAt="i69cef6e845a54239a64f47b3895fb085" escape="true">Financial Instruments</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i69cef6e845a54239a64f47b3895fb085" continuedAt="idd07b0134f874dcf88622b40618ea8d9">Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life science products account for a substantial portion of our trade receivables; collateral is generally not required. We seek to mitigate the risk associated with this concentration through our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions. We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings.</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="idd07b0134f874dcf88622b40618ea8d9" continuedAt="i4a20beb0043942df95fd20c36916059e"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our equity investments are accounted for using three different methods depending on the type of equity investment:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review equity investments other than public equity investments for indications of impairment and observable price changes on a regular basis.</span></div><ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTQ4Mjk_40b19818-1fc9-4819-a30b-6ed9b2b414d2" continuedAt="i3eb8245f5510494a9e0e8ada2bf8ff08" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market, with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3eb8245f5510494a9e0e8ada2bf8ff08">We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, and Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other&#8211;net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months.</ix:continuation> At March&#160;31, 2021, we had outstanding foreign currency forward commitments to purchase <ix:nonFraction unitRef="usd" contextRef="if8fd6ec70f034998b9025e47bf69042a_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNDMwNw_8be969a2-8fe0-4880-82ff-1005831944be">1.11</ix:nonFraction> billion U.S. dollars and sell <ix:nonFraction unitRef="eur" contextRef="if8fd6ec70f034998b9025e47bf69042a_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNDMzMg_6a7555b9-1f54-4db3-aaf1-3f84d1eea9c9">941.7</ix:nonFraction> million euro, commitments to purchase <ix:nonFraction unitRef="eur" contextRef="iacc428f5b7444f79a59f33bd449c5b64_I20210331" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNDM2NQ_67d67f1b-3a87-44dc-be01-d12b6a1e0b21">4.19</ix:nonFraction> billion euro and sell <ix:nonFraction unitRef="usd" contextRef="iacc428f5b7444f79a59f33bd449c5b64_I20210331" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:DerivativeAssetNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNDM4Mg_fd0805d8-975b-40fb-acc4-d9fe68fdb67a">4.98</ix:nonFraction> billion U.S. dollars, commitments to purchase <ix:nonFraction unitRef="usd" contextRef="i53cacc69bc7f436e8384c8ab4a5a9044_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNDQyMw_76a0d582-3444-414c-9051-da55b8a5f3b9">140.7</ix:nonFraction> million U.S. dollars and sell <ix:nonFraction unitRef="jpy" contextRef="i53cacc69bc7f436e8384c8ab4a5a9044_I20210331" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:DerivativeAssetNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNDQ0OA_cf717cae-fa36-4235-8b99-b2d2cd207e92">15.47</ix:nonFraction> billion Japanese yen, and commitments to purchase <ix:nonFraction unitRef="gbp" contextRef="i196a382db4dd474f9215758c00592480_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNDQ5Mw_40187227-e041-4000-b2c6-4cfa926f665a">285.2</ix:nonFraction> million British pounds and sell <ix:nonFraction unitRef="usd" contextRef="i196a382db4dd474f9215758c00592480_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNDUyMA_863c582d-9f72-44fe-9a20-9f8c8ec2e42e">396.5</ix:nonFraction> million U.S. dollars, which all settled within <ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" format="ixt-sec:durday" name="us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNDU2Ng_69718dcf-f14e-4ae0-8b38-43c80559d386">30</ix:nonNumeric> days.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency exchange risk is also managed through the use of foreign currency debt and cross-currency interest rate swaps. Our foreign currency-denominated notes had carrying amounts of $<ix:nonFraction unitRef="usd" contextRef="i790e81260a954cde9599960f6c59fcd6_I20210331" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNDc2MQ_7c437e4b-194d-43d8-ad4a-9e541eac160d">5.72</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="iee91d9656eb3472e8cf1ac38a3807882_I20201231" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNDc2OA_fe04fae3-298e-4961-a3d7-a00e04179265">6.02</ix:nonFraction> billion as of March&#160;31, 2021 and December&#160;31, 2020, respectively, of which $<ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNDgxMQ_d228b96e-a9fd-481d-afe9-265751887a71">4.30</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNDgxOA_7cacecac-dad8-4076-969e-14cb318f9f66">4.50</ix:nonFraction> billion have been designated as, and are effective as, economic hedges of net investments in certain of our euro-denominated foreign operations as of March&#160;31, 2021 and December&#160;31, 2020, respectively. At March&#160;31, 2021, we had outstanding cross currency swaps with notional amounts of $<ix:nonFraction unitRef="usd" contextRef="ifca25d1668f0447a8c0fb8e92c444a46_I20210331" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNTA2MA_f68a4f95-40c5-4b24-a7bf-2b2bda01656b">3.79</ix:nonFraction> billion swapping U.S. dollars to euro and $<ix:nonFraction unitRef="usd" contextRef="icd062c4f7c644c92a3bd0c5fc8d3cd2c_I20210331" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNTA5Nw_f783611f-44ac-4387-acda-a0a0b17e922f">1.00</ix:nonFraction> billion swapping Swiss francs to U.S. dollars which have settlement dates ranging through 2028. Our cross-currency interest rate swaps, for which a majority convert a portion of our U.S. dollar-denominated fixed-rate debt to foreign-denominated fixed-rate debt, have also been designated as, and are effective as, economic hedges of net investments.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4a20beb0043942df95fd20c36916059e" continuedAt="i5a4a5e658e7749f285b927855e6cc7fd"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated condensed statements of cash flows. At March&#160;31, 2021, substantially all of our total long-term debt is at a fixed rate. We have converted approximately <ix:nonFraction unitRef="number" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="2" format="ixt:numdotdecimal" name="lly:DescriptionOfDerivativeActivityVolumePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNjg4MA_c0501b28-d2d1-4e34-84c7-4030225792fb">13</ix:nonFraction> percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. The change in fair value of these instruments is recorded as part of other comprehensive income (loss), and upon completion of a debt issuance and termination of the swap, is amortized to interest expense over the life of the underlying debt. As of March 31, 2021, the total notional amounts of forward-starting interest rate contracts in designated cash flow hedging instruments were $<ix:nonFraction unitRef="usd" contextRef="i08261dc843c546e282dc7746c9935f3a_I20210331" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNzYwMQ_264bf1da-2105-4b73-a0bc-69c24b6fc7ed">1.75</ix:nonFraction> billion, which have settlement dates ranging between 2023 and 2025.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Effect of Risk-Management Instruments on the Consolidated Condensed Statements of Operations</span></div><ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTQ4MzA_a9f88747-6636-408d-abdd-7e994387c2e3" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following effects of risk-management instruments were recognized in other&#8211;net, (income) expense:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from hedged fixed-rate debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i40ae6e16034149ffab19351331c55b6a_D20210101-20210331" decimals="-5" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM3MjY4OGZhODliZDQ3ZTE4MjM2ZTg1NjY0NTU5Y2YyL3RhYmxlcmFuZ2U6YzcyNjg4ZmE4OWJkNDdlMTgyMzZlODU2NjQ1NTljZjJfMy0xLTEtMS0w_091d97c9-6ec4-4d84-b4c8-e69aed54569e">81.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bc95e47cf6e4f3da137f20ede5e2282_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM3MjY4OGZhODliZDQ3ZTE4MjM2ZTg1NjY0NTU5Y2YyL3RhYmxlcmFuZ2U6YzcyNjg4ZmE4OWJkNDdlMTgyMzZlODU2NjQ1NTljZjJfMy0zLTEtMS0w_91b5e364-0421-4d52-bdce-b7bfd05366e5">117.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from interest rate contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02b03c88c1f84031a54577f36537d1bb_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM3MjY4OGZhODliZDQ3ZTE4MjM2ZTg1NjY0NTU5Y2YyL3RhYmxlcmFuZ2U6YzcyNjg4ZmE4OWJkNDdlMTgyMzZlODU2NjQ1NTljZjJfNC0xLTEtMS0w_e8d47989-4b87-453f-8cb5-d018ce9c4ce9">81.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5492a540a4eb4396826f07e4a6429720_D20200101-20200331" decimals="-5" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM3MjY4OGZhODliZDQ3ZTE4MjM2ZTg1NjY0NTU5Y2YyL3RhYmxlcmFuZ2U6YzcyNjg4ZmE4OWJkNDdlMTgyMzZlODU2NjQ1NTljZjJfNC0zLTEtMS0w_e09c8394-16c2-4554-b58e-7187a7bc84eb">117.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02b03c88c1f84031a54577f36537d1bb_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM3MjY4OGZhODliZDQ3ZTE4MjM2ZTg1NjY0NTU5Y2YyL3RhYmxlcmFuZ2U6YzcyNjg4ZmE4OWJkNDdlMTgyMzZlODU2NjQ1NTljZjJfNi0xLTEtMS0w_ecb3f3e2-92a4-44b0-8e06-cc815d661450">4.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5492a540a4eb4396826f07e4a6429720_D20200101-20200331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM3MjY4OGZhODliZDQ3ZTE4MjM2ZTg1NjY0NTU5Y2YyL3RhYmxlcmFuZ2U6YzcyNjg4ZmE4OWJkNDdlMTgyMzZlODU2NjQ1NTljZjJfNi0zLTEtMS0w_d91e23e2-1e04-4c14-a32c-97c35600eeb4">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e9ced055f4647d1b7ac5f1b13d3dcdb_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM3MjY4OGZhODliZDQ3ZTE4MjM2ZTg1NjY0NTU5Y2YyL3RhYmxlcmFuZ2U6YzcyNjg4ZmE4OWJkNDdlMTgyMzZlODU2NjQ1NTljZjJfNy0xLTEtMS0w_ab927ed0-044d-41d0-988f-11ddc7f04ed3">71.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0675cae41ecf4fad80226860b67627c8_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM3MjY4OGZhODliZDQ3ZTE4MjM2ZTg1NjY0NTU5Y2YyL3RhYmxlcmFuZ2U6YzcyNjg4ZmE4OWJkNDdlMTgyMzZlODU2NjQ1NTljZjJfNy0zLTEtMS0w_43004df9-1d6f-4c61-8d58-ab58bd2c47cb">12.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc6b325c96343679b6ae5ded2b4017a_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM3MjY4OGZhODliZDQ3ZTE4MjM2ZTg1NjY0NTU5Y2YyL3RhYmxlcmFuZ2U6YzcyNjg4ZmE4OWJkNDdlMTgyMzZlODU2NjQ1NTljZjJfOC0xLTEtMS0w_929d33de-317f-4130-bb31-cac405be335f">133.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ebf8484d97442a79f3fb0056a0a0636_D20200101-20200331" decimals="-5" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM3MjY4OGZhODliZDQ3ZTE4MjM2ZTg1NjY0NTU5Y2YyL3RhYmxlcmFuZ2U6YzcyNjg4ZmE4OWJkNDdlMTgyMzZlODU2NjQ1NTljZjJfOC0zLTEtMS0w_13bee5ee-39f7-4f2f-a482-8de94bd1039a">5.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" sign="-" name="lly:DerivativeInstrumentsGainLossRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM3MjY4OGZhODliZDQ3ZTE4MjM2ZTg1NjY0NTU5Y2YyL3RhYmxlcmFuZ2U6YzcyNjg4ZmE4OWJkNDdlMTgyMzZlODU2NjQ1NTljZjJfOS0xLTEtMS0w_51e24626-faf7-4389-b313-c1588fa23c2d">208.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="lly:DerivativeInstrumentsGainLossRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM3MjY4OGZhODliZDQ3ZTE4MjM2ZTg1NjY0NTU5Y2YyL3RhYmxlcmFuZ2U6YzcyNjg4ZmE4OWJkNDdlMTgyMzZlODU2NjQ1NTljZjJfOS0zLTEtMS0w_568c8bdc-9a39-492c-9d09-e2ca30f6d94a">14.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021 and 2020, the amortization of losses related to the portion of our risk management hedging instruments, fair value hedges, and cash flow hedges that was excluded from the assessment of effectiveness was not material.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Effect of Risk-Management Instruments on Other Comprehensive Income (Loss)</span></div><ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTQ4MjM_d444bfe7-d7a5-45b7-8f18-91271a909470" escape="true"><ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTQ4NTU_f2563394-95a8-40f8-960d-2c2f01b65ead" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Foreign currency-denominated notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48597227bfbf4037b23b06218e7f576b_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmNkOGI2OTVlYTY0NjQxODVhYTZlNzFhNGMzZmY4MzMxL3RhYmxlcmFuZ2U6Y2Q4YjY5NWVhNjQ2NDE4NWFhNmU3MWE0YzNmZjgzMzFfMy0xLTEtMS0w_4cf4ac8e-05de-4dc8-b6e4-a163850f5cc9">207.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733a2380e7734f87b92e3f8aed9fe6ac_D20200101-20200331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmNkOGI2OTVlYTY0NjQxODVhYTZlNzFhNGMzZmY4MzMxL3RhYmxlcmFuZ2U6Y2Q4YjY5NWVhNjQ2NDE4NWFhNmU3MWE0YzNmZjgzMzFfMy0zLTEtMS0w_79c330e7-f109-4bd0-90e2-6e13af8dd268">67.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4ed115b785a4ad9a93f7287cb139b8e_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmNkOGI2OTVlYTY0NjQxODVhYTZlNzFhNGMzZmY4MzMxL3RhYmxlcmFuZ2U6Y2Q4YjY5NWVhNjQ2NDE4NWFhNmU3MWE0YzNmZjgzMzFfNC0xLTEtMS0w_2a1dcbdd-bcdb-45b8-afcb-ab620dc55d96">150.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d351595dea941808d14c80b2e44c3b3_D20200101-20200331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmNkOGI2OTVlYTY0NjQxODVhYTZlNzFhNGMzZmY4MzMxL3RhYmxlcmFuZ2U6Y2Q4YjY5NWVhNjQ2NDE4NWFhNmU3MWE0YzNmZjgzMzFfNC0zLTEtMS0w_b99945b8-2f81-42cf-8481-656b648458f8">115.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Forward-starting interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02bf6e1811a43e7a3d115fc98ca56c9_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmNkOGI2OTVlYTY0NjQxODVhYTZlNzFhNGMzZmY4MzMxL3RhYmxlcmFuZ2U6Y2Q4YjY5NWVhNjQ2NDE4NWFhNmU3MWE0YzNmZjgzMzFfNy0xLTEtMS0w_7fcba855-c0d2-4984-8c93-0329ffa7b396">295.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8a0cc4c13104fccbd1c69dcb601af62_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmNkOGI2OTVlYTY0NjQxODVhYTZlNzFhNGMzZmY4MzMxL3RhYmxlcmFuZ2U6Y2Q4YjY5NWVhNjQ2NDE4NWFhNmU3MWE0YzNmZjgzMzFfNy0zLTEtMS0w_bca4f9a9-69af-400f-9a10-1b14d65eab4a">369.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4ed115b785a4ad9a93f7287cb139b8e_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmNkOGI2OTVlYTY0NjQxODVhYTZlNzFhNGMzZmY4MzMxL3RhYmxlcmFuZ2U6Y2Q4YjY5NWVhNjQ2NDE4NWFhNmU3MWE0YzNmZjgzMzFfOC0xLTEtMS0w_08a7ac18-daff-4724-af5d-f2f5ee314191">26.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d351595dea941808d14c80b2e44c3b3_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmNkOGI2OTVlYTY0NjQxODVhYTZlNzFhNGMzZmY4MzMxL3RhYmxlcmFuZ2U6Y2Q4YjY5NWVhNjQ2NDE4NWFhNmU3MWE0YzNmZjgzMzFfOC0zLTEtMS0w_0c7b6d49-b939-41ca-834c-3fa2dfabac83">69.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the next 12&#160;months, we expect to reclassify $<ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfODkyOQ_e4ca65fe-9ca3-488e-9af9-b7ce78764d0b">16.9</ix:nonFraction>&#160;million of pretax net losses on cash flow hedges from accumulated other comprehensive loss to other&#8211;net, (income) expense. During the three months ended March&#160;31, 2021 and 2020, the amounts excluded from the assessment of hedge effectiveness recognized in other comprehensive income (loss) were not material.</span></div></ix:continuation><div style="margin-top:9pt"><span><br/></span></div><div style="margin-top:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i5a4a5e658e7749f285b927855e6cc7fd" continuedAt="i64ded331eb5a429a8a17f28c70a6cac3"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Financial Instruments</span></div><ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTQ4NTA_b38730a1-9e8f-499a-98d2-1a61a5fc301a" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize certain fair value information at March&#160;31, 2021 and December&#160;31, 2020 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:34.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other<br/>Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0468ac52ec0a40758c116186c956d819_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMy0xLTEtMS0w_305307bc-3e5e-4f81-b0d7-b14e9cbf2786">1,554.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i259ea4a4728c4829bf5a1d53b88fe316_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMy0zLTEtMS0w_ab5c1787-e111-481f-bcde-2c43c950ce72">1,554.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i379b7bdd53b04924a6915f7b6f539ae9_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMy01LTEtMS0w_1b44dc38-278c-4fe2-8504-843ff8eea6f0">1,554.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i502fd03d8e8b42f384a0637943ac9227_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMy03LTEtMS0w_cee65b4d-1992-489d-9d97-c6341118c48a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i110e7dd739b14882b203dd13e31a425d_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMy05LTEtMS0w_d8363081-4d3d-4407-b24c-e15a832e8561">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b1fc639100545e8b40e4cfd5886def1_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMy0xMS0xLTEtMA_08e0db31-f09c-4ade-8fcf-8f9a05fa040d">1,554.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50db401e52d34c6bbb22d8b87c712ee3_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNi0xLTEtMS0w_5001c7cf-479f-444f-b868-632ccefc2172">20.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d9b74593ec94447a6448aee79dc1a4f_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNi0zLTEtMS0w_a4d29ff9-e3db-4b60-b4b3-54987a8e32ef">20.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11210e6bf5044a31804dbf8297477c5b_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNi01LTEtMS0w_444894d1-5db3-48c5-82fa-3d9b9aa7991d">20.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4fe1622f184cf9a797fcf2b732d7fe_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNi03LTEtMS0w_76e9970c-c30a-43d0-bcd5-c8b234d4587a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c35346f0f3b44448000e57b1d0d71cf_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNi05LTEtMS0w_c17ed7a8-d156-4aef-a74e-0d0ee0287a21">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e2ffab98d7f45a0a3b806e73e461745_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNi0xMS0xLTEtMA_8b507bd8-f009-49db-b88e-19e4e97d7bf3">20.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab695d20c84c457e96ce06476d8e182f_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfOC0xLTEtMS0w_c8f0cd03-6171-40cf-b0c7-f313ac338a91">7.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6474daeefd44828fcb9effa40e0c54_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfOC0zLTEtMS0w_c3ae9805-60a7-4394-b476-49532a51b9d0">7.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e03a9ef9cef4a99bcd45329382a4b01_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfOC01LTEtMS0w_8296b48b-6da1-4553-a42d-848fdf9cb558">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6f572bcda8c4de4b675b9afeb36f32c_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfOC03LTEtMS0w_3f38441b-e0db-4fb3-ae63-5e5a49bdfbba">7.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5321b80fe49f4dc4a8096c02973ab7ab_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfOC05LTEtMS0w_4a8c1046-4ad0-4750-b68d-8f5cdc53ba84">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5fc37a695a4b88b864b0b0f8a57e93_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfOC0xMS0xLTEtMA_75316296-594f-49e9-a6ac-8bbb3472b260">7.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94d22e93a3ad41848489c4810cedd352_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfOS0xLTEtMS0w_43e593c4-52ad-404c-b177-c95af62823a8">2.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8aef2fe7df7413a99dc9b367490fdba_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfOS0zLTEtMS0w_0e339da6-ca0f-48eb-b0ec-2056d473139f">2.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21ff33225cde42d38dd508e225243ffe_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfOS01LTEtMS0w_0eec8368-0515-4fd7-b894-e33dc599f5cd">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i094cfa08457b4639b53077e02b7b579b_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfOS03LTEtMS0w_85db2fa0-f1da-4d49-b36f-768b89c1fd1f">2.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39943827be2c4f9ea50a2cdfca84df2b_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfOS05LTEtMS0w_bbb57532-4d72-404e-bbec-f1c1bddc89b8">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaeb507e6d804976ad515b86786c2663_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfOS0xMS0xLTEtMA_cc18196e-23a7-4093-a913-1255b3415609">2.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd103e4954f440de8adec2b901b7d26f_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTAtMS0xLTEtMA_6c33b19e-dd1f-4f0f-8059-e24d5ef0cf39">18.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2765888bb9a44e86856eb0e40a7a95a1_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTAtMy0xLTEtMA_bdae86e9-270f-4789-a4ed-dab0c91d6798">18.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i937ee9f927b84aafaa8fd46c3071e390_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTAtNS0xLTEtMA_bf96ca64-0d7f-4879-bde3-a724ef9f18f9">18.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5623a1b5a79348899d40b0b51b54335e_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTAtNy0xLTEtMA_915ac37f-a9eb-4127-89a9-b8d8593ed452">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i273c3175cdf54c6d9bd6414b446f3ab2_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTAtOS0xLTEtMA_2b2a6575-0455-4d5d-8faf-bfbfef2418bd">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib521cd4c99774b97881a80a2a1c9c35d_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTAtMTEtMS0xLTA_af9df4bd-b40e-44d8-b1e0-3c4751883e4e">18.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0468ac52ec0a40758c116186c956d819_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTItMS0xLTEtMA_630e609a-c67e-43e4-8681-b578671c2d0f">49.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50db401e52d34c6bbb22d8b87c712ee3_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTUtMS0xLTEtMA_c657e494-da39-4bde-b0b5-93f55008ebbc">109.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d9b74593ec94447a6448aee79dc1a4f_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTUtMy0xLTEtMA_8415a7c8-5d4b-4a15-aeba-12171ebb931b">108.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11210e6bf5044a31804dbf8297477c5b_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTUtNS0xLTEtMA_7985bec2-d53e-409e-bdd5-e5ff093e49f9">109.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4fe1622f184cf9a797fcf2b732d7fe_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTUtNy0xLTEtMA_09b1cbda-25b9-4e55-a37f-c9bd524ceea4">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c35346f0f3b44448000e57b1d0d71cf_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTUtOS0xLTEtMA_5fe18368-4f6e-45c8-b4d5-fc68bfcff512">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e2ffab98d7f45a0a3b806e73e461745_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTUtMTEtMS0xLTA_48baff9d-d3eb-48ac-8702-c7ab12810e14">109.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab695d20c84c457e96ce06476d8e182f_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTctMS0xLTEtMA_4455579c-d0ca-446f-8732-328ba91caa80">177.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6474daeefd44828fcb9effa40e0c54_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTctMy0xLTEtMA_ee61749e-aebf-4e38-a1db-3315c64b67d7">175.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e03a9ef9cef4a99bcd45329382a4b01_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTctNS0xLTEtMA_a2867d81-a71e-4476-9c72-ec2b236370bc">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6f572bcda8c4de4b675b9afeb36f32c_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTctNy0xLTEtMA_086816f0-0921-49ff-8a89-8b39908b22d3">177.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5321b80fe49f4dc4a8096c02973ab7ab_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTctOS0xLTEtMA_67dbe50e-b0cd-4afe-8fae-7efc580d6b21">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5fc37a695a4b88b864b0b0f8a57e93_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTctMTEtMS0xLTA_e922801e-bc1e-41bf-832c-09ace39ebae4">177.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49b67199341a409fb3c610a89020e4e4_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTgtMS0xLTEtMA_ddf23040-3a23-4b79-99c5-a7c7c082f80f">102.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d997ddd2afa4e4aa435ed61a0039a79_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTgtMy0xLTEtMA_6071b5fd-2d65-425a-896e-273ed0c73de8">99.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i162abcddb00540a6b88917d1b8c94bc8_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTgtNS0xLTEtMA_7470e1a4-f8f9-4699-84a6-0f4ac50e5781">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70666e8c06ae4150b3d53ba8f358e55b_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTgtNy0xLTEtMA_18179c9f-996f-459c-bbea-6c05c4013ad7">102.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b8e28324e994e5a9e7af4dd5abbfa4b_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTgtOS0xLTEtMA_a14ff7dd-d173-4ddb-ab67-e7956567f0b6">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cef5c921b4d4a13aa14e51caae1e54c_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTgtMTEtMS0xLTA_683cab71-6b95-4d41-8aca-b124efc7afad">102.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94d22e93a3ad41848489c4810cedd352_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTktMS0xLTEtMA_eeba3c59-197e-4460-bb85-361047755a32">23.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8aef2fe7df7413a99dc9b367490fdba_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTktMy0xLTEtMA_6585d34d-02aa-4827-b473-a3aaf46b2244">23.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21ff33225cde42d38dd508e225243ffe_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTktNS0xLTEtMA_e3300b37-d303-4379-b4f0-7271b1e31a99">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i094cfa08457b4639b53077e02b7b579b_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTktNy0xLTEtMA_d8efcf92-3bc8-4a66-9568-5f3838c7ff76">23.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39943827be2c4f9ea50a2cdfca84df2b_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTktOS0xLTEtMA_7c511fbe-9544-4989-a4d6-335e365268fe">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaeb507e6d804976ad515b86786c2663_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTktMTEtMS0xLTA_f0af32d1-6642-442b-b28f-ef8b20323e6c">23.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45eb28a2afb843b5a7599d09796ba47a_I20210331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjAtMS0xLTEtMA_f1f2a827-a7bd-4404-bca9-071a301ee27c">110.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c96a7e6ebdb4b5894e42f4f674afc2f_I20210331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjAtMy0xLTEtMA_2155c07a-ee33-440a-a18a-bb40e3ca9646">30.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35a6dbafa15745eabd7e346fc0404f3c_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjAtNS0xLTEtMA_02a4de54-2cfa-433c-a29c-2382746976fa">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie03e1c230dbe49b5b1a23948beb4fdf8_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjAtNy0xLTEtMA_9466ec16-967b-4045-9b07-5d3b6007219e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4814dc5f3094945b14b09c32634e414_I20210331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjAtOS0xLTEtMA_79bf8922-6baa-476b-be66-90b689dedf0c">110.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5428a6a7e77a4afc87dbec371aa0e81b_I20210331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjAtMTEtMS0xLTA_182e5dd5-b07f-41ca-a545-889c72e4a758">110.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b460fcffdff4102b1a5f350e775eb50_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjEtMS0xLTEtMA_d80e48d9-7dae-4684-8ec8-fbaffad9d186">1,645.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68b41c9f5b24461e99ffaf90ae7df35e_I20210331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjEtMy0xLTEtMA_3c94ee45-f007-4d98-a54b-6e2ec1433d83">386.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07692a7baeb34e989f264a119af0c6a3_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjEtNS0xLTEtMA_8e82fbd1-fac4-4a1e-98ce-ff673eb202fa">1,645.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cc36d48d552416e883d9009bfca5133_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjEtNy0xLTEtMA_6b6c4f8e-5b17-4f54-be54-44653ac9a75f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id251b7aadbd741c38319af027dda2015_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjEtOS0xLTEtMA_9dfa2938-0e29-4296-9b4e-d6b31c7aef7a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie57e8b8550a94ed3a3001f7258f40509_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjEtMTEtMS0xLTA_d47ab838-3910-4a6a-9cb9-766161dfde1a">1,645.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0468ac52ec0a40758c116186c956d819_I20210331" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjItMS0xLTEtMA_56f5323f-f7a3-4992-9b64-853bb18725c7">384.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie22efb639d76469d92d9d05b55c13b2e_I20210331" decimals="-5" name="us-gaap:OtherLongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjMtMS0xLTEtMA_570f0405-9674-4d15-a351-e7db8b3fec1f">679.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0468ac52ec0a40758c116186c956d819_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjQtMS0xLTEtMA_b1f7147f-a7af-4e0a-a124-f6b449bc6db0">3,232.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5244871105b411bba98a34bdca3bb0f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjctMS0xLTEtMA_3b56f49c-2559-4d49-9964-c155d7dd316e">2,097.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7364db11b9f4acc956a7d2db362e700_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjctMy0xLTEtMA_a72d586c-c4e3-42de-924c-16a634e54c58">2,097.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc89d6e873484ce2a724580ab1fb0293_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjctNS0xLTEtMA_d84f1b00-8057-4800-b5b0-f119a95d2b53">2,097.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib227796e6d934483a3898110d9a529dd_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjctNy0xLTEtMA_cf853136-5202-4e92-8fe8-393a021304b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic99278c5824b4d0d9f4dabbc783d760a_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjctOS0xLTEtMA_674c70b6-6f9f-4672-8e60-fe4493994ed6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i173d02bf976949bb9c2fff706b29e7c8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjctMTEtMS0xLTA_bbbc985b-9e6b-4a70-9356-3b886ad1dcab">2,097.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaca67a3e336f480dbf5c62f2d4887602_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzAtMS0xLTEtMA_e605251d-cf6a-4e6f-86b3-df45b2fdf25d">9.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2385ee7845f44db9928643d251ba010f_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzAtMy0xLTEtMA_b7ba7d81-4620-4df7-928c-f9edd416d250">9.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2a7caef4a994ecfa2504a1f8fab161d_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzAtNS0xLTEtMA_61e620d8-c63b-4de4-a787-10963787c0bb">9.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i674d272a65ea4e939a918cbd40640fad_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzAtNy0xLTEtMA_d82a5741-bc5a-4e1e-b28e-6b3bf2ad2155">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5ba42bd6f784aae8d55cfe3e64aaebb_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzAtOS0xLTEtMA_5f750a51-2f0b-4418-aeff-f726d04329d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8e950975814a17bb0570d6ed036339_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzAtMTEtMS0xLTA_988f0318-c280-4e45-8a18-105c6049bdfd">9.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab6a22cd5a3647489cfa1868842fce27_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzEtMS0xLTEtMA_9520042f-813a-4413-a18a-6d8abe4e6a1c">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id94556bfa50648c6896a229ad967ebdb_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzEtMy0xLTEtMA_392b6ac7-c081-480c-a4c7-cdc70f32f2a5">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ba9c3716f03494583ac46573df6d898_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzEtNS0xLTEtMA_8f224b66-824e-49ba-ab34-d1cf93893309">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3f1ae733c62431ea7747e533857a063_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzEtNy0xLTEtMA_7b1fbba1-1785-46be-b96a-15d1ee3d4663">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e05c6e58a3e45f9bbc6bfe65eb5fb24_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzEtOS0xLTEtMA_80d8ce9d-0064-4469-9b23-9ac8477ab784">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15f60e22ff78453692beb5eecfca6ffc_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzEtMTEtMS0xLTA_854c0199-4848-4295-bcc9-29505a7b4a36">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd7549721eee45bb8a3527258d461fd4_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzItMS0xLTEtMA_6dcfd230-d788-4d0a-bccb-44788dc5f576">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f9525a450be44ef9048544d4294da74_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzItMy0xLTEtMA_445a44a8-1d00-488a-bd4c-5fc40974eda7">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65bf701b377c4beda33939db2d2f21ff_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzItNS0xLTEtMA_480fc4bb-7966-45db-b254-21bee997941d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55aec24c88d44f4fa43277cc7538aab2_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzItNy0xLTEtMA_484e2818-3659-4d91-b278-43f536981550">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a3b14dc8874f0c86a0d3eb37f253a0_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzItOS0xLTEtMA_d7d89220-7dd7-4451-94d1-3d7069b0d618">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i853e5949474b4d67b1db52061559bac8_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzItMTEtMS0xLTA_8a3f7853-de78-481c-8005-40e968e76b64">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb0f7206c077458c83a576a665d51173_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzMtMS0xLTEtMA_210b37b2-fa22-4b66-b53d-1047e827621a">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb18caa1f88e42d389a9b17c85b0d9bd_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzMtMy0xLTEtMA_1e950c07-af93-4ae2-8003-f7fd961ce22b">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43215dcd05be459096efcec752179430_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzMtNS0xLTEtMA_8269aa0f-7754-44e4-ab90-173d93e2bba2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c52e457bd4422ca65d6e22cb0ade48_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzMtNy0xLTEtMA_06f65f5d-505e-4cda-9379-b69c6c9f2b27">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1389fc9ec68d4b2db27d6a8e3bbd4bf1_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzMtOS0xLTEtMA_9c8fba3a-50aa-47a6-819c-c5e0928d3482">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3c4f4f185ab4ad881bcc56455b80c21_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzMtMTEtMS0xLTA_34f80914-83a2-4238-bab2-fcc13ae39c16">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5244871105b411bba98a34bdca3bb0f_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzUtMS0xLTEtMA_bef91bd3-e4cb-472c-b643-99379d7b920c">24.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaca67a3e336f480dbf5c62f2d4887602_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzgtMS0xLTEtMA_970a8ca8-e7c3-49b1-9245-4b59c910a902">78.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2385ee7845f44db9928643d251ba010f_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzgtMy0xLTEtMA_b932469e-39b9-4ccd-b808-f2f64898e09b">74.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2a7caef4a994ecfa2504a1f8fab161d_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzgtNS0xLTEtMA_ba5ad492-fefe-4689-9d01-deeb83bdeef9">78.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i674d272a65ea4e939a918cbd40640fad_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzgtNy0xLTEtMA_bf664bef-9459-4093-b1a3-20c667ae9267">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5ba42bd6f784aae8d55cfe3e64aaebb_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzgtOS0xLTEtMA_ef1d6cb6-756c-406b-85a1-b21bcfc17fa4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8e950975814a17bb0570d6ed036339_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzgtMTEtMS0xLTA_d821f161-d7aa-4c96-abad-d77974949bb1">78.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab6a22cd5a3647489cfa1868842fce27_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzktMS0xLTEtMA_5199021c-b611-47f7-b995-fab6c6b6910f">137.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id94556bfa50648c6896a229ad967ebdb_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzktMy0xLTEtMA_d9cea973-06e8-446f-b32b-726e052a891e">126.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ba9c3716f03494583ac46573df6d898_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzktNS0xLTEtMA_eea61346-585c-4b51-80ad-17bad380ec69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3f1ae733c62431ea7747e533857a063_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzktNy0xLTEtMA_6474128e-b873-4556-8c5e-5b5174ee949f">137.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e05c6e58a3e45f9bbc6bfe65eb5fb24_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzktOS0xLTEtMA_302433ad-7cce-44ab-9380-1c14040bd15f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15f60e22ff78453692beb5eecfca6ffc_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzktMTEtMS0xLTA_aea5a02e-4edf-4c31-9a42-c2b6654c03f5">137.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79853a9b5da14a6fac53703381e9a418_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDAtMS0xLTEtMA_cbc05334-f109-40c1-8b9c-d08705942e39">106.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33320e06f4274ef9845c5efab8d73bb1_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDAtMy0xLTEtMA_1ab017d1-c28c-42c5-a265-21a9f55d7122">101.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b2eb8a9c98a498ca9bf40a99de8f49a_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDAtNS0xLTEtMA_64851bc3-1a16-4d34-9feb-6c08dd391cad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib04cc817383740faa1e617ece927631a_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDAtNy0xLTEtMA_1dde1e21-4f0f-41c4-8356-7daa8dd30677">106.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id384954fa3fa4e6095584ab30e130a4e_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDAtOS0xLTEtMA_da4e22fd-ec6f-4dc1-ada8-6d9f95497cf4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8955bee463a4261b77faca6da120420_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDAtMTEtMS0xLTA_fc1dde88-c332-419a-9986-c8a188e08c25">106.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd7549721eee45bb8a3527258d461fd4_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDEtMS0xLTEtMA_f22b66ff-3ad3-41b2-8c58-42eb20000f72">24.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f9525a450be44ef9048544d4294da74_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDEtMy0xLTEtMA_f142f20d-8cee-40d4-be59-ba554646d9a7">23.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65bf701b377c4beda33939db2d2f21ff_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDEtNS0xLTEtMA_ac588570-9bae-4a63-a80d-a011e15d99d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55aec24c88d44f4fa43277cc7538aab2_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDEtNy0xLTEtMA_d7b59a16-ef0c-4904-9023-c9ee619fda65">24.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a3b14dc8874f0c86a0d3eb37f253a0_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDEtOS0xLTEtMA_2bee3c94-7f9a-4c29-a422-7ed2451318c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i853e5949474b4d67b1db52061559bac8_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDEtMTEtMS0xLTA_b2cce36a-89d0-4ef6-8d26-a56b8220f244">24.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e8796c582de405f85453b6be2e3dc09_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDItMS0xLTEtMA_47f0261e-1a0f-46d6-acd6-58796897fb68">110.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57b6463cf5a4132bbba6db81c527ec0_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDItMy0xLTEtMA_fe9a1c65-048a-4007-ac7f-8d9410ab9f7a">31.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65887bb8147d4233b2936ee964d36760_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDItNS0xLTEtMA_117ec505-425a-492a-add4-be46679dee5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45624739b2404896b6fe384552b5797f_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDItNy0xLTEtMA_42eb1b7c-3056-4b85-a1b9-1cbd6c785c47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bd77315f3640e2b75151bd1a403bd6_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDItOS0xLTEtMA_2bbcb288-22d1-4837-9f97-259a30ab10a0">110.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095078139e5147baa3f7c5a93913c9f2_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDItMTEtMS0xLTA_da18f102-f9a8-45c3-9b19-6c518346062c">110.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41723e47817543c98de3be1e9ac4e77b_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDMtMS0xLTEtMA_97a97ecc-1927-4a58-8fef-0003df5cd589">1,664.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide25b210128b49279f9dcc009920c562_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDMtMy0xLTEtMA_07c1d570-71a7-43ea-96cf-b19e5fdbe5f1">311.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ed173a5c7554ed8a6efa974dce7de56_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDMtNS0xLTEtMA_99f26ccd-48ba-478f-b792-d0265d6e6810">1,664.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8841002a34004d4d894ac4dd47bba8cf_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDMtNy0xLTEtMA_f0fdfca5-b7e7-4449-a26f-bdd29661abc8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd5d2cfe7b1c4e6293342168871eb584_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDMtOS0xLTEtMA_e9097022-477c-4449-a44b-6a43697da0d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1862e16eb5894cbb872c6ebca5ff8dda_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDMtMTEtMS0xLTA_bc6bc761-a47b-4980-8b13-89cd76a2f9d7">1,664.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5244871105b411bba98a34bdca3bb0f_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDQtMS0xLTEtMA_b55220ed-5538-4faa-89d3-ab7ab161c67c">373.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a8f781677394edcb970a7db2a230211_I20201231" decimals="-5" name="us-gaap:OtherLongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDUtMS0xLTEtMA_86d1ff83-be72-44a8-b004-7431f6cce0b5">471.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5244871105b411bba98a34bdca3bb0f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDYtMS0xLTEtMA_ab120fab-f284-4bb7-8a70-307bb77701ff">2,966.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments.</span></div></ix:nonNumeric></ix:continuation><ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTQ4ODY_62bbef02-549b-410e-ab88-b58c8704c202" continuedAt="if6f44c3e90d94250ac5b37e16e1910c8" escape="true"></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><ix:continuation id="i64ded331eb5a429a8a17f28c70a6cac3" continuedAt="i1d62df419fa945308db6f1acecd83e81"><ix:continuation id="if6f44c3e90d94250ac5b37e16e1910c8"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:38.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.916%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt, including current portion</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0468ac52ec0a40758c116186c956d819_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjU3NDI3NzkxMTg2NzRmNDJhZjQ5MWU2YzhkM2UyNTlmL3RhYmxlcmFuZ2U6NTc0Mjc3OTExODY3NGY0MmFmNDkxZTZjOGQzZTI1OWZfNi0xLTEtMS0w_aa7ed7bc-3614-499b-8c28-8aae4291562d">16,204.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i379b7bdd53b04924a6915f7b6f539ae9_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjU3NDI3NzkxMTg2NzRmNDJhZjQ5MWU2YzhkM2UyNTlmL3RhYmxlcmFuZ2U6NTc0Mjc3OTExODY3NGY0MmFmNDkxZTZjOGQzZTI1OWZfNi0zLTEtMS0w_677ab780-b0ce-4862-835a-8c58a0af7c19">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i502fd03d8e8b42f384a0637943ac9227_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjU3NDI3NzkxMTg2NzRmNDJhZjQ5MWU2YzhkM2UyNTlmL3RhYmxlcmFuZ2U6NTc0Mjc3OTExODY3NGY0MmFmNDkxZTZjOGQzZTI1OWZfNi01LTEtMS0w_bafb101a-287a-44d9-baa5-549e58618d49">17,462.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i110e7dd739b14882b203dd13e31a425d_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjU3NDI3NzkxMTg2NzRmNDJhZjQ5MWU2YzhkM2UyNTlmL3RhYmxlcmFuZ2U6NTc0Mjc3OTExODY3NGY0MmFmNDkxZTZjOGQzZTI1OWZfNi03LTEtMS0w_31d6fce1-e1a8-4a28-baca-203f72940ff7">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b1fc639100545e8b40e4cfd5886def1_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjU3NDI3NzkxMTg2NzRmNDJhZjQ5MWU2YzhkM2UyNTlmL3RhYmxlcmFuZ2U6NTc0Mjc3OTExODY3NGY0MmFmNDkxZTZjOGQzZTI1OWZfNi05LTEtMS0w_b0708977-c750-4bda-904f-fa1cd373b3f4">17,462.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5244871105b411bba98a34bdca3bb0f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjU3NDI3NzkxMTg2NzRmNDJhZjQ5MWU2YzhkM2UyNTlmL3RhYmxlcmFuZ2U6NTc0Mjc3OTExODY3NGY0MmFmNDkxZTZjOGQzZTI1OWZfNy0xLTEtMS0w_fba37efc-19b8-4f59-bf1c-a01c094ecf7b">16,595.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc89d6e873484ce2a724580ab1fb0293_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjU3NDI3NzkxMTg2NzRmNDJhZjQ5MWU2YzhkM2UyNTlmL3RhYmxlcmFuZ2U6NTc0Mjc3OTExODY3NGY0MmFmNDkxZTZjOGQzZTI1OWZfNy0zLTEtMS0w_e63b4510-a86e-49de-b880-36904010d300">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib227796e6d934483a3898110d9a529dd_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjU3NDI3NzkxMTg2NzRmNDJhZjQ5MWU2YzhkM2UyNTlmL3RhYmxlcmFuZ2U6NTc0Mjc3OTExODY3NGY0MmFmNDkxZTZjOGQzZTI1OWZfNy01LTEtMS0w_6a0437b5-45cd-4060-8b06-1e25e901bf7c">19,038.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic99278c5824b4d0d9f4dabbc783d760a_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjU3NDI3NzkxMTg2NzRmNDJhZjQ5MWU2YzhkM2UyNTlmL3RhYmxlcmFuZ2U6NTc0Mjc3OTExODY3NGY0MmFmNDkxZTZjOGQzZTI1OWZfNy03LTEtMS0w_0bf073e6-1fe1-4ec1-83fc-8989bb1ec36c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i173d02bf976949bb9c2fff706b29e7c8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjU3NDI3NzkxMTg2NzRmNDJhZjQ5MWU2YzhkM2UyNTlmL3RhYmxlcmFuZ2U6NTc0Mjc3OTExODY3NGY0MmFmNDkxZTZjOGQzZTI1OWZfNy05LTEtMS0w_74eb80c7-fae0-4ebb-89a0-45fea65cc1dd">19,038.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTQ4NTI_418f5d28-67f4-4993-b6f1-46d1bb1738db" continuedAt="id115a781d8614a49a5fc47709721b2fc" escape="true"></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1d62df419fa945308db6f1acecd83e81" continuedAt="iefeeeb2db2294664bccd8c84b545e9e8"><div style="margin-top:11pt"><ix:continuation id="id115a781d8614a49a5fc47709721b2fc"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.981%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-management instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0320b4ac23843468622fdd30e513355_I20210331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNi0xLTEtMS0w_1c36095a-1ac3-4f2a-a70e-72eeaa7ab1ac">87.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id725308cf9eb4e51afe628b2f6dd2bfa_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNi0zLTEtMS0w_953271b3-eadf-4b6d-82c0-198ee835ab6c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df56ec982804883a504fffec19bec2b_I20210331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNi01LTEtMS0w_06874db9-8311-429a-a113-a993e69c65bf">87.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i818be88d8b754d358fa8f0f48530989d_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNi03LTEtMS0w_6b1beb08-608e-480e-8932-e14e458b0c22">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4605596f0c549af8b2aa8ac2b0821f7_I20210331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNi05LTEtMS0w_8f699b1d-ebaa-4357-928d-7104912569f5">87.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0320b4ac23843468622fdd30e513355_I20210331" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfOC0xLTEtMS0w_7dbae019-a024-4457-9032-74013df60bea">9.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id725308cf9eb4e51afe628b2f6dd2bfa_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfOC0zLTEtMS0w_afa251bd-85f0-4975-a2e8-7bef580087ab">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df56ec982804883a504fffec19bec2b_I20210331" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfOC01LTEtMS0w_6df1c79f-3d4f-4d12-8939-708bd7d328bd">9.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i818be88d8b754d358fa8f0f48530989d_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfOC03LTEtMS0w_f7676b95-0f38-4b50-9af3-42b7a6b2d014">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4605596f0c549af8b2aa8ac2b0821f7_I20210331" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfOC05LTEtMS0w_38e13996-c331-4a63-a093-6f59891567e6">9.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff50ed7383624a5dabf03016acb58cb4_I20210331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTItMS0xLTEtMA_c6f712b5-13b0-4388-83e7-f024dd5a290b">235.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic22a911ebb564c3e8e5e11aebe36daf2_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTItMy0xLTEtMA_b826fac3-2586-4cc5-b4fc-7219e12cb2c7">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3791d236011c495c9a6bc09f31e0e651_I20210331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTItNS0xLTEtMA_f826691c-1c93-4c8a-99dc-5d57c016feff">235.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eef9a676fef442f8cc0df6224b88661_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTItNy0xLTEtMA_851f1258-42b6-45ea-ab20-a7663f61b7eb">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f4f985dfc4c4913b6b477e42c5b7abf_I20210331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTItOS0xLTEtMA_340bc596-6b1e-409a-ae23-498108bcacff">235.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97f888ed727b47c4969964bbc26cee74_I20210331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTUtMS0xLTEtMA_a94e044c-d8a7-433a-b313-294d535a3f0e">12.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb9cad6e8ee145a28421160b0fd93ac8_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTUtMy0xLTEtMA_d79d385a-bb9b-42b4-a79f-0eaf18c9c894">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc00ea5651d44a68866912b87e772f32_I20210331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTUtNS0xLTEtMA_eadd6b5a-c837-4f1c-b569-cfa6257ae56a">12.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9728137c063040fdb217c0c575d24e90_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTUtNy0xLTEtMA_1999e081-f4af-4b86-9aab-16c129289bfa">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5691e9a962e48b9bab39a38eebafc58_I20210331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTUtOS0xLTEtMA_b21aadb2-0bfd-4b1c-ac59-c6532071e6d2">12.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97f888ed727b47c4969964bbc26cee74_I20210331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTYtMS0xLTEtMA_f07fc2c8-4da0-40d8-a700-691bb87b77e3">39.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb9cad6e8ee145a28421160b0fd93ac8_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTYtMy0xLTEtMA_f1715ef5-1023-40e4-926d-45e0d19c41da">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc00ea5651d44a68866912b87e772f32_I20210331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTYtNS0xLTEtMA_e38d1b8c-18fd-46a2-a975-2d578d822fc6">39.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9728137c063040fdb217c0c575d24e90_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTYtNy0xLTEtMA_5631ebc0-d01d-4225-96f7-f2d6fd6ea0d0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5691e9a962e48b9bab39a38eebafc58_I20210331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTYtOS0xLTEtMA_5cb98137-7c44-43f5-a6d6-f72d893c2777">39.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97f888ed727b47c4969964bbc26cee74_I20210331" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTctMS0xLTEtMA_87e2c300-8796-4e2d-9969-d2722bdd4ba9">45.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb9cad6e8ee145a28421160b0fd93ac8_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTctMy0xLTEtMA_faaeb623-8962-4d77-a897-228e0bd658eb">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc00ea5651d44a68866912b87e772f32_I20210331" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTctNS0xLTEtMA_16cf1f95-ca19-47e0-a2e1-e5cbfab5f8dc">45.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9728137c063040fdb217c0c575d24e90_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTctNy0xLTEtMA_d0e8946d-f687-43c7-8f68-1ab6df90d93a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5691e9a962e48b9bab39a38eebafc58_I20210331" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTctOS0xLTEtMA_60c5d0a2-9886-48a7-90b6-79e016fe84f6">45.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97f888ed727b47c4969964bbc26cee74_I20210331" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTgtMS0xLTEtMA_42beaf6d-45c1-4c25-83be-788d38339c67">19.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb9cad6e8ee145a28421160b0fd93ac8_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTgtMy0xLTEtMA_1d5dd257-81af-4633-abbd-6f02e83788c7">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc00ea5651d44a68866912b87e772f32_I20210331" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTgtNS0xLTEtMA_daa52edc-3907-4a79-b637-09161544f8a5">19.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9728137c063040fdb217c0c575d24e90_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTgtNy0xLTEtMA_1abec63d-78ce-42a5-84a9-0e93cc5f8654">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5691e9a962e48b9bab39a38eebafc58_I20210331" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTgtOS0xLTEtMA_442b2f8c-b002-4e46-8e2f-43de3868dd1b">19.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8f794d05abe4bb88fcbc982b4151ef0_I20210331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjAtMS0xLTEtMA_f5ffaa5c-bd09-4305-80b1-15f790dd40e0">3.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i083270152267493cab8ef4a98752605d_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjAtMy0xLTEtMzI4Mg_f788c07e-0e7d-4472-836e-025b0261a946">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb4db963049a418ebc24c7b6962c9c42_I20210331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjAtNS0xLTEtMA_92692327-e6a7-4b60-8662-9b8d499d7bee">3.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df54907b9c740578baa39b1f16db346_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjAtNy0xLTEtMzI4Mg_7e5fd5db-0b26-4043-ba61-c251ecb7fc72">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9868066d4bf64c67b21b80f50a543d09_I20210331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjAtOS0xLTEtMA_42ded5ab-0eba-423b-a190-8ceb2ff7c96b">3.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8f794d05abe4bb88fcbc982b4151ef0_I20210331" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjEtMS0xLTEtMA_826331c7-e264-447d-82c4-f5853f31a466">16.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i083270152267493cab8ef4a98752605d_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjEtMy0xLTEtMA_ae2c15e2-becb-475b-bbeb-f8880c0cae45">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb4db963049a418ebc24c7b6962c9c42_I20210331" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjEtNS0xLTEtMA_dcddb1e6-27cb-4854-961f-da0ef48f179b">16.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df54907b9c740578baa39b1f16db346_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjEtNy0xLTEtMA_6979ccf7-670d-4e36-8852-1b32798acc4e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9868066d4bf64c67b21b80f50a543d09_I20210331" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjEtOS0xLTEtMA_1324c55e-9db6-419a-bbfa-1e59f2e6c675">16.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3477ea907754af1b237c11ecd845a8c_I20210331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjMtMS0xLTEtMA_3dadf9e3-90e2-4eca-bb48-bf31562f2835">14.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5579461ee30641f5866f90f7f973fc2d_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjMtMy0xLTEtMA_28ebe9b2-fc77-49a0-96cf-3e46e08c0a0b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c522dc4d3644e6b89e1c04ae748b784_I20210331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjMtNS0xLTEtMA_72da6b88-ecce-41bc-acfc-775a3d774f59">14.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4028304ed5344f378d4d8453889c1244_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjMtNy0xLTEtMA_cb1e3809-7c08-41cc-beca-4c5cd19e4c32">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c3b7e0e20ce4aa79064e5c448631a6e_I20210331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjMtOS0xLTEtMA_c7d668d3-e879-4b6d-ab8e-6f5f82677006">14.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3477ea907754af1b237c11ecd845a8c_I20210331" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjQtMS0xLTEtMA_2b6834f0-7d7c-4ec1-b624-b1c8221ea16a">66.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5579461ee30641f5866f90f7f973fc2d_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjQtMy0xLTEtMA_ec9a237e-9be6-43f1-aa89-0db903fbcf66">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c522dc4d3644e6b89e1c04ae748b784_I20210331" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjQtNS0xLTEtMA_7ebba9a8-6f27-44c4-9b48-655920986ed5">66.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4028304ed5344f378d4d8453889c1244_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjQtNy0xLTEtMA_a1e101b8-427b-4d43-9725-a45a66ffefb4">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c3b7e0e20ce4aa79064e5c448631a6e_I20210331" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjQtOS0xLTEtMA_675cf999-46bd-4391-9fc5-03ff0d642205">66.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liability:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0468ac52ec0a40758c116186c956d819_I20210331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjktMS0xLTEtNzY4NQ_84da6db7-cdbb-4006-a62c-9962566b886d">71.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i379b7bdd53b04924a6915f7b6f539ae9_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjktMy0xLTEtNzY4NQ_4cb0aa99-ee22-4980-8fdb-e634405a4abe">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i502fd03d8e8b42f384a0637943ac9227_I20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjktNS0xLTEtNzY4NQ_1cfa9373-5edd-4bbf-a7ed-f90d9bcbd758">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i110e7dd739b14882b203dd13e31a425d_I20210331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjktNy0xLTEtNzY4NQ_ba6bdddb-8fd6-4353-897c-ab0885682359">71.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b1fc639100545e8b40e4cfd5886def1_I20210331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjktOS0xLTEtNzY4NQ_ba0c4b2c-2d34-4d66-98cb-f43c116ae983">71.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-management instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i835b04928dc34e3d9eb5b6a882d6a434_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMzUtMS0xLTEtMA_7462ab78-c251-4a85-8c1b-064be14e96cd">158.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59341bae0f284bb79a7771c86ff861f4_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMzUtMy0xLTEtMA_52a151a4-bca3-4334-bbe0-22ef4d0b3aa4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i253bfddb6f414fe3a582437856252d99_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMzUtNS0xLTEtMA_32e2bb8c-d58b-41f6-8069-d3ebf953b843">158.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd815ed694bb4b1da50025622caa47df_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMzUtNy0xLTEtMA_eeef826e-c79c-4769-9135-3ac87867518a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39cd3b104234bdfbcbaedb52a41b15c_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMzUtOS0xLTEtMA_372bcab0-0e55-4d66-97d0-d0bb8a0be136">158.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94f25e4c5e4b42cca659ef04248013aa_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMzktMS0xLTEtMA_f0965049-e4be-4f0e-9c68-ea23d3510745">38.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1893ad6b0e8c4f9d9ce45848acc79e12_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMzktMy0xLTEtMA_c646d7cc-a4ed-4d7e-9ec0-b12dce3d3dc4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541afb2da75d43639f7fec2ae5748d7f_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMzktNS0xLTEtMA_786d6733-2a45-41c5-9fba-28eb2a6223c8">38.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i014bd38c39aa4b1895340e1de5390e79_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMzktNy0xLTEtMA_da61d7da-2328-467a-be32-3d43211ca3c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79425d230e734042bd4df00c16901373_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMzktOS0xLTEtMA_ad139b9e-e51d-40a5-88a5-7aaae14db0a6">38.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94f25e4c5e4b42cca659ef04248013aa_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDAtMS0xLTEtNTQ1Nw_24f78da9-27cd-47e5-a7b9-a94d064d6ca8">97.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1893ad6b0e8c4f9d9ce45848acc79e12_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDAtMy0xLTEtNTQ1Nw_7f405576-7e71-4676-923f-9304bb35d1fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i541afb2da75d43639f7fec2ae5748d7f_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDAtNS0xLTEtNTQ1Nw_bef65268-7a52-42aa-ba56-48878e6ae59b">97.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i014bd38c39aa4b1895340e1de5390e79_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDAtNy0xLTEtNTQ1Nw_c496a71f-34ab-4c86-ae11-12e0cb6a4426">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79425d230e734042bd4df00c16901373_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDAtOS0xLTEtNTQ1Nw_c06cbc78-c248-47f0-ab6e-9cb276e795d6">97.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2553d800f08240b1b782fd37f8f03377_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDMtMS0xLTEtMA_5b1c93cf-c133-47bd-9a3d-d5c537c1c107">92.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdf6391061294c348287bce4418a7767_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDMtMy0xLTEtMA_4591e762-167e-45bf-91ab-a1a3b69a03a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i326c763bfd9e49bdb908141c5104c4c6_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDMtNS0xLTEtMA_8ce13888-830e-43b6-ac05-3e6d1a40ebea">92.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72250a4fe7543458ef88e49f913f39a_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDMtNy0xLTEtMA_0ebd982c-b3b0-446a-ad3a-5cc9e6b88620">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53ee22718d2249e6932918034d9479f7_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDMtOS0xLTEtMA_e2ef42d6-e39d-472e-9a5e-6fbe3a885160">92.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2553d800f08240b1b782fd37f8f03377_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDQtMS0xLTEtMA_8739e0bd-701a-498a-be78-7702ac7f2bf2">97.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdf6391061294c348287bce4418a7767_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDQtMy0xLTEtMA_bead6971-afb8-454c-b2cb-12c627ec6f42">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i326c763bfd9e49bdb908141c5104c4c6_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDQtNS0xLTEtMA_4107cc8e-ded8-49e8-8e22-fe4e0788aa3b">97.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72250a4fe7543458ef88e49f913f39a_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDQtNy0xLTEtMA_18dcc2ba-1c9c-4232-bcb5-e521ab9b92e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53ee22718d2249e6932918034d9479f7_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDQtOS0xLTEtMA_bd2fa48f-21f3-4f56-bca1-02c13ca20b19">97.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11784cd0180b4240bfe628b8a935091b_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDYtMS0xLTEtMA_4d0231af-1c84-41fd-9169-202558746e6c">34.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2b7165b4f9f4b159f2f118447ef21b2_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDYtMy0xLTEtMA_a9a33290-14b2-409c-a41a-cd02e1b57508">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c9d21e349b44826bb9ff73def0b0f9b_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDYtNS0xLTEtMA_bd4a307e-0928-4ddc-8c12-376d4be1b443">34.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i492cf935c87d44ea908c1584da4f932b_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDYtNy0xLTEtMA_5dcc239c-0df9-4aa0-ad0d-e55f9aca31ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86f5f0213b924cf4a2443b1755e0e558_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDYtOS0xLTEtMA_975d87f5-8649-45d9-be8e-b0009b9a0627">34.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11784cd0180b4240bfe628b8a935091b_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDctMS0xLTEtMA_6481c109-1f96-4b51-9540-0c638b2ca246">2.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2b7165b4f9f4b159f2f118447ef21b2_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDctMy0xLTEtMA_82dec22c-a8c9-48ba-b590-12020a9ee4a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c9d21e349b44826bb9ff73def0b0f9b_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDctNS0xLTEtMA_250ca144-49b4-4358-9be8-060016628308">2.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i492cf935c87d44ea908c1584da4f932b_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDctNy0xLTEtMA_c3e0882a-374d-441d-b15c-58d2f8f332fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86f5f0213b924cf4a2443b1755e0e558_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDctOS0xLTEtMA_1d8d58ba-6e27-43a4-8af8-b36234c8f98f">2.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie913be1662fb496dadd88c102ecc6d7f_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDktMS0xLTEtMA_6a691c2f-3202-4546-ac4b-9bd2e95eb6af">41.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5133f4445b424b37b5a24aee0f8c8ad5_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDktMy0xLTEtMA_87cf09b7-f212-4109-a345-5bf081725e9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb9d49fc86e54fa4aef040dc305765cc_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDktNS0xLTEtMA_07d14ea2-d573-48c1-9f2d-72646e032788">41.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34c34c5498af462390f43272c1214aad_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDktNy0xLTEtMA_b5fb6dfc-3cc8-405f-a471-ca33fa834e6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80e1536360e0467e919e75a282b9c273_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDktOS0xLTEtMA_1fb0670a-7226-4a2c-9df2-e9074c274f7a">41.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie913be1662fb496dadd88c102ecc6d7f_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNTAtMS0xLTEtMA_ce6759fe-4323-4a88-8ecc-1af9cf7c75de">15.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5133f4445b424b37b5a24aee0f8c8ad5_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNTAtMy0xLTEtMA_28e08b7e-a601-431a-aaa9-209b90426601">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb9d49fc86e54fa4aef040dc305765cc_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNTAtNS0xLTEtMA_7409c232-216a-4746-833c-c0bcdf9b1aa1">15.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34c34c5498af462390f43272c1214aad_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNTAtNy0xLTEtMA_e372d0a3-ff66-404c-944e-73466e950505">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80e1536360e0467e919e75a282b9c273_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNTAtOS0xLTEtMA_95c96cce-077d-4bb8-b73d-32de64188eda">15.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iefeeeb2db2294664bccd8c84b545e9e8" continuedAt="i0c81e19cfeff48f38c359c634f73f632"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-management instruments above are disclosed on a gross basis. There are various rights of setoff associated with certain of the risk-management instruments above that are subject to enforceable master netting arrangements or similar agreements. Although various rights of setoff and master netting arrangements or similar agreements may exist with the individual counterparties to the risk-management instruments above, individually, these financial rights are not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine our Level 1 and Level 2 fair value measurements based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. Level 3 fair value measurements for other investment securities are determined using unobservable inputs, including the investments' cost adjusted for impairments and price changes from orderly transactions. The fair values of equity method investments and investments measured under the measurement alternative for equity investments that do not have readily determinable fair values are not readily available. As of March 31, 2021, we had approximately $<ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTA5MzM_fb644623-add0-4654-8be0-42bdd5349919">736</ix:nonFraction> million of unfunded commitments to invest in venture capital funds, which we anticipate will be paid over a period of up to <ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" format="ixt-sec:duryear" name="lly:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTEwNTI_43edea2e-b25d-473c-9111-73de4e6f9de9">10</ix:nonNumeric> years. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration liability relates to our liability arising in connection with the CVR issued as a result of the Prevail acquisition. The fair value of the CVR liability was estimated using a discounted cash flow analysis and Level 3 inputs, including projections representative of a market participant's view of the expected cash payment associated with the first potential regulatory approval of a Prevail compound in the applicable countries based on probabilities of technical success, timing of the potential approval events for the compounds, and an estimated discount rate. See Note 3 for additional information related to the CVR arrangement. </span></div><ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTQ4Nzc_fe6c1cc3-3eca-4d12-b6f8-b31c0fffae99" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of March&#160;31, 2021:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:40.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturities by Period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less&#160;Than<br/>1 Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1-5<br/>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6-10<br/>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More&#160;Than<br/>10 Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjcyNmI3YWIwNTg3NTRlOWNiMjY2MGRlOTQwMmQ2ZGQ3L3RhYmxlcmFuZ2U6NzI2YjdhYjA1ODc1NGU5Y2IyNjYwZGU5NDAyZDZkZDdfMi0xLTEtMS0w_a0c8f488-046b-493d-876b-a5c521fadae2">443.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjcyNmI3YWIwNTg3NTRlOWNiMjY2MGRlOTQwMmQ2ZGQ3L3RhYmxlcmFuZ2U6NzI2YjdhYjA1ODc1NGU5Y2IyNjYwZGU5NDAyZDZkZDdfMi0zLTEtMS0w_2c57ac94-4f9f-471c-89e9-d2c9da62c2fa">30.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjcyNmI3YWIwNTg3NTRlOWNiMjY2MGRlOTQwMmQ2ZGQ3L3RhYmxlcmFuZ2U6NzI2YjdhYjA1ODc1NGU5Y2IyNjYwZGU5NDAyZDZkZDdfMi01LTEtMS0w_3f5447fb-617a-4b03-bbf1-03ac0c5ecefc">147.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjcyNmI3YWIwNTg3NTRlOWNiMjY2MGRlOTQwMmQ2ZGQ3L3RhYmxlcmFuZ2U6NzI2YjdhYjA1ODc1NGU5Y2IyNjYwZGU5NDAyZDZkZDdfMi03LTEtMS0w_c1db2b5b-dbb9-4339-bd85-e3b90188c587">125.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjcyNmI3YWIwNTg3NTRlOWNiMjY2MGRlOTQwMmQ2ZGQ3L3RhYmxlcmFuZ2U6NzI2YjdhYjA1ODc1NGU5Y2IyNjYwZGU5NDAyZDZkZDdfMi05LTEtMS0w_fd035206-29a3-45ed-87fb-80d8f75d9c17">139.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net gains recognized in our consolidated condensed statements of operations for equity securities were $<ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTEyOTM_1603b77d-5a4a-4a3e-8cc3-1d7d6863f508">301.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTEzMDA_87075633-ef07-464b-b626-2e752c780cc0">186.6</ix:nonFraction> million for the three months ended March&#160;31, 2021 and 2020, respectively. The net gains/losses recognized during the three months ended March&#160;31, 2021 and 2020 on equity securities sold during the respective periods were not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adjust our equity investments without readily determinable fair values based upon changes in the equity instruments' values resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Downward adjustments resulting from an impairment are recorded based upon impairment considerations, including the financial condition and near term prospects of the issuer, general market conditions, and industry specific factors. Adjustments recorded during the three months ended March&#160;31, 2021 and 2020 were not material.</span></div><ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTQ4MzM_e76ecccd-0895-4923-939d-4c2beb6e2beb" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value of available-for-sale securities in an unrealized gain or loss position and the amount of unrealized gains and losses in accumulated other comprehensive loss follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.249%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.860%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross gains</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjlkNGFlNGFhNTNiOTRmMWQ4YzcwNzQ0M2VjN2E0MzVlL3RhYmxlcmFuZ2U6OWQ0YWU0YWE1M2I5NGYxZDhjNzA3NDQzZWM3YTQzNWVfMS0xLTEtMS0w_eb255352-fa6a-4c64-a225-8e62a4dcd83c">12.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjlkNGFlNGFhNTNiOTRmMWQ4YzcwNzQ0M2VjN2E0MzVlL3RhYmxlcmFuZ2U6OWQ0YWU0YWE1M2I5NGYxZDhjNzA3NDQzZWM3YTQzNWVfMS0zLTEtMS0w_f369aa22-544a-4427-8e14-70d740fd8b57">20.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjlkNGFlNGFhNTNiOTRmMWQ4YzcwNzQ0M2VjN2E0MzVlL3RhYmxlcmFuZ2U6OWQ0YWU0YWE1M2I5NGYxZDhjNzA3NDQzZWM3YTQzNWVfMi0xLTEtMS0w_c0915cec-1b69-4c8a-a618-1a69bb19e2ea">6.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjlkNGFlNGFhNTNiOTRmMWQ4YzcwNzQ0M2VjN2E0MzVlL3RhYmxlcmFuZ2U6OWQ0YWU0YWE1M2I5NGYxZDhjNzA3NDQzZWM3YTQzNWVfMi0zLTEtMS0w_b73a4321-d243-49ea-a565-f3e11d1da308">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized gain position</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" name="lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjlkNGFlNGFhNTNiOTRmMWQ4YzcwNzQ0M2VjN2E0MzVlL3RhYmxlcmFuZ2U6OWQ0YWU0YWE1M2I5NGYxZDhjNzA3NDQzZWM3YTQzNWVfMy0xLTEtMS0w_bb6ad23a-2187-4cbf-af30-90c366edb8c6">273.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" name="lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjlkNGFlNGFhNTNiOTRmMWQ4YzcwNzQ0M2VjN2E0MzVlL3RhYmxlcmFuZ2U6OWQ0YWU0YWE1M2I5NGYxZDhjNzA3NDQzZWM3YTQzNWVfMy0zLTEtMS0w_c077b1a3-8626-446e-b83d-8c2b073a1f10">348.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized loss position</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjlkNGFlNGFhNTNiOTRmMWQ4YzcwNzQ0M2VjN2E0MzVlL3RhYmxlcmFuZ2U6OWQ0YWU0YWE1M2I5NGYxZDhjNzA3NDQzZWM3YTQzNWVfNC0xLTEtMS0w_a59137b2-2304-4833-9ff7-ecf499863d91">170.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjlkNGFlNGFhNTNiOTRmMWQ4YzcwNzQ0M2VjN2E0MzVlL3RhYmxlcmFuZ2U6OWQ0YWU0YWE1M2I5NGYxZDhjNzA3NDQzZWM3YTQzNWVfNC0zLTEtMS0w_327a8289-f28a-4d10-8cd6-795132a6c38e">11.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically assess our investment in available-for-sale securities for impairment losses and credit losses. The amount of credit losses are determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration. Impairment and credit losses related to available-for-sale securities were not material in the three months ended March&#160;31, 2021 and 2020.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i0c81e19cfeff48f38c359c634f73f632"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, the available-for-sale securities in an unrealized loss position include primarily fixed-rate debt securities of varying maturities, which are sensitive to changes in the yield curve and other market conditions. Approximately <ix:nonFraction unitRef="number" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="2" format="ixt:numdotdecimal" name="us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTMyNTY_6b9c8d39-fdea-48e5-afa2-2fa95285814f">94</ix:nonFraction> percent&#160;of the fixed-rate debt securities in a loss position are investment-grade debt securities. As of March&#160;31, 2021, we do not intend to sell, and it is not more likely than not that we will be required to sell, the securities in a loss position before the market values recover or the underlying cash flows have been received, and there is no indication of default on interest or principal payments for any of our debt securities.</span></div><ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:GainLossOnInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTQ4NzE_a9839108-e652-4358-9573-53d2df9f6f11" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity related to our available-for-sale securities was as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjQyZWFmZDVlMzBjNzQ2YzY4NmJmYjcyNzI3ZDc1NDI3L3RhYmxlcmFuZ2U6NDJlYWZkNWUzMGM3NDZjNjg2YmZiNzI3MjdkNzU0MjdfMi0xLTEtMS0w_bd13b639-b34e-4f9d-8c65-fecbc648f30a">43.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjQyZWFmZDVlMzBjNzQ2YzY4NmJmYjcyNzI3ZDc1NDI3L3RhYmxlcmFuZ2U6NDJlYWZkNWUzMGM3NDZjNjg2YmZiNzI3MjdkNzU0MjdfMi0zLTEtMS0w_51bf6c4b-aa29-420c-8eec-0747e7429ade">38.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross gains on sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjQyZWFmZDVlMzBjNzQ2YzY4NmJmYjcyNzI3ZDc1NDI3L3RhYmxlcmFuZ2U6NDJlYWZkNWUzMGM3NDZjNjg2YmZiNzI3MjdkNzU0MjdfMy0xLTEtMS0w_040ad5a7-692f-4540-b5be-9523369e19e0">1.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjQyZWFmZDVlMzBjNzQ2YzY4NmJmYjcyNzI3ZDc1NDI3L3RhYmxlcmFuZ2U6NDJlYWZkNWUzMGM3NDZjNjg2YmZiNzI3MjdkNzU0MjdfMy0zLTEtMS0w_1e653ddc-ff54-4c93-96a1-4537196160e8">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross losses on sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjQyZWFmZDVlMzBjNzQ2YzY4NmJmYjcyNzI3ZDc1NDI3L3RhYmxlcmFuZ2U6NDJlYWZkNWUzMGM3NDZjNjg2YmZiNzI3MjdkNzU0MjdfNC0xLTEtMS0w_ce19e297-533d-413d-941d-046530b9e687">0.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjQyZWFmZDVlMzBjNzQ2YzY4NmJmYjcyNzI3ZDc1NDI3L3RhYmxlcmFuZ2U6NDJlYWZkNWUzMGM3NDZjNjg2YmZiNzI3MjdkNzU0MjdfNC0zLTEtMS0w_0e4a31a8-7d95-4afe-ad61-d332c6113e29">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on sales of available-for-sale investments are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable Factoring Arrangements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into accounts receivable factoring agreements with financial institutions to sell certain of our non-U.S. accounts receivable. These transactions are accounted for as sales and result in a reduction in accounts receivable because the agreements transfer effective control over and, risk related to, the receivables to the buyers. Our factoring agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. We derecognized $<ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTQ1NTM_822085b7-de69-4f12-9fcc-f4f09f0b1a9e">637.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTQ1NjA_a48ab26b-779b-4f99-a61f-9aa4caaccad6">754.9</ix:nonFraction> million&#160;of accounts receivable as of March&#160;31, 2021 and December 31, 2020, respectively, under these factoring arrangements. The costs of factoring such accounts receivable on our consolidated condensed results of operations for the three months ended March&#160;31, 2021 and 2020&#160;were&#160;not material.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_64"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7: <ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82NC9mcmFnOjZjMGVjOWIwOWYwZDQ1ZWI5ODU3MTJhMmFhY2Y2YzRlL3RleHRyZWdpb246NmMwZWM5YjA5ZjBkNDVlYjk4NTcxMmEyYWFjZjZjNGVfNzUw_734b6905-09e7-46b9-b56e-c95a9f489cad" continuedAt="idbfc2ddd18374407b894c36814e2001a" escape="true">Income Taxes </ix:nonNumeric></span></div><ix:continuation id="idbfc2ddd18374407b894c36814e2001a"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate was <ix:nonFraction unitRef="number" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82NC9mcmFnOjZjMGVjOWIwOWYwZDQ1ZWI5ODU3MTJhMmFhY2Y2YzRlL3RleHRyZWdpb246NmMwZWM5YjA5ZjBkNDVlYjk4NTcxMmEyYWFjZjZjNGVfNTQ_8b9ec730-8fe7-4646-93eb-2dd09797521a">8.2</ix:nonFraction> percent for the three months ended March&#160;31, 2021, compared with <ix:nonFraction unitRef="number" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82NC9mcmFnOjZjMGVjOWIwOWYwZDQ1ZWI5ODU3MTJhMmFhY2Y2YzRlL3RleHRyZWdpb246NmMwZWM5YjA5ZjBkNDVlYjk4NTcxMmEyYWFjZjZjNGVfMTAy_d13e69a1-1cfe-478e-bff8-2abee110c4fe">13.3</ix:nonFraction> percent for the three months ended March 31, 2020. The effective tax rates for both periods were reduced by net discrete tax benefits, with a larger net discrete tax benefit reflected for the three months ended March&#160;31, 2021. </span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. examination of tax years 2016-2018 began in the fourth quarter of 2019 and remains ongoing; therefore, the resolution of this audit period will likely extend beyond the next 12 months.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8: <ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RleHRyZWdpb246MDRjZmJhNmZlZTM1NGY1OGE1MWIwYjc4NTgzOTM0OWRfMTM3MQ_caa192cb-ee93-4553-aef9-ddbce1695e61" continuedAt="i9efcd6874112422f96d673b62266c60e" escape="true">Retirement Benefits</ix:nonNumeric></span></div><ix:continuation id="i9efcd6874112422f96d673b62266c60e"><ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RleHRyZWdpb246MDRjZmJhNmZlZTM1NGY1OGE1MWIwYjc4NTgzOTM0OWRfMTM3OQ_cf41afce-f762-4aa3-8f6f-81e7433c79b9" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net pension and retiree health benefit (income) cost included the following components:</span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Pension Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of net periodic benefit cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d9dae1aca8e45a9bd0624944e8a56ca_D20210101-20210331" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmQ3YWVjZjVjNzdkNjQxNThhMGUyNjgzZjliMTk3NzYzL3RhYmxlcmFuZ2U6ZDdhZWNmNWM3N2Q2NDE1OGEwZTI2ODNmOWIxOTc3NjNfNC0xLTEtMS0w_c749ef18-861e-4463-8169-6b7321b9482f">92.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e38511a533b4a35afcd45b88276b271_D20200101-20200331" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmQ3YWVjZjVjNzdkNjQxNThhMGUyNjgzZjliMTk3NzYzL3RhYmxlcmFuZ2U6ZDdhZWNmNWM3N2Q2NDE1OGEwZTI2ODNmOWIxOTc3NjNfNC0zLTEtMS0w_66c9e723-0d24-4c12-b562-f9b4fe13e8b4">78.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d9dae1aca8e45a9bd0624944e8a56ca_D20210101-20210331" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmQ3YWVjZjVjNzdkNjQxNThhMGUyNjgzZjliMTk3NzYzL3RhYmxlcmFuZ2U6ZDdhZWNmNWM3N2Q2NDE1OGEwZTI2ODNmOWIxOTc3NjNfNS0xLTEtMS0w_4160c028-e794-43a7-b407-2ab58f1cfd97">84.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e38511a533b4a35afcd45b88276b271_D20200101-20200331" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmQ3YWVjZjVjNzdkNjQxNThhMGUyNjgzZjliMTk3NzYzL3RhYmxlcmFuZ2U6ZDdhZWNmNWM3N2Q2NDE1OGEwZTI2ODNmOWIxOTc3NjNfNS0zLTEtMS0w_6fab79d3-3582-4597-8fc6-c9c63d6aae5b">105.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d9dae1aca8e45a9bd0624944e8a56ca_D20210101-20210331" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmQ3YWVjZjVjNzdkNjQxNThhMGUyNjgzZjliMTk3NzYzL3RhYmxlcmFuZ2U6ZDdhZWNmNWM3N2Q2NDE1OGEwZTI2ODNmOWIxOTc3NjNfNi0xLTEtMS0w_75b99afd-39d5-4de9-b5dd-a9422b47c1ca">238.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e38511a533b4a35afcd45b88276b271_D20200101-20200331" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmQ3YWVjZjVjNzdkNjQxNThhMGUyNjgzZjliMTk3NzYzL3RhYmxlcmFuZ2U6ZDdhZWNmNWM3N2Q2NDE1OGEwZTI2ODNmOWIxOTc3NjNfNi0zLTEtMS0w_a0507bf2-b131-42f0-9a2e-d4c6ccb73012">221.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d9dae1aca8e45a9bd0624944e8a56ca_D20210101-20210331" decimals="-5" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmQ3YWVjZjVjNzdkNjQxNThhMGUyNjgzZjliMTk3NzYzL3RhYmxlcmFuZ2U6ZDdhZWNmNWM3N2Q2NDE1OGEwZTI2ODNmOWIxOTc3NjNfNy0xLTEtMS0w_1f3eb112-d031-4e42-9398-91a0920ea90f">1.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e38511a533b4a35afcd45b88276b271_D20200101-20200331" decimals="-5" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmQ3YWVjZjVjNzdkNjQxNThhMGUyNjgzZjliMTk3NzYzL3RhYmxlcmFuZ2U6ZDdhZWNmNWM3N2Q2NDE1OGEwZTI2ODNmOWIxOTc3NjNfNy0zLTEtMS0w_ff144d49-c207-48bb-a801-2cde463b6744">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d9dae1aca8e45a9bd0624944e8a56ca_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmQ3YWVjZjVjNzdkNjQxNThhMGUyNjgzZjliMTk3NzYzL3RhYmxlcmFuZ2U6ZDdhZWNmNWM3N2Q2NDE1OGEwZTI2ODNmOWIxOTc3NjNfOC0xLTEtMS0w_f72501ab-f6b2-4260-8d28-e6536ac33f37">121.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e38511a533b4a35afcd45b88276b271_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmQ3YWVjZjVjNzdkNjQxNThhMGUyNjgzZjliMTk3NzYzL3RhYmxlcmFuZ2U6ZDdhZWNmNWM3N2Q2NDE1OGEwZTI2ODNmOWIxOTc3NjNfOC0zLTEtMS0w_f9a3aa4e-371f-498b-8324-5addef9c1b42">111.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d9dae1aca8e45a9bd0624944e8a56ca_D20210101-20210331" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmQ3YWVjZjVjNzdkNjQxNThhMGUyNjgzZjliMTk3NzYzL3RhYmxlcmFuZ2U6ZDdhZWNmNWM3N2Q2NDE1OGEwZTI2ODNmOWIxOTc3NjNfMTAtMS0xLTEtMA_1b1ca009-20c4-46d2-9fbf-310b18bd0525">61.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e38511a533b4a35afcd45b88276b271_D20200101-20200331" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmQ3YWVjZjVjNzdkNjQxNThhMGUyNjgzZjliMTk3NzYzL3RhYmxlcmFuZ2U6ZDdhZWNmNWM3N2Q2NDE1OGEwZTI2ODNmOWIxOTc3NjNfMTAtMy0xLTEtMA_6d29c3a4-449b-4d8f-afa5-a32acc199740">74.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of net periodic benefit income:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4b0ceabb1674432983305cc3a962999_D20210101-20210331" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmRkNjFmYjAxNDc3ZDQ2NDU4YWY0NzJhZjA3NmJjYzg4L3RhYmxlcmFuZ2U6ZGQ2MWZiMDE0NzdkNDY0NThhZjQ3MmFmMDc2YmNjODhfNC0xLTEtMS0w_4b78ce6c-5dcf-422e-93d6-5d7495f3e7dc">11.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf4e9376f20b4a76a67b9874281b82b7_D20200101-20200331" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmRkNjFmYjAxNDc3ZDQ2NDU4YWY0NzJhZjA3NmJjYzg4L3RhYmxlcmFuZ2U6ZGQ2MWZiMDE0NzdkNDY0NThhZjQ3MmFmMDc2YmNjODhfNC0zLTEtMS0w_1ac7dda9-eaa5-4e32-a706-962f1d76fc41">9.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4b0ceabb1674432983305cc3a962999_D20210101-20210331" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmRkNjFmYjAxNDc3ZDQ2NDU4YWY0NzJhZjA3NmJjYzg4L3RhYmxlcmFuZ2U6ZGQ2MWZiMDE0NzdkNDY0NThhZjQ3MmFmMDc2YmNjODhfNS0xLTEtMS0w_88391b3c-4df5-48fb-bb30-56dff9c9101c">8.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf4e9376f20b4a76a67b9874281b82b7_D20200101-20200331" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmRkNjFmYjAxNDc3ZDQ2NDU4YWY0NzJhZjA3NmJjYzg4L3RhYmxlcmFuZ2U6ZGQ2MWZiMDE0NzdkNDY0NThhZjQ3MmFmMDc2YmNjODhfNS0zLTEtMS0w_d99f1b0f-9a0c-4406-9d96-439b6f0e583e">11.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4b0ceabb1674432983305cc3a962999_D20210101-20210331" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmRkNjFmYjAxNDc3ZDQ2NDU4YWY0NzJhZjA3NmJjYzg4L3RhYmxlcmFuZ2U6ZGQ2MWZiMDE0NzdkNDY0NThhZjQ3MmFmMDc2YmNjODhfNi0xLTEtMS0w_90809314-5d2b-4b89-a8d2-40ca87064ecb">36.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf4e9376f20b4a76a67b9874281b82b7_D20200101-20200331" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmRkNjFmYjAxNDc3ZDQ2NDU4YWY0NzJhZjA3NmJjYzg4L3RhYmxlcmFuZ2U6ZGQ2MWZiMDE0NzdkNDY0NThhZjQ3MmFmMDc2YmNjODhfNi0zLTEtMS0w_48cede54-448f-4596-91c2-cc8a1506d172">37.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4b0ceabb1674432983305cc3a962999_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmRkNjFmYjAxNDc3ZDQ2NDU4YWY0NzJhZjA3NmJjYzg4L3RhYmxlcmFuZ2U6ZGQ2MWZiMDE0NzdkNDY0NThhZjQ3MmFmMDc2YmNjODhfNy0xLTEtMS0w_17f324ef-efcd-4ef1-8486-e02d323f3abc">14.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf4e9376f20b4a76a67b9874281b82b7_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmRkNjFmYjAxNDc3ZDQ2NDU4YWY0NzJhZjA3NmJjYzg4L3RhYmxlcmFuZ2U6ZGQ2MWZiMDE0NzdkNDY0NThhZjQ3MmFmMDc2YmNjODhfNy0zLTEtMS0w_2db2b24c-ce8a-40bf-89f3-8e807f16ee3b">14.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4b0ceabb1674432983305cc3a962999_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmRkNjFmYjAxNDc3ZDQ2NDU4YWY0NzJhZjA3NmJjYzg4L3RhYmxlcmFuZ2U6ZGQ2MWZiMDE0NzdkNDY0NThhZjQ3MmFmMDc2YmNjODhfOC0xLTEtMS0w_21906c70-f75e-4962-ba14-09758e501411">0.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf4e9376f20b4a76a67b9874281b82b7_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmRkNjFmYjAxNDc3ZDQ2NDU4YWY0NzJhZjA3NmJjYzg4L3RhYmxlcmFuZ2U6ZGQ2MWZiMDE0NzdkNDY0NThhZjQ3MmFmMDc2YmNjODhfOC0zLTEtMS0w_6b2f4ab4-968e-4cf1-b85f-55497ae88986">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit income</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4b0ceabb1674432983305cc3a962999_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmRkNjFmYjAxNDc3ZDQ2NDU4YWY0NzJhZjA3NmJjYzg4L3RhYmxlcmFuZ2U6ZGQ2MWZiMDE0NzdkNDY0NThhZjQ3MmFmMDc2YmNjODhfMTAtMS0xLTEtMA_b3623aaa-13f1-42ae-82d2-678517f5ee5a">30.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf4e9376f20b4a76a67b9874281b82b7_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmRkNjFmYjAxNDc3ZDQ2NDU4YWY0NzJhZjA3NmJjYzg4L3RhYmxlcmFuZ2U6ZGQ2MWZiMDE0NzdkNDY0NThhZjQ3MmFmMDc2YmNjODhfMTAtMy0xLTEtMA_19889fc8-568c-45d2-be18-99802445b28f">30.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We contributed approximately $<ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PensionContributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RleHRyZWdpb246MDRjZmJhNmZlZTM1NGY1OGE1MWIwYjc4NTgzOTM0OWRfMTU1_458f3c34-cdc8-4ba2-900f-20f868f7c017">15</ix:nonFraction> million to satisfy minimum funding requirements to our defined benefit pension and retiree health benefit plans during the three months ended March&#160;31, 2021. We contributed approximately $<ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="lly:PaymentforPensionBenefitsAdditionalDiscretionaryFunding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RleHRyZWdpb246MDRjZmJhNmZlZTM1NGY1OGE1MWIwYjc4NTgzOTM0OWRfMjk1_90cd8118-d75c-44f5-91cc-b4c455bcc489">10</ix:nonFraction> million in discretionary funding during the three months ended March&#160;31, 2021. During the remainder of 2021, we expect to make contributions of approximately $<ix:nonFraction unitRef="usd" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RleHRyZWdpb246MDRjZmJhNmZlZTM1NGY1OGE1MWIwYjc4NTgzOTM0OWRfNDE4_fd66c107-99d1-4312-bd66-ec6a72109add">20</ix:nonFraction> million to our defined benefit pension and retiree health plans to satisfy minimum funding requirements.</span></div></ix:continuation><div><span><br/></span></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_70"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9: <ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTY4NTU_3e47f319-aeb5-4506-bae7-0def76065ce3" continuedAt="i816a27d1e3ac4996b61371136fd5aab6" escape="true">Contingencies</ix:nonNumeric></span></div><ix:continuation id="i816a27d1e3ac4996b61371136fd5aab6" continuedAt="i8f120c0c060e4a3083609b7a24033659"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in various lawsuits, claims, government investigations and other legal proceedings that arise in the ordinary course of business. These claims or proceedings can involve various types of parties, including governments, competitors, customers, suppliers, service providers, licensees, employees, or shareholders, among others. These matters may involve patent infringement, antitrust, securities, pricing, sales and marketing practices, environmental, commercial, contractual rights, licensing obligations, health and safety matters, consumer fraud, employment matters, product liability and insurance coverage, among others. The resolution of these matters often develops over a long period of time and expectations can change as a result of new findings, rulings, appeals or settlement arrangements. Legal proceedings that are significant or that we believe could become significant or material are described below.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the legal proceedings in which we are named as defendants are without merit and we are defending against them vigorously. It is not possible to determine the outcome of these matters, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i8f120c0c060e4a3083609b7a24033659" continuedAt="i30a413e2352c469b8c44f2c1777f026c"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated condensed balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of additional product liability and related claims in the future. Due to a very restrictive market for product liability insurance, we are self-insured for product liability losses for all our currently and previously marketed products. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Alimta Patent Litigation </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of manufacturers are seeking approvals in the U.S. and a number of countries in Europe to market generic forms of Alimta prior to the expiration of our vitamin regimen patents, alleging that those patents are invalid, not infringed, or both. We believe our Alimta vitamin regimen patents are valid and enforceable against these generic manufacturers.&#160;However, it is not possible to determine the ultimate outcome of the proceedings, and accordingly, we can provide no assurance that we will prevail.&#160;The loss of exclusivity in the U.S. could have a material adverse impact on our future consolidated results of operations and cash flows and would result in a rapid and severe decline in future revenue for the product.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alimta (pemetrexed) is protected by a vitamin regimen patent until 2021, plus pediatric exclusivity through May 2022. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2017, we filed a lawsuit in the U.S. District Court for the Southern District of Indiana against Apotex Inc. (Apotex) alleging infringement of Alimta's vitamin regimen patent for its application to market a pemetrexed product. In December 2019, the U.S. District Court for the Southern District of Indiana granted our motion for summary judgment of infringement, and in December 2020, the U.S. Court of Appeals for the Federal Circuit affirmed that ruling. Apotex did not request reconsideration or a rehearing of that ruling. However, Apotex could petition the U.S. Supreme Court to review the case. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we settled a lawsuit we filed against Eagle Pharmaceuticals, Inc. (Eagle) in response to its application to market a product using an alternative form of pemetrexed. Per the settlement agreement, Eagle has a limited initial entry into the market with its product starting February 2022 (up to an approximate three-week supply) and subsequent unlimited entry starting April 2022.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Patent Litigation</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, Alimta (pemetrexed) is prot</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ected by the vitamin regimen patent through June of 2021. Notwithstanding the existence of our vitamin regimen patent, several companies launched generic pemetrexed products at risk in France, Germany, and the Netherlands but those products were subsequently removed from those markets as a consequence of patent infringement actions brought by us. In many cases, those patent infringement actions are subject to appeals filed by the generic manufacturer. In March 2021, we entered into a settlement agreement with Fresenius Kabi Aktienngesellschaft that discontinued all pending European patent litigation involving the Fresenius Kabi group of companies including that between us and Fresenius Kabi France and Fresenius Kabi Groupe France.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal proceedings are ongoing regarding </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our Alimta patents in various national courts throughout Europe. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to seek to remove any generic pemetrexed products launched at risk in other European markets, seek damages with respect to such launches, and defend our patents against validity challenges.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i30a413e2352c469b8c44f2c1777f026c" continuedAt="i3dd6f65ddfed46a29e9c6baf9f5fa23d"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Emgality Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, we were</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> named as a defendant in litigation filed by Teva Pharmaceuticals International GMBH and Teva Pharmaceuticals USA, Inc. (collectively, Teva) in the U.S. District Court for the District of Massachusetts seeking a ruling that various claims in <ix:nonFraction unitRef="patent" contextRef="i9472948bb7f947afa49886afa824b300_I20210331" decimals="0" format="ixt-sec:numwordsen" name="lly:LossContingencyNumberOfPatents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY2MzQwMQ_d819cedb-081b-42e5-82ad-0618fa7ebdb1">nine</ix:nonFraction> differ</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ent Teva patents would be infringed by our launch and continued sales of Emgality for the prevention of migraine in adults. Trial is expected in February 2022. Separately, the U.S. Patent and Trademark Office (USPTO) granted our request to initiate an&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes review</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(IPR) to reexamine the validity of the <ix:nonFraction unitRef="patent" contextRef="i9472948bb7f947afa49886afa824b300_I20210331" decimals="0" format="ixt-sec:numwordsen" name="lly:LossContingencyNumberOfPatents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY2MzcyMg_d819cedb-081b-42e5-82ad-0618fa7ebdb1">nine</ix:nonFraction> Teva patents asserted against us in the litigation. In February 2020, the USPTO ruled in our favor and found that the claims asserted against us in <ix:nonFraction unitRef="patent" contextRef="i7408050434b1433f9057403b967bc044_D20200201-20200229" decimals="0" format="ixt-sec:numwordsen" name="lly:LossContingencyNumberOfPatentsClaimsDismissed" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY2Mzg3NA_d1b46b31-11b8-410b-97f0-7baa102975c3">six</ix:nonFraction> of Teva's <ix:nonFraction unitRef="patent" contextRef="i1dfd4b4b1d2a4b459b67e2e9c72eac8d_I20200229" decimals="0" format="ixt-sec:numwordsen" name="lly:LossContingencyNumberOfPatents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY2Mzg4OA_f9a97bbf-14fe-48fd-9c9e-d7a2414e5d7a">nine</ix:nonFraction> patents were invalid. In March 2020, the USPTO ruled against us on the remaining <ix:nonFraction unitRef="patent" contextRef="ie6e455b81cdd4b63a8577a6c3f916221_D20200301-20200331" decimals="0" format="ixt-sec:numwordsen" name="lly:LossContingencyNumberOfPatentsRuledUnpatentable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY2Mzk3Mw_b26ab727-7d6e-48ea-8ac3-d0257fc5b729">three</ix:nonFraction> Teva patents, finding that we failed to show that the remaining <ix:nonFraction unitRef="patent" contextRef="ie6e455b81cdd4b63a8577a6c3f916221_D20200301-20200331" decimals="0" format="ixt-sec:numwordsen" name="lly:LossContingencyNumberOfPatentsRuledUnpatentable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY2NDA0MQ_f841c985-1711-4e5b-8ad4-45b8745cc52e">three</ix:nonFraction> patents were unpatentable based on the subset of invalidity arguments available in an IPR proceeding. In April 2020, we appealed the USPTO&#8217;s March 2020 ruling, and Teva appealed the USPTO&#8217;s February 2020 ruling to the U.S. Court of Appeals for the Federal Circuit. The district court litigation will proceed in parallel with the IPR appeals.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Jardiance Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, Boehringer Ingelheim (BI), our partner in marketing and development of Jardiance, initiated U.S. patent litigation in the U.S. District Court of Delaware alleging infringement arising from Alkem Laboratories Ltd.'s (Alkem) and Ascend Laboratories, LLC's (Ascend) submissions of Abbreviated New Drug Applications (ANDA) seeking approval to market generic versions of Jardiance, Glyxambi, and Synjardy in accordance with the procedures set out in the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). Particularly with respect to Jardiance, Alkem's and Ascend's ANDAs seek approval to market generic versions of Jardiance prior to the expiration of the relevant patents, and allege that certain patents, including in some allegations the compound patent, are invalid or would not be infringed. We are not a party to this litigation. Trial is scheduled for September 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Taltz Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, we petitioned the High Court of Ireland to declare invalid the patent that Novartis Pharma AG (Novartis) purchased from Genentech, Inc. in 2020. Novartis responded by filing a claim against us alleging patent infringement related to our commercialization of Taltz and seeking damages for past infringement and an injunction against future infringement. This matter is ongoing. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Zyprexa Canada Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the mid-2000&#8217;s, several generic companies in Canada challenged the validity of our Zyprexa compound patent. In 2012, the Canadian Federal Court of Appeals denied our appeal of a lower court's decision that certain patent claims were invalid for lack of utility. In 2013, Apotex Inc. and Apotex Pharmachem Inc. (collectively, Apotex) brought claims against us in the Ontario Superior Court of Justice at Toronto for damages related to our enforcement of the Zyprexa compound patent under Canadian regulations governing patented drugs. Apotex seeks compensation based on novel legal theories under the Statute of Monopolies, Trade-Mark Act, and common law. In March 2021, the Ontario Superior Court granted our motion for summary judgement, thereby dismissing Apotex&#8217;s case. Apotex appealed that ruling to the Court of Appeal for Ontario in April 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Actos&#174;  Product Liability</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are named along with Takeda Chemical Industries, Ltd. and Takeda affiliates (collectively, Takeda) as a defendant in <ix:nonFraction unitRef="lawsuit" contextRef="i19d9bfc8635f470e9a7adb121100256d_I20210331" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MDIyMg_fd9f7f9e-96ce-44ba-aeb1-732170eed896">four</ix:nonFraction> purported product liability class actions in Canada related to Actos, which we commercialized with Takeda in Canada until 2009, including <ix:nonFraction unitRef="lawsuit" contextRef="i4fbb93a5eb8140d2b2faeef2de2e7c59_I20111231" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MDM2NA_5dc345bd-832d-4e39-a834-aab4b34a17eb">one</ix:nonFraction> in Ontario filed December 2011 (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Casseres et al. v. Takeda Pharmaceutical North America, Inc., et al.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), <ix:nonFraction unitRef="lawsuit" contextRef="i9877de074e3b4cd68f3e14e738b53b96_I20120731" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MDQ3MQ_8300ea75-acf6-4387-9ce4-b79101fdfa15">one</ix:nonFraction> in Quebec filed July 2012 (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Whyte et al. v. Eli Lilly et al.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), <ix:nonFraction unitRef="lawsuit" contextRef="idac89cba080843258ae570efc0620a18_I20171130" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MDUzNw_8c08b91c-fe40-417a-857a-4fd8f7da97a7">one</ix:nonFraction> in Saskatchewan filed November 2017 (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Weiler v. Takeda Canada Inc. et al.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), and <ix:nonFraction unitRef="lawsuit" contextRef="iad757e1928624ece99a2023c2b06db4a_I20130131" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MDYyMA_f2e89a15-0906-40b6-a1af-a626faf6b9c1">one</ix:nonFraction> in Alberta filed January 2013 (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Epp v. Takeda Canada Inc. et al.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). In general, plaintiffs in these actions alleged that Actos caused or contributed to their bladder cancer. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i3dd6f65ddfed46a29e9c6baf9f5fa23d" continuedAt="ia949258b688d4858a595f35696c7a35a"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Byetta&#174; Product Liability</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First initiated in March 2009, we are named as a defendant in approximately <ix:nonFraction unitRef="lawsuit" contextRef="ic92b96cca8ef435288a260a7692a4296_I20210331" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MDk2MA_bc860445-55e5-40b4-8741-58b5d2212caa">570</ix:nonFraction> Byetta product liability lawsuits in the U.S. involving approximately <ix:nonFraction unitRef="plaintiff" contextRef="i87320df79b3f461da082a107fa7a8e57_D20090301-20210331" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MTAzNA_86b8f62f-945f-4edb-a91b-1038d1e3f232">810</ix:nonFraction> plaintiffs. Approximately <ix:nonFraction unitRef="lawsuit" contextRef="i15f9ce4e2e9f47789b45d86896781f54_I20210331" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MTA2NA_15aedd19-9c24-4fe8-9599-8945a8a4bd62">55</ix:nonFraction> of these lawsuits, covering about <ix:nonFraction unitRef="plaintiff" contextRef="i6776f7310a5341a3b3f6bfdef846dfea_D20090301-20210331" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MTEwMg_89f54836-76a3-49aa-8e0d-532932ad120f">285</ix:nonFraction> plaintiffs, are filed in California state court and coordinated in a Los Angeles Superior Court. Approximately <ix:nonFraction unitRef="lawsuit" contextRef="ib44052b397dc4098a69265e6060b79a8_I20210331" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MTIxNw_45d66bec-80bd-4d70-b314-6702de437aa8">515</ix:nonFraction> of the lawsuits, covering about <ix:nonFraction unitRef="plaintiff" contextRef="i121dcf9b52ce46eead9ac16494dd1642_D20090301-20210331" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MTI1Mw_acb14dce-f1d9-4125-8b14-f74d953212ef">515</ix:nonFraction> plaintiffs, are filed in federal court, the majority of which are coordinated in a multi-district litigation (MDL) in the U.S. District Court for the Southern District of California. <ix:nonFraction unitRef="lawsuit" contextRef="ib73e27481f2e44bcb74fda4f3cecf682_I20210331" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MTQ0MA_2b62ad20-83f9-4943-94f7-10b6ae9e0435">Three</ix:nonFraction> lawsuits, representing approximately <ix:nonFraction unitRef="plaintiff" contextRef="i2fa2b0f3392543f2b160709e35c124d7_D20090301-20210331" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MTQ4MQ_a7e9b17c-d70e-48bc-a6c0-1a80cecaaaeb">four</ix:nonFraction> plaintiffs, have also been filed in various state courts. Approximately <ix:nonFraction unitRef="lawsuit" contextRef="i9b029559694b48b08c94d12ad381445e_I20210331" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MTU1Nw_cd332168-7b7e-4def-969e-33524d253994">565</ix:nonFraction> of the lawsuits, involving approximately <ix:nonFraction unitRef="plaintiff" contextRef="if02307f1292e42dd8aa0a8c7f88d014f_D20090301-20210331" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MTYwMg_fa925bbc-0fe5-4176-8cf1-192d4bbac2a7">800</ix:nonFraction> plaintiffs, contain allegations that Byetta caused or contributed to the plaintiffs' cancer (primarily pancreatic cancer or thyroid cancer); while <ix:nonFraction unitRef="plaintiff" contextRef="i7ccdd965fb0d44ed8eaa51cd4f6af3a8_D20090301-20210331" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MTc1Mw_0eaf45c3-96d4-42d7-9040-09a345f22958">six</ix:nonFraction> plaintiffs allege Byetta caused or contributed to pancreatitis. In addition, <ix:nonFraction unitRef="plaintiff" contextRef="id5a9904ee8fe4ee9900bba9f1c855eb9_D20090301-20210331" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MTgzNA_18fae89c-55a5-4de4-9f71-64269e4be7c3">one</ix:nonFraction> case alleges that Byetta caused or contributed to ampullary cancer. The federal and state trial courts granted summary judgment in favor of us and our co-defendants on the claims alleging pancreatic cancer. The plaintiffs appealed those rulings. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, the U.S. Court of Appeals for the Ninth Circuit reversed the U.S. District Court for the Southern District of California's grant of summary judgment in the MDL based on that court's discovery rulings and remanded the cases back to the U.S. District Court for further proceedings. In March 2021, the U.S. District Court granted summary judgment for the defendants and in April 2021, the plaintiffs filed a notice of appeal to the U.S. Court of Appeals for the Ninth Circuit. In the state court actions, in November 2018, the California Court of Appeal reversed the Los Angeles County Superior Court of California&#8217;s grant of summary judgment based on that court's discovery rulings and remanded for further proceedings. In April 2021, the Los Angeles County Superior Court of California granted summary judgment for the defendants.   </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of approximately <ix:nonFraction unitRef="claimant" contextRef="ic92b96cca8ef435288a260a7692a4296_I20210331" decimals="0" name="lly:LossContingencyNumberOfClaimants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MjUwOQ_b0c3cb9e-0d42-4405-8c75-73d4627b2cc5">20</ix:nonFraction> additional claimants who have not yet filed suit. These additional claims allege damages for pancreatic cancer or thyroid cancer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cialis Product Liability</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First initiated in August 2015, we are named as a defendant in approximately <ix:nonFraction unitRef="lawsuit" contextRef="i0ac86530d3c243cca63aa23529e06624_I20210331" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MjgwMg_512f4d10-9cb5-4101-8426-0383a09ea45a">350</ix:nonFraction> Cialis product liability lawsuits in the U.S. These cases, many of which were originally filed in various federal courts, contain allegations that Cialis caused or contributed to the plaintiffs' cancer (melanoma). In December 2016, the Judicial Panel on Multidistrict Litigation (JPML) granted the plaintiffs' petition to have filed cases and an unspecified number of future cases coordinated into a federal multidistrict litigation (MDL) in the U.S. District Court for the Northern District of California, alongside an existing coordinated proceeding involving Viagra&#174;. The JPML ordered the transfer of the existing cases to the now-renamed MDL </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Viagra (Sildenafil Citrate) and Cialis (Tadalafil) Products Liability Litigation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In April 2020, the MDL court granted summary judgment to the defendants on all of the claims brought against them by the plaintiffs. In May 2020, plaintiffs filed an appeal in the U.S. Court of Appeals for the Ninth Circuit. The plaintiffs&#8217; appeal has been administratively closed until August 2021 pending completion of a procedure to resolve the claims in this litigation.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Jardiance Product Liability </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First initiated in January 2019, we and Boehringer Ingelheim Pharmaceuticals, Inc., a subsidiary of BI, have been named as a defendant in approximately <ix:nonFraction unitRef="lawsuit" contextRef="i9f7430fd06b947ef84b255b6fb8aee26_I20210331" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3Mzk3Mw_f463ff8b-9fc9-4e1e-ac4e-f170e34292e2">95</ix:nonFraction> product liability lawsuits in the U.S., mostly in Stamford Superior Court in Connecticut, alleging that Jardiance caused or contributed to plaintiffs&#8217; Fournier&#8217;s gangrene.  Our agreement with BI calls for BI to defend and indemnify us against any damages, costs, expenses, and certain other losses with respect to product liability claims in accordance with the terms of the agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Proceedings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as "Superfund," we have been designated as one of several potentially responsible parties with respect to the cleanup of fewer than <ix:nonFraction unitRef="site" contextRef="ida0a952118b340e6ba680f7df96d7075_I20210331" decimals="INF" name="lly:LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfNDk0NzgwMjM5OTk4OQ_906b66e0-190e-4cf0-968b-6c4dd4326930">10</ix:nonFraction> sites. Under Superfund, each responsible party may be jointly and severally liable for the entire amount of the cleanup.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia949258b688d4858a595f35696c7a35a" continuedAt="i4b97466932e446e4a6aa6ac24c62d8f9"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">340B Litigation and Investigations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the plaintiff in a lawsuit filed in January 2021 in the U.S. District Court for the Southern District of Indiana against the U.S. Department of Health and Human Services (HHS), the Secretary of HHS, the Health Resources and Services Administration (HRSA), and the Administrator of HRSA. The lawsuit challenges the HHS's December 30, 2020 advisory opinion stating that drug manufacturers are required to deliver discounts under the 340B program to all contract pharmacies. We seek a declaratory judgment that the defendants violated the Administrative Procedures Act and the U.S. Constitution, a preliminary injunction enjoining implementation of the administrative dispute resolution process created by defendants and, with it, their application of the advisory opinion, and other related relief. In March 2021, the court entered an order preliminarily enjoining the government&#8217;s enforcement of the administrative dispute resolution process against Lilly. The matter is ongoing. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2021, we, along with other pharmaceutical manufacturers, were named as a defendant in a petition currently pending before the HHS Administration Dispute Resolution Panel. Petitioner seeks declaratory and other injunctive relief related to the 340B program. As described above, the U.S. District Court for the Southern District of Indiana has entered a preliminary injunction enjoining the government&#8217;s enforcement of this administrative dispute resolution process against us.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2021, we received a civil investigative subpoena from the Office of the Attorney General for the State of Vermont relating to the sale of pharmaceutical products to Vermont covered entities under the 340B program. We are cooperating with this subpoena. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Brazil Litigation &#8211; Cosmopolis Facility </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Labor Attorney Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First initiated in 2008, our subsidiary in Brazil, Eli Lilly do Brasil Limitada (Lilly Brasil), is named in a lawsuit brought by the Labor Attorney for the 15th Region in the Labor Court of Paulinia, State of Sao Paulo, Brazil, alleging possible harm to employees and former employees caused by exposure to heavy metals at a former Lilly Brasil manufacturing facility in Cosmopolis, Brazil, operated by the company between 1977 and 2003. In May 2014, the labor court judge ruled against Lilly Brasil, ordering it to undertake several actions of unspecified financial impact, including paying lifetime health coverage for the employees and contractors who worked at the Cosmopolis facility more than six months during the affected years and their children born during and after this period. We appealed this decision. In July 2018, the appeals court affirmed the labor court's ruling with a liquidated award of&#160;<ix:nonFraction unitRef="brl" contextRef="ib5001859aff84e2dbe43c4543f7e5dbc_D20180701-20180731" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfNDk0NzgwMjM5MDc3NA_6857a45c-3819-4d34-970a-cb762631fb45">300</ix:nonFraction>&#160;million&#160;Brazilian real (for moral damages, donation of equipment, and creation of a foundation) which, adjusted for inflation and interest using the current Central Bank of Brazil's special system of clearance and custody rate (SELIC), is approximately <ix:nonFraction unitRef="brl" contextRef="ieb85b610e8d84b4788f9a42c2d175b66_D20210331-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfNDk0NzgwMjM5MDc0Nw_e2d789bf-3bcd-4fca-8f7a-2d820feb62ea">950</ix:nonFraction>&#160;million Brazilian real (approximately $<ix:nonFraction unitRef="usd" contextRef="ieb85b610e8d84b4788f9a42c2d175b66_D20210331-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfNDk0NzgwMjM5MDg1Mw_c4220554-edd4-46b2-b093-463ecdb9076e">165</ix:nonFraction>&#160;million as of March 31, 2021). The appeals court restricted the broad health coverage awarded by the labor court to health problems that claimants could show arose from exposure to the alleged contamination. In August 2019, Lilly Brasil filed an appeal to the superior labor court. In September 2019, the appeals court stayed a number of elements of its prior decision, including the obligation to provide health coverage for contractors, their children, and children of employees who worked at the Cosmopolis facility, pending the determination of Lilly Brasil&#8217;s appeal to the superior labor court. The cost of any such health coverage has not been determined.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the Labor Attorney filed an application in the labor court for enforcement of the healthcare coverage granted by the appeals court in its July 2018 ruling and requested restrictions on Lilly Brasil&#8217;s assets in Brazil. In July 2019, the labor court issued a ruling requiring either a freeze of Lilly Brasil&#8217;s immovable property or, alternatively, a security deposit of <ix:nonFraction unitRef="brl" contextRef="i877919e055e34b8eb3844514babacc6f_D20190701-20190731" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3OTIwOQ_90f3f437-1fd7-4da5-8caa-7ed08056a46b">500</ix:nonFraction> million Brazilian real. Lilly Brasil filed a writ of mandamus challenging this ruling</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> but the court has stayed its decision on this writ and instead directed the parties to attend conciliation hearings, a process that concluded unsuccessfully in September 2020. Consequently, the partial stay of the proceedings relating to Lilly Brasil's application to appeal in the main proceedings has been lifted. In addition, the Labor Attorney's application for preliminary enforcement of the July 2018 healthcare coverage ruling was granted. As the conciliation hearings have been unsuccessful, we have filed a brief to strike the Labor Attorney&#8217;s application to enforce the previous healthcare coverage. Lilly Brasil is currently awaiting a determination as to whether its application seeking leave to appeal to the superior labor court has been successful.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Individual Former Employee Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also named in approximately <ix:nonFraction unitRef="lawsuit" contextRef="iaa67ffc334f74fdd88aeff3e17eb06fd_I20210331" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTE4NDY_e4ab0d19-3135-4405-b46c-585670ed37e7">30</ix:nonFraction>&#160;lawsuits filed in the same labor court by individual former employees making similar claims. These lawsuits are each at various stages in the litigation process, with judgments being handed down in approximately half of the lawsuits, nearly all of which are on appeal in the labor courts.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4b97466932e446e4a6aa6ac24c62d8f9" continuedAt="i5909ff122cab477196ae7720a1a75ac7"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">China NDRC Antitrust Matter</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The competition authority in China has investigated our distributor pricing practices in China in connection with a broader inquiry into pharmaceutical industry pricing. We have cooperated with this investigation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Eastern District of Pennsylvania Pricing (Average Manufacturer Price) Inquiry</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2014, we, along with another pharmaceutical manufacturer, are named as co-defendants in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States et al. ex rel. Streck v. Takeda Pharm. Am., Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was filed in November 2014 and unsealed in the U.S. District Court for the Northern District of Illinois. The complaint alleges that the defendants should have treated certain credits from distributors as retroactive price increases and included such increases in calculating average manufacturer prices. Trial is scheduled for February 2022.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Health Choice Alliance </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are named as a defendant in a lawsuit filed in June 2017 in the U.S. District Court for the Eastern District of Texas seeking damages under the federal anti-kickback statute and state and federal false claims acts for certain patient support programs related to our products Humalog, Humulin, and Forteo. In September 2019, the U.S. District Court granted the U.S. Department of Justice&#8217;s motion to dismiss the relator&#8217;s second amended complaint. In January 2020, the relator appealed the District Court&#8217;s dismissal to the U.S. Court of Appeals for the Fifth Circuit. We are also named as a defendant in <ix:nonFraction unitRef="lawsuit" contextRef="i69f451428d3e45a3a75cd744529fea05_I20210331" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY4MzcyMw_41ae0345-139e-4f6a-becd-690569738367">two</ix:nonFraction> similar lawsuits filed in Texas and New Jersey state courts in October 2019 seeking damages under the Texas Medicaid Fraud Prevention Act and New Jersey Medicaid False Claims Act, respectively. In November 2020, the Texas state court action was stayed pending a decision by the U.S. Court of Appeals for the Fifth Circuit on the aforementioned District Court appeal. In April 2021, the New Jersey state court action was dismissed with prejudice.   </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Pricing Litigation, Investigations, and Inquiries</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we, along with Sanofi-Aventis U.S. LLC (Sanofi) and Novo Nordisk, Inc. (Novo Nordisk) were named as defendants in a consolidated purported class action lawsuit,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re. Insulin Pricing Litigation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the U.S. District Court for the District of New Jersey relating to insulin pricing seeking damages under various state consumer protection laws and the Federal Racketeer Influenced and Corrupt Organization Act (federal RICO Act). Separately, in February 2018, we, along with Sanofi and Novo Nordisk, were named as defendants in&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MSP Recovery Claims, Series, LLC et al. v. Sanofi Aventis U.S. LLC et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the same court, seeking damages under various state consumer protection laws, common law fraud, unjust enrichment, and the federal RICO Act. In both</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> In re. Insulin Pricing Litigation </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> MSP Recovery Claims</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> litigation, the court dismissed claims under the federal RICO Act and certain state laws. Also, filed in the same court in November 2020, we, along with Sanofi, Novo Nordisk, CVS, Express Scripts, and Optum, have been sued in a purported class action, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FWK Holdings, LLC v. Novo Nordisk Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for alleged violations of the federal RICO Act as well as the New Jersey RICO Act and anti-trust law. That same group of defendants, along with Medco Health and United Health Group, also have been sued in other purported class actions in the same court, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rochester Drug Co-Operative Inc. v. Eli Lilly &amp; Co. et al. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Value Drug Co. v. Eli Lilly &amp; Co. et al. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">both initiated in March 2020, for alleged violations of the federal RICO Act. In September 2020, the U.S. District Court for the District of New Jersey granted plaintiffs&#8217; motion to consolidate </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FWK Holdings, LLC v. Novo Nordisk Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rochester Drug Co-Operative Inc. v. Eli Lilly &amp; Co. et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Value Drug Co. v. Eli Lilly &amp; Co. et al.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Minnesota Attorney General&#8217;s Office initiated litigation against us, Sanofi, and Novo Nordisk,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">State of Minnesota v. Sanofi-Aventis U.S. LLC et al.,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;in the U.S. District Court for the District of New Jersey, alleging unjust enrichment, violations of various Minnesota state consumer protection laws, and the federal RICO Act. In March 2021, the U.S. District Court for the District of New Jersey dismissed with prejudice the Minnesota Attorney General&#8217;s federal RICO claims and false advertising claims under state law; the consumer fraud and other related state law claims remain ongoing. Additionally, in May 2019, the Kentucky Attorney General&#8217;s Office filed a complaint against us, Sanofi, and Novo Nordisk,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commonwealth of Kentucky v. Novo Nordisk, Inc. et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in Kentucky state court, alleging violations of the Kentucky consumer protection law, false advertising, and unjust enrichment. In November 2019, Harris County in Texas initiated litigation against us, Sanofi, Novo Nordisk, Express Scripts, CVS, Optum, and Aetna, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">County of</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Harris Texas v. Eli Lilly &amp; Co., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in federal court in the Southern District of Texas alleging violations of the federal RICO Act, federal and state antitrust law, and the state deceptive trade practices-consumer protection act. Harris County also alleges common law claims such as fraud, unjust enrichment, and civil conspiracy. This lawsuit relates to our insulin products as well as Trulicity. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i5909ff122cab477196ae7720a1a75ac7" continuedAt="i430cf19227fa4b2ca85c054676d30ead"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigations, Subpoenas, and Inquiries</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received a subpoena from the New York a</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd Vermont Attorney General Offices and civil investigative demands from the Washington, New Mexico, and Colorado Attorney General Offices relating to the pricing and sale of our insulin products. The Offices of the Attorney General in Mississippi, Washington D.C., California, Florida, Hawaii, and Nevada have requested information relating to the pricing and sale of our insulin products. We also received interrogatories and a subpoena from the California Attorney General's Office regarding our competition in the long-acting insulin market. We received <ix:nonFraction unitRef="request" contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331" decimals="0" format="ixt-sec:numwordsen" name="lly:LossContingencyNumberOfRequestsForInformation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY5MTkyOQ_3fb9f236-ddf0-4450-a1cd-db4abbe7ce3b">two</ix:nonFraction>&#160;requests from the House of Representatives&#8217; Committee on Energy and Commerce and a request from the Senate&#8217;s Committee on Health, Education, Labor, and Pensions seeking certain information related to the pricing of insulin products, among other issues. We also received requests from the House of Representatives&#8217; Committee on Oversight and Reform and the Senate&#8217;s Committee on Finance, which seek detailed commercial information and business records. In January 2021, the Senate&#8217;s Committee on Finance released a report summarizing the findings of its investigation. We are cooperating with all of these aforementioned investigations, subpoenas, and inquiries.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Research Corporation Technologies, Inc. </span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i430cf19227fa4b2ca85c054676d30ead">In April 2016, we were named as a defendant in litigation filed by Research Corporation Technologies, Inc. (RCT) in the U.S. District Court for the District of Arizona. RCT is seeking damages for breach of contract, unjust enrichment, and conversion related to processes used to manufacture certain products, including Humalog and Humulin. A trial date has not been set.</ix:continuation> </span></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_76"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10: <ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RleHRyZWdpb246YTcwNmY0MTNhNTkyNDdiOGI4ZmM0NDJjZjA4ZjE2NGVfMTQ3NQ_9cce71f0-5a2e-4a07-9024-04767baba9c5" continuedAt="iabe2760b4b6f4a1e84f180e95df32b04" escape="true">Other Comprehensive Income (Loss)</ix:nonNumeric></span></div><ix:continuation id="iabe2760b4b6f4a1e84f180e95df32b04" continuedAt="id03adcbd63e44e8f9d0fa1df59af90ab"><ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RleHRyZWdpb246YTcwNmY0MTNhNTkyNDdiOGI4ZmM0NDJjZjA4ZjE2NGVfMTQ5MA_f78d9883-ca92-4385-aa58-9aa0f82dde75" continuedAt="ia5d403a94542481caa41a304ed41e058" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the activity related to each component of other comprehensive income (loss) during the three months ended March&#160;31, 2021 and 2020:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&#160;Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&#160;Flow Hedges</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b10da171de74c8882000a2f696152fd_I20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfMi0xLTEtMS0w_78a39739-9b63-41a4-acd4-d7c83d35e235">1,427.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5614d38977b64c168c1b9fc251c757ca_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfMi0zLTEtMS0w_1df9d921-1253-48a6-b48e-07878593c7f5">14.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffd75cb32c5543a891d689e8933d4949_I20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfMi01LTEtMS0w_a3ac93ca-4247-4c91-9f58-db825ba70e44">4,751.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icaa91bb6c1a24ffcb202a27011d73dd0_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfMi03LTEtMS0w_0e08d2f4-cfbc-4fbc-8196-9a9e6d373397">332.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2845560a0ba2491a904c84ba82f35819_I20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfMi0xMS0xLTEtMA_b95c5add-ec2e-4b00-8bc4-f85b5201cc4c">6,496.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i743947277250425485ee1e0a26d90120_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNC0xLTEtMS0w_c0ab2da5-9e0d-4189-aeee-e08fdd18f3c7">249.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i205a56c975a443f7b7c7708eb29b679c_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNC0zLTEtMS0w_3d827e58-00b2-4ae4-b8b7-dfb7d50de94d">10.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebbc7661fa041f1ba2dd368ac1ee896_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNC01LTEtMS0w_5c8b798f-9924-483e-b1ca-c4f4bc08608f">18.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c5b25a00f1643c98078aba97cc80b62_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNC03LTEtMS0w_21befebb-4339-4a0a-bc26-9c2d3b91f906">252.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNC0xMS0xLTEtMA_95d4a7dd-f9c6-4ba6-9915-9437f2213d69">11.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743947277250425485ee1e0a26d90120_D20210101-20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNS0xLTEtMS0w_6d6a1854-f0e0-42f9-a898-8c64ceb85f5d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i205a56c975a443f7b7c7708eb29b679c_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNS0zLTEtMS0w_320fb153-f84f-4e11-b2f9-96c16696c0fe">0.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebbc7661fa041f1ba2dd368ac1ee896_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNS01LTEtMS0w_0ec7980a-a4bb-45d8-8dc8-2a226dcc585b">85.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c5b25a00f1643c98078aba97cc80b62_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNS03LTEtMS0w_03c419d7-967c-4b5d-aa6a-e34325e5373d">3.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNS0xMS0xLTEtMA_e6d33f7c-83e3-4e2e-9756-f17f22ca71bb">89.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i743947277250425485ee1e0a26d90120_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNi0xLTEtMS0w_6e4c48a7-6803-4fc6-9fd5-dadab0c4f22b">249.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i205a56c975a443f7b7c7708eb29b679c_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNi0zLTEtMS0w_2949c66b-7f13-435d-b171-a8739189b485">10.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebbc7661fa041f1ba2dd368ac1ee896_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNi01LTEtMS0w_2ba96491-feb1-4e5b-9958-10acda5f8691">104.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c5b25a00f1643c98078aba97cc80b62_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNi03LTEtMS0w_960576ee-c2bf-49ad-8a55-17240931e525">256.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNi0xMS0xLTEtMA_ab0fd064-1948-434c-8075-bd0ee7ba1e42">100.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9655bade5b00400dba7752533cb6743c_I20210331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfOC0xLTEtMS0w_f72807ab-04e3-42f3-9b91-5ac517970c4d">1,677.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i577b7fef6c2c49bf87fe8cb8121248ce_I20210331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfOC0zLTEtMS0w_d9518527-dcd6-45b9-8d95-a00451ca25f9">4.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie23fc76e1a5a432a8db78dd624ef5cc1_I20210331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfOC01LTEtMS0w_d5cae3be-3e8e-4950-b836-c1394a1d646f">4,646.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7caab5ff3a4d4ca8a64128cbbeb05cdd_I20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfOC03LTEtMS0w_923b98dd-798d-4af2-9f50-195d791242ea">76.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b8b459cd1fc47f6baa6f11b48145ac4_I20210331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfOC0xMS0xLTEtMA_2dc7c19e-1afa-4059-9cd7-5948bdeb4517">6,395.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.455%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&#160;Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&#160;Flow Hedges</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2020</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1eeb66393264479aecf1f1d2fcd51b1_I20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfMi0xLTEtMS0w_a3e188dd-4ba7-4572-a5c9-8b781fb445ad">1,678.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cc74d110d0145598aeabdd970d87f17_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfMi0zLTEtMS0w_80d6720d-cdfb-4179-832f-a38f54409d00">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa58ad2146314403b3eff9eaf3e10324_I20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfMi01LTEtMS0w_a124b393-22dd-4e3f-a5ca-f5c3e8f20a93">4,638.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ebe01e7039a44a4888856db6e4a7d39_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfMi03LTEtMS0w_838cd285-3c6f-4681-9151-2c31d5065336">211.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffabc6d5c4614780a93ce1b21d701159_I20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfMi0xMS0xLTEtMA_e7a45a8e-ea31-4d72-9553-4f33caf001e9">6,523.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96ce660d25654b37a7243b236eca576b_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNC0xLTEtMS0w_5ee49e98-0d2b-45a4-8ee5-13478ae20a40">126.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55b8fd6090834514913a2977fd43623e_D20200101-20200331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNC0zLTEtMS0w_8b90cd77-a86d-4854-b65e-dca8a0514fd3">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17796a268f3742fda454ebd20b70ba1d_D20200101-20200331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNC01LTEtMS0w_3d06fc95-dea7-4d75-86d2-8bc01b238856">30.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bc687d07e3f4ff4bcb96e53bc8d83ec_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNC03LTEtMS0w_1fa5f343-0920-4563-90c5-f00ef034fcd7">348.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNC0xMS0xLTEtMA_fe43ed8f-5010-43a9-a55d-f8e75257b4ff">442.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96ce660d25654b37a7243b236eca576b_D20200101-20200331" decimals="-5" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNS0xLTEtMS0w_0c56285c-7dd2-4c09-b312-7ca3dd62a9cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55b8fd6090834514913a2977fd43623e_D20200101-20200331" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNS0zLTEtMS0w_6553ead3-dd79-41e2-9687-66065dd392e2">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17796a268f3742fda454ebd20b70ba1d_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNS01LTEtMS0w_e1810fab-5447-4173-b344-778a15891af0">77.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bc687d07e3f4ff4bcb96e53bc8d83ec_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNS03LTEtMS0w_3f86e489-453d-4c01-b65e-4a57c7e0b7ae">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNS0xMS0xLTEtMA_e9dfd8fb-e550-4868-8161-5f36488a7c1c">80.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96ce660d25654b37a7243b236eca576b_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNi0xLTEtMS0w_ffc7465a-49cb-43c3-bd78-576a1c44556c">126.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55b8fd6090834514913a2977fd43623e_D20200101-20200331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNi0zLTEtMS0w_f03f954a-abd8-4f7a-9c83-be3e7b43e1eb">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17796a268f3742fda454ebd20b70ba1d_D20200101-20200331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNi01LTEtMS0w_947d3455-091a-41bc-bea4-c4d115fa53aa">108.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bc687d07e3f4ff4bcb96e53bc8d83ec_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNi03LTEtMS0w_2ed5dc6e-1c4d-405e-b8b4-d1e51d7e649e">345.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNi0xMS0xLTEtMA_9440ac46-1488-4f69-b265-56aa4318bfdd">362.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd5fe3b1199247e6a91eb8d01efc2392_I20200331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfOC0xLTEtMS0w_4a0538de-b7d1-4273-b463-848b2baa3e91">1,804.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41d912b5241343a9b988106cef8e0215_I20200331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfOC0zLTEtMS0w_3bdd29a2-6af8-4a51-b9c7-c593b6190737">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33afbb7d73484c0a83d56114c6756d5c_I20200331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfOC01LTEtMS0w_8cd48e6f-77a1-4bdf-9521-23fc0923036a">4,530.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i194e7735259d438eb363e7d9f3ae1523_I20200331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfOC03LTEtMS0w_8d439137-8e26-47ea-97b2-cae09bb23921">556.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i986fb3e559c0490ca09848e9ac9bf901_I20200331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfOC0xMS0xLTEtMA_b5ca2f5c-ab0e-4270-bff9-174d4ab913b6">6,885.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id03adcbd63e44e8f9d0fa1df59af90ab"><ix:continuation id="ia5d403a94542481caa41a304ed41e058"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects on the net activity related to each component of other comprehensive income (loss) were as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tax benefit (expense) </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation gains/losses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i743947277250425485ee1e0a26d90120_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjE1ZjMxMTEyNjliMTRlNThiZDRiODVlYjRjMDcxY2ZhL3RhYmxlcmFuZ2U6MTVmMzExMTI2OWIxNGU1OGJkNGI4NWViNGMwNzFjZmFfMi0xLTEtMS0w_4f5cb6fd-9422-448f-8f98-77ac4555bbd0">75.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96ce660d25654b37a7243b236eca576b_D20200101-20200331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjE1ZjMxMTEyNjliMTRlNThiZDRiODVlYjRjMDcxY2ZhL3RhYmxlcmFuZ2U6MTVmMzExMTI2OWIxNGU1OGJkNGI4NWViNGMwNzFjZmFfMi0zLTEtMS0w_f525edf9-0348-4d1b-82bb-51f0e93b9789">38.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized net gains/losses on securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i205a56c975a443f7b7c7708eb29b679c_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjE1ZjMxMTEyNjliMTRlNThiZDRiODVlYjRjMDcxY2ZhL3RhYmxlcmFuZ2U6MTVmMzExMTI2OWIxNGU1OGJkNGI4NWViNGMwNzFjZmFfMy0xLTEtMS0w_883bddba-fea5-4f3a-ad3f-6474fe6f4a7b">4.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55b8fd6090834514913a2977fd43623e_D20200101-20200331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjE1ZjMxMTEyNjliMTRlNThiZDRiODVlYjRjMDcxY2ZhL3RhYmxlcmFuZ2U6MTVmMzExMTI2OWIxNGU1OGJkNGI4NWViNGMwNzFjZmFfMy0zLTEtMS0w_c16ca3f2-ba44-4e24-8ac9-1945561dbe1f">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit pension and retiree health benefit plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ebbc7661fa041f1ba2dd368ac1ee896_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjE1ZjMxMTEyNjliMTRlNThiZDRiODVlYjRjMDcxY2ZhL3RhYmxlcmFuZ2U6MTVmMzExMTI2OWIxNGU1OGJkNGI4NWViNGMwNzFjZmFfNC0xLTEtMS0w_bce29064-79f1-400a-a8e5-459edad3293d">31.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17796a268f3742fda454ebd20b70ba1d_D20200101-20200331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjE1ZjMxMTEyNjliMTRlNThiZDRiODVlYjRjMDcxY2ZhL3RhYmxlcmFuZ2U6MTVmMzExMTI2OWIxNGU1OGJkNGI4NWViNGMwNzFjZmFfNC0zLTEtMS0w_0ebd877e-b1a4-4431-8f1b-6210cf69c41f">25.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of cash flow hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf742f7aff334b05a91842e894677604_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjE1ZjMxMTEyNjliMTRlNThiZDRiODVlYjRjMDcxY2ZhL3RhYmxlcmFuZ2U6MTVmMzExMTI2OWIxNGU1OGJkNGI4NWViNGMwNzFjZmFfNS0xLTEtMS0w_c9ddf321-9843-49d2-aa1b-6fb091d5962a">68.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02045ea33c7d43d4a34c42a37721b125_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjE1ZjMxMTEyNjliMTRlNThiZDRiODVlYjRjMDcxY2ZhL3RhYmxlcmFuZ2U6MTVmMzExMTI2OWIxNGU1OGJkNGI4NWViNGMwNzFjZmFfNS0zLTEtMS0w_d2f63020-8259-4d96-81c1-8d60430234ee">91.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit (provision) for income taxes allocated to other comprehensive income (loss) items</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjE1ZjMxMTEyNjliMTRlNThiZDRiODVlYjRjMDcxY2ZhL3RhYmxlcmFuZ2U6MTVmMzExMTI2OWIxNGU1OGJkNGI4NWViNGMwNzFjZmFfNi0xLTEtMS0w_258adb7c-aaf1-4b6a-b1e6-9ecb832080fd">170.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjE1ZjMxMTEyNjliMTRlNThiZDRiODVlYjRjMDcxY2ZhL3RhYmxlcmFuZ2U6MTVmMzExMTI2OWIxNGU1OGJkNGI4NWViNGMwNzFjZmFfNi0zLTEtMS0w_801435d4-4ca8-4021-81d8-6449d5486f99">27.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for the tax effects of foreign currency translation gains and losses related to our foreign currency-denominated notes, cross-currency interest rate swaps, and other foreign currency exchange contracts designated as net investment hedges (see Note 6), income taxes were not provided for foreign currency translation. Generally, the assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows; therefore, resulting translation adjustments are made in shareholders' equity rather than in the consolidated condensed statements of operations.</span></div><ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RleHRyZWdpb246YTcwNmY0MTNhNTkyNDdiOGI4ZmM0NDJjZjA4ZjE2NGVfMTQ4NQ_f66e70a5-a9cd-4fa5-a881-07c935aacb9e" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassifications out of accumulated other comprehensive loss were as follows:</span></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:33.552%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Details about Accumulated Other Comprehensive Loss Components</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Affected Line Item in the Consolidated Condensed Statements of Operations</span></td></tr><tr style="height:6pt"><td colspan="30" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of retirement benefit items:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service benefits, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if48b9be7413d42df903afc9bf15c3c13_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmYxMjU5ZDQ5Y2YwMTQ1ZWU5ODBkMzE4ZWI0ZWZkZTJhL3RhYmxlcmFuZ2U6ZjEyNTlkNDljZjAxNDVlZTk4MGQzMThlYjRlZmRlMmFfNC0yLTEtMS0w_5a2a977e-38e5-4ebe-958c-f7d3077840f8">13.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i492583e2c9b044f29ac4a51092ddfbe8_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmYxMjU5ZDQ5Y2YwMTQ1ZWU5ODBkMzE4ZWI0ZWZkZTJhL3RhYmxlcmFuZ2U6ZjEyNTlkNDljZjAxNDVlZTk4MGQzMThlYjRlZmRlMmFfNC00LTEtMS0w_0d6a518d-7b11-4826-b884-532e1d038418">13.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial losses, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfdc30c8362d4397a4020c9b938662fa_D20210101-20210331" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmYxMjU5ZDQ5Y2YwMTQ1ZWU5ODBkMzE4ZWI0ZWZkZTJhL3RhYmxlcmFuZ2U6ZjEyNTlkNDljZjAxNDVlZTk4MGQzMThlYjRlZmRlMmFfNS0yLTEtMS0w_d158155b-030d-4959-b25c-888722621ea5">122.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2917edad81e5463e9d61cceea8f62ea4_D20200101-20200331" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmYxMjU5ZDQ5Y2YwMTQ1ZWU5ODBkMzE4ZWI0ZWZkZTJhL3RhYmxlcmFuZ2U6ZjEyNTlkNDljZjAxNDVlZTk4MGQzMThlYjRlZmRlMmFfNS00LTEtMS0w_c8129a61-84b9-4a70-9a92-383fb30d61df">111.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if82cce099c354dd78182619455a05af1_D20210101-20210331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmYxMjU5ZDQ5Y2YwMTQ1ZWU5ODBkMzE4ZWI0ZWZkZTJhL3RhYmxlcmFuZ2U6ZjEyNTlkNDljZjAxNDVlZTk4MGQzMThlYjRlZmRlMmFfNi0yLTEtMS0w_efccc077-c89d-4b27-9b85-b8fa673d1071">108.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25e6d224ac334db98fbf37d17ced616d_D20200101-20200331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmYxMjU5ZDQ5Y2YwMTQ1ZWU5ODBkMzE4ZWI0ZWZkZTJhL3RhYmxlcmFuZ2U6ZjEyNTlkNDljZjAxNDVlZTk4MGQzMThlYjRlZmRlMmFfNi00LTEtMS0w_1e6b4d10-6706-4d86-b337-2e9eab37f7bf">98.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if82cce099c354dd78182619455a05af1_D20210101-20210331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmYxMjU5ZDQ5Y2YwMTQ1ZWU5ODBkMzE4ZWI0ZWZkZTJhL3RhYmxlcmFuZ2U6ZjEyNTlkNDljZjAxNDVlZTk4MGQzMThlYjRlZmRlMmFfNy0yLTEtMS0w_c580848a-e94a-41cd-8dfa-878e0b170f9f">22.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25e6d224ac334db98fbf37d17ced616d_D20200101-20200331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmYxMjU5ZDQ5Y2YwMTQ1ZWU5ODBkMzE4ZWI0ZWZkZTJhL3RhYmxlcmFuZ2U6ZjEyNTlkNDljZjAxNDVlZTk4MGQzMThlYjRlZmRlMmFfNy00LTEtMS0w_8d83bd4a-1aa4-4939-aa2a-bbeb5c9d3091">20.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if82cce099c354dd78182619455a05af1_D20210101-20210331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmYxMjU5ZDQ5Y2YwMTQ1ZWU5ODBkMzE4ZWI0ZWZkZTJhL3RhYmxlcmFuZ2U6ZjEyNTlkNDljZjAxNDVlZTk4MGQzMThlYjRlZmRlMmFfOC0yLTEtMS0w_3e0d06c5-6706-4bd4-bbb5-a1eba33a5fb8">85.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25e6d224ac334db98fbf37d17ced616d_D20200101-20200331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmYxMjU5ZDQ5Y2YwMTQ1ZWU5ODBkMzE4ZWI0ZWZkZTJhL3RhYmxlcmFuZ2U6ZjEyNTlkNDljZjAxNDVlZTk4MGQzMThlYjRlZmRlMmFfOC00LTEtMS0w_4031e400-0895-4917-9390-56bd30269776">77.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net of tax</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i191727da20c34eae98d4dbc93f0337fe_D20210101-20210331" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmYxMjU5ZDQ5Y2YwMTQ1ZWU5ODBkMzE4ZWI0ZWZkZTJhL3RhYmxlcmFuZ2U6ZjEyNTlkNDljZjAxNDVlZTk4MGQzMThlYjRlZmRlMmFfMTAtMi0xLTEtMA_4e04b0d9-6b5b-4808-aaa3-80bea98b8414">3.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9638221883d14af2935d735e8cc9a360_D20200101-20200331" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmYxMjU5ZDQ5Y2YwMTQ1ZWU5ODBkMzE4ZWI0ZWZkZTJhL3RhYmxlcmFuZ2U6ZjEyNTlkNDljZjAxNDVlZTk4MGQzMThlYjRlZmRlMmFfMTAtNC0xLTEtMA_c04baaf6-8fd1-40e6-ab09-fb6107dcd0fa">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37bfd76d6ecb46708142e81e2d19a33c_D20210101-20210331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmYxMjU5ZDQ5Y2YwMTQ1ZWU5ODBkMzE4ZWI0ZWZkZTJhL3RhYmxlcmFuZ2U6ZjEyNTlkNDljZjAxNDVlZTk4MGQzMThlYjRlZmRlMmFfMTMtMi0xLTEtMA_85064f7a-6b84-4c31-8ac4-ac975595f81f">89.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0ff30fbf7f474f9b43c59d3bc7e538_D20200101-20200331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmYxMjU5ZDQ5Y2YwMTQ1ZWU5ODBkMzE4ZWI0ZWZkZTJhL3RhYmxlcmFuZ2U6ZjEyNTlkNDljZjAxNDVlZTk4MGQzMThlYjRlZmRlMmFfMTMtNC0xLTEtMA_f1a4b31d-bd84-436e-bb67-660bbc26f190">80.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i3cd151b5d83246a98b0e0ef4a9feb269_82"></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11: <ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV84Mi9mcmFnOmVlYWM2MTIyMDVhYjRjYzhhMmZmY2VkYmMzYjk1NzFiL3RleHRyZWdpb246ZWVhYzYxMjIwNWFiNGNjOGEyZmZjZWRiYzNiOTU3MWJfMjMy_1a318be7-1d3c-48ef-806e-69be3396eac0" continuedAt="ib39298d189b74de2a1cd015c8b67d895" escape="true">Other&#8211;Net, (Income) Expense</ix:nonNumeric></span></div><ix:continuation id="ib39298d189b74de2a1cd015c8b67d895"><ix:nonNumeric contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV84Mi9mcmFnOmVlYWM2MTIyMDVhYjRjYzhhMmZmY2VkYmMzYjk1NzFiL3RleHRyZWdpb246ZWVhYzYxMjIwNWFiNGNjOGEyZmZjZWRiYzNiOTU3MWJfMjM1_d4756328-bc79-42ca-8998-9b628fa1d557" escape="true"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other&#8211;net, (income) expense consisted of the following:</span></div><div style="margin-bottom:12pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV84Mi9mcmFnOmVlYWM2MTIyMDVhYjRjYzhhMmZmY2VkYmMzYjk1NzFiL3RhYmxlOjQ0MTRmMmZlZjcyYzRhZTZhZDVmZjI2ZjhjN2M5MTU3L3RhYmxlcmFuZ2U6NDQxNGYyZmVmNzJjNGFlNmFkNWZmMjZmOGM3YzkxNTdfMi0xLTEtMS0w_0682fe7c-5a78-4669-a10b-d87c3985d48a">87.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV84Mi9mcmFnOmVlYWM2MTIyMDVhYjRjYzhhMmZmY2VkYmMzYjk1NzFiL3RhYmxlOjQ0MTRmMmZlZjcyYzRhZTZhZDVmZjI2ZjhjN2M5MTU3L3RhYmxlcmFuZ2U6NDQxNGYyZmVmNzJjNGFlNmFkNWZmMjZmOGM3YzkxNTdfMi0zLTEtMS0w_fab98565-94d1-4ace-87fa-9bae2aaa930d">92.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV84Mi9mcmFnOmVlYWM2MTIyMDVhYjRjYzhhMmZmY2VkYmMzYjk1NzFiL3RhYmxlOjQ0MTRmMmZlZjcyYzRhZTZhZDVmZjI2ZjhjN2M5MTU3L3RhYmxlcmFuZ2U6NDQxNGYyZmVmNzJjNGFlNmFkNWZmMjZmOGM3YzkxNTdfMy0xLTEtMS0w_3e1a5b04-1acf-471e-b99e-009bc4001da6">5.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV84Mi9mcmFnOmVlYWM2MTIyMDVhYjRjYzhhMmZmY2VkYmMzYjk1NzFiL3RhYmxlOjQ0MTRmMmZlZjcyYzRhZTZhZDVmZjI2ZjhjN2M5MTU3L3RhYmxlcmFuZ2U6NDQxNGYyZmVmNzJjNGFlNmFkNWZmMjZmOGM3YzkxNTdfMy0zLTEtMS0w_b492304a-08d1-4b0a-8050-87077da727db">14.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment gains on equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV84Mi9mcmFnOmVlYWM2MTIyMDVhYjRjYzhhMmZmY2VkYmMzYjk1NzFiL3RhYmxlOjQ0MTRmMmZlZjcyYzRhZTZhZDVmZjI2ZjhjN2M5MTU3L3RhYmxlcmFuZ2U6NDQxNGYyZmVmNzJjNGFlNmFkNWZmMjZmOGM3YzkxNTdfNC0xLTEtMS04Mzgx_db9b03ee-c25d-4f68-bfc5-7cd3e608f98c">301.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV84Mi9mcmFnOmVlYWM2MTIyMDVhYjRjYzhhMmZmY2VkYmMzYjk1NzFiL3RhYmxlOjQ0MTRmMmZlZjcyYzRhZTZhZDVmZjI2ZjhjN2M5MTU3L3RhYmxlcmFuZ2U6NDQxNGYyZmVmNzJjNGFlNmFkNWZmMjZmOGM3YzkxNTdfNC0zLTEtMS04NDA5_84491e38-880a-484c-a954-d38d6bfae84e">186.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement benefit plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV84Mi9mcmFnOmVlYWM2MTIyMDVhYjRjYzhhMmZmY2VkYmMzYjk1NzFiL3RhYmxlOjQ0MTRmMmZlZjcyYzRhZTZhZDVmZjI2ZjhjN2M5MTU3L3RhYmxlcmFuZ2U6NDQxNGYyZmVmNzJjNGFlNmFkNWZmMjZmOGM3YzkxNTdfNC0xLTEtMS0w_096ee406-ccac-4068-814f-d35a09b6962c">73.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV84Mi9mcmFnOmVlYWM2MTIyMDVhYjRjYzhhMmZmY2VkYmMzYjk1NzFiL3RhYmxlOjQ0MTRmMmZlZjcyYzRhZTZhZDVmZjI2ZjhjN2M5MTU3L3RhYmxlcmFuZ2U6NDQxNGYyZmVmNzJjNGFlNmFkNWZmMjZmOGM3YzkxNTdfNC0zLTEtMS0w_3b90c007-552a-4def-ae05-14cf9e733cb5">44.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV84Mi9mcmFnOmVlYWM2MTIyMDVhYjRjYzhhMmZmY2VkYmMzYjk1NzFiL3RhYmxlOjQ0MTRmMmZlZjcyYzRhZTZhZDVmZjI2ZjhjN2M5MTU3L3RhYmxlcmFuZ2U6NDQxNGYyZmVmNzJjNGFlNmFkNWZmMjZmOGM3YzkxNTdfNS0xLTEtMS0w_5752735c-e01b-4f10-b8ef-54d6f0e747f0">28.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV84Mi9mcmFnOmVlYWM2MTIyMDVhYjRjYzhhMmZmY2VkYmMzYjk1NzFiL3RhYmxlOjQ0MTRmMmZlZjcyYzRhZTZhZDVmZjI2ZjhjN2M5MTU3L3RhYmxlcmFuZ2U6NDQxNGYyZmVmNzJjNGFlNmFkNWZmMjZmOGM3YzkxNTdfNS0zLTEtMS0w_24c35329-0d10-4a2f-98ce-dd071e05f304">63.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV84Mi9mcmFnOmVlYWM2MTIyMDVhYjRjYzhhMmZmY2VkYmMzYjk1NzFiL3RhYmxlOjQ0MTRmMmZlZjcyYzRhZTZhZDVmZjI2ZjhjN2M5MTU3L3RhYmxlcmFuZ2U6NDQxNGYyZmVmNzJjNGFlNmFkNWZmMjZmOGM3YzkxNTdfNi0xLTEtMS0w_8c109cd8-0fc7-4fc2-8165-adb4a3c3602d">321.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV84Mi9mcmFnOmVlYWM2MTIyMDVhYjRjYzhhMmZmY2VkYmMzYjk1NzFiL3RhYmxlOjQ0MTRmMmZlZjcyYzRhZTZhZDVmZjI2ZjhjN2M5MTU3L3RhYmxlcmFuZ2U6NDQxNGYyZmVmNzJjNGFlNmFkNWZmMjZmOGM3YzkxNTdfNi0zLTEtMS0w_001f4e46-c11f-44a8-8d7f-1c46208bf7eb">89.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:12pt;margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&#160;2. Management&#8217;s Discussion and Analysis of Results of Operations and Financial Condition</span></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_88"></div><div><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Results of Operations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Tables present dollars in millions, except per-share data)</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management&#8217;s discussion and analysis of results of operations and financial condition is intended to assist the reader in understanding and assessing significant changes and trends related to the results of operations and financial position of our consolidated company. This discussion and analysis should be read in conjunction with the consolidated condensed financial statements and accompanying footnotes in Part I, Item 1 of this Quarterly Report on Form 10-Q. Certain statements in this Part I, Item 2 of this Quarterly Report on Form 10-Q constitute forward-looking statements. Various risks and uncertainties, including those discussed in "Forward-Looking Statements" in this Quarterly Report on Form 10-Q and &#8220;Risk Factors&#8221; in Part I, Item 1A of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2020, may cause our actual results, financial position, and cash generated from operations to differ materially from these forward-looking statements.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This section provides an overview of our financial results, recent product and late-stage pipeline developments, and other matters affecting our company and the pharmaceutical industry. Earnings per share (EPS) data are presented on a diluted basis.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, we have been focused on maintaining a reliable supply of our medicines; reducing the strain on the medical system; developing treatments for COVID-19; protecting the health, safety, and well-being of our employees; supporting our communities; and ensuring affordability of and access to our medicines, particularly insulin.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced negative impacts to our underlying business due to the COVID-19 pandemic, including decreases in new prescriptions as a result of fewer patient visits to physician&#8217;s offices to begin or change treatment, changes in payer segment mix, and the use of patient affordability programs in the United States (U.S.) due to increased unemployment. Additionally, we have experienced, and may continue to experience, decreased demand as a result of lack of normal access and fewer in-person interactions by patients and our employees with the healthcare system. In certain locations in the U.S. and around the world with COVID-19 outbreaks, we temporarily halted in-person interactions by our employees with healthcare providers and increased virtual interactions. While in-person interactions have resumed in many locations, we may decide to halt such activity in the future and, in those cases, expect to resume such interactions as it is safe to do so and in compliance with applicable guidance and requirements. We may experience additional pricing pressures resulting from the financial strain of the COVID-19 pandemic on government-funded healthcare systems around the world. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remain committed to discovering and developing new treatments for the patients we serve. At the beginning of the COVID-19 pandemic, we paused new clinical trial starts and enrollment in new trials in order to reduce the strain on the medical system, and we have resumed this activity in our clinical trials. However, significant delays or unexpected issues, such as higher discontinuation rates or delays accumulating data, affecting the timing, conduct, or regulatory review of our clinical trials, could adversely affect our ability to commercialize some assets in our product pipeline if the COVID-19 pandemic continues for a protracted period. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the start of the pandemic we have been working with a variety of organizations, including governmental agencies, to facilitate access to our COVID-19 therapies in various countries. The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorizations (EUA) for bamlanivimab and bamlanivimab and etesevimab administered together for higher-risk patients who have been recently diagnosed with mild-to-moderate COVID-19 and for baricitinib in combination with remdesivir in hospitalized COVID-19 patients. We have taken several steps in order to transition from bamlanivimab administered alone to bamlanivimab and etesevimab administered together in the U.S. for the treatment of COVID-19. In April 2021, we requested the FDA revoke the EUA for bamlanivimab alone. This request was not due to any new safety concern. The FDA subsequently revoked the EUA for bamlanivimab alone. We have agreed with the U.S. government to supply bamlanivimab and etesevimab together and to supply etesevimab to complement doses of bamlanivimab that the U.S. government previously purchased. As a result, we terminated the purchase agreement with the U.S. government to supply bamlanivimab alone and cancelled orders for any remaining doses scheduled to be delivered. The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for bamlanivimab alone and for bamlanivimab and etesevimab administered together for patients that do not require supplemental oxygen and who are at high risk of progressing to severe COVID-19.  </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face unique risks and uncertainties in our development, manufacture, and uptake of potential treatments for COVID-19, including vulnerability to supply chain disruptions, higher manufacturing costs, difficulties in manufacturing sufficient quantities of our therapies, heightened regulatory scrutiny of our manufacturing practices,  restrictions on administration that limit widespread and timely access to our therapies, and risks related to handling, return, and/or refund of product after delivery by us. Expedited authorization processes, including our EUA for bamlanivimab and etesevimab administered together, have allowed restricted distribution of products with less than typical safety and efficacy data, and additional data that become available may call into question the safety or effectiveness of our COVID-19 therapies. Additionally, the availability of superior or competitive therapies, or preventative measures, such as vaccines, coupled with the transient nature of pandemics, could negatively impact or eliminate demand for our COVID-19 therapies. Mutations or the spread of other variants of the coronavirus could also render our therapies ineffective. We may also be required to accept returns of certain bamlanivimab and etesevimab previously supplied together in the U.S. if the relevant EUA is revoked or terminated due to safety and efficacy concerns. In addition, evolving regulatory priorities have intensified governmental scrutiny of our operations, including our compliance with Good Manufacturing Practices (cGMP), quality assurance, and similar regulations relating to our manufacture of COVID-19 therapies and other medicines. Any of these risks could prevent us from recouping our substantial investments in the research, development, and manufacture of our COVID-19 therapies. These risks could also affect other aspects of our business, including potentially resulting in delays or denials in the approval or launch of other products. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to continue to operate without significant negative impacts will in part depend on our ability to protect our employees and our supply chain. We have taken steps to protect our employees worldwide, with particular measures in place for those working in our manufacturing sites and distribution facilities. We have been able to largely maintain our normal operations. However, uncertainty resulting from the COVID-19 pandemic could have an adverse impact on our manufacturing operations, global supply chain, and distribution systems, which could impact our ability to produce and distribute our products and the ability of third parties on which we rely to fulfill their obligations to us, and could increase our expenses.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the COVID-19 pandemic has affected our operations and demand for our products, it has not negatively impacted our liquidity position. We expect to continue to generate cash flows to meet our short-term liquidity needs and to have access to liquidity via the short-term and long-term debt markets. As part of our response to the COVID-19 pandemic, we worked quickly to ramp up the manufacturing of our COVID-19 antibodies in order to ensure ample supply. Due in part to the termination of the purchase agreement with the U.S. government to supply bamlanivimab alone and the cancellation of orders for the remaining doses of bamlanivimab alone that were scheduled to be delivered pursuant to the agreement, we have experienced impairment charges for excess inventory related to our COVID-19 antibodies during the three months ended March 31, 2021. We could experience additional impairments of our assets, including inventory related to our COVID-19 antibodies, or significant changes in the fair value of our assets due to the COVID-19 pandemic, including as a result of the factors discussed above. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Risk Factors&#8221; in Part I, Item 1A of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2020 for additional information on risk factors that could impact our results.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Results</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our key operating results:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.675%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,805.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,859.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,927.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,644.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin as a percent of revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,260.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,941.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development (IPR&amp;D)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">299.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring, and other special charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">211.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,355.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,456.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.49</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NM - not meaningful</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue increased for the three months ended March&#160;31, 2021 driven by increased volume and the favorable impact of foreign exchange rates, partially offset by lower realized prices. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses, defined as the sum of research and development and marketing, selling, and administrative expenses, increased for the three months ended March&#160;31, 2021, primarily due to</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> research and development expenses for COVID-19 antibody therapies and baricitinib, as well as higher research and development expenses for late-stage assets.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The decrease in net income and EPS for the three months ended March&#160;31, 2021 was primarily driven by </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">higher research and development expenses, higher acquired IPR&amp;D, and higher asset impairment, restructuring, and other special charges,</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> partially offset by higher gross margin, higher other income, and lower income tax expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following highlighted items also affect comparisons of our financial results for the three months ended March&#160;31, 2021 and 2020:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021 </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D (See Note 3 to the consolidated condensed financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized acquired IPR&amp;D charges of $299.3 million for the three months ended March 31, 2021 related to collaborations with Rigel Pharmaceuticals, Inc. (Rigel), Precision BioSciences, Inc. (Precision), Merus N.V. (Merus), and Asahi Kasei Pharma Corporation (Asahi). </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset Impairment, Restructuring, and Other Special Charges (See Note 5 to the consolidated condensed financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized charges of $211.6 million for the three months ended March 31, 2021 primarily related to an intangible asset impairment resulting from the decision to sell the rights to Qbrexza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as acquisition and integration costs associated with the acquisition of Prevail Therapeutics Inc. (Prevail). </span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other-Net, (Income) Expense (See Note 6 to the consolidated condensed financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized other income of $301.5&#160;million of net investment gains on equity securities. </span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020 </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D (See Note 3 to the consolidated condensed financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized acquired IPR&amp;D charges of $52.3 million for the three months ended March 31, 2020 related to a collaboration with Sitryx Therapeutics Limited (Sitryx). </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset Impairment, Restructuring, and Other Special Charges (See Note 5 to the consolidated condensed financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized charges of $59.9 million for the three months ended March 31, 2020 primarily related to acquisition and integration costs associated with the acquisition of Dermira, Inc. (Dermira). </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other-Net, (Income) Expense (See Note 6 to the consolidated condensed financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized other income of $186.6 million of net investment gains on equity securities. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Late-Stage Pipeline</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative new medicines. We currently have approximately 45 candidates in clinical development or under regulatory review, and a larger number of projects in the discovery phase.</span></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following new molecular entities (NMEs) are currently in Phase III clinical trials or have been submitted for regulatory review or have received first regulatory approval in the U.S., Europe, or Japan in 2021. In addition, the following table includes certain NMEs currently in Phase I or Phase II clinical trials. The following table reflects the status of these NMEs, including certain other developments since January&#160;1, 2021.  </span></div><div style="margin-bottom:5pt;margin-top:11pt;padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compound</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Developments</span></td></tr><tr><td colspan="12" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">COVID-19 Therapies</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bamlanivimab administered alone</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emergency Use Authorization</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Announced in the first quarter of 2021 that a Phase III trial met the primary and all key secondary endpoints. The EMA's CHMP issued a positive scientific opinion in the first quarter of 2021. In April 2021 the FDA revoked the EUA for bamlanivimab alone in the U.S.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bamlanivimab and etesevimab administered together</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emergency Use Authorization</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Announced in the first quarter of 2021 that Phase III trials met the primary and key secondary endpoints. Additional Phase III trials are ongoing. The FDA granted EUA for higher-risk patients recently diagnosed with mild-to-moderate COVID-19 in the first quarter of 2021. We intend to submit to the FDA for approval in the second half of 2021. The EMA's CHMP issued a positive scientific opinion in the first quarter of 2021. Submitted in Europe in the first quarter of 2021. </span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VIR-7831 and  bamlanivimab administered together</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial initiated in the first quarter of 2021.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bamlanivimab, etesevimab and LY-CoV1404 administered together</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I trial initiated in April 2021.</span></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Endocrinology</span></td></tr><tr style="height:38pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tirzepatide </span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Type 2 diabetes</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Announced in the first quarter of 2021 that Phase III trials met the primary and key secondary endpoints. Additional Phase III trials are ongoing.</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obesity</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trials are ongoing. </span></td></tr><tr style="height:27pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonalcoholic steatohepatitis</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing. </span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basal Insulin-Fc</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Type 1 and 2 diabetes</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trials are ongoing. </span></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lebrikizumab</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Atopic dermatitis</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted FDA Fast Track designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Phase III trials are ongoing.</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mirikizumab</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Crohn's disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trials are ongoing. </span></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Psoriasis</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not pursuing submission</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Announced in April 2021 that we do not plan to pursue submission. </span></td></tr><tr style="height:36pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ulcerative colitis</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Announced in the first quarter of 2021 that a Phase III trial met the primary and key secondary endpoints. Additional Phase III trials are ongoing. </span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CXCR1/2 Ligands Monoclonal Antibody</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hidradenitis suppurativa</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing. </span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:11pt;padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compound</span></td><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status</span></td><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Developments</span></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IL-2 Conjugate</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Systemic lupus erythematosus</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing. </span></td></tr><tr style="height:17pt"><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ulcerative colitis</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial initiated in April 2021. </span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PD-1 MAB Agonist</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rheumatoid arthritis</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial initiated in the first quarter of 2021.</span></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Neuroscience</span></td></tr><tr style="height:59pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tanezumab</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Osteoarthritis pain</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submitted</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In the first quarter of 2021 an Advisory Committee to the FDA concluded that the proposed risk evaluation and mitigation strategy will not ensure that the benefits outweigh the risks. In collaboration with Pfizer, we plan to continue to work with the FDA as it continues to review the submission. </span></div></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer pain</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trial is ongoing. </span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Donanemab</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Early Alzheimer&#8217;s disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Announced in the first quarter of 2021 that a Phase II trial met the primary endpoint and that we expanded a Phase II trial to become a Phase III trial.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solanezumab</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical Alzheimer's disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trial is ongoing.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Epiregulin/TGF&#945; MAB</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic pain</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trials are ongoing.</span></td></tr><tr style="height:35pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GBA1 Gene Therapy (PR001)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Parkinson's disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in the Prevail acquisition in January 2021. Granted FDA Fast Track designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Phase II trials are ongoing. </span></div></td></tr><tr style="height:35pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GRN Gene Therapy (PR006)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frontotemporal dementia</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PACAP38 Antibody</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic pain</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SSTR4 Agonist</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic pain</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trials are ongoing.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zagotenemab</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alzheimer&#8217;s disease</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing.</span></td></tr><tr><td colspan="12" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selpercatinib (Retevmo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thyroid cancer</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Launched</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted conditional marketing authorisation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> in Europe in the first quarter of 2021. Phase III trials are ongoing. </span></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lung cancer </span></td></tr><tr style="height:35pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pirtobrutinib (LOXO-305)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic lymphocytic leukemia</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trial initiated in the first quarter of 2021.</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mantle cell lymphoma</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing.</span></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">EUAs remain active for certain countries outside of the U.S.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In collaboration with Vir Biotechnology, Inc. and GlaxoSmithKline plc. </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> In collaboration with Almirall, S.A. (Almirall) in Europe.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fast Track designation is designated to expedite the development and review of new therapies to treat serious conditions and address unmet medical needs.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> In collaboration with Pfizer, Inc (Pfizer). </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Continued approval may be contingent on verification and description of clinical benefit in confirmatory Phase III trials.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our collaboration with Innovent Biologics, Inc. (Innovent), Innovent, with collaboration from us, will pursue the initial registration of sintilimab injection (Tyvyt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) in the U.S., and we will pursue initial registration of Tyvyt in other markets and all other subsequent registrations of Tyvyt.  </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pipeline also contains several new indication line extension (NILEX) products. The following certain NILEX products are currently in Phase II or Phase III clinical testing, have been submitted for regulatory review, or have received first regulatory approval in the U.S., Europe, or Japan for use in the indication described in 2021. The following table reflects the status of certain NILEX products, including certain other developments since January 1, 2021:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:18.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.327%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compound</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Developments</span></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Endocrinology</span></td></tr><tr style="height:35pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Empagliflozin (Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Heart failure with reduced ejection fraction</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submitted</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted FDA Fast Track designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic kidney disease</span></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted FDA Fast Track designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Phase III trials are ongoing.</span></div></td></tr><tr style="height:33pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Heart failure with preserved ejection fraction</span></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td></tr><tr style="height:45pt"><td colspan="3" rowspan="4" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baricitinib (Olumiant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Atopic dermatitis</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Approved</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In April 2021 the FDA extended the review period for the submission in the U.S. to the third quarter of 2021.</span></div></td></tr><tr style="height:53pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emergency Use Authorization</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Announced in April 2021 that a Phase III trial evaluating baricitinib 4 mg once daily plus standard of care did not meet the primary endpoint, but did result in a significant reduction in death.</span></td></tr><tr style="height:54pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alopecia areata</span></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted FDA Breakthrough Therapy designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Announced in the first quarter of 2021 and in April 2021 that Phase III trials met the primary endpoint. Phase III trials are ongoing. </span></div></td></tr><tr style="height:26pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Systemic lupus erythematosus</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trials are ongoing. </span></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td></tr><tr style="height:51pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Abemaciclib (Verzenio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Adjuvant breast cancer</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Submitted</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Announced in the first quarter of 2021 patient-reported outcomes in combination with standard adjuvant endocrine therapy. Submitted in Japan in the first quarter of 2021.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prostate cancer</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Phase II</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Phase II trials are ongoing. </span></td></tr></table></div><div style="margin-top:9pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In collaboration with Boehringer Ingelheim. </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fast Track designation is designated to expedite the development and review of new therapies to treat serious conditions and address unmet medical needs.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The FDA granted EUA in combination with remdesivir in hospitalized COVID-19 patients.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Breakthrough Therapy designation is designed to expedite the development and review of potential medicines that are intended to treat a serious condition where preliminary clinical evidence indicates that the treatment may demonstrate substantial improvement over available therapy on a clinically significant endpoint.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Patent Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on patents or other forms of intellectual property protection for most of our revenue, cash flows, and earnings. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the Alimta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vitamin regimen patents to provide us with patent protection for Alimta through June 2021 in major European countries and Japan and through May 2022 in the U.S. These patents have been challenged in each of these jurisdictions and in many cases have been finally resolved in our favor. However, we and Eagle Pharmaceuticals, Inc. (Eagle) reached an agreement in December 2019 to settle all pending U.S. patent litigation, allowing Eagle a limited initial entry into the market with its product starting February 2022 (up to an approximate three-week supply) and subsequent unlimited entry starting April 2022. We expect that the entry of generic competition in the U.S., major European countries, and Japan following the loss of patent exclusivity will cause a rapid and severe decline in revenue, and we expect that the entry of generic competition in the U.S. will have a material adverse effect on our consolidated results of operations and cash flows.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 9 to the consolidated condensed financial statements for a more detailed account of the legal proceedings currently pending regarding, among others, our Alimta patents.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The compound patent for Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (insulin lispro) has expired in major markets. Global regulators have different legal pathways to approve similar versions of insulin lispro. A competitor launched a similar version of insulin lispro in certain European markets in 2017 and in the U.S. in the second quarter of 2018. While it is difficult to estimate the severity of the impact of insulin lispro products entering the market, we do not expect and have not experienced a rapid and severe decline in revenue; however, we expect additional pricing pressure and some loss of market share that would continue over time.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The formulation and use patents for Forteo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have expired in major markets. We expect further decline in revenue as a result of the anticipated entry of generic and biosimilar competition due to the loss of patent exclusivity in major markets. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our compound patent protection for Cymbalta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expired in Japan in January 2020. We expect generics to enter the market in mid-2021. We expect that the entry of generic competition will cause a rapid and severe decline in revenue.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Foreign Currency Exchange Rates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a global company with substantial operations outside the U.S., we face foreign currency risk exposure from fluctuating currency exchange rates, primarily the U.S. dollar against the euro and Japanese yen. While we manage a portion of these exposures through hedging and other risk management techniques, significant fluctuations in currency rates can have a substantial impact, either positive or negative, on our revenue, cost of sales, and operating expenses. While there is uncertainty in the future movements in foreign exchange rates, fluctuations in these rates could negatively impact our future consolidated results of operations and cash flows.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Trends Affecting Pharmaceutical Pricing, Reimbursement, Access, and Other Regulatory Matters </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., public concern over access to and affordability of pharmaceuticals continues to drive the regulatory and legislative debate.&#160;These policy and political issues increase the risk that taxes, fees, rebates, or other cost control measures may be enacted to manage federal and state budgets. Evolving regulatory priorities could further intensify these efforts and otherwise increase regulatory scrutiny over our operations. Key health policy initiatives affecting biopharmaceuticals include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Coronavirus Aid, Relief, and Economic Security (CARES) Act and subsequent stimulus bills that focus on ensuring availability and access to lifesaving drugs during a public health crisis, </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign reference pricing in Medicare and private insurance,</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">modifications to Medicare Parts B and D,</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provisions that would allow the Department of Health and Human Services (HHS) to negotiate prices for biologics and drugs in Medicare,</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a reduction in biologic data exclusivity,</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">proposals related to Medicaid prescription drug coverage and manufacturer drug rebates,</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">proposals that would require biopharmaceutical manufacturers to disclose proprietary drug pricing information, </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state-level proposals related to prescription drug prices and reducing the cost of pharmaceuticals purchased by government health care programs,</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal and state proposals to permit importation of pharmaceuticals, including insulin, intended for sale in foreign markets, and </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Biden administration's regulatory rule freeze affecting all federal agency rules that had not gone into effect as of January 20, 2021, impacting the implementation or effectiveness, as applicable, of final rules related to the 340B prescription drug program, rebate reform in Medicare Part D, drug importation including insulin, and foreign reference pricing in Medicare Parts B and D. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 1, 2020, we announced we would distribute all 340B ceiling priced products directly to covered entities and their child sites only. We provide 340B discounts to a contract pharmacy only if it is a wholly owned subsidiary of a covered entity, if a covered entity does not have an in-house retail pharmacy or, in the case of insulin, if the subject covered entity and its contract pharmacies agree to pass along the discount to patients without any markup for dispensing fees and without billing insurance or collecting duplicate discounts. We have been transparent with regulators on our distribution activity and continue to comply with all 340B program requirements. Certain covered entities and their trade associations have initiated litigation questioning whether our program, and similar actions by other manufacturers, violate 340B program requirements. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 9, 2020, three covered entities sued HHS and the Health Resources and Services Administration (HRSA) in the U.S. District Court for the District of Columbia seeking to compel the agencies to take enforcement action against us and three other companies, among other requested relief. On October 21, 2020, a trade association representing certain covered entities sued HHS in the same court seeking to compel the agency to promulgate administrative dispute resolution regulations. On December 11, 2020, a number of associations and entities filed suit against HHS in the U.S. District Court for the Northern District of California requesting immediate enforcement of the contract pharmacy guidance. On December 31, 2020, the General Counsel of HHS issued an advisory opinion alleging that honoring contract pharmacy agreements is mandatory. In January 2021, we filed suit against HHS, the Secretary of HHS, the HRSA, and the Administrator of the HRSA in the U.S. District Court for the Southern District of Indiana seeking a declaratory judgment that HHS's attempt to require manufacturers to permit contract pharmacy distribution is unlawful and a preliminary injunction enjoining implementation of the administrative dispute resolution process created by defendants and, with it, their application of the advisory opinion, and other related relief. On March 16, 2021, the U.S. District Court for the Southern District of Indiana issued an order granting our request for a preliminary injunction.  See Note 9 to the consolidated condensed financial statements for additional information.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">California and several other states have enacted legislation related to prescription drug pricing transparency and it is unclear the effect this legislation or future legislation will have on our business. Several states have also passed importation legislation, including Colorado, Florida, Maine, New Hampshire, New Mexico, and Vermont. As of late 2020 several of these states were actively working with the former presidential administration to implement an importation program from Canada. On November 22, 2020, Florida announced it submitted a proposed importation plan to the U.S. In 2020, HHS and the FDA also took several actions to advance state importation initiatives, including issuing requests for proposals for personal importation and reimportation of insulin and a final rule on the Importation of Prescription Drugs. We continue to review these state proposals and legislation, as well as federal rules, commentary to the rulemaking, and guidance published by HHS and the FDA, the impact of which is uncertain at this time. Currently, it is unclear if the Biden administration will adopt any of the importation initiatives put forth by the former presidential administration. We will continue to monitor and assess these developments.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the private sector, consolidation and integration among healthcare providers significantly affects the competitive marketplace for pharmaceuticals.&#160;Health plans, pharmacy benefit managers, wholesalers, and other supply chain stakeholders have been consolidating into fewer, larger entities, thus enhancing their purchasing strength and importance.&#160;Private third-party insurers, as well as governments, typically maintain formularies that specify coverage (the conditions under which drugs are included on a plan's formulary) and reimbursement (the associated out-of-pocket cost to the consumer)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to control costs by negotiating discounted prices in exchange for formulary inclusion. Formulary placement can lead to reduced usage of a drug for the relevant patient population due to coverage restrictions, such as prior authorizations and formulary exclusions, or due to reimbursement limitations that result in higher consumer out-of-pocket cost, such as non-preferred co-pay tiers, increased co-insurance levels, and higher deductibles. Consequently, pharmaceutical companies compete for formulary placement not only on the basis of product attributes such as efficacy, safety profile, or patient ease of use, but also by providing rebates. Value-based agreements, where pricing is based on achievement (or not) of specified outcomes, are another tool that may be utilized between payers and pharmaceutical companies as formulary placement and pricing are negotiated. Price is an increasingly important factor in formulary decisions, particularly in treatment areas in which the payer has taken the position that multiple branded products are therapeutically comparable. We anticipate these downward pricing pressures will continue to negatively affect our consolidated results of operations. In addition to formulary placement, changes in insurance designs continue to drive greater consumer cost-sharing through high deductible plans and higher co-insurance or co-pays. We continue to invest in patient affordability solutions (resulting in lower revenue) in an effort to assist patients in affording their medicines.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The main coverage expansion provisions of the Affordable Care Act (ACA) are currently in effect through both state-based exchanges and the expansion of Medicaid.&#160;A trend has been the prevalence of benefit designs containing high out-of-pocket costs for patients, particularly for pharmaceuticals. In addition to the coverage expansions, many employers in the commercial market continue to evaluate strategies such as private exchanges and wider use of consumer-driven health plans to reduce their healthcare liabilities over time.&#160;Federal legislation, litigation, or administrative actions to repeal or modify some or all of the provisions of the ACA could have a material adverse effect on our consolidated results of operations and cash flows. At the same time, the broader paradigm shift towards performance-based reimbursement and the launch of several value-based purchasing initiatives have placed demands on the pharmaceutical industry to offer products with proven real-world outcomes data and a favorable economic profile.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, the Centers for Medicare and Medicaid Services published in the Federal Register a final regulation impacting the rules for calculating Medicaid rebate amounts, though the provision most likely to have a material impact on us relates to the inclusion of copayment assistance programs in best price and will take effect January 1, 2023. We are evaluating the impact of this regulation. We do not anticipate the changes related to "line extensions," which are scheduled to take effect January 1, 2022, to be material. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 11, 2021, President Biden signed into law the American Rescue Plan Act of 2021 (ARP). Section 9816 of the ARP removed Medicaid's maximum rebate percentage effective January 1, 2024. We are evaluating the impact of this legislation. We expect to see continued focus on regulating pricing, potentially resulting in additional legislation and regulation under the newly elected Congress and the Biden administration. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, evolving regulatory priorities have intensified governmental scrutiny of our operations, including our compliance with cGMP, quality assurance, and similar regulations. Any regulatory issues concerning these matters could lead to regulatory and legal actions, product recalls and seizures, fines and penalties, interruption of production leading to product shortages, import bans or denials of import certifications, delays or denials in the approvals of new products pending resolution of the issues, and reputational harm, any of which would adversely affect our business. See &#8220;Risk Factors&#8221; in Part I, Item 1A of our Annual Report on  </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December 31, 2020. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International operations also are generally subject to extensive price and market regulations.&#160;Cost-containment measures exist in a number of countries, including additional price controls and mechanisms to limit reimbursement for our products.&#160;Such policies are anticipated to increase in impact and reach, given the pressures on national and regional health care budgets that come from a growing, aging population and ongoing economic challenges. As additional reforms are finalized, we will assess their impact on future revenues. In addition, governments in many emerging markets are becoming increasingly active in expanding health care system offerings.&#160;Given the budget challenges of increasing health care coverage for citizens, policies may be proposed that promote generics and biosimilars only and reduce current and future access to branded pharmaceutical products. The COVID-19 pandemic is also creating additional pressure on health systems worldwide. As a result, cost containment and other measures may intensify as governments manage and emerge from the pandemic.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Tax Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income taxes and various other taxes in the U.S. and in many foreign jurisdictions; therefore, changes in both domestic and international tax laws or regulations could affect our effective tax rate, results of operations, and cash flows. Countries around the world, including the U.S., are actively considering and enacting tax law changes. The Biden administration's tax proposal contains significant changes, including increases to the tax rates at which both domestic and foreign income of U.S. companies would be taxed. Further, actions taken with respect to tax-related matters by associations such as the Organisation for Economic Co-operation and Development and the European Commission could influence tax policy in countries in which we operate. In addition, global tax authorities routinely examine our tax returns and are expected to become more aggressive in their examinations of profit allocations among jurisdictions, which could affect our anticipated tax liabilities.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Acquisitions</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strategically invest in external research and technologies that we believe to complement and strengthen our own efforts. These investments can take many forms, including acquisitions, strategic alliances, collaborations, investments, and licensing arrangements. We view our business development activity as an important way to achieve our strategies, as we seek to bolster our pipeline and enhance shareholder value. We continuously evaluate business development transactions that have the potential to strengthen our business. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we acquired all shares of Dermira for a purchase price of $849.3 million, net of cash acquired. Under the terms of the agreement, we acquired lebrikizumab, a novel, investigational, monoclonal antibody being evaluated for the treatment of moderate-to-severe atopic dermatitis. Lebrikizumab was granted Fast Track designation from the FDA. We also acquired Qbrexza cloth, a medicated cloth for the topical treatment of primary axillary hyperhidrosis (uncontrolled excessive underarm sweating). During the three months ended March&#160;31, 2021, we decided to sell the rights to Qbrexza. See Note 5 to the consolidated condensed financial statements for additional information. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we acquired all shares of Prevail for a purchase price that included $22.50 per share in cash (or an aggregate of $747.4 million, net of cash acquired) plus one non-tradable contingent value right (CVR) per share. The CVR entitles Prevail stockholders to up to an additional $4.00 per share in cash (or an aggregate of approximately $160 million) payable, subject to certain terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom, Germany, France, Italy, or Spain. Under the terms of the agreement, we acquired a gene therapy program for patients with neurodegenerative diseases.  </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 3 to the consolidated condensed financial statements for further discussion regarding our recent acquisitions.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Revenue</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue activity by region:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.698%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,941.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,328.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside U.S.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,864.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,531.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,805.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,859.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are components of the change in revenue compared with the prior year:</span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 vs. 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volume</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Price</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percent change</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 %</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that revenue for the three months ended March 31, 2020 for many of our products was favorably impacted by increased customer buying patterns and patient prescription trends resulting from the COVID-19 pandemic that increased revenue by approximately $250 million worldwide, including approximately $200 million in the U.S. and approximately $50 million outside the U.S. We believe that this increase in U.S. revenue primarily impacted our diabetes portfolio, with estimated increases of approximately $70 million to $80 million for insulin products and approximately $30 million to $40 million for Trulicity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We also estimate that U.S. revenue for Taltz</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was favorably impacted by approximately $20 million to $25 million. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. for the three months ended March&#160;31, 2021, the increase in volume was primarily driven by COVID-19 antibodies, Trulicity, and Taltz, partially offset by lower volume for Alimta. In the U.S. for the three months ended March&#160;31, 2021, the decrease in realized prices was primarily driven by increased rebates to gain broad commercial access for Taltz, partially offset by modest list price increases. Segment mix was not a major driver of U.S. price performance during the three months ended March 31, 2021, as increased utilization in more highly-rebated government segments was offset by lower utilization in the 340B segment, primarily for the diabetes portfolio. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S. for the three months ended March&#160;31, 2021, the increase in volume was primarily driven by COVID-19 antibodies, Alimta, Olumiant, Tyvyt, and Verzenio, partially offset by decreased volume for Cialis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Forteo, and Cymbalta.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue activity by product for the three months ended March&#160;31, 2021 and 2020: </span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" rowspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent Change</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trulicity</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,116.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">335.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,452.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,229.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19 antibodies </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">650.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">159.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">810.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humalog </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">332.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">284.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">617.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alimta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">261.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">297.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">559.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taltz</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">249.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">153.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">403.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humulin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">219.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">102.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">321.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">151.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">160.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">312.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Verzenio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">172.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">96.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">269.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">175.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">71.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">246.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cyramza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">80.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">160.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">240.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forteo</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">97.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">198.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olumiant</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">169.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">193.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cymbalta</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">165.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">176.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cialis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">118.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">126.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Erbitux</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">107.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">122.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emgality</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">101.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">119.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tyvyt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">109.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">109.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zyprexa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">88.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">95.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">173.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">257.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">431.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,941.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,864.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,805.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,859.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NM - not meaningful</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to EUAs.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Humalog revenue includes insulin lispro.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Jardiance revenue includes Glyxambi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Synjardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, and Trijardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> XR. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Trulicity, a treatment for type 2 diabetes and to reduce the risk of major adverse cardiovascular events in adult patients with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors, increased  20 percent in the U.S. during the three months ended March&#160;31, 2021, driven by increased demand, partially offset by lower realized prices. Trulicity's lower realized prices in the U.S. were primarily due to higher contracted rebates, partially offset by a favorable segment mix that reflected lower utilization in the 340B segment, and modest list price increases. Revenue outside the U.S. increased 12 percent during the three months ended March&#160;31, 2021, driven by increased volume and, to a lesser extent, favorable foreign exchange rates, partially offset by lower realized prices.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of COVID-19 antibodies, treatments that were authorized pursuant to EUAs for mild to moderate COVID-19 for higher-risk patients, was $650.6&#160;million in the U.S. during the three months ended March&#160;31, 2021. Revenue outside the U.S. was $159.5&#160;million during the three months ended March&#160;31, 2021. The availability of vaccines and other preventative measures, coupled with the transient nature of pandemics, could negatively impact or eliminate demand for these COVID-19 antibodies. In addition, mutations or the spread of other variants of the coronavirus could also render our COVID-19 antibodies ineffective.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Humalog, an injectable human insulin analog for the treatment of diabetes, decreased 17 percent in the U.S. during the three months ended March&#160;31, 2021, driven by lower realized prices as higher contracted rebates and discounts were partially offset by lower utilization in the 340B segment. Revenue outside the U.S. decreased 4 percent during the three months ended March&#160;31, 2021, driven by decreased volume, partially offset by the favorable impact of foreign exchange rates. While it is difficult to estimate the severity of the impact of insulin lispro products entering the market, we do not expect and have not experienced a rapid and severe decline in revenue. However, due to the impact of competition and due to pricing pressure in the U.S. and some international markets, we expect some price decline and loss of market share to continue over time. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Alimta, a treatment for various cancers, decreased 19 percent in the U.S. during the three months ended March&#160;31, 2021, primarily driven by lower volume as a result of customer buying patterns and, to a lesser extent, lower realized prices. Revenue outside the U.S. increased 26 percent during the three months ended March&#160;31, 2021, primarily driven by increased volume in Germany and, to a lesser extent, the favorable impact of foreign exchange rates. We will lose our patent protection for Alimta in Japan and major European countries in June 2021. We expect the limited entry of generic competition in the U.S. starting February 2022 and subsequent unlimited entry starting April 2022. We expect that the entry of generic competition following the loss of exclusivity will cause a rapid and severe decline in revenue. See "Executive Overview - Other Matters- Patent Matters" for more information. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Taltz, a treatment for moderate-to-severe plaque psoriasis, active psoriatic arthritis, ankylosing spondylitis, and active non-radiographic axial spondyloarthritis, decreased 24 percent in the U.S. during the three months ended March&#160;31, 2021, primarily driven by lower realized prices due to increased rebates to gain broad commercial access, partially offset by increased demand. Revenue outside the U.S. increased 32 percent during the three months ended March&#160;31, 2021, primarily driven by increased volume and, to a lesser extent, the favorable impact of foreign exchange rates. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Humulin, an injectable human insulin for the treatment of diabetes, increased 2 percent in the U.S. during the three months ended March&#160;31, 2021, driven by higher realized prices, partially offset by decreased demand. Revenue outside the U.S. increased 1 percent during the three months ended March&#160;31, 2021, driven by the favorable impact of foreign exchange rates and higher realized prices, largely offset by decreased volume. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Jardiance, a treatment for type 2 diabetes and to reduce the risk of cardiovascular death in adult patients with type 2 diabetes and established cardiovascular disease, increased 5 percent in the U.S. during the three months ended March&#160;31, 2021, driven by increased demand. Revenue outside the U.S. increased 31 percent during the three months ended March&#160;31, 2021, driven by increased volume and, to a lesser extent, the favorable impact of foreign exchange rates. See Note 4 to the consolidated condensed financial statements for information regarding our collaboration with Boehringer Ingelheim involving Jardiance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Verzenio, a treatment for HR+, HER2- metastatic breast cancer, increased 34 percent in the U.S. during the three months ended March&#160;31, 2021, primarily driven by increased demand, and, to a lesser extent, higher realized prices. Revenue outside the U.S. increased 64 percent during the three months ended March&#160;31, 2021, primarily driven by increased volume.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Basaglar, a long-acting human insulin analog for the treatment of diabetes, decreased 24 percent in the U.S. during the three months ended March&#160;31, 2021, driven by decreased demand caused by competitive pressures and, to a lesser extent, lower realized prices. Revenue outside the U.S. decreased 3 percent during the three months ended March&#160;31, 2021, driven by lower realized prices and decreased volume, partially offset by the favorable impact of foreign exchange rates. See Note 4 to the consolidated condensed financial statements for information regarding our collaboration with Boehringer Ingelheim involving Basaglar. A competitor launched a similar version of glargine in the U.S. in 2020. Due to the impact of competitive pressures, we expect some price decline and loss of market share over time. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Cyramza, a treatment for various cancers, decreased 10 percent in the U.S. during the three months ended March&#160;31, 2021, primarily driven by decreased demand and lower realized prices. Revenue outside the U.S. increased</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7 percent for the three months ended March&#160;31, 2021, driven by the favorable impact of foreign exchange rates and increased volume. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_97"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross Margin, Costs, and Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin as a percent of revenue was 72.4 percent for the three months ended March&#160;31, 2021, a decrease of 6.9 percentage points compared with the three months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2020</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The decrease in gross margin percent was primarily due to unfavorable product mix driven by sales of COVID-19 antibodies, the unfavorable effect of foreign exchange rates on international inventories sold, higher amortization of intangibles expense related to Retevmo, charges resulting from excess inventory of COVID-19 antibodies due in part to the termination of the purchase agreement with the U.S. government for bamlanivimab following discontinuation of the product's distribution on its own in the U.S., and, to a lesser extent, the impact of lower realized prices on revenue.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increased </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21 percent</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.68 billion for the three months ended March&#160;31, 2021. The increase </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in research and development expenses for the three months ended March&#160;31, 2021 was driven primarily by approximately $220 million of research and development expenses for COVID-19 antibody therapies and baricitinib, as well as higher research and development expenses for late-stage assets. </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketing, selling, and administrative expenses increased 2 percent</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to $1.58 billion for the three months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized $299.3 million of acquired IPR&amp;D charges for the three months ended March&#160;31, 2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to collaborations with Rigel, Precision, Merus, and Asahi. We recognized $52.3 million of acquired IPR&amp;D charges for the three months ended March&#160;31, 2020 related to a col</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">laboration with Sitryx.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized asset impairment, restructuring, and other special charges of $211.6 million for the three months ended March&#160;31, 2021. The charges for the three months ended March&#160;31, 2021 were </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily related to an intangible asset impairment resulting from the decision to sell the rights to Qbrexza, as well as acquisition and integration costs associated with the acquisition of Prevail. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized asset impairment, restructuring, and other special charges of $59.9 million for the three months ended March&#160;31, 2020, primarily related to acquisition and integration costs associated with the acquisition of Dermira. </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other&#8211;net, (income) expense was income of $321.1 million for the three months ended March&#160;31, 2021 compared with income of $89.1 million for the three months ended March&#160;31, 2020.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The increase in other income was driven primarily by higher net gains on investment securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate was 8.2 percent for the three months ended March&#160;31, 2021, compared with 13.3 percent for the three months ended March 31, 2020. The effective tax rates for both periods were reduced by net discrete tax benefits, with a larger net discrete tax benefit reflected for the three months ended March&#160;31, 2021. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Condition and Liquidity&#160;&#160;&#160;&#160;</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our available cash and cash equivalents, together with our ability to generate operating cash flow and our access to short-term and long-term borrowings, are sufficient to fund our existing and planned capital requirements. For a discussion of our capital requirements, see &#8220;Management's Discussion and Analysis of Results of Operations and Financial Condition&#8221; in Part II, Item 7 of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2020. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents decreased to $3.00 billion as of March&#160;31, 2021, compared with $3.66 billion as of December&#160;31, 2020. Refer to the consolidated condensed statements of cash flows for additional information on the significant sources and uses of cash for the three months ended March&#160;31, 2021 and 2020. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our cash and cash equivalents, we held total investments of $3.28 billion and $2.99 billion as of March&#160;31, 2021 and December&#160;31, 2020, respectively. See Note 6 to the consolidated condensed financial statements for additional information. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we acquired all shares of Prevail for a purchase price that included $22.50 per share in cash (or an aggregate of $747.4 million, net of cash acquired) plus one non-tradable CVR per share. The CVR entitles Prevail stockholders to up to an additional $4.00 per share in cash (or an aggregate of approximately $160 million) payable, subject to certain terms and conditions. The acquisition was funded primarily through cash on hand. See Note 3 to the consolidated condensed financial statements for additional information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, total debt was $16.20 billion, a decrease of $390.8&#160;million compared with $16.60&#160;billion as of December&#160;31, 2020. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, we had a total of $5.24 billion of unused committed bank credit facilities, $5.00 billion of which is available to support our commercial paper program. We believe that amounts accessible through existing commercial paper markets should be adequate to fund short-term borrowing needs. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021, we did not repurchase any shares under our $8.00 billion share repurchase program authorized in June 2018. As of March&#160;31, 2021, we had $1.00 billion remaining under this program. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021, we paid dividends of approximately $774.8 million, or $0.85 per share, to our shareholders. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See "Executive Overview - Other Matters - Patent Matters" for information regarding recent and upcoming losses of patent protection.</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both domestically and abroad, we continue to monitor the potential impacts of the economic environment; the creditworthiness of our wholesalers and other customers, including foreign government-backed agencies and suppliers; the uncertain impact of health care legislation; various international government funding levels; and fluctuations in interest rates, foreign currency exchange rates (see "Executive Overview - Other Matters - Foreign Currency Exchange Rates"), and fair values of equity securities.</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Financial Expectations</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have updated certain elements of our 2021 financial guidance. The update to our 2021 financial guidance includes acquired IPR&amp;D charges, asset impairment, restructuring and other special charges, and excess inventory charges related to COVID-19 antibodies, as well as net gains on investments in equity securities recognized during the three months ended March 31, 2021. The update to 2021 financial guidance also reflects lower expected revenue from COVID-19 antibody sales due to lower expected demand and higher expected research and development expenses.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share for 2021 are now expected to be in the range of $7.03 to $7.23. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We now anticipate 2021 revenue to be between $26.6 billion and $27.6 billion, including an estimated $1.0 billion to $1.5 billion of revenue from COVID-19 therapies. Revenue growth is additionally expected to be driven by volume from Trulicity, Taltz, Verzenio, Jardiance, Olumiant, Cyramza, Emgality, Tyvyt, and Retevmo, as well as by COVID-19 therapies. Revenue growth is expected to be partially offset by lower revenue for products that have lost patent exclusivity. We expect mid-single digit net price declines globally in 2021. In the U.S., we expect low-to-mid-single digit net price declines, driven primarily by increased rebates to maintain broad commercial access and segment mix, partially offset by lower utilization in the 340B segment. Outside the U.S., we expect net price declines in China, Japan and Europe.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin as a percent of revenue for 2021 is still expected to be approximately 77 percent. Research and development expenses for 2021 are now expected to be in the range of $6.9 billion to $7.1 billion, reflecting additional investments in potential therapies for Alzheimer's disease and approximately $400 million to $500 million of continued investment in COVID-19 therapies. Marketing, selling, and administrative expenses for 2021 are still expected to be in the range of $6.2 billion to $6.4 billion. Other&#8212;net, (income) expense for 2021 is now expected to be income in the range of $150 million to $250 million. The 2021 effective tax rate is now expected to be approximately 13 percent. </span></div><div style="margin-bottom:12pt;margin-top:6pt"><span><br/></span></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_109"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Available Information on our Website</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make available through our company website, free of charge, our company filings with the Securities and Exchange Commission (SEC) as soon as reasonably practicable after we electronically file them with, or furnish them to, the SEC. The reports we make available include annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements, registration statements, and any amendments to those documents.</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The website link to our SEC filings is </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">investor.lilly.com/financial-information/sec-filings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The information contained in, or that can be accessed through, our website is not a part of, or incorporated by reference in, this Quarterly Report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&#160;4. Controls and Procedures</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.78pt">Evaluation of Disclosure Controls and Procedures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under applicable SEC regulations, management of a reporting company, with the participation of the principal executive officer and principal financial officer, must periodically evaluate the company&#8217;s &#8220;disclosure controls and procedures,&#8221; which are defined generally as controls and other procedures of a reporting company designed to ensure that information required to be disclosed by the reporting company in its periodic reports filed with the SEC (such as this Quarterly Report on Form&#160;10-Q) is recorded, processed, summarized, and reported on a timely basis.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of David A. Ricks, president and chief executive officer, and Anat Ashkenazi, senior vice president and chief financial officer, evaluated our disclosure controls and procedures (as such terms are defined in our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December 31, 2020) as of March&#160;31, 2021, and concluded that they were effective.</span></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.78pt">Changes in Internal Controls</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the first quarter of 2021, there were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:400;line-height:120%;text-decoration:underline">PART II. Other Information</span></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_118"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&#160;1. Legal Proceedings</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various currently pending legal actions, government investigations, and environmental proceedings. See Note 9 to the consolidated condensed financial statements for information on various legal proceedings. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Item should be read in conjunction with "Legal Proceedings" in Part I, Item 3 of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/59478/000005947820000057/lly-20191231x10xk.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2020.</span></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_121"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&#160;1A. Risk Factors</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our material risk factors are disclosed in "Risk Factors" in Part I, Item 1A of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2020. There have been no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December&#160;31, 2020. </span></div><div style="margin-bottom:12pt;margin-top:6pt"><span><br/></span></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_124"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_127"></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to the principal market for our common stock and related shareholder matters is described in "Management's Discussion and Analysis of Results of Operations and Financial Condition" in Part II, Item 7 and in "Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters" in Part III, Item 12 of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December 31, 2020. </span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to repurchases of our equity securities during the three months ended March&#160;31, 2021:</span></div><div style="margin-bottom:11pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:23.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.735%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.017%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of<br/>Shares Purchased<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average&#160;Price Paid&#160;<br/>per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number of Shares<br/>Purchased&#160;as Part of<br/>Publicly Announced<br/>Plans or Programs<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate Dollar&#160;Value&#160;<br/>of Shares that May Yet Be <br/>Purchased Under&#160;the&#160;<br/>Plans or Programs<br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, we did not repurchase any shares under our $8.00 billion share repurchase program authorized in June 2018.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&#160;6. Exhibits</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following documents are filed as a part of this Quarterly Report:</span></div><div style="margin-bottom:17pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:16.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.232%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT 3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/59478/000005947814000078/lly-20131231x10kexhibit31.htm">Amended Articles of Incorporation are incorporated by reference to Exhibit 3.1 to the Company's Annual Report on Form 10-K for the year ended December 31, 2013</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT 3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000119312521033302/d111779dex31.htm">Bylaws, as amended, are incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on February 9, 2021</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT 10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-3312021x10qxexhibit101.htm">Form of Restricted Stock Unit Award under the 2002 Lilly Stock Plan (with non-compete)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT 10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-3312021x10qxexhibit102.htm">Release Agreement, effective as of February 9, 2021, by and between Eli Lilly and Company and Joshua L. Smiley</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT&#160;31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-3312021x10qxexhibit311.htm">Rule&#160;13a-14(a) Certification of David A. Ricks, Chairman, President, and Chief Executive Officer</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT 31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-3312021x10qxexhibit312.htm">Rule&#160;13a-14(a) Certification of Anat Ashkenazi, Senior Vice President and Chief Financial Officer</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT 32.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-3312021x10qxexhibit32.htm">Section 1350 Certification</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT 101.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interactive Data Files (embedded within the Inline XBRL document)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT 104.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(i) Long-term debt instruments under which the total amount of securities authorized does not exceed 10% of our consolidated assets are not filed as exhibits to this Quarterly Report. We will furnish a copy of these agreements to the SEC upon request.</span></div><div id="i3cd151b5d83246a98b0e0ef4a9feb269_136"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signatures</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.298%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.646%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">ELI LILLY AND COMPANY</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/Anat Ashkenazi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anat Ashkenazi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/Donald A. Zakrowski</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Donald A. Zakrowski</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President, Finance, and Chief Accounting Officer</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>lly-3312021x10qxexhibit101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="iefc899be7041418d881376dad8578a49_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 10.1 Form of Restricted Stock Unit Award under the 2002 Lilly Stock Plan (with non-compete)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Eli Lilly and Company</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Restricted Stock Unit Award Agreement</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">(for Executive Officer)</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Restricted Stock Unit Award has been granted on &#91;INSERT DATE&#93; (&#8220;Grant Date&#8221;) by Eli Lilly and Company, an Indiana corporation, with its principal offices in Indianapolis, Indiana (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), to the Eligible Individual who has received this Restricted Stock Unit Award Agreement (the &#8220;Grantee&#8221;).</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:180pt;text-indent:-144pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vesting Date&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">100% on &#91;INSERT DATE&#93; </font></div><div style="padding-left:180pt;text-indent:-144pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;(except as otherwise provided in this </font></div><div style="padding-left:180pt;text-indent:-144pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Restricted Stock Unit Award Agreement)</font></div><div style="padding-left:36pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eli Lilly and Company Restricted Stock Unit Award Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-right:-2.7pt"><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Table of Contents</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.327%"><tr><td style="width:1.0%"></td><td style="width:93.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.293%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 1.&#160;&#160;&#160;&#160;Grant of Restricted Stock Units</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 2.&#160;&#160;&#160;&#160;Vesting</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 3.&#160;&#160;&#160;&#160;Change in Control</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 4.&#160;&#160;&#160;&#160;Settlement</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 5.&#160;&#160;&#160;&#160;Rights of the Grantee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 6.&#160;&#160;&#160;&#160;Prohibition Against Transfer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.&#160;&#160;&#160;&#160;Responsibility for Taxes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 8.&#160;&#160;&#160;&#160;Section 409A Compliance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 9.&#160;&#160;&#160;&#160;Grantee&#8217;s Acknowledgement</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 10.&#160;&#160;&#160;&#160;Data Privacy</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 11.&#160;&#160;&#160;&#160;Restrictive Covenants, Remedies, and Additional Terms and Conditions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 12.&#160;&#160;&#160;&#160;Governing Law and Choice of Venue</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13.&#160;&#160;&#160;&#160;Miscellaneous Provisions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 14.&#160;&#160;&#160;&#160;Compensation Recovery</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 15.&#160;&#160;&#160;&#160;Award Subject to Acknowledgement of Acceptance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-right:-2.7pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 2</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eli Lilly and Company Restricted Stock Unit Award Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section 1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.82pt">Grant of Restricted Stock Units</font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eli Lilly and Company, an Indiana corporation (&#8220;Lilly&#8221; or the &#8220;Company&#8221;), has granted to the Eligible Individual who has received this Restricted Stock Unit Award Agreement (the &#8220;Grantee&#8221;) an award of restricted stock units (the &#8220;Restricted Stock Units&#8221; or the &#8220;Award&#8221;) with respect to the number of shares of Lilly Common Stock (the &#8220;Shares&#8221;) that the Grantee may view by logging on to the Merrill Lynch website at </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">http&#58;&#47;&#47;myequity.lilly.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Award is made pursuant to and subject to the terms and conditions set forth in the Amended and Restated 2002 Lilly Stock Plan (the &#8220;Plan&#8221;) and to the terms and conditions set forth in this Restricted Stock Unit Award Agreement, including all appendices, exhibits and addenda hereto (the &#8220;Award Agreement&#8221;).  In the event of any conflict between the terms of the Plan and this Award Agreement, the terms of the Plan shall govern except with respect to the provisions described in Section 11 below (in which case, the terms of the Award Agreement shall govern). </font></div><div style="padding-left:27pt;text-align:justify"><font><br></font></div><div style="padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any capitalized terms used but not defined in this Award Agreement shall have the meanings set forth in the Plan.  </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section 2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.82pt">Vesting </font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">For purposes of the vesting provisions set forth in Section 2 of this Award Agreement, the following definitions will apply&#58;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:99pt;text-align:justify;text-indent:-26.88pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">&#8220;Disability&#8221; means that the Grantee would qualify to receive benefit payments under the long-term disability plan or policy, as it may be amended from time to time, of the Company or the Affiliate that employs the Grantee (the &#8220;Employer&#8221;).  If the Company or the Employer does not have a long-term disability plan or policy, &#8220;Disability&#8221; means that the Grantee is unable to carry out the responsibilities and functions of the position held by the Grantee by reason of any medically determined physical or mental impairment for a period of at least ninety (90) consecutive days as may be determined by the Company or Employer.  The Grantee shall not be considered to have incurred a Disability unless he or she furnishes proof of such impairment sufficient to satisfy the Company as it determines in its sole discretion.</font></div><div style="padding-left:99pt;text-align:justify"><font><br></font></div><div style="padding-left:99pt;text-align:justify;text-indent:-29.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">&#8220;Qualifying Termination&#8221; means the termination of the Grantee's Service under any one of the following circumstances&#58;</font></div><div style="padding-left:99pt;text-align:justify"><font><br></font></div><div style="padding-left:126pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17.57pt">due to a plant closing or reduction in workforce (as defined below)&#59;</font></div><div style="margin-top:6pt;padding-left:126pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17.57pt">as a result of the Grantee&#8217;s failure to locate a position within the Company or an Affiliate following the placement of the Grantee on reallocation or medical reassignment in the United States (or equivalent as determined by the Committee).</font></div><div style="padding-left:126pt;text-align:justify"><font><br></font></div><div style="padding-left:99pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Plant closing&#8221; means the closing of a plant site or other corporate location that directly results in termination of the Grantee&#8217;s Service.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:99pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Reduction in workforce&#8221; means the elimination of a work group, functional or business unit or other broadly applicable reduction in job positions that directly results in termination of the Grantee&#8217;s Service.</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The Award shall vest at the close of business in Indianapolis, Indiana, U.S.A. on the earliest of the following dates (each, a &#8220;Vesting Date&#8221;)&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 3</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eli Lilly and Company Restricted Stock Unit Award Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div><div style="margin-top:12pt;padding-left:99pt;padding-right:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.12pt">&#91;INSERT DATE&#93; with respect to 100% of the Award, provided the Grantee is still in active Service on the Vesting Date, </font></div><div style="padding-left:99pt;padding-right:36pt;text-align:justify"><font><br></font></div><div style="padding-left:99pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subject to any alternative date(s) set forth in any appendix attached hereto (the &#8220;Appendix&#8221;), or </font></div><div style="padding-left:99pt;padding-right:36pt;text-align:justify"><font><br></font></div><div style="padding-left:99pt;padding-right:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.9pt">the date the Grantee&#8217;s Service is terminated (A) due to the Grantee&#8217;s death or (B) by reason of the Grantee&#8217;s Disability, with respect to 100% of the Award, or</font></div><div style="padding-left:99pt"><font><br></font></div><div style="padding-left:99pt;padding-right:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.68pt">the date the Grantee is subject to a Qualifying Termination, in which case the number of Restricted Stock Units that shall vest shall be reduced proportionally for the portion of the total days between the Grant Date and the Vesting Date specified in 2(b)(i) that the Grantee was not in active Service. </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee&#8217;s determination as to whether (A) the Grantee&#8217;s Service has been terminated by reason of Disability, (B) the Grantee&#8217;s Service has been terminated as a direct result of either a plant closing or a reduction in workforce, (C) the Grantee&#8217;s Service has been terminated as a result of the failure to locate a position within the Company or an Affiliate following reallocation or medical reassignment, and (D) a leave of absence or a transfer of employment between Lilly and an Affiliate or between Affiliates constitutes a termination of Service shall be final and binding on the Grantee.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">In the event the Grantee's Service with the Company or an Affiliate is terminated prior to a Vesting Date for any reason or in any circumstance other than those specified in Sections 2(b)(ii) or 2(b)(iii), any unvested portion of the Award will be forfeited.  </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The Committee may, at its discretion, cancel the Award or reduce the number of Restricted Stock Units and any accrued Dividend Equivalent Rights, prorated according to time or other measure as deemed appropriate by the Committee, if at any time prior to the Vesting Date, the Grantee has been (i) subject to disciplinary action by the Company, or (ii) determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such conduct causes significant harm to the Company.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section 3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.82pt">Change in Control</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The provisions of Section 13.2 of the Plan apply to this Award with the following modifications&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The only Change in Control event that shall result in a benefit under this Section 3 shall be the consummation of a merger, share exchange, or consolidation of the Company, as defined in Section 2.6(c) of the Plan (a &#8220;Transaction&#8221;).</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">In the event that the Award is not converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with a Transaction, then immediately prior to the Transaction, the Award shall vest automatically in full.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">In the event that the Award is converted, assumed, substituted, continued or replaced by a successor or surviving corporation, or a parent or subsidiary thereof, in connection with a Transaction and the Grantee is subject to a Covered Termination (as defined below) prior to any applicable Vesting Date, the Award shall vest automatically in full. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 4</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eli Lilly and Company Restricted Stock Unit Award Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this provision, &#8220;Covered Termination&#8221; shall mean a termination of Service as described in Sections 2(b)(ii) and 2(b)(iii), Grantee&#8217;s termination without Cause or the Grantee&#8217;s resignation for Good Reason.  &#8220;Cause&#8221; and &#8220;Good Reason&#8221; shall have the meanings ascribed to them in the Eli Lilly and Company 2007 Change in Control Severance Pay Plan for Employees or the Eli Lilly and Company 2007 Change in Control Severance Pay Plan for Select Employees (both as amended from time to time) or any successor plan or arrangement thereto, as applicable.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">If the Grantee is entitled to receive stock of the acquiring entity or successor to the Company as a result of the application of this Section 3, then references to Shares in this Award Agreement shall be read to mean stock of the successor or surviving corporation, or a parent or subsidiary thereof, as and when applicable.&#160;&#160;&#160;&#160; </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section 4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.82pt">Settlement  </font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Except as provided below, the Award shall be paid to the Grantee as soon as practicable and generally within sixty (60) days following the applicable Vesting Date, or, if earlier, a vesting event contemplated under the Section 3 above.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">At such time,</font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lilly shall issue or transfer Shares or the cash equivalent, as contemplated under Section 4(c) below, to the Grantee.  In the event the Grantee is entitled to a fractional Share, the fraction may be paid in cash or rounded, in the Committee&#8217;s discretion.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">At any time prior to the applicable Vesting Date or until the Award is paid in accordance with this Section 4, the Committee may, if it so elects, determine to pay part or all of the Award in cash in lieu of issuing or transferring Shares. The amount of cash shall be calculated based on the Fair Market Value of the Shares on the applicable Vesting Date. </font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">In the event of the death of the Grantee, the payments described above shall be made to the successor of the Grantee.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:40.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section 5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:2.32pt">Rights of the Grantee </font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">No Shareholder Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Restricted Stock Units do not entitle the Grantee to any rights of a shareholder of Lilly until such time as the Restricted Stock Units vest and Shares are issued or transferred to the Grantee.  </font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Dividend Equivalent Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  As long as the Grantee holds Restricted Stock Units granted pursuant to this Award, the Company shall accrue for the Grantee, on each date that the Company pays a cash dividend to holders of Company Shares, Dividend Equivalent Rights equal to the total number of Restricted Stock Units credited to the Grantee under this Award multiplied by the dollar amount of the cash dividend paid per Share by the Company on such date. Dividend Equivalent Rights shall accrue in an account denominated in U.S. dollars and shall not accrue interest or other credits prior to being paid.  A report showing the accrued Dividend Equivalent Rights shall be sent to the Grantee periodically, as determined by the Company.  The accrued Dividend Equivalent Rights shall be subject to the same vesting conditions as the Restricted Stock Units to which the Dividend Equivalent Rights relate, and the Dividend Equivalent Rights shall be forfeited in the event that the Restricted Stock Units with respect to which such Dividend Equivalent Rights were credited are forfeited. Following the applicable Vesting Date, Lilly shall pay to the Grantee in cash all accrued Dividend Equivalent Rights in accordance with Section 4 above.</font></div><div style="padding-left:45pt;padding-right:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt;text-decoration:underline">No Trust&#59; Grantee&#8217;s Rights Unsecured.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Neither this Award Agreement nor any action in accordance with this Award Agreement shall be construed to create a trust of any kind.  The </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 5</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eli Lilly and Company Restricted Stock Unit Award Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">right of the Grantee to receive payments of cash or Shares pursuant to this Award Agreement shall be an unsecured claim against the general assets of the Company.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section 6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.82pt">Prohibition Against Transfer</font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The right of a Grantee to receive payments of Shares and&#47;or cash under this Award may not be transferred except to a duly appointed guardian of the estate of the Grantee or to a successor of the Grantee by will or the applicable laws of descent and distribution and then only subject to the provisions of this Award Agreement.  A Grantee may not assign, sell, pledge, or otherwise transfer Shares or cash to which he or she may be entitled hereunder prior to transfer or payment thereof to the Grantee, and any such attempted assignment, sale, pledge or transfer shall be void.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section 7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.82pt">Responsibility for Taxes</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Regardless of any action Lilly and&#47;or the Grantee&#8217;s Employer takes with respect to any or all income tax (including federal, state, local and non-U.S. tax), social insurance, payroll tax, fringe benefits tax, payment on account or other tax related items related to the Grantee&#8217;s participation in the Plan and legally applicable to the Grantee (&#8220;Tax Related Items&#8221;), the Grantee acknowledges that the ultimate liability for all Tax Related Items is and remains the Grantee&#8217;s responsibility and may exceed the amount actually withheld by Lilly or the Employer.  The Grantee further acknowledges that Lilly and the Employer (i)&#160;make no representations or undertakings regarding the treatment of any Tax Related Items in connection with any aspect of the Award, including the grant of the Restricted Stock Units, the accrual of Dividend Equivalent Rights, the vesting of the Restricted Stock Units and the lapse of restrictions, the transfer and issuance of any Shares, the receipt of any cash payment pursuant to the Award and&#47;or Dividend Equivalent Rights, the receipt of any dividends and the sale of any Shares acquired pursuant to this Award&#59; and (ii)&#160;do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Award to reduce or eliminate the Grantee&#8217;s liability for Tax Related Items or achieve any particular tax result.  Furthermore, if the Grantee becomes subject to Tax Related Items in more than one jurisdiction, the Grantee acknowledges that the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax Related Items in more than one jurisdiction.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Prior to the applicable taxable or tax withholding event, as applicable, the Grantee shall pay or make adequate arrangements satisfactory to Lilly and&#47;or the Employer to satisfy all Tax Related Items.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-35.88pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27pt">In the case of Dividend Equivalent Rights paid to the Grantee and if the Restricted Stock Units are paid to the Grantee in cash in lieu of Shares, the Grantee authorizes the Company and&#47;or the Employer, or their respective agents, at their discretion, to satisfy any obligation for Tax Related Items by withholding from the cash amount paid to the Grantee pursuant to the Award or from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer.</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-38.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27pt">If the Restricted Stock Units are paid to the Grantee in Shares and the Grantee is not subject to the short-swing profit rules of Section 16(b) of the Exchange Act, the Grantee authorizes Lilly and&#47;or the Employer, or their respective agents, at their discretion, to (A) withhold from the Grantee&#8217;s wages or other cash compensation paid to the Grantee by the Company and&#47;or the Employer, (B) arrange for the sale of Shares to be issued upon settlement of the Award  (on the Grantee&#8217;s behalf and at the Grantee&#8217;s direction pursuant to this authorization or such other authorization as the Grantee may be required to provide to Lilly or its designated broker in order for such sale to be effectuated) and withhold from the proceeds of such sale,  (C) withhold in Shares otherwise issuable to the Grantee pursuant to this Award, and&#47;or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 6</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eli Lilly and Company Restricted Stock Unit Award Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(D) apply any other method of withholding determined by the Company and, to the extent required by Applicable Laws or the Plan, approved by the Committee.</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-40.32pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27pt">If the Restricted Stock Units are paid to the Grantee in Shares and the Grantee is subject to the short-swing profit rules of Section 16(b) of the Exchange Act, Lilly will withhold in Shares otherwise issuable to the Grantee pursuant to this Award, unless the use of such withholding method is prevented by Applicable Laws or has materially adverse accounting or tax consequences, in which case the withholding obligation for Tax Related Items may be satisfied by one or a combination of the methods set forth in Section 7(b)(ii)(A) and (B) above.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">Depending on the withholding method, Lilly and&#47;or the Employer may withhold or account for Tax Related Items by considering applicable statutory or other withholding rates, including minimum or maximum rates in the jurisdiction(s) applicable to the Grantee, in which case the Grantee may receive a refund of any over-withheld amount in cash (without interest and without entitlement to the equivalent amount in Shares).  If the obligation for Tax Related Items is satisfied by withholding Shares, for tax purposes, the Grantee will be deemed to have been issued the full number of Shares to which he or she is entitled pursuant to this Award, notwithstanding that a number of Shares are withheld to satisfy the obligation for Tax Related Items.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Lilly may require the Grantee to pay Lilly and&#47;or the Employer any amount of Tax Related Items that Lilly and&#47;or the Employer may be required to withhold or account for as a result of any aspect of this Award that cannot be satisfied by the means previously described.  Lilly may refuse to deliver Shares or any cash payment to the Grantee if the Grantee fails to comply with the Grantee&#8217;s obligation in connection with the Tax Related Items as described in this Section 7. </font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section 8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.82pt">Section 409A Compliance</font></div><div style="padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent applicable, it is intended that this Award comply with the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended and the Treasury Regulations and other guidance issued thereunder (&#8220;Section 409A&#8221;) and this Award shall be interpreted and applied by the Committee in a manner consistent with this intent in order to avoid the imposition of any additional tax under Section 409A.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section 9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.82pt">Grantee&#8217;s Acknowledgement</font></div><div style="padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accepting this Award, the Grantee acknowledges, understands and agrees that&#58;</font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the Plan is established voluntarily by Lilly, it is discretionary in nature and it may be modified, amended, suspended or terminated by Lilly at any time, as provided in the Plan&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the Award is voluntary and occasional and does not create any contractual or other right to receive future awards of Restricted Stock Units and&#47;or Dividend Equivalent Rights, or benefits in lieu thereof, even if Restricted Stock Units and&#47;or Dividend Equivalent Rights have been granted in the past&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">all decisions with respect to future awards of Restricted Stock Units, Dividend Equivalent Rights or other awards, if any, will be at the sole discretion of the Committee&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the Grantee&#8217;s participation in the Plan is voluntary&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the Award and any Shares subject to the Award are not intended to replace any pension rights or compensation&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 7</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eli Lilly and Company Restricted Stock Unit Award Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:30.46pt">the Award and any Shares subject to the Award, and the income and value of same, are not part of normal or expected compensation for any purpose, including but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, holiday pay, leave pay, pension or welfare or retirement benefits or similar mandatory payments&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">unless otherwise agreed with Lilly, the Award and any Shares subject to the Award, and the income and value of same, are not granted as consideration for, or in connection with, the service the Grantee may provide as a director of an Affiliate&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">neither the Award nor any provision of this Award Agreement, the Plan or the policies adopted pursuant to the Plan, confer upon the Grantee any right with respect to employment or continuation of current employment, and in the event that the Grantee is not an employee of Lilly or any subsidiary of Lilly, the Award shall not be interpreted to form an employment contract or relationship with Lilly or any Affiliate&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.01pt">the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">j.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.01pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the Award resulting from the Grantee ceasing to provide employment or other services to Lilly or the Employer (for any reason whatsoever, whether or not later found to be invalid or in breach of local labor laws in the jurisdiction where the Grantee is employed or the terms of Grantee&#8217;s employment agreement, if any)&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">k.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt">for purposes of the Award, the Grantee&#8217;s employment will be considered terminated as of the date he or she is no longer actively providing services to the Company or an Affiliate and the Grantee&#8217;s right, if any, to earn and be paid any portion of the Award after such termination of employment&#160;or services (regardless of the reason for such termination&#160;and whether or not such termination is later found to be invalid or in breach of employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee's employment agreement, if any)&#160;will be measured by the date the Grantee ceases to&#160;actively&#160;provide services and will not be extended by any notice period (e.g., active&#160;service would not include any contractual notice period or any&#160;period of &#8220;garden leave&#8221; or similar period&#160;mandated under employment laws in the jurisdiction where the Grantee is employed or the terms of the Grantee's employment agreement, if any)&#59; the Committee shall have the exclusive discretion to determine when the Grantee is no longer actively&#160;providing services&#160;for purposes of the Award (including whether the Grantee may still be considered&#160;to be actively&#160;providing services&#160;while on a leave of absence)&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">l.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.01pt">unless otherwise provided in the Plan or by the Committee in its discretion, the Award and the benefits evidenced by this Award Agreement do not create any entitlement to have the Award or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">m.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.9pt">neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between the Grantee&#8217;s local currency and the United States Dollar that may affect the value of the Award or any amounts due to the Grantee pursuant to the settlement of the Award or the subsequent sale of any Shares acquired upon settlement.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 8</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eli Lilly and Company Restricted Stock Unit Award Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section 10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:1.26pt">Data Privacy</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Data Collection and Usage</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  The Company and the Employer may collect, process and use certain personal information about the Grantee, and persons closely associated with the Grantee, including, but not limited to, the Grantee&#8217;s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of stock or directorships held in the Company, details of all Restricted Share Units or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in the Grantee&#8217;s favor (&#8220;Data&#8221;), for the purposes of implementing, administering and managing the Plan.  The legal basis, where required, for the processing of Data is the Grantee&#8217;s consent. Where required under applicable law, Data may also be disclosed to certain securities or other regulatory authorities where the Company's securities are listed or traded or regulatory filings are made and the legal basis, where required, for such disclosure are the applicable laws.  </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  The Company transfers Data to Bank of America Merrill Lynch and&#47;or its affiliated companies (&#8220;Merrill Lynch&#8221;), an independent service provider, which is assisting the Company with the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner. The Grantee may be asked to agree on separate terms and data processing practices with the service provider, with such agreement being a condition to the ability to participate in the Plan.  The Company may also transfer Data to KPMG, an independent service provider, which is also assisting the Company with certain aspects of the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:28.23pt;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. The Company and its service providers are based in the United States. The Grantee&#8217;s country or jurisdiction may have different data privacy laws and protections than the United States.  The Company's legal basis, where required, for the transfer of Data is Grantee&#8217;s consent.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. The Company will hold and use the Data only as long as is necessary to implement, administer and manage the Grantee&#8217;s participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax and security laws.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Voluntariness and Consequences of Consent Denial or Withdrawal</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. Participation in the Plan is voluntary and the Grantee is providing the consents herein on a purely voluntary basis.  If the Grantee does not consent, or if the Grantee later seeks to revoke the Grantee&#8217;s consent, the Grantee&#8217;s salary from or employment and career with the Employer will not be affected&#59; the only consequence of refusing or withdrawing the Grantee&#8217;s consent is that the Company would not be able to grant this Award or other awards to the Grantee or administer or maintain such awards.  </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:30.46pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. The Grantee understands that data subject rights regarding the processing of Data vary depending on applicable law and that, depending on where the Grantee is based and subject to the conditions set out in such applicable law, the Grantee may have, without limitation, the right to (i) inquire whether and what kind of Data the Company holds about the Grantee and how it is processed, and to access or request copies of such Data, (ii) request the correction or supplementation of Data about the Grantee that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Data no longer necessary for the purposes underlying the processing, (iv) request the Company to restrict the processing of the Grantee&#8217;s Data in certain </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 9</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eli Lilly and Company Restricted Stock Unit Award Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">situations where the Grantee feels its processing is inappropriate, (v) object, in certain circumstances, to the processing of Data for legitimate interests, and to (vi) request portability of the Grantee&#8217;s Data that the Grantee has actively or passively provided to the Company or the Employer (which does not include data derived or inferred from the collected data), where the processing of such Data is based on consent or the Grantee&#8217;s employment and is carried out by automated means.  In case of concerns, the Grantee understands that he or she may also have the right to lodge a complaint with the competent local data protection authority.  Further, to receive clarification of, or to exercise any of, the Grantee&#8217;s rights, the Grantee understands that he or she should contact his or her local human resources representative.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. By accepting the Award and indicating consent via the Company&#8217;s online acceptance procedure, the Grantee is declaring that he or she agrees with the data processing practices described herein and consents to the collection, processing and use of Data by the Company and the transfer of Data to the recipients mentioned above, including recipients located in countries which do not offer an adequate level of protection from a European (or other non-U.S.) data protection law perspective, for the purposes described above.</font></div><div style="margin-bottom:12pt;padding-left:18pt;padding-right:-4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section 11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:1.26pt">Restrictive Covenants, Remedies, and Additional Terms and Conditions</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Restrictive Covenants</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In consideration of the Grantee&#8217;s receipt of the Award from Lilly, the Grantee agrees that during the Grantee&#8217;s employment with Lilly or an Affiliate that the Grantee provided services to or had access to confidential information concerning (&#8220;Covered Affiliate&#8221;) and for twelve (12) months immediately following the end of the Grantee&#8217;s employment (regardless of reason), the Grantee will not directly or indirectly, on a worldwide basis, engage in any of the following activities&#58;</font></div><div style="padding-left:90pt;text-align:justify;text-indent:-26.88pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Work for, advise, manage, act as an agent, employee or consultant for, or otherwise provide any services, in a Competitively-Sensitive Capacity, to&#58; (a) any person or entity engaged in research, development, production, sale or distribution of a product or service competitive with or substantially similar to any product or service in research, development or design, or manufactured, produced, sold or distributed by Lilly or a Covered Affiliate&#59; or (b) any person or entity that otherwise competes or intends to compete with Lilly or a Covered Affiliate.</font></div><div style="padding-left:90pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify;text-indent:-29.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Solicit, urge, divert, induce, or seek to induce any of Lilly&#8217;s (or Covered Affiliate&#8217;s) independent contractors, subcontractors, business partners, distributors, brokers, consultants, sales representatives, customers, vendors, suppliers or any other person with whom Lilly or Covered Affiliate has a business relationship and with whom the Grantee interacted during the Grantee&#8217;s employment with Lilly or Covered Affiliate to terminate their relationship with, or representation of, Lilly or Covered Affiliate or to cancel, withdraw, reduce, limit or in any manner modify any such person&#8217;s business with,  or representation of, Lilly or a Covered Affiliate.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Grantee acknowledges and agrees that any Lilly Affiliate is an intended third-party beneficiary of this Award Agreement, which may be enforced by Lilly or any such Affiliate, either singularly or jointly.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this Award Agreement, &#8220;Competitively-Sensitive Capacity&#8221; means&#58; (i) the same or similar capacity or function in which the Grantee worked for Lilly or a Covered Affiliate at any time during the two (2) years immediately preceding the end of the Grantee&#8217;s employment&#59; (ii) any officer, director, executive or senior management capacity or function&#59; (iii) any research and development capacity or function&#59; (iv) any sales management or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 10</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eli Lilly and Company Restricted Stock Unit Award Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business development management capacity or function&#59; (v) any ownership capacity (except the Grantee may own as a passive investment up to 2% of any publicly traded securities)&#59; and&#47;or (vi) any other capacity or function in which there is a material risk that the Grantee likely would inevitably use or disclose trade secrets and&#47;or confidential information of Lilly or a Covered Affiliate. For purposes of clarity, if a competing business has multiple divisions, lines or segments, some of which are not competitive with the business of Lilly, including its Covered Affiliates, nothing in this Award Agreement will prohibit the Grantee from being employed by, working for or assisting only that division, line or segment of such competing business that is not competitive with the business of Lilly or a Covered Affiliate, provided the Grantee is not involved in a Competitively-Sensitive Capacity in the research, development, manufacture, provision or sale of any products that compete with any products of Lilly or a Covered Affiliate.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Grantee and Lilly acknowledge and agree that the worldwide geographic scope of the foregoing covenants is reasonable and necessary given, among other things, that&#58; (i) absent the restrictions, the Grantee could utilize Lilly&#8217;s (or its Affiliates) trade secrets and&#47;or confidential information and compete with Lilly or Affiliate from virtually anywhere&#59; and (ii) such scope is the only way for Lilly and its Affiliates to protect their trade secrets and confidential information. In the event the Grantee violates any of the restrictive covenants contained herein, their duration will automatically be extended by the length of time during which the Grantee was in violation of any of the restrictive covenants.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Grantee acknowledges and agrees that, during the course of the Grantee&#8217;s employment with Lilly or a Covered Affiliate, the Grantee will become intimately familiar with confidential information and trade secrets key to its unique competitive advantage. The Grantee also acknowledges and agrees that Lilly&#8217;s (and Covered Affiliate&#8217;s) confidential information and trade secrets will retain continuing vitality throughout and beyond the twelve-month restricted period. And, the Grantee acknowledges and agrees that, should the Grantee leave Lilly or Covered Affiliate and, near the Grantee&#8217;s departure from Lilly or Covered Affiliate, work with another person or entity that engages in business activities similar to those of Lilly and&#47;or Covered Affiliate, it would be highly likely, if not inevitable, that the Grantee would rely on confidential information of Lilly and&#47;or Covered Affiliate in the course of the Grantee&#8217;s work, either consciously or subconsciously, harming Lilly and any Covered Affiliates. For these and other reasons, the Grantee agrees that the restrictions above are reasonably necessary to protect Lilly&#8217;s and its Covered Affiliate&#8217;s legitimate business interests and do so by creating a specific amount of time after the Grantee&#8217;s employment ends during which the Grantee will not be able to engage or prepare to engage in the activities above.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Grantee and Lilly further acknowledge and agree that if any particular covenant or provision is determined to be unreasonable or unenforceable for any reason, including, without limitation, the time period, geographic area, and&#47;or scope of activity covered by any restrictive covenant within this Award Agreement, such covenant or provision will automatically be deemed reformed so that the contested covenant or provision will have the closest effect permitted by applicable law to the original form and will be given effect and enforced as so reformed to whatever would be reasonable and extent enforceable under applicable law. Any court interpreting any restrictive covenant provision of this Award Agreement will, if necessary, reform any such provision to make it enforceable under applicable law.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Award Agreement is intended, among other things, to supplement (and not supersede) all applicable statutes protecting trade secrets and the duties the Grantee owes to Lilly and&#47;or Covered Affiliates under the common law, as well as any other non-competition, non-solicitation, or confidentiality provisions that the Grantee agreed in the past, including those </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 11</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eli Lilly and Company Restricted Stock Unit Award Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the Grantee&#8217;s Employee Confidentiality and Invention Agreement, each of which remains in full force and effect, or that the Grantee agrees in the future.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Grantee acknowledges that a breach by the Grantee of this Award Agreement will give rise to irreparable injury to Lilly and Covered Affiliates and money damages will not provide adequate relief for such injury. As a result, the Grantee agrees that Lilly (including any third-party beneficiary) will be entitled to obtain equitable or injunctive relief without having to post any bond or other security to restrain or prohibit any such breach or threatened breach, in addition to any other remedies which may be available, including the recovery of monetary damages from the Grantee.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If the Company determines that the Grantee has violated any applicable provisions of this Section 11, in addition to injunctive relief and damages, the Grantee agrees and covenants that&#58; (i) the Award shall be immediately rescinded&#59; (ii) the Grantee shall automatically forfeit any rights the Grantee may have with respect to the Award as of the date of such determination, including the rights to continue to be eligible to vest or receive a payment under the Award&#59; and (iii) the foregoing remedies set forth in this Section 11 shall not be Lilly&#8217;s (or any third-party beneficiary&#8217;s) exclusive remedies. Lilly reserves all other rights and remedies available to it at law or in equity.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt;text-decoration:underline">Insider Trading&#47;Market Abuse Laws</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Grantee may be subject to insider trading restrictions and&#47;or market abuse laws in applicable jurisdictions, including but not limited to the United States and the Grantee&#8217;s country of residence, which may affect the Grantee&#8217;s ability to directly or indirectly, for the Grantee or for a third party, acquire or sell, or attempt to sell,&#160; or otherwise dispose of Shares or rights to acquire Shares (e.g., Restricted Stock Units) under the Plan during such times as the Grantee is considered to have &#8220;inside information&#8221; regarding the Company (as determined under the laws or regulations in the applicable jurisdictions).&#160; Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.&#160; The Grantee acknowledges that it is his or her responsibility to comply with any applicable restrictions, and the Grantee should consult with his or her personal legal advisor on this matter.  </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Imposition of Other Requirements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Company reserves the right to impose other requirements on the Award and any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require the Grantee to execute any additional agreements or undertakings that may be necessary to accomplish the foregoing. Without limitation to the foregoing, the Grantee agrees that the Restricted Stock Unit Award and any benefits or proceeds the Grantee may receive hereunder shall be subject to forfeiture and&#47;or repayment to the Company to the extent required to comply with any requirements imposed under Applicable Laws or any compensation recovery policy of the Company that reflects the provisions of Applicable Laws.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section 12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:1.26pt">Governing Law and Choice of Venue</font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The validity, construction, and enforcement of this Award Agreement shall be governed by the laws of the State of Indiana, U.S.A. without regard to laws that might cause other law to govern under applicable principles of conflict of laws or cause the application of substantive law of any jurisdiction other than Indiana. For purposes of litigating any dispute that arises under this Award Agreement, the parties hereby submit to and consent to the jurisdiction and venue of the State of Indiana, and agree that such litigation shall be conducted exclusively in the courts having appropriate subject matter jurisdiction in Marion</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">County, Indiana, or the federal courts for the United States for the Southern District of Indiana</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and no other courts, where this Award is granted and&#47;or to be performed.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 12</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eli Lilly and Company Restricted Stock Unit Award Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section 13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:1.26pt">Miscellaneous Provisions</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Notices and Electronic Delivery and Participation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Any notice to be given by the Grantee or successor Grantee shall be in writing, and any notice shall be deemed to have been given or made only upon receipt thereof by the Corporate Secretary of Lilly at Lilly Corporate Center, Indianapolis, Indiana 46285, U.S.A.  Any notice or communication by Lilly in writing shall be deemed to have been given in the case of the Grantee if mailed or delivered to the Grantee at any address specified in writing to Lilly by the Grantee and, in the case of any successor Grantee, at the address specified in writing to Lilly by the successor Grantee.  In addition, Lilly may, in its sole discretion, decide to deliver any documents related to the Award and participation in the Plan by electronic means or request the Grantee&#8217;s consent to participate in the Plan by electronic means.  By accepting this Award, the Grantee hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by Lilly or a third party designated by Lilly.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Grantee acknowledges that he or she is proficient in the English language, or has consulted with an advisor who is sufficiently proficient in English, so as to allow the Grantee to understand the terms and conditions of this Award Agreement.  If the Grantee has received this Award Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.23pt;text-decoration:underline">Waiver.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The waiver by Lilly of any provision of this Award Agreement at any time or for any purpose shall not operate as or be construed to be a waiver of the same or any other provision of this Award Agreement at any subsequent time or for any other purpose.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Severability and Section Headings</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If one or more of the provisions of this Award Agreement shall be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and the invalid, illegal or unenforceable provisions shall be deemed null and void&#59; however, to the extent permissible by law, any provisions which could be deemed null and void shall first be construed, interpreted or revised retroactively to permit this Award Agreement to be construed so as to foster the intent of this Award Agreement and the Plan.  </font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The section headings in this Award Agreement are for convenience of reference only and shall not be deemed a part of, or germane to, the interpretation or construction of this instrument.</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Lilly is not providing any tax, legal or financial advice, nor is Lilly making any recommendations regarding the Grantee&#8217;s participation in the Plan or the Grantee&#8217;s acquisition or sale of the underlying Shares.  The Grantee should consult with his or her own personal tax, legal and financial advisors regarding the Grantee&#8217;s participation in the Plan before taking any action related to the Plan.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section 14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:1.26pt">Compensation Recovery</font></div><div style="margin-bottom:12pt;padding-left:22.5pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At any time during the three years following the date on which the number of shares of Lilly Stock subject to this Award was determined, the Company reserves the right to and, in appropriate cases, will seek restitution of all or part of any&#160;shares&#160;of Lilly Stock subject to or issued (or cash paid) pursuant to this Award if&#58;</font></div><div style="padding-left:72pt;padding-right:0.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. (i)&#160;&#160;&#160;&#160;the number of&#160;shares of Lilly Stock subject to the Award was calculated based, directly or indirectly, upon the achievement of&#160;financial results (e.g., earnings per share) that were </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 13</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eli Lilly and Company Restricted Stock Unit Award Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div><div style="padding-left:72pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsequently the subject of restatement of all or a portion of the Company&#8217;s financial statements&#59;</font></div><div style="padding-left:72pt;padding-right:0.9pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;the Grantee engaged in intentional misconduct that caused or partially caused the need for such a restatement&#59; and</font></div><div style="padding-left:72pt;padding-right:0.9pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;the number of&#160;shares of Lilly Stock that would have been subject to the Award had the financial results been properly reported would have been lower than the number of&#160;shares&#160;of Lilly Stock actually&#160;subject to the Award.</font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:0.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;the Grantee has been determined to have committed a material violation of law or Company policy or to have failed to properly manage or monitor the conduct of an employee who has committed a material violation of law or Company policy whereby, in either case, such conduct causes significant harm to the company.</font></div><div style="margin-bottom:12pt;padding-left:22.5pt;padding-right:0.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event the number of shares of Lilly Stock subject to the Award is determined to have been based on materially inaccurate financial statements or other Company performance measures or on calculation errors (without any misconduct on the part of the Grantee), the Company reserves the right to and, in appropriate cases, will&#58;</font></div><div style="padding-left:72pt;padding-right:0.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">seek restitution of the shares of Lilly Stock subject to or issued (or cash paid) pursuant to this Award to the extent that the number of shares of Lilly Stock subject to the Award exceeded the number of shares of Lilly Stock that would have been subject to the Award had the inaccuracy or error not occurred, or</font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:0.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">issue additional shares of Lilly Stock or make additional cash payment to the extent that the number of shares of Lilly Stock subject to the Award was less than the correct amount.</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Section 14 is not intended to limit the Company&#8217;s power to take such action as it deems necessary to remedy any misconduct, prevent its reoccurrence and, if appropriate, based on all relevant facts and circumstances, punish the wrongdoer in a manner it deems appropriate.</font></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section 15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:1.26pt">Award Subject to Acknowledgement of Acceptance</font></div><div style="margin-top:6pt;padding-left:22.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding any provisions of this Award Agreement, the Award is subject to acknowledgement of acceptance by the Grantee prior to 4&#58;00 PM (EDT) &#91;INSERT DATE&#93;, through the website of Merrill Lynch, the Company&#8217;s stock plan administrator.  If the Grantee does not acknowledge acceptance of the Award prior to 4&#58;00 PM (EDT) &#91;INSERT DATE&#93;, the Award will be cancelled, subject to the Committee's discretion for unforeseen circumstances. </font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, Lilly has caused this Award Agreement to be executed in Indianapolis, Indiana, by its proper officer.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ELI LILLY AND COMPANY</font></div><div style="padding-left:288pt;text-align:justify"><font><br></font></div><div style="padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:288pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; _________________________</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 14</font><font style="color:#000000;font-family:'Celeste',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>lly-3312021x10qxexhibit102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i3ef86b080ee54423b70c366f8480aca9_38"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 10.2 Release Agreement, effective as of February 9, 2021, by and between Eli Lilly and Company and Joshua L. Smiley</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:232%">Release Agreement</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%">This RELEASE AGREEMENT (&#8220;Agreement&#8221;) is entered into by and between Eli Lilly and Company (&#8220;Lilly&#8221;) and Joshua L. Smiley (&#8220;Executive&#8221;).</font></div><div style="text-align:center;text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%;text-decoration:underline">Agreement</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%">In consideration of the mutual covenants and conditions set forth in this Agreement, Lilly and Executive agree as follows&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%;padding-left:27.67pt">The parties have agreed that Executive will resign from his officer position with Lilly and assist in the transition of his duties to his successor, and desire to set forth certain mutual understandings related to such resignation and transition in this Agreement.  By carrying out the terms of this Agreement, neither admits any wrongful action or any liability to the other.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%;padding-left:27.67pt">As a result, Executive and Lilly agree that Executive will resign from his position as Senior Vice President and Chief Financial Officer as of February 9, 2021 (the &#8220;Transition Date&#8221;).  Executive agrees that his resignation as of the Transition Date includes resignation from any officer or director positions at Lilly or any of its subsidiaries or affiliates, and agrees to deliver the resignation letter attached hereto as </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:232%">Exhibit A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%">.  Beginning on the Transition Date and continuing through July 31, 2021 (the &#8220;Transition Period&#8221;), Executive will provide advice and assistance related to transition matters as directed by Lilly&#8217;s Chief Executive Officer and&#47;or his designee.  During the Transition Period, Executive will be eligible to receive a biweekly base salary of $9,000.00, less all applicable taxes and withholdings, and remain eligible to participate in the benefit plans and programs for which he is eligible.  On the day following the Transition Period (&#8220;the &#8220;Non-Compete Transition Date&#8221;) and continuing through July 31, 2022 (the &#8220;Separation Date&#8221; and such period, the &#8220;Non-Compete Period&#8221;), Executive and Lilly agree that Executive will no longer receive any compensation from Lilly. Executive acknowledges that during the Non-Compete Period, (i) he will remain available for consultation with his successor and Lilly&#8217;s Chief Executive Officer from time to time as may reasonably be requested related to matters with which he was responsible while an officer of Lilly, and (ii) he will comply with the restrictive covenants set forth in this </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%">Agreement, including paragraphs 18, 20 and 21. During the Transition Period and the Non-Compete Period, Executive will remain an employee of Lilly, subject to compliance with the terms of this Agreement, and Lilly has the right to sever Executive&#8217;s employment at any time in its sole discretion without any additional liability to Executive (other than for accrued base pay through the date of termination and then-vested benefits under the applicable terms of Lilly benefit plans). Executive understands and agrees that he has no right or entitlement under The Lilly Severance Pay Plan or any other plan, program or arrangement to any severance benefit.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%;padding-left:27.67pt">Executive acknowledges that he will not receive a bonus for calendar year 2020 or 2021 under the terms and conditions of The Eli Lilly and Company Bonus Plan (&#8220;Bonus Plan&#8221;).</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%;padding-left:27.67pt">Lilly agrees that so long as Executive timely signs and returns this Agreement to Lilly by no later than the deadline provided pursuant to paragraph 26 of this Agreement (and does not revoke it within the time period prescribed therein), Lilly agrees that Executive will receive 75% of his Shareholder Value Award for the period 2018-2020, less all applicable taxes and withholdings (the &#8220;Award Payout&#8221;), payable within seven (7) days following the expiration of the revocation period set forth in paragraph 26.  Executive acknowledges and agrees that he is not entitled to the Award Payout or the other consideration set forth above other than as consideration for entering into this Agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%;padding-left:27.67pt">For the consideration stated in this Agreement, Executive (for himself, his heirs, successors, and assigns) hereby releases and forever discharges Lilly, its subsidiaries and affiliated companies and all of their present or former representatives, officers, employees, agents, directors, shareholders, predecessors, successors, purchasers, and assigns, or any other persons whom he may claim to be responsible for any alleged damages (the &#8220;Releasees&#8221;), to the fullest extent permitted by law, from any and all grievances, claims, liability, damages, demands, debts, obligations, actions and causes of action, of any nature whatsoever (including, but not limited to, all causes of action arising under worker&#8217;s compensation non-interference or non-retaliation statutes), whether based on statutory, tort, contract or other legal or equitable theory of recovery, which Executive may now have or has had, whether known or unknown, in any way arising out of or relating to Executive&#8217;s employment with Lilly, the terms and conditions of that employment or the cessation of such employment (collectively, &#8220;Released Claims&#8221;).  Released Claims include, but are not limited to, all claims for compensation of any kind&#59; all </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%">claims for reinstatement or other equitable relief&#59; claims for fringe benefits&#59; all claims to any right to accept or receive any award or portion of any award resulting from a settlement or judgment against Lilly arising out of any action brought by Executive or on his behalf, or on behalf of any government, including any right to recover, directly or indirectly, under the False Claims Act or similar state laws, and all claims arising out of or relating to federal or state fraud and abuse, reimbursement, price reporting, compliance with laws or regulations, and&#47;or federal healthcare programs (collectively, &#8220;Healthcare Laws&#8221;) (other than those claims that cannot be released)&#59; or any other statutory or common law claim which could be brought by, on behalf of, or through Executive under any legal or equitable theory. Executive will not join or participate as a class representative or class member in any class action or collective action against the Releasees relating to any claims covered by this Agreement. By signing this Agreement, Executive does not, however, give up his charge-filing rights as described in paragraph 6 below or his right to report governmental actions as described in paragraph&#160;7 below. Executive expressly acknowledges that his Released Claims also include, but are not limited to, release of the Releasees to the fullest extent permitted by law from any claim of failure to provide adequate notice of the termination of Executive&#8217;s employment&#59; of race, color, or national origin discrimination&#59; of disability discrimination&#59; of sex discrimination, sexual harassment or other harassment&#59; of retaliation&#59; or of any other claim of employment discrimination under any laws prohibiting employment discrimination, including, but not limited to, The Worker Adjustment and Retraining Notification Act, Title VII of The Civil Rights Act of 1964, as amended, the Older Workers Benefit Protection Act, the Civil Rights Act of 1866, 42 U.S.C. &#167; 1981, Executive Order 11246, The Americans With Disabilities Act, as amended, and the Family and Medical Leave Act, or based on other alleged unlawful practices under any federal, state or local statute, ordinance or regulation, including, without limitation, claims under the Employee Retirement Income Security Act and the Equal Pay Act. Executive hereby agrees and acknowledges that the Released Claims are not limited to matters which are known or have been disclosed, as of the date hereof, to him. In addition, Executive&#8217;s employment relationship with Lilly is covered by the Age Discrimination in Employment Act of 1967, 29 U.S.C. &#167; 621 et seq., as amended. By signing this Agreement, Executive waives any rights or claims against the Releasees, or any other persons whom he may claim to be responsible for any alleged </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%">damages that have arisen or may arise under the Age Discrimination in Employment Act on or before the date he signs this Agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%;padding-left:27.67pt">Executive understands and agrees that although by signing this Agreement and accepting the Award Payout as described above in paragraph 4 he does not waive his right to file an Equal Employment Opportunity Commission (&#8220;EEOC&#8221;) charge against Lilly, or to file a charge with any comparable state or local administrative agency, or to cooperate in an EEOC or agency investigation of any such charge, he does waive and release, to the fullest extent permitted by law, any and all entitlement to any form of personal relief arising from any such charge he has filed or may file in the future against Lilly related to his employment with Lilly. Executive understands that this waiver and release of personal relief would not affect the EEOC&#8217;s or state or local administrative agency&#8217;s ability to investigate such a charge or to pursue relief on behalf of other individuals.  If Executive has filed such a charge prior to his signing of this Agreement, he agrees that he will, within two&#160;(2) business days of signing this Agreement, prepare, sign, and deliver to the EEOC or state or local administrative agency with which the charge is pending a letter that states as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This letter is in regard to charge number ________ (&#8220;Charge&#8221;) which I have filed with this agency. This is to advise you that I have entered into an agreement, under which, in exchange for sufficient consideration, I have fully waived and released all claims to any personal relief, including any form of monetary relief, arising out of any claims related to my employment with Lilly through the date of my signing of the Agreement. This waiver and release includes any and all claims for personal relief related to the above-referenced Charge. I have also, again in exchange for sufficient consideration, fully waived and released all rights to file a lawsuit against Lilly in any court of law asserting claims arising out of my employment with Lilly, up through and including the date of my signing of the Agreement.  These waivers and releases are effective to the fullest extent permitted by applicable law. I understand that this Agreement does not affect this agency&#8217;s ability to investigate the above-referenced Charge or to pursue relief on behalf of other individuals.</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I entered into this Agreement with Lilly voluntarily and without coercion and with sufficient opportunity to consult an attorney for advice. Thank you for your assistance.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%">Executive further agrees to provide to Lilly a copy of the letter as signed and delivered.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%">7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%;padding-left:27.67pt">Executive also understands and agrees that although by signing this Agreement and accepting the Award Payout as described above he does not waive his right to report actual or potential violations by Lilly to appropriate governmental authorities or employees or to cooperate in a governmental investigation of any such report, he does waive and release, to the fullest extent permitted by law, any and all entitlement to any form of personal relief arising from any such allegations he, or another party, </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%">have filed or may file in the future against Lilly related to any Healthcare Law. &#160;Executive understands that this waiver and release of personal relief would not affect the governmental entity&#8217;s ability to investigate such a report or to pursue relief on behalf of others.&#160; Executive is not aware of any actual or potential violations of any Healthcare Law by Lilly, its affiliates, employees or agents and is not a party to any governmental action involving Lilly.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%">8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%;padding-left:27.67pt">Lilly agrees to pay Executive his gross monthly base salary (less all applicable taxes and withholdings) set forth in paragraph 2 through the Transition Period (&#8220;Final Pay&#8221;). In addition, Executive shall receive payment by no later than the first payroll period following the Transition Period for any 2021 vacation which he may have accrued but not used pursuant to The Eli Lilly and Company Holiday and Vacation Plan in effect during 2021. Likewise, if Executive used more vacation days than he accrued, the overpayment will be adjusted from his Final Pay.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%">9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%;padding-left:27.67pt">The parties recognize that Executive has previously been awarded certain equity grants. Executive understands that, pursuant to the terms and conditions of the outstanding equity award(s) and action by the Lilly Compensation Committee, each such award, other than the Award Payout described above, will be forfeited as of the Transition Date.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%">10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%;padding-left:22.11pt">Executive understands that he shall remain eligible as an active employee under The Eli Lilly and Company Health Plan and any other Lilly employee benefit plans and programs only through the Transition Period. Executive understands that coverage for him and any covered dependents under The Eli Lilly and Company Health Plan will be terminated as of the last day of the Transition Period. As will be explained more fully in the COBRA election notice and information he will receive, Executive and any of his covered dependents are eligible for continuation of coverage of dental, vision, and&#47;or medical benefits pursuant to COBRA. </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%">11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%;padding-left:22.11pt">The parties recognize that Executive has accrued certain benefits under The Lilly Retirement Plan and that those benefits continue in full force and effect, subject to the terms of The Lilly Retirement Plan, and that nothing in this Agreement serves to modify the terms of such plan. Accordingly, Executive will receive any and all vested benefits to which he is entitled under The Lilly Retirement Plan, in accordance with the terms of such plan, and additional retirement benefits under The Lilly Excess Benefit Plan &#8211; Retirement (&#8220;Excess Retirement Plan&#8221;). Executive understands that he will be responsible </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%">for all required FICA taxes associated with his Excess Retirement Plan benefits and other applicable taxes. Additionally, Executive will receive any and all vested benefits to which he is entitled under The Lilly Employee 401(k) Plan, in accordance with the terms of such plan, and additional savings benefits under The Lilly Excess Savings Plan (&#8220;Excess Savings Plan&#8221;). Executive understands that any benefits provided through the Excess Retirement Plan will not begin sooner than age fifty-five consistent with Section 409A of the Internal Revenue Code and the terms of such plan. Executive also understands that any benefits provided through the Excess Savings Plan will be provided consistent with Section 409A of the Internal Revenue Code and the terms of such plan. All of the terms of the applicable benefit plans apply, except as otherwise required by applicable law.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%">12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%;padding-left:22.11pt">Executive agrees that he is not entitled to reinstatement of active employment or reemployment with Lilly or any of its subsidiaries or related companies, he waives any such right or claim, and he agrees that he will not seek employment in the future with Lilly or any of its subsidiaries or related companies.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%">13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%;padding-left:22.11pt">Except as provided herein, Lilly&#8217;s U.S. Human Resources component agrees to follow its standard practice in responding to inquiries from a third party (other than a government entity) about Executive&#8217;s employment at Lilly, which is to provide only dates of employment and last position held.  Notwithstanding the foregoing, Lilly may make public disclosures related to Executive&#8217;s resignation as its chief financial officer as it deems appropriate in its sole discretion, which disclosures may include, without limitation, the following statement (or like statements)&#58; </font></div><div style="padding-left:36pt;padding-right:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 9, 2021, the Company also announced that Joshua L. Smiley, senior vice president and chief financial officer of the Company, informed the Company of his resignation from the Company. The Company was recently made aware of allegations of an inappropriate relationship between Mr. Smiley and a Lilly employee.&#160;Lilly immediately engaged external counsel to conduct a thorough, independent investigation.&#160;That investigation revealed consensual though inappropriate personal communications between Mr. Smiley and certain Lilly employees and behavior that Lilly leadership concluded exhibited poor judgment by Mr. Smiley.&#160;Lilly holds all employees accountable to its core values and strongly believes its executive officers carry an even higher burden in ensuring those values are upheld. Mr. Smiley did not meet that standard. For clarity, Mr. Smiley&#8217;s conduct in question was not related to financial controls, financial statements or any other business matters or judgments.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%">Executive understands and agrees that he will direct any employment verification inquiries concerning his employment at Lilly to Stephen F. Fry, Sr. Vice President, Human Resources and Diversity.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%">14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%;padding-left:22.11pt">Executive agrees that he will not disparage or otherwise communicate any information damaging or potentially damaging to Lilly&#8217;s business or reputation to any third party, including without limitation the media, consultants, physicians, vendors, and any customers or others with whom Lilly has a business relationship.  Notwithstanding the foregoing, nothing in this Agreement will prohibit or restrict Executive (or Executive&#8217;s attorney) from (i) making any disclosure of information required by law, including with respect to possible violations of law or providing truthful testimony if required to do so by court order or legal process, (ii) responding to any inquiry about this Agreement or its underlying facts and circumstances by the Securities and Exchange Commission (SEC) or the Financial Industry Regulatory Authority (FINRA), or participating, cooperating, or testifying in any action, investigation, or proceeding with, or providing information to, any governmental entity or legislative body, any self-regulatory organization, and&#47;or pursuant to the Sarbanes-Oxley Act, or (iii) accepting any whistleblower incentive awards from the SEC.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%">15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%;padding-left:22.11pt">Executive agrees that he will, at any future time before or after the Separation Date, upon notice from Lilly that Lilly or its attorneys believe that his compliance would be helpful in the resolution of an investigation or the prosecution or defense of litigation, be available upon reasonable notice from Lilly and discussion with Executive as to reasonable time and day of the week, with or without subpoena, to be interviewed, review documents or things, give depositions, testify, or engage in other reasonable activities, with respect to matters concerning which he has or may have knowledge as a result of or in connection with his employment by Lilly.  In performing Executive&#8217;s obligations under this paragraph to testify or otherwise provide information, Executive will honestly, truthfully, forthrightly, and completely provide the information requested.  In addition, Executive hereby represents and warrants to Lilly that he has participated honestly, truthfully, forthrightly, and completely with respect to the investigation of his behavior conducted to date by Lilly and its counsel.  Following the Separation Date, Lilly will pay Executive for the time he spends in activities described in this paragraph, at Lilly&#8217;s request, in one-half day or whole-day increments, at his final Lilly rate of pay, and it will pay all reasonable and necessary expenses that Executive incurs at Lilly&#8217;s request in performing those activities&#59; however, nothing in this Agreement shall require Lilly to pay Executive for in-court testimony. Moreover, nothing in this paragraph </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%">15 shall, however, obligate Executive to provide such cooperation to Lilly in connection with any EEOC or comparable state or local administrative agency charge filed against Lilly.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%">16.&#160;&#160;&#160;&#160;Executive agrees to cooperate fully with Lilly in effecting a smooth transfer of responsibilities&#59; to return to Lilly by the last day of the Transition Period all identification and credit cards, keys, telephones, computers, company-issued devices, mobile devices, USB devices (e.g., thumbdrives, hard-drives, etc.), or other equipment, and other things owned by Lilly and all documents, materials, records, or other things belonging to Lilly or containing Lilly&#8217;s property and&#47;or confidential information, including such property and&#47;or information on personal devices. </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%">17.&#160;&#160;&#160;&#160;Executive understands and acknowledges that the Award Payout and any other bonus payments and&#47;or incentive awards previously received by Executive remain subject to recoupment by the Company pursuant to the terms of the Executive Compensation Recovery Policy for the period of time specified therein, and any recoupment consistent with the terms of the Executive Compensation Recovery Policy will not affect the validity of this Agreement or the release provided by Executive herein.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%">18.&#160;&#160;&#160;&#160;Executive understands and acknowledges that given his role and position of trust with Lilly, and pursuant to the terms of his Employee Confidentiality and Invention Agreement, he has ongoing duties to Lilly, including duties to protect and not disclose Lilly&#8217;s confidential and proprietary information.  Executive represents and acknowledges that all non-public financial information about Lilly and its products (both in market and in development products) is confidential and proprietary information subject to the terms of the Confidentiality and Invention Agreement and that Executive will not disclose such information to, discuss such information with, or use such information on behalf of, any third party, including any competitor, customer, supplier, or payor.  Executive further represents and warrants to Lilly that he has not at any time before executing this Agreement disclosed any of the terms or conditions of compromise and settlement set forth in this Agreement to any person other than his attorney and his financial advisor (if any). Nothing in this Agreement shall prohibit or restrict Executive from participating, cooperating, or testifying in any action, investigation, or proceeding with, or providing relevant and truthful information to, any court, governmental agency or legislative body, including but not limited to the IRS, any self-regulatory organization and&#47;or pursuant to the Sarbanes-Oxley Act&#59; provided that, to the extent permitted by law, upon receipt of any subpoena, court order or other legal process compelling the </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%">disclosure of any such information or documents, including this Agreement, Executive gives ten (10) days&#8217; written notice to Lilly prior to responding to such subpoena, court order or other legal process so as to permit Lilly to protect its interests in confidentiality to the fullest extent possible. This notice requirement does not, however, apply to Executive&#8217;s non-waived rights related to his filing of or cooperation in the investigation of any charge of the type referenced in paragraph 7 of this Agreement, nor does it apply to his non-waived rights related to Executive&#8217;s rights to report governmental actions of the types referenced in paragraph&#160;8 of this Agreement.  </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%">Executive agrees that in any communication he has other than with his attorney and financial advisor (if any) regarding his departure from Lilly, he shall state only that he resigned from Lilly unless that communication is in connection with his participation, cooperation, or testimony in any action, investigation, or proceeding with, or his provision of relevant and truthful information to any court, governmental agency or legislative body. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:232%">These promises of confidentiality are material terms of this Agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%">19.&#160;&#160;&#160;&#160;Executive further agrees to indemnify Lilly to the fullest extent permitted by law from all claims, costs and expenses, including all attorneys&#8217; fees, arising out of any misrepresentation made by him in this Agreement. In the event Executive personally sues Lilly based on any claim, complaint, action, injury or right of action for which he has released and agreed not to sue Lilly in this Agreement (other than a suit under the Age Discrimination in Employment Act), Executive agrees, to the fullest extent permitted by law, to pay all costs and attorneys&#8217; fees incurred by Lilly in defending such lawsuit.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%">Nothing in this paragraph shall limit Executive&#8217;s charge-filing rights as described in paragraph 6 of this Agreement or Executive&#8217;s rights to report governmental actions as described in paragraph&#160;7 of this Agreement, and Executive shall have no obligation to pay Lilly for costs or attorney&#8217;s fees incurred by Lilly in defending against an EEOC or state or local administrative agency charge filed by Executive against Lilly, or any report of actual or potential violations by Lilly, as long as Executive waives and releases any and all entitlement to any form of personal relief arising from any such charge or report as described in paragraphs 6 and 7 of this Agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%">20.&#160;&#160;&#160;&#160;During Executive&#8217;s employment with Lilly and for a period of twelve (12) months after the Separation Date, Executive will not, directly or indirectly&#58; (a) solicit, recruit, hire, employ, engage or </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%">attempt to hire, employ or engage any person who is an employee of Lilly or any of its subsidiaries or affiliates&#59; (b) assist any person or entity in the recruitment, hiring or engagement of any person who is an employee of Lilly or any of its subsidiaries or affiliates&#59; (c) urge, induce or seek to induce any person to terminate his&#47;her employment with Lilly or any of its subsidiaries or affiliates&#59; or (d) advise, suggest to or recommend to any Competitive Business that it employ, engage or seek to employ or engage any person who is an employee of Lilly or any of its subsidiaries or affiliates. For purposes of this Agreement, &#8220;Competitive Business&#8221; means any entity that (1) competes with Lilly (including its subsidiaries and affiliates)&#59; or (2) develops, manufacturers, sells, offers or provides any products and&#47;or services that are similar to and&#47;or competitive with any products and&#47;or services that Lilly or any of its subsidiaries or affiliates was developing, manufacturing, selling, offering or providing as of the time Executive&#8217;s employment with Lilly ended.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%">21.&#160;&#160;&#160;&#160;During Executive&#8217;s employment with Lilly and for a period of twelve (12) months after the Non-Compete Transition Date, Executive agrees that he will not, directly or indirectly, provide any services (as an employee, advisor, consultant, or otherwise) in an executive or financial capacity, to any Competitive Business (or any owner of or investor of a Competitive Business, to the extent the services provided to such owner or investor relate to the Competitive Business).  Executive agrees and acknowledges that this restriction is reasonable and necessary to protect Lilly&#8217;s trade secrets and confidential information because, if Executive were to violate the restriction, it would be highly likely, if not inevitable, that he would rely on Lilly&#8217;s confidential information in the course of his work, either consciously or subconsciously, harming Lilly.  </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%">22.&#160;&#160;&#160;&#160;Executive acknowledges that a breach by Executive of paragraphs 18, 20 and 21 of this Agreement will give rise to irreparable injury to Lilly and money damages will not be adequate relief for such injury.  As a result, Executive agrees that Lilly (including any third-party beneficiary) will be entitled to obtain equitable or injunctive relief without having to post any bond or other security to restrain or prohibit any such breach or threatened breach, in addition to any other remedies which may be available, including the recovery of monetary damages from Executive.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%">23.&#160;&#160;&#160;&#160;This Agreement shall be governed by and construed in accordance with the laws of the State of Indiana. The courts of the State of Indiana will have exclusive jurisdiction in relation to matters connected with or concerning this Agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%">24.&#160;&#160;&#160;&#160;If any term or provision of this Agreement shall to any extent be invalid or unenforceable, the remainder of this Agreement shall not be affected, and each term and provision of this Agreement shall be valid and able to be enforced to the fullest extent permitted by law.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%">25.&#160;&#160;&#160;&#160;Executive acknowledges that he has contractual obligations pursuant to the Employee Confidentiality and Invention Agreement which he signed previously with Lilly and agrees that those obligations are not extinguished by this Agreement.  Except as described herein, this Agreement, the Employee Confidentiality and Invention Agreement, and the exhibits attached hereto, contain the entire understanding between the parties relating to the subject matter hereof and may not be amended, supplemented or otherwise modified except by an instrument in writing signed by both parties.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%">26.&#160;&#160;&#160;&#160;Executive acknowledges that Lilly (i) provided him this Agreement on February 7, 2021&#59; (ii) any revisions to this Agreement since originally provided to him are not material changes to this Agreement&#59; (iii) has advised and advises him to consult an attorney prior to signing the Agreement&#59; (iv) informed him that he could have until twenty-one (21) days from receipt to consider this Agreement&#59; and (v) advised him that this Agreement shall not be effective or enforceable against him or Lilly if he revokes it in writing not later than seven (7) days after he signs it. If Executive decides to revoke the Agreement, then he must deliver written notice to Stephen F. Fry, Senior Vice President, Human Resources and Diversity, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, within such seven (7) day period after signing. The other terms and conditions contained herein will not be enforceable by the parties hereto until the expiration of the seven (7) day period.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:232%">IN WITNESS WHEREOF, Lilly and Executive have executed this Agreement on this 8th day of February, 2021.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> &#47;s&#47; Joshua L. Smiley</font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Joshua L. Smiley</font></div><div style="text-align:right"><font><br></font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ELI LILLY AND COMPANY</font></div><div><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Stephen F. Fry</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Stephen F. Fry                            </font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Sr. Vice President, Human Resources </font></div><div style="margin-bottom:12pt;padding-left:252pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;and Diversity</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>lly-3312021x10qxexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ieee8a1809440482997db954d84d072ef_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:14pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 31.1 Rule 13a-14(a) Certification of David A. Ricks, Chairman, President, and Chief Executive Officer</font></div><div style="margin-top:14pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David A. Ricks, Chairman, President, and Chief Executive Officer, certify that&#58;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">I have reviewed this report on Form 10-Q of Eli Lilly and Company&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s Board of Directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize, and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:57.456%"><tr><td style="width:1.0%"></td><td style="width:9.078%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 30, 2021</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;David A. Ricks</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David A. Ricks</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman, President, and Chief Executive Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>lly-3312021x10qxexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ib9eba8bc5b5e4ceba23da0ceb4882db6_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:14pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 31.2 Rule 13a-14(a) Certification of Anat Ashkenazi, Senior Vice President and Chief Financial Officer</font></div><div style="margin-top:14pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Anat Ashkenazi, Senior Vice President and Chief Financial Officer, certify that&#58;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">I have reviewed this report on Form 10-Q of Eli Lilly and Company&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s Board of Directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize, and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:57.456%"><tr><td style="width:1.0%"></td><td style="width:9.078%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 30, 2021</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;Anat Ashkenazi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anat Ashkenazi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>6
<FILENAME>lly-3312021x10qxexhibit32.htm
<DESCRIPTION>EX-32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ib0e2b98f65144bc3b66a2162e768587e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 32. Section 1350 Certification</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&#160;and (b)&#160;of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Eli Lilly and Company, an Indiana corporation (the &#8220;Company&#8221;), does hereby certify that, to the best of their knowledge&#58;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2021 (the &#8220;Form 10-Q&#8221;) of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 30, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;David A. Ricks</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David A. Ricks</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman, President, and Chief Executive Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 30, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Anat Ashkenazi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anat Ashkenazi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>lly-20210331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:e048f7a3-28f3-4092-a916-bde5dfced0f0,g:3190a302-79f3-4ce3-a4d9-ac703a7bb0fb-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lly="http://www.lilly.com/20210331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.lilly.com/20210331">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20210331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20210331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20210331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20210331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.lilly.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedCondensedStatementsofOperations" roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations">
        <link:definition>1001002 - Statement - Consolidated Condensed Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedCondensedStatementsofComprehensiveIncomeLoss" roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeLoss">
        <link:definition>1002003 - Statement - Consolidated Condensed Statements of Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedCondensedBalanceSheets" roleURI="http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets">
        <link:definition>1003004 - Statement - Consolidated Condensed Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedCondensedBalanceSheetsParenthetical" roleURI="http://www.lilly.com/role/ConsolidatedCondensedBalanceSheetsParenthetical">
        <link:definition>1004005 - Statement - Consolidated Condensed Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedCondensedStatementsofEquity" roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity">
        <link:definition>1005006 - Statement - Consolidated Condensed Statements of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedCondensedStatementsofEquityParenthetical" roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquityParenthetical">
        <link:definition>1006007 - Statement - Consolidated Condensed Statements of Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedCondensedStatementsofCashFlows" roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows">
        <link:definition>1007008 - Statement - Consolidated Condensed Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentation" roleURI="http://www.lilly.com/role/BasisofPresentation">
        <link:definition>2101101 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationPolicies" roleURI="http://www.lilly.com/role/BasisofPresentationPolicies">
        <link:definition>2202201 - Disclosure - Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://www.lilly.com/role/Revenue">
        <link:definition>2103102 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueTables" roleURI="http://www.lilly.com/role/RevenueTables">
        <link:definition>2304301 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueSummaryofRevenueRecognizedDetails" roleURI="http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails">
        <link:definition>2405401 - Disclosure - Revenue (Summary of Revenue Recognized) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueAdjustmentstoRevenueDetails" roleURI="http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails">
        <link:definition>2406402 - Disclosure - Revenue (Adjustments to Revenue) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueContractLiabilitiesDetails" roleURI="http://www.lilly.com/role/RevenueContractLiabilitiesDetails">
        <link:definition>2407403 - Disclosure - Revenue (Contract Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueDisaggregationofRevenuebyProductDetails" roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails">
        <link:definition>2408404 - Disclosure - Revenue (Disaggregation of Revenue by Product) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueDisaggregationofRevenuebyGeographicalAreaDetails" roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails">
        <link:definition>2409405 - Disclosure - Revenue (Disaggregation of Revenue by Geographical Area) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://www.lilly.com/role/Acquisitions">
        <link:definition>2110103 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsTables" roleURI="http://www.lilly.com/role/AcquisitionsTables">
        <link:definition>2311302 - Disclosure - Acquisitions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsNarrativeDetails" roleURI="http://www.lilly.com/role/AcquisitionsNarrativeDetails">
        <link:definition>2412406 - Disclosure - Acquisitions (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>2413407 - Disclosure - Acquisitions (Assets Acquired and Liabilities Assumed) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsAssetAcquisitionsDetails" roleURI="http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails">
        <link:definition>2414408 - Disclosure - Acquisitions (Asset Acquisitions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsandOtherArrangements" roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangements">
        <link:definition>2115104 - Disclosure - Collaborations and Other Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsandOtherArrangementsTables" roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsTables">
        <link:definition>2316303 - Disclosure - Collaborations and Other Arrangements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsandOtherArrangementsDetails" roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails">
        <link:definition>2417409 - Disclosure - Collaborations and Other Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetImpairmentRestructuringandOtherSpecialCharges" roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges">
        <link:definition>2118105 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetImpairmentRestructuringandOtherSpecialChargesTables" roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables">
        <link:definition>2319304 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetImpairmentRestructuringandOtherSpecialChargesDetails" roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails">
        <link:definition>2420410 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.lilly.com/role/FinancialInstruments">
        <link:definition>2121106 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.lilly.com/role/FinancialInstrumentsTables">
        <link:definition>2322305 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsNarrativeDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails">
        <link:definition>2423411 - Disclosure - Financial Instruments (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsEffectofRiskManagementInstrumentsDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails">
        <link:definition>2424412 - Disclosure - Financial Instruments (Effect of Risk-Management Instruments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFairValueofFinancialInstrumentsDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails">
        <link:definition>2425413 - Disclosure - Financial Instruments (Fair Value of Financial Instruments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsRiskManagementInstrumentsDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails">
        <link:definition>2426414 - Disclosure - Financial Instruments (Risk Management Instruments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsContractualMaturitiesDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails">
        <link:definition>2427415 - Disclosure - Financial Instruments (Contractual Maturities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsUnrealizedGainsandLossesDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails">
        <link:definition>2428416 - Disclosure - Financial Instruments (Unrealized Gains and Losses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsRealizedGainsandLossesDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails">
        <link:definition>2429417 - Disclosure - Financial Instruments (Realized Gains and Losses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.lilly.com/role/IncomeTaxes">
        <link:definition>2130107 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.lilly.com/role/IncomeTaxesDetails">
        <link:definition>2431418 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefits" roleURI="http://www.lilly.com/role/RetirementBenefits">
        <link:definition>2132108 - Disclosure - Retirement Benefits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitsTables" roleURI="http://www.lilly.com/role/RetirementBenefitsTables">
        <link:definition>2333306 - Disclosure - Retirement Benefits (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails" roleURI="http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails">
        <link:definition>2434419 - Disclosure - Retirement Benefits (Components of Net Periodic Benefit Cost) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitsNarrativeDetails" roleURI="http://www.lilly.com/role/RetirementBenefitsNarrativeDetails">
        <link:definition>2435420 - Disclosure - Retirement Benefits (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contingencies" roleURI="http://www.lilly.com/role/Contingencies">
        <link:definition>2136109 - Disclosure - Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesDetails" roleURI="http://www.lilly.com/role/ContingenciesDetails">
        <link:definition>2437421 - Disclosure - Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLoss" roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLoss">
        <link:definition>2138110 - Disclosure - Other Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossTables" roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossTables">
        <link:definition>2339307 - Disclosure - Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossAOCIDetails" roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails">
        <link:definition>2440422 - Disclosure - Other Comprehensive Income (Loss) (AOCI) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossTaxEffectDetails" roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails">
        <link:definition>2441423 - Disclosure - Other Comprehensive Income (Loss) (Tax Effect) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossReclassificationDetails" roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails">
        <link:definition>2442424 - Disclosure - Other Comprehensive Income (Loss) (Reclassification) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNetIncomeExpense" roleURI="http://www.lilly.com/role/OtherNetIncomeExpense">
        <link:definition>2143111 - Disclosure - Other&#8211;Net, (Income) Expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNetIncomeExpenseTables" roleURI="http://www.lilly.com/role/OtherNetIncomeExpenseTables">
        <link:definition>2344308 - Disclosure - Other&#8211;Net, (Income) Expense (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNetIncomeExpenseDetails" roleURI="http://www.lilly.com/role/OtherNetIncomeExpenseDetails">
        <link:definition>2445425 - Disclosure - Other&#8211;Net, (Income) Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="lly_EmployeeLitigationMember" abstract="true" name="EmployeeLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_DiabetesMember" abstract="true" name="DiabetesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_CostOfSalesOperatingExpensesAndOtherNet" abstract="false" name="CostOfSalesOperatingExpensesAndOtherNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_CymbaltaMember" abstract="true" name="CymbaltaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_BuyEuroSellUsDollarMember" abstract="true" name="BuyEuroSellUsDollarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_PrecisionBiosciencesIncMember" abstract="true" name="PrecisionBiosciencesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_DrReddysLabMember" abstract="true" name="DrReddysLabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold" abstract="false" name="CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_InnoventBiologicsIncMember" abstract="true" name="InnoventBiologicsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_ActosMember" abstract="true" name="ActosMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember" abstract="true" name="MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_ErbituxMember" abstract="true" name="ErbituxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_PancreaticCancerOrThyroidCancerMember" abstract="true" name="PancreaticCancerOrThyroidCancerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_TanezumabMember" abstract="true" name="TanezumabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_DomicileOfLitigationDomain" abstract="true" name="DomicileOfLitigationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_OtherEquitySecuritiesMember" abstract="true" name="OtherEquitySecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A6.77NotesDueJanuary12036Member" abstract="true" name="A6.77NotesDueJanuary12036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A1.000NotesDueJune22022Member" abstract="true" name="A1.000NotesDueJune22022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_EquityMethodAndOtherInvestmentsMember" abstract="true" name="EquityMethodAndOtherInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_EmgalityMember" abstract="true" name="EmgalityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_BuyUsDollarSellEuroMember" abstract="true" name="BuyUsDollarSellEuroMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_CollaborativeArrangementRightsAndObligationsRightsObligations" abstract="false" name="CollaborativeArrangementRightsAndObligationsRightsObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" abstract="false" name="BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lly_PlaintiffAllegationsAxis" abstract="true" name="PlaintiffAllegationsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="lly_ForeignCurrencyDenominatedDebtMember" abstract="true" name="ForeignCurrencyDenominatedDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A718NotesDueJune12025Member" abstract="true" name="A718NotesDueJune12025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_AcquiredInProcessResearchAndDevelopment" abstract="false" name="AcquiredInProcessResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_BasaglarMember" abstract="true" name="BasaglarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_ZyprexaMember" abstract="true" name="ZyprexaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" abstract="false" name="AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_AlimtaMember" abstract="true" name="AlimtaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_ForteoMember" abstract="true" name="ForteoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" abstract="false" name="DebtSecuritiesAvailableforsaleUnrealizedGainPosition" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_BuyBritishPoundandSellUSDollarsMember" abstract="true" name="BuyBritishPoundandSellUSDollarsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" abstract="false" name="LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" abstract="false" name="AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_NonCHINAMember" abstract="true" name="NonCHINAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A2.125NotesDueJune32030Member" abstract="true" name="A2.125NotesDueJune32030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_LossContingencyNumberOfRequestsForInformation" abstract="false" name="LossContingencyNumberOfRequestsForInformation" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lly_OutsideUSAndJapanMember" abstract="true" name="OutsideUSAndJapanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_LossContingencyNumberOfPatents" abstract="false" name="LossContingencyNumberOfPatents" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" abstract="false" name="ProceedsfromSaleofEquityandAvailableforSaleSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_DermiraInc.Member" abstract="true" name="DermiraInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_A625Notesdue2031Member" abstract="true" name="A625Notesdue2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_SitryxTherapeuticsLimitedMember" abstract="true" name="SitryxTherapeuticsLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_DescriptionOfDerivativeActivityVolumePercent" abstract="false" name="DescriptionOfDerivativeActivityVolumePercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lly_PaymentforPensionBenefitsAdditionalDiscretionaryFunding" abstract="false" name="PaymentforPensionBenefitsAdditionalDiscretionaryFunding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember" abstract="true" name="CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_OtherImmunologyMember" abstract="true" name="OtherImmunologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_AsahiKaseiPharmaCorporationMember" abstract="true" name="AsahiKaseiPharmaCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_CyramzaMember" abstract="true" name="CyramzaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_BuyUSdollarSellJapaneseYenMember" abstract="true" name="BuyUSdollarSellJapaneseYenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_MilestonePaymentsSalesBasedMember" abstract="true" name="MilestonePaymentsSalesBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_OtherForeignCountriesMember" abstract="true" name="OtherForeignCountriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" abstract="false" name="BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember" abstract="true" name="MilestonePaymentsCapitalizedAsIntangibleAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_OtherProductMember" abstract="true" name="OtherProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_HumulinMember" abstract="true" name="HumulinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_LossContingencyNumberOfPatentsRuledUnpatentable" abstract="false" name="LossContingencyNumberOfPatentsRuledUnpatentable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lly_JunshiBiosciencesMember" abstract="true" name="JunshiBiosciencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_OncologyMember" abstract="true" name="OncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_OtherProductTotalMember" abstract="true" name="OtherProductTotalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_TaltzMember" abstract="true" name="TaltzMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_PurchasedInProcessResearchAndDevelopment" abstract="false" name="PurchasedInProcessResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_PancreatitisMember" abstract="true" name="PancreatitisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_HumalogMember" abstract="true" name="HumalogMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_COVID19AntibodiesMember" abstract="true" name="COVID19AntibodiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_OtherNeuroscienceMember" abstract="true" name="OtherNeuroscienceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_OtherOncologyMember" abstract="true" name="OtherOncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_MilestonePaymentsDevelopmentAndRegulatoryMember" abstract="true" name="MilestonePaymentsDevelopmentAndRegulatoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_RocheMember" abstract="true" name="RocheMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_SouthernDistrictOfCaliforniaMember" abstract="true" name="SouthernDistrictOfCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_LossContingencyNumberOfClaimants" abstract="false" name="LossContingencyNumberOfClaimants" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lly_ByettaMember" abstract="true" name="ByettaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_LosAngelesMember" abstract="true" name="LosAngelesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm" abstract="false" name="LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lly_AmpullaryCancerMember" abstract="true" name="AmpullaryCancerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_LossContingencyNumberOfPatentsClaimsDismissed" abstract="false" name="LossContingencyNumberOfPatentsClaimsDismissed" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lly_DerivativeInstrumentsGainLossRecognized" abstract="false" name="DerivativeInstrumentsGainLossRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_FairValueHedgeAbstract" abstract="true" name="FairValueHedgeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" abstract="false" name="RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lly_PrevailTherapeuticsIncMember" abstract="true" name="PrevailTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_CashFlowHedgeAbstract" abstract="true" name="CashFlowHedgeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lly_SalesRebatesAndDiscounts" abstract="false" name="SalesRebatesAndDiscounts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_A1.625NotesDueJune22026Member" abstract="true" name="A1.625NotesDueJune22026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_MerusNVMember" abstract="true" name="MerusNVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_OlumiantMember" abstract="true" name="OlumiantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" abstract="false" name="FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lly_MilestonePaymentsSuccessBasedRegulatoryMember" abstract="true" name="MilestonePaymentsSuccessBasedRegulatoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_VerzenioMember" abstract="true" name="VerzenioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" abstract="false" name="BusinessAcquisitionContingentValueRightAdditionalPricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="lly_SwapU.S.DollarsToEuroMember" abstract="true" name="SwapU.S.DollarsToEuroMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_OtherDiabetesMember" abstract="true" name="OtherDiabetesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_PlaintiffAllegationsDomain" abstract="true" name="PlaintiffAllegationsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_HedgedFixedRateDebtMember" abstract="true" name="HedgedFixedRateDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_MarketableSecuritiesMember" abstract="true" name="MarketableSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_TrulicityMemberMember" abstract="true" name="TrulicityMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_TrajentaBIMember" abstract="true" name="TrajentaBIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_HumalogHumulinAndForteoMember" abstract="true" name="HumalogHumulinAndForteoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_VariousStateDomicilesMember" abstract="true" name="VariousStateDomicilesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" abstract="true" name="AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_ImmunologyMember" abstract="true" name="ImmunologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" abstract="false" name="AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_NeuroscienceMember" abstract="true" name="NeuroscienceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_TYVYTMember" abstract="true" name="TYVYTMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_CialisMember" abstract="true" name="CialisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_LebrikizumabMember" abstract="true" name="LebrikizumabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_EppVTakedaCanadaIncEtAlMember" abstract="true" name="EppVTakedaCanadaIncEtAlMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_CollaborativeArrangementRightsAndObligationsPercent" abstract="false" name="CollaborativeArrangementRightsAndObligationsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lly_WeilerVTakedaCanadaIncEtAlMember" abstract="true" name="WeilerVTakedaCanadaIncEtAlMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_JardianceMember" abstract="true" name="JardianceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_EmgalityPatentLitigationMember" abstract="true" name="EmgalityPatentLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_CollaborationandOtherRevenueMember" abstract="true" name="CollaborationandOtherRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_SwapSwissFrancsToU.S.DollarsMember" abstract="true" name="SwapSwissFrancsToU.S.DollarsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_WhyteEtAlVEliLillyEtAlMember" abstract="true" name="WhyteEtAlVEliLillyEtAlMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A1.700Notesdue2049Member" abstract="true" name="A1.700Notesdue2049Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" abstract="true" name="MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_AbCelleraBiologicsInc.Member" abstract="true" name="AbCelleraBiologicsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_RigelPharmaceuticalsIncMember" abstract="true" name="RigelPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_ProductLiabilityMember" abstract="true" name="ProductLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_DomicileOfLitigationAxis" abstract="true" name="DomicileOfLitigationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>lly-20210331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:e048f7a3-28f3-4092-a916-bde5dfced0f0,g:3190a302-79f3-4ce3-a4d9-ac703a7bb0fb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lilly.com/role/CoverPage" xlink:type="simple" xlink:href="lly-20210331.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations" xlink:type="simple" xlink:href="lly-20210331.xsd#ConsolidatedCondensedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_bc3fdb7a-ae30-4503-b74c-57f119ec44f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_579027d1-8b23-49d0-8623-46ae75f46404" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_bc3fdb7a-ae30-4503-b74c-57f119ec44f0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_579027d1-8b23-49d0-8623-46ae75f46404" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a4fe9ca3-0d3d-4fe9-a631-9613a25e5db9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_bc3fdb7a-ae30-4503-b74c-57f119ec44f0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a4fe9ca3-0d3d-4fe9-a631-9613a25e5db9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a2144206-4953-4775-8b6c-e9edc125f0e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_324a9710-42d9-4912-896f-8be49852e2d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a2144206-4953-4775-8b6c-e9edc125f0e6" xlink:to="loc_us-gaap_Revenues_324a9710-42d9-4912-896f-8be49852e2d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_937c0ef8-df6c-416b-867f-0468f5147fb9" xlink:href="lly-20210331.xsd#lly_CostOfSalesOperatingExpensesAndOtherNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a2144206-4953-4775-8b6c-e9edc125f0e6" xlink:to="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_937c0ef8-df6c-416b-867f-0468f5147fb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_fda03868-c024-496b-9533-c760223df97c" xlink:href="lly-20210331.xsd#lly_CostOfSalesOperatingExpensesAndOtherNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_fdb91e8f-7d29-4a83-92f6-34bb44a34b04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_fda03868-c024-496b-9533-c760223df97c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_fdb91e8f-7d29-4a83-92f6-34bb44a34b04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0e4a6d59-38c5-43fc-bde7-9cf407dbe42e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_fda03868-c024-496b-9533-c760223df97c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0e4a6d59-38c5-43fc-bde7-9cf407dbe42e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_084ccd5c-b628-4227-ad0c-d91044f1f2f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_fda03868-c024-496b-9533-c760223df97c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_084ccd5c-b628-4227-ad0c-d91044f1f2f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopment_a39faff2-7c84-4be2-94c0-4a510e36a407" xlink:href="lly-20210331.xsd#lly_AcquiredInProcessResearchAndDevelopment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_fda03868-c024-496b-9533-c760223df97c" xlink:to="loc_lly_AcquiredInProcessResearchAndDevelopment_a39faff2-7c84-4be2-94c0-4a510e36a407" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_08bf651d-e8a6-4a58-9ece-b553ccaed574" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringSettlementAndImpairmentProvisions"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_fda03868-c024-496b-9533-c760223df97c" xlink:to="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_08bf651d-e8a6-4a58-9ece-b553ccaed574" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_2b3efae7-0ca6-4131-8154-ddb43b3dece7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_fda03868-c024-496b-9533-c760223df97c" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_2b3efae7-0ca6-4131-8154-ddb43b3dece7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="lly-20210331.xsd#ConsolidatedCondensedStatementsofComprehensiveIncomeLoss"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_35ac326a-d0fa-477e-bd2a-c8ba7b2d73ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b46b343b-6995-4efb-a198-127078d6b527" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_35ac326a-d0fa-477e-bd2a-c8ba7b2d73ab" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b46b343b-6995-4efb-a198-127078d6b527" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_074dbc67-25fa-4949-a53e-fd05accf7d18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_35ac326a-d0fa-477e-bd2a-c8ba7b2d73ab" xlink:to="loc_us-gaap_ProfitLoss_074dbc67-25fa-4949-a53e-fd05accf7d18" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets" xlink:type="simple" xlink:href="lly-20210331.xsd#ConsolidatedCondensedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f259c568-a243-47fd-98db-636298a0a88c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1cab8a7e-fdec-42ba-99ae-d90a0b337cf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f259c568-a243-47fd-98db-636298a0a88c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1cab8a7e-fdec-42ba-99ae-d90a0b337cf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_fbad86f8-33aa-4d7c-9602-a75297c95e49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f259c568-a243-47fd-98db-636298a0a88c" xlink:to="loc_us-gaap_ShortTermInvestments_fbad86f8-33aa-4d7c-9602-a75297c95e49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8d6172b4-2a90-4673-a0aa-b3dc51d41e27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f259c568-a243-47fd-98db-636298a0a88c" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8d6172b4-2a90-4673-a0aa-b3dc51d41e27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_17881587-c575-4769-9540-3efdbdac4c78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f259c568-a243-47fd-98db-636298a0a88c" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_17881587-c575-4769-9540-3efdbdac4c78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_f2b5b229-e184-4e9f-8970-f854d08891a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f259c568-a243-47fd-98db-636298a0a88c" xlink:to="loc_us-gaap_InventoryNet_f2b5b229-e184-4e9f-8970-f854d08891a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_430aea45-9194-413b-b928-74b6762f5292" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f259c568-a243-47fd-98db-636298a0a88c" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_430aea45-9194-413b-b928-74b6762f5292" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e7aa5e68-7b26-4265-aeeb-22103e0d097d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a30c40f9-f656-4b0b-a709-37dd85e95f71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e7aa5e68-7b26-4265-aeeb-22103e0d097d" xlink:to="loc_us-gaap_StockholdersEquity_a30c40f9-f656-4b0b-a709-37dd85e95f71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_d3707b95-e106-45a0-bc84-7f128519c136" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e7aa5e68-7b26-4265-aeeb-22103e0d097d" xlink:to="loc_us-gaap_MinorityInterest_d3707b95-e106-45a0-bc84-7f128519c136" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ff1e12ad-e372-4e91-be85-69eb25bf98d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_fcce46c4-e884-49ee-a2cf-042706aaff7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ff1e12ad-e372-4e91-be85-69eb25bf98d5" xlink:to="loc_us-gaap_CommonStockValue_fcce46c4-e884-49ee-a2cf-042706aaff7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_4a5a0f09-0177-41ff-843d-b1192fba2982" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ff1e12ad-e372-4e91-be85-69eb25bf98d5" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_4a5a0f09-0177-41ff-843d-b1192fba2982" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9fe33a80-2699-41d5-bb87-10448c044d82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ff1e12ad-e372-4e91-be85-69eb25bf98d5" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9fe33a80-2699-41d5-bb87-10448c044d82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_dd9b25f9-61e5-440b-adc9-288c7102c0a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesHeldInEmployeeTrust"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ff1e12ad-e372-4e91-be85-69eb25bf98d5" xlink:to="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_dd9b25f9-61e5-440b-adc9-288c7102c0a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_cd499015-3f77-4e85-b1a2-3f4df5bfd0cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ff1e12ad-e372-4e91-be85-69eb25bf98d5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_cd499015-3f77-4e85-b1a2-3f4df5bfd0cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_83dfd3aa-6782-4150-af4b-fc5b953530c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ff1e12ad-e372-4e91-be85-69eb25bf98d5" xlink:to="loc_us-gaap_TreasuryStockValue_83dfd3aa-6782-4150-af4b-fc5b953530c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_33e6f5a8-e67e-4731-89d1-140d70173548" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_3d243bf1-b9ce-4bcb-aba8-3b6bed8339dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_33e6f5a8-e67e-4731-89d1-140d70173548" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_3d243bf1-b9ce-4bcb-aba8-3b6bed8339dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_48a7184f-13c2-4c9a-8fab-2a855758e968" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_33e6f5a8-e67e-4731-89d1-140d70173548" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_48a7184f-13c2-4c9a-8fab-2a855758e968" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_a53319e2-0336-4758-bae6-52ce80422fbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_33e6f5a8-e67e-4731-89d1-140d70173548" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_a53319e2-0336-4758-bae6-52ce80422fbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_d8fda233-6296-4967-b396-bdf085de65f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_33e6f5a8-e67e-4731-89d1-140d70173548" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_d8fda233-6296-4967-b396-bdf085de65f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_163c5144-05b1-4715-849b-6875162e2a76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_33e6f5a8-e67e-4731-89d1-140d70173548" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_163c5144-05b1-4715-849b-6875162e2a76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_5730d2c0-94e8-4045-89fa-cc92bb227251" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_36c2b861-f0ea-477c-9eed-e45934c70c99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5730d2c0-94e8-4045-89fa-cc92bb227251" xlink:to="loc_us-gaap_LiabilitiesCurrent_36c2b861-f0ea-477c-9eed-e45934c70c99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_67771c08-ac6b-4e02-9442-84b4a2d9e4b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5730d2c0-94e8-4045-89fa-cc92bb227251" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_67771c08-ac6b-4e02-9442-84b4a2d9e4b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cf7920f4-00b5-42fa-9016-915726e05c9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5730d2c0-94e8-4045-89fa-cc92bb227251" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cf7920f4-00b5-42fa-9016-915726e05c9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f9b331d0-a16d-4a39-8220-37654ed91454" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5730d2c0-94e8-4045-89fa-cc92bb227251" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f9b331d0-a16d-4a39-8220-37654ed91454" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3a803baf-d07e-40b9-93c2-b0478d7d63b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4df0ae95-ad25-4d83-8069-afe485bf778d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3a803baf-d07e-40b9-93c2-b0478d7d63b1" xlink:to="loc_us-gaap_AssetsCurrent_4df0ae95-ad25-4d83-8069-afe485bf778d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_579a69dc-15bd-4d7f-984f-951e705de63c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3a803baf-d07e-40b9-93c2-b0478d7d63b1" xlink:to="loc_us-gaap_LongTermInvestments_579a69dc-15bd-4d7f-984f-951e705de63c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_540565ea-534f-403f-9c28-25a7b193bf5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3a803baf-d07e-40b9-93c2-b0478d7d63b1" xlink:to="loc_us-gaap_Goodwill_540565ea-534f-403f-9c28-25a7b193bf5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_35faf57e-1eea-45e6-ac26-e50c0bb80d88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3a803baf-d07e-40b9-93c2-b0478d7d63b1" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_35faf57e-1eea-45e6-ac26-e50c0bb80d88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_eaef4106-7219-4b43-b65e-48050d076e10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3a803baf-d07e-40b9-93c2-b0478d7d63b1" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_eaef4106-7219-4b43-b65e-48050d076e10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_4ce97e7a-5492-4a28-9d1a-276166d01d30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3a803baf-d07e-40b9-93c2-b0478d7d63b1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_4ce97e7a-5492-4a28-9d1a-276166d01d30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b64afbad-37c8-43b9-a0f5-768ce40a9618" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3a803baf-d07e-40b9-93c2-b0478d7d63b1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b64afbad-37c8-43b9-a0f5-768ce40a9618" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_025e5dad-9774-4aa5-8bff-ed90cc362e92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_8d192240-602a-41c6-bd90-7cd6aec7b0d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_025e5dad-9774-4aa5-8bff-ed90cc362e92" xlink:to="loc_us-gaap_AccountsPayableCurrent_8d192240-602a-41c6-bd90-7cd6aec7b0d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e5d43686-1662-42a6-9531-dee55e30188b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_025e5dad-9774-4aa5-8bff-ed90cc362e92" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e5d43686-1662-42a6-9531-dee55e30188b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SalesRebatesAndDiscounts_2dda4fc8-d43b-4866-aecb-deb01a3bf505" xlink:href="lly-20210331.xsd#lly_SalesRebatesAndDiscounts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_025e5dad-9774-4aa5-8bff-ed90cc362e92" xlink:to="loc_lly_SalesRebatesAndDiscounts_2dda4fc8-d43b-4866-aecb-deb01a3bf505" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_7a185d21-e8a0-4b72-8e18-25992df0223b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_025e5dad-9774-4aa5-8bff-ed90cc362e92" xlink:to="loc_us-gaap_DividendsPayableCurrent_7a185d21-e8a0-4b72-8e18-25992df0223b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_95507190-fcbf-4260-8a3e-db61d9d138d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_025e5dad-9774-4aa5-8bff-ed90cc362e92" xlink:to="loc_us-gaap_TaxesPayableCurrent_95507190-fcbf-4260-8a3e-db61d9d138d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_9bef984c-12b0-474a-a069-ea6711230fb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_025e5dad-9774-4aa5-8bff-ed90cc362e92" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_9bef984c-12b0-474a-a069-ea6711230fb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_f7d04bbf-b7fa-46d9-ad89-9b7eb85c715f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_025e5dad-9774-4aa5-8bff-ed90cc362e92" xlink:to="loc_us-gaap_DebtCurrent_f7d04bbf-b7fa-46d9-ad89-9b7eb85c715f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="lly-20210331.xsd#ConsolidatedCondensedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity" xlink:type="simple" xlink:href="lly-20210331.xsd#ConsolidatedCondensedStatementsofEquity"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquityParenthetical" xlink:type="simple" xlink:href="lly-20210331.xsd#ConsolidatedCondensedStatementsofEquityParenthetical"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquityParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows" xlink:type="simple" xlink:href="lly-20210331.xsd#ConsolidatedCondensedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0dec387f-6938-4bb7-ba49-e1b70b194be5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_77b8669c-e561-493f-bce3-7e404a0e4691" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0dec387f-6938-4bb7-ba49-e1b70b194be5" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_77b8669c-e561-493f-bce3-7e404a0e4691" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8517941d-0a62-4dbc-ac37-67cc5522b9db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0dec387f-6938-4bb7-ba49-e1b70b194be5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8517941d-0a62-4dbc-ac37-67cc5522b9db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bfe9aea5-96b0-4767-9989-703a2d9499b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0dec387f-6938-4bb7-ba49-e1b70b194be5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bfe9aea5-96b0-4767-9989-703a2d9499b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b8b802d6-d659-47fe-bbdc-e13d34a4f536" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0dec387f-6938-4bb7-ba49-e1b70b194be5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b8b802d6-d659-47fe-bbdc-e13d34a4f536" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_108260c7-5cdd-4f4c-b725-9132c1c82e73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_0e6a9ef1-51ac-43ba-a5e9-e97ea74337d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_108260c7-5cdd-4f4c-b725-9132c1c82e73" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_0e6a9ef1-51ac-43ba-a5e9-e97ea74337d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_1a1a3f60-6279-4b45-8853-de025e1bfb0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_108260c7-5cdd-4f4c-b725-9132c1c82e73" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_1a1a3f60-6279-4b45-8853-de025e1bfb0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfLongtermInvestments_d11af64c-b65f-461b-80fe-0f3d7a4feeef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfLongtermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_108260c7-5cdd-4f4c-b725-9132c1c82e73" xlink:to="loc_us-gaap_ProceedsFromSaleOfLongtermInvestments_d11af64c-b65f-461b-80fe-0f3d7a4feeef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_97d07347-b581-4938-88ee-1031ad26fafa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_108260c7-5cdd-4f4c-b725-9132c1c82e73" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_97d07347-b581-4938-88ee-1031ad26fafa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments_07b6ea73-2703-4259-9b60-94ca05b69962" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_108260c7-5cdd-4f4c-b725-9132c1c82e73" xlink:to="loc_us-gaap_PaymentsToAcquireLongtermInvestments_07b6ea73-2703-4259-9b60-94ca05b69962" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PurchasedInProcessResearchAndDevelopment_1dcd1308-b75e-4ca3-a297-32ffda29e854" xlink:href="lly-20210331.xsd#lly_PurchasedInProcessResearchAndDevelopment"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_108260c7-5cdd-4f4c-b725-9132c1c82e73" xlink:to="loc_lly_PurchasedInProcessResearchAndDevelopment_1dcd1308-b75e-4ca3-a297-32ffda29e854" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_a1b1f21a-c2f8-48d7-9884-afe3cdf22cf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_108260c7-5cdd-4f4c-b725-9132c1c82e73" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_a1b1f21a-c2f8-48d7-9884-afe3cdf22cf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_206201e5-2eb5-4985-b536-efa12b331bc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_108260c7-5cdd-4f4c-b725-9132c1c82e73" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_206201e5-2eb5-4985-b536-efa12b331bc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_53aa7925-f6e2-480f-802e-3d46556088b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_eaca9bab-1e9d-463e-964b-936c86fa564f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_53aa7925-f6e2-480f-802e-3d46556088b8" xlink:to="loc_us-gaap_PaymentsOfDividends_eaca9bab-1e9d-463e-964b-936c86fa564f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_27528ca6-07be-42ac-b11a-6e46c7bf7a95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_53aa7925-f6e2-480f-802e-3d46556088b8" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_27528ca6-07be-42ac-b11a-6e46c7bf7a95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_e3630ae3-91e4-461c-9c95-97970ee97c81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_53aa7925-f6e2-480f-802e-3d46556088b8" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_e3630ae3-91e4-461c-9c95-97970ee97c81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_5cb04c9f-880e-408f-a92b-3524bc7aa57d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_53aa7925-f6e2-480f-802e-3d46556088b8" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_5cb04c9f-880e-408f-a92b-3524bc7aa57d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_9fb21f87-297a-4b7f-ae78-75353503a961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_53aa7925-f6e2-480f-802e-3d46556088b8" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_9fb21f87-297a-4b7f-ae78-75353503a961" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_1542587b-5f35-4b8f-a51d-ab03534e038b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_53aa7925-f6e2-480f-802e-3d46556088b8" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_1542587b-5f35-4b8f-a51d-ab03534e038b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8ebd2e37-1895-4e65-8b71-999086961753" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_796f786d-98ef-4a99-9988-7f5af9e74f85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8ebd2e37-1895-4e65-8b71-999086961753" xlink:to="loc_us-gaap_NetIncomeLoss_796f786d-98ef-4a99-9988-7f5af9e74f85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_c353b226-f2a3-4fe8-b5e2-718bf94f80c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8ebd2e37-1895-4e65-8b71-999086961753" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_c353b226-f2a3-4fe8-b5e2-718bf94f80c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_2bfbbcd6-f089-4ce0-9973-00d56e8c63f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8ebd2e37-1895-4e65-8b71-999086961753" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_2bfbbcd6-f089-4ce0-9973-00d56e8c63f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_9353d83c-d1eb-460a-8d18-0f9374724dd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8ebd2e37-1895-4e65-8b71-999086961753" xlink:to="loc_us-gaap_ShareBasedCompensation_9353d83c-d1eb-460a-8d18-0f9374724dd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopment_8813b3c8-5a7c-4590-82d7-7ce4d2dcb421" xlink:href="lly-20210331.xsd#lly_AcquiredInProcessResearchAndDevelopment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8ebd2e37-1895-4e65-8b71-999086961753" xlink:to="loc_lly_AcquiredInProcessResearchAndDevelopment_8813b3c8-5a7c-4590-82d7-7ce4d2dcb421" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_92fb6eed-b14a-49fc-b632-1f3d116f01d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8ebd2e37-1895-4e65-8b71-999086961753" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_92fb6eed-b14a-49fc-b632-1f3d116f01d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_89844239-509a-4452-be30-e1ea7f2e55b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8ebd2e37-1895-4e65-8b71-999086961753" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_89844239-509a-4452-be30-e1ea7f2e55b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_17e62401-28a3-4988-beca-90203c23c3c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8ebd2e37-1895-4e65-8b71-999086961753" xlink:to="loc_us-gaap_GainLossOnInvestments_17e62401-28a3-4988-beca-90203c23c3c8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BasisofPresentation" xlink:type="simple" xlink:href="lly-20210331.xsd#BasisofPresentation"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/BasisofPresentation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/BasisofPresentationPolicies" xlink:type="simple" xlink:href="lly-20210331.xsd#BasisofPresentationPolicies"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/BasisofPresentationPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/Revenue" xlink:type="simple" xlink:href="lly-20210331.xsd#Revenue"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/Revenue" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueTables" xlink:type="simple" xlink:href="lly-20210331.xsd#RevenueTables"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/RevenueTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#RevenueSummaryofRevenueRecognizedDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#RevenueAdjustmentstoRevenueDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueContractLiabilitiesDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#RevenueContractLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/RevenueContractLiabilitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#RevenueDisaggregationofRevenuebyProductDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#RevenueDisaggregationofRevenuebyGeographicalAreaDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/Acquisitions" xlink:type="simple" xlink:href="lly-20210331.xsd#Acquisitions"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/Acquisitions" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsTables" xlink:type="simple" xlink:href="lly-20210331.xsd#AcquisitionsTables"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/AcquisitionsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#AcquisitionsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/AcquisitionsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2441d8f3-301b-4b4c-8fad-9b836eb3672d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_456427f3-07cd-4458-b822-d6bb2b38064c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2441d8f3-301b-4b4c-8fad-9b836eb3672d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_456427f3-07cd-4458-b822-d6bb2b38064c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_486064d9-8bce-47ff-b310-c91403ac5196" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2441d8f3-301b-4b4c-8fad-9b836eb3672d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_486064d9-8bce-47ff-b310-c91403ac5196" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_5b0e1bfe-9763-4aa5-ab51-0b52ae68ddfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2441d8f3-301b-4b4c-8fad-9b836eb3672d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_5b0e1bfe-9763-4aa5-ab51-0b52ae68ddfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_4f3b2e84-09b2-4904-bcbe-a281fa22b452" xlink:href="lly-20210331.xsd#lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2441d8f3-301b-4b4c-8fad-9b836eb3672d" xlink:to="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_4f3b2e84-09b2-4904-bcbe-a281fa22b452" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a01b8340-7ea3-4610-ae60-266cf325fcfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2441d8f3-301b-4b4c-8fad-9b836eb3672d" xlink:to="loc_us-gaap_Goodwill_a01b8340-7ea3-4610-ae60-266cf325fcfe" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#AcquisitionsAssetAcquisitionsDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangements" xlink:type="simple" xlink:href="lly-20210331.xsd#CollaborationsandOtherArrangements"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsTables" xlink:type="simple" xlink:href="lly-20210331.xsd#CollaborationsandOtherArrangementsTables"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#CollaborationsandOtherArrangementsDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges" xlink:type="simple" xlink:href="lly-20210331.xsd#AssetImpairmentRestructuringandOtherSpecialCharges"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables" xlink:type="simple" xlink:href="lly-20210331.xsd#AssetImpairmentRestructuringandOtherSpecialChargesTables"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#AssetImpairmentRestructuringandOtherSpecialChargesDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_c355fa17-5e2e-4b65-8e19-c944d20843b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringSettlementAndImpairmentProvisions"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_4ec49cf8-91c4-4ba1-87d0-bcd5c102a104" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_c355fa17-5e2e-4b65-8e19-c944d20843b9" xlink:to="loc_us-gaap_SeveranceCosts1_4ec49cf8-91c4-4ba1-87d0-bcd5c102a104" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_e126abd5-7f24-47a3-917f-5dc40fda609e" xlink:href="lly-20210331.xsd#lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_c355fa17-5e2e-4b65-8e19-c944d20843b9" xlink:to="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_e126abd5-7f24-47a3-917f-5dc40fda609e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstruments" xlink:type="simple" xlink:href="lly-20210331.xsd#FinancialInstruments"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/FinancialInstruments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="lly-20210331.xsd#FinancialInstrumentsTables"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#FinancialInstrumentsEffectofRiskManagementInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lly_DerivativeInstrumentsGainLossRecognized_58329fb6-053e-4cf8-969c-e223e9079843" xlink:href="lly-20210331.xsd#lly_DerivativeInstrumentsGainLossRecognized"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_fe56b227-53d4-4b6f-b69f-9b630eb4ce91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_DerivativeInstrumentsGainLossRecognized_58329fb6-053e-4cf8-969c-e223e9079843" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_fe56b227-53d4-4b6f-b69f-9b630eb4ce91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_4cb31a5e-55b5-4057-b4e3-0932c1a180fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_DerivativeInstrumentsGainLossRecognized_58329fb6-053e-4cf8-969c-e223e9079843" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_4cb31a5e-55b5-4057-b4e3-0932c1a180fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_bfa65e9a-f114-4bb7-a52e-cc6f58b71d79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_DerivativeInstrumentsGainLossRecognized_58329fb6-053e-4cf8-969c-e223e9079843" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_bfa65e9a-f114-4bb7-a52e-cc6f58b71d79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_580388b3-5dc6-4c45-91eb-fd66e0e4995d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_DerivativeInstrumentsGainLossRecognized_58329fb6-053e-4cf8-969c-e223e9079843" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_580388b3-5dc6-4c45-91eb-fd66e0e4995d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#FinancialInstrumentsFairValueofFinancialInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_f0354444-ee1f-4a7f-987b-24c1adfbdd33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_4d51c8f8-9718-4db6-9b3d-a5ee97398bb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_f0354444-ee1f-4a7f-987b-24c1adfbdd33" xlink:to="loc_us-gaap_OtherLongTermInvestments_4d51c8f8-9718-4db6-9b3d-a5ee97398bb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_46c5d1dc-d6d8-4f62-8ace-cd8b8e9708ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_f0354444-ee1f-4a7f-987b-24c1adfbdd33" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_46c5d1dc-d6d8-4f62-8ace-cd8b8e9708ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_aeeb8f12-cd35-4ef4-95d6-6411b2aedc1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_f0354444-ee1f-4a7f-987b-24c1adfbdd33" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_aeeb8f12-cd35-4ef4-95d6-6411b2aedc1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_e46a34d0-038c-464a-8396-3c7b017f1179" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_f0354444-ee1f-4a7f-987b-24c1adfbdd33" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_e46a34d0-038c-464a-8396-3c7b017f1179" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#FinancialInstrumentsRiskManagementInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#FinancialInstrumentsContractualMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_653da4e5-0910-42b0-90f8-6f0de4bb9d92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_9d262832-566a-4be9-99af-a92c2d974a43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_653da4e5-0910-42b0-90f8-6f0de4bb9d92" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_9d262832-566a-4be9-99af-a92c2d974a43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_97439e84-c491-4d02-b736-5ee5942d7374" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_653da4e5-0910-42b0-90f8-6f0de4bb9d92" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_97439e84-c491-4d02-b736-5ee5942d7374" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_39a10849-1d4a-40cd-a0fb-6416a90c8d3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_653da4e5-0910-42b0-90f8-6f0de4bb9d92" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_39a10849-1d4a-40cd-a0fb-6416a90c8d3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_889433a0-36e1-48b5-adbd-7f204a3abe97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_653da4e5-0910-42b0-90f8-6f0de4bb9d92" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_889433a0-36e1-48b5-adbd-7f204a3abe97" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#FinancialInstrumentsUnrealizedGainsandLossesDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#FinancialInstrumentsRealizedGainsandLossesDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxes" xlink:type="simple" xlink:href="lly-20210331.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#IncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/IncomeTaxesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefits" xlink:type="simple" xlink:href="lly-20210331.xsd#RetirementBenefits"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/RetirementBenefits" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsTables" xlink:type="simple" xlink:href="lly-20210331.xsd#RetirementBenefitsTables"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_78492a37-49a7-49b5-b5f3-95046840d249" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_5d60bb3f-a1c4-4e80-ad69-55aec0721a44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_78492a37-49a7-49b5-b5f3-95046840d249" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_5d60bb3f-a1c4-4e80-ad69-55aec0721a44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_c0e64160-cda3-414b-8978-79dc03cb7b5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_78492a37-49a7-49b5-b5f3-95046840d249" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_c0e64160-cda3-414b-8978-79dc03cb7b5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_bb97391d-a3a3-4c95-96f9-97d4d3e2566a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_78492a37-49a7-49b5-b5f3-95046840d249" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_bb97391d-a3a3-4c95-96f9-97d4d3e2566a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_f206c3d0-391f-4c66-9d36-d6ed95a886e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_78492a37-49a7-49b5-b5f3-95046840d249" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_f206c3d0-391f-4c66-9d36-d6ed95a886e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_1d1974bd-9f29-4053-a2d0-8fec95e8f97b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_78492a37-49a7-49b5-b5f3-95046840d249" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_1d1974bd-9f29-4053-a2d0-8fec95e8f97b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsNarrativeDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#RetirementBenefitsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/Contingencies" xlink:type="simple" xlink:href="lly-20210331.xsd#Contingencies"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/Contingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/ContingenciesDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#ContingenciesDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/ContingenciesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLoss" xlink:type="simple" xlink:href="lly-20210331.xsd#OtherComprehensiveIncomeLoss"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLoss" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="lly-20210331.xsd#OtherComprehensiveIncomeLossTables"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#OtherComprehensiveIncomeLossAOCIDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3af2e051-e3db-4878-a211-ac12883a0da5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_9d296616-12a5-4164-bbf5-1a13597de5bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3af2e051-e3db-4878-a211-ac12883a0da5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_9d296616-12a5-4164-bbf5-1a13597de5bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_4600a0d8-1dc6-4eed-9d90-ff36e5d54740" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3af2e051-e3db-4878-a211-ac12883a0da5" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_4600a0d8-1dc6-4eed-9d90-ff36e5d54740" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#OtherComprehensiveIncomeLossTaxEffectDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#OtherComprehensiveIncomeLossReclassificationDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherNetIncomeExpense" xlink:type="simple" xlink:href="lly-20210331.xsd#OtherNetIncomeExpense"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/OtherNetIncomeExpense" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherNetIncomeExpenseTables" xlink:type="simple" xlink:href="lly-20210331.xsd#OtherNetIncomeExpenseTables"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/OtherNetIncomeExpenseTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherNetIncomeExpenseDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#OtherNetIncomeExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/OtherNetIncomeExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d8c6ed7c-f756-4c9d-a329-587ebc455f51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_fbda99db-20dd-4f1e-9a93-105eedc2ac40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_d8c6ed7c-f756-4c9d-a329-587ebc455f51" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_fbda99db-20dd-4f1e-9a93-105eedc2ac40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_a03cac71-bfc7-49c0-9607-2c8665c0616d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_d8c6ed7c-f756-4c9d-a329-587ebc455f51" xlink:to="loc_us-gaap_InterestExpense_a03cac71-bfc7-49c0-9607-2c8665c0616d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_9d8b10ec-5d2f-434d-b52c-48c217cd5649" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_d8c6ed7c-f756-4c9d-a329-587ebc455f51" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_9d8b10ec-5d2f-434d-b52c-48c217cd5649" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_df3bab07-4282-45f6-b268-21eb8b97231f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_d8c6ed7c-f756-4c9d-a329-587ebc455f51" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_df3bab07-4282-45f6-b268-21eb8b97231f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_f356a7ec-13df-4462-8179-bcf5adfd9ceb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_d8c6ed7c-f756-4c9d-a329-587ebc455f51" xlink:to="loc_us-gaap_InvestmentIncomeInterest_f356a7ec-13df-4462-8179-bcf5adfd9ceb" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>lly-20210331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:e048f7a3-28f3-4092-a916-bde5dfced0f0,g:3190a302-79f3-4ce3-a4d9-ac703a7bb0fb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.lilly.com/role/CoverPage" xlink:type="simple" xlink:href="lly-20210331.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/CoverPage" xlink:type="extended" id="ie9ccb8c261954252b4642abc0bb35341_CoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_0134de50-8a86-4e3a-aa94-1773908cc338" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_DocumentQuarterlyReport_0134de50-8a86-4e3a-aa94-1773908cc338" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_addce232-c330-4302-8e92-ec14d043b84b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_DocumentTransitionReport_addce232-c330-4302-8e92-ec14d043b84b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_acb9f23f-aa75-40ce-93bb-188bb294872c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_AmendmentFlag_acb9f23f-aa75-40ce-93bb-188bb294872c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_6a9e69f5-aa46-450f-8082-12af2a63b384" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_DocumentFiscalYearFocus_6a9e69f5-aa46-450f-8082-12af2a63b384" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_e7adac5c-7644-4a1a-9484-2fec00193b5d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_DocumentFiscalPeriodFocus_e7adac5c-7644-4a1a-9484-2fec00193b5d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_e816e6e6-26df-463f-98e2-7737821f44f1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_EntityCentralIndexKey_e816e6e6-26df-463f-98e2-7737821f44f1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_b82c0a38-7b7b-4b6c-aa39-20f78f2c6665" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_CurrentFiscalYearEndDate_b82c0a38-7b7b-4b6c-aa39-20f78f2c6665" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_c42902da-c8d1-488a-b4d3-575bc6670222" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_DocumentType_c42902da-c8d1-488a-b4d3-575bc6670222" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_1cc30459-d5b2-480b-a5b6-f5e42a040f35" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_DocumentPeriodEndDate_1cc30459-d5b2-480b-a5b6-f5e42a040f35" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_46a64381-14ff-4ac8-9a34-1e2fd26cea5d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_EntityFileNumber_46a64381-14ff-4ac8-9a34-1e2fd26cea5d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_c4179197-0062-44ba-ba20-ed34ffe23386" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_EntityRegistrantName_c4179197-0062-44ba-ba20-ed34ffe23386" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_b93a4635-d913-493a-8c2a-adc08ecbf92e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_EntityIncorporationStateCountryCode_b93a4635-d913-493a-8c2a-adc08ecbf92e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_01042a1c-10a0-4862-84a7-91e273ac1b82" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_EntityTaxIdentificationNumber_01042a1c-10a0-4862-84a7-91e273ac1b82" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_bcddae94-266a-4be1-a35f-fa8bb2606f3f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_EntityAddressAddressLine1_bcddae94-266a-4be1-a35f-fa8bb2606f3f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_3dbf07f5-bb98-4e21-8c34-2a2da9583c8f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_EntityAddressCityOrTown_3dbf07f5-bb98-4e21-8c34-2a2da9583c8f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_7fadbc6b-0402-44fa-bff4-d16e9a099c13" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_EntityAddressStateOrProvince_7fadbc6b-0402-44fa-bff4-d16e9a099c13" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_9408b67b-b0ff-4735-917b-c3efeb70bc5a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_EntityAddressPostalZipCode_9408b67b-b0ff-4735-917b-c3efeb70bc5a" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_afbda0c8-7708-4ea5-8b09-6afdd3a566e8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_CityAreaCode_afbda0c8-7708-4ea5-8b09-6afdd3a566e8" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_0965c934-abc0-4266-a1c2-6e25cc01babe" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_LocalPhoneNumber_0965c934-abc0-4266-a1c2-6e25cc01babe" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_02fdddd5-7932-435f-9d69-f20283176542" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_Security12bTitle_02fdddd5-7932-435f-9d69-f20283176542" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_7eb3995f-99ce-4458-837a-43f52d8fc4ba" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_TradingSymbol_7eb3995f-99ce-4458-837a-43f52d8fc4ba" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_ae55ce4a-dc94-4cc6-b937-8a67cd27b9f6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_SecurityExchangeName_ae55ce4a-dc94-4cc6-b937-8a67cd27b9f6" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_8cae12b2-e941-41f2-87a9-670d9d0aa987" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_EntityCurrentReportingStatus_8cae12b2-e941-41f2-87a9-670d9d0aa987" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_57aa70aa-ce0a-43c2-b103-1fe9fbd36700" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_EntityInteractiveDataCurrent_57aa70aa-ce0a-43c2-b103-1fe9fbd36700" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_9b432ec8-c2d3-4500-84ab-393d08c518f9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_EntityFilerCategory_9b432ec8-c2d3-4500-84ab-393d08c518f9" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_1bd771ad-67ee-43de-ba4d-62a5c131c340" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_EntitySmallBusiness_1bd771ad-67ee-43de-ba4d-62a5c131c340" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_647ffb72-7996-458d-8487-a5fd0ec6954e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_EntityEmergingGrowthCompany_647ffb72-7996-458d-8487-a5fd0ec6954e" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_811ec157-42cb-4dbd-8d47-ec637c99e052" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_EntityShellCompany_811ec157-42cb-4dbd-8d47-ec637c99e052" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_6885c62b-a6a6-4a62-9669-61cb65f3d7ed" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_6885c62b-a6a6-4a62-9669-61cb65f3d7ed" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_ab5713ba-059a-4e54-812b-fe3439ab3b16" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_DocumentInformationTable_ab5713ba-059a-4e54-812b-fe3439ab3b16" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_380c98ef-905c-47c5-8b82-fb3ff44d1161" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_ab5713ba-059a-4e54-812b-fe3439ab3b16" xlink:to="loc_us-gaap_StatementClassOfStockAxis_380c98ef-905c-47c5-8b82-fb3ff44d1161" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_380c98ef-905c-47c5-8b82-fb3ff44d1161_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_380c98ef-905c-47c5-8b82-fb3ff44d1161" xlink:to="loc_us-gaap_ClassOfStockDomain_380c98ef-905c-47c5-8b82-fb3ff44d1161_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6a71c04a-6574-4260-84f2-3c90e8de8991" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_380c98ef-905c-47c5-8b82-fb3ff44d1161" xlink:to="loc_us-gaap_ClassOfStockDomain_6a71c04a-6574-4260-84f2-3c90e8de8991" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_a4067a16-f416-4cc1-9edc-56ef9d17e7df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6a71c04a-6574-4260-84f2-3c90e8de8991" xlink:to="loc_us-gaap_CommonClassAMember_a4067a16-f416-4cc1-9edc-56ef9d17e7df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.000NotesDueJune22022Member_b2821fe1-59ae-4507-9429-6b8c7a05c531" xlink:href="lly-20210331.xsd#lly_A1.000NotesDueJune22022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6a71c04a-6574-4260-84f2-3c90e8de8991" xlink:to="loc_lly_A1.000NotesDueJune22022Member_b2821fe1-59ae-4507-9429-6b8c7a05c531" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A718NotesDueJune12025Member_3bbadef4-cbc9-4e08-8f14-afdf7140c60c" xlink:href="lly-20210331.xsd#lly_A718NotesDueJune12025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6a71c04a-6574-4260-84f2-3c90e8de8991" xlink:to="loc_lly_A718NotesDueJune12025Member_3bbadef4-cbc9-4e08-8f14-afdf7140c60c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.625NotesDueJune22026Member_e80f68da-1687-411c-a4cd-4498bd8a6c5f" xlink:href="lly-20210331.xsd#lly_A1.625NotesDueJune22026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6a71c04a-6574-4260-84f2-3c90e8de8991" xlink:to="loc_lly_A1.625NotesDueJune22026Member_e80f68da-1687-411c-a4cd-4498bd8a6c5f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member_9d412fe2-07ba-4584-a0f3-7227cff62e82" xlink:href="lly-20210331.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6a71c04a-6574-4260-84f2-3c90e8de8991" xlink:to="loc_lly_A2.125NotesDueJune32030Member_9d412fe2-07ba-4584-a0f3-7227cff62e82" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625Notesdue2031Member_6acf675f-97fe-4260-ad98-e9a0ae3cf48d" xlink:href="lly-20210331.xsd#lly_A625Notesdue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6a71c04a-6574-4260-84f2-3c90e8de8991" xlink:to="loc_lly_A625Notesdue2031Member_6acf675f-97fe-4260-ad98-e9a0ae3cf48d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member_46287674-cb88-44bb-920b-f0639e36b4cd" xlink:href="lly-20210331.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6a71c04a-6574-4260-84f2-3c90e8de8991" xlink:to="loc_lly_A6.77NotesDueJanuary12036Member_46287674-cb88-44bb-920b-f0639e36b4cd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.700Notesdue2049Member_0c385aa7-77dc-4e84-a870-cdf5def50ee3" xlink:href="lly-20210331.xsd#lly_A1.700Notesdue2049Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6a71c04a-6574-4260-84f2-3c90e8de8991" xlink:to="loc_lly_A1.700Notesdue2049Member_0c385aa7-77dc-4e84-a870-cdf5def50ee3" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations" xlink:type="simple" xlink:href="lly-20210331.xsd#ConsolidatedCondensedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations" xlink:type="extended" id="ifb36deaa3f754ed2913a547dcf02397a_ConsolidatedCondensedStatementsofOperations"/>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="lly-20210331.xsd#ConsolidatedCondensedStatementsofComprehensiveIncomeLoss"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeLoss" xlink:type="extended" id="i5e997f7634b44b9492e16a52febbb964_ConsolidatedCondensedStatementsofComprehensiveIncomeLoss"/>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets" xlink:type="simple" xlink:href="lly-20210331.xsd#ConsolidatedCondensedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets" xlink:type="extended" id="idaf2c0b128d14d2cb3d1a98bfba378e4_ConsolidatedCondensedBalanceSheets"/>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="lly-20210331.xsd#ConsolidatedCondensedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedBalanceSheetsParenthetical" xlink:type="extended" id="ie5b473fb825f49a69b2cb205265a58e2_ConsolidatedCondensedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity" xlink:type="simple" xlink:href="lly-20210331.xsd#ConsolidatedCondensedStatementsofEquity"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity" xlink:type="extended" id="i95e85a016e7841ea8c0210551ba593a5_ConsolidatedCondensedStatementsofEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a63bce87-b81e-4c36-9e3f-cbbd590ab2ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3630b7cc-2492-4303-9578-6bfe5f059774" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a63bce87-b81e-4c36-9e3f-cbbd590ab2ed" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3630b7cc-2492-4303-9578-6bfe5f059774" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_cb477dfb-136f-4139-bec9-5c4f952c22c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3630b7cc-2492-4303-9578-6bfe5f059774" xlink:to="loc_us-gaap_SharesIssued_cb477dfb-136f-4139-bec9-5c4f952c22c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d1dfd154-ecda-4564-8c89-e46717193b7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3630b7cc-2492-4303-9578-6bfe5f059774" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d1dfd154-ecda-4564-8c89-e46717193b7c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e58113fd-9444-4f26-95d7-d8632f628367" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3630b7cc-2492-4303-9578-6bfe5f059774" xlink:to="loc_us-gaap_ProfitLoss_e58113fd-9444-4f26-95d7-d8632f628367" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0518ebd0-341a-498a-b583-b9f2c154dd5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3630b7cc-2492-4303-9578-6bfe5f059774" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0518ebd0-341a-498a-b583-b9f2c154dd5f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_326475a1-ebe1-40ea-96d7-964367006573" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3630b7cc-2492-4303-9578-6bfe5f059774" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_326475a1-ebe1-40ea-96d7-964367006573" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_1d0a1ac6-4db5-47a5-aa7b-bfde97b3181f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3630b7cc-2492-4303-9578-6bfe5f059774" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_1d0a1ac6-4db5-47a5-aa7b-bfde97b3181f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_cf650599-baee-473f-bafc-0ab106c1bfed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3630b7cc-2492-4303-9578-6bfe5f059774" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_cf650599-baee-473f-bafc-0ab106c1bfed" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_a827abab-933e-4be7-a30b-fd1057d1ff87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3630b7cc-2492-4303-9578-6bfe5f059774" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_a827abab-933e-4be7-a30b-fd1057d1ff87" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ab034eeb-1a2e-49da-b061-4206539b2f11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3630b7cc-2492-4303-9578-6bfe5f059774" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ab034eeb-1a2e-49da-b061-4206539b2f11" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_67d16f5c-dacc-472a-8fdf-62eaa91d2498" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3630b7cc-2492-4303-9578-6bfe5f059774" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_67d16f5c-dacc-472a-8fdf-62eaa91d2498" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_af1b6bd8-1db0-4dc8-9cd2-99d8716f7a39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3630b7cc-2492-4303-9578-6bfe5f059774" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_af1b6bd8-1db0-4dc8-9cd2-99d8716f7a39" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_c1745101-24b4-4001-8165-f1f94b4699fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3630b7cc-2492-4303-9578-6bfe5f059774" xlink:to="loc_us-gaap_StockholdersEquityOther_c1745101-24b4-4001-8165-f1f94b4699fc" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_20a848a3-7578-469b-aca1-335b54233a89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_96253185-4ea7-456a-9dc3-fd0f67fa6cd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4a6b3d17-6f5b-4958-bffe-6eb6390a5ea0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_a63bce87-b81e-4c36-9e3f-cbbd590ab2ed" xlink:to="loc_us-gaap_StatementTable_4a6b3d17-6f5b-4958-bffe-6eb6390a5ea0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1bb5abfc-2dc6-41ea-9828-c5c57cc1a0eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4a6b3d17-6f5b-4958-bffe-6eb6390a5ea0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1bb5abfc-2dc6-41ea-9828-c5c57cc1a0eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1bb5abfc-2dc6-41ea-9828-c5c57cc1a0eb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1bb5abfc-2dc6-41ea-9828-c5c57cc1a0eb" xlink:to="loc_us-gaap_EquityComponentDomain_1bb5abfc-2dc6-41ea-9828-c5c57cc1a0eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ed592edd-fd07-4822-b036-b18646e821cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1bb5abfc-2dc6-41ea-9828-c5c57cc1a0eb" xlink:to="loc_us-gaap_EquityComponentDomain_ed592edd-fd07-4822-b036-b18646e821cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_15f246b5-8537-4bf4-aba3-aef0cc3fdca4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ed592edd-fd07-4822-b036-b18646e821cd" xlink:to="loc_us-gaap_CommonStockMember_15f246b5-8537-4bf4-aba3-aef0cc3fdca4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_e0a46ddb-71d3-4596-a795-46559552b32c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ed592edd-fd07-4822-b036-b18646e821cd" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_e0a46ddb-71d3-4596-a795-46559552b32c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_f155f5fb-3cab-427f-aafa-ad877ba64a13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ed592edd-fd07-4822-b036-b18646e821cd" xlink:to="loc_us-gaap_RetainedEarningsMember_f155f5fb-3cab-427f-aafa-ad877ba64a13" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrustForBenefitOfEmployeesMember_84b92d58-9581-4335-93f3-0f9658078452" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrustForBenefitOfEmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ed592edd-fd07-4822-b036-b18646e821cd" xlink:to="loc_us-gaap_TrustForBenefitOfEmployeesMember_84b92d58-9581-4335-93f3-0f9658078452" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4cbddb7f-d71b-48b2-82ef-98225a60f722" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ed592edd-fd07-4822-b036-b18646e821cd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4cbddb7f-d71b-48b2-82ef-98225a60f722" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_593b66d3-4ad5-4c02-bacd-6d8311481d9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ed592edd-fd07-4822-b036-b18646e821cd" xlink:to="loc_us-gaap_TreasuryStockMember_593b66d3-4ad5-4c02-bacd-6d8311481d9e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_87ab8bee-40e3-4dd3-b952-2760a0a51b96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ed592edd-fd07-4822-b036-b18646e821cd" xlink:to="loc_us-gaap_NoncontrollingInterestMember_87ab8bee-40e3-4dd3-b952-2760a0a51b96" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquityParenthetical" xlink:type="simple" xlink:href="lly-20210331.xsd#ConsolidatedCondensedStatementsofEquityParenthetical"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquityParenthetical" xlink:type="extended" id="ibc299c2d3d244d5398e89836fe874a6c_ConsolidatedCondensedStatementsofEquityParenthetical"/>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows" xlink:type="simple" xlink:href="lly-20210331.xsd#ConsolidatedCondensedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows" xlink:type="extended" id="iec025168cc404070bb7516af3889561e_ConsolidatedCondensedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://www.lilly.com/role/BasisofPresentation" xlink:type="simple" xlink:href="lly-20210331.xsd#BasisofPresentation"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/BasisofPresentation" xlink:type="extended" id="i1ebe25bf0c5c4711acc3480467b90e35_BasisofPresentation"/>
  <link:roleRef roleURI="http://www.lilly.com/role/BasisofPresentationPolicies" xlink:type="simple" xlink:href="lly-20210331.xsd#BasisofPresentationPolicies"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/BasisofPresentationPolicies" xlink:type="extended" id="i020a585d6ccf411998366796229644dc_BasisofPresentationPolicies"/>
  <link:roleRef roleURI="http://www.lilly.com/role/Revenue" xlink:type="simple" xlink:href="lly-20210331.xsd#Revenue"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/Revenue" xlink:type="extended" id="iea81c9edd41748aaa9a516b60d021b42_Revenue"/>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueTables" xlink:type="simple" xlink:href="lly-20210331.xsd#RevenueTables"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RevenueTables" xlink:type="extended" id="i44a6f2057e424698b02c6f6305f5e202_RevenueTables"/>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#RevenueSummaryofRevenueRecognizedDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails" xlink:type="extended" id="ida83317a076a4ec7b48c168adff472df_RevenueSummaryofRevenueRecognizedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_54ef57e4-d9a8-4e94-b285-3f90b2e03c66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_0a2c4083-a07c-4a26-94a2-f79f9d4ee81a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_54ef57e4-d9a8-4e94-b285-3f90b2e03c66" xlink:to="loc_us-gaap_Revenues_0a2c4083-a07c-4a26-94a2-f79f9d4ee81a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_3e4ff84e-4a6d-4320-b213-f94e5773c6ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_54ef57e4-d9a8-4e94-b285-3f90b2e03c66" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_3e4ff84e-4a6d-4320-b213-f94e5773c6ad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a339f74c-3efd-49b6-9d5a-44db68ba2d11" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3e4ff84e-4a6d-4320-b213-f94e5773c6ad" xlink:to="loc_srt_ProductOrServiceAxis_a339f74c-3efd-49b6-9d5a-44db68ba2d11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a339f74c-3efd-49b6-9d5a-44db68ba2d11_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a339f74c-3efd-49b6-9d5a-44db68ba2d11" xlink:to="loc_srt_ProductsAndServicesDomain_a339f74c-3efd-49b6-9d5a-44db68ba2d11_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1256e814-b80f-4144-b2f6-e62fedd0ee3c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a339f74c-3efd-49b6-9d5a-44db68ba2d11" xlink:to="loc_srt_ProductsAndServicesDomain_1256e814-b80f-4144-b2f6-e62fedd0ee3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_919f2eeb-35ab-4d30-b348-491597b69b15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1256e814-b80f-4144-b2f6-e62fedd0ee3c" xlink:to="loc_us-gaap_ProductMember_919f2eeb-35ab-4d30-b348-491597b69b15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborationandOtherRevenueMember_2653c14f-2cb8-491e-ae1e-bbec43ccfc60" xlink:href="lly-20210331.xsd#lly_CollaborationandOtherRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1256e814-b80f-4144-b2f6-e62fedd0ee3c" xlink:to="loc_lly_CollaborationandOtherRevenueMember_2653c14f-2cb8-491e-ae1e-bbec43ccfc60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_dc59b33f-9f7f-4f1e-9c7a-720e7e39544f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1256e814-b80f-4144-b2f6-e62fedd0ee3c" xlink:to="loc_us-gaap_RoyaltyMember_dc59b33f-9f7f-4f1e-9c7a-720e7e39544f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#RevenueAdjustmentstoRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails" xlink:type="extended" id="ia06674a274c44ec6ae89fcb1f2d8a332_RevenueAdjustmentstoRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateLineItems_5a836ca1-e4ad-4bd6-a9c4-91da4c585acf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_33da39f1-c1c7-48af-b062-d95b27ff3316" xlink:href="lly-20210331.xsd#lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_5a836ca1-e4ad-4bd6-a9c4-91da4c585acf" xlink:to="loc_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_33da39f1-c1c7-48af-b062-d95b27ff3316" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_2f12411f-d981-40e4-82ba-c60791a7c817" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_5a836ca1-e4ad-4bd6-a9c4-91da4c585acf" xlink:to="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_2f12411f-d981-40e4-82ba-c60791a7c817" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_c082119b-7ad6-4fcf-8379-77c7336f33e5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_2f12411f-d981-40e4-82ba-c60791a7c817" xlink:to="loc_srt_StatementGeographicalAxis_c082119b-7ad6-4fcf-8379-77c7336f33e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c082119b-7ad6-4fcf-8379-77c7336f33e5_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_c082119b-7ad6-4fcf-8379-77c7336f33e5" xlink:to="loc_srt_SegmentGeographicalDomain_c082119b-7ad6-4fcf-8379-77c7336f33e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f5a0fb5d-ab55-4693-a747-0eacdf1d2f47" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_c082119b-7ad6-4fcf-8379-77c7336f33e5" xlink:to="loc_srt_SegmentGeographicalDomain_f5a0fb5d-ab55-4693-a747-0eacdf1d2f47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_757f83bd-2496-46e1-a07d-8e391e3cba7c" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f5a0fb5d-ab55-4693-a747-0eacdf1d2f47" xlink:to="loc_country_US_757f83bd-2496-46e1-a07d-8e391e3cba7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_407b1f42-c6ed-401d-bf2c-4303fe58e70d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_2f12411f-d981-40e4-82ba-c60791a7c817" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_407b1f42-c6ed-401d-bf2c-4303fe58e70d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_407b1f42-c6ed-401d-bf2c-4303fe58e70d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_407b1f42-c6ed-401d-bf2c-4303fe58e70d" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_407b1f42-c6ed-401d-bf2c-4303fe58e70d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_62f7eddc-0255-4dcf-9f62-2189af5e1c95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_407b1f42-c6ed-401d-bf2c-4303fe58e70d" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_62f7eddc-0255-4dcf-9f62-2189af5e1c95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_bd05d820-b7bf-4857-ba6a-940e46ab3735" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_62f7eddc-0255-4dcf-9f62-2189af5e1c95" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_bd05d820-b7bf-4857-ba6a-940e46ab3735" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueContractLiabilitiesDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#RevenueContractLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RevenueContractLiabilitiesDetails" xlink:type="extended" id="i9f495fa54a5141a295597fc2da305d91_RevenueContractLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#RevenueDisaggregationofRevenuebyProductDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails" xlink:type="extended" id="i98a5d252c9d941358f05eb9e4ef24533_RevenueDisaggregationofRevenuebyProductDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_b9f8ae07-0f92-4369-9852-24a35a6f1b7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_eac97ef8-b5c4-4598-91d0-0095ae99c16f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b9f8ae07-0f92-4369-9852-24a35a6f1b7f" xlink:to="loc_us-gaap_Revenues_eac97ef8-b5c4-4598-91d0-0095ae99c16f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_53aa2f4a-3dad-4a23-a8ee-280d2e200acc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b9f8ae07-0f92-4369-9852-24a35a6f1b7f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_53aa2f4a-3dad-4a23-a8ee-280d2e200acc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_475a80b1-88ab-44ca-af35-f1b64238219f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_53aa2f4a-3dad-4a23-a8ee-280d2e200acc" xlink:to="loc_srt_ProductOrServiceAxis_475a80b1-88ab-44ca-af35-f1b64238219f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_475a80b1-88ab-44ca-af35-f1b64238219f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_475a80b1-88ab-44ca-af35-f1b64238219f" xlink:to="loc_srt_ProductsAndServicesDomain_475a80b1-88ab-44ca-af35-f1b64238219f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_51d668a8-137b-473d-90fd-dd0ffeb82fd5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_475a80b1-88ab-44ca-af35-f1b64238219f" xlink:to="loc_srt_ProductsAndServicesDomain_51d668a8-137b-473d-90fd-dd0ffeb82fd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DiabetesMember_6e6e1e31-7b63-4f6c-9ce0-abc0c9c9cae8" xlink:href="lly-20210331.xsd#lly_DiabetesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_51d668a8-137b-473d-90fd-dd0ffeb82fd5" xlink:to="loc_lly_DiabetesMember_6e6e1e31-7b63-4f6c-9ce0-abc0c9c9cae8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrulicityMemberMember_dbd9008a-91f4-497c-8639-733fa1ff8553" xlink:href="lly-20210331.xsd#lly_TrulicityMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_6e6e1e31-7b63-4f6c-9ce0-abc0c9c9cae8" xlink:to="loc_lly_TrulicityMemberMember_dbd9008a-91f4-497c-8639-733fa1ff8553" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumalogMember_6e4e77b7-fb33-4fb6-92bc-af959be80fd6" xlink:href="lly-20210331.xsd#lly_HumalogMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_6e6e1e31-7b63-4f6c-9ce0-abc0c9c9cae8" xlink:to="loc_lly_HumalogMember_6e4e77b7-fb33-4fb6-92bc-af959be80fd6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumulinMember_e1ac5e98-eeb0-4731-a95f-565218731ebf" xlink:href="lly-20210331.xsd#lly_HumulinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_6e6e1e31-7b63-4f6c-9ce0-abc0c9c9cae8" xlink:to="loc_lly_HumulinMember_e1ac5e98-eeb0-4731-a95f-565218731ebf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_0fb74cef-3534-4bb4-985e-25ee01d7d263" xlink:href="lly-20210331.xsd#lly_JardianceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_6e6e1e31-7b63-4f6c-9ce0-abc0c9c9cae8" xlink:to="loc_lly_JardianceMember_0fb74cef-3534-4bb4-985e-25ee01d7d263" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember_7c64ca4c-39a4-47bf-8b9d-a4c16a7c64a4" xlink:href="lly-20210331.xsd#lly_BasaglarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_6e6e1e31-7b63-4f6c-9ce0-abc0c9c9cae8" xlink:to="loc_lly_BasaglarMember_7c64ca4c-39a4-47bf-8b9d-a4c16a7c64a4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherDiabetesMember_1b6c9f03-1ca9-4041-aa1d-f302f6541329" xlink:href="lly-20210331.xsd#lly_OtherDiabetesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_6e6e1e31-7b63-4f6c-9ce0-abc0c9c9cae8" xlink:to="loc_lly_OtherDiabetesMember_1b6c9f03-1ca9-4041-aa1d-f302f6541329" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OncologyMember_0ed4784f-ac2c-4d20-aee2-5f8315c02277" xlink:href="lly-20210331.xsd#lly_OncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_51d668a8-137b-473d-90fd-dd0ffeb82fd5" xlink:to="loc_lly_OncologyMember_0ed4784f-ac2c-4d20-aee2-5f8315c02277" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AlimtaMember_ffa408b6-4056-4d8f-a325-08fe1ab65ae8" xlink:href="lly-20210331.xsd#lly_AlimtaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OncologyMember_0ed4784f-ac2c-4d20-aee2-5f8315c02277" xlink:to="loc_lly_AlimtaMember_ffa408b6-4056-4d8f-a325-08fe1ab65ae8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_VerzenioMember_ce8d1946-59b3-4a84-b8ff-1e0491670f75" xlink:href="lly-20210331.xsd#lly_VerzenioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OncologyMember_0ed4784f-ac2c-4d20-aee2-5f8315c02277" xlink:to="loc_lly_VerzenioMember_ce8d1946-59b3-4a84-b8ff-1e0491670f75" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CyramzaMember_fa3d2c75-31b9-4e48-9813-e7180b67ab86" xlink:href="lly-20210331.xsd#lly_CyramzaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OncologyMember_0ed4784f-ac2c-4d20-aee2-5f8315c02277" xlink:to="loc_lly_CyramzaMember_fa3d2c75-31b9-4e48-9813-e7180b67ab86" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ErbituxMember_84e5e487-14b0-4376-b0d8-1520ab3f61dd" xlink:href="lly-20210331.xsd#lly_ErbituxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OncologyMember_0ed4784f-ac2c-4d20-aee2-5f8315c02277" xlink:to="loc_lly_ErbituxMember_84e5e487-14b0-4376-b0d8-1520ab3f61dd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TYVYTMember_0655ee28-6b26-4b9c-866b-5cddfba68077" xlink:href="lly-20210331.xsd#lly_TYVYTMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OncologyMember_0ed4784f-ac2c-4d20-aee2-5f8315c02277" xlink:to="loc_lly_TYVYTMember_0655ee28-6b26-4b9c-866b-5cddfba68077" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherOncologyMember_81ea35a0-be9f-4a90-a194-bbdc2bba2acf" xlink:href="lly-20210331.xsd#lly_OtherOncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OncologyMember_0ed4784f-ac2c-4d20-aee2-5f8315c02277" xlink:to="loc_lly_OtherOncologyMember_81ea35a0-be9f-4a90-a194-bbdc2bba2acf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ImmunologyMember_bbd0efdf-f3bc-43fd-a197-367e826b4257" xlink:href="lly-20210331.xsd#lly_ImmunologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_51d668a8-137b-473d-90fd-dd0ffeb82fd5" xlink:to="loc_lly_ImmunologyMember_bbd0efdf-f3bc-43fd-a197-367e826b4257" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaltzMember_bb6bfaf3-450e-4c92-a192-77c68a71f912" xlink:href="lly-20210331.xsd#lly_TaltzMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_ImmunologyMember_bbd0efdf-f3bc-43fd-a197-367e826b4257" xlink:to="loc_lly_TaltzMember_bb6bfaf3-450e-4c92-a192-77c68a71f912" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember_045161b3-13b1-44e7-95dc-0134479570d9" xlink:href="lly-20210331.xsd#lly_OlumiantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_ImmunologyMember_bbd0efdf-f3bc-43fd-a197-367e826b4257" xlink:to="loc_lly_OlumiantMember_045161b3-13b1-44e7-95dc-0134479570d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherImmunologyMember_9d9bd125-28ec-47c6-a023-c581999085c8" xlink:href="lly-20210331.xsd#lly_OtherImmunologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_ImmunologyMember_bbd0efdf-f3bc-43fd-a197-367e826b4257" xlink:to="loc_lly_OtherImmunologyMember_9d9bd125-28ec-47c6-a023-c581999085c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NeuroscienceMember_03b17cd1-7b11-40fa-bc26-65fc6cf9b17c" xlink:href="lly-20210331.xsd#lly_NeuroscienceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_51d668a8-137b-473d-90fd-dd0ffeb82fd5" xlink:to="loc_lly_NeuroscienceMember_03b17cd1-7b11-40fa-bc26-65fc6cf9b17c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CymbaltaMember_a8985a03-3f01-47ab-a0b1-24d5d9cd44e1" xlink:href="lly-20210331.xsd#lly_CymbaltaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_NeuroscienceMember_03b17cd1-7b11-40fa-bc26-65fc6cf9b17c" xlink:to="loc_lly_CymbaltaMember_a8985a03-3f01-47ab-a0b1-24d5d9cd44e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmgalityMember_0a228969-7633-4aac-9487-ab8870e53c60" xlink:href="lly-20210331.xsd#lly_EmgalityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_NeuroscienceMember_03b17cd1-7b11-40fa-bc26-65fc6cf9b17c" xlink:to="loc_lly_EmgalityMember_0a228969-7633-4aac-9487-ab8870e53c60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ZyprexaMember_d16b7bf6-1589-4e44-8c75-a8f252e13791" xlink:href="lly-20210331.xsd#lly_ZyprexaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_NeuroscienceMember_03b17cd1-7b11-40fa-bc26-65fc6cf9b17c" xlink:to="loc_lly_ZyprexaMember_d16b7bf6-1589-4e44-8c75-a8f252e13791" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherNeuroscienceMember_0f198e26-3c7e-4a80-aebb-244a10b6ca2c" xlink:href="lly-20210331.xsd#lly_OtherNeuroscienceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_NeuroscienceMember_03b17cd1-7b11-40fa-bc26-65fc6cf9b17c" xlink:to="loc_lly_OtherNeuroscienceMember_0f198e26-3c7e-4a80-aebb-244a10b6ca2c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherProductTotalMember_8d5d66e1-da92-4e88-8e5c-9e560f853151" xlink:href="lly-20210331.xsd#lly_OtherProductTotalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_51d668a8-137b-473d-90fd-dd0ffeb82fd5" xlink:to="loc_lly_OtherProductTotalMember_8d5d66e1-da92-4e88-8e5c-9e560f853151" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_COVID19AntibodiesMember_865c96a8-86f9-4dab-b7e2-ce6dcbaad654" xlink:href="lly-20210331.xsd#lly_COVID19AntibodiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OtherProductTotalMember_8d5d66e1-da92-4e88-8e5c-9e560f853151" xlink:to="loc_lly_COVID19AntibodiesMember_865c96a8-86f9-4dab-b7e2-ce6dcbaad654" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForteoMember_805bfb06-9ed5-417c-ad6a-e71603c4237a" xlink:href="lly-20210331.xsd#lly_ForteoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OtherProductTotalMember_8d5d66e1-da92-4e88-8e5c-9e560f853151" xlink:to="loc_lly_ForteoMember_805bfb06-9ed5-417c-ad6a-e71603c4237a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CialisMember_da9f0a9c-5428-45b9-bba0-f4cb5cea10e7" xlink:href="lly-20210331.xsd#lly_CialisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OtherProductTotalMember_8d5d66e1-da92-4e88-8e5c-9e560f853151" xlink:to="loc_lly_CialisMember_da9f0a9c-5428-45b9-bba0-f4cb5cea10e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherProductMember_67184f80-136e-4347-8d2e-8d4e70830748" xlink:href="lly-20210331.xsd#lly_OtherProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OtherProductTotalMember_8d5d66e1-da92-4e88-8e5c-9e560f853151" xlink:to="loc_lly_OtherProductMember_67184f80-136e-4347-8d2e-8d4e70830748" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d59effd2-e528-41e0-9aef-3081b6719257" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_53aa2f4a-3dad-4a23-a8ee-280d2e200acc" xlink:to="loc_srt_StatementGeographicalAxis_d59effd2-e528-41e0-9aef-3081b6719257" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d59effd2-e528-41e0-9aef-3081b6719257_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_d59effd2-e528-41e0-9aef-3081b6719257" xlink:to="loc_srt_SegmentGeographicalDomain_d59effd2-e528-41e0-9aef-3081b6719257_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ca937bd0-9657-414d-9921-93b171e37a95" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_d59effd2-e528-41e0-9aef-3081b6719257" xlink:to="loc_srt_SegmentGeographicalDomain_ca937bd0-9657-414d-9921-93b171e37a95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_ae9bd9e2-f542-4864-8e34-2b56228c3c1a" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ca937bd0-9657-414d-9921-93b171e37a95" xlink:to="loc_country_US_ae9bd9e2-f542-4864-8e34-2b56228c3c1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_075d26bd-f7f5-4be1-8e76-82074d252e19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ca937bd0-9657-414d-9921-93b171e37a95" xlink:to="loc_us-gaap_NonUsMember_075d26bd-f7f5-4be1-8e76-82074d252e19" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#RevenueDisaggregationofRevenuebyGeographicalAreaDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails" xlink:type="extended" id="i7c688a20e07449a1ac55471ea2e47174_RevenueDisaggregationofRevenuebyGeographicalAreaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a3628593-4751-4ff3-9d06-afc00499aa00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_0f835592-5855-42b9-b751-221cd7c54db5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a3628593-4751-4ff3-9d06-afc00499aa00" xlink:to="loc_us-gaap_Revenues_0f835592-5855-42b9-b751-221cd7c54db5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_86b67221-ba91-466e-b7b2-90000d867103" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a3628593-4751-4ff3-9d06-afc00499aa00" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_86b67221-ba91-466e-b7b2-90000d867103" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_c6154dea-bc2b-4ec9-9f76-0b5ac59d2adc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_86b67221-ba91-466e-b7b2-90000d867103" xlink:to="loc_srt_StatementGeographicalAxis_c6154dea-bc2b-4ec9-9f76-0b5ac59d2adc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c6154dea-bc2b-4ec9-9f76-0b5ac59d2adc_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_c6154dea-bc2b-4ec9-9f76-0b5ac59d2adc" xlink:to="loc_srt_SegmentGeographicalDomain_c6154dea-bc2b-4ec9-9f76-0b5ac59d2adc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ca11bc05-70a9-47cb-aba9-14a088023509" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_c6154dea-bc2b-4ec9-9f76-0b5ac59d2adc" xlink:to="loc_srt_SegmentGeographicalDomain_ca11bc05-70a9-47cb-aba9-14a088023509" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b565a35c-dea8-471e-be8a-e7a227d4489c" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ca11bc05-70a9-47cb-aba9-14a088023509" xlink:to="loc_country_US_b565a35c-dea8-471e-be8a-e7a227d4489c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_18b638bf-258b-4496-ad3c-4f600aaa80cf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ca11bc05-70a9-47cb-aba9-14a088023509" xlink:to="loc_srt_EuropeMember_18b638bf-258b-4496-ad3c-4f600aaa80cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_c8d2209b-d833-47e4-8545-2d23f3563b11" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ca11bc05-70a9-47cb-aba9-14a088023509" xlink:to="loc_country_JP_c8d2209b-d833-47e4-8545-2d23f3563b11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_c021cc61-87c8-4c25-b75c-6f45959b33fb" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ca11bc05-70a9-47cb-aba9-14a088023509" xlink:to="loc_country_CN_c021cc61-87c8-4c25-b75c-6f45959b33fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherForeignCountriesMember_be814731-d049-4f9f-803a-d9ead9d59df1" xlink:href="lly-20210331.xsd#lly_OtherForeignCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ca11bc05-70a9-47cb-aba9-14a088023509" xlink:to="loc_lly_OtherForeignCountriesMember_be814731-d049-4f9f-803a-d9ead9d59df1" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/Acquisitions" xlink:type="simple" xlink:href="lly-20210331.xsd#Acquisitions"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/Acquisitions" xlink:type="extended" id="icf496559d425412490f16f5a00d9acbd_Acquisitions"/>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsTables" xlink:type="simple" xlink:href="lly-20210331.xsd#AcquisitionsTables"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/AcquisitionsTables" xlink:type="extended" id="i450ddf9fb714477aa14085fc3148fe6a_AcquisitionsTables"/>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#AcquisitionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/AcquisitionsNarrativeDetails" xlink:type="extended" id="i5ee706f5a27a4cdeace7a90dc5820671_AcquisitionsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_3c158862-19fe-4379-a2cd-83156660fc20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_5fc08a9f-7f06-4a17-9cac-4ff7268d872c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c158862-19fe-4379-a2cd-83156660fc20" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_5fc08a9f-7f06-4a17-9cac-4ff7268d872c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_ed65ede3-37e0-4004-a0ab-b2d5b0c16223" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c158862-19fe-4379-a2cd-83156660fc20" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_ed65ede3-37e0-4004-a0ab-b2d5b0c16223" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_a5e60241-4ed4-4d89-b972-8a21d295ad38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c158862-19fe-4379-a2cd-83156660fc20" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_a5e60241-4ed4-4d89-b972-8a21d295ad38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights_f8201363-16cc-467c-87c5-ca52bafd7443" xlink:href="lly-20210331.xsd#lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c158862-19fe-4379-a2cd-83156660fc20" xlink:to="loc_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights_f8201363-16cc-467c-87c5-ca52bafd7443" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_f7d74b9d-a1f6-4c18-a068-ec795f2a9c78" xlink:href="lly-20210331.xsd#lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c158862-19fe-4379-a2cd-83156660fc20" xlink:to="loc_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_f7d74b9d-a1f6-4c18-a068-ec795f2a9c78" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_edeec5bd-f0d2-48f9-aa10-513cca4efd69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c158862-19fe-4379-a2cd-83156660fc20" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_edeec5bd-f0d2-48f9-aa10-513cca4efd69" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction_2e7cc17b-7d07-4de7-b3c6-227de53c3e22" xlink:href="lly-20210331.xsd#lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c158862-19fe-4379-a2cd-83156660fc20" xlink:to="loc_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction_2e7cc17b-7d07-4de7-b3c6-227de53c3e22" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_b7cb359a-6ecd-4528-95ee-ea4ba61bf7bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c158862-19fe-4379-a2cd-83156660fc20" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_b7cb359a-6ecd-4528-95ee-ea4ba61bf7bc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3b1341f2-c8a6-4249-afed-f1fcf2e3b2fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c158862-19fe-4379-a2cd-83156660fc20" xlink:to="loc_us-gaap_Goodwill_3b1341f2-c8a6-4249-afed-f1fcf2e3b2fe" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_5c76bd95-b42f-4e9c-b9f6-73a508b3314c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c158862-19fe-4379-a2cd-83156660fc20" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_5c76bd95-b42f-4e9c-b9f6-73a508b3314c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_8bd98439-94f6-462a-a071-3c165955db69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c158862-19fe-4379-a2cd-83156660fc20" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_8bd98439-94f6-462a-a071-3c165955db69" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_cf1b5036-5ba2-4655-bd60-d4bb41081a68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c158862-19fe-4379-a2cd-83156660fc20" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_cf1b5036-5ba2-4655-bd60-d4bb41081a68" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_9acc4c71-550d-4b64-9d6e-e1fdf332927e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c158862-19fe-4379-a2cd-83156660fc20" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_9acc4c71-550d-4b64-9d6e-e1fdf332927e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d9fe1cb9-f3fd-4e56-b5ea-4cab41e1f596" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c158862-19fe-4379-a2cd-83156660fc20" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d9fe1cb9-f3fd-4e56-b5ea-4cab41e1f596" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f81fd95b-9dfd-44f9-8c7f-a55000d02f55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d9fe1cb9-f3fd-4e56-b5ea-4cab41e1f596" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f81fd95b-9dfd-44f9-8c7f-a55000d02f55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f81fd95b-9dfd-44f9-8c7f-a55000d02f55_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f81fd95b-9dfd-44f9-8c7f-a55000d02f55" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f81fd95b-9dfd-44f9-8c7f-a55000d02f55_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0f51281c-cbe3-4b0f-90e4-d51ccc84888c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f81fd95b-9dfd-44f9-8c7f-a55000d02f55" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0f51281c-cbe3-4b0f-90e4-d51ccc84888c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrevailTherapeuticsIncMember_d468d924-3ed6-45f5-bd13-aa4952effc0d" xlink:href="lly-20210331.xsd#lly_PrevailTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0f51281c-cbe3-4b0f-90e4-d51ccc84888c" xlink:to="loc_lly_PrevailTherapeuticsIncMember_d468d924-3ed6-45f5-bd13-aa4952effc0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DermiraInc.Member_0fd73a20-e2f3-4cb7-b45b-9eb17c4d825c" xlink:href="lly-20210331.xsd#lly_DermiraInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0f51281c-cbe3-4b0f-90e4-d51ccc84888c" xlink:to="loc_lly_DermiraInc.Member_0fd73a20-e2f3-4cb7-b45b-9eb17c4d825c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended" id="ida62f016620e4dcc86d1a92fa29dd4ec_AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_621ee8f6-63cd-4302-8e5e-ac0d6b8aad0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1b800106-9fa2-4c05-8dd3-e8a33bfd8f8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_621ee8f6-63cd-4302-8e5e-ac0d6b8aad0e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1b800106-9fa2-4c05-8dd3-e8a33bfd8f8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9d253995-7eeb-435f-9fda-723050d81494" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_621ee8f6-63cd-4302-8e5e-ac0d6b8aad0e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9d253995-7eeb-435f-9fda-723050d81494" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_076f57c9-083f-4138-bbcd-3d199cc614bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_621ee8f6-63cd-4302-8e5e-ac0d6b8aad0e" xlink:to="loc_us-gaap_Goodwill_076f57c9-083f-4138-bbcd-3d199cc614bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_e30bc9c6-eef4-4dfd-ace1-d794c56b210a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_621ee8f6-63cd-4302-8e5e-ac0d6b8aad0e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_e30bc9c6-eef4-4dfd-ace1-d794c56b210a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_6475ca24-f595-47af-9d82-731e2405adae" xlink:href="lly-20210331.xsd#lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_621ee8f6-63cd-4302-8e5e-ac0d6b8aad0e" xlink:to="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_6475ca24-f595-47af-9d82-731e2405adae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_b69554c5-0aae-49b6-bd1f-2023e17c7d0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_621ee8f6-63cd-4302-8e5e-ac0d6b8aad0e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_b69554c5-0aae-49b6-bd1f-2023e17c7d0a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_d68e2baa-b7a8-43c3-8de7-adeddc66bbc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_621ee8f6-63cd-4302-8e5e-ac0d6b8aad0e" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_d68e2baa-b7a8-43c3-8de7-adeddc66bbc3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_d489ecdb-4ca7-409f-8cb4-8e1e635a263d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_621ee8f6-63cd-4302-8e5e-ac0d6b8aad0e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_d489ecdb-4ca7-409f-8cb4-8e1e635a263d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_23eb3a77-f9d6-4d60-9cad-b0172fd39a8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_621ee8f6-63cd-4302-8e5e-ac0d6b8aad0e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_23eb3a77-f9d6-4d60-9cad-b0172fd39a8b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8947d868-a2c7-4143-8da5-2266358dd43e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_621ee8f6-63cd-4302-8e5e-ac0d6b8aad0e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8947d868-a2c7-4143-8da5-2266358dd43e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e3f5fd41-7a7f-4e7a-b010-6dbcfc69f2c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8947d868-a2c7-4143-8da5-2266358dd43e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e3f5fd41-7a7f-4e7a-b010-6dbcfc69f2c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e3f5fd41-7a7f-4e7a-b010-6dbcfc69f2c4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e3f5fd41-7a7f-4e7a-b010-6dbcfc69f2c4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e3f5fd41-7a7f-4e7a-b010-6dbcfc69f2c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_428c0748-e4d2-4f35-ab7b-a5c5d916311d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e3f5fd41-7a7f-4e7a-b010-6dbcfc69f2c4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_428c0748-e4d2-4f35-ab7b-a5c5d916311d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrevailTherapeuticsIncMember_62e60ff8-d063-42e3-bd92-a6399a40327a" xlink:href="lly-20210331.xsd#lly_PrevailTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_428c0748-e4d2-4f35-ab7b-a5c5d916311d" xlink:to="loc_lly_PrevailTherapeuticsIncMember_62e60ff8-d063-42e3-bd92-a6399a40327a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#AcquisitionsAssetAcquisitionsDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails" xlink:type="extended" id="i2e7fc6d612454df09500a3ae17f18b3e_AcquisitionsAssetAcquisitionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_9587b760-7323-4be7-a9fa-6bacbc2644a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_d643e244-a214-4e1f-b479-e4836d332d09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9587b760-7323-4be7-a9fa-6bacbc2644a2" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_d643e244-a214-4e1f-b479-e4836d332d09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7d50acee-0b25-4e73-8383-5db49380a2b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9587b760-7323-4be7-a9fa-6bacbc2644a2" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7d50acee-0b25-4e73-8383-5db49380a2b6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0abb90d2-c578-4692-9c89-a11b70e7d8c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7d50acee-0b25-4e73-8383-5db49380a2b6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0abb90d2-c578-4692-9c89-a11b70e7d8c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0abb90d2-c578-4692-9c89-a11b70e7d8c7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0abb90d2-c578-4692-9c89-a11b70e7d8c7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0abb90d2-c578-4692-9c89-a11b70e7d8c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_469333af-796a-4e30-a801-5d00511cf498" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0abb90d2-c578-4692-9c89-a11b70e7d8c7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_469333af-796a-4e30-a801-5d00511cf498" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrecisionBiosciencesIncMember_25ccd83c-1bfc-439c-a4e7-5f6f47fab565" xlink:href="lly-20210331.xsd#lly_PrecisionBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_469333af-796a-4e30-a801-5d00511cf498" xlink:to="loc_lly_PrecisionBiosciencesIncMember_25ccd83c-1bfc-439c-a4e7-5f6f47fab565" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MerusNVMember_8805194a-49b1-4236-beb6-298ad4e9416f" xlink:href="lly-20210331.xsd#lly_MerusNVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_469333af-796a-4e30-a801-5d00511cf498" xlink:to="loc_lly_MerusNVMember_8805194a-49b1-4236-beb6-298ad4e9416f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AsahiKaseiPharmaCorporationMember_5a67605f-1d72-4728-aa40-916c4efb1315" xlink:href="lly-20210331.xsd#lly_AsahiKaseiPharmaCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_469333af-796a-4e30-a801-5d00511cf498" xlink:to="loc_lly_AsahiKaseiPharmaCorporationMember_5a67605f-1d72-4728-aa40-916c4efb1315" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RigelPharmaceuticalsIncMember_a453685b-b31f-4e11-98e3-d5e88c688bf4" xlink:href="lly-20210331.xsd#lly_RigelPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_469333af-796a-4e30-a801-5d00511cf498" xlink:to="loc_lly_RigelPharmaceuticalsIncMember_a453685b-b31f-4e11-98e3-d5e88c688bf4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SitryxTherapeuticsLimitedMember_01125420-b6d7-4eb5-8b73-31246c8a64c5" xlink:href="lly-20210331.xsd#lly_SitryxTherapeuticsLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_469333af-796a-4e30-a801-5d00511cf498" xlink:to="loc_lly_SitryxTherapeuticsLimitedMember_01125420-b6d7-4eb5-8b73-31246c8a64c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AbCelleraBiologicsInc.Member_c54ee418-c89d-4d44-a46b-69eccde8f537" xlink:href="lly-20210331.xsd#lly_AbCelleraBiologicsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_469333af-796a-4e30-a801-5d00511cf498" xlink:to="loc_lly_AbCelleraBiologicsInc.Member_c54ee418-c89d-4d44-a46b-69eccde8f537" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangements" xlink:type="simple" xlink:href="lly-20210331.xsd#CollaborationsandOtherArrangements"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangements" xlink:type="extended" id="id6189698c79f46baaf4ed61b69d00b08_CollaborationsandOtherArrangements"/>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsTables" xlink:type="simple" xlink:href="lly-20210331.xsd#CollaborationsandOtherArrangementsTables"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsTables" xlink:type="extended" id="id7aba245c9a64c91b0b47fc0f6b1c447_CollaborationsandOtherArrangementsTables"/>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#CollaborationsandOtherArrangementsDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails" xlink:type="extended" id="i8965b84d7f4a4fe6a3f4355e524a1680_CollaborationsandOtherArrangementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8ba266dc-a562-40d2-a9f0-02d3f054e568" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_7bcdc5cd-3abf-4e97-b4bf-26f5490cbe20" xlink:href="lly-20210331.xsd#lly_CollaborativeArrangementRightsAndObligationsRightsObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8ba266dc-a562-40d2-a9f0-02d3f054e568" xlink:to="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_7bcdc5cd-3abf-4e97-b4bf-26f5490cbe20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_18e7e3a4-411b-45cc-8d48-60e059a90d44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8ba266dc-a562-40d2-a9f0-02d3f054e568" xlink:to="loc_us-gaap_Revenues_18e7e3a4-411b-45cc-8d48-60e059a90d44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsPercent_13ad70d0-40bb-4f42-9820-e5c575396640" xlink:href="lly-20210331.xsd#lly_CollaborativeArrangementRightsAndObligationsPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8ba266dc-a562-40d2-a9f0-02d3f054e568" xlink:to="loc_lly_CollaborativeArrangementRightsAndObligationsPercent_13ad70d0-40bb-4f42-9820-e5c575396640" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold_da4c0b8e-1385-40c7-b02f-2dfa668ef107" xlink:href="lly-20210331.xsd#lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8ba266dc-a562-40d2-a9f0-02d3f054e568" xlink:to="loc_lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold_da4c0b8e-1385-40c7-b02f-2dfa668ef107" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_f2a87e65-fdde-4575-b243-3f2372d3c006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8ba266dc-a562-40d2-a9f0-02d3f054e568" xlink:to="loc_us-gaap_ContractWithCustomerLiability_f2a87e65-fdde-4575-b243-3f2372d3c006" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9108bbe7-6c7a-4e3c-8894-020414f27b68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8ba266dc-a562-40d2-a9f0-02d3f054e568" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9108bbe7-6c7a-4e3c-8894-020414f27b68" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_26bcd127-f6e0-4eef-bd08-59d051099fbb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9108bbe7-6c7a-4e3c-8894-020414f27b68" xlink:to="loc_dei_LegalEntityAxis_26bcd127-f6e0-4eef-bd08-59d051099fbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_26bcd127-f6e0-4eef-bd08-59d051099fbb_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_26bcd127-f6e0-4eef-bd08-59d051099fbb" xlink:to="loc_dei_EntityDomain_26bcd127-f6e0-4eef-bd08-59d051099fbb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b5f74c80-c8ec-4a05-9bf9-9f7bda19403e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_26bcd127-f6e0-4eef-bd08-59d051099fbb" xlink:to="loc_dei_EntityDomain_b5f74c80-c8ec-4a05-9bf9-9f7bda19403e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_InnoventBiologicsIncMember_8ceca863-302d-4b2f-bb88-fa0a56598b07" xlink:href="lly-20210331.xsd#lly_InnoventBiologicsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b5f74c80-c8ec-4a05-9bf9-9f7bda19403e" xlink:to="loc_lly_InnoventBiologicsIncMember_8ceca863-302d-4b2f-bb88-fa0a56598b07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RocheMember_f3346854-3bf6-4924-a606-7a36a7b4ce6d" xlink:href="lly-20210331.xsd#lly_RocheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b5f74c80-c8ec-4a05-9bf9-9f7bda19403e" xlink:to="loc_lly_RocheMember_f3346854-3bf6-4924-a606-7a36a7b4ce6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c95821e7-2617-47d4-9fa8-7e5026d5e4b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9108bbe7-6c7a-4e3c-8894-020414f27b68" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c95821e7-2617-47d4-9fa8-7e5026d5e4b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c95821e7-2617-47d4-9fa8-7e5026d5e4b2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c95821e7-2617-47d4-9fa8-7e5026d5e4b2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c95821e7-2617-47d4-9fa8-7e5026d5e4b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d99a00f4-ee97-47b6-b3a7-48a31e53cb23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c95821e7-2617-47d4-9fa8-7e5026d5e4b2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d99a00f4-ee97-47b6-b3a7-48a31e53cb23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_16ddbbf2-775b-4979-83fb-028fac1cd718" xlink:href="lly-20210331.xsd#lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d99a00f4-ee97-47b6-b3a7-48a31e53cb23" xlink:to="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_16ddbbf2-775b-4979-83fb-028fac1cd718" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementTermsMember_b1a8fdba-99af-48e4-9969-41056c8fa84c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyAgreementTermsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d99a00f4-ee97-47b6-b3a7-48a31e53cb23" xlink:to="loc_us-gaap_RoyaltyAgreementTermsMember_b1a8fdba-99af-48e4-9969-41056c8fa84c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember_59c4dfc7-6295-4ec7-99a0-e4b4ee4b6505" xlink:href="lly-20210331.xsd#lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d99a00f4-ee97-47b6-b3a7-48a31e53cb23" xlink:to="loc_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember_59c4dfc7-6295-4ec7-99a0-e4b4ee4b6505" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_4dc148f4-2ba7-4dae-8e29-3e3c70a2e495" xlink:href="lly-20210331.xsd#lly_MilestonePaymentsDevelopmentAndRegulatoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d99a00f4-ee97-47b6-b3a7-48a31e53cb23" xlink:to="loc_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_4dc148f4-2ba7-4dae-8e29-3e3c70a2e495" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsSalesBasedMember_f0b1c073-2e3b-4acc-b0f3-7c3e5429e2eb" xlink:href="lly-20210331.xsd#lly_MilestonePaymentsSalesBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d99a00f4-ee97-47b6-b3a7-48a31e53cb23" xlink:to="loc_lly_MilestonePaymentsSalesBasedMember_f0b1c073-2e3b-4acc-b0f3-7c3e5429e2eb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsSuccessBasedRegulatoryMember_d495f6d0-c7f2-4cca-8355-24fee58d91d6" xlink:href="lly-20210331.xsd#lly_MilestonePaymentsSuccessBasedRegulatoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d99a00f4-ee97-47b6-b3a7-48a31e53cb23" xlink:to="loc_lly_MilestonePaymentsSuccessBasedRegulatoryMember_d495f6d0-c7f2-4cca-8355-24fee58d91d6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember_6330cbd7-09bf-4b17-98e6-f8046867d083" xlink:href="lly-20210331.xsd#lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d99a00f4-ee97-47b6-b3a7-48a31e53cb23" xlink:to="loc_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember_6330cbd7-09bf-4b17-98e6-f8046867d083" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a2a11e76-c34d-4ffd-915a-02b0c0134a55" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9108bbe7-6c7a-4e3c-8894-020414f27b68" xlink:to="loc_srt_ProductOrServiceAxis_a2a11e76-c34d-4ffd-915a-02b0c0134a55" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a2a11e76-c34d-4ffd-915a-02b0c0134a55_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a2a11e76-c34d-4ffd-915a-02b0c0134a55" xlink:to="loc_srt_ProductsAndServicesDomain_a2a11e76-c34d-4ffd-915a-02b0c0134a55_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fd60de86-e6e2-4bdd-98cc-29e4dae37207" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a2a11e76-c34d-4ffd-915a-02b0c0134a55" xlink:to="loc_srt_ProductsAndServicesDomain_fd60de86-e6e2-4bdd-98cc-29e4dae37207" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_1a3699f3-0513-4f89-b492-e34c2ecf1b7e" xlink:href="lly-20210331.xsd#lly_JardianceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fd60de86-e6e2-4bdd-98cc-29e4dae37207" xlink:to="loc_lly_JardianceMember_1a3699f3-0513-4f89-b492-e34c2ecf1b7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrajentaBIMember_a1e22600-b265-4baa-a55d-7fc1bee9654a" xlink:href="lly-20210331.xsd#lly_TrajentaBIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fd60de86-e6e2-4bdd-98cc-29e4dae37207" xlink:to="loc_lly_TrajentaBIMember_a1e22600-b265-4baa-a55d-7fc1bee9654a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember_82ae3cc5-6552-497c-be1c-a3acc4d74221" xlink:href="lly-20210331.xsd#lly_BasaglarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fd60de86-e6e2-4bdd-98cc-29e4dae37207" xlink:to="loc_lly_BasaglarMember_82ae3cc5-6552-497c-be1c-a3acc4d74221" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember_1e094101-8054-4ed1-a5e7-c03911602dc9" xlink:href="lly-20210331.xsd#lly_OlumiantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fd60de86-e6e2-4bdd-98cc-29e4dae37207" xlink:to="loc_lly_OlumiantMember_1e094101-8054-4ed1-a5e7-c03911602dc9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_COVID19AntibodiesMember_6d43006b-eda0-4f38-9d09-f5baeeb09285" xlink:href="lly-20210331.xsd#lly_COVID19AntibodiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fd60de86-e6e2-4bdd-98cc-29e4dae37207" xlink:to="loc_lly_COVID19AntibodiesMember_6d43006b-eda0-4f38-9d09-f5baeeb09285" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TYVYTMember_9733327c-6f2c-43ab-a348-1ffcdf757c33" xlink:href="lly-20210331.xsd#lly_TYVYTMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fd60de86-e6e2-4bdd-98cc-29e4dae37207" xlink:to="loc_lly_TYVYTMember_9733327c-6f2c-43ab-a348-1ffcdf757c33" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TanezumabMember_fe9f5735-489e-4633-9a1a-6b1d32742e90" xlink:href="lly-20210331.xsd#lly_TanezumabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fd60de86-e6e2-4bdd-98cc-29e4dae37207" xlink:to="loc_lly_TanezumabMember_fe9f5735-489e-4633-9a1a-6b1d32742e90" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LebrikizumabMember_a62ef794-3264-47ee-bbc7-ce37a63da506" xlink:href="lly-20210331.xsd#lly_LebrikizumabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fd60de86-e6e2-4bdd-98cc-29e4dae37207" xlink:to="loc_lly_LebrikizumabMember_a62ef794-3264-47ee-bbc7-ce37a63da506" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_87a88848-4a0c-47c7-b708-91960bd7a745" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9108bbe7-6c7a-4e3c-8894-020414f27b68" xlink:to="loc_srt_StatementGeographicalAxis_87a88848-4a0c-47c7-b708-91960bd7a745" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_87a88848-4a0c-47c7-b708-91960bd7a745_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_87a88848-4a0c-47c7-b708-91960bd7a745" xlink:to="loc_srt_SegmentGeographicalDomain_87a88848-4a0c-47c7-b708-91960bd7a745_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7e99053f-d29b-4a58-a922-cfe3b240b86f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_87a88848-4a0c-47c7-b708-91960bd7a745" xlink:to="loc_srt_SegmentGeographicalDomain_7e99053f-d29b-4a58-a922-cfe3b240b86f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NonCHINAMember_c70d04ef-40a2-4ed5-a537-9359c83961f3" xlink:href="lly-20210331.xsd#lly_NonCHINAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7e99053f-d29b-4a58-a922-cfe3b240b86f" xlink:to="loc_lly_NonCHINAMember_c70d04ef-40a2-4ed5-a537-9359c83961f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_970e5fb8-103a-43e0-890e-f439c54def5c" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7e99053f-d29b-4a58-a922-cfe3b240b86f" xlink:to="loc_country_CN_970e5fb8-103a-43e0-890e-f439c54def5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OutsideUSAndJapanMember_70dc0c76-363d-48f3-ad3b-33546f5e28b0" xlink:href="lly-20210331.xsd#lly_OutsideUSAndJapanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7e99053f-d29b-4a58-a922-cfe3b240b86f" xlink:to="loc_lly_OutsideUSAndJapanMember_70dc0c76-363d-48f3-ad3b-33546f5e28b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_12695ed7-d0e9-4717-abe6-9b2360826548" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7e99053f-d29b-4a58-a922-cfe3b240b86f" xlink:to="loc_us-gaap_NonUsMember_12695ed7-d0e9-4717-abe6-9b2360826548" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6e65f6a9-f294-4e46-b55e-4a7d2788b454" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9108bbe7-6c7a-4e3c-8894-020414f27b68" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6e65f6a9-f294-4e46-b55e-4a7d2788b454" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e65f6a9-f294-4e46-b55e-4a7d2788b454_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6e65f6a9-f294-4e46-b55e-4a7d2788b454" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e65f6a9-f294-4e46-b55e-4a7d2788b454_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5f47c961-0710-4699-95e9-77e9306f4e50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6e65f6a9-f294-4e46-b55e-4a7d2788b454" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5f47c961-0710-4699-95e9-77e9306f4e50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JunshiBiosciencesMember_6c4f40eb-f8dd-405f-a97f-fb5db40e89b8" xlink:href="lly-20210331.xsd#lly_JunshiBiosciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5f47c961-0710-4699-95e9-77e9306f4e50" xlink:to="loc_lly_JunshiBiosciencesMember_6c4f40eb-f8dd-405f-a97f-fb5db40e89b8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges" xlink:type="simple" xlink:href="lly-20210331.xsd#AssetImpairmentRestructuringandOtherSpecialCharges"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges" xlink:type="extended" id="i5698612c941c48198549bdf622403d81_AssetImpairmentRestructuringandOtherSpecialCharges"/>
  <link:roleRef roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables" xlink:type="simple" xlink:href="lly-20210331.xsd#AssetImpairmentRestructuringandOtherSpecialChargesTables"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables" xlink:type="extended" id="i45399a141ea54b5897f9da76c94788df_AssetImpairmentRestructuringandOtherSpecialChargesTables"/>
  <link:roleRef roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#AssetImpairmentRestructuringandOtherSpecialChargesDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails" xlink:type="extended" id="i2ebf85788713474e849d38c66802937c_AssetImpairmentRestructuringandOtherSpecialChargesDetails"/>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstruments" xlink:type="simple" xlink:href="lly-20210331.xsd#FinancialInstruments"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstruments" xlink:type="extended" id="i8057bc45c6b342e59b7a5c07bc666704_FinancialInstruments"/>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="lly-20210331.xsd#FinancialInstrumentsTables"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsTables" xlink:type="extended" id="i7d7301ec5db343d69ecb5a3a0d63ae33_FinancialInstrumentsTables"/>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended" id="icf32cd93c72d46dda8c1b85017546cf7_FinancialInstrumentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_adf35fd9-8721-4921-a3b8-3d73e3766db0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_08310bd9-74f0-4e29-b51c-5f14efbc635b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_adf35fd9-8721-4921-a3b8-3d73e3766db0" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_08310bd9-74f0-4e29-b51c-5f14efbc635b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_0344dabb-5113-4c05-a6bf-323090449236" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_adf35fd9-8721-4921-a3b8-3d73e3766db0" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_0344dabb-5113-4c05-a6bf-323090449236" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_ffddbf03-975a-4101-8efb-d5055a1c77c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_adf35fd9-8721-4921-a3b8-3d73e3766db0" xlink:to="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_ffddbf03-975a-4101-8efb-d5055a1c77c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_ef57d127-ec25-4d4f-ad5c-54f4c2667444" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_adf35fd9-8721-4921-a3b8-3d73e3766db0" xlink:to="loc_us-gaap_LongTermDebt_ef57d127-ec25-4d4f-ad5c-54f4c2667444" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax_53e9cecf-04e7-4e34-a5ab-dfb6b6c10b5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_adf35fd9-8721-4921-a3b8-3d73e3766db0" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax_53e9cecf-04e7-4e34-a5ab-dfb6b6c10b5f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_4b4757cf-1032-4913-b428-f92b2f041944" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_adf35fd9-8721-4921-a3b8-3d73e3766db0" xlink:to="loc_us-gaap_DerivativeNotionalAmount_4b4757cf-1032-4913-b428-f92b2f041944" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DescriptionOfDerivativeActivityVolumePercent_f8a43af8-cfc2-47bb-a7b4-66a581231149" xlink:href="lly-20210331.xsd#lly_DescriptionOfDerivativeActivityVolumePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_adf35fd9-8721-4921-a3b8-3d73e3766db0" xlink:to="loc_lly_DescriptionOfDerivativeActivityVolumePercent_f8a43af8-cfc2-47bb-a7b4-66a581231149" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_440e4849-b883-496f-aa4d-26c64fe5adca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_adf35fd9-8721-4921-a3b8-3d73e3766db0" xlink:to="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_440e4849-b883-496f-aa4d-26c64fe5adca" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_69be14c0-d348-460b-bd82-85d0dcc9ec2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_adf35fd9-8721-4921-a3b8-3d73e3766db0" xlink:to="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_69be14c0-d348-460b-bd82-85d0dcc9ec2b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_13c37c4c-ef02-4f6c-bc53-bbbba3bc43a4" xlink:href="lly-20210331.xsd#lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_adf35fd9-8721-4921-a3b8-3d73e3766db0" xlink:to="loc_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_13c37c4c-ef02-4f6c-bc53-bbbba3bc43a4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_7a5dc759-0964-4d30-81c6-e35aff2e61a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_adf35fd9-8721-4921-a3b8-3d73e3766db0" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_7a5dc759-0964-4d30-81c6-e35aff2e61a5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets_ef2971c1-2f93-449b-8d32-930365ae20c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_adf35fd9-8721-4921-a3b8-3d73e3766db0" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets_ef2971c1-2f93-449b-8d32-930365ae20c7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_f95a8d85-9f5f-45fb-8a12-5303971acab9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_adf35fd9-8721-4921-a3b8-3d73e3766db0" xlink:to="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_f95a8d85-9f5f-45fb-8a12-5303971acab9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0952f4ef-4999-4e4e-a1e8-220c29e0f460" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_adf35fd9-8721-4921-a3b8-3d73e3766db0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0952f4ef-4999-4e4e-a1e8-220c29e0f460" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_8dee71d3-f937-43aa-883a-dd90fae5ed98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0952f4ef-4999-4e4e-a1e8-220c29e0f460" xlink:to="loc_us-gaap_HedgingDesignationAxis_8dee71d3-f937-43aa-883a-dd90fae5ed98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_8dee71d3-f937-43aa-883a-dd90fae5ed98_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_8dee71d3-f937-43aa-883a-dd90fae5ed98" xlink:to="loc_us-gaap_HedgingDesignationDomain_8dee71d3-f937-43aa-883a-dd90fae5ed98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_07bf97ec-b7d3-48c3-bfa0-cbe623731068" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_8dee71d3-f937-43aa-883a-dd90fae5ed98" xlink:to="loc_us-gaap_HedgingDesignationDomain_07bf97ec-b7d3-48c3-bfa0-cbe623731068" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_a08e7ebe-5de0-45e4-882e-af9ceb0aca1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_07bf97ec-b7d3-48c3-bfa0-cbe623731068" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_a08e7ebe-5de0-45e4-882e-af9ceb0aca1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_423a7b5a-a398-40a2-9d8a-d627b67a8cad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0952f4ef-4999-4e4e-a1e8-220c29e0f460" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_423a7b5a-a398-40a2-9d8a-d627b67a8cad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_423a7b5a-a398-40a2-9d8a-d627b67a8cad_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_423a7b5a-a398-40a2-9d8a-d627b67a8cad" xlink:to="loc_us-gaap_HedgingRelationshipDomain_423a7b5a-a398-40a2-9d8a-d627b67a8cad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_770d76dd-09de-4fb4-913d-de7bd24457a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_423a7b5a-a398-40a2-9d8a-d627b67a8cad" xlink:to="loc_us-gaap_HedgingRelationshipDomain_770d76dd-09de-4fb4-913d-de7bd24457a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_21073233-95ad-43c1-af5c-977bbb54b632" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_770d76dd-09de-4fb4-913d-de7bd24457a8" xlink:to="loc_us-gaap_CashFlowHedgingMember_21073233-95ad-43c1-af5c-977bbb54b632" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ea62c3d1-d9f5-4860-8662-321db5a51f5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0952f4ef-4999-4e4e-a1e8-220c29e0f460" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ea62c3d1-d9f5-4860-8662-321db5a51f5a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ea62c3d1-d9f5-4860-8662-321db5a51f5a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ea62c3d1-d9f5-4860-8662-321db5a51f5a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ea62c3d1-d9f5-4860-8662-321db5a51f5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_dae11b78-d395-4819-83b4-edf555e99417" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ea62c3d1-d9f5-4860-8662-321db5a51f5a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_dae11b78-d395-4819-83b4-edf555e99417" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForeignCurrencyDenominatedDebtMember_3cc9ae74-805b-4994-bfb0-f09093dd5edd" xlink:href="lly-20210331.xsd#lly_ForeignCurrencyDenominatedDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dae11b78-d395-4819-83b4-edf555e99417" xlink:to="loc_lly_ForeignCurrencyDenominatedDebtMember_3cc9ae74-805b-4994-bfb0-f09093dd5edd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_1791c2d4-2357-4fba-b35f-83dbbad7e108" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0952f4ef-4999-4e4e-a1e8-220c29e0f460" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_1791c2d4-2357-4fba-b35f-83dbbad7e108" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1791c2d4-2357-4fba-b35f-83dbbad7e108_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1791c2d4-2357-4fba-b35f-83dbbad7e108" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1791c2d4-2357-4fba-b35f-83dbbad7e108_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6f4fb931-b5f7-44c0-98de-50c34fb5b800" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1791c2d4-2357-4fba-b35f-83dbbad7e108" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6f4fb931-b5f7-44c0-98de-50c34fb5b800" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUsDollarSellEuroMember_cbf5d153-eee5-4996-9970-5f1a44ce92d8" xlink:href="lly-20210331.xsd#lly_BuyUsDollarSellEuroMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6f4fb931-b5f7-44c0-98de-50c34fb5b800" xlink:to="loc_lly_BuyUsDollarSellEuroMember_cbf5d153-eee5-4996-9970-5f1a44ce92d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyEuroSellUsDollarMember_11c933a8-7e88-4288-b38d-c2b3358c6490" xlink:href="lly-20210331.xsd#lly_BuyEuroSellUsDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6f4fb931-b5f7-44c0-98de-50c34fb5b800" xlink:to="loc_lly_BuyEuroSellUsDollarMember_11c933a8-7e88-4288-b38d-c2b3358c6490" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUSdollarSellJapaneseYenMember_db170a53-0dd8-44ff-b659-b848543ebca4" xlink:href="lly-20210331.xsd#lly_BuyUSdollarSellJapaneseYenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6f4fb931-b5f7-44c0-98de-50c34fb5b800" xlink:to="loc_lly_BuyUSdollarSellJapaneseYenMember_db170a53-0dd8-44ff-b659-b848543ebca4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyBritishPoundandSellUSDollarsMember_37fe1cda-a25a-4782-8dac-78077da9b879" xlink:href="lly-20210331.xsd#lly_BuyBritishPoundandSellUSDollarsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6f4fb931-b5f7-44c0-98de-50c34fb5b800" xlink:to="loc_lly_BuyBritishPoundandSellUSDollarsMember_37fe1cda-a25a-4782-8dac-78077da9b879" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SwapU.S.DollarsToEuroMember_e5d52aa1-bb8e-4e80-996e-fde665f5d23f" xlink:href="lly-20210331.xsd#lly_SwapU.S.DollarsToEuroMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6f4fb931-b5f7-44c0-98de-50c34fb5b800" xlink:to="loc_lly_SwapU.S.DollarsToEuroMember_e5d52aa1-bb8e-4e80-996e-fde665f5d23f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SwapSwissFrancsToU.S.DollarsMember_b0993be3-dc81-4c96-a9e3-66df5297362e" xlink:href="lly-20210331.xsd#lly_SwapSwissFrancsToU.S.DollarsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6f4fb931-b5f7-44c0-98de-50c34fb5b800" xlink:to="loc_lly_SwapSwissFrancsToU.S.DollarsMember_b0993be3-dc81-4c96-a9e3-66df5297362e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_5c5e81a8-a9ba-4f7c-8839-20164480ac43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6f4fb931-b5f7-44c0-98de-50c34fb5b800" xlink:to="loc_us-gaap_InterestRateSwapMember_5c5e81a8-a9ba-4f7c-8839-20164480ac43" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#FinancialInstrumentsEffectofRiskManagementInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails" xlink:type="extended" id="i5a2b48c1920749b2a5d976d45e47665c_FinancialInstrumentsEffectofRiskManagementInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_751158da-2edf-41e1-801c-69d1f7b7942c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FairValueHedgeAbstract_ca8b6826-155f-4d3a-ac0f-b96297dd885d" xlink:href="lly-20210331.xsd#lly_FairValueHedgeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_751158da-2edf-41e1-801c-69d1f7b7942c" xlink:to="loc_lly_FairValueHedgeAbstract_ca8b6826-155f-4d3a-ac0f-b96297dd885d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_01f6dc3c-c929-4212-94d5-ed3376432d9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_FairValueHedgeAbstract_ca8b6826-155f-4d3a-ac0f-b96297dd885d" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_01f6dc3c-c929-4212-94d5-ed3376432d9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_c85f6e8f-85f9-428a-a1d4-6a46710fee07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_FairValueHedgeAbstract_ca8b6826-155f-4d3a-ac0f-b96297dd885d" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_c85f6e8f-85f9-428a-a1d4-6a46710fee07" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CashFlowHedgeAbstract_d570c496-78a1-4935-88a6-cee0ced01526" xlink:href="lly-20210331.xsd#lly_CashFlowHedgeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_751158da-2edf-41e1-801c-69d1f7b7942c" xlink:to="loc_lly_CashFlowHedgeAbstract_d570c496-78a1-4935-88a6-cee0ced01526" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_ffdd1598-5555-4286-9d65-31ce64226bee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_CashFlowHedgeAbstract_d570c496-78a1-4935-88a6-cee0ced01526" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_ffdd1598-5555-4286-9d65-31ce64226bee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_88e46833-9710-4a69-a75f-0f25814f28a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_751158da-2edf-41e1-801c-69d1f7b7942c" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_88e46833-9710-4a69-a75f-0f25814f28a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DerivativeInstrumentsGainLossRecognized_7c7a2106-fdea-4e59-a7f1-d3d353d5ae25" xlink:href="lly-20210331.xsd#lly_DerivativeInstrumentsGainLossRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_751158da-2edf-41e1-801c-69d1f7b7942c" xlink:to="loc_lly_DerivativeInstrumentsGainLossRecognized_7c7a2106-fdea-4e59-a7f1-d3d353d5ae25" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_96b757a5-dfd5-4239-a52e-884e5a2a47d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_751158da-2edf-41e1-801c-69d1f7b7942c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_96b757a5-dfd5-4239-a52e-884e5a2a47d8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_fb53b156-29d3-476d-9c7c-c5c11d17c333" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_751158da-2edf-41e1-801c-69d1f7b7942c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_fb53b156-29d3-476d-9c7c-c5c11d17c333" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_997ff6ed-b042-4553-886e-48bbb85ce8db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_751158da-2edf-41e1-801c-69d1f7b7942c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_997ff6ed-b042-4553-886e-48bbb85ce8db" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_e828de25-5da9-4944-86f7-fda3525d1ba7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_997ff6ed-b042-4553-886e-48bbb85ce8db" xlink:to="loc_us-gaap_HedgingDesignationAxis_e828de25-5da9-4944-86f7-fda3525d1ba7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_e828de25-5da9-4944-86f7-fda3525d1ba7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_e828de25-5da9-4944-86f7-fda3525d1ba7" xlink:to="loc_us-gaap_HedgingDesignationDomain_e828de25-5da9-4944-86f7-fda3525d1ba7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_34045ce0-6015-4a23-a117-e3ee4df03538" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_e828de25-5da9-4944-86f7-fda3525d1ba7" xlink:to="loc_us-gaap_HedgingDesignationDomain_34045ce0-6015-4a23-a117-e3ee4df03538" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_254112f0-0c20-43eb-a00a-52745c97770b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_34045ce0-6015-4a23-a117-e3ee4df03538" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_254112f0-0c20-43eb-a00a-52745c97770b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_1a71fdc5-6f9b-406d-be2e-cd104bc8d8bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_34045ce0-6015-4a23-a117-e3ee4df03538" xlink:to="loc_us-gaap_NondesignatedMember_1a71fdc5-6f9b-406d-be2e-cd104bc8d8bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_15e43493-595d-4823-a2a6-33fa9e211247" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_997ff6ed-b042-4553-886e-48bbb85ce8db" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_15e43493-595d-4823-a2a6-33fa9e211247" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_15e43493-595d-4823-a2a6-33fa9e211247_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_15e43493-595d-4823-a2a6-33fa9e211247" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_15e43493-595d-4823-a2a6-33fa9e211247_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0ed43062-ed06-42d5-82b4-29f37df6b540" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_15e43493-595d-4823-a2a6-33fa9e211247" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0ed43062-ed06-42d5-82b4-29f37df6b540" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HedgedFixedRateDebtMember_f9c115bb-42b7-4bca-9b77-96ab83989b1f" xlink:href="lly-20210331.xsd#lly_HedgedFixedRateDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0ed43062-ed06-42d5-82b4-29f37df6b540" xlink:to="loc_lly_HedgedFixedRateDebtMember_f9c115bb-42b7-4bca-9b77-96ab83989b1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_9424e183-2ce9-4d7e-8f26-7e8283368bc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0ed43062-ed06-42d5-82b4-29f37df6b540" xlink:to="loc_us-gaap_InterestRateContractMember_9424e183-2ce9-4d7e-8f26-7e8283368bc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_ac5f6dd5-8591-46a8-b2e9-50db83d6f4f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0ed43062-ed06-42d5-82b4-29f37df6b540" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_ac5f6dd5-8591-46a8-b2e9-50db83d6f4f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_9e8e9937-242e-4dd1-b943-93bfec695a13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0ed43062-ed06-42d5-82b4-29f37df6b540" xlink:to="loc_us-gaap_ForeignExchangeContractMember_9e8e9937-242e-4dd1-b943-93bfec695a13" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_50963c55-6742-4a9b-ae54-2eff15f09264" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0ed43062-ed06-42d5-82b4-29f37df6b540" xlink:to="loc_us-gaap_InterestRateSwapMember_50963c55-6742-4a9b-ae54-2eff15f09264" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#FinancialInstrumentsFairValueofFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails" xlink:type="extended" id="i76fd6c6252194e7e9c1164c664276b56_FinancialInstrumentsFairValueofFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_28d6da0a-02a7-4d74-9839-219eebd30e2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_693130d3-7a0f-4554-87ed-c13edfaff0a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_28d6da0a-02a7-4d74-9839-219eebd30e2b" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_693130d3-7a0f-4554-87ed-c13edfaff0a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c02d8608-cc73-460e-af46-a2914187f0b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_28d6da0a-02a7-4d74-9839-219eebd30e2b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c02d8608-cc73-460e-af46-a2914187f0b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_a9c0b173-5240-4b25-a84b-077f7824175e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_28d6da0a-02a7-4d74-9839-219eebd30e2b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_a9c0b173-5240-4b25-a84b-077f7824175e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_24d9731d-d466-41a7-b356-d48c9df84404" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_28d6da0a-02a7-4d74-9839-219eebd30e2b" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_24d9731d-d466-41a7-b356-d48c9df84404" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_c2b6e0c3-8e12-46ca-8710-945060bd0b9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_28d6da0a-02a7-4d74-9839-219eebd30e2b" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_c2b6e0c3-8e12-46ca-8710-945060bd0b9c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_d2a3db5f-4a6b-4c41-b18d-34d0f1afce33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_28d6da0a-02a7-4d74-9839-219eebd30e2b" xlink:to="loc_us-gaap_OtherLongTermInvestments_d2a3db5f-4a6b-4c41-b18d-34d0f1afce33" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_39e36a4f-9a69-48b3-8a18-77b33203a822" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_28d6da0a-02a7-4d74-9839-219eebd30e2b" xlink:to="loc_us-gaap_LongTermInvestments_39e36a4f-9a69-48b3-8a18-77b33203a822" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_f3b20649-bfe3-414a-b2aa-3f9b8526e6a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_28d6da0a-02a7-4d74-9839-219eebd30e2b" xlink:to="loc_us-gaap_LongTermDebt_f3b20649-bfe3-414a-b2aa-3f9b8526e6a8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4ec1a449-c378-4bcd-9622-8eef40b3d9a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_28d6da0a-02a7-4d74-9839-219eebd30e2b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4ec1a449-c378-4bcd-9622-8eef40b3d9a7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_3e9aba55-53c5-4f32-95e6-2df6252cddb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4ec1a449-c378-4bcd-9622-8eef40b3d9a7" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_3e9aba55-53c5-4f32-95e6-2df6252cddb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_3e9aba55-53c5-4f32-95e6-2df6252cddb7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_3e9aba55-53c5-4f32-95e6-2df6252cddb7" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_3e9aba55-53c5-4f32-95e6-2df6252cddb7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_bcfdc6b5-0291-4de2-995c-89ee0e9498ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_3e9aba55-53c5-4f32-95e6-2df6252cddb7" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_bcfdc6b5-0291-4de2-995c-89ee0e9498ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2f66fc76-3552-4fdf-b14b-beff8364ff59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_bcfdc6b5-0291-4de2-995c-89ee0e9498ff" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2f66fc76-3552-4fdf-b14b-beff8364ff59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_302c0b02-51af-475a-97ae-09bc44688432" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_bcfdc6b5-0291-4de2-995c-89ee0e9498ff" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_302c0b02-51af-475a-97ae-09bc44688432" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_d645404d-ae5b-4d40-8512-204caa983496" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_bcfdc6b5-0291-4de2-995c-89ee0e9498ff" xlink:to="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_d645404d-ae5b-4d40-8512-204caa983496" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_2d50943e-b0df-4ae4-8175-aa380a7b47ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_bcfdc6b5-0291-4de2-995c-89ee0e9498ff" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_2d50943e-b0df-4ae4-8175-aa380a7b47ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2c57234e-d1e5-4e0b-96f9-5285bf082961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4ec1a449-c378-4bcd-9622-8eef40b3d9a7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2c57234e-d1e5-4e0b-96f9-5285bf082961" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2c57234e-d1e5-4e0b-96f9-5285bf082961_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2c57234e-d1e5-4e0b-96f9-5285bf082961" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2c57234e-d1e5-4e0b-96f9-5285bf082961_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a59e4711-669f-4f80-ab63-6964d1e58964" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2c57234e-d1e5-4e0b-96f9-5285bf082961" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a59e4711-669f-4f80-ab63-6964d1e58964" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_b50301d6-29c1-4f5f-b92a-491d074225c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a59e4711-669f-4f80-ab63-6964d1e58964" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_b50301d6-29c1-4f5f-b92a-491d074225c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_7ce01efb-8498-4cd5-9d3c-4326d419469d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a59e4711-669f-4f80-ab63-6964d1e58964" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_7ce01efb-8498-4cd5-9d3c-4326d419469d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_4dab4092-528b-4531-b0a4-01d5b00807cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a59e4711-669f-4f80-ab63-6964d1e58964" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_4dab4092-528b-4531-b0a4-01d5b00807cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_548ce93f-a5b9-4748-a071-4ea44e1dbbde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a59e4711-669f-4f80-ab63-6964d1e58964" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_548ce93f-a5b9-4748-a071-4ea44e1dbbde" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember_6d5c1de5-d194-4419-9e0b-2d2b9b0d6f61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a59e4711-669f-4f80-ab63-6964d1e58964" xlink:to="loc_us-gaap_MortgageBackedSecuritiesMember_6d5c1de5-d194-4419-9e0b-2d2b9b0d6f61" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherEquitySecuritiesMember_0a8f3f5a-5e56-4c55-aba7-e230d8e5d121" xlink:href="lly-20210331.xsd#lly_OtherEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a59e4711-669f-4f80-ab63-6964d1e58964" xlink:to="loc_lly_OtherEquitySecuritiesMember_0a8f3f5a-5e56-4c55-aba7-e230d8e5d121" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MarketableSecuritiesMember_933cf1fb-2282-43a9-a838-4f3b4bed7e12" xlink:href="lly-20210331.xsd#lly_MarketableSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a59e4711-669f-4f80-ab63-6964d1e58964" xlink:to="loc_lly_MarketableSecuritiesMember_933cf1fb-2282-43a9-a838-4f3b4bed7e12" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EquityMethodAndOtherInvestmentsMember_17468f6a-4484-40c8-a41c-37e886879ed1" xlink:href="lly-20210331.xsd#lly_EquityMethodAndOtherInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a59e4711-669f-4f80-ab63-6964d1e58964" xlink:to="loc_lly_EquityMethodAndOtherInvestmentsMember_17468f6a-4484-40c8-a41c-37e886879ed1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d9d3de97-30ef-4403-9a6b-c6e20fe78d51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4ec1a449-c378-4bcd-9622-8eef40b3d9a7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d9d3de97-30ef-4403-9a6b-c6e20fe78d51" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d9d3de97-30ef-4403-9a6b-c6e20fe78d51_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d9d3de97-30ef-4403-9a6b-c6e20fe78d51" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d9d3de97-30ef-4403-9a6b-c6e20fe78d51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c671464c-fb14-4c02-8aad-521243a471f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d9d3de97-30ef-4403-9a6b-c6e20fe78d51" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c671464c-fb14-4c02-8aad-521243a471f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_188c3e47-fe6d-4a13-83d7-0cbf2e769353" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c671464c-fb14-4c02-8aad-521243a471f1" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_188c3e47-fe6d-4a13-83d7-0cbf2e769353" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_409053de-e74c-4355-acf2-fc8792174c78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c671464c-fb14-4c02-8aad-521243a471f1" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_409053de-e74c-4355-acf2-fc8792174c78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_cb7bd515-6103-4023-b385-1057c9b4f0da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c671464c-fb14-4c02-8aad-521243a471f1" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_cb7bd515-6103-4023-b385-1057c9b4f0da" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#FinancialInstrumentsRiskManagementInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails" xlink:type="extended" id="i36230c8de9434c9baf5ea10a3e1742e2_FinancialInstrumentsRiskManagementInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_df0fb750-4678-48ca-9506-73808304bb41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_8b1c270b-b9f0-430a-845c-e3b009e3cf28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_df0fb750-4678-48ca-9506-73808304bb41" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_8b1c270b-b9f0-430a-845c-e3b009e3cf28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_a3cd5699-df0b-425a-a178-df54a7d14ff0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_df0fb750-4678-48ca-9506-73808304bb41" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_a3cd5699-df0b-425a-a178-df54a7d14ff0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_05a1f91b-f1ee-45d7-a78e-a5ac0df78c57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_df0fb750-4678-48ca-9506-73808304bb41" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_05a1f91b-f1ee-45d7-a78e-a5ac0df78c57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_55752126-f23c-4d42-b0bc-fabf77c2d13e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_df0fb750-4678-48ca-9506-73808304bb41" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_55752126-f23c-4d42-b0bc-fabf77c2d13e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4cc4ea6e-2fdf-4d4f-bcc6-613b0559015e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_df0fb750-4678-48ca-9506-73808304bb41" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4cc4ea6e-2fdf-4d4f-bcc6-613b0559015e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3e9cc9a7-b812-4b78-a2d3-850334831b53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_df0fb750-4678-48ca-9506-73808304bb41" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3e9cc9a7-b812-4b78-a2d3-850334831b53" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_99ec58d6-5144-4623-898a-b24ea527cfbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3e9cc9a7-b812-4b78-a2d3-850334831b53" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_99ec58d6-5144-4623-898a-b24ea527cfbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_99ec58d6-5144-4623-898a-b24ea527cfbf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_99ec58d6-5144-4623-898a-b24ea527cfbf" xlink:to="loc_us-gaap_HedgingRelationshipDomain_99ec58d6-5144-4623-898a-b24ea527cfbf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_19179d7d-33d4-460e-bb18-c2e1094ce2ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_99ec58d6-5144-4623-898a-b24ea527cfbf" xlink:to="loc_us-gaap_HedgingRelationshipDomain_19179d7d-33d4-460e-bb18-c2e1094ce2ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_3734f44a-7d1c-4dde-85fe-88ea34f242bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_19179d7d-33d4-460e-bb18-c2e1094ce2ef" xlink:to="loc_us-gaap_FairValueHedgingMember_3734f44a-7d1c-4dde-85fe-88ea34f242bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_01b99251-5e6f-4b9d-8619-103bc04b0075" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_19179d7d-33d4-460e-bb18-c2e1094ce2ef" xlink:to="loc_us-gaap_CashFlowHedgingMember_01b99251-5e6f-4b9d-8619-103bc04b0075" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_990e469c-18a7-4934-9562-ed167eaa20c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_19179d7d-33d4-460e-bb18-c2e1094ce2ef" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_990e469c-18a7-4934-9562-ed167eaa20c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_9b99d27c-3317-4534-b284-f3049397b869" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3e9cc9a7-b812-4b78-a2d3-850334831b53" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_9b99d27c-3317-4534-b284-f3049397b869" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_9b99d27c-3317-4534-b284-f3049397b869_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_9b99d27c-3317-4534-b284-f3049397b869" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_9b99d27c-3317-4534-b284-f3049397b869_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_baef8bbe-5459-4f8b-be56-ece89566a3f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_9b99d27c-3317-4534-b284-f3049397b869" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_baef8bbe-5459-4f8b-be56-ece89566a3f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c79fd35a-1937-4688-9345-11aa8398f329" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_baef8bbe-5459-4f8b-be56-ece89566a3f6" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c79fd35a-1937-4688-9345-11aa8398f329" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_ac40e24e-5d79-4986-b324-ce236ecbd52d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_baef8bbe-5459-4f8b-be56-ece89566a3f6" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_ac40e24e-5d79-4986-b324-ce236ecbd52d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_03cfc68d-d8c7-4283-980a-538099dd6088" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_baef8bbe-5459-4f8b-be56-ece89566a3f6" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_03cfc68d-d8c7-4283-980a-538099dd6088" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_00efe8ac-5fcd-441e-84f1-2c61fcdd7b1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3e9cc9a7-b812-4b78-a2d3-850334831b53" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_00efe8ac-5fcd-441e-84f1-2c61fcdd7b1c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_00efe8ac-5fcd-441e-84f1-2c61fcdd7b1c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_00efe8ac-5fcd-441e-84f1-2c61fcdd7b1c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_00efe8ac-5fcd-441e-84f1-2c61fcdd7b1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e3a5be5e-6de2-499d-8014-829d395cd471" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_00efe8ac-5fcd-441e-84f1-2c61fcdd7b1c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e3a5be5e-6de2-499d-8014-829d395cd471" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_d70ae6a0-275d-470b-b557-997c23452fbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e3a5be5e-6de2-499d-8014-829d395cd471" xlink:to="loc_us-gaap_InterestRateContractMember_d70ae6a0-275d-470b-b557-997c23452fbf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_34fa3446-ebd7-496b-b961-665bf78be575" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e3a5be5e-6de2-499d-8014-829d395cd471" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_34fa3446-ebd7-496b-b961-665bf78be575" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_ae1fb8f3-7002-4906-b10e-fdd5403597e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e3a5be5e-6de2-499d-8014-829d395cd471" xlink:to="loc_us-gaap_ForeignExchangeContractMember_ae1fb8f3-7002-4906-b10e-fdd5403597e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_6f314b97-0850-47d4-944e-b19c0614ec7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3e9cc9a7-b812-4b78-a2d3-850334831b53" xlink:to="loc_us-gaap_HedgingDesignationAxis_6f314b97-0850-47d4-944e-b19c0614ec7f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_6f314b97-0850-47d4-944e-b19c0614ec7f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_6f314b97-0850-47d4-944e-b19c0614ec7f" xlink:to="loc_us-gaap_HedgingDesignationDomain_6f314b97-0850-47d4-944e-b19c0614ec7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_0cc375ae-96ce-436d-8cab-4af1bccfc8c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_6f314b97-0850-47d4-944e-b19c0614ec7f" xlink:to="loc_us-gaap_HedgingDesignationDomain_0cc375ae-96ce-436d-8cab-4af1bccfc8c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_4f5bd4a0-f13b-4ac0-aa57-29bbd69f940c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_0cc375ae-96ce-436d-8cab-4af1bccfc8c3" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_4f5bd4a0-f13b-4ac0-aa57-29bbd69f940c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_a23fc233-57e4-4218-8791-4f1a04dd62d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_0cc375ae-96ce-436d-8cab-4af1bccfc8c3" xlink:to="loc_us-gaap_NondesignatedMember_a23fc233-57e4-4218-8791-4f1a04dd62d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_79aa4a9b-8b06-4b77-82b9-50c1a7686c2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3e9cc9a7-b812-4b78-a2d3-850334831b53" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_79aa4a9b-8b06-4b77-82b9-50c1a7686c2e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_79aa4a9b-8b06-4b77-82b9-50c1a7686c2e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_79aa4a9b-8b06-4b77-82b9-50c1a7686c2e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_79aa4a9b-8b06-4b77-82b9-50c1a7686c2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6b7f395a-2277-4275-b3ae-3c1b6a157104" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_79aa4a9b-8b06-4b77-82b9-50c1a7686c2e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6b7f395a-2277-4275-b3ae-3c1b6a157104" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_0dee082a-ff55-4eee-b9ea-218bb670a8ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6b7f395a-2277-4275-b3ae-3c1b6a157104" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_0dee082a-ff55-4eee-b9ea-218bb670a8ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_caa3ff3f-97d9-42c4-adc3-e083727a6040" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6b7f395a-2277-4275-b3ae-3c1b6a157104" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_caa3ff3f-97d9-42c4-adc3-e083727a6040" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_801ce60c-62fb-453b-afe1-3ae79c7ac917" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6b7f395a-2277-4275-b3ae-3c1b6a157104" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_801ce60c-62fb-453b-afe1-3ae79c7ac917" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#FinancialInstrumentsContractualMaturitiesDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails" xlink:type="extended" id="i6dc84b1afda3419ea0e4c9f7b00dcf65_FinancialInstrumentsContractualMaturitiesDetails"/>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#FinancialInstrumentsUnrealizedGainsandLossesDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails" xlink:type="extended" id="i236e824dcebd4d85932031d81a186b85_FinancialInstrumentsUnrealizedGainsandLossesDetails"/>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#FinancialInstrumentsRealizedGainsandLossesDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails" xlink:type="extended" id="ia13478f4447944438ed6b1d9872f3726_FinancialInstrumentsRealizedGainsandLossesDetails"/>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxes" xlink:type="simple" xlink:href="lly-20210331.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/IncomeTaxes" xlink:type="extended" id="idcfedc4b74364974b09a5758fcfabb5c_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#IncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/IncomeTaxesDetails" xlink:type="extended" id="icddab8a8df7745c3bfb87d7b18305506_IncomeTaxesDetails"/>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefits" xlink:type="simple" xlink:href="lly-20210331.xsd#RetirementBenefits"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RetirementBenefits" xlink:type="extended" id="ic0d92f660c4b454292d210f52a4d5a3e_RetirementBenefits"/>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsTables" xlink:type="simple" xlink:href="lly-20210331.xsd#RetirementBenefitsTables"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RetirementBenefitsTables" xlink:type="extended" id="i514db338cb0847bba0a6febd51582501_RetirementBenefitsTables"/>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended" id="i82c42ce4d8234ae2ae572cedfcf30073_RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1dab591e-fb3b-4188-a3a0-15d75d41ca08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_1b9aa6cb-92cd-4120-bb59-59a63460e8c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1dab591e-fb3b-4188-a3a0-15d75d41ca08" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_1b9aa6cb-92cd-4120-bb59-59a63460e8c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_60d5477a-c0b1-4373-8961-b9ef3bdd8e0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1dab591e-fb3b-4188-a3a0-15d75d41ca08" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_60d5477a-c0b1-4373-8961-b9ef3bdd8e0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_f2f86b67-b0da-4d18-9efc-f2e4ffb47b0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1dab591e-fb3b-4188-a3a0-15d75d41ca08" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_f2f86b67-b0da-4d18-9efc-f2e4ffb47b0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_8594142d-9346-467b-aafc-7207526db8fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1dab591e-fb3b-4188-a3a0-15d75d41ca08" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_8594142d-9346-467b-aafc-7207526db8fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_213b7f76-36f9-406f-9c15-6cc0901ffc41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1dab591e-fb3b-4188-a3a0-15d75d41ca08" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_213b7f76-36f9-406f-9c15-6cc0901ffc41" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_cd3531e7-7e7b-4a7c-a6ef-03dc14099710" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1dab591e-fb3b-4188-a3a0-15d75d41ca08" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_cd3531e7-7e7b-4a7c-a6ef-03dc14099710" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_d514aff9-3811-4ff4-853f-01bf17752bd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1dab591e-fb3b-4188-a3a0-15d75d41ca08" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_d514aff9-3811-4ff4-853f-01bf17752bd0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_592468eb-fff3-4fd6-bdca-65eb76307c28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_d514aff9-3811-4ff4-853f-01bf17752bd0" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_592468eb-fff3-4fd6-bdca-65eb76307c28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_592468eb-fff3-4fd6-bdca-65eb76307c28_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_592468eb-fff3-4fd6-bdca-65eb76307c28" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_592468eb-fff3-4fd6-bdca-65eb76307c28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_478a992f-d488-4ba2-8308-c0657f651b04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_592468eb-fff3-4fd6-bdca-65eb76307c28" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_478a992f-d488-4ba2-8308-c0657f651b04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_a91ee94d-2b73-4bef-9520-231144f155a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_478a992f-d488-4ba2-8308-c0657f651b04" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_a91ee94d-2b73-4bef-9520-231144f155a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_8804a6fb-b015-40b4-89b4-b48107476e0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_478a992f-d488-4ba2-8308-c0657f651b04" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_8804a6fb-b015-40b4-89b4-b48107476e0c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsNarrativeDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#RetirementBenefitsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RetirementBenefitsNarrativeDetails" xlink:type="extended" id="i60e96ebf60704a458fa51fd0bea8a933_RetirementBenefitsNarrativeDetails"/>
  <link:roleRef roleURI="http://www.lilly.com/role/Contingencies" xlink:type="simple" xlink:href="lly-20210331.xsd#Contingencies"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/Contingencies" xlink:type="extended" id="i5565c29d5cc74ece8b8c2328187c26b5_Contingencies"/>
  <link:roleRef roleURI="http://www.lilly.com/role/ContingenciesDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#ContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/ContingenciesDetails" xlink:type="extended" id="i73ec11add291473c862a3d6eeea017f5_ContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_1c690e1e-d660-4b29-a761-7057c7c7d980" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm_38dd3512-3aeb-40c5-b74e-9024878db664" xlink:href="lly-20210331.xsd#lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1c690e1e-d660-4b29-a761-7057c7c7d980" xlink:to="loc_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm_38dd3512-3aeb-40c5-b74e-9024878db664" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfPatents_913fe99d-a65f-46e4-b948-f635b36d35d4" xlink:href="lly-20210331.xsd#lly_LossContingencyNumberOfPatents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1c690e1e-d660-4b29-a761-7057c7c7d980" xlink:to="loc_lly_LossContingencyNumberOfPatents_913fe99d-a65f-46e4-b948-f635b36d35d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfPatentsClaimsDismissed_177b45b3-1633-46db-9108-15f5648c6a44" xlink:href="lly-20210331.xsd#lly_LossContingencyNumberOfPatentsClaimsDismissed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1c690e1e-d660-4b29-a761-7057c7c7d980" xlink:to="loc_lly_LossContingencyNumberOfPatentsClaimsDismissed_177b45b3-1633-46db-9108-15f5648c6a44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfPatentsRuledUnpatentable_a11815d7-51f4-4d13-9cae-1f1fedc54d75" xlink:href="lly-20210331.xsd#lly_LossContingencyNumberOfPatentsRuledUnpatentable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1c690e1e-d660-4b29-a761-7057c7c7d980" xlink:to="loc_lly_LossContingencyNumberOfPatentsRuledUnpatentable_a11815d7-51f4-4d13-9cae-1f1fedc54d75" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_59857b25-100e-4442-827b-79dfe1dbc59f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1c690e1e-d660-4b29-a761-7057c7c7d980" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_59857b25-100e-4442-827b-79dfe1dbc59f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_2ea176b6-f116-4418-8f13-06c66b315a07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1c690e1e-d660-4b29-a761-7057c7c7d980" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_2ea176b6-f116-4418-8f13-06c66b315a07" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfClaimants_6400ac1c-6b68-419d-8138-4922277b69da" xlink:href="lly-20210331.xsd#lly_LossContingencyNumberOfClaimants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1c690e1e-d660-4b29-a761-7057c7c7d980" xlink:to="loc_lly_LossContingencyNumberOfClaimants_6400ac1c-6b68-419d-8138-4922277b69da" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup_f5ce0bcf-3451-411c-bd45-343a27b925b9" xlink:href="lly-20210331.xsd#lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1c690e1e-d660-4b29-a761-7057c7c7d980" xlink:to="loc_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup_f5ce0bcf-3451-411c-bd45-343a27b925b9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_fce23ba8-cd65-4fb4-b1b6-48b4a7720af4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1c690e1e-d660-4b29-a761-7057c7c7d980" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_fce23ba8-cd65-4fb4-b1b6-48b4a7720af4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfRequestsForInformation_531a286a-d31b-4607-8e89-bf210960d65c" xlink:href="lly-20210331.xsd#lly_LossContingencyNumberOfRequestsForInformation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1c690e1e-d660-4b29-a761-7057c7c7d980" xlink:to="loc_lly_LossContingencyNumberOfRequestsForInformation_531a286a-d31b-4607-8e89-bf210960d65c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_32801a9b-7f49-4ae8-86e3-43e7a9f683ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_1c690e1e-d660-4b29-a761-7057c7c7d980" xlink:to="loc_us-gaap_LossContingenciesTable_32801a9b-7f49-4ae8-86e3-43e7a9f683ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_504673ca-35d6-404e-80fe-c13c0ee6cb57" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_32801a9b-7f49-4ae8-86e3-43e7a9f683ba" xlink:to="loc_srt_StatementGeographicalAxis_504673ca-35d6-404e-80fe-c13c0ee6cb57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_504673ca-35d6-404e-80fe-c13c0ee6cb57_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_504673ca-35d6-404e-80fe-c13c0ee6cb57" xlink:to="loc_srt_SegmentGeographicalDomain_504673ca-35d6-404e-80fe-c13c0ee6cb57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6d542446-be73-4280-a7dc-5dac1cb59f99" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_504673ca-35d6-404e-80fe-c13c0ee6cb57" xlink:to="loc_srt_SegmentGeographicalDomain_6d542446-be73-4280-a7dc-5dac1cb59f99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_BR_527888fb-9c02-4905-80ec-020cf82b46ff" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_BR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6d542446-be73-4280-a7dc-5dac1cb59f99" xlink:to="loc_country_BR_527888fb-9c02-4905-80ec-020cf82b46ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_90a72255-ff94-4bab-a089-8f5f61b9e308" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_32801a9b-7f49-4ae8-86e3-43e7a9f683ba" xlink:to="loc_srt_LitigationCaseAxis_90a72255-ff94-4bab-a089-8f5f61b9e308" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_90a72255-ff94-4bab-a089-8f5f61b9e308_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_90a72255-ff94-4bab-a089-8f5f61b9e308" xlink:to="loc_srt_LitigationCaseTypeDomain_90a72255-ff94-4bab-a089-8f5f61b9e308_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_eea9a6e5-001d-4c4b-a864-ffc579b9229e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_90a72255-ff94-4bab-a089-8f5f61b9e308" xlink:to="loc_srt_LitigationCaseTypeDomain_eea9a6e5-001d-4c4b-a864-ffc579b9229e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DrReddysLabMember_3f7ac731-3584-424c-b4fb-0f94c851ff82" xlink:href="lly-20210331.xsd#lly_DrReddysLabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_eea9a6e5-001d-4c4b-a864-ffc579b9229e" xlink:to="loc_lly_DrReddysLabMember_3f7ac731-3584-424c-b4fb-0f94c851ff82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmgalityPatentLitigationMember_22190af3-20e2-4d5e-9bbc-017e675c4c64" xlink:href="lly-20210331.xsd#lly_EmgalityPatentLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_eea9a6e5-001d-4c4b-a864-ffc579b9229e" xlink:to="loc_lly_EmgalityPatentLitigationMember_22190af3-20e2-4d5e-9bbc-017e675c4c64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember_23658d9b-a486-4381-a341-38eb6bfc4c89" xlink:href="lly-20210331.xsd#lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_eea9a6e5-001d-4c4b-a864-ffc579b9229e" xlink:to="loc_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember_23658d9b-a486-4381-a341-38eb6bfc4c89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_WhyteEtAlVEliLillyEtAlMember_1941f3f7-bc8b-4d47-895e-cce57026be54" xlink:href="lly-20210331.xsd#lly_WhyteEtAlVEliLillyEtAlMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_eea9a6e5-001d-4c4b-a864-ffc579b9229e" xlink:to="loc_lly_WhyteEtAlVEliLillyEtAlMember_1941f3f7-bc8b-4d47-895e-cce57026be54" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_WeilerVTakedaCanadaIncEtAlMember_f1cf096f-addd-4b21-8f5b-681abc31cb7c" xlink:href="lly-20210331.xsd#lly_WeilerVTakedaCanadaIncEtAlMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_eea9a6e5-001d-4c4b-a864-ffc579b9229e" xlink:to="loc_lly_WeilerVTakedaCanadaIncEtAlMember_f1cf096f-addd-4b21-8f5b-681abc31cb7c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EppVTakedaCanadaIncEtAlMember_9dac1693-b208-4d60-9dfc-75d7afe7725b" xlink:href="lly-20210331.xsd#lly_EppVTakedaCanadaIncEtAlMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_eea9a6e5-001d-4c4b-a864-ffc579b9229e" xlink:to="loc_lly_EppVTakedaCanadaIncEtAlMember_9dac1693-b208-4d60-9dfc-75d7afe7725b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmployeeLitigationMember_51a3b154-0b64-4b63-a94c-80361cf23af9" xlink:href="lly-20210331.xsd#lly_EmployeeLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_eea9a6e5-001d-4c4b-a864-ffc579b9229e" xlink:to="loc_lly_EmployeeLitigationMember_51a3b154-0b64-4b63-a94c-80361cf23af9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a97e5bcd-6f53-4aa6-8686-cb09e1b3c132" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_32801a9b-7f49-4ae8-86e3-43e7a9f683ba" xlink:to="loc_srt_ProductOrServiceAxis_a97e5bcd-6f53-4aa6-8686-cb09e1b3c132" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a97e5bcd-6f53-4aa6-8686-cb09e1b3c132_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a97e5bcd-6f53-4aa6-8686-cb09e1b3c132" xlink:to="loc_srt_ProductsAndServicesDomain_a97e5bcd-6f53-4aa6-8686-cb09e1b3c132_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_78e90a10-87bf-4bb7-a994-31a1a1a047ca" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a97e5bcd-6f53-4aa6-8686-cb09e1b3c132" xlink:to="loc_srt_ProductsAndServicesDomain_78e90a10-87bf-4bb7-a994-31a1a1a047ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ActosMember_f905f210-7d52-4085-accd-975cad08a771" xlink:href="lly-20210331.xsd#lly_ActosMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_78e90a10-87bf-4bb7-a994-31a1a1a047ca" xlink:to="loc_lly_ActosMember_f905f210-7d52-4085-accd-975cad08a771" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ByettaMember_14ad7ce6-4eef-43cd-94a0-5a40e82254cb" xlink:href="lly-20210331.xsd#lly_ByettaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_78e90a10-87bf-4bb7-a994-31a1a1a047ca" xlink:to="loc_lly_ByettaMember_14ad7ce6-4eef-43cd-94a0-5a40e82254cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CialisMember_c93734f3-b7f7-4743-aa14-29b4ebcd6f0f" xlink:href="lly-20210331.xsd#lly_CialisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_78e90a10-87bf-4bb7-a994-31a1a1a047ca" xlink:to="loc_lly_CialisMember_c93734f3-b7f7-4743-aa14-29b4ebcd6f0f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_7db32335-45b0-43e1-b1e7-ee0986318e3b" xlink:href="lly-20210331.xsd#lly_JardianceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_78e90a10-87bf-4bb7-a994-31a1a1a047ca" xlink:to="loc_lly_JardianceMember_7db32335-45b0-43e1-b1e7-ee0986318e3b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumalogHumulinAndForteoMember_09de4c8d-50c6-475a-a838-a82e67c91134" xlink:href="lly-20210331.xsd#lly_HumalogHumulinAndForteoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_78e90a10-87bf-4bb7-a994-31a1a1a047ca" xlink:to="loc_lly_HumalogHumulinAndForteoMember_09de4c8d-50c6-475a-a838-a82e67c91134" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DomicileOfLitigationAxis_69052e37-5c07-47b8-b457-a2d3f9c6cc20" xlink:href="lly-20210331.xsd#lly_DomicileOfLitigationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_32801a9b-7f49-4ae8-86e3-43e7a9f683ba" xlink:to="loc_lly_DomicileOfLitigationAxis_69052e37-5c07-47b8-b457-a2d3f9c6cc20" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DomicileOfLitigationDomain_69052e37-5c07-47b8-b457-a2d3f9c6cc20_default" xlink:href="lly-20210331.xsd#lly_DomicileOfLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_lly_DomicileOfLitigationAxis_69052e37-5c07-47b8-b457-a2d3f9c6cc20" xlink:to="loc_lly_DomicileOfLitigationDomain_69052e37-5c07-47b8-b457-a2d3f9c6cc20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DomicileOfLitigationDomain_305eba41-58c9-43de-b751-a940cf83abd7" xlink:href="lly-20210331.xsd#lly_DomicileOfLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_lly_DomicileOfLitigationAxis_69052e37-5c07-47b8-b457-a2d3f9c6cc20" xlink:to="loc_lly_DomicileOfLitigationDomain_305eba41-58c9-43de-b751-a940cf83abd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LosAngelesMember_07c535c4-8502-48f4-acd3-31f45ff1a138" xlink:href="lly-20210331.xsd#lly_LosAngelesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DomicileOfLitigationDomain_305eba41-58c9-43de-b751-a940cf83abd7" xlink:to="loc_lly_LosAngelesMember_07c535c4-8502-48f4-acd3-31f45ff1a138" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SouthernDistrictOfCaliforniaMember_32376e5c-1b3c-437a-8527-cca6ffa15bbf" xlink:href="lly-20210331.xsd#lly_SouthernDistrictOfCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DomicileOfLitigationDomain_305eba41-58c9-43de-b751-a940cf83abd7" xlink:to="loc_lly_SouthernDistrictOfCaliforniaMember_32376e5c-1b3c-437a-8527-cca6ffa15bbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_VariousStateDomicilesMember_7218acad-e8a5-43df-b36e-1dd8d30ccdff" xlink:href="lly-20210331.xsd#lly_VariousStateDomicilesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DomicileOfLitigationDomain_305eba41-58c9-43de-b751-a940cf83abd7" xlink:to="loc_lly_VariousStateDomicilesMember_7218acad-e8a5-43df-b36e-1dd8d30ccdff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PlaintiffAllegationsAxis_213af3f3-bacc-4528-87c1-f51a6b0f2877" xlink:href="lly-20210331.xsd#lly_PlaintiffAllegationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_32801a9b-7f49-4ae8-86e3-43e7a9f683ba" xlink:to="loc_lly_PlaintiffAllegationsAxis_213af3f3-bacc-4528-87c1-f51a6b0f2877" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PlaintiffAllegationsDomain_213af3f3-bacc-4528-87c1-f51a6b0f2877_default" xlink:href="lly-20210331.xsd#lly_PlaintiffAllegationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_lly_PlaintiffAllegationsAxis_213af3f3-bacc-4528-87c1-f51a6b0f2877" xlink:to="loc_lly_PlaintiffAllegationsDomain_213af3f3-bacc-4528-87c1-f51a6b0f2877_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PlaintiffAllegationsDomain_e04e1079-7014-4f02-8908-873ea2f652c9" xlink:href="lly-20210331.xsd#lly_PlaintiffAllegationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_lly_PlaintiffAllegationsAxis_213af3f3-bacc-4528-87c1-f51a6b0f2877" xlink:to="loc_lly_PlaintiffAllegationsDomain_e04e1079-7014-4f02-8908-873ea2f652c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PancreaticCancerOrThyroidCancerMember_d7bf04a2-1b19-4a32-a89d-2fd3ee588867" xlink:href="lly-20210331.xsd#lly_PancreaticCancerOrThyroidCancerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_PlaintiffAllegationsDomain_e04e1079-7014-4f02-8908-873ea2f652c9" xlink:to="loc_lly_PancreaticCancerOrThyroidCancerMember_d7bf04a2-1b19-4a32-a89d-2fd3ee588867" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PancreatitisMember_2719cedb-8cb1-45c5-87bb-55ac585976f1" xlink:href="lly-20210331.xsd#lly_PancreatitisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_PlaintiffAllegationsDomain_e04e1079-7014-4f02-8908-873ea2f652c9" xlink:to="loc_lly_PancreatitisMember_2719cedb-8cb1-45c5-87bb-55ac585976f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AmpullaryCancerMember_a58e0560-66ea-4d52-9955-ac27aeeb3336" xlink:href="lly-20210331.xsd#lly_AmpullaryCancerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_PlaintiffAllegationsDomain_e04e1079-7014-4f02-8908-873ea2f652c9" xlink:to="loc_lly_AmpullaryCancerMember_a58e0560-66ea-4d52-9955-ac27aeeb3336" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6b2ca16d-f79e-4f24-962c-a8c48ee9957f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_32801a9b-7f49-4ae8-86e3-43e7a9f683ba" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6b2ca16d-f79e-4f24-962c-a8c48ee9957f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_6b2ca16d-f79e-4f24-962c-a8c48ee9957f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6b2ca16d-f79e-4f24-962c-a8c48ee9957f" xlink:to="loc_us-gaap_LossContingencyNatureDomain_6b2ca16d-f79e-4f24-962c-a8c48ee9957f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_7763ad7f-2a12-46b4-99b2-4344935466a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6b2ca16d-f79e-4f24-962c-a8c48ee9957f" xlink:to="loc_us-gaap_LossContingencyNatureDomain_7763ad7f-2a12-46b4-99b2-4344935466a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProductLiabilityMember_3a3d5f91-4d14-4231-aeb5-9bb075daf08b" xlink:href="lly-20210331.xsd#lly_ProductLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_7763ad7f-2a12-46b4-99b2-4344935466a0" xlink:to="loc_lly_ProductLiabilityMember_3a3d5f91-4d14-4231-aeb5-9bb075daf08b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember_6cee22dc-ad47-4e07-bfac-03131b58fc66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnfavorableRegulatoryActionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_7763ad7f-2a12-46b4-99b2-4344935466a0" xlink:to="loc_us-gaap_UnfavorableRegulatoryActionMember_6cee22dc-ad47-4e07-bfac-03131b58fc66" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLoss" xlink:type="simple" xlink:href="lly-20210331.xsd#OtherComprehensiveIncomeLoss"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLoss" xlink:type="extended" id="i2e86906543204b36a897ddd4ed5cc289_OtherComprehensiveIncomeLoss"/>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="lly-20210331.xsd#OtherComprehensiveIncomeLossTables"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossTables" xlink:type="extended" id="ia84dc84490b041cfb4042266aee7fc67_OtherComprehensiveIncomeLossTables"/>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#OtherComprehensiveIncomeLossAOCIDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails" xlink:type="extended" id="i72a6b7f8285146c4b41f68095ad95482_OtherComprehensiveIncomeLossAOCIDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_08c75747-b4d3-427f-855d-e4101af34c5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_03d31278-524c-486b-8ce6-d1552472491a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_08c75747-b4d3-427f-855d-e4101af34c5f" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_03d31278-524c-486b-8ce6-d1552472491a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_25052755-b188-46e4-9514-219182165982" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_03d31278-524c-486b-8ce6-d1552472491a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_25052755-b188-46e4-9514-219182165982" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_2a5ce90a-ca77-424d-90d8-89f10ec4d8f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_03d31278-524c-486b-8ce6-d1552472491a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_2a5ce90a-ca77-424d-90d8-89f10ec4d8f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_ea10d205-0c88-4c99-88a7-63faac6da2bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_03d31278-524c-486b-8ce6-d1552472491a" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_ea10d205-0c88-4c99-88a7-63faac6da2bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d2c830f7-44cd-47e8-a7a6-26e411c32b80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_03d31278-524c-486b-8ce6-d1552472491a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d2c830f7-44cd-47e8-a7a6-26e411c32b80" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a24c9a78-ef97-4362-a108-927d2b8b1cc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c3b4d31c-fbf7-4c7a-8a56-7b22ae189416" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_08c75747-b4d3-427f-855d-e4101af34c5f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c3b4d31c-fbf7-4c7a-8a56-7b22ae189416" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fba13d9b-fd68-4bc3-9960-f905a5f1b3df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c3b4d31c-fbf7-4c7a-8a56-7b22ae189416" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fba13d9b-fd68-4bc3-9960-f905a5f1b3df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fba13d9b-fd68-4bc3-9960-f905a5f1b3df_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fba13d9b-fd68-4bc3-9960-f905a5f1b3df" xlink:to="loc_us-gaap_EquityComponentDomain_fba13d9b-fd68-4bc3-9960-f905a5f1b3df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f9f86046-f80c-4218-91ac-42c4db742087" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fba13d9b-fd68-4bc3-9960-f905a5f1b3df" xlink:to="loc_us-gaap_EquityComponentDomain_f9f86046-f80c-4218-91ac-42c4db742087" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_73f5a2b9-3627-4795-aecb-115b0f76fa78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f9f86046-f80c-4218-91ac-42c4db742087" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_73f5a2b9-3627-4795-aecb-115b0f76fa78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_f8585906-e79e-4c83-be4e-d21f96661921" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_73f5a2b9-3627-4795-aecb-115b0f76fa78" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_f8585906-e79e-4c83-be4e-d21f96661921" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_9070b67d-d95d-42f2-ac0a-55a3b7c5510d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_73f5a2b9-3627-4795-aecb-115b0f76fa78" xlink:to="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_9070b67d-d95d-42f2-ac0a-55a3b7c5510d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_008c0fc2-fb57-47d9-ab42-62352dd489cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_73f5a2b9-3627-4795-aecb-115b0f76fa78" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_008c0fc2-fb57-47d9-ab42-62352dd489cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_9ecd6ff4-c79f-43f1-976c-d5abcd09ed25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_73f5a2b9-3627-4795-aecb-115b0f76fa78" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_9ecd6ff4-c79f-43f1-976c-d5abcd09ed25" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#OtherComprehensiveIncomeLossTaxEffectDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails" xlink:type="extended" id="ia363dab1fcbe4e7a8d8c988e612b33d5_OtherComprehensiveIncomeLossTaxEffectDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_10a420f0-ce6c-4316-8f9c-ed1b43eb58a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_4f229a7c-a65e-4224-95bd-a97100f1a5e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_10a420f0-ce6c-4316-8f9c-ed1b43eb58a4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_4f229a7c-a65e-4224-95bd-a97100f1a5e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_76f32386-7c71-4555-b9eb-03fbe825c6e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_10a420f0-ce6c-4316-8f9c-ed1b43eb58a4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_76f32386-7c71-4555-b9eb-03fbe825c6e9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_aff16e8c-d1c4-47db-b86c-9a15b6cf5ce0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_76f32386-7c71-4555-b9eb-03fbe825c6e9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_aff16e8c-d1c4-47db-b86c-9a15b6cf5ce0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_aff16e8c-d1c4-47db-b86c-9a15b6cf5ce0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_aff16e8c-d1c4-47db-b86c-9a15b6cf5ce0" xlink:to="loc_us-gaap_EquityComponentDomain_aff16e8c-d1c4-47db-b86c-9a15b6cf5ce0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_83a56c8f-8df1-43cd-b15a-b2df1de09b2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_aff16e8c-d1c4-47db-b86c-9a15b6cf5ce0" xlink:to="loc_us-gaap_EquityComponentDomain_83a56c8f-8df1-43cd-b15a-b2df1de09b2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_ac593ded-b7c8-4349-8fc3-b2de5c155498" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_83a56c8f-8df1-43cd-b15a-b2df1de09b2e" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_ac593ded-b7c8-4349-8fc3-b2de5c155498" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_b849982d-bbd7-4cec-b18d-65678f85a313" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_83a56c8f-8df1-43cd-b15a-b2df1de09b2e" xlink:to="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_b849982d-bbd7-4cec-b18d-65678f85a313" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_9fb76a3f-967d-4378-9305-e9ccb997f884" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_83a56c8f-8df1-43cd-b15a-b2df1de09b2e" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_9fb76a3f-967d-4378-9305-e9ccb997f884" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_23f102ad-7df1-4d9b-b613-899fdc5c2aa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_83a56c8f-8df1-43cd-b15a-b2df1de09b2e" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_23f102ad-7df1-4d9b-b613-899fdc5c2aa1" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#OtherComprehensiveIncomeLossReclassificationDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails" xlink:type="extended" id="i85e5d0dfc45546af8e89ef1e107f3f43_OtherComprehensiveIncomeLossReclassificationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_6fefcdb2-f731-4b8a-a6fa-dc917897776c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_fec53d9a-126b-4720-913e-ceff713c1387" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_6fefcdb2-f731-4b8a-a6fa-dc917897776c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_fec53d9a-126b-4720-913e-ceff713c1387" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d82703a0-4b93-4e22-9fb2-a20fefa155f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_6fefcdb2-f731-4b8a-a6fa-dc917897776c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d82703a0-4b93-4e22-9fb2-a20fefa155f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f36dda22-3dba-480c-a689-53e176ecf261" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_6fefcdb2-f731-4b8a-a6fa-dc917897776c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f36dda22-3dba-480c-a689-53e176ecf261" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e6143cf2-bb72-41dd-a185-31047c6ff952" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_6fefcdb2-f731-4b8a-a6fa-dc917897776c" xlink:to="loc_us-gaap_ProfitLoss_e6143cf2-bb72-41dd-a185-31047c6ff952" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_64390716-4879-4936-bceb-89067c1dcff0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_6fefcdb2-f731-4b8a-a6fa-dc917897776c" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_64390716-4879-4936-bceb-89067c1dcff0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b17d9bc9-63bb-4497-afdd-8cb21da5517b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_64390716-4879-4936-bceb-89067c1dcff0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b17d9bc9-63bb-4497-afdd-8cb21da5517b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b17d9bc9-63bb-4497-afdd-8cb21da5517b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b17d9bc9-63bb-4497-afdd-8cb21da5517b" xlink:to="loc_us-gaap_EquityComponentDomain_b17d9bc9-63bb-4497-afdd-8cb21da5517b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8ffd8d6f-f291-43fe-af82-8e6b2a6a63f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b17d9bc9-63bb-4497-afdd-8cb21da5517b" xlink:to="loc_us-gaap_EquityComponentDomain_8ffd8d6f-f291-43fe-af82-8e6b2a6a63f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_6499782e-9935-45c7-8bc4-8d362634abb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8ffd8d6f-f291-43fe-af82-8e6b2a6a63f0" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_6499782e-9935-45c7-8bc4-8d362634abb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember_fbe90100-2c31-41d7-9542-fe98d8747f1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_6499782e-9935-45c7-8bc4-8d362634abb5" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember_fbe90100-2c31-41d7-9542-fe98d8747f1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_a9ae762a-8e00-48de-a6fd-e148db0e0915" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_6499782e-9935-45c7-8bc4-8d362634abb5" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_a9ae762a-8e00-48de-a6fd-e148db0e0915" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_f818948d-4393-41d5-a56f-401fb7aa5261" xlink:href="lly-20210331.xsd#lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8ffd8d6f-f291-43fe-af82-8e6b2a6a63f0" xlink:to="loc_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_f818948d-4393-41d5-a56f-401fb7aa5261" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_990ef70f-b05f-41cc-900d-2c3ab6476d7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_64390716-4879-4936-bceb-89067c1dcff0" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_990ef70f-b05f-41cc-900d-2c3ab6476d7b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_990ef70f-b05f-41cc-900d-2c3ab6476d7b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_990ef70f-b05f-41cc-900d-2c3ab6476d7b" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_990ef70f-b05f-41cc-900d-2c3ab6476d7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_0e363c4b-b945-4132-8138-962adc6a205c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_990ef70f-b05f-41cc-900d-2c3ab6476d7b" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_0e363c4b-b945-4132-8138-962adc6a205c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_6e1e7394-6568-4cc8-9d6a-e97d39cb3523" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_0e363c4b-b945-4132-8138-962adc6a205c" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_6e1e7394-6568-4cc8-9d6a-e97d39cb3523" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherNetIncomeExpense" xlink:type="simple" xlink:href="lly-20210331.xsd#OtherNetIncomeExpense"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/OtherNetIncomeExpense" xlink:type="extended" id="ie07272a341d24741a01dad1d3749fd67_OtherNetIncomeExpense"/>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherNetIncomeExpenseTables" xlink:type="simple" xlink:href="lly-20210331.xsd#OtherNetIncomeExpenseTables"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/OtherNetIncomeExpenseTables" xlink:type="extended" id="i60db93d4956849c29460873b2e6f3580_OtherNetIncomeExpenseTables"/>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherNetIncomeExpenseDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#OtherNetIncomeExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/OtherNetIncomeExpenseDetails" xlink:type="extended" id="i11b4a692974640ab9d2685fc00235484_OtherNetIncomeExpenseDetails"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>lly-20210331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:e048f7a3-28f3-4092-a916-bde5dfced0f0,g:3190a302-79f3-4ce3-a4d9-ac703a7bb0fb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_lly_AmpullaryCancerMember_bb564b7d-954b-4350-8f72-0c43405498c1_terseLabel_en-US" xlink:label="lab_lly_AmpullaryCancerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ampullary Cancer</link:label>
    <link:label id="lab_lly_AmpullaryCancerMember_label_en-US" xlink:label="lab_lly_AmpullaryCancerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ampullary Cancer [Member]</link:label>
    <link:label id="lab_lly_AmpullaryCancerMember_documentation_en-US" xlink:label="lab_lly_AmpullaryCancerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ampullary Cancer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AmpullaryCancerMember" xlink:href="lly-20210331.xsd#lly_AmpullaryCancerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AmpullaryCancerMember" xlink:to="lab_lly_AmpullaryCancerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_7f1e23a5-9342-4abd-b8e4-c89aa1c049c0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OlumiantMember_4b2382aa-fed9-4e29-90f1-53530faf5ac5_terseLabel_en-US" xlink:label="lab_lly_OlumiantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olumiant&#174;</link:label>
    <link:label id="lab_lly_OlumiantMember_label_en-US" xlink:label="lab_lly_OlumiantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olumiant [Member]</link:label>
    <link:label id="lab_lly_OlumiantMember_documentation_en-US" xlink:label="lab_lly_OlumiantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olumiant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember" xlink:href="lly-20210331.xsd#lly_OlumiantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OlumiantMember" xlink:to="lab_lly_OlumiantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_e7e311b4-5247-4d79-a968-9135fdeac3b9_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_0ea327d5-cf4b-4d3a-9270-978d6b353d75_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other&#8211;net, (income) expense</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_31952b59-783e-495e-9323-5293c0aa529b_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_bd5c5079-a095-4d9a-9ece-b785612994ba_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesRetired_58a1404a-9b6a-4b77-a725-1bc3c2822cda_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesRetired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of treasury shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesRetired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesRetired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Retired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesRetired" xlink:to="lab_us-gaap_TreasuryStockSharesRetired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_6d0a3a79-4356-4a78-8d95-f6f27492f9a6_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock in Treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1.000NotesDueJune22022Member_d5da88a4-f81f-424f-bd13-fc01acc151be_terseLabel_en-US" xlink:label="lab_lly_A1.000NotesDueJune22022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.000% Notes due 2022</link:label>
    <link:label id="lab_lly_A1.000NotesDueJune22022Member_label_en-US" xlink:label="lab_lly_A1.000NotesDueJune22022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.000% Notes Due June 2, 2022 [Member]</link:label>
    <link:label id="lab_lly_A1.000NotesDueJune22022Member_documentation_en-US" xlink:label="lab_lly_A1.000NotesDueJune22022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.000% Notes Due June 2, 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.000NotesDueJune22022Member" xlink:href="lly-20210331.xsd#lly_A1.000NotesDueJune22022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1.000NotesDueJune22022Member" xlink:to="lab_lly_A1.000NotesDueJune22022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_083b2569-99f6-496d-a6d3-27d20eff51ae_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_1348fa10-199a-42cc-afcc-5d0cbc914bfa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LebrikizumabMember_774b6b6b-a2df-48f9-8290-1a927e60c24e_terseLabel_en-US" xlink:label="lab_lly_LebrikizumabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lebrikizumab</link:label>
    <link:label id="lab_lly_LebrikizumabMember_label_en-US" xlink:label="lab_lly_LebrikizumabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lebrikizumab [Member]</link:label>
    <link:label id="lab_lly_LebrikizumabMember_documentation_en-US" xlink:label="lab_lly_LebrikizumabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lebrikizumab [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LebrikizumabMember" xlink:href="lly-20210331.xsd#lly_LebrikizumabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LebrikizumabMember" xlink:to="lab_lly_LebrikizumabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_NeuroscienceMember_27e457a0-3118-4453-aded-9cdc99b376ea_terseLabel_en-US" xlink:label="lab_lly_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience</link:label>
    <link:label id="lab_lly_NeuroscienceMember_label_en-US" xlink:label="lab_lly_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience [Member]</link:label>
    <link:label id="lab_lly_NeuroscienceMember_documentation_en-US" xlink:label="lab_lly_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue to unaffiliated customers, Neuroscience</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NeuroscienceMember" xlink:href="lly-20210331.xsd#lly_NeuroscienceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_NeuroscienceMember" xlink:to="lab_lly_NeuroscienceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_a10ef7d6-00e4-4d7d-b1f8-2a6d9b8a79f3_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MilestonePaymentsSuccessBasedRegulatoryMember_2162db86-9779-4652-bd42-bd9234198449_terseLabel_en-US" xlink:label="lab_lly_MilestonePaymentsSuccessBasedRegulatoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Success-based Regulatory</link:label>
    <link:label id="lab_lly_MilestonePaymentsSuccessBasedRegulatoryMember_label_en-US" xlink:label="lab_lly_MilestonePaymentsSuccessBasedRegulatoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Success-based Regulatory [Member]</link:label>
    <link:label id="lab_lly_MilestonePaymentsSuccessBasedRegulatoryMember_documentation_en-US" xlink:label="lab_lly_MilestonePaymentsSuccessBasedRegulatoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Success-based Regulatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsSuccessBasedRegulatoryMember" xlink:href="lly-20210331.xsd#lly_MilestonePaymentsSuccessBasedRegulatoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MilestonePaymentsSuccessBasedRegulatoryMember" xlink:to="lab_lly_MilestonePaymentsSuccessBasedRegulatoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_485b33c3-6732-449d-ba2d-c13a20721b87_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at January&#160;1</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_450cb6e5-8603-48b5-b950-e5fb383bce4d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents at March 31</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_5dbc9b2d-6a94-4c94-bfe7-a2db20a7a876_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of components of other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CN_37406ceb-0cbd-4ccb-b82d-4c32d588b0dc_terseLabel_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">China</link:label>
    <link:label id="lab_country_CN_label_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CN" xlink:to="lab_country_CN" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_86cf7df5-5ff8-44d5-9965-82eab14a5a6a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherDiabetesMember_388c53fc-d187-47a6-a0e3-7ef4c6a217af_terseLabel_en-US" xlink:label="lab_lly_OtherDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Diabetes</link:label>
    <link:label id="lab_lly_OtherDiabetesMember_label_en-US" xlink:label="lab_lly_OtherDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Diabetes [Member]</link:label>
    <link:label id="lab_lly_OtherDiabetesMember_documentation_en-US" xlink:label="lab_lly_OtherDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Diabetes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherDiabetesMember" xlink:href="lly-20210331.xsd#lly_OtherDiabetesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherDiabetesMember" xlink:to="lab_lly_OtherDiabetesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DermiraInc.Member_53f8196a-a348-4a53-8446-b7c97c774b90_terseLabel_en-US" xlink:label="lab_lly_DermiraInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dermira</link:label>
    <link:label id="lab_lly_DermiraInc.Member_label_en-US" xlink:label="lab_lly_DermiraInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dermira, Inc. [Member]</link:label>
    <link:label id="lab_lly_DermiraInc.Member_documentation_en-US" xlink:label="lab_lly_DermiraInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dermira, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DermiraInc.Member" xlink:href="lly-20210331.xsd#lly_DermiraInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DermiraInc.Member" xlink:to="lab_lly_DermiraInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_a57ca073-4297-457a-922c-0f50123f0ea4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1-5 Years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_f4150acf-ca2c-4193-a274-29becd072c9f_terseLabel_en-US" xlink:label="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, information used to determine revenue recognized, change in accounting estimate, percent (less than)</link:label>
    <link:label id="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_label_en-US" xlink:label="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent</link:label>
    <link:label id="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_documentation_en-US" xlink:label="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" xlink:href="lly-20210331.xsd#lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" xlink:to="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_df3aa4a6-0dfb-4aec-8a42-8de2581ff121_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_db9bb989-42aa-435f-b3a1-bf9b67195806_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrentAbstract_c243cc23-8f54-4d44-84c6-b8d2b214a8ac_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current [Abstract]</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrentAbstract" xlink:to="lab_us-gaap_ReceivablesNetCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_591d88e3-c271-4705-abd5-bea868479aa3_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_7b0d734f-12ad-4752-a20d-9bf7a0e097df_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangibles, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_28591450-e39d-4cf6-8b8d-908cb447ea10_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of treasury shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_label_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Retired, Cost Method, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:to="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CashFlowHedgeAbstract_257cff81-03d7-4c5c-9f46-77cd21bd7f6c_terseLabel_en-US" xlink:label="lab_lly_CashFlowHedgeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedges:</link:label>
    <link:label id="lab_lly_CashFlowHedgeAbstract_label_en-US" xlink:label="lab_lly_CashFlowHedgeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedge [Abstract]</link:label>
    <link:label id="lab_lly_CashFlowHedgeAbstract_documentation_en-US" xlink:label="lab_lly_CashFlowHedgeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedge [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CashFlowHedgeAbstract" xlink:href="lly-20210331.xsd#lly_CashFlowHedgeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CashFlowHedgeAbstract" xlink:to="lab_lly_CashFlowHedgeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RigelPharmaceuticalsIncMember_cc215377-11e1-4130-b0c2-e272552ed24f_terseLabel_en-US" xlink:label="lab_lly_RigelPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rigel Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_lly_RigelPharmaceuticalsIncMember_label_en-US" xlink:label="lab_lly_RigelPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rigel Pharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_lly_RigelPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_lly_RigelPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rigel Pharmaceuticals, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RigelPharmaceuticalsIncMember" xlink:href="lly-20210331.xsd#lly_RigelPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RigelPharmaceuticalsIncMember" xlink:to="lab_lly_RigelPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_044e9247-617c-4d69-99b9-ce579c185e75_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MarketableSecuritiesMember_b4761f7b-c17f-4b95-b12f-ab0eb092a5ab_terseLabel_en-US" xlink:label="lab_lly_MarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_lly_MarketableSecuritiesMember_label_en-US" xlink:label="lab_lly_MarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Member]</link:label>
    <link:label id="lab_lly_MarketableSecuritiesMember_documentation_en-US" xlink:label="lab_lly_MarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MarketableSecuritiesMember" xlink:href="lly-20210331.xsd#lly_MarketableSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MarketableSecuritiesMember" xlink:to="lab_lly_MarketableSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_05f215cf-93c7-4f2e-ba42-557e5446b99a_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_339b089e-75ef-4319-8e36-48a8a2866b05_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_98af5fca-9a22-4fcf-a944-35790662abf1_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of amounts recorded for contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm_6edeb89b-09e2-4621-86e2-e66b0a0fbab9_terseLabel_en-US" xlink:label="lab_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limited initial market entry, supply term</link:label>
    <link:label id="lab_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm_label_en-US" xlink:label="lab_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Settled And Dismissed, Limited Initial Market Entry, Supply Term</link:label>
    <link:label id="lab_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm_documentation_en-US" xlink:label="lab_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Settled And Dismissed, Limited Initial Market Entry, Supply Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm" xlink:href="lly-20210331.xsd#lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm" xlink:to="lab_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8f4d91af-8c53-4ef0-8ae4-b6390d9619ce_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_c35a4c70-1457-42d4-98e0-fd12367f22dc_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies (Note 9)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_e6bb60e7-300e-41c2-bf5f-636a877b87aa_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent investments, debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_8d11f492-6a46-4963-8d0b-a1dade2e74b3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_0e39e698-b8e0-41fc-8015-ef273b3cfcb4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_e25ed48c-889c-4c16-a174-9f16612a20f0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash acquired</link:label>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_label_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAcquiredFromAcquisition" xlink:to="lab_us-gaap_CashAcquiredFromAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_bde3212e-d78d-468d-be40-0ad54af4cab1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_d483b66a-c97c-4eb6-b2e0-9db4a7e0a4bc_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_8352dec4-ec4b-4731-b822-0c1af7de7f69_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_a24cc6d8-22b0-41d7-805f-fee584b62c8a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_4e66a012-53b4-43ce-ad61-fb49981b2da0_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_37d9ba6c-a25a-4ca1-822a-5cf8cce5eb74_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsCurrent" xlink:to="lab_us-gaap_DerivativeAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_a2718971-74b0-469a-8587-a476770b3260_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_6963eb58-e459-466f-bbf4-0ccee6c6e75e_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:to="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_2d5342a4-705d-46d9-9bae-9c76b3150d1e_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_92364b47-8032-493d-9a72-a56eaae792f6_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly and Company Shareholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_b989d320-6ec7-4417-b1c7-f04a251527d5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:to="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MerusNVMember_db7011ef-3e4f-4d56-b98e-a75d0fefaf4e_terseLabel_en-US" xlink:label="lab_lly_MerusNVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merus N.V.</link:label>
    <link:label id="lab_lly_MerusNVMember_label_en-US" xlink:label="lab_lly_MerusNVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merus N.V. [Member]</link:label>
    <link:label id="lab_lly_MerusNVMember_documentation_en-US" xlink:label="lab_lly_MerusNVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merus N.V.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MerusNVMember" xlink:href="lly-20210331.xsd#lly_MerusNVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MerusNVMember" xlink:to="lab_lly_MerusNVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_c586d023-fd03-42d5-af01-7665fb5a5e9f_terseLabel_en-US" xlink:label="lab_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairment and other special charges</link:label>
    <link:label id="lab_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_label_en-US" xlink:label="lab_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges (Recoveries) And Other Special Charges</link:label>
    <link:label id="lab_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_documentation_en-US" xlink:label="lab_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges (Recoveries) And Other Special Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" xlink:href="lly-20210331.xsd#lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" xlink:to="lab_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SouthernDistrictOfCaliforniaMember_a8ef7e2c-5275-43b5-96a6-80feb8e95efd_terseLabel_en-US" xlink:label="lab_lly_SouthernDistrictOfCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Southern District of California</link:label>
    <link:label id="lab_lly_SouthernDistrictOfCaliforniaMember_label_en-US" xlink:label="lab_lly_SouthernDistrictOfCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Southern District Of California [Member]</link:label>
    <link:label id="lab_lly_SouthernDistrictOfCaliforniaMember_documentation_en-US" xlink:label="lab_lly_SouthernDistrictOfCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Southern District Of California</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SouthernDistrictOfCaliforniaMember" xlink:href="lly-20210331.xsd#lly_SouthernDistrictOfCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SouthernDistrictOfCaliforniaMember" xlink:to="lab_lly_SouthernDistrictOfCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_020684cb-24e9-41fd-beab-93eae204aa58_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_JunshiBiosciencesMember_bbf0c0dc-7737-4026-a999-d9d13295a9d0_terseLabel_en-US" xlink:label="lab_lly_JunshiBiosciencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shanghai Junshi Biosciences Co., Ltd.</link:label>
    <link:label id="lab_lly_JunshiBiosciencesMember_label_en-US" xlink:label="lab_lly_JunshiBiosciencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Junshi Biosciences [Member]</link:label>
    <link:label id="lab_lly_JunshiBiosciencesMember_documentation_en-US" xlink:label="lab_lly_JunshiBiosciencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Junshi Biosciences</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JunshiBiosciencesMember" xlink:href="lly-20210331.xsd#lly_JunshiBiosciencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_JunshiBiosciencesMember" xlink:to="lab_lly_JunshiBiosciencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_0631208d-6845-45c9-bac2-0562a42b3774_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_6e5109f5-6563-406d-aba0-06060c7b70e9_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_EmployeeLitigationMember_db4e2aa5-84b6-4e08-8de1-4d856dac5c0b_terseLabel_en-US" xlink:label="lab_lly_EmployeeLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Litigation</link:label>
    <link:label id="lab_lly_EmployeeLitigationMember_label_en-US" xlink:label="lab_lly_EmployeeLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Litigation [Member]</link:label>
    <link:label id="lab_lly_EmployeeLitigationMember_documentation_en-US" xlink:label="lab_lly_EmployeeLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmployeeLitigationMember" xlink:href="lly-20210331.xsd#lly_EmployeeLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_EmployeeLitigationMember" xlink:to="lab_lly_EmployeeLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets_5f6f88f2-9792-4898-92f0-b00f153ec9a3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, percentage of nonperforming assets</link:label>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets_label_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Other, Percentage of Nonperforming Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets" xlink:to="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_6c800914-b2c7-4600-8c70-11694b59f2d4_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other investing activities, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_country_BR_4a941509-80e0-4da1-a6dc-5750dc18ea3a_terseLabel_en-US" xlink:label="lab_country_BR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brazil</link:label>
    <link:label id="lab_country_BR_label_en-US" xlink:label="lab_country_BR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BRAZIL</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_BR" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_BR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_BR" xlink:to="lab_country_BR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_c9dc902d-f517-498a-a64b-a2c0c22f02da_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_9c6e7121-cea3-4ebb-9266-1bcf6e16d6e8_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments</link:label>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_label_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:to="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_cee49662-e551-40ec-8796-937976ca0e71_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4a4886a5-85bc-496f-958a-a523bf7ae5a2_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_2e912930-46f2-46e5-8a01-b47b5e638509_terseLabel_en-US" xlink:label="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative investments, unfunded commitments, payment period</link:label>
    <link:label id="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_label_en-US" xlink:label="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period</link:label>
    <link:label id="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_documentation_en-US" xlink:label="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" xlink:href="lly-20210331.xsd#lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" xlink:to="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_1426e118-a1ea-42d8-83ed-0b6b91dc2534_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_854dc5a6-6832-44bf-b1fb-471940bb3c03_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PlaintiffAllegationsAxis_aac03f69-5ef0-4076-9709-407a961b7d75_terseLabel_en-US" xlink:label="lab_lly_PlaintiffAllegationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Allegations [Axis]</link:label>
    <link:label id="lab_lly_PlaintiffAllegationsAxis_label_en-US" xlink:label="lab_lly_PlaintiffAllegationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Allegations [Axis]</link:label>
    <link:label id="lab_lly_PlaintiffAllegationsAxis_documentation_en-US" xlink:label="lab_lly_PlaintiffAllegationsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Allegations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PlaintiffAllegationsAxis" xlink:href="lly-20210331.xsd#lly_PlaintiffAllegationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PlaintiffAllegationsAxis" xlink:to="lab_lly_PlaintiffAllegationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_bd5efdec-5331-4753-b10c-2fecf488d35b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of asset acquisitions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Assets Acquired Other than Through Business Combination [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_4cbc6c59-02b4-400f-a9cd-2429a2df83c5_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_84eb2d38-aa02-4071-833e-c1894cc0ed88_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6-10 Years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear_96a19b57-2227-482a-bcbc-761aa30ecc3f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated future employer contributions in current fiscal year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Employer Contributions, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_2ec8b2d7-a8e3-40a3-87fb-3d117e39a0b9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_8edae80d-be4a-49cc-80f4-587a954da7eb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_InnoventBiologicsIncMember_d3aff8e2-d64f-4480-b0c4-0c514b9d1836_terseLabel_en-US" xlink:label="lab_lly_InnoventBiologicsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovent Biologics, Inc.</link:label>
    <link:label id="lab_lly_InnoventBiologicsIncMember_label_en-US" xlink:label="lab_lly_InnoventBiologicsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovent Biologics, Inc. [Member]</link:label>
    <link:label id="lab_lly_InnoventBiologicsIncMember_documentation_en-US" xlink:label="lab_lly_InnoventBiologicsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovent Biologics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_InnoventBiologicsIncMember" xlink:href="lly-20210331.xsd#lly_InnoventBiologicsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_InnoventBiologicsIncMember" xlink:to="lab_lly_InnoventBiologicsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherNeuroscienceMember_c4a15ad5-7959-42c9-b766-97d3e9be74d0_terseLabel_en-US" xlink:label="lab_lly_OtherNeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Neuroscience</link:label>
    <link:label id="lab_lly_OtherNeuroscienceMember_label_en-US" xlink:label="lab_lly_OtherNeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Neuroscience [Member]</link:label>
    <link:label id="lab_lly_OtherNeuroscienceMember_documentation_en-US" xlink:label="lab_lly_OtherNeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Neuroscience [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherNeuroscienceMember" xlink:href="lly-20210331.xsd#lly_OtherNeuroscienceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherNeuroscienceMember" xlink:to="lab_lly_OtherNeuroscienceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_4cc68a09-19fe-47b1-a091-79d2bd7f1d1b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in deferred income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_95f49b9e-93d8-4743-aefc-4f19c7032012_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_551a103e-8613-41d6-a2f4-21f47510eb4b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_fb63802f-19a0-412a-9989-42781c89c278_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LossContingencyNumberOfClaimants_1abb9895-c518-41e4-bcbc-ceafe09a7e98_terseLabel_en-US" xlink:label="lab_lly_LossContingencyNumberOfClaimants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claimants</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfClaimants_label_en-US" xlink:label="lab_lly_LossContingencyNumberOfClaimants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Claimants</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfClaimants_documentation_en-US" xlink:label="lab_lly_LossContingencyNumberOfClaimants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Claimants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfClaimants" xlink:href="lly-20210331.xsd#lly_LossContingencyNumberOfClaimants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LossContingencyNumberOfClaimants" xlink:to="lab_lly_LossContingencyNumberOfClaimants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_5a213c26-1fc3-41a5-9e43-44f27cd876c5_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ByettaMember_45ec9df4-56cc-458d-87bb-e95454c5429a_terseLabel_en-US" xlink:label="lab_lly_ByettaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Byetta</link:label>
    <link:label id="lab_lly_ByettaMember_label_en-US" xlink:label="lab_lly_ByettaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Byetta [Member]</link:label>
    <link:label id="lab_lly_ByettaMember_documentation_en-US" xlink:label="lab_lly_ByettaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Byetta</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ByettaMember" xlink:href="lly-20210331.xsd#lly_ByettaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ByettaMember" xlink:to="lab_lly_ByettaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_0393fed6-143a-4dca-8215-92da8952ed88_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">More&#160;Than 10 Years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherForeignCountriesMember_8785c955-8838-4c3c-91bc-5d6a116bb81f_terseLabel_en-US" xlink:label="lab_lly_OtherForeignCountriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other foreign countries</link:label>
    <link:label id="lab_lly_OtherForeignCountriesMember_label_en-US" xlink:label="lab_lly_OtherForeignCountriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Foreign Countries [Member]</link:label>
    <link:label id="lab_lly_OtherForeignCountriesMember_documentation_en-US" xlink:label="lab_lly_OtherForeignCountriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Foreign Countries [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherForeignCountriesMember" xlink:href="lly-20210331.xsd#lly_OtherForeignCountriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherForeignCountriesMember" xlink:to="lab_lly_OtherForeignCountriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_9af2c9c0-af5e-4a24-9f84-6da79145c990_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government and agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_f8b257d4-9ba3-4ada-ad24-7de39a9ab1d2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_78704267-d33e-45b1-ac08-06a060ce1e71_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of effects of risk-management instruments were recognized in other&#8211;net, (income) expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_2400979f-2481-48c6-81bd-5f6d61de8ffd_terseLabel_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones capitalized</link:label>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_label_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Rights (Obligations)</link:label>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_documentation_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Terms or rights and obligations under collaborative arrangements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations" xlink:href="lly-20210331.xsd#lly_CollaborativeArrangementRightsAndObligationsRightsObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations" xlink:to="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_46641964-dc80-448a-8def-33e493dca3ef_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_14556ae4-5522-40a0-a686-6e937471eb0d_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_0dd49d73-82fc-4c35-9bdc-b3a41314b9bc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BasaglarMember_c5820a6a-6a68-41dd-97e6-bdf31a416f05_terseLabel_en-US" xlink:label="lab_lly_BasaglarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basaglar&#174;</link:label>
    <link:label id="lab_lly_BasaglarMember_78cfa090-787d-42c8-8773-da8531137584_verboseLabel_en-US" xlink:label="lab_lly_BasaglarMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basaglar</link:label>
    <link:label id="lab_lly_BasaglarMember_label_en-US" xlink:label="lab_lly_BasaglarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basaglar [Member]</link:label>
    <link:label id="lab_lly_BasaglarMember_documentation_en-US" xlink:label="lab_lly_BasaglarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basaglar [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember" xlink:href="lly-20210331.xsd#lly_BasaglarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BasaglarMember" xlink:to="lab_lly_BasaglarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_e92b55a5-0707-4bd9-92b2-045a3f812f6c_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9b7140e3-e9fd-4f3c-b975-d566f5151fa5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Shareholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyAgreementTermsMember_95284ac7-9944-41d8-b916-7a486a1ff7be_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreement Terms</link:label>
    <link:label id="lab_us-gaap_RoyaltyAgreementTermsMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreement Terms [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementTermsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyAgreementTermsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyAgreementTermsMember" xlink:to="lab_us-gaap_RoyaltyAgreementTermsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9fe56f9e-f642-461a-a239-0457d188da4a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction_59eceab9-4e17-42f9-88ef-ac9ba46a9a21_terseLabel_en-US" xlink:label="lab_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent value right, monthly reduction (in cents per share)</link:label>
    <link:label id="lab_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction_label_en-US" xlink:label="lab_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Value Right, Regulatory Approval Delay, Monthly Reduction</link:label>
    <link:label id="lab_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction_documentation_en-US" xlink:label="lab_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Value Right, Covenant, Regulatory Approval Occurs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" xlink:href="lly-20210331.xsd#lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" xlink:to="lab_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_f215f546-edb6-4134-86a0-1eed0b300d82_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_876d6fe0-b709-4738-9ecb-1b4294cb4cbc_terseLabel_en-US" xlink:label="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets and liabilities, net</link:label>
    <link:label id="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_label_en-US" xlink:label="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net</link:label>
    <link:label id="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_documentation_en-US" xlink:label="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" xlink:href="lly-20210331.xsd#lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" xlink:to="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_ec0a7fbb-6fb2-4e9b-b605-4f12094bf7f8_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c334ece2-f410-46cb-9fa1-a1f057f56b94_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in calculation of earnings per share:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_af9ef91c-5b12-4ea0-a1d0-5081b4b4da50_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the amounts recognized for assets acquired and liabilities assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_67080ce6-869d-437b-a606-bcc7b83e6cb7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary certain fair value information</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_5add6c1b-f5e5-4a2c-9183-2e0a6396a702_terseLabel_en-US" xlink:label="lab_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net of tax</link:label>
    <link:label id="lab_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge And Foreign Currency Adjustment, Including Portion Attributable To Noncontrolling Interest [Member]</link:label>
    <link:label id="lab_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_documentation_en-US" xlink:label="lab_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge And Foreign Currency Adjustment, Including Portion Attributable To Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="lly-20210331.xsd#lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LossContingencyNumberOfPatents_d116c79b-d825-444d-83dd-cecd5b77a6da_terseLabel_en-US" xlink:label="lab_lly_LossContingencyNumberOfPatents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfPatents_label_en-US" xlink:label="lab_lly_LossContingencyNumberOfPatents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Patents</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfPatents_documentation_en-US" xlink:label="lab_lly_LossContingencyNumberOfPatents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Patents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfPatents" xlink:href="lly-20210331.xsd#lly_LossContingencyNumberOfPatents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LossContingencyNumberOfPatents" xlink:to="lab_lly_LossContingencyNumberOfPatents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_fe0122d6-8d44-4ab2-9b1c-ec07a9da932e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_c03dc26e-8beb-4510-96e3-f9edea652b15_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_824b9f5d-8040-476d-8d73-cc350db821cf_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_9d12125d-e96e-4a74-9912-44e2b8fbf2f4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of CVR liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_381380a2-b758-4a4b-b8fb-25dac2375841_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments, debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PrecisionBiosciencesIncMember_b71c2526-6d30-4ce1-a2f6-05675bdae0c8_terseLabel_en-US" xlink:label="lab_lly_PrecisionBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precision Biosciences, Inc.</link:label>
    <link:label id="lab_lly_PrecisionBiosciencesIncMember_label_en-US" xlink:label="lab_lly_PrecisionBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precision Biosciences, Inc. [Member]</link:label>
    <link:label id="lab_lly_PrecisionBiosciencesIncMember_documentation_en-US" xlink:label="lab_lly_PrecisionBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precision Biosciences, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrecisionBiosciencesIncMember" xlink:href="lly-20210331.xsd#lly_PrecisionBiosciencesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PrecisionBiosciencesIncMember" xlink:to="lab_lly_PrecisionBiosciencesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_5e2a5e9d-4a6e-4f14-a978-b6a452d5c1e7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_452b7d2d-776b-4806-95d5-0cc98285d6eb_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_36b59626-d372-44ed-ad51-7c74b09beaac_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_16244511-f13b-4224-9ab3-04a4233d808c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, by balance sheet grouping</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_14a0ea6d-5ab5-4dfe-8e69-526d3eb3c83a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_9e66b0c2-4da9-4187-a1c6-b94b74c9788b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in short-term borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_e7d3a8c0-6375-4339-ac1f-4246badfd7b0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Derivative Risk Management Policy</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_bb9ae76e-75f0-429d-88b8-50f54024a969_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_f8a656b6-42b0-4c1e-b41a-402a86d75021_terseLabel_en-US" xlink:label="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement benefit plans</link:label>
    <link:label id="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_label_en-US" xlink:label="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:to="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TaltzMember_2751806c-562b-41fd-a86c-68af1a8240e3_terseLabel_en-US" xlink:label="lab_lly_TaltzMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taltz&#174;</link:label>
    <link:label id="lab_lly_TaltzMember_label_en-US" xlink:label="lab_lly_TaltzMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taltz [Member]</link:label>
    <link:label id="lab_lly_TaltzMember_documentation_en-US" xlink:label="lab_lly_TaltzMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taltz [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaltzMember" xlink:href="lly-20210331.xsd#lly_TaltzMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TaltzMember" xlink:to="lab_lly_TaltzMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c6008650-ef04-44ba-a55f-fbd5a8e08a8d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gross gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_b5e2ef8b-86fb-4921-b41b-3e71d48b2c19_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_93f42be8-22c3-4e09-8946-acc61068f61b_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_49d89dfc-f26d-4a26-889f-44915c2adb4b_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowances for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_VerzenioMember_e1e68dd6-bd49-46b8-9f0a-b6ff37c840f1_terseLabel_en-US" xlink:label="lab_lly_VerzenioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verzenio&#174;</link:label>
    <link:label id="lab_lly_VerzenioMember_label_en-US" xlink:label="lab_lly_VerzenioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verzenio [Member]</link:label>
    <link:label id="lab_lly_VerzenioMember_documentation_en-US" xlink:label="lab_lly_VerzenioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verzenio [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_VerzenioMember" xlink:href="lly-20210331.xsd#lly_VerzenioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_VerzenioMember" xlink:to="lab_lly_VerzenioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_f2034c6c-56ef-4c34-be5d-d953d7b16d41_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_0c767564-d388-4ba6-88ab-fa989c6cd2f8_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective portion of cash flow hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_9f71ce95-e8ef-41a7-aa10-8960db985192_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of effective portion of risk-management instruments that was recognized in other comprehensive income (loss), net investment hedges</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OutsideUSAndJapanMember_7240cbe1-0e7e-43f6-9552-708705ac0a04_terseLabel_en-US" xlink:label="lab_lly_OutsideUSAndJapanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside US And Japan</link:label>
    <link:label id="lab_lly_OutsideUSAndJapanMember_label_en-US" xlink:label="lab_lly_OutsideUSAndJapanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside US And Japan [Member]</link:label>
    <link:label id="lab_lly_OutsideUSAndJapanMember_documentation_en-US" xlink:label="lab_lly_OutsideUSAndJapanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside US And Japan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OutsideUSAndJapanMember" xlink:href="lly-20210331.xsd#lly_OutsideUSAndJapanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OutsideUSAndJapanMember" xlink:to="lab_lly_OutsideUSAndJapanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bf0da16a-70f8-417e-a90f-921f1db77d1f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_68bd32e7-f814-4437-a06d-70c9eb9f1383_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pretax net losses on cash flow hedges expected to be reclassified during the next 12 months</link:label>
    <link:label id="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_label_en-US" xlink:label="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:to="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_14863a84-be0f-4868-852d-8a72873269ca_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketing, selling, and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherDebtSecuritiesMember_be580304-b881-430f-87ea-3d8fac9303b5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other securities, current investments</link:label>
    <link:label id="lab_us-gaap_OtherDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_OtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Debt Obligations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherDebtSecuritiesMember" xlink:to="lab_us-gaap_OtherDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_424a9fab-4468-4263-b029-9754ba6db81b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_1ef3d30d-9c8f-4f3f-855f-0eada54b1db0_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency exchange contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_f62c9b73-58e7-49e6-9ad6-55dc094b0bc7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b24b2b79-5e0e-4d31-b6f0-6de72c28a491_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_0b869db7-e3ca-48cf-a7dc-6ae52d8fc269_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_61897a62-98ce-4adb-8f79-cb645bcc1c8b_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset impairment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PancreatitisMember_d86b40fd-467c-47b1-b26d-72ebdd41a1c5_terseLabel_en-US" xlink:label="lab_lly_PancreatitisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pancreatitis</link:label>
    <link:label id="lab_lly_PancreatitisMember_label_en-US" xlink:label="lab_lly_PancreatitisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pancreatitis [Member]</link:label>
    <link:label id="lab_lly_PancreatitisMember_documentation_en-US" xlink:label="lab_lly_PancreatitisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pancreatitis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PancreatitisMember" xlink:href="lly-20210331.xsd#lly_PancreatitisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PancreatitisMember" xlink:to="lab_lly_PancreatitisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_7b39c642-977d-448f-88f1-e020fd5bead9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_EquityMethodAndOtherInvestmentsMember_f78407e7-1e8e-46cc-b5af-3b807a6c8250_verboseLabel_en-US" xlink:label="lab_lly_EquityMethodAndOtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments</link:label>
    <link:label id="lab_lly_EquityMethodAndOtherInvestmentsMember_label_en-US" xlink:label="lab_lly_EquityMethodAndOtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method And Other Investments [Member]</link:label>
    <link:label id="lab_lly_EquityMethodAndOtherInvestmentsMember_documentation_en-US" xlink:label="lab_lly_EquityMethodAndOtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method and Other Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EquityMethodAndOtherInvestmentsMember" xlink:href="lly-20210331.xsd#lly_EquityMethodAndOtherInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_EquityMethodAndOtherInvestmentsMember" xlink:to="lab_lly_EquityMethodAndOtherInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_7cda1dba-923a-46c8-9391-913709ef2ef2_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_a0671d32-0147-4ff6-bc61-cc2c7769952b_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities, net unrealized gains</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_6a1c25ba-a819-4a64-a14d-07d87f06710d_negatedLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment gains</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_53fecbe7-d4d0-42ec-b543-57475d177712_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of prior service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_WhyteEtAlVEliLillyEtAlMember_964252f2-a4d7-4d6a-b576-79e998d57cf3_terseLabel_en-US" xlink:label="lab_lly_WhyteEtAlVEliLillyEtAlMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weiler v. Takeda Canada Inc. et al.</link:label>
    <link:label id="lab_lly_WhyteEtAlVEliLillyEtAlMember_label_en-US" xlink:label="lab_lly_WhyteEtAlVEliLillyEtAlMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Whyte Et Al. V. Eli Lilly Et Al. [Member]</link:label>
    <link:label id="lab_lly_WhyteEtAlVEliLillyEtAlMember_documentation_en-US" xlink:label="lab_lly_WhyteEtAlVEliLillyEtAlMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Whyte Et Al. V. Eli Lilly Et Al.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_WhyteEtAlVEliLillyEtAlMember" xlink:href="lly-20210331.xsd#lly_WhyteEtAlVEliLillyEtAlMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_WhyteEtAlVEliLillyEtAlMember" xlink:to="lab_lly_WhyteEtAlVEliLillyEtAlMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_9bc8a999-a6f2-4a40-a4d5-da03819363bf_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_e9f3d707-015e-4445-a642-f81f49b3c75d_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_8058f71d-4ea2-47cf-9f45-c85d9fa5f666_terseLabel_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mergers, Acquisitions and Dispositions Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherOncologyMember_a9592048-efff-4f77-9e54-b305b187cf38_terseLabel_en-US" xlink:label="lab_lly_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology</link:label>
    <link:label id="lab_lly_OtherOncologyMember_label_en-US" xlink:label="lab_lly_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology [Member]</link:label>
    <link:label id="lab_lly_OtherOncologyMember_documentation_en-US" xlink:label="lab_lly_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherOncologyMember" xlink:href="lly-20210331.xsd#lly_OtherOncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherOncologyMember" xlink:to="lab_lly_OtherOncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_d19fd24f-59aa-477b-ba99-9633fd1d7b2c_negatedLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_3c952419-7e8f-4abc-b8ea-22230b8d1801_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_507c96af-9e1a-4d8d-990d-25e439f45658_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_6f697ca7-20a9-44ca-af1d-c0734194316b_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the fair value of available-for-sale securities in an unrealized gain or loss position</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_77acc565-1e72-4aa7-8363-e4db82af8da3_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_e9d52517-29c7-4aa9-a84b-c4110c6378f8_negatedLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect from interest rate contracts</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_3c30e300-62ea-4c65-b68b-e37a45a7b265_terseLabel_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross-currency interest rate swaps</link:label>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross Currency Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CrossCurrencyInterestRateContractMember" xlink:to="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_HedgedFixedRateDebtMember_72d2b6f3-4e08-4a14-86e4-db77f616791f_terseLabel_en-US" xlink:label="lab_lly_HedgedFixedRateDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency-denominated notes</link:label>
    <link:label id="lab_lly_HedgedFixedRateDebtMember_label_en-US" xlink:label="lab_lly_HedgedFixedRateDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Fixed Rate Debt [Member]</link:label>
    <link:label id="lab_lly_HedgedFixedRateDebtMember_documentation_en-US" xlink:label="lab_lly_HedgedFixedRateDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Fixed-Rate Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HedgedFixedRateDebtMember" xlink:href="lly-20210331.xsd#lly_HedgedFixedRateDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_HedgedFixedRateDebtMember" xlink:to="lab_lly_HedgedFixedRateDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_eb4c8e34-6168-4f57-ba8d-87a3aa614a50_terseLabel_en-US" xlink:label="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of receivable derecognized</link:label>
    <link:label id="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_label_en-US" xlink:label="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer of Financial Assets Accounted for as Sales, Amount Derecognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" xlink:to="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_d43e9e97-4010-4941-b87d-71e50b0b593b_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_1b733511-e1ea-4980-85f2-fb2bbdd76f58_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside U.S.</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AsahiKaseiPharmaCorporationMember_9480b1f8-0c0b-4e8a-b6f8-4925f1491aeb_terseLabel_en-US" xlink:label="lab_lly_AsahiKaseiPharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asahi Kasei Pharma Corporation</link:label>
    <link:label id="lab_lly_AsahiKaseiPharmaCorporationMember_label_en-US" xlink:label="lab_lly_AsahiKaseiPharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asahi Kasei Pharma Corporation [Member]</link:label>
    <link:label id="lab_lly_AsahiKaseiPharmaCorporationMember_documentation_en-US" xlink:label="lab_lly_AsahiKaseiPharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asahi Kasei Pharma Corporation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AsahiKaseiPharmaCorporationMember" xlink:href="lly-20210331.xsd#lly_AsahiKaseiPharmaCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AsahiKaseiPharmaCorporationMember" xlink:to="lab_lly_AsahiKaseiPharmaCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_09f550ce-5ff7-46e7-b785-5784774ed1c9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of securities in an unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AcquiredInProcessResearchAndDevelopment_439e9d5f-dc05-423c-8431-9f1c8e41f0e8_terseLabel_en-US" xlink:label="lab_lly_AcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development (Note 3)</link:label>
    <link:label id="lab_lly_AcquiredInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_lly_AcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_lly_AcquiredInProcessResearchAndDevelopment_documentation_en-US" xlink:label="lab_lly_AcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of EXPENSE related to research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore written off in the period of acquisition (INCOME STATEMENT)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopment" xlink:href="lly-20210331.xsd#lly_AcquiredInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AcquiredInProcessResearchAndDevelopment" xlink:to="lab_lly_AcquiredInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e155a982-b918-49d5-9939-f49721549736_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_fa50e9d0-67ac-4207-b13d-d72ca20c98fe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets for Identical Assets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_3219060d-86ec-4839-ae22-fd1311f4671c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_903e42f6-fc38-4225-870e-5a89fded605b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss), cash flow hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_77d8c9ed-846d-45bb-ac58-76cff05567b6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_5059490c-f39d-420d-b2d0-9bf91b3ede60_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other changes in operating assets and liabilities, net of acquisitions and divestitures</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_FairValueHedgeAbstract_93baa219-5159-43ed-a3e7-4e2f9699e766_terseLabel_en-US" xlink:label="lab_lly_FairValueHedgeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value hedges:</link:label>
    <link:label id="lab_lly_FairValueHedgeAbstract_label_en-US" xlink:label="lab_lly_FairValueHedgeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedge [Abstract]</link:label>
    <link:label id="lab_lly_FairValueHedgeAbstract_documentation_en-US" xlink:label="lab_lly_FairValueHedgeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedge [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FairValueHedgeAbstract" xlink:href="lly-20210331.xsd#lly_FairValueHedgeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_FairValueHedgeAbstract" xlink:to="lab_lly_FairValueHedgeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_4236caaa-70e2-4ae3-a560-5fc4818ceeaa_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_e27c3210-2c28-4fde-8fda-6249c76cd0b7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of other&#8211;net, (income) expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueHedgingMember_1b3d345f-d73f-4ead-8203-524253ef05e1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember" xlink:to="lab_us-gaap_FairValueHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_ff5fc634-02ac-4c4f-9c05-9d67f700cd98_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-cash operating activities, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_7e1afe63-44c0-4513-8fe9-3b98c8331e58_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_05a8c417-6350-4af9-b31b-f2f012304ad5_terseLabel_en-US" xlink:label="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative</link:label>
    <link:label id="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_label_en-US" xlink:label="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative [Member]</link:label>
    <link:label id="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_documentation_en-US" xlink:label="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" xlink:href="lly-20210331.xsd#lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" xlink:to="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_0e1a20cd-719b-4a56-a16f-bea114c25e7c_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_6fe2506c-c359-4a36-bbf9-db447e299504_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AlimtaMember_4f45aa2f-5681-4839-b178-467598c7168b_terseLabel_en-US" xlink:label="lab_lly_AlimtaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alimta&#174;</link:label>
    <link:label id="lab_lly_AlimtaMember_label_en-US" xlink:label="lab_lly_AlimtaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alimta [Member]</link:label>
    <link:label id="lab_lly_AlimtaMember_documentation_en-US" xlink:label="lab_lly_AlimtaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alimta [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AlimtaMember" xlink:href="lly-20210331.xsd#lly_AlimtaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AlimtaMember" xlink:to="lab_lly_AlimtaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0d32fa25-9096-4a1a-97be-afdb936aa83e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_a0999011-47c7-4a3a-913d-5bc57dd5d24b_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_76945e3d-415d-441b-bc89-ae9711a6df70_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_4b714993-ed4b-4f7e-9395-a7ca646fb5eb_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_1f2e4d8d-3585-4dc7-9bdc-94ee2614806e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_3d610596-5dc9-4ec1-a2b6-9597507923f1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SwapSwissFrancsToU.S.DollarsMember_228541b6-ed50-4b41-93f6-0b6ea96b9e56_terseLabel_en-US" xlink:label="lab_lly_SwapSwissFrancsToU.S.DollarsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swap Swiss Francs to U.S. Dollars</link:label>
    <link:label id="lab_lly_SwapSwissFrancsToU.S.DollarsMember_label_en-US" xlink:label="lab_lly_SwapSwissFrancsToU.S.DollarsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swap Swiss Francs To U.S. Dollars [Member]</link:label>
    <link:label id="lab_lly_SwapSwissFrancsToU.S.DollarsMember_documentation_en-US" xlink:label="lab_lly_SwapSwissFrancsToU.S.DollarsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swap Swiss Francs To U.S. Dollars [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SwapSwissFrancsToU.S.DollarsMember" xlink:href="lly-20210331.xsd#lly_SwapSwissFrancsToU.S.DollarsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SwapSwissFrancsToU.S.DollarsMember" xlink:to="lab_lly_SwapSwissFrancsToU.S.DollarsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2e75d366-236d-475f-84c6-11da668a3e05_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ddf052fb-8489-4829-b8f7-9c6a7a393541_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total before tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_d6ee8641-df97-4003-8f3e-7180b3fa34f9_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_d300deb5-b2f8-480d-a57a-91443d8d39cd_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_105ac25e-1dd4-4f69-ba21-518c507e8898_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and other revenue associated with prior period transfers of intellectual property</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ErbituxMember_46d50581-6499-478f-9e5a-564d93a64055_terseLabel_en-US" xlink:label="lab_lly_ErbituxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erbitux&#174;</link:label>
    <link:label id="lab_lly_ErbituxMember_label_en-US" xlink:label="lab_lly_ErbituxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erbitux [Member]</link:label>
    <link:label id="lab_lly_ErbituxMember_documentation_en-US" xlink:label="lab_lly_ErbituxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erbitux [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ErbituxMember" xlink:href="lly-20210331.xsd#lly_ErbituxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ErbituxMember" xlink:to="lab_lly_ErbituxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_72afd388-7e4f-4d2c-bd01-35f8a46841c3_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for acquisitions, net of cash acquired (Note 3)</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_bb43b8f2-b22e-4dab-80f1-3bb073757ea2_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrustForBenefitOfEmployeesMember_9de0f3be-2239-447d-979f-9b00c00601db_terseLabel_en-US" xlink:label="lab_us-gaap_TrustForBenefitOfEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Trust</link:label>
    <link:label id="lab_us-gaap_TrustForBenefitOfEmployeesMember_label_en-US" xlink:label="lab_us-gaap_TrustForBenefitOfEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trust for Benefit of Employees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrustForBenefitOfEmployeesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrustForBenefitOfEmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrustForBenefitOfEmployeesMember" xlink:to="lab_us-gaap_TrustForBenefitOfEmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A718NotesDueJune12025Member_71064a48-c8a1-422a-89c9-fc625575d1e7_terseLabel_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7 1/8% Notes due 2025</link:label>
    <link:label id="lab_lly_A718NotesDueJune12025Member_label_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7 1/8% Notes Due June&#160;1, 2025 [Member]</link:label>
    <link:label id="lab_lly_A718NotesDueJune12025Member_documentation_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7 1/8% Notes Due June&#160;1, 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A718NotesDueJune12025Member" xlink:href="lly-20210331.xsd#lly_A718NotesDueJune12025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A718NotesDueJune12025Member" xlink:to="lab_lly_A718NotesDueJune12025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax_405c888e-bad8-4b3b-8906-51d4e1159cc3_terseLabel_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives used in net investment hedge, net of tax</link:label>
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax_label_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives used in Net Investment Hedge, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax" xlink:to="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_739d51be-e62a-44fe-b955-b9c7ee775589_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_4a734648-3bfc-4572-b569-3bb8334e0cf6_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_fb151408-defc-4f03-94eb-57c53f177d64_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e6bfd0ca-80d9-4dd7-b4ef-caec3c09469c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateLineItems_5e15abee-bde2-4067-adbd-ac28296fab10_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate [Line Items]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateLineItems_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="lab_us-gaap_ChangeInAccountingEstimateLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CostOfSalesOperatingExpensesAndOtherNet_a8e5d199-e242-4890-af3c-5c24bb83892b_totalLabel_en-US" xlink:label="lab_lly_CostOfSalesOperatingExpensesAndOtherNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs, expenses, and other</link:label>
    <link:label id="lab_lly_CostOfSalesOperatingExpensesAndOtherNet_label_en-US" xlink:label="lab_lly_CostOfSalesOperatingExpensesAndOtherNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales, operating expenses, and other-net</link:label>
    <link:label id="lab_lly_CostOfSalesOperatingExpensesAndOtherNet_documentation_en-US" xlink:label="lab_lly_CostOfSalesOperatingExpensesAndOtherNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales, operating expenses, and other-net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CostOfSalesOperatingExpensesAndOtherNet" xlink:href="lly-20210331.xsd#lly_CostOfSalesOperatingExpensesAndOtherNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet" xlink:to="lab_lly_CostOfSalesOperatingExpensesAndOtherNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable_674e0977-a0e6-433b-9bc8-56e0b7992048_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Change in Accounting Estimate [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Change in Accounting Estimate [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:to="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ImmunologyMember_073814f9-8353-45f5-810f-ffa8b7745d27_terseLabel_en-US" xlink:label="lab_lly_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology</link:label>
    <link:label id="lab_lly_ImmunologyMember_label_en-US" xlink:label="lab_lly_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology [Member]</link:label>
    <link:label id="lab_lly_ImmunologyMember_documentation_en-US" xlink:label="lab_lly_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ImmunologyMember" xlink:href="lly-20210331.xsd#lly_ImmunologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ImmunologyMember" xlink:to="lab_lly_ImmunologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_d5863284-5855-4917-ae8b-a9fe15f32e30_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_60c68fd6-9d18-4156-a981-db4076630751_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_a9b0c916-6fba-461b-b9b6-215742be6c93_terseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ProductLiabilityMember_9b78405e-5e68-4504-9134-cd8d264da015_terseLabel_en-US" xlink:label="lab_lly_ProductLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability</link:label>
    <link:label id="lab_lly_ProductLiabilityMember_label_en-US" xlink:label="lab_lly_ProductLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability [Member]</link:label>
    <link:label id="lab_lly_ProductLiabilityMember_documentation_en-US" xlink:label="lab_lly_ProductLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProductLiabilityMember" xlink:href="lly-20210331.xsd#lly_ProductLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ProductLiabilityMember" xlink:to="lab_lly_ProductLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DomicileOfLitigationAxis_ef536d1b-1b81-423d-8dc7-9fe9158b2c96_terseLabel_en-US" xlink:label="lab_lly_DomicileOfLitigationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domicile of Litigation [Axis]</link:label>
    <link:label id="lab_lly_DomicileOfLitigationAxis_label_en-US" xlink:label="lab_lly_DomicileOfLitigationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domicile Of Litigation [Axis]</link:label>
    <link:label id="lab_lly_DomicileOfLitigationAxis_documentation_en-US" xlink:label="lab_lly_DomicileOfLitigationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domicile Of Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DomicileOfLitigationAxis" xlink:href="lly-20210331.xsd#lly_DomicileOfLitigationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DomicileOfLitigationAxis" xlink:to="lab_lly_DomicileOfLitigationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_c9ecb407-52aa-4fe3-9e7a-bf0cecf0e845_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining authorized repurchase amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_c33c7144-1fef-4aef-85c2-cf1b517d4bb0_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_cd751319-0fb9-4bea-a944-cdffafdad9be_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_794c9d29-8019-44b5-897a-3cdcb5b61664_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_3012701c-48fc-410f-ab23-7755fc11e164_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_a944f84f-8bdd-418a-bafc-865c6d397dd6_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liability, other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_f84f7a2b-aecb-4ba7-b156-d7749d5c03f0_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment hedges</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_6eccb027-ae68-40f0-b483-db910dff78a4_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain_fddfb1c1-3f6d-4c91-a4ed-4e1baa6e630e_terseLabel_en-US" xlink:label="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gross gains on sales</link:label>
    <link:label id="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain_label_en-US" xlink:label="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for Sale Securities and Equity Securities, FV-NI, Realized Gain</link:label>
    <link:label id="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain_documentation_en-US" xlink:label="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for Sale Securities and Equity Securities, FV-NI, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" xlink:href="lly-20210331.xsd#lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" xlink:to="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_748d7c62-8923-438a-b4f5-f5e1f11ef534_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_5b18b706-86d3-410f-bc17-22e085164150_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_88cb6021-de5d-4c4e-ad20-4918b7d97f9e_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total reclassifications, net of tax</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_9a4e1fb0-65a5-486d-837d-43c24420a8bc_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of disaggregation of revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_27fb4b53-8550-4d7c-a51b-4dbde8874aba_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amount reclassified from accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_7eff8c23-7647-4643-af2d-b64228e9a1f9_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_0e233762-66da-473a-9ef1-b139c0b6eb88_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_b4c563b1-af17-4a07-a7d5-e8ef1b959cc4_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_01bec520-69ef-4776-939a-85492c2a5297_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_fd145d1f-9f7e-45d9-975f-24031ae2e24f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_9f9f9a48-18aa-42e2-ac51-ba9a8a2d0ccc_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_adb47a7f-f732-4721-9b55-f50603c7a6db_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherProductTotalMember_6b418391-583c-4949-b025-0d5674b23a5a_terseLabel_en-US" xlink:label="lab_lly_OtherProductTotalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_lly_OtherProductTotalMember_label_en-US" xlink:label="lab_lly_OtherProductTotalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Product, Total [Member]</link:label>
    <link:label id="lab_lly_OtherProductTotalMember_documentation_en-US" xlink:label="lab_lly_OtherProductTotalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Product, Total [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherProductTotalMember" xlink:href="lly-20210331.xsd#lly_OtherProductTotalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherProductTotalMember" xlink:to="lab_lly_OtherProductTotalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_5ec5fb7f-3d61-4f91-995b-3b308bc97ded_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_91ab0305-92dd-4662-bcb6-79527217aa8a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other financing activities, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_1585a7ee-bb50-4664-8c0c-d9b839c28347_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_fbe28f86-3985-47e4-90a6-ae89ac98f86b_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_d9490b39-47f2-48cf-bba7-70eed2a02bcb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The components of the charges included in asset impairment, restructuring, and other special charges</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_30f6fb0b-23b8-42f7-87dd-bcc80a4c2362_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary the contractual maturities of our investments in debt securities measured at fair value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_c422e4c2-7e1f-416a-a3ed-d55586489ccf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) before reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember_373f57fc-98c0-489b-8c78-fdd9e3f5b112_terseLabel_en-US" xlink:label="lab_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Casseres et al. v. Takeda Pharmaceutical North America, Inc., et al.</link:label>
    <link:label id="lab_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember_label_en-US" xlink:label="lab_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Casseres Et Al. V. Takeda Pharmaceutical North America, Inc., Et Al. [Member]</link:label>
    <link:label id="lab_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember_documentation_en-US" xlink:label="lab_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Casseres Et Al. V. Takeda Pharmaceutical North America, Inc., Et Al.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember" xlink:href="lly-20210331.xsd#lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember" xlink:to="lab_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_80db29c5-6fce-496e-9128-9e887f4cb98b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_1f653b0d-e998-464f-825f-0fc9c64e1e94_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum remaining maturity of foreign currency derivatives</link:label>
    <link:label id="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_label_en-US" xlink:label="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Remaining Maturity of Foreign Currency Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:to="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities_7498339a-08b4-4523-9bd7-074f4e532d94_terseLabel_en-US" xlink:label="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales</link:label>
    <link:label id="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities_label_en-US" xlink:label="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Equity and Available for Sale Securities</link:label>
    <link:label id="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities_documentation_en-US" xlink:label="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Equity and Available for Sale Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" xlink:href="lly-20210331.xsd#lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" xlink:to="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_c1d579d6-ee6a-4bdf-96ca-5fb5e133f917_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, including current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_6e2152ea-8c99-4088-a73d-6467a8c9fac4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, including current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_cb23e81f-73de-4b7c-bda9-6f68ba05a7e1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_WeilerVTakedaCanadaIncEtAlMember_412a5f63-7f52-4e48-b48d-4e5452940d2f_terseLabel_en-US" xlink:label="lab_lly_WeilerVTakedaCanadaIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weiler v. Takeda Canada Inc. et al.</link:label>
    <link:label id="lab_lly_WeilerVTakedaCanadaIncEtAlMember_label_en-US" xlink:label="lab_lly_WeilerVTakedaCanadaIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weiler V. Takeda Canada Inc. Et Al. [Member]</link:label>
    <link:label id="lab_lly_WeilerVTakedaCanadaIncEtAlMember_documentation_en-US" xlink:label="lab_lly_WeilerVTakedaCanadaIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weiler V. Takeda Canada Inc. Et Al.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_WeilerVTakedaCanadaIncEtAlMember" xlink:href="lly-20210331.xsd#lly_WeilerVTakedaCanadaIncEtAlMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_WeilerVTakedaCanadaIncEtAlMember" xlink:to="lab_lly_WeilerVTakedaCanadaIncEtAlMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionContributions_b4e6b059-7347-4b08-a196-68afa739dad0_terseLabel_en-US" xlink:label="lab_us-gaap_PensionContributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension contributions</link:label>
    <link:label id="lab_us-gaap_PensionContributions_label_en-US" xlink:label="lab_us-gaap_PensionContributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Pension Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionContributions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionContributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionContributions" xlink:to="lab_us-gaap_PensionContributions" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsPercent_2aee6c0d-ce24-4f5b-9b36-187218f96a37_terseLabel_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, rights and obligations, percentage (up to)</link:label>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsPercent_label_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations Percent</link:label>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsPercent_documentation_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of rights and obligations under the collaborative arrangements, including but not limited to - percent share in various revenues and costs, percent interest earned on related party notes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsPercent" xlink:href="lly-20210331.xsd#lly_CollaborativeArrangementRightsAndObligationsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CollaborativeArrangementRightsAndObligationsPercent" xlink:to="lab_lly_CollaborativeArrangementRightsAndObligationsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_620dfa7b-5035-4c2f-a601-aad3fe22af91_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_f504ac50-ddcc-4a83-b0f6-44e2fa1f4a82_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other&#8211;Net, (Income) Expense</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_e04e3bef-518d-4c13-93a3-e39c33a10073_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_46194a0e-2829-4bc8-802a-be02bbb0f351_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TrulicityMemberMember_2d8a9013-52e3-4d0c-8589-113e188aed39_terseLabel_en-US" xlink:label="lab_lly_TrulicityMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trulicity&#174;</link:label>
    <link:label id="lab_lly_TrulicityMemberMember_label_en-US" xlink:label="lab_lly_TrulicityMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trulicity [Member] [Member]</link:label>
    <link:label id="lab_lly_TrulicityMemberMember_documentation_en-US" xlink:label="lab_lly_TrulicityMemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trulicity [Member] [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrulicityMemberMember" xlink:href="lly-20210331.xsd#lly_TrulicityMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TrulicityMemberMember" xlink:to="lab_lly_TrulicityMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_d95ea606-13eb-49c6-90bb-f033aae669ab_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_1f77defb-1415-404e-bbfd-d71231fc3d9c_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of pending lawsuits</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_HumalogHumulinAndForteoMember_242d94dc-6b9e-41b8-8aa9-ffb18d39f939_terseLabel_en-US" xlink:label="lab_lly_HumalogHumulinAndForteoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humalog, Humulin and Forteo</link:label>
    <link:label id="lab_lly_HumalogHumulinAndForteoMember_label_en-US" xlink:label="lab_lly_HumalogHumulinAndForteoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humalog, Humulin, And Forteo [Member]</link:label>
    <link:label id="lab_lly_HumalogHumulinAndForteoMember_documentation_en-US" xlink:label="lab_lly_HumalogHumulinAndForteoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humalog, Humulin, And Forteo</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumalogHumulinAndForteoMember" xlink:href="lly-20210331.xsd#lly_HumalogHumulinAndForteoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_HumalogHumulinAndForteoMember" xlink:to="lab_lly_HumalogHumulinAndForteoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LossContingencyNumberOfRequestsForInformation_3bac0730-16aa-44e5-a1fe-2b7eb3bb426a_terseLabel_en-US" xlink:label="lab_lly_LossContingencyNumberOfRequestsForInformation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of requests for information</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfRequestsForInformation_label_en-US" xlink:label="lab_lly_LossContingencyNumberOfRequestsForInformation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Requests For Information</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfRequestsForInformation_documentation_en-US" xlink:label="lab_lly_LossContingencyNumberOfRequestsForInformation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Requests For Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfRequestsForInformation" xlink:href="lly-20210331.xsd#lly_LossContingencyNumberOfRequestsForInformation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LossContingencyNumberOfRequestsForInformation" xlink:to="lab_lly_LossContingencyNumberOfRequestsForInformation" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PurchasedInProcessResearchAndDevelopment_c2dbf533-f7e8-463b-879f-e11f88140cec_negatedTerseLabel_en-US" xlink:label="lab_lly_PurchasedInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of in-process research and development</link:label>
    <link:label id="lab_lly_PurchasedInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_lly_PurchasedInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased in-process research and development</link:label>
    <link:label id="lab_lly_PurchasedInProcessResearchAndDevelopment_documentation_en-US" xlink:label="lab_lly_PurchasedInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of CASH paid for research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore, written off in the period of acquisition (CASH FLOWS).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PurchasedInProcessResearchAndDevelopment" xlink:href="lly-20210331.xsd#lly_PurchasedInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PurchasedInProcessResearchAndDevelopment" xlink:to="lab_lly_PurchasedInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CyramzaMember_fa2d5249-dcf1-4b41-8107-c85a110cc5b1_terseLabel_en-US" xlink:label="lab_lly_CyramzaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cyramza&#174;</link:label>
    <link:label id="lab_lly_CyramzaMember_label_en-US" xlink:label="lab_lly_CyramzaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cyramza [Member]</link:label>
    <link:label id="lab_lly_CyramzaMember_documentation_en-US" xlink:label="lab_lly_CyramzaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cyramza [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CyramzaMember" xlink:href="lly-20210331.xsd#lly_CyramzaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CyramzaMember" xlink:to="lab_lly_CyramzaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_b21d02e5-f38a-4d13-a026-43955175fa73_terseLabel_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Notes due 2030</link:label>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_label_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Notes Due June 3, 2030 [Member]</link:label>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_documentation_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Notes Due June 3, 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member" xlink:href="lly-20210331.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A2.125NotesDueJune32030Member" xlink:to="lab_lly_A2.125NotesDueJune32030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MilestonePaymentsSalesBasedMember_07f75504-33f7-442d-8768-a1b6e8af630e_terseLabel_en-US" xlink:label="lab_lly_MilestonePaymentsSalesBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Sales-based</link:label>
    <link:label id="lab_lly_MilestonePaymentsSalesBasedMember_label_en-US" xlink:label="lab_lly_MilestonePaymentsSalesBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Sales-based [Member]</link:label>
    <link:label id="lab_lly_MilestonePaymentsSalesBasedMember_documentation_en-US" xlink:label="lab_lly_MilestonePaymentsSalesBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Sales-based [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsSalesBasedMember" xlink:href="lly-20210331.xsd#lly_MilestonePaymentsSalesBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MilestonePaymentsSalesBasedMember" xlink:to="lab_lly_MilestonePaymentsSalesBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DiabetesMember_19ce10f3-d9ad-441e-86ba-32e0d17a20dd_terseLabel_en-US" xlink:label="lab_lly_DiabetesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diabetes</link:label>
    <link:label id="lab_lly_DiabetesMember_label_en-US" xlink:label="lab_lly_DiabetesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diabetes [Member]</link:label>
    <link:label id="lab_lly_DiabetesMember_documentation_en-US" xlink:label="lab_lly_DiabetesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diabetes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DiabetesMember" xlink:href="lly-20210331.xsd#lly_DiabetesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DiabetesMember" xlink:to="lab_lly_DiabetesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_e0f6fd2e-5a05-40ae-b36a-c0561ef32b6c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_4a053bba-8c39-49ea-8013-bb8aa46ac2e7_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_VariousStateDomicilesMember_472c377b-98c4-4dd4-8959-65e39043ef8b_terseLabel_en-US" xlink:label="lab_lly_VariousStateDomicilesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Various State Domiciles</link:label>
    <link:label id="lab_lly_VariousStateDomicilesMember_label_en-US" xlink:label="lab_lly_VariousStateDomicilesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Various State Domiciles [Member]</link:label>
    <link:label id="lab_lly_VariousStateDomicilesMember_documentation_en-US" xlink:label="lab_lly_VariousStateDomicilesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Various State Domiciles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_VariousStateDomicilesMember" xlink:href="lly-20210331.xsd#lly_VariousStateDomicilesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_VariousStateDomicilesMember" xlink:to="lab_lly_VariousStateDomicilesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherProductMember_d62ee646-aeea-4aab-9fb7-2a437d6c5cd0_terseLabel_en-US" xlink:label="lab_lly_OtherProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_lly_OtherProductMember_label_en-US" xlink:label="lab_lly_OtherProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Product [Member]</link:label>
    <link:label id="lab_lly_OtherProductMember_documentation_en-US" xlink:label="lab_lly_OtherProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherProductMember" xlink:href="lly-20210331.xsd#lly_OtherProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherProductMember" xlink:to="lab_lly_OtherProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BuyBritishPoundandSellUSDollarsMember_e6bf7a3e-6ce7-4073-80c7-e1b7217ce6c9_terseLabel_en-US" xlink:label="lab_lly_BuyBritishPoundandSellUSDollarsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy British Pounds and Sell U.S. Dollars</link:label>
    <link:label id="lab_lly_BuyBritishPoundandSellUSDollarsMember_label_en-US" xlink:label="lab_lly_BuyBritishPoundandSellUSDollarsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy British Pound and Sell US Dollars [Member]</link:label>
    <link:label id="lab_lly_BuyBritishPoundandSellUSDollarsMember_documentation_en-US" xlink:label="lab_lly_BuyBritishPoundandSellUSDollarsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy British Pound and Sell US Dollars [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyBritishPoundandSellUSDollarsMember" xlink:href="lly-20210331.xsd#lly_BuyBritishPoundandSellUSDollarsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BuyBritishPoundandSellUSDollarsMember" xlink:to="lab_lly_BuyBritishPoundandSellUSDollarsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_4ebba888-ceb8-41ab-8d97-8cd96378bdc6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary certain fair value information, liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_f9564307-db61-4f88-8000-604b247a4d0f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_1a2a6536-4507-40d7-b6f0-cea7262befd3_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_1707f4e3-2d0d-4bd8-9ec2-b8c9b8cc6b61_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss_df3ba621-efd7-4d11-902d-91c96762d03f_terseLabel_en-US" xlink:label="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gross losses on sales</link:label>
    <link:label id="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss_label_en-US" xlink:label="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale Securities and Equity Securities, FV-NI, Realized Loss</link:label>
    <link:label id="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss_documentation_en-US" xlink:label="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale Securities and Equity Securities, FV-NI, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" xlink:href="lly-20210331.xsd#lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" xlink:to="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_33a17798-98b7-4d89-bade-140b9b04d3bd_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_c918a520-a536-45dd-8b1f-eae50a37edc5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b401425d-4789-42f7-8327-752473ca92f9_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_5aedda90-6e1b-45cd-ac2c-45c15bb9dacd_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward-starting interest rate swaps</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_e182c81c-261e-4583-956e-6da2b343a307_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial losses, net</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_f24e2131-fc7d-4897-aa53-44042ab8da5f_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_b608577a-1366-4b69-adba-e2f1fa754069_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_5fae5b81-670a-4eb6-9a10-c71cc60270c4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_79dd93dc-eb51-4058-afac-198b7938b1c3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_EppVTakedaCanadaIncEtAlMember_407f78ac-867a-4edc-b6fd-c84a40586368_terseLabel_en-US" xlink:label="lab_lly_EppVTakedaCanadaIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Epp v. Takeda Canada Inc. et al.</link:label>
    <link:label id="lab_lly_EppVTakedaCanadaIncEtAlMember_label_en-US" xlink:label="lab_lly_EppVTakedaCanadaIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Epp V. Takeda Canada Inc. Et Al. [Member]</link:label>
    <link:label id="lab_lly_EppVTakedaCanadaIncEtAlMember_documentation_en-US" xlink:label="lab_lly_EppVTakedaCanadaIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Epp V. Takeda Canada Inc. Et Al.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EppVTakedaCanadaIncEtAlMember" xlink:href="lly-20210331.xsd#lly_EppVTakedaCanadaIncEtAlMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_EppVTakedaCanadaIncEtAlMember" xlink:to="lab_lly_EppVTakedaCanadaIncEtAlMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_45223f20-2251-4071-b6cf-a8e33e789748_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_882de301-92d2-4faf-b1cb-6db12c553f77_terseLabel_en-US" xlink:label="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent value right, additional price per share (up to) (in dollars per share)</link:label>
    <link:label id="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_label_en-US" xlink:label="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Value Right, Additional Price Per Share</link:label>
    <link:label id="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_documentation_en-US" xlink:label="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Value Right, Additional Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" xlink:href="lly-20210331.xsd#lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" xlink:to="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_d8130f8d-de26-448a-aa9a-cab014e2f5dd_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment, Restructuring, and Other Special Charges</link:label>
    <link:label id="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Impairment, and Other Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TanezumabMember_e104e76b-43ce-490c-b7b6-702a0a9a462f_terseLabel_en-US" xlink:label="lab_lly_TanezumabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tanezumab</link:label>
    <link:label id="lab_lly_TanezumabMember_label_en-US" xlink:label="lab_lly_TanezumabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tanezumab [Member]</link:label>
    <link:label id="lab_lly_TanezumabMember_documentation_en-US" xlink:label="lab_lly_TanezumabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tanezumab [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TanezumabMember" xlink:href="lly-20210331.xsd#lly_TanezumabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TanezumabMember" xlink:to="lab_lly_TanezumabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_1d71c294-bd27-4e3e-9a37-899cb92df6de_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_0925a4f1-e63c-493d-ac26-9671ca4cbf1c_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_75f6056d-9905-4f3e-bdbd-440790f06831_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net of allowances of $23.9 (2021) and $25.9 (2020)</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ab99c14d-8b56-4d5c-a325-1273df81a7fb_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gross losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_e3a0f624-c451-4286-937a-79556538024c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CymbaltaMember_3ec5e295-dc92-4523-9810-30ef80b6c9f5_terseLabel_en-US" xlink:label="lab_lly_CymbaltaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cymbalta&#174;</link:label>
    <link:label id="lab_lly_CymbaltaMember_label_en-US" xlink:label="lab_lly_CymbaltaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cymbalta [Member]</link:label>
    <link:label id="lab_lly_CymbaltaMember_documentation_en-US" xlink:label="lab_lly_CymbaltaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cymbalta [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CymbaltaMember" xlink:href="lly-20210331.xsd#lly_CymbaltaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CymbaltaMember" xlink:to="lab_lly_CymbaltaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_b6d9353c-e93f-420c-9220-ac58dda09fcc_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Portion of Cash&#160;Flow Hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember_79dbb6ba-2dbb-4dc1-ac12-b32a5af689da_terseLabel_en-US" xlink:label="lab_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Capitalized as Intangible Assets</link:label>
    <link:label id="lab_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember_label_en-US" xlink:label="lab_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Capitalized As Intangible Assets [Member]</link:label>
    <link:label id="lab_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember_documentation_en-US" xlink:label="lab_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Capitalized As Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember" xlink:href="lly-20210331.xsd#lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember" xlink:to="lab_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_ebd5a26c-d590-442d-a068-793a6f74eee5_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_1d903d05-0966-46bf-a7f5-4454c6ff255c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less&#160;Than 1 Year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_4c2a5037-82bc-4683-a451-34065390b3bc_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireLongtermInvestments_a45ddf6f-4a56-43ea-9fe6-254080e6a9eb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of noncurrent investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireLongtermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A625Notesdue2031Member_f104d10f-fb16-41e4-b3b0-e515938c6f06_terseLabel_en-US" xlink:label="lab_lly_A625Notesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.625% Notes due 2031</link:label>
    <link:label id="lab_lly_A625Notesdue2031Member_label_en-US" xlink:label="lab_lly_A625Notesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.625% Notes due 2031 [Member]</link:label>
    <link:label id="lab_lly_A625Notesdue2031Member_documentation_en-US" xlink:label="lab_lly_A625Notesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.625% Notes due 2031 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625Notesdue2031Member" xlink:href="lly-20210331.xsd#lly_A625Notesdue2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A625Notesdue2031Member" xlink:to="lab_lly_A625Notesdue2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2c785437-8f90-4776-8d51-5e59df735b7e_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_fd49c030-e333-43ed-bdba-4295cd6bc42a_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_d70bb06b-87b9-452a-b4e9-2e3e3329d048_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_70f6c165-d942-434b-8009-2c54daaeba6f_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_e34efb54-bfe4-4d2f-a983-e3c5f69dc678_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetNotionalAmount_da765342-38bf-4874-bcc9-e2082c1ea110_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative asset, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetNotionalAmount" xlink:to="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_64e63a87-180f-439d-bb74-f86497d71c79_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Activity related to our available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:to="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_00698daf-5261-4600-b0c9-0a5655646dce_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in short-term borrowings</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_a3bf5e0f-508f-4b9b-bb8a-5b743d5c7b8c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_73fca5c5-4386-4099-ab45-f3bc69de2c6d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_03c94a32-5eff-4298-8174-640fa91c1bc5_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case Type [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_5b27115a-65db-431e-8c05-5b91c582244b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_d5903a57-14a9-4729-8814-b9e5f0865058_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SitryxTherapeuticsLimitedMember_e30b1bf1-efbb-48b2-bd80-8932dfe8cb14_terseLabel_en-US" xlink:label="lab_lly_SitryxTherapeuticsLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sitryx Therapeutics Limited</link:label>
    <link:label id="lab_lly_SitryxTherapeuticsLimitedMember_label_en-US" xlink:label="lab_lly_SitryxTherapeuticsLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sitryx Therapeutics Limited [Member]</link:label>
    <link:label id="lab_lly_SitryxTherapeuticsLimitedMember_documentation_en-US" xlink:label="lab_lly_SitryxTherapeuticsLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sitryx Therapeutics Limited [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SitryxTherapeuticsLimitedMember" xlink:href="lly-20210331.xsd#lly_SitryxTherapeuticsLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SitryxTherapeuticsLimitedMember" xlink:to="lab_lly_SitryxTherapeuticsLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_4b53cc3c-6d9c-453a-9e3b-5942cefdae35_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss), net investment hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_1f31d5b4-5eda-426d-92f1-d71591e8b5f7_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued retirement benefits (Note 8)</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Plan, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_8375f2cc-6e9c-469f-b654-54b5432f3525_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Other than Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_8b14652d-07a0-4e87-b002-b1d38844c2f1_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash (Used for) Provided by Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_0bae72ee-d2b7-46b5-a5dc-22bd1ad9a1d1_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_93de38a7-f347-4fb9-8b2f-f560a9e50502_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_NonCHINAMember_08ff45d2-4a7b-43f0-b779-7b2f0d7019b6_terseLabel_en-US" xlink:label="lab_lly_NonCHINAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-CHINA</link:label>
    <link:label id="lab_lly_NonCHINAMember_label_en-US" xlink:label="lab_lly_NonCHINAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-CHINA [Member]</link:label>
    <link:label id="lab_lly_NonCHINAMember_documentation_en-US" xlink:label="lab_lly_NonCHINAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-CHINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NonCHINAMember" xlink:href="lly-20210331.xsd#lly_NonCHINAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_NonCHINAMember" xlink:to="lab_lly_NonCHINAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_cf524bcd-d829-4731-a70e-debde5686e95_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of plaintiffs</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:to="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_53dd85bc-86d0-4e33-9ea2-da35ebd989cf_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock under employee stock plans, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_435ad88d-bfe3-4109-9daa-1d6e58f2feee_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_4f6e37c6-fb0d-44d6-82b8-1dd55b232d4c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments (Note 6)</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_7c1deb69-1c24-4196-824f-a89f74c24578_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_9a275d24-6ff1-40a0-9a3c-71165eee7d7b_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_6c50c0a5-9ebd-4160-8636-fbf643474704_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments</link:label>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_label_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermInvestments" xlink:to="lab_us-gaap_OtherLongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherImmunologyMember_d621a8e1-54cb-45b3-b43d-e1417f230ff1_terseLabel_en-US" xlink:label="lab_lly_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Immunology</link:label>
    <link:label id="lab_lly_OtherImmunologyMember_label_en-US" xlink:label="lab_lly_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Immunology [Member]</link:label>
    <link:label id="lab_lly_OtherImmunologyMember_documentation_en-US" xlink:label="lab_lly_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Immunology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherImmunologyMember" xlink:href="lly-20210331.xsd#lly_OtherImmunologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherImmunologyMember" xlink:to="lab_lly_OtherImmunologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_c93b60ff-0305-4546-898d-7502e3ee2c54_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrent_6616587b-b3b4-4829-b52a-d6c5f475089e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term borrowings and current maturities of long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_label_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_495f3644-3977-46f9-8039-fce2a61f3986_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LossContingencyNumberOfPatentsClaimsDismissed_613605d6-e088-4623-8cf9-bd4d6b9083f5_terseLabel_en-US" xlink:label="lab_lly_LossContingencyNumberOfPatentsClaimsDismissed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents, claims dismissed</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfPatentsClaimsDismissed_label_en-US" xlink:label="lab_lly_LossContingencyNumberOfPatentsClaimsDismissed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Patents, Claims Dismissed</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfPatentsClaimsDismissed_documentation_en-US" xlink:label="lab_lly_LossContingencyNumberOfPatentsClaimsDismissed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Patents, Claims Dismissed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfPatentsClaimsDismissed" xlink:href="lly-20210331.xsd#lly_LossContingencyNumberOfPatentsClaimsDismissed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LossContingencyNumberOfPatentsClaimsDismissed" xlink:to="lab_lly_LossContingencyNumberOfPatentsClaimsDismissed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_620da905-9851-43ba-bf3c-440cd1f74fca_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_065d7ae9-95ad-4501-adec-371da38baa18_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LosAngelesMember_a85aab48-bfc1-42c9-9b55-266f2b5aac81_terseLabel_en-US" xlink:label="lab_lly_LosAngelesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Los Angeles</link:label>
    <link:label id="lab_lly_LosAngelesMember_label_en-US" xlink:label="lab_lly_LosAngelesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Los Angeles [Member]</link:label>
    <link:label id="lab_lly_LosAngelesMember_documentation_en-US" xlink:label="lab_lly_LosAngelesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Los Angeles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LosAngelesMember" xlink:href="lly-20210331.xsd#lly_LosAngelesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LosAngelesMember" xlink:to="lab_lly_LosAngelesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_4c310d87-5e1c-43aa-9d0a-bcb836d3f1d1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_e06ff1be-0702-4197-ab0d-8e62dc4ae127_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborations and Other Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d0a62d1e-50bd-474f-b931-3313b1ebcd86_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_44b7eb43-44a4-4eeb-b1f2-b5cba0c53bce_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents (Note 6)</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_COVID19AntibodiesMember_f8384a6d-6189-46c8-b497-6245722c1719_terseLabel_en-US" xlink:label="lab_lly_COVID19AntibodiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Antibodies</link:label>
    <link:label id="lab_lly_COVID19AntibodiesMember_label_en-US" xlink:label="lab_lly_COVID19AntibodiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Antibodies [Member]</link:label>
    <link:label id="lab_lly_COVID19AntibodiesMember_documentation_en-US" xlink:label="lab_lly_COVID19AntibodiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Antibodies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_COVID19AntibodiesMember" xlink:href="lly-20210331.xsd#lly_COVID19AntibodiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_COVID19AntibodiesMember" xlink:to="lab_lly_COVID19AntibodiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust_f35384aa-2647-4188-9487-e62916f17f08_negatedLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefit trust</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Held in Employee Trust</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesHeldInEmployeeTrust"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:to="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition_87e0c695-4a98-4876-abbd-42703f31b648_terseLabel_en-US" xlink:label="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of securities in an unrealized gain position</link:label>
    <link:label id="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition_label_en-US" xlink:label="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Gain Position</link:label>
    <link:label id="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition_documentation_en-US" xlink:label="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Gain Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" xlink:href="lly-20210331.xsd#lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" xlink:to="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_a18ec82d-3c28-45af-8d7f-abbaa3140ee5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesMember_6ba698e8-c237-456b-a09e-8717fb6802fd_terseLabel_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage-backed securities</link:label>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateralized Mortgage Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgageBackedSecuritiesMember" xlink:to="lab_us-gaap_MortgageBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_b3f3301f-d0d8-452c-9f81-078a1c45fee3_terseLabel_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales returns, rebates, and discounts</link:label>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_label_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Returns and Allowances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesReturnsAndAllowancesMember" xlink:to="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_e8536a53-04ec-4656-9d0d-4a87bfe4c458_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_65a3c1b3-bd4f-4f5f-a56e-584c348a6c08_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized actuarial loss</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Actuarial Gain (Loss), Immediate Recognition as Component in Net Periodic Benefit (Cost) Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_94a36ff3-14e0-4548-8ad6-64d54c5200d8_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Eli Lilly and Company shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6b785bec-5e60-4b7a-bb2b-7f4512c19b42_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_f244aa38-02f8-4b82-9ed9-16566713b0a2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ForeignCurrencyDenominatedDebtMember_fc44a8cc-98bd-4a88-9800-72174f5f01e2_terseLabel_en-US" xlink:label="lab_lly_ForeignCurrencyDenominatedDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Denominated Debt</link:label>
    <link:label id="lab_lly_ForeignCurrencyDenominatedDebtMember_label_en-US" xlink:label="lab_lly_ForeignCurrencyDenominatedDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Denominated Debt [Member]</link:label>
    <link:label id="lab_lly_ForeignCurrencyDenominatedDebtMember_documentation_en-US" xlink:label="lab_lly_ForeignCurrencyDenominatedDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Denominated Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForeignCurrencyDenominatedDebtMember" xlink:href="lly-20210331.xsd#lly_ForeignCurrencyDenominatedDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ForeignCurrencyDenominatedDebtMember" xlink:to="lab_lly_ForeignCurrencyDenominatedDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_1ab554b6-076e-4aa9-946b-44f97d75b089_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_3b21307c-ae2d-40a6-abfa-589ce6b0c9b3_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b2fe2959-61c8-4510-80c9-139bf9c8d4e4_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss (Note 10)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_36dfe7b1-40f6-498d-bcd6-62b45dc7966d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_5f7b1897-b454-4439-b2c0-36291206ee31_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_1eca89d3-d61f-4ae0-86ff-7c18dde8a6a3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_5c06984e-5fbb-4f9d-bd28-0496c5070a7a_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_a3ba41bd-31a5-4cb1-8cdb-666775ddec01_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_76ee3cb9-2963-45a1-9aa3-cb566d81ab28_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_04f3db3b-0625-4e3c-9e3f-f56dc7844b89_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D Expense</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_5a052801-86f8-4564-adfb-becef710c770_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages awarded, value</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Awarded, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:to="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_a17bc7ec-f82b-4f50-b79e-92b243a2a8e5_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition date fair value of consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_939239a3-6ffa-4d94-96fc-f44663e6019a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_580e6b4a-2f18-4bd5-a3d8-4c0dd00b272e_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_EmgalityPatentLitigationMember_eb9149ee-be4a-4d93-9e8f-bae791090231_terseLabel_en-US" xlink:label="lab_lly_EmgalityPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emgality Patent Litigation</link:label>
    <link:label id="lab_lly_EmgalityPatentLitigationMember_label_en-US" xlink:label="lab_lly_EmgalityPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emgality Patent Litigation [Member]</link:label>
    <link:label id="lab_lly_EmgalityPatentLitigationMember_documentation_en-US" xlink:label="lab_lly_EmgalityPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emgality Patent Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmgalityPatentLitigationMember" xlink:href="lly-20210331.xsd#lly_EmgalityPatentLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_EmgalityPatentLitigationMember" xlink:to="lab_lly_EmgalityPatentLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_d2fac4bf-8289-45ff-8661-3efd6751239d_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenue</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_2bdbfac8-3bdd-4f88-bac3-50d76a083603_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_1cb9d91a-3e74-4366-9d36-137bf5fa39a9_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_e4419358-5973-4945-9058-0693b943479e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsNoncurrent" xlink:to="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_1afede42-4fb0-4476-b016-cf21a8f5229d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of effective portion of risk-management instruments that was recognized in other comprehensive income (loss), cash flow hedges</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_e36a1c06-972d-45e3-8b09-e1c5d25d3bed_terseLabel_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes due 2026</link:label>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_label_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes Due June 2, 2026 [Member]</link:label>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_documentation_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes Due June 2, 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.625NotesDueJune22026Member" xlink:href="lly-20210331.xsd#lly_A1.625NotesDueJune22026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1.625NotesDueJune22026Member" xlink:to="lab_lly_A1.625NotesDueJune22026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividends_edd1cc7f-47b0-4100-822b-8e8445aa5b5b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividends" xlink:to="lab_us-gaap_PaymentsOfDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_c14d9fd7-4cdc-4287-87da-4b9a59b88bc8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net of accumulated depreciation of $9,643.4 (2021) and $9,570.7 (2020)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_892ada63-cfc1-4253-a48f-255b0dc2f77e_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ActosMember_af24dc78-10bd-433d-b4e7-d9f2abd4e0a4_terseLabel_en-US" xlink:label="lab_lly_ActosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actos</link:label>
    <link:label id="lab_lly_ActosMember_label_en-US" xlink:label="lab_lly_ActosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actos [Member]</link:label>
    <link:label id="lab_lly_ActosMember_documentation_en-US" xlink:label="lab_lly_ActosMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actos</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ActosMember" xlink:href="lly-20210331.xsd#lly_ActosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ActosMember" xlink:to="lab_lly_ActosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateContractMember_14364cf2-c62b-4d91-8349-ff507e5409a7_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate contracts</link:label>
    <link:label id="lab_us-gaap_InterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateContractMember" xlink:to="lab_us-gaap_InterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_a1bb1b27-f344-46e6-b066-6d90d42b6ced_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DomicileOfLitigationDomain_28894a26-ef0c-4589-9089-f8ef4a754725_terseLabel_en-US" xlink:label="lab_lly_DomicileOfLitigationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domicile of Litigation [Domain]</link:label>
    <link:label id="lab_lly_DomicileOfLitigationDomain_label_en-US" xlink:label="lab_lly_DomicileOfLitigationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domicile Of Litigation [Domain]</link:label>
    <link:label id="lab_lly_DomicileOfLitigationDomain_documentation_en-US" xlink:label="lab_lly_DomicileOfLitigationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domicile Of Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DomicileOfLitigationDomain" xlink:href="lly-20210331.xsd#lly_DomicileOfLitigationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DomicileOfLitigationDomain" xlink:to="lab_lly_DomicileOfLitigationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_0e31f7fe-e8da-4e45-b814-56ab94481608_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3d59d181-2b19-42a5-896d-7922feffc49d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax (Note 10)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_46be83fe-65e0-4579-b3ed-e787003f24e6_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_77c51a17-0af3-43ae-8928-ea6a88b73489_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_7b794092-ca2c-4138-a544-d67b5979dd6c_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_90d4d12b-db7f-4dd3-8400-26235e4f09dc_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_e7e888e1-ec38-4c3f-a82d-c1004f63597f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TYVYTMember_0561f0f2-d955-4fe1-aeb8-05214300e554_terseLabel_en-US" xlink:label="lab_lly_TYVYTMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tyvyt&#174;</link:label>
    <link:label id="lab_lly_TYVYTMember_label_en-US" xlink:label="lab_lly_TYVYTMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TYVYT [Member]</link:label>
    <link:label id="lab_lly_TYVYTMember_documentation_en-US" xlink:label="lab_lly_TYVYTMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TYVYT</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TYVYTMember" xlink:href="lly-20210331.xsd#lly_TYVYTMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TYVYTMember" xlink:to="lab_lly_TYVYTMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PancreaticCancerOrThyroidCancerMember_f4224e53-019f-4ef9-ae2c-3de1dbcc8007_terseLabel_en-US" xlink:label="lab_lly_PancreaticCancerOrThyroidCancerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pancreatic Cancer or Thyroid Cancer</link:label>
    <link:label id="lab_lly_PancreaticCancerOrThyroidCancerMember_label_en-US" xlink:label="lab_lly_PancreaticCancerOrThyroidCancerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pancreatic Cancer Or Thyroid Cancer [Member]</link:label>
    <link:label id="lab_lly_PancreaticCancerOrThyroidCancerMember_documentation_en-US" xlink:label="lab_lly_PancreaticCancerOrThyroidCancerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pancreatic Cancer Or Thyroid Cancer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PancreaticCancerOrThyroidCancerMember" xlink:href="lly-20210331.xsd#lly_PancreaticCancerOrThyroidCancerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PancreaticCancerOrThyroidCancerMember" xlink:to="lab_lly_PancreaticCancerOrThyroidCancerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_3b7cb388-ec2e-440c-b01b-f95ab5370197_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8a5e8517-9714-461e-97d5-b43b36a9839f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_41c74d94-a76b-4d73-b5d8-76b7a953422f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_b3f48300-8120-4799-862f-0f0d21152f13_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup_5f38c7ad-7062-43b0-9ea4-12b527c404e0_terseLabel_en-US" xlink:label="lab_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of sites jointly and severally liable for cleanup (fewer than)</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup_label_en-US" xlink:label="lab_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup_documentation_en-US" xlink:label="lab_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" xlink:href="lly-20210331.xsd#lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" xlink:to="lab_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OncologyMember_3c176777-4a23-4db1-a41b-d661ee3ceefa_terseLabel_en-US" xlink:label="lab_lly_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology</link:label>
    <link:label id="lab_lly_OncologyMember_label_en-US" xlink:label="lab_lly_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology [Member]</link:label>
    <link:label id="lab_lly_OncologyMember_documentation_en-US" xlink:label="lab_lly_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue to unaffiliated customers, Oncology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OncologyMember" xlink:href="lly-20210331.xsd#lly_OncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OncologyMember" xlink:to="lab_lly_OncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember_b4e09c30-617f-452d-81bc-331d15c795ea_terseLabel_en-US" xlink:label="lab_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Success-based Regulatory and Sales-based</link:label>
    <link:label id="lab_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember_label_en-US" xlink:label="lab_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Success-based Regulatory And Sales-based [Member]</link:label>
    <link:label id="lab_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember_documentation_en-US" xlink:label="lab_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Success-based Regulatory And Sales-based</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember" xlink:href="lly-20210331.xsd#lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember" xlink:to="lab_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_EmgalityMember_7192d875-3529-4212-a087-a1387e33d89b_terseLabel_en-US" xlink:label="lab_lly_EmgalityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emgality&#174;</link:label>
    <link:label id="lab_lly_EmgalityMember_label_en-US" xlink:label="lab_lly_EmgalityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emgality [Member]</link:label>
    <link:label id="lab_lly_EmgalityMember_documentation_en-US" xlink:label="lab_lly_EmgalityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emgality [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmgalityMember" xlink:href="lly-20210331.xsd#lly_EmgalityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_EmgalityMember" xlink:to="lab_lly_EmgalityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_253ab80f-2918-470d-8cac-2c46649217ac_terseLabel_en-US" xlink:label="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Development and Regulatory</link:label>
    <link:label id="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_label_en-US" xlink:label="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Development and Regulatory [Member]</link:label>
    <link:label id="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_documentation_en-US" xlink:label="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Development and Regulatory [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentAndRegulatoryMember" xlink:href="lly-20210331.xsd#lly_MilestonePaymentsDevelopmentAndRegulatoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MilestonePaymentsDevelopmentAndRegulatoryMember" xlink:to="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_4578a306-99c6-4673-a345-6075e5e6eb03_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1.700Notesdue2049Member_80322004-80b3-41ad-99d0-e26e8b67b737_terseLabel_en-US" xlink:label="lab_lly_A1.700Notesdue2049Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes due 2049</link:label>
    <link:label id="lab_lly_A1.700Notesdue2049Member_label_en-US" xlink:label="lab_lly_A1.700Notesdue2049Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes due 2049 [Member]</link:label>
    <link:label id="lab_lly_A1.700Notesdue2049Member_documentation_en-US" xlink:label="lab_lly_A1.700Notesdue2049Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes due 2049 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.700Notesdue2049Member" xlink:href="lly-20210331.xsd#lly_A1.700Notesdue2049Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1.700Notesdue2049Member" xlink:to="lab_lly_A1.700Notesdue2049Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PaymentforPensionBenefitsAdditionalDiscretionaryFunding_8916ba9e-2c8e-40be-9045-0218c4e2d10f_terseLabel_en-US" xlink:label="lab_lly_PaymentforPensionBenefitsAdditionalDiscretionaryFunding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for additional discretionary funding</link:label>
    <link:label id="lab_lly_PaymentforPensionBenefitsAdditionalDiscretionaryFunding_label_en-US" xlink:label="lab_lly_PaymentforPensionBenefitsAdditionalDiscretionaryFunding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Pension Benefits, Additional Discretionary Funding</link:label>
    <link:label id="lab_lly_PaymentforPensionBenefitsAdditionalDiscretionaryFunding_documentation_en-US" xlink:label="lab_lly_PaymentforPensionBenefitsAdditionalDiscretionaryFunding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Pension Benefits, Additional Discretionary Funding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PaymentforPensionBenefitsAdditionalDiscretionaryFunding" xlink:href="lly-20210331.xsd#lly_PaymentforPensionBenefitsAdditionalDiscretionaryFunding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PaymentforPensionBenefitsAdditionalDiscretionaryFunding" xlink:to="lab_lly_PaymentforPensionBenefitsAdditionalDiscretionaryFunding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_ea00b999-dafa-45e2-a7aa-95405ecc3a25_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_783d9c93-3d5d-4c47-911c-71664351fd7c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock under employee stock plans, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_b318a836-ecb5-4eef-8744-3d3a5c6dbf51_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_5602b53d-b450-4545-97ca-038d9398cc77_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_7af4b8dc-2eda-47e7-9843-8069c8093830_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_ae90f4f1-74e3-4259-9258-00aea7c5c858_terseLabel_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77%&#160;Notes due 2036</link:label>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_label_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77%&#160;Notes Due January&#160;1, 2036 [Member]</link:label>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_documentation_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77%&#160;Notes Due January&#160;1, 2036 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member" xlink:href="lly-20210331.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A6.77NotesDueJanuary12036Member" xlink:to="lab_lly_A6.77NotesDueJanuary12036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SalesRebatesAndDiscounts_e6b1f794-87bd-40c1-9b7c-ad2ca423439c_terseLabel_en-US" xlink:label="lab_lly_SalesRebatesAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales rebates and discounts</link:label>
    <link:label id="lab_lly_SalesRebatesAndDiscounts_label_en-US" xlink:label="lab_lly_SalesRebatesAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales rebates and discounts</link:label>
    <link:label id="lab_lly_SalesRebatesAndDiscounts_documentation_en-US" xlink:label="lab_lly_SalesRebatesAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales rebates and discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SalesRebatesAndDiscounts" xlink:href="lly-20210331.xsd#lly_SalesRebatesAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SalesRebatesAndDiscounts" xlink:to="lab_lly_SalesRebatesAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_9fee37d5-0fe0-4970-976b-c0841818eff9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of significant milestones and revenue recognized</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DrReddysLabMember_3829e9d3-13b6-4e76-af0e-3339f32f4c27_terseLabel_en-US" xlink:label="lab_lly_DrReddysLabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr Reddy's Lab</link:label>
    <link:label id="lab_lly_DrReddysLabMember_label_en-US" xlink:label="lab_lly_DrReddysLabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr Reddy's Lab [Member]</link:label>
    <link:label id="lab_lly_DrReddysLabMember_documentation_en-US" xlink:label="lab_lly_DrReddysLabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr Reddy's Lab [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DrReddysLabMember" xlink:href="lly-20210331.xsd#lly_DrReddysLabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DrReddysLabMember" xlink:to="lab_lly_DrReddysLabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_9658c72e-faea-4968-8048-959a3582a198_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of reclassifications out of accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DerivativeInstrumentsGainLossRecognized_68c4bf5a-7519-410b-9241-6aacf6baca3e_negatedTotalLabel_en-US" xlink:label="lab_lly_DerivativeInstrumentsGainLossRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_lly_DerivativeInstrumentsGainLossRecognized_label_en-US" xlink:label="lab_lly_DerivativeInstrumentsGainLossRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Recognized</link:label>
    <link:label id="lab_lly_DerivativeInstrumentsGainLossRecognized_documentation_en-US" xlink:label="lab_lly_DerivativeInstrumentsGainLossRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DerivativeInstrumentsGainLossRecognized" xlink:href="lly-20210331.xsd#lly_DerivativeInstrumentsGainLossRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DerivativeInstrumentsGainLossRecognized" xlink:to="lab_lly_DerivativeInstrumentsGainLossRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CialisMember_fa40909c-67e1-4256-aac2-d95627fc0b58_terseLabel_en-US" xlink:label="lab_lly_CialisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cialis&#174;</link:label>
    <link:label id="lab_lly_CialisMember_label_en-US" xlink:label="lab_lly_CialisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cialis [Member]</link:label>
    <link:label id="lab_lly_CialisMember_documentation_en-US" xlink:label="lab_lly_CialisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cialis [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CialisMember" xlink:href="lly-20210331.xsd#lly_CialisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CialisMember" xlink:to="lab_lly_CialisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_6cebd258-7de6-430d-9269-016aab6e4fb7_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_1ef8c665-1268-4c59-a484-dd406fc86b4a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit (provision) for income taxes allocated to other comprehensive income (loss) items</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherEquitySecuritiesMember_0a6fc2e5-6b3a-4cd4-8cc2-cd1690708249_terseLabel_en-US" xlink:label="lab_lly_OtherEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other securities, noncurrent investments</link:label>
    <link:label id="lab_lly_OtherEquitySecuritiesMember_label_en-US" xlink:label="lab_lly_OtherEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Equity Securities [Member]</link:label>
    <link:label id="lab_lly_OtherEquitySecuritiesMember_documentation_en-US" xlink:label="lab_lly_OtherEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherEquitySecuritiesMember" xlink:href="lly-20210331.xsd#lly_OtherEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherEquitySecuritiesMember" xlink:to="lab_lly_OtherEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfLongtermInvestments_6166c37d-d9b7-40c5-b1de-f4a7017094e3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfLongtermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of noncurrent investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfLongtermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfLongtermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfLongtermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfLongtermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfLongtermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfLongtermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_f031fd05-c963-4bbc-ac36-f7104b82e1d9_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrent" xlink:to="lab_us-gaap_DividendsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a60353bf-c484-46fe-bf36-9f74e23f8c27_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_5bea4ccc-2ab5-4f3f-bdc0-2ad968082333_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock (no par value)</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d0275984-4a32-4d96-83d3-6043ae974250_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_b438e721-40a1-412c-93c0-739a4a364524_negatedLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other&#8211;net, (income) expense (Note 11)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_2c0543a2-823f-4968-80c0-66f66710c913_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other&#8211;net, (income) expense</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CollaborationandOtherRevenueMember_32b932b5-9c4e-42fe-9654-2d31a63f9339_verboseLabel_en-US" xlink:label="lab_lly_CollaborationandOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and other revenue</link:label>
    <link:label id="lab_lly_CollaborationandOtherRevenueMember_label_en-US" xlink:label="lab_lly_CollaborationandOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Other Revenue [Member]</link:label>
    <link:label id="lab_lly_CollaborationandOtherRevenueMember_documentation_en-US" xlink:label="lab_lly_CollaborationandOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Other Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborationandOtherRevenueMember" xlink:href="lly-20210331.xsd#lly_CollaborationandOtherRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CollaborationandOtherRevenueMember" xlink:to="lab_lly_CollaborationandOtherRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_24a23011-e923-4a18-aeb8-99daeac8eb10_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_aa7f3ff5-95e6-4610-8564-863224de8853_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_b55c2634-0ad9-4cdf-8c49-adfbcac94fdf_negatedLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect from hedged fixed-rate debt</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_18932054-9ddf-4add-a999-bce6e599e945_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Gains&#160;(Losses)</link:label>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_54aa4c20-0706-4e6a-872e-9abcf4e3704d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_90b8b93f-f3ad-4530-93f3-ff5486d72b4c_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs, expenses, and other:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_4eebbe27-ca5f-4697-b062-c52eb9d3478f_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_063a5a67-a9bb-4707-a76f-7f3fa44c12b5_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Net Gains (Losses) on&#160;Securities</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_68e7b4db-88f5-4c7e-9d9c-4081b6ce2118_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized net gains/losses on securities</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Including Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_6dfb72a2-4a44-468c-80d0-b45efc59b73e_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights_f1aecdba-7a70-4f4a-b483-4d4cbc134e70_terseLabel_en-US" xlink:label="lab_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred, number of contingent value rights</link:label>
    <link:label id="lab_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights_label_en-US" xlink:label="lab_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Number Of Contingent Value Rights</link:label>
    <link:label id="lab_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights_documentation_en-US" xlink:label="lab_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Number Of Contingent Value Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" xlink:href="lly-20210331.xsd#lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" xlink:to="lab_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_88cec385-6a6b-4aa3-935a-db6c74fc6e08_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_adc0584b-10ff-4dc0-a830-6600811a2598_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_156d3cea-8b7a-410d-a856-a1ced9f7e0c6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_47083a6a-5871-48e1-9703-ae0a09feda4b_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments without readily determinable fair values</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_94094a93-d12a-4ec3-af9b-e53c6b7bea78_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0f675d3e-130a-4000-87e9-1a78eabe0023_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_99c6e9ad-e178-48a7-b994-aa52c7794056_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1e4cb968-2cb5-43f2-bef1-9be950e5f60f_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PrevailTherapeuticsIncMember_2a1bce2b-c983-4fa4-b470-1883ef42ad7e_terseLabel_en-US" xlink:label="lab_lly_PrevailTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevail Therapeutics Inc.</link:label>
    <link:label id="lab_lly_PrevailTherapeuticsIncMember_label_en-US" xlink:label="lab_lly_PrevailTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevail Therapeutics Inc. [Member]</link:label>
    <link:label id="lab_lly_PrevailTherapeuticsIncMember_documentation_en-US" xlink:label="lab_lly_PrevailTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevail Therapeutics Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrevailTherapeuticsIncMember" xlink:href="lly-20210331.xsd#lly_PrevailTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PrevailTherapeuticsIncMember" xlink:to="lab_lly_PrevailTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_HumulinMember_ced835f2-de39-41c6-ae96-a7bacac1e565_terseLabel_en-US" xlink:label="lab_lly_HumulinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humulin&#174;</link:label>
    <link:label id="lab_lly_HumulinMember_label_en-US" xlink:label="lab_lly_HumulinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humulin [Member]</link:label>
    <link:label id="lab_lly_HumulinMember_documentation_en-US" xlink:label="lab_lly_HumulinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humulin [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumulinMember" xlink:href="lly-20210331.xsd#lly_HumulinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_HumulinMember" xlink:to="lab_lly_HumulinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_b3cf86c4-85f7-43ba-b01b-706f3568cd25_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue (Note 2)</link:label>
    <link:label id="lab_us-gaap_Revenues_c8993bc5-d611-42b7-a51b-016779bb4a42_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_86d758ee-630e-4f9a-9a80-4a23cc9d6a39_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_fa728cb4-167a-43b6-a384-7a788014ba4a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes (Note 7)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_797db656-9c50-4c1a-a0f2-47751e03a647_negatedNetLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_JardianceMember_c45755a8-e9f2-4e5e-abff-42d6ccbf3ed2_terseLabel_en-US" xlink:label="lab_lly_JardianceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jardiance</link:label>
    <link:label id="lab_lly_JardianceMember_label_en-US" xlink:label="lab_lly_JardianceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jardiance [Member]</link:label>
    <link:label id="lab_lly_JardianceMember_documentation_en-US" xlink:label="lab_lly_JardianceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jardiance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember" xlink:href="lly-20210331.xsd#lly_JardianceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_JardianceMember" xlink:to="lab_lly_JardianceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_HumalogMember_1240fece-8b96-4645-bcae-cbfdc93b9a78_terseLabel_en-US" xlink:label="lab_lly_HumalogMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humalog&#174;</link:label>
    <link:label id="lab_lly_HumalogMember_label_en-US" xlink:label="lab_lly_HumalogMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humalog [Member]</link:label>
    <link:label id="lab_lly_HumalogMember_documentation_en-US" xlink:label="lab_lly_HumalogMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humalog [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumalogMember" xlink:href="lly-20210331.xsd#lly_HumalogMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_HumalogMember" xlink:to="lab_lly_HumalogMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PlaintiffAllegationsDomain_587ac931-5fdd-4f04-b6ff-9d090a58143c_terseLabel_en-US" xlink:label="lab_lly_PlaintiffAllegationsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Allegations [Domain]</link:label>
    <link:label id="lab_lly_PlaintiffAllegationsDomain_label_en-US" xlink:label="lab_lly_PlaintiffAllegationsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Allegations [Domain]</link:label>
    <link:label id="lab_lly_PlaintiffAllegationsDomain_documentation_en-US" xlink:label="lab_lly_PlaintiffAllegationsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Allegations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PlaintiffAllegationsDomain" xlink:href="lly-20210331.xsd#lly_PlaintiffAllegationsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PlaintiffAllegationsDomain" xlink:to="lab_lly_PlaintiffAllegationsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LossContingencyNumberOfPatentsRuledUnpatentable_911b8ea0-7780-48f9-86b6-5e50b72b0476_terseLabel_en-US" xlink:label="lab_lly_LossContingencyNumberOfPatentsRuledUnpatentable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents ruled unpatentable</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfPatentsRuledUnpatentable_label_en-US" xlink:label="lab_lly_LossContingencyNumberOfPatentsRuledUnpatentable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Patents Ruled Unpatentable</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfPatentsRuledUnpatentable_documentation_en-US" xlink:label="lab_lly_LossContingencyNumberOfPatentsRuledUnpatentable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Patents Ruled Unpatentable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfPatentsRuledUnpatentable" xlink:href="lly-20210331.xsd#lly_LossContingencyNumberOfPatentsRuledUnpatentable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LossContingencyNumberOfPatentsRuledUnpatentable" xlink:to="lab_lly_LossContingencyNumberOfPatentsRuledUnpatentable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_cbaefd30-c56a-4f34-9c6f-7df8a09b5a13_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_8a4467ce-9ece-48ab-9375-5ce9e25b51c3_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnfavorableRegulatoryActionMember_96bf8c4c-b8e0-417a-aa5a-5c595f34b816_terseLabel_en-US" xlink:label="lab_us-gaap_UnfavorableRegulatoryActionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfavorable Regulatory Action</link:label>
    <link:label id="lab_us-gaap_UnfavorableRegulatoryActionMember_label_en-US" xlink:label="lab_us-gaap_UnfavorableRegulatoryActionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfavorable Regulatory Action [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnfavorableRegulatoryActionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnfavorableRegulatoryActionMember" xlink:to="lab_us-gaap_UnfavorableRegulatoryActionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_12678cfc-a6e3-49fb-a6f5-dd1ede8594e5_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangements [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ForteoMember_ed502469-f209-4e90-aa7f-a7633ef31c6e_terseLabel_en-US" xlink:label="lab_lly_ForteoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forteo&#174;</link:label>
    <link:label id="lab_lly_ForteoMember_label_en-US" xlink:label="lab_lly_ForteoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forteo [Member]</link:label>
    <link:label id="lab_lly_ForteoMember_documentation_en-US" xlink:label="lab_lly_ForteoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forteo [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForteoMember" xlink:href="lly-20210331.xsd#lly_ForteoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ForteoMember" xlink:to="lab_lly_ForteoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember_d7f648dc-d46e-428d-9a23-15fc16711719_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior service benefits, net</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment, Net Prior Service Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_f2e84970-1a23-4e38-aefc-96b63645490c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TrajentaBIMember_ed9ae68c-d02a-4295-ac63-d0d140e24ccb_terseLabel_en-US" xlink:label="lab_lly_TrajentaBIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trajenta</link:label>
    <link:label id="lab_lly_TrajentaBIMember_label_en-US" xlink:label="lab_lly_TrajentaBIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trajenta (BI) [Member]</link:label>
    <link:label id="lab_lly_TrajentaBIMember_documentation_en-US" xlink:label="lab_lly_TrajentaBIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trajenta (BI) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrajentaBIMember" xlink:href="lly-20210331.xsd#lly_TrajentaBIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TrajentaBIMember" xlink:to="lab_lly_TrajentaBIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_a553b421-7ebf-4274-b6d5-a15023f9c6f0_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_43c4830c-11cd-452c-8e15-02efdedf4bd3_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_782217a4-4f70-4c31-9cf6-544ac97d6465_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent value right, additional price per share, aggregate amount</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RocheMember_d1c52a1d-9a19-4ef6-b90b-63315da70471_terseLabel_en-US" xlink:label="lab_lly_RocheMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche</link:label>
    <link:label id="lab_lly_RocheMember_label_en-US" xlink:label="lab_lly_RocheMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche [Member]</link:label>
    <link:label id="lab_lly_RocheMember_documentation_en-US" xlink:label="lab_lly_RocheMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RocheMember" xlink:href="lly-20210331.xsd#lly_RocheMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RocheMember" xlink:to="lab_lly_RocheMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BuyUSdollarSellJapaneseYenMember_b35dd6e6-9234-4b8e-9d51-4b3ee522d6ef_terseLabel_en-US" xlink:label="lab_lly_BuyUSdollarSellJapaneseYenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy U.S. Dollars Sell Japanese Yen</link:label>
    <link:label id="lab_lly_BuyUSdollarSellJapaneseYenMember_label_en-US" xlink:label="lab_lly_BuyUSdollarSellJapaneseYenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy US dollar Sell Japanese Yen [Member]</link:label>
    <link:label id="lab_lly_BuyUSdollarSellJapaneseYenMember_documentation_en-US" xlink:label="lab_lly_BuyUSdollarSellJapaneseYenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy US dollar Sell Japanese Yen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUSdollarSellJapaneseYenMember" xlink:href="lly-20210331.xsd#lly_BuyUSdollarSellJapaneseYenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BuyUSdollarSellJapaneseYenMember" xlink:to="lab_lly_BuyUSdollarSellJapaneseYenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BuyEuroSellUsDollarMember_4c8886e8-75f3-4baf-a630-b20a60354564_terseLabel_en-US" xlink:label="lab_lly_BuyEuroSellUsDollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy Euros Sell U.S. Dollars</link:label>
    <link:label id="lab_lly_BuyEuroSellUsDollarMember_label_en-US" xlink:label="lab_lly_BuyEuroSellUsDollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy Euro Sell Us Dollar [Member]</link:label>
    <link:label id="lab_lly_BuyEuroSellUsDollarMember_documentation_en-US" xlink:label="lab_lly_BuyEuroSellUsDollarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Forward Commitment to Buy euro Sell US dollar</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyEuroSellUsDollarMember" xlink:href="lly-20210331.xsd#lly_BuyEuroSellUsDollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BuyEuroSellUsDollarMember" xlink:to="lab_lly_BuyEuroSellUsDollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BuyUsDollarSellEuroMember_00f5b316-faf7-4171-b368-8f3b3a61f3e2_terseLabel_en-US" xlink:label="lab_lly_BuyUsDollarSellEuroMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy U.S. Dollars Sell Euros</link:label>
    <link:label id="lab_lly_BuyUsDollarSellEuroMember_label_en-US" xlink:label="lab_lly_BuyUsDollarSellEuroMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy Us Dollar Sell Euro [Member]</link:label>
    <link:label id="lab_lly_BuyUsDollarSellEuroMember_documentation_en-US" xlink:label="lab_lly_BuyUsDollarSellEuroMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Forward commitment to Buy US dollar Sell euro</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUsDollarSellEuroMember" xlink:href="lly-20210331.xsd#lly_BuyUsDollarSellEuroMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BuyUsDollarSellEuroMember" xlink:to="lab_lly_BuyUsDollarSellEuroMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_ef0fc71e-6d47-4ab8-a27b-c7f3539667d9_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestments_3411e556-b9d3-4a92-838a-a02e0a6cbaea_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment gains</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments" xlink:to="lab_us-gaap_GainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_17240782-cbf6-4bfb-a955-18db3c7b808f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_4af07a01-0c95-4307-8ac2-a1b3c836b4f3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative investments, unfunded commitments</link:label>
    <link:label id="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_label_en-US" xlink:label="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unfunded Commitments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:to="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_c3da1ffc-26b0-4443-a579-e6a5d0d8f954_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_3bd18dc8-cd1c-4a4e-a197-eaaa3d327952_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold_e75c5438-d788-4888-be8a-5c4698d1b14f_terseLabel_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, rights and obligations, terms, annual net sales threshold (up to)</link:label>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold_label_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Terms, Annual Net Sales Threshold</link:label>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold_documentation_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Terms, Annual Net Sales Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold" xlink:href="lly-20210331.xsd#lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold" xlink:to="lab_lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_bb7d48cf-136e-4657-9177-925052d08855_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of net pension and retiree health benefit (income) cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c04e8638-eefe-4867-9d7e-72c0c8325a09_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate, percentage</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ea77b0c6-be19-42c6-8aad-7766a49a8c48_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_42af6dbe-04a5-4d9b-8687-6f4e0aa17523_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Used for Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SwapU.S.DollarsToEuroMember_74c71f16-794c-47bc-8f2d-de83ea32d422_terseLabel_en-US" xlink:label="lab_lly_SwapU.S.DollarsToEuroMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swap U.S. Dollars to Euro</link:label>
    <link:label id="lab_lly_SwapU.S.DollarsToEuroMember_label_en-US" xlink:label="lab_lly_SwapU.S.DollarsToEuroMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swap U.S. Dollars To Euro [Member]</link:label>
    <link:label id="lab_lly_SwapU.S.DollarsToEuroMember_documentation_en-US" xlink:label="lab_lly_SwapU.S.DollarsToEuroMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swap U.S. Dollars To Euro [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SwapU.S.DollarsToEuroMember" xlink:href="lly-20210331.xsd#lly_SwapU.S.DollarsToEuroMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SwapU.S.DollarsToEuroMember" xlink:to="lab_lly_SwapU.S.DollarsToEuroMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_962d36a3-cc26-4c61-8ba3-925f46ce81ae_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_383d47a9-9c2d-413f-8ea6-8a25ff19dc03_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retiree Health Benefit Plans</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_eb2fe0f5-2f7f-49ce-8df1-2ca80e3718aa_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_4cfd87e1-869e-4a3c-ac6d-8bbd3b5e867a_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_19e23331-c791-481b-afc3-0f0ab5cca10b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_b9e8c9a6-30a1-4120-ad9c-21914d373999_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of common stock in treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions_b72e1736-a0c8-4628-ac71-ace2a8eff284_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairment, restructuring, and other special charges (Note 5)</link:label>
    <link:label id="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions_fd0acc84-9146-427f-9020-b393971815a9_totalLabel_en-US" xlink:label="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total asset impairment, restructuring, and other special charges</link:label>
    <link:label id="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions_label_en-US" xlink:label="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Settlement and Impairment Provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringSettlementAndImpairmentProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:to="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_e21b19a2-c016-4a28-8ad2-84fd5d29aaec_verboseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Pension Plans</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6ed4b1b4-dbd4-4870-a6ea-3937fb284bb2_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_c4c958d4-c50a-4aad-a6d0-2d5f1b50603c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DescriptionOfDerivativeActivityVolumePercent_a1795886-2622-4ec5-8585-51e7b67f97b4_terseLabel_en-US" xlink:label="lab_lly_DescriptionOfDerivativeActivityVolumePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of long-term fixed-rate notes to floating rates through the use of interest rate swaps converted</link:label>
    <link:label id="lab_lly_DescriptionOfDerivativeActivityVolumePercent_label_en-US" xlink:label="lab_lly_DescriptionOfDerivativeActivityVolumePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Derivative Activity Volume Percent</link:label>
    <link:label id="lab_lly_DescriptionOfDerivativeActivityVolumePercent_documentation_en-US" xlink:label="lab_lly_DescriptionOfDerivativeActivityVolumePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Label: Description of Derivative Activity Volume Element ID: us-gaap_DescriptionOfDerivativeActivityVolume Balance Type: na Data Type: PERCENT Period Type: duration --------------------------------------------------------------------- Definition: Information that would enable users to understand the volume of the entity's derivative activity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 133 -Paragraph 44 -Subparagraph 2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DescriptionOfDerivativeActivityVolumePercent" xlink:href="lly-20210331.xsd#lly_DescriptionOfDerivativeActivityVolumePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DescriptionOfDerivativeActivityVolumePercent" xlink:to="lab_lly_DescriptionOfDerivativeActivityVolumePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_a7554517-f282-4564-a3f7-b08a75814b8d_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AbCelleraBiologicsInc.Member_c7f16307-6079-45d5-b35b-4956b6cb5ecf_terseLabel_en-US" xlink:label="lab_lly_AbCelleraBiologicsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbCellera Biologics Inc.</link:label>
    <link:label id="lab_lly_AbCelleraBiologicsInc.Member_label_en-US" xlink:label="lab_lly_AbCelleraBiologicsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbCellera Biologics Inc. [Member]</link:label>
    <link:label id="lab_lly_AbCelleraBiologicsInc.Member_documentation_en-US" xlink:label="lab_lly_AbCelleraBiologicsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbCellera Biologics Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AbCelleraBiologicsInc.Member" xlink:href="lly-20210331.xsd#lly_AbCelleraBiologicsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AbCelleraBiologicsInc.Member" xlink:to="lab_lly_AbCelleraBiologicsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ZyprexaMember_dabf3b48-6e92-465d-8563-0c05621c0ae2_terseLabel_en-US" xlink:label="lab_lly_ZyprexaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zyprexa&#174;</link:label>
    <link:label id="lab_lly_ZyprexaMember_label_en-US" xlink:label="lab_lly_ZyprexaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zyprexa [Member]</link:label>
    <link:label id="lab_lly_ZyprexaMember_documentation_en-US" xlink:label="lab_lly_ZyprexaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zyprexa [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ZyprexaMember" xlink:href="lly-20210331.xsd#lly_ZyprexaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ZyprexaMember" xlink:to="lab_lly_ZyprexaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_ed9e9431-97f0-4736-b9d4-ada74d8d5950_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_ec2ca838-a876-4e24-b83d-a061c0807c61_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments (Note 6)</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>lly-20210331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:e048f7a3-28f3-4092-a916-bde5dfced0f0,g:3190a302-79f3-4ce3-a4d9-ac703a7bb0fb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lilly.com/role/CoverPage" xlink:type="simple" xlink:href="lly-20210331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_5252183e-2b09-4dc4-a61c-a5da97de7637" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_ab5713ba-059a-4e54-812b-fe3439ab3b16" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5252183e-2b09-4dc4-a61c-a5da97de7637" xlink:to="loc_dei_DocumentInformationTable_ab5713ba-059a-4e54-812b-fe3439ab3b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_380c98ef-905c-47c5-8b82-fb3ff44d1161" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_ab5713ba-059a-4e54-812b-fe3439ab3b16" xlink:to="loc_us-gaap_StatementClassOfStockAxis_380c98ef-905c-47c5-8b82-fb3ff44d1161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6a71c04a-6574-4260-84f2-3c90e8de8991" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_380c98ef-905c-47c5-8b82-fb3ff44d1161" xlink:to="loc_us-gaap_ClassOfStockDomain_6a71c04a-6574-4260-84f2-3c90e8de8991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_a4067a16-f416-4cc1-9edc-56ef9d17e7df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6a71c04a-6574-4260-84f2-3c90e8de8991" xlink:to="loc_us-gaap_CommonClassAMember_a4067a16-f416-4cc1-9edc-56ef9d17e7df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.000NotesDueJune22022Member_b2821fe1-59ae-4507-9429-6b8c7a05c531" xlink:href="lly-20210331.xsd#lly_A1.000NotesDueJune22022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6a71c04a-6574-4260-84f2-3c90e8de8991" xlink:to="loc_lly_A1.000NotesDueJune22022Member_b2821fe1-59ae-4507-9429-6b8c7a05c531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A718NotesDueJune12025Member_3bbadef4-cbc9-4e08-8f14-afdf7140c60c" xlink:href="lly-20210331.xsd#lly_A718NotesDueJune12025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6a71c04a-6574-4260-84f2-3c90e8de8991" xlink:to="loc_lly_A718NotesDueJune12025Member_3bbadef4-cbc9-4e08-8f14-afdf7140c60c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.625NotesDueJune22026Member_e80f68da-1687-411c-a4cd-4498bd8a6c5f" xlink:href="lly-20210331.xsd#lly_A1.625NotesDueJune22026Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6a71c04a-6574-4260-84f2-3c90e8de8991" xlink:to="loc_lly_A1.625NotesDueJune22026Member_e80f68da-1687-411c-a4cd-4498bd8a6c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member_9d412fe2-07ba-4584-a0f3-7227cff62e82" xlink:href="lly-20210331.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6a71c04a-6574-4260-84f2-3c90e8de8991" xlink:to="loc_lly_A2.125NotesDueJune32030Member_9d412fe2-07ba-4584-a0f3-7227cff62e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625Notesdue2031Member_6acf675f-97fe-4260-ad98-e9a0ae3cf48d" xlink:href="lly-20210331.xsd#lly_A625Notesdue2031Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6a71c04a-6574-4260-84f2-3c90e8de8991" xlink:to="loc_lly_A625Notesdue2031Member_6acf675f-97fe-4260-ad98-e9a0ae3cf48d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member_46287674-cb88-44bb-920b-f0639e36b4cd" xlink:href="lly-20210331.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6a71c04a-6574-4260-84f2-3c90e8de8991" xlink:to="loc_lly_A6.77NotesDueJanuary12036Member_46287674-cb88-44bb-920b-f0639e36b4cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.700Notesdue2049Member_0c385aa7-77dc-4e84-a870-cdf5def50ee3" xlink:href="lly-20210331.xsd#lly_A1.700Notesdue2049Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6a71c04a-6574-4260-84f2-3c90e8de8991" xlink:to="loc_lly_A1.700Notesdue2049Member_0c385aa7-77dc-4e84-a870-cdf5def50ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_ab5713ba-059a-4e54-812b-fe3439ab3b16" xlink:to="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_0134de50-8a86-4e3a-aa94-1773908cc338" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_DocumentQuarterlyReport_0134de50-8a86-4e3a-aa94-1773908cc338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_addce232-c330-4302-8e92-ec14d043b84b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_DocumentTransitionReport_addce232-c330-4302-8e92-ec14d043b84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_acb9f23f-aa75-40ce-93bb-188bb294872c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_AmendmentFlag_acb9f23f-aa75-40ce-93bb-188bb294872c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_6a9e69f5-aa46-450f-8082-12af2a63b384" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_DocumentFiscalYearFocus_6a9e69f5-aa46-450f-8082-12af2a63b384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_e7adac5c-7644-4a1a-9484-2fec00193b5d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_DocumentFiscalPeriodFocus_e7adac5c-7644-4a1a-9484-2fec00193b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_e816e6e6-26df-463f-98e2-7737821f44f1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_EntityCentralIndexKey_e816e6e6-26df-463f-98e2-7737821f44f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_b82c0a38-7b7b-4b6c-aa39-20f78f2c6665" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_CurrentFiscalYearEndDate_b82c0a38-7b7b-4b6c-aa39-20f78f2c6665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_c42902da-c8d1-488a-b4d3-575bc6670222" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_DocumentType_c42902da-c8d1-488a-b4d3-575bc6670222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_1cc30459-d5b2-480b-a5b6-f5e42a040f35" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_DocumentPeriodEndDate_1cc30459-d5b2-480b-a5b6-f5e42a040f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_46a64381-14ff-4ac8-9a34-1e2fd26cea5d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_EntityFileNumber_46a64381-14ff-4ac8-9a34-1e2fd26cea5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_c4179197-0062-44ba-ba20-ed34ffe23386" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_EntityRegistrantName_c4179197-0062-44ba-ba20-ed34ffe23386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_b93a4635-d913-493a-8c2a-adc08ecbf92e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_EntityIncorporationStateCountryCode_b93a4635-d913-493a-8c2a-adc08ecbf92e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_01042a1c-10a0-4862-84a7-91e273ac1b82" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_EntityTaxIdentificationNumber_01042a1c-10a0-4862-84a7-91e273ac1b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_bcddae94-266a-4be1-a35f-fa8bb2606f3f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_EntityAddressAddressLine1_bcddae94-266a-4be1-a35f-fa8bb2606f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_3dbf07f5-bb98-4e21-8c34-2a2da9583c8f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_EntityAddressCityOrTown_3dbf07f5-bb98-4e21-8c34-2a2da9583c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_7fadbc6b-0402-44fa-bff4-d16e9a099c13" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_EntityAddressStateOrProvince_7fadbc6b-0402-44fa-bff4-d16e9a099c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_9408b67b-b0ff-4735-917b-c3efeb70bc5a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_EntityAddressPostalZipCode_9408b67b-b0ff-4735-917b-c3efeb70bc5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_afbda0c8-7708-4ea5-8b09-6afdd3a566e8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_CityAreaCode_afbda0c8-7708-4ea5-8b09-6afdd3a566e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_0965c934-abc0-4266-a1c2-6e25cc01babe" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_LocalPhoneNumber_0965c934-abc0-4266-a1c2-6e25cc01babe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_02fdddd5-7932-435f-9d69-f20283176542" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_Security12bTitle_02fdddd5-7932-435f-9d69-f20283176542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_7eb3995f-99ce-4458-837a-43f52d8fc4ba" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_TradingSymbol_7eb3995f-99ce-4458-837a-43f52d8fc4ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_ae55ce4a-dc94-4cc6-b937-8a67cd27b9f6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_SecurityExchangeName_ae55ce4a-dc94-4cc6-b937-8a67cd27b9f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_8cae12b2-e941-41f2-87a9-670d9d0aa987" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_EntityCurrentReportingStatus_8cae12b2-e941-41f2-87a9-670d9d0aa987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_57aa70aa-ce0a-43c2-b103-1fe9fbd36700" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_EntityInteractiveDataCurrent_57aa70aa-ce0a-43c2-b103-1fe9fbd36700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_9b432ec8-c2d3-4500-84ab-393d08c518f9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_EntityFilerCategory_9b432ec8-c2d3-4500-84ab-393d08c518f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_1bd771ad-67ee-43de-ba4d-62a5c131c340" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_EntitySmallBusiness_1bd771ad-67ee-43de-ba4d-62a5c131c340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_647ffb72-7996-458d-8487-a5fd0ec6954e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_EntityEmergingGrowthCompany_647ffb72-7996-458d-8487-a5fd0ec6954e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_811ec157-42cb-4dbd-8d47-ec637c99e052" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_EntityShellCompany_811ec157-42cb-4dbd-8d47-ec637c99e052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_6885c62b-a6a6-4a62-9669-61cb65f3d7ed" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a37a5df8-0f37-4f97-9ffd-e4416465a275" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_6885c62b-a6a6-4a62-9669-61cb65f3d7ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations" xlink:type="simple" xlink:href="lly-20210331.xsd#ConsolidatedCondensedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_28a4ad73-c742-47be-8b8c-eca0451d51e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_6c99aba6-55f1-4395-9d26-192c9156315a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_28a4ad73-c742-47be-8b8c-eca0451d51e5" xlink:to="loc_us-gaap_Revenues_6c99aba6-55f1-4395-9d26-192c9156315a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_52585d8f-95dc-49db-bead-bf9283ce4da7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_28a4ad73-c742-47be-8b8c-eca0451d51e5" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_52585d8f-95dc-49db-bead-bf9283ce4da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_e67ccc5e-592a-4717-b62b-ee39976e2d44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_52585d8f-95dc-49db-bead-bf9283ce4da7" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_e67ccc5e-592a-4717-b62b-ee39976e2d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_dc9a1cc6-594b-4a5e-b5da-c5240020bece" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_52585d8f-95dc-49db-bead-bf9283ce4da7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_dc9a1cc6-594b-4a5e-b5da-c5240020bece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c48651cf-df0f-48a2-8cf8-9a18ca2527c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_52585d8f-95dc-49db-bead-bf9283ce4da7" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c48651cf-df0f-48a2-8cf8-9a18ca2527c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopment_b07d2599-473b-40e1-a92c-ff96a4df0b5c" xlink:href="lly-20210331.xsd#lly_AcquiredInProcessResearchAndDevelopment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_52585d8f-95dc-49db-bead-bf9283ce4da7" xlink:to="loc_lly_AcquiredInProcessResearchAndDevelopment_b07d2599-473b-40e1-a92c-ff96a4df0b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_c93b1c58-1ac2-42c2-a712-935eac7241a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringSettlementAndImpairmentProvisions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_52585d8f-95dc-49db-bead-bf9283ce4da7" xlink:to="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_c93b1c58-1ac2-42c2-a712-935eac7241a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_0d16bba1-fae7-4343-a0a7-1a697b366028" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_52585d8f-95dc-49db-bead-bf9283ce4da7" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_0d16bba1-fae7-4343-a0a7-1a697b366028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_aa983108-6054-4fd0-ba99-db1f558e8edd" xlink:href="lly-20210331.xsd#lly_CostOfSalesOperatingExpensesAndOtherNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_52585d8f-95dc-49db-bead-bf9283ce4da7" xlink:to="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_aa983108-6054-4fd0-ba99-db1f558e8edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2bf88249-a10a-4939-8c34-9c2e0c95361a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_28a4ad73-c742-47be-8b8c-eca0451d51e5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2bf88249-a10a-4939-8c34-9c2e0c95361a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_19dc8444-3076-4ebe-967a-d5855e9104dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_28a4ad73-c742-47be-8b8c-eca0451d51e5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_19dc8444-3076-4ebe-967a-d5855e9104dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3e254c64-f691-414b-b91e-5e70538b0c54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_28a4ad73-c742-47be-8b8c-eca0451d51e5" xlink:to="loc_us-gaap_ProfitLoss_3e254c64-f691-414b-b91e-5e70538b0c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c5831a14-4ac1-4bfc-8028-02c0c3f2db9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_28a4ad73-c742-47be-8b8c-eca0451d51e5" xlink:to="loc_us-gaap_EarningsPerShareAbstract_c5831a14-4ac1-4bfc-8028-02c0c3f2db9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_305de9ec-ad62-4198-807b-ec7314c2e8d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c5831a14-4ac1-4bfc-8028-02c0c3f2db9e" xlink:to="loc_us-gaap_EarningsPerShareBasic_305de9ec-ad62-4198-807b-ec7314c2e8d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3b6650e7-e068-4f4a-a1ea-342c9f004951" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c5831a14-4ac1-4bfc-8028-02c0c3f2db9e" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3b6650e7-e068-4f4a-a1ea-342c9f004951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_916c835c-b020-4c14-a72c-e22a43042306" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_28a4ad73-c742-47be-8b8c-eca0451d51e5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_916c835c-b020-4c14-a72c-e22a43042306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_42b6afb8-8cff-460c-a150-29ca1c24a44f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_916c835c-b020-4c14-a72c-e22a43042306" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_42b6afb8-8cff-460c-a150-29ca1c24a44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_264a9500-7d87-4ce6-bc21-cc8a6d59d36c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_916c835c-b020-4c14-a72c-e22a43042306" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_264a9500-7d87-4ce6-bc21-cc8a6d59d36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="lly-20210331.xsd#ConsolidatedCondensedStatementsofComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9298a4bd-5550-4ff7-b99c-da9d7d54fb61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_eef6dd1f-15fc-43e2-9074-585241461e69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9298a4bd-5550-4ff7-b99c-da9d7d54fb61" xlink:to="loc_us-gaap_ProfitLoss_eef6dd1f-15fc-43e2-9074-585241461e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_16477d82-c006-4756-a2fe-752a6dcec894" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9298a4bd-5550-4ff7-b99c-da9d7d54fb61" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_16477d82-c006-4756-a2fe-752a6dcec894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0bd9707f-6002-4398-9ef8-2c1ebb2419e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9298a4bd-5550-4ff7-b99c-da9d7d54fb61" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_0bd9707f-6002-4398-9ef8-2c1ebb2419e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets" xlink:type="simple" xlink:href="lly-20210331.xsd#ConsolidatedCondensedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_df88f55c-312e-42b5-ab49-daf7ad75bb40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_47c241e5-e64c-47c6-bac0-6d4afac82376" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_df88f55c-312e-42b5-ab49-daf7ad75bb40" xlink:to="loc_us-gaap_AssetsAbstract_47c241e5-e64c-47c6-bac0-6d4afac82376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_797b63e1-d435-4683-9238-a4f2573350f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_47c241e5-e64c-47c6-bac0-6d4afac82376" xlink:to="loc_us-gaap_AssetsCurrentAbstract_797b63e1-d435-4683-9238-a4f2573350f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2fb17510-f9d8-4378-a1f9-b4b4af9778a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_797b63e1-d435-4683-9238-a4f2573350f5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2fb17510-f9d8-4378-a1f9-b4b4af9778a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_f3d27c2e-fb32-493d-9d4a-9a65057d7e3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_797b63e1-d435-4683-9238-a4f2573350f5" xlink:to="loc_us-gaap_ShortTermInvestments_f3d27c2e-fb32-493d-9d4a-9a65057d7e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4c4d47ba-c9d9-4f5a-b28d-bde094c54a3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_797b63e1-d435-4683-9238-a4f2573350f5" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4c4d47ba-c9d9-4f5a-b28d-bde094c54a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_c768d585-eb61-4733-ad3a-0668c4ffcd49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_797b63e1-d435-4683-9238-a4f2573350f5" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_c768d585-eb61-4733-ad3a-0668c4ffcd49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_bd8022ac-eb55-4040-b9f0-c74cdc9c9b59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_797b63e1-d435-4683-9238-a4f2573350f5" xlink:to="loc_us-gaap_InventoryNet_bd8022ac-eb55-4040-b9f0-c74cdc9c9b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_8b99b4be-f350-4d09-92e0-c03b9eb105db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_797b63e1-d435-4683-9238-a4f2573350f5" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_8b99b4be-f350-4d09-92e0-c03b9eb105db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_da4aa82c-173d-459f-9bfb-a52b3c1c76bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_797b63e1-d435-4683-9238-a4f2573350f5" xlink:to="loc_us-gaap_AssetsCurrent_da4aa82c-173d-459f-9bfb-a52b3c1c76bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_c53147f1-e56a-4d92-ba12-fd49908deffd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_47c241e5-e64c-47c6-bac0-6d4afac82376" xlink:to="loc_us-gaap_LongTermInvestments_c53147f1-e56a-4d92-ba12-fd49908deffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a4a53520-b9c4-4a33-a13f-806204134fdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_47c241e5-e64c-47c6-bac0-6d4afac82376" xlink:to="loc_us-gaap_Goodwill_a4a53520-b9c4-4a33-a13f-806204134fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9997cfad-c5c4-445f-9750-86d655a4be41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_47c241e5-e64c-47c6-bac0-6d4afac82376" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9997cfad-c5c4-445f-9750-86d655a4be41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_90aaf59f-8a5a-4511-a66d-e8152515673e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_47c241e5-e64c-47c6-bac0-6d4afac82376" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_90aaf59f-8a5a-4511-a66d-e8152515673e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e51ea2df-838a-46eb-aa3a-8b448590aef7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_47c241e5-e64c-47c6-bac0-6d4afac82376" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e51ea2df-838a-46eb-aa3a-8b448590aef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_aa73fd44-b6fe-4d9d-ab7c-b33ed1904da4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_47c241e5-e64c-47c6-bac0-6d4afac82376" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_aa73fd44-b6fe-4d9d-ab7c-b33ed1904da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e7463ead-fde5-44ab-9316-5716d5b6009f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_47c241e5-e64c-47c6-bac0-6d4afac82376" xlink:to="loc_us-gaap_Assets_e7463ead-fde5-44ab-9316-5716d5b6009f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_339843a2-8d44-4de8-a579-86a00f0487d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_df88f55c-312e-42b5-ab49-daf7ad75bb40" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_339843a2-8d44-4de8-a579-86a00f0487d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_c7d40429-e017-48bf-a370-f8cc524f14cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_339843a2-8d44-4de8-a579-86a00f0487d4" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_c7d40429-e017-48bf-a370-f8cc524f14cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_b16b65ae-714f-479c-b122-6154c269e5d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c7d40429-e017-48bf-a370-f8cc524f14cd" xlink:to="loc_us-gaap_DebtCurrent_b16b65ae-714f-479c-b122-6154c269e5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b78568cb-da22-4d6e-842e-31b10e0fb717" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c7d40429-e017-48bf-a370-f8cc524f14cd" xlink:to="loc_us-gaap_AccountsPayableCurrent_b78568cb-da22-4d6e-842e-31b10e0fb717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e02560d6-e590-4bf8-a5da-7c07c69534e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c7d40429-e017-48bf-a370-f8cc524f14cd" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e02560d6-e590-4bf8-a5da-7c07c69534e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SalesRebatesAndDiscounts_97f9b4cb-ae78-4549-8d20-719fe9bc728f" xlink:href="lly-20210331.xsd#lly_SalesRebatesAndDiscounts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c7d40429-e017-48bf-a370-f8cc524f14cd" xlink:to="loc_lly_SalesRebatesAndDiscounts_97f9b4cb-ae78-4549-8d20-719fe9bc728f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_5590dd15-2945-4a7b-8366-1eeb1e694f4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c7d40429-e017-48bf-a370-f8cc524f14cd" xlink:to="loc_us-gaap_DividendsPayableCurrent_5590dd15-2945-4a7b-8366-1eeb1e694f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_ea6eb510-bdc5-401a-b725-2362cb796a0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c7d40429-e017-48bf-a370-f8cc524f14cd" xlink:to="loc_us-gaap_TaxesPayableCurrent_ea6eb510-bdc5-401a-b725-2362cb796a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_0b46869d-a7a4-4f1c-8642-756fa736f998" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c7d40429-e017-48bf-a370-f8cc524f14cd" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_0b46869d-a7a4-4f1c-8642-756fa736f998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8cd8de1b-4617-4f7b-b243-6ab1759ef371" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c7d40429-e017-48bf-a370-f8cc524f14cd" xlink:to="loc_us-gaap_LiabilitiesCurrent_8cd8de1b-4617-4f7b-b243-6ab1759ef371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_583cad76-5a4a-4832-8f4c-1f653be604c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_339843a2-8d44-4de8-a579-86a00f0487d4" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_583cad76-5a4a-4832-8f4c-1f653be604c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_3454036b-1554-4f4e-b05c-bd0dd799a195" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_583cad76-5a4a-4832-8f4c-1f653be604c0" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_3454036b-1554-4f4e-b05c-bd0dd799a195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_99dda843-cfe9-4c3f-bc8e-08131331ef6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_583cad76-5a4a-4832-8f4c-1f653be604c0" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_99dda843-cfe9-4c3f-bc8e-08131331ef6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_f14cf049-7882-4058-97a5-883377f74c96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_583cad76-5a4a-4832-8f4c-1f653be604c0" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_f14cf049-7882-4058-97a5-883377f74c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_7edbe21c-4737-462c-b669-e592e9be30e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_583cad76-5a4a-4832-8f4c-1f653be604c0" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_7edbe21c-4737-462c-b669-e592e9be30e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_acb4a748-6302-488a-a959-a97164db4f0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_583cad76-5a4a-4832-8f4c-1f653be604c0" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_acb4a748-6302-488a-a959-a97164db4f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_0a10114b-0eaa-45da-ad45-d57f0eb33541" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_583cad76-5a4a-4832-8f4c-1f653be604c0" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_0a10114b-0eaa-45da-ad45-d57f0eb33541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_7ac7d32b-b5e3-44ec-a2e8-b672217ca9b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_339843a2-8d44-4de8-a579-86a00f0487d4" xlink:to="loc_us-gaap_CommitmentsAndContingencies_7ac7d32b-b5e3-44ec-a2e8-b672217ca9b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a0f1743d-6633-46bc-8c81-058427d4a3a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_339843a2-8d44-4de8-a579-86a00f0487d4" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a0f1743d-6633-46bc-8c81-058427d4a3a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_2148ab41-d9ec-4bd2-a040-fb7b74e590ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a0f1743d-6633-46bc-8c81-058427d4a3a1" xlink:to="loc_us-gaap_CommonStockValue_2148ab41-d9ec-4bd2-a040-fb7b74e590ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_e8303266-d282-4f9d-b027-17a6fdecf9f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a0f1743d-6633-46bc-8c81-058427d4a3a1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_e8303266-d282-4f9d-b027-17a6fdecf9f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_81f22b2a-62ab-4313-86a6-9cc081c9851c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a0f1743d-6633-46bc-8c81-058427d4a3a1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_81f22b2a-62ab-4313-86a6-9cc081c9851c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_11436fb4-25f3-453d-ac21-2c397bcd3337" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesHeldInEmployeeTrust"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a0f1743d-6633-46bc-8c81-058427d4a3a1" xlink:to="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_11436fb4-25f3-453d-ac21-2c397bcd3337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e24315b3-7dfe-40ad-b44f-39c1ecfa172b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a0f1743d-6633-46bc-8c81-058427d4a3a1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e24315b3-7dfe-40ad-b44f-39c1ecfa172b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_ed32341f-8af6-43bd-b541-50272480878b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a0f1743d-6633-46bc-8c81-058427d4a3a1" xlink:to="loc_us-gaap_TreasuryStockValue_ed32341f-8af6-43bd-b541-50272480878b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a03dfe86-0650-492c-9ca5-265e61ca20b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a0f1743d-6633-46bc-8c81-058427d4a3a1" xlink:to="loc_us-gaap_StockholdersEquity_a03dfe86-0650-492c-9ca5-265e61ca20b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_4b95aa5a-55a8-4150-b14b-b1c181e595c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_339843a2-8d44-4de8-a579-86a00f0487d4" xlink:to="loc_us-gaap_MinorityInterest_4b95aa5a-55a8-4150-b14b-b1c181e595c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ed8101d8-46a7-47f9-8c64-13e6703aacd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_339843a2-8d44-4de8-a579-86a00f0487d4" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ed8101d8-46a7-47f9-8c64-13e6703aacd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_cb64af41-60dd-43d3-8ad5-9fbcbafff3f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_339843a2-8d44-4de8-a579-86a00f0487d4" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_cb64af41-60dd-43d3-8ad5-9fbcbafff3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="lly-20210331.xsd#ConsolidatedCondensedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrentAbstract_c4e680bb-a42d-4743-ad06-5c954ffdee89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_07ee1936-d23a-4cb1-ba43-2918dbdfe3e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesNetCurrentAbstract_c4e680bb-a42d-4743-ad06-5c954ffdee89" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_07ee1936-d23a-4cb1-ba43-2918dbdfe3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_aaf93337-4b20-4518-8563-31e6f3f78943" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesNetCurrentAbstract_c4e680bb-a42d-4743-ad06-5c954ffdee89" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_aaf93337-4b20-4518-8563-31e6f3f78943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity" xlink:type="simple" xlink:href="lly-20210331.xsd#ConsolidatedCondensedStatementsofEquity"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_422b8287-ca0d-46bc-b69f-c55821d86e3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4a6b3d17-6f5b-4958-bffe-6eb6390a5ea0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_422b8287-ca0d-46bc-b69f-c55821d86e3b" xlink:to="loc_us-gaap_StatementTable_4a6b3d17-6f5b-4958-bffe-6eb6390a5ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1bb5abfc-2dc6-41ea-9828-c5c57cc1a0eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4a6b3d17-6f5b-4958-bffe-6eb6390a5ea0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1bb5abfc-2dc6-41ea-9828-c5c57cc1a0eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ed592edd-fd07-4822-b036-b18646e821cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1bb5abfc-2dc6-41ea-9828-c5c57cc1a0eb" xlink:to="loc_us-gaap_EquityComponentDomain_ed592edd-fd07-4822-b036-b18646e821cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_15f246b5-8537-4bf4-aba3-aef0cc3fdca4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ed592edd-fd07-4822-b036-b18646e821cd" xlink:to="loc_us-gaap_CommonStockMember_15f246b5-8537-4bf4-aba3-aef0cc3fdca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_e0a46ddb-71d3-4596-a795-46559552b32c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ed592edd-fd07-4822-b036-b18646e821cd" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_e0a46ddb-71d3-4596-a795-46559552b32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_f155f5fb-3cab-427f-aafa-ad877ba64a13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ed592edd-fd07-4822-b036-b18646e821cd" xlink:to="loc_us-gaap_RetainedEarningsMember_f155f5fb-3cab-427f-aafa-ad877ba64a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrustForBenefitOfEmployeesMember_84b92d58-9581-4335-93f3-0f9658078452" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrustForBenefitOfEmployeesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ed592edd-fd07-4822-b036-b18646e821cd" xlink:to="loc_us-gaap_TrustForBenefitOfEmployeesMember_84b92d58-9581-4335-93f3-0f9658078452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4cbddb7f-d71b-48b2-82ef-98225a60f722" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ed592edd-fd07-4822-b036-b18646e821cd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4cbddb7f-d71b-48b2-82ef-98225a60f722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_593b66d3-4ad5-4c02-bacd-6d8311481d9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ed592edd-fd07-4822-b036-b18646e821cd" xlink:to="loc_us-gaap_TreasuryStockMember_593b66d3-4ad5-4c02-bacd-6d8311481d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_87ab8bee-40e3-4dd3-b952-2760a0a51b96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ed592edd-fd07-4822-b036-b18646e821cd" xlink:to="loc_us-gaap_NoncontrollingInterestMember_87ab8bee-40e3-4dd3-b952-2760a0a51b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a63bce87-b81e-4c36-9e3f-cbbd590ab2ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4a6b3d17-6f5b-4958-bffe-6eb6390a5ea0" xlink:to="loc_us-gaap_StatementLineItems_a63bce87-b81e-4c36-9e3f-cbbd590ab2ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3630b7cc-2492-4303-9578-6bfe5f059774" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a63bce87-b81e-4c36-9e3f-cbbd590ab2ed" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3630b7cc-2492-4303-9578-6bfe5f059774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_cb477dfb-136f-4139-bec9-5c4f952c22c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3630b7cc-2492-4303-9578-6bfe5f059774" xlink:to="loc_us-gaap_SharesIssued_cb477dfb-136f-4139-bec9-5c4f952c22c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d1dfd154-ecda-4564-8c89-e46717193b7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3630b7cc-2492-4303-9578-6bfe5f059774" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d1dfd154-ecda-4564-8c89-e46717193b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e58113fd-9444-4f26-95d7-d8632f628367" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3630b7cc-2492-4303-9578-6bfe5f059774" xlink:to="loc_us-gaap_ProfitLoss_e58113fd-9444-4f26-95d7-d8632f628367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0518ebd0-341a-498a-b583-b9f2c154dd5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3630b7cc-2492-4303-9578-6bfe5f059774" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0518ebd0-341a-498a-b583-b9f2c154dd5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_326475a1-ebe1-40ea-96d7-964367006573" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3630b7cc-2492-4303-9578-6bfe5f059774" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_326475a1-ebe1-40ea-96d7-964367006573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_1d0a1ac6-4db5-47a5-aa7b-bfde97b3181f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3630b7cc-2492-4303-9578-6bfe5f059774" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_1d0a1ac6-4db5-47a5-aa7b-bfde97b3181f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_cf650599-baee-473f-bafc-0ab106c1bfed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3630b7cc-2492-4303-9578-6bfe5f059774" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_cf650599-baee-473f-bafc-0ab106c1bfed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_a827abab-933e-4be7-a30b-fd1057d1ff87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3630b7cc-2492-4303-9578-6bfe5f059774" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_a827abab-933e-4be7-a30b-fd1057d1ff87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ab034eeb-1a2e-49da-b061-4206539b2f11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3630b7cc-2492-4303-9578-6bfe5f059774" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ab034eeb-1a2e-49da-b061-4206539b2f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_67d16f5c-dacc-472a-8fdf-62eaa91d2498" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3630b7cc-2492-4303-9578-6bfe5f059774" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_67d16f5c-dacc-472a-8fdf-62eaa91d2498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_af1b6bd8-1db0-4dc8-9cd2-99d8716f7a39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3630b7cc-2492-4303-9578-6bfe5f059774" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_af1b6bd8-1db0-4dc8-9cd2-99d8716f7a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_c1745101-24b4-4001-8165-f1f94b4699fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3630b7cc-2492-4303-9578-6bfe5f059774" xlink:to="loc_us-gaap_StockholdersEquityOther_c1745101-24b4-4001-8165-f1f94b4699fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_20a848a3-7578-469b-aca1-335b54233a89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3630b7cc-2492-4303-9578-6bfe5f059774" xlink:to="loc_us-gaap_SharesIssued_20a848a3-7578-469b-aca1-335b54233a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_96253185-4ea7-456a-9dc3-fd0f67fa6cd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3630b7cc-2492-4303-9578-6bfe5f059774" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_96253185-4ea7-456a-9dc3-fd0f67fa6cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquityParenthetical" xlink:type="simple" xlink:href="lly-20210331.xsd#ConsolidatedCondensedStatementsofEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_cb8d8805-5892-4f77-907a-96108c9eec93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_552771dd-3c01-4a5f-8323-93653325b104" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_cb8d8805-5892-4f77-907a-96108c9eec93" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_552771dd-3c01-4a5f-8323-93653325b104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_a556d68b-1dc7-4f6a-af1f-862648b04a10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_cb8d8805-5892-4f77-907a-96108c9eec93" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_a556d68b-1dc7-4f6a-af1f-862648b04a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows" xlink:type="simple" xlink:href="lly-20210331.xsd#ConsolidatedCondensedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_441c6791-29b1-49eb-903f-fc5ce1db2f37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8758e497-5492-4025-943f-80af46ec81b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_441c6791-29b1-49eb-903f-fc5ce1db2f37" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8758e497-5492-4025-943f-80af46ec81b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_05edcfbe-a266-4c6e-8328-fcca101b7493" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8758e497-5492-4025-943f-80af46ec81b7" xlink:to="loc_us-gaap_NetIncomeLoss_05edcfbe-a266-4c6e-8328-fcca101b7493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_505a14b2-5be4-4d7b-8d37-f2527776dbab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8758e497-5492-4025-943f-80af46ec81b7" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_505a14b2-5be4-4d7b-8d37-f2527776dbab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_5faacbf7-afc0-4d57-9e4a-2fe4ef5cd72a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_505a14b2-5be4-4d7b-8d37-f2527776dbab" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_5faacbf7-afc0-4d57-9e4a-2fe4ef5cd72a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_136cb241-83f9-4258-8ad5-865c6c31d041" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_505a14b2-5be4-4d7b-8d37-f2527776dbab" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_136cb241-83f9-4258-8ad5-865c6c31d041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_87b794e5-64de-4e23-aa79-9a1846740def" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_505a14b2-5be4-4d7b-8d37-f2527776dbab" xlink:to="loc_us-gaap_ShareBasedCompensation_87b794e5-64de-4e23-aa79-9a1846740def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_5c58ec7a-1334-425a-9e0d-4fdee5eb7924" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_505a14b2-5be4-4d7b-8d37-f2527776dbab" xlink:to="loc_us-gaap_GainLossOnInvestments_5c58ec7a-1334-425a-9e0d-4fdee5eb7924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopment_e809e7dd-1938-4f6c-8f34-a4c3b4aa0db7" xlink:href="lly-20210331.xsd#lly_AcquiredInProcessResearchAndDevelopment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_505a14b2-5be4-4d7b-8d37-f2527776dbab" xlink:to="loc_lly_AcquiredInProcessResearchAndDevelopment_e809e7dd-1938-4f6c-8f34-a4c3b4aa0db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_f5b8381d-c1cc-4b52-b3ee-41d3e98b88de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_505a14b2-5be4-4d7b-8d37-f2527776dbab" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_f5b8381d-c1cc-4b52-b3ee-41d3e98b88de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_48d3d222-89be-40df-9ae5-3cfd5fb63fd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_505a14b2-5be4-4d7b-8d37-f2527776dbab" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_48d3d222-89be-40df-9ae5-3cfd5fb63fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_77c128b4-8ce7-4fb2-ae3e-7d8a8c86ef4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8758e497-5492-4025-943f-80af46ec81b7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_77c128b4-8ce7-4fb2-ae3e-7d8a8c86ef4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ce01441a-875a-4e5c-b556-c5bf4346e958" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_441c6791-29b1-49eb-903f-fc5ce1db2f37" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ce01441a-875a-4e5c-b556-c5bf4346e958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_204cb3c0-5557-428e-bbb8-08a3f18b1fe3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ce01441a-875a-4e5c-b556-c5bf4346e958" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_204cb3c0-5557-428e-bbb8-08a3f18b1fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_0f95313e-cd4e-4dd4-8190-c69abbe26b5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ce01441a-875a-4e5c-b556-c5bf4346e958" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_0f95313e-cd4e-4dd4-8190-c69abbe26b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_9277ab0e-5e60-48da-a654-45de1882213a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ce01441a-875a-4e5c-b556-c5bf4346e958" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_9277ab0e-5e60-48da-a654-45de1882213a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfLongtermInvestments_32720382-680a-4359-8e20-77e779c2aa84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfLongtermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ce01441a-875a-4e5c-b556-c5bf4346e958" xlink:to="loc_us-gaap_ProceedsFromSaleOfLongtermInvestments_32720382-680a-4359-8e20-77e779c2aa84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments_161537fa-01ec-4d5d-9ca7-fc4ac4c672da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ce01441a-875a-4e5c-b556-c5bf4346e958" xlink:to="loc_us-gaap_PaymentsToAcquireLongtermInvestments_161537fa-01ec-4d5d-9ca7-fc4ac4c672da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_587af850-9205-4b87-bbef-0d27dc6bac3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ce01441a-875a-4e5c-b556-c5bf4346e958" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_587af850-9205-4b87-bbef-0d27dc6bac3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PurchasedInProcessResearchAndDevelopment_4d2bd274-6aa2-41de-b4d1-2981927fd786" xlink:href="lly-20210331.xsd#lly_PurchasedInProcessResearchAndDevelopment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ce01441a-875a-4e5c-b556-c5bf4346e958" xlink:to="loc_lly_PurchasedInProcessResearchAndDevelopment_4d2bd274-6aa2-41de-b4d1-2981927fd786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_f833f6d7-2499-4010-b085-6b496192c980" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ce01441a-875a-4e5c-b556-c5bf4346e958" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_f833f6d7-2499-4010-b085-6b496192c980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_86e01226-7b16-43d3-a512-fab580e48f2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ce01441a-875a-4e5c-b556-c5bf4346e958" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_86e01226-7b16-43d3-a512-fab580e48f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4424c6fc-28d0-4449-80df-e34d8e466ae4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_441c6791-29b1-49eb-903f-fc5ce1db2f37" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4424c6fc-28d0-4449-80df-e34d8e466ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_d1e457ea-dd8c-4842-afa0-9fc8d0fafbef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4424c6fc-28d0-4449-80df-e34d8e466ae4" xlink:to="loc_us-gaap_PaymentsOfDividends_d1e457ea-dd8c-4842-afa0-9fc8d0fafbef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_101f11dc-941f-44ff-ab7d-425833b1c4d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4424c6fc-28d0-4449-80df-e34d8e466ae4" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_101f11dc-941f-44ff-ab7d-425833b1c4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_ae7039e2-b6be-46f7-8f1c-d40bda57eadf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4424c6fc-28d0-4449-80df-e34d8e466ae4" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_ae7039e2-b6be-46f7-8f1c-d40bda57eadf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_becfdfd6-e4ea-4498-be89-13db8af64d09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4424c6fc-28d0-4449-80df-e34d8e466ae4" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_becfdfd6-e4ea-4498-be89-13db8af64d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_cd51066e-1dbc-489a-a334-98684f7071de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4424c6fc-28d0-4449-80df-e34d8e466ae4" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_cd51066e-1dbc-489a-a334-98684f7071de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_22a24dd3-8c70-484b-9665-6f6627f9f97d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4424c6fc-28d0-4449-80df-e34d8e466ae4" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_22a24dd3-8c70-484b-9665-6f6627f9f97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_442a979f-f6f0-4878-b618-74b27c18bd02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4424c6fc-28d0-4449-80df-e34d8e466ae4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_442a979f-f6f0-4878-b618-74b27c18bd02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0cd0995a-26ee-417e-8b7e-30a04b276e06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_441c6791-29b1-49eb-903f-fc5ce1db2f37" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0cd0995a-26ee-417e-8b7e-30a04b276e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4e3c8c70-95cc-469d-bc70-e9b9edf30be3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_441c6791-29b1-49eb-903f-fc5ce1db2f37" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4e3c8c70-95cc-469d-bc70-e9b9edf30be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_7b2b3979-3819-452b-80f8-61a41d620ae9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_441c6791-29b1-49eb-903f-fc5ce1db2f37" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_7b2b3979-3819-452b-80f8-61a41d620ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_e994facc-010e-4654-a8bf-1087acd376e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_441c6791-29b1-49eb-903f-fc5ce1db2f37" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_e994facc-010e-4654-a8bf-1087acd376e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BasisofPresentation" xlink:type="simple" xlink:href="lly-20210331.xsd#BasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/BasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4873197b-c779-48e6-806b-2a27e528619f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_7c535214-5999-4b50-a80a-793ab91cce61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4873197b-c779-48e6-806b-2a27e528619f" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_7c535214-5999-4b50-a80a-793ab91cce61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BasisofPresentationPolicies" xlink:type="simple" xlink:href="lly-20210331.xsd#BasisofPresentationPolicies"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/BasisofPresentationPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1976581d-800a-45b1-ba8f-6b6d028e04a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_2fba6147-0b5d-4a8b-8e8c-a22deddea0a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1976581d-800a-45b1-ba8f-6b6d028e04a5" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_2fba6147-0b5d-4a8b-8e8c-a22deddea0a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_185f2e72-58e3-486d-b547-d45aaf48e4c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1976581d-800a-45b1-ba8f-6b6d028e04a5" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_185f2e72-58e3-486d-b547-d45aaf48e4c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/Revenue" xlink:type="simple" xlink:href="lly-20210331.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_deda256e-db1e-43ce-9b79-fc7fc3ed28c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_5029c35b-053d-4499-b0f3-628e53e7b65f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_deda256e-db1e-43ce-9b79-fc7fc3ed28c8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_5029c35b-053d-4499-b0f3-628e53e7b65f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueTables" xlink:type="simple" xlink:href="lly-20210331.xsd#RevenueTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ab56ca3c-25fa-4431-97d6-43d2aa050784" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_b6173557-4b1e-44d3-8ed1-7586265c65b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ab56ca3c-25fa-4431-97d6-43d2aa050784" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_b6173557-4b1e-44d3-8ed1-7586265c65b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_91b1a6ee-df50-4772-a174-13bbd8e20e02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ab56ca3c-25fa-4431-97d6-43d2aa050784" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_91b1a6ee-df50-4772-a174-13bbd8e20e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#RevenueSummaryofRevenueRecognizedDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_637e7e65-f1b0-418b-be6c-23dc942626d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_3e4ff84e-4a6d-4320-b213-f94e5773c6ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_637e7e65-f1b0-418b-be6c-23dc942626d1" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_3e4ff84e-4a6d-4320-b213-f94e5773c6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a339f74c-3efd-49b6-9d5a-44db68ba2d11" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3e4ff84e-4a6d-4320-b213-f94e5773c6ad" xlink:to="loc_srt_ProductOrServiceAxis_a339f74c-3efd-49b6-9d5a-44db68ba2d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1256e814-b80f-4144-b2f6-e62fedd0ee3c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a339f74c-3efd-49b6-9d5a-44db68ba2d11" xlink:to="loc_srt_ProductsAndServicesDomain_1256e814-b80f-4144-b2f6-e62fedd0ee3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_919f2eeb-35ab-4d30-b348-491597b69b15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1256e814-b80f-4144-b2f6-e62fedd0ee3c" xlink:to="loc_us-gaap_ProductMember_919f2eeb-35ab-4d30-b348-491597b69b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborationandOtherRevenueMember_2653c14f-2cb8-491e-ae1e-bbec43ccfc60" xlink:href="lly-20210331.xsd#lly_CollaborationandOtherRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1256e814-b80f-4144-b2f6-e62fedd0ee3c" xlink:to="loc_lly_CollaborationandOtherRevenueMember_2653c14f-2cb8-491e-ae1e-bbec43ccfc60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_dc59b33f-9f7f-4f1e-9c7a-720e7e39544f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1256e814-b80f-4144-b2f6-e62fedd0ee3c" xlink:to="loc_us-gaap_RoyaltyMember_dc59b33f-9f7f-4f1e-9c7a-720e7e39544f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_54ef57e4-d9a8-4e94-b285-3f90b2e03c66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3e4ff84e-4a6d-4320-b213-f94e5773c6ad" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_54ef57e4-d9a8-4e94-b285-3f90b2e03c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_0a2c4083-a07c-4a26-94a2-f79f9d4ee81a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_54ef57e4-d9a8-4e94-b285-3f90b2e03c66" xlink:to="loc_us-gaap_Revenues_0a2c4083-a07c-4a26-94a2-f79f9d4ee81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#RevenueAdjustmentstoRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_26e6178c-5fcd-4efb-86ee-9dc090f32626" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_2f12411f-d981-40e4-82ba-c60791a7c817" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_26e6178c-5fcd-4efb-86ee-9dc090f32626" xlink:to="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_2f12411f-d981-40e4-82ba-c60791a7c817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_c082119b-7ad6-4fcf-8379-77c7336f33e5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_2f12411f-d981-40e4-82ba-c60791a7c817" xlink:to="loc_srt_StatementGeographicalAxis_c082119b-7ad6-4fcf-8379-77c7336f33e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f5a0fb5d-ab55-4693-a747-0eacdf1d2f47" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_c082119b-7ad6-4fcf-8379-77c7336f33e5" xlink:to="loc_srt_SegmentGeographicalDomain_f5a0fb5d-ab55-4693-a747-0eacdf1d2f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_757f83bd-2496-46e1-a07d-8e391e3cba7c" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f5a0fb5d-ab55-4693-a747-0eacdf1d2f47" xlink:to="loc_country_US_757f83bd-2496-46e1-a07d-8e391e3cba7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_407b1f42-c6ed-401d-bf2c-4303fe58e70d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_2f12411f-d981-40e4-82ba-c60791a7c817" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_407b1f42-c6ed-401d-bf2c-4303fe58e70d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_62f7eddc-0255-4dcf-9f62-2189af5e1c95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_407b1f42-c6ed-401d-bf2c-4303fe58e70d" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_62f7eddc-0255-4dcf-9f62-2189af5e1c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_bd05d820-b7bf-4857-ba6a-940e46ab3735" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_62f7eddc-0255-4dcf-9f62-2189af5e1c95" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_bd05d820-b7bf-4857-ba6a-940e46ab3735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateLineItems_5a836ca1-e4ad-4bd6-a9c4-91da4c585acf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_2f12411f-d981-40e4-82ba-c60791a7c817" xlink:to="loc_us-gaap_ChangeInAccountingEstimateLineItems_5a836ca1-e4ad-4bd6-a9c4-91da4c585acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_33da39f1-c1c7-48af-b062-d95b27ff3316" xlink:href="lly-20210331.xsd#lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_5a836ca1-e4ad-4bd6-a9c4-91da4c585acf" xlink:to="loc_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_33da39f1-c1c7-48af-b062-d95b27ff3316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueContractLiabilitiesDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#RevenueContractLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RevenueContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9e618313-ec89-45f1-9d63-bc0fa24811b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_81bbada7-dc58-4713-b963-e307bd528391" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9e618313-ec89-45f1-9d63-bc0fa24811b2" xlink:to="loc_us-gaap_ContractWithCustomerLiability_81bbada7-dc58-4713-b963-e307bd528391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#RevenueDisaggregationofRevenuebyProductDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5aa2447b-3599-4600-99c7-e026f9999778" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_53aa2f4a-3dad-4a23-a8ee-280d2e200acc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5aa2447b-3599-4600-99c7-e026f9999778" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_53aa2f4a-3dad-4a23-a8ee-280d2e200acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_475a80b1-88ab-44ca-af35-f1b64238219f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_53aa2f4a-3dad-4a23-a8ee-280d2e200acc" xlink:to="loc_srt_ProductOrServiceAxis_475a80b1-88ab-44ca-af35-f1b64238219f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_51d668a8-137b-473d-90fd-dd0ffeb82fd5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_475a80b1-88ab-44ca-af35-f1b64238219f" xlink:to="loc_srt_ProductsAndServicesDomain_51d668a8-137b-473d-90fd-dd0ffeb82fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DiabetesMember_6e6e1e31-7b63-4f6c-9ce0-abc0c9c9cae8" xlink:href="lly-20210331.xsd#lly_DiabetesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_51d668a8-137b-473d-90fd-dd0ffeb82fd5" xlink:to="loc_lly_DiabetesMember_6e6e1e31-7b63-4f6c-9ce0-abc0c9c9cae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrulicityMemberMember_dbd9008a-91f4-497c-8639-733fa1ff8553" xlink:href="lly-20210331.xsd#lly_TrulicityMemberMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_6e6e1e31-7b63-4f6c-9ce0-abc0c9c9cae8" xlink:to="loc_lly_TrulicityMemberMember_dbd9008a-91f4-497c-8639-733fa1ff8553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumalogMember_6e4e77b7-fb33-4fb6-92bc-af959be80fd6" xlink:href="lly-20210331.xsd#lly_HumalogMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_6e6e1e31-7b63-4f6c-9ce0-abc0c9c9cae8" xlink:to="loc_lly_HumalogMember_6e4e77b7-fb33-4fb6-92bc-af959be80fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumulinMember_e1ac5e98-eeb0-4731-a95f-565218731ebf" xlink:href="lly-20210331.xsd#lly_HumulinMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_6e6e1e31-7b63-4f6c-9ce0-abc0c9c9cae8" xlink:to="loc_lly_HumulinMember_e1ac5e98-eeb0-4731-a95f-565218731ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_0fb74cef-3534-4bb4-985e-25ee01d7d263" xlink:href="lly-20210331.xsd#lly_JardianceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_6e6e1e31-7b63-4f6c-9ce0-abc0c9c9cae8" xlink:to="loc_lly_JardianceMember_0fb74cef-3534-4bb4-985e-25ee01d7d263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember_7c64ca4c-39a4-47bf-8b9d-a4c16a7c64a4" xlink:href="lly-20210331.xsd#lly_BasaglarMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_6e6e1e31-7b63-4f6c-9ce0-abc0c9c9cae8" xlink:to="loc_lly_BasaglarMember_7c64ca4c-39a4-47bf-8b9d-a4c16a7c64a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherDiabetesMember_1b6c9f03-1ca9-4041-aa1d-f302f6541329" xlink:href="lly-20210331.xsd#lly_OtherDiabetesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_6e6e1e31-7b63-4f6c-9ce0-abc0c9c9cae8" xlink:to="loc_lly_OtherDiabetesMember_1b6c9f03-1ca9-4041-aa1d-f302f6541329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OncologyMember_0ed4784f-ac2c-4d20-aee2-5f8315c02277" xlink:href="lly-20210331.xsd#lly_OncologyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_51d668a8-137b-473d-90fd-dd0ffeb82fd5" xlink:to="loc_lly_OncologyMember_0ed4784f-ac2c-4d20-aee2-5f8315c02277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AlimtaMember_ffa408b6-4056-4d8f-a325-08fe1ab65ae8" xlink:href="lly-20210331.xsd#lly_AlimtaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OncologyMember_0ed4784f-ac2c-4d20-aee2-5f8315c02277" xlink:to="loc_lly_AlimtaMember_ffa408b6-4056-4d8f-a325-08fe1ab65ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_VerzenioMember_ce8d1946-59b3-4a84-b8ff-1e0491670f75" xlink:href="lly-20210331.xsd#lly_VerzenioMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OncologyMember_0ed4784f-ac2c-4d20-aee2-5f8315c02277" xlink:to="loc_lly_VerzenioMember_ce8d1946-59b3-4a84-b8ff-1e0491670f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CyramzaMember_fa3d2c75-31b9-4e48-9813-e7180b67ab86" xlink:href="lly-20210331.xsd#lly_CyramzaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OncologyMember_0ed4784f-ac2c-4d20-aee2-5f8315c02277" xlink:to="loc_lly_CyramzaMember_fa3d2c75-31b9-4e48-9813-e7180b67ab86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ErbituxMember_84e5e487-14b0-4376-b0d8-1520ab3f61dd" xlink:href="lly-20210331.xsd#lly_ErbituxMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OncologyMember_0ed4784f-ac2c-4d20-aee2-5f8315c02277" xlink:to="loc_lly_ErbituxMember_84e5e487-14b0-4376-b0d8-1520ab3f61dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TYVYTMember_0655ee28-6b26-4b9c-866b-5cddfba68077" xlink:href="lly-20210331.xsd#lly_TYVYTMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OncologyMember_0ed4784f-ac2c-4d20-aee2-5f8315c02277" xlink:to="loc_lly_TYVYTMember_0655ee28-6b26-4b9c-866b-5cddfba68077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherOncologyMember_81ea35a0-be9f-4a90-a194-bbdc2bba2acf" xlink:href="lly-20210331.xsd#lly_OtherOncologyMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OncologyMember_0ed4784f-ac2c-4d20-aee2-5f8315c02277" xlink:to="loc_lly_OtherOncologyMember_81ea35a0-be9f-4a90-a194-bbdc2bba2acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ImmunologyMember_bbd0efdf-f3bc-43fd-a197-367e826b4257" xlink:href="lly-20210331.xsd#lly_ImmunologyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_51d668a8-137b-473d-90fd-dd0ffeb82fd5" xlink:to="loc_lly_ImmunologyMember_bbd0efdf-f3bc-43fd-a197-367e826b4257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaltzMember_bb6bfaf3-450e-4c92-a192-77c68a71f912" xlink:href="lly-20210331.xsd#lly_TaltzMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_ImmunologyMember_bbd0efdf-f3bc-43fd-a197-367e826b4257" xlink:to="loc_lly_TaltzMember_bb6bfaf3-450e-4c92-a192-77c68a71f912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember_045161b3-13b1-44e7-95dc-0134479570d9" xlink:href="lly-20210331.xsd#lly_OlumiantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_ImmunologyMember_bbd0efdf-f3bc-43fd-a197-367e826b4257" xlink:to="loc_lly_OlumiantMember_045161b3-13b1-44e7-95dc-0134479570d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherImmunologyMember_9d9bd125-28ec-47c6-a023-c581999085c8" xlink:href="lly-20210331.xsd#lly_OtherImmunologyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_ImmunologyMember_bbd0efdf-f3bc-43fd-a197-367e826b4257" xlink:to="loc_lly_OtherImmunologyMember_9d9bd125-28ec-47c6-a023-c581999085c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NeuroscienceMember_03b17cd1-7b11-40fa-bc26-65fc6cf9b17c" xlink:href="lly-20210331.xsd#lly_NeuroscienceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_51d668a8-137b-473d-90fd-dd0ffeb82fd5" xlink:to="loc_lly_NeuroscienceMember_03b17cd1-7b11-40fa-bc26-65fc6cf9b17c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CymbaltaMember_a8985a03-3f01-47ab-a0b1-24d5d9cd44e1" xlink:href="lly-20210331.xsd#lly_CymbaltaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_NeuroscienceMember_03b17cd1-7b11-40fa-bc26-65fc6cf9b17c" xlink:to="loc_lly_CymbaltaMember_a8985a03-3f01-47ab-a0b1-24d5d9cd44e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmgalityMember_0a228969-7633-4aac-9487-ab8870e53c60" xlink:href="lly-20210331.xsd#lly_EmgalityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_NeuroscienceMember_03b17cd1-7b11-40fa-bc26-65fc6cf9b17c" xlink:to="loc_lly_EmgalityMember_0a228969-7633-4aac-9487-ab8870e53c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ZyprexaMember_d16b7bf6-1589-4e44-8c75-a8f252e13791" xlink:href="lly-20210331.xsd#lly_ZyprexaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_NeuroscienceMember_03b17cd1-7b11-40fa-bc26-65fc6cf9b17c" xlink:to="loc_lly_ZyprexaMember_d16b7bf6-1589-4e44-8c75-a8f252e13791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherNeuroscienceMember_0f198e26-3c7e-4a80-aebb-244a10b6ca2c" xlink:href="lly-20210331.xsd#lly_OtherNeuroscienceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_NeuroscienceMember_03b17cd1-7b11-40fa-bc26-65fc6cf9b17c" xlink:to="loc_lly_OtherNeuroscienceMember_0f198e26-3c7e-4a80-aebb-244a10b6ca2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherProductTotalMember_8d5d66e1-da92-4e88-8e5c-9e560f853151" xlink:href="lly-20210331.xsd#lly_OtherProductTotalMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_51d668a8-137b-473d-90fd-dd0ffeb82fd5" xlink:to="loc_lly_OtherProductTotalMember_8d5d66e1-da92-4e88-8e5c-9e560f853151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_COVID19AntibodiesMember_865c96a8-86f9-4dab-b7e2-ce6dcbaad654" xlink:href="lly-20210331.xsd#lly_COVID19AntibodiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OtherProductTotalMember_8d5d66e1-da92-4e88-8e5c-9e560f853151" xlink:to="loc_lly_COVID19AntibodiesMember_865c96a8-86f9-4dab-b7e2-ce6dcbaad654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForteoMember_805bfb06-9ed5-417c-ad6a-e71603c4237a" xlink:href="lly-20210331.xsd#lly_ForteoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OtherProductTotalMember_8d5d66e1-da92-4e88-8e5c-9e560f853151" xlink:to="loc_lly_ForteoMember_805bfb06-9ed5-417c-ad6a-e71603c4237a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CialisMember_da9f0a9c-5428-45b9-bba0-f4cb5cea10e7" xlink:href="lly-20210331.xsd#lly_CialisMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OtherProductTotalMember_8d5d66e1-da92-4e88-8e5c-9e560f853151" xlink:to="loc_lly_CialisMember_da9f0a9c-5428-45b9-bba0-f4cb5cea10e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherProductMember_67184f80-136e-4347-8d2e-8d4e70830748" xlink:href="lly-20210331.xsd#lly_OtherProductMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OtherProductTotalMember_8d5d66e1-da92-4e88-8e5c-9e560f853151" xlink:to="loc_lly_OtherProductMember_67184f80-136e-4347-8d2e-8d4e70830748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d59effd2-e528-41e0-9aef-3081b6719257" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_53aa2f4a-3dad-4a23-a8ee-280d2e200acc" xlink:to="loc_srt_StatementGeographicalAxis_d59effd2-e528-41e0-9aef-3081b6719257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ca937bd0-9657-414d-9921-93b171e37a95" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_d59effd2-e528-41e0-9aef-3081b6719257" xlink:to="loc_srt_SegmentGeographicalDomain_ca937bd0-9657-414d-9921-93b171e37a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_ae9bd9e2-f542-4864-8e34-2b56228c3c1a" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ca937bd0-9657-414d-9921-93b171e37a95" xlink:to="loc_country_US_ae9bd9e2-f542-4864-8e34-2b56228c3c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_075d26bd-f7f5-4be1-8e76-82074d252e19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ca937bd0-9657-414d-9921-93b171e37a95" xlink:to="loc_us-gaap_NonUsMember_075d26bd-f7f5-4be1-8e76-82074d252e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_b9f8ae07-0f92-4369-9852-24a35a6f1b7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_53aa2f4a-3dad-4a23-a8ee-280d2e200acc" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_b9f8ae07-0f92-4369-9852-24a35a6f1b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_eac97ef8-b5c4-4598-91d0-0095ae99c16f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b9f8ae07-0f92-4369-9852-24a35a6f1b7f" xlink:to="loc_us-gaap_Revenues_eac97ef8-b5c4-4598-91d0-0095ae99c16f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#RevenueDisaggregationofRevenuebyGeographicalAreaDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b3cd43b9-007d-43b0-bd2c-230f6277da2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_86b67221-ba91-466e-b7b2-90000d867103" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b3cd43b9-007d-43b0-bd2c-230f6277da2c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_86b67221-ba91-466e-b7b2-90000d867103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_c6154dea-bc2b-4ec9-9f76-0b5ac59d2adc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_86b67221-ba91-466e-b7b2-90000d867103" xlink:to="loc_srt_StatementGeographicalAxis_c6154dea-bc2b-4ec9-9f76-0b5ac59d2adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ca11bc05-70a9-47cb-aba9-14a088023509" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_c6154dea-bc2b-4ec9-9f76-0b5ac59d2adc" xlink:to="loc_srt_SegmentGeographicalDomain_ca11bc05-70a9-47cb-aba9-14a088023509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b565a35c-dea8-471e-be8a-e7a227d4489c" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ca11bc05-70a9-47cb-aba9-14a088023509" xlink:to="loc_country_US_b565a35c-dea8-471e-be8a-e7a227d4489c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_18b638bf-258b-4496-ad3c-4f600aaa80cf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ca11bc05-70a9-47cb-aba9-14a088023509" xlink:to="loc_srt_EuropeMember_18b638bf-258b-4496-ad3c-4f600aaa80cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_c8d2209b-d833-47e4-8545-2d23f3563b11" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ca11bc05-70a9-47cb-aba9-14a088023509" xlink:to="loc_country_JP_c8d2209b-d833-47e4-8545-2d23f3563b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_c021cc61-87c8-4c25-b75c-6f45959b33fb" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ca11bc05-70a9-47cb-aba9-14a088023509" xlink:to="loc_country_CN_c021cc61-87c8-4c25-b75c-6f45959b33fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherForeignCountriesMember_be814731-d049-4f9f-803a-d9ead9d59df1" xlink:href="lly-20210331.xsd#lly_OtherForeignCountriesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ca11bc05-70a9-47cb-aba9-14a088023509" xlink:to="loc_lly_OtherForeignCountriesMember_be814731-d049-4f9f-803a-d9ead9d59df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a3628593-4751-4ff3-9d06-afc00499aa00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_86b67221-ba91-466e-b7b2-90000d867103" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_a3628593-4751-4ff3-9d06-afc00499aa00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_0f835592-5855-42b9-b751-221cd7c54db5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a3628593-4751-4ff3-9d06-afc00499aa00" xlink:to="loc_us-gaap_Revenues_0f835592-5855-42b9-b751-221cd7c54db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/Acquisitions" xlink:type="simple" xlink:href="lly-20210331.xsd#Acquisitions"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_7816a509-e061-4877-aa06-8fefae3f372d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_f1829b65-ac61-42e3-bffb-6b2b67e1f30e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_7816a509-e061-4877-aa06-8fefae3f372d" xlink:to="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_f1829b65-ac61-42e3-bffb-6b2b67e1f30e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsTables" xlink:type="simple" xlink:href="lly-20210331.xsd#AcquisitionsTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AcquisitionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_f3e9a8ea-34ff-4daa-81cd-21de3098e032" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_8e682e36-ea5e-485c-8a53-694c21edcd6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_f3e9a8ea-34ff-4daa-81cd-21de3098e032" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_8e682e36-ea5e-485c-8a53-694c21edcd6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_9cb0c21e-6822-430a-9359-d9d664488190" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_f3e9a8ea-34ff-4daa-81cd-21de3098e032" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_9cb0c21e-6822-430a-9359-d9d664488190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#AcquisitionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AcquisitionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_d5eb08a6-7181-4ba7-9781-bc0f12b53e7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d9fe1cb9-f3fd-4e56-b5ea-4cab41e1f596" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_d5eb08a6-7181-4ba7-9781-bc0f12b53e7d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d9fe1cb9-f3fd-4e56-b5ea-4cab41e1f596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f81fd95b-9dfd-44f9-8c7f-a55000d02f55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d9fe1cb9-f3fd-4e56-b5ea-4cab41e1f596" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f81fd95b-9dfd-44f9-8c7f-a55000d02f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0f51281c-cbe3-4b0f-90e4-d51ccc84888c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f81fd95b-9dfd-44f9-8c7f-a55000d02f55" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0f51281c-cbe3-4b0f-90e4-d51ccc84888c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrevailTherapeuticsIncMember_d468d924-3ed6-45f5-bd13-aa4952effc0d" xlink:href="lly-20210331.xsd#lly_PrevailTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0f51281c-cbe3-4b0f-90e4-d51ccc84888c" xlink:to="loc_lly_PrevailTherapeuticsIncMember_d468d924-3ed6-45f5-bd13-aa4952effc0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DermiraInc.Member_0fd73a20-e2f3-4cb7-b45b-9eb17c4d825c" xlink:href="lly-20210331.xsd#lly_DermiraInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0f51281c-cbe3-4b0f-90e4-d51ccc84888c" xlink:to="loc_lly_DermiraInc.Member_0fd73a20-e2f3-4cb7-b45b-9eb17c4d825c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_3c158862-19fe-4379-a2cd-83156660fc20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d9fe1cb9-f3fd-4e56-b5ea-4cab41e1f596" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_3c158862-19fe-4379-a2cd-83156660fc20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_5fc08a9f-7f06-4a17-9cac-4ff7268d872c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c158862-19fe-4379-a2cd-83156660fc20" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_5fc08a9f-7f06-4a17-9cac-4ff7268d872c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_ed65ede3-37e0-4004-a0ab-b2d5b0c16223" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c158862-19fe-4379-a2cd-83156660fc20" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_ed65ede3-37e0-4004-a0ab-b2d5b0c16223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_a5e60241-4ed4-4d89-b972-8a21d295ad38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c158862-19fe-4379-a2cd-83156660fc20" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_a5e60241-4ed4-4d89-b972-8a21d295ad38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights_f8201363-16cc-467c-87c5-ca52bafd7443" xlink:href="lly-20210331.xsd#lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c158862-19fe-4379-a2cd-83156660fc20" xlink:to="loc_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights_f8201363-16cc-467c-87c5-ca52bafd7443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_f7d74b9d-a1f6-4c18-a068-ec795f2a9c78" xlink:href="lly-20210331.xsd#lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c158862-19fe-4379-a2cd-83156660fc20" xlink:to="loc_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_f7d74b9d-a1f6-4c18-a068-ec795f2a9c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_edeec5bd-f0d2-48f9-aa10-513cca4efd69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c158862-19fe-4379-a2cd-83156660fc20" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_edeec5bd-f0d2-48f9-aa10-513cca4efd69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction_2e7cc17b-7d07-4de7-b3c6-227de53c3e22" xlink:href="lly-20210331.xsd#lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c158862-19fe-4379-a2cd-83156660fc20" xlink:to="loc_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction_2e7cc17b-7d07-4de7-b3c6-227de53c3e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_b7cb359a-6ecd-4528-95ee-ea4ba61bf7bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c158862-19fe-4379-a2cd-83156660fc20" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_b7cb359a-6ecd-4528-95ee-ea4ba61bf7bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3b1341f2-c8a6-4249-afed-f1fcf2e3b2fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c158862-19fe-4379-a2cd-83156660fc20" xlink:to="loc_us-gaap_Goodwill_3b1341f2-c8a6-4249-afed-f1fcf2e3b2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_5c76bd95-b42f-4e9c-b9f6-73a508b3314c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c158862-19fe-4379-a2cd-83156660fc20" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_5c76bd95-b42f-4e9c-b9f6-73a508b3314c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_8bd98439-94f6-462a-a071-3c165955db69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c158862-19fe-4379-a2cd-83156660fc20" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_8bd98439-94f6-462a-a071-3c165955db69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_cf1b5036-5ba2-4655-bd60-d4bb41081a68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c158862-19fe-4379-a2cd-83156660fc20" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_cf1b5036-5ba2-4655-bd60-d4bb41081a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_9acc4c71-550d-4b64-9d6e-e1fdf332927e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3c158862-19fe-4379-a2cd-83156660fc20" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_9acc4c71-550d-4b64-9d6e-e1fdf332927e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_9e3c51fe-fa30-48d2-9326-df954cb5e61f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8947d868-a2c7-4143-8da5-2266358dd43e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_9e3c51fe-fa30-48d2-9326-df954cb5e61f" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8947d868-a2c7-4143-8da5-2266358dd43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e3f5fd41-7a7f-4e7a-b010-6dbcfc69f2c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8947d868-a2c7-4143-8da5-2266358dd43e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e3f5fd41-7a7f-4e7a-b010-6dbcfc69f2c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_428c0748-e4d2-4f35-ab7b-a5c5d916311d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e3f5fd41-7a7f-4e7a-b010-6dbcfc69f2c4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_428c0748-e4d2-4f35-ab7b-a5c5d916311d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrevailTherapeuticsIncMember_62e60ff8-d063-42e3-bd92-a6399a40327a" xlink:href="lly-20210331.xsd#lly_PrevailTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_428c0748-e4d2-4f35-ab7b-a5c5d916311d" xlink:to="loc_lly_PrevailTherapeuticsIncMember_62e60ff8-d063-42e3-bd92-a6399a40327a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_621ee8f6-63cd-4302-8e5e-ac0d6b8aad0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8947d868-a2c7-4143-8da5-2266358dd43e" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_621ee8f6-63cd-4302-8e5e-ac0d6b8aad0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1b800106-9fa2-4c05-8dd3-e8a33bfd8f8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_621ee8f6-63cd-4302-8e5e-ac0d6b8aad0e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1b800106-9fa2-4c05-8dd3-e8a33bfd8f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9d253995-7eeb-435f-9fda-723050d81494" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_621ee8f6-63cd-4302-8e5e-ac0d6b8aad0e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9d253995-7eeb-435f-9fda-723050d81494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_076f57c9-083f-4138-bbcd-3d199cc614bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_621ee8f6-63cd-4302-8e5e-ac0d6b8aad0e" xlink:to="loc_us-gaap_Goodwill_076f57c9-083f-4138-bbcd-3d199cc614bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_e30bc9c6-eef4-4dfd-ace1-d794c56b210a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_621ee8f6-63cd-4302-8e5e-ac0d6b8aad0e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_e30bc9c6-eef4-4dfd-ace1-d794c56b210a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_6475ca24-f595-47af-9d82-731e2405adae" xlink:href="lly-20210331.xsd#lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_621ee8f6-63cd-4302-8e5e-ac0d6b8aad0e" xlink:to="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_6475ca24-f595-47af-9d82-731e2405adae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_b69554c5-0aae-49b6-bd1f-2023e17c7d0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_621ee8f6-63cd-4302-8e5e-ac0d6b8aad0e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_b69554c5-0aae-49b6-bd1f-2023e17c7d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_d68e2baa-b7a8-43c3-8de7-adeddc66bbc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_621ee8f6-63cd-4302-8e5e-ac0d6b8aad0e" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_d68e2baa-b7a8-43c3-8de7-adeddc66bbc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_d489ecdb-4ca7-409f-8cb4-8e1e635a263d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_621ee8f6-63cd-4302-8e5e-ac0d6b8aad0e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_d489ecdb-4ca7-409f-8cb4-8e1e635a263d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_23eb3a77-f9d6-4d60-9cad-b0172fd39a8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_621ee8f6-63cd-4302-8e5e-ac0d6b8aad0e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_23eb3a77-f9d6-4d60-9cad-b0172fd39a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#AcquisitionsAssetAcquisitionsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_44d06277-359a-4a65-8ca4-f6989de15b44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7d50acee-0b25-4e73-8383-5db49380a2b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_44d06277-359a-4a65-8ca4-f6989de15b44" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7d50acee-0b25-4e73-8383-5db49380a2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0abb90d2-c578-4692-9c89-a11b70e7d8c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7d50acee-0b25-4e73-8383-5db49380a2b6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0abb90d2-c578-4692-9c89-a11b70e7d8c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_469333af-796a-4e30-a801-5d00511cf498" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0abb90d2-c578-4692-9c89-a11b70e7d8c7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_469333af-796a-4e30-a801-5d00511cf498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrecisionBiosciencesIncMember_25ccd83c-1bfc-439c-a4e7-5f6f47fab565" xlink:href="lly-20210331.xsd#lly_PrecisionBiosciencesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_469333af-796a-4e30-a801-5d00511cf498" xlink:to="loc_lly_PrecisionBiosciencesIncMember_25ccd83c-1bfc-439c-a4e7-5f6f47fab565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MerusNVMember_8805194a-49b1-4236-beb6-298ad4e9416f" xlink:href="lly-20210331.xsd#lly_MerusNVMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_469333af-796a-4e30-a801-5d00511cf498" xlink:to="loc_lly_MerusNVMember_8805194a-49b1-4236-beb6-298ad4e9416f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AsahiKaseiPharmaCorporationMember_5a67605f-1d72-4728-aa40-916c4efb1315" xlink:href="lly-20210331.xsd#lly_AsahiKaseiPharmaCorporationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_469333af-796a-4e30-a801-5d00511cf498" xlink:to="loc_lly_AsahiKaseiPharmaCorporationMember_5a67605f-1d72-4728-aa40-916c4efb1315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RigelPharmaceuticalsIncMember_a453685b-b31f-4e11-98e3-d5e88c688bf4" xlink:href="lly-20210331.xsd#lly_RigelPharmaceuticalsIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_469333af-796a-4e30-a801-5d00511cf498" xlink:to="loc_lly_RigelPharmaceuticalsIncMember_a453685b-b31f-4e11-98e3-d5e88c688bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SitryxTherapeuticsLimitedMember_01125420-b6d7-4eb5-8b73-31246c8a64c5" xlink:href="lly-20210331.xsd#lly_SitryxTherapeuticsLimitedMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_469333af-796a-4e30-a801-5d00511cf498" xlink:to="loc_lly_SitryxTherapeuticsLimitedMember_01125420-b6d7-4eb5-8b73-31246c8a64c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AbCelleraBiologicsInc.Member_c54ee418-c89d-4d44-a46b-69eccde8f537" xlink:href="lly-20210331.xsd#lly_AbCelleraBiologicsInc.Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_469333af-796a-4e30-a801-5d00511cf498" xlink:to="loc_lly_AbCelleraBiologicsInc.Member_c54ee418-c89d-4d44-a46b-69eccde8f537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_9587b760-7323-4be7-a9fa-6bacbc2644a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7d50acee-0b25-4e73-8383-5db49380a2b6" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_9587b760-7323-4be7-a9fa-6bacbc2644a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_d643e244-a214-4e1f-b479-e4836d332d09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9587b760-7323-4be7-a9fa-6bacbc2644a2" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_d643e244-a214-4e1f-b479-e4836d332d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangements" xlink:type="simple" xlink:href="lly-20210331.xsd#CollaborationsandOtherArrangements"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d5612c1d-1a8b-4fff-9057-5066cbe759d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_b388d6d7-49b9-480f-8131-3c938b24015b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d5612c1d-1a8b-4fff-9057-5066cbe759d8" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_b388d6d7-49b9-480f-8131-3c938b24015b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsTables" xlink:type="simple" xlink:href="lly-20210331.xsd#CollaborationsandOtherArrangementsTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e6229059-a1b8-4541-9d76-be856f6c9db2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_d7e71e37-0468-47a4-bf1a-28a77978bc4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e6229059-a1b8-4541-9d76-be856f6c9db2" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_d7e71e37-0468-47a4-bf1a-28a77978bc4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#CollaborationsandOtherArrangementsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_89aebc81-bdec-4278-af14-d16a633fea08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9108bbe7-6c7a-4e3c-8894-020414f27b68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_89aebc81-bdec-4278-af14-d16a633fea08" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9108bbe7-6c7a-4e3c-8894-020414f27b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_26bcd127-f6e0-4eef-bd08-59d051099fbb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9108bbe7-6c7a-4e3c-8894-020414f27b68" xlink:to="loc_dei_LegalEntityAxis_26bcd127-f6e0-4eef-bd08-59d051099fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b5f74c80-c8ec-4a05-9bf9-9f7bda19403e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_26bcd127-f6e0-4eef-bd08-59d051099fbb" xlink:to="loc_dei_EntityDomain_b5f74c80-c8ec-4a05-9bf9-9f7bda19403e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_InnoventBiologicsIncMember_8ceca863-302d-4b2f-bb88-fa0a56598b07" xlink:href="lly-20210331.xsd#lly_InnoventBiologicsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b5f74c80-c8ec-4a05-9bf9-9f7bda19403e" xlink:to="loc_lly_InnoventBiologicsIncMember_8ceca863-302d-4b2f-bb88-fa0a56598b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RocheMember_f3346854-3bf6-4924-a606-7a36a7b4ce6d" xlink:href="lly-20210331.xsd#lly_RocheMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b5f74c80-c8ec-4a05-9bf9-9f7bda19403e" xlink:to="loc_lly_RocheMember_f3346854-3bf6-4924-a606-7a36a7b4ce6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c95821e7-2617-47d4-9fa8-7e5026d5e4b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9108bbe7-6c7a-4e3c-8894-020414f27b68" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c95821e7-2617-47d4-9fa8-7e5026d5e4b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d99a00f4-ee97-47b6-b3a7-48a31e53cb23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c95821e7-2617-47d4-9fa8-7e5026d5e4b2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d99a00f4-ee97-47b6-b3a7-48a31e53cb23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_16ddbbf2-775b-4979-83fb-028fac1cd718" xlink:href="lly-20210331.xsd#lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d99a00f4-ee97-47b6-b3a7-48a31e53cb23" xlink:to="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_16ddbbf2-775b-4979-83fb-028fac1cd718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementTermsMember_b1a8fdba-99af-48e4-9969-41056c8fa84c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyAgreementTermsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d99a00f4-ee97-47b6-b3a7-48a31e53cb23" xlink:to="loc_us-gaap_RoyaltyAgreementTermsMember_b1a8fdba-99af-48e4-9969-41056c8fa84c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember_59c4dfc7-6295-4ec7-99a0-e4b4ee4b6505" xlink:href="lly-20210331.xsd#lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d99a00f4-ee97-47b6-b3a7-48a31e53cb23" xlink:to="loc_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember_59c4dfc7-6295-4ec7-99a0-e4b4ee4b6505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_4dc148f4-2ba7-4dae-8e29-3e3c70a2e495" xlink:href="lly-20210331.xsd#lly_MilestonePaymentsDevelopmentAndRegulatoryMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d99a00f4-ee97-47b6-b3a7-48a31e53cb23" xlink:to="loc_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_4dc148f4-2ba7-4dae-8e29-3e3c70a2e495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsSalesBasedMember_f0b1c073-2e3b-4acc-b0f3-7c3e5429e2eb" xlink:href="lly-20210331.xsd#lly_MilestonePaymentsSalesBasedMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d99a00f4-ee97-47b6-b3a7-48a31e53cb23" xlink:to="loc_lly_MilestonePaymentsSalesBasedMember_f0b1c073-2e3b-4acc-b0f3-7c3e5429e2eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsSuccessBasedRegulatoryMember_d495f6d0-c7f2-4cca-8355-24fee58d91d6" xlink:href="lly-20210331.xsd#lly_MilestonePaymentsSuccessBasedRegulatoryMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d99a00f4-ee97-47b6-b3a7-48a31e53cb23" xlink:to="loc_lly_MilestonePaymentsSuccessBasedRegulatoryMember_d495f6d0-c7f2-4cca-8355-24fee58d91d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember_6330cbd7-09bf-4b17-98e6-f8046867d083" xlink:href="lly-20210331.xsd#lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d99a00f4-ee97-47b6-b3a7-48a31e53cb23" xlink:to="loc_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember_6330cbd7-09bf-4b17-98e6-f8046867d083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a2a11e76-c34d-4ffd-915a-02b0c0134a55" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9108bbe7-6c7a-4e3c-8894-020414f27b68" xlink:to="loc_srt_ProductOrServiceAxis_a2a11e76-c34d-4ffd-915a-02b0c0134a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fd60de86-e6e2-4bdd-98cc-29e4dae37207" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a2a11e76-c34d-4ffd-915a-02b0c0134a55" xlink:to="loc_srt_ProductsAndServicesDomain_fd60de86-e6e2-4bdd-98cc-29e4dae37207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_1a3699f3-0513-4f89-b492-e34c2ecf1b7e" xlink:href="lly-20210331.xsd#lly_JardianceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fd60de86-e6e2-4bdd-98cc-29e4dae37207" xlink:to="loc_lly_JardianceMember_1a3699f3-0513-4f89-b492-e34c2ecf1b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrajentaBIMember_a1e22600-b265-4baa-a55d-7fc1bee9654a" xlink:href="lly-20210331.xsd#lly_TrajentaBIMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fd60de86-e6e2-4bdd-98cc-29e4dae37207" xlink:to="loc_lly_TrajentaBIMember_a1e22600-b265-4baa-a55d-7fc1bee9654a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember_82ae3cc5-6552-497c-be1c-a3acc4d74221" xlink:href="lly-20210331.xsd#lly_BasaglarMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fd60de86-e6e2-4bdd-98cc-29e4dae37207" xlink:to="loc_lly_BasaglarMember_82ae3cc5-6552-497c-be1c-a3acc4d74221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember_1e094101-8054-4ed1-a5e7-c03911602dc9" xlink:href="lly-20210331.xsd#lly_OlumiantMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fd60de86-e6e2-4bdd-98cc-29e4dae37207" xlink:to="loc_lly_OlumiantMember_1e094101-8054-4ed1-a5e7-c03911602dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_COVID19AntibodiesMember_6d43006b-eda0-4f38-9d09-f5baeeb09285" xlink:href="lly-20210331.xsd#lly_COVID19AntibodiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fd60de86-e6e2-4bdd-98cc-29e4dae37207" xlink:to="loc_lly_COVID19AntibodiesMember_6d43006b-eda0-4f38-9d09-f5baeeb09285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TYVYTMember_9733327c-6f2c-43ab-a348-1ffcdf757c33" xlink:href="lly-20210331.xsd#lly_TYVYTMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fd60de86-e6e2-4bdd-98cc-29e4dae37207" xlink:to="loc_lly_TYVYTMember_9733327c-6f2c-43ab-a348-1ffcdf757c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TanezumabMember_fe9f5735-489e-4633-9a1a-6b1d32742e90" xlink:href="lly-20210331.xsd#lly_TanezumabMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fd60de86-e6e2-4bdd-98cc-29e4dae37207" xlink:to="loc_lly_TanezumabMember_fe9f5735-489e-4633-9a1a-6b1d32742e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LebrikizumabMember_a62ef794-3264-47ee-bbc7-ce37a63da506" xlink:href="lly-20210331.xsd#lly_LebrikizumabMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fd60de86-e6e2-4bdd-98cc-29e4dae37207" xlink:to="loc_lly_LebrikizumabMember_a62ef794-3264-47ee-bbc7-ce37a63da506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_87a88848-4a0c-47c7-b708-91960bd7a745" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9108bbe7-6c7a-4e3c-8894-020414f27b68" xlink:to="loc_srt_StatementGeographicalAxis_87a88848-4a0c-47c7-b708-91960bd7a745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7e99053f-d29b-4a58-a922-cfe3b240b86f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_87a88848-4a0c-47c7-b708-91960bd7a745" xlink:to="loc_srt_SegmentGeographicalDomain_7e99053f-d29b-4a58-a922-cfe3b240b86f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NonCHINAMember_c70d04ef-40a2-4ed5-a537-9359c83961f3" xlink:href="lly-20210331.xsd#lly_NonCHINAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7e99053f-d29b-4a58-a922-cfe3b240b86f" xlink:to="loc_lly_NonCHINAMember_c70d04ef-40a2-4ed5-a537-9359c83961f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_970e5fb8-103a-43e0-890e-f439c54def5c" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7e99053f-d29b-4a58-a922-cfe3b240b86f" xlink:to="loc_country_CN_970e5fb8-103a-43e0-890e-f439c54def5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OutsideUSAndJapanMember_70dc0c76-363d-48f3-ad3b-33546f5e28b0" xlink:href="lly-20210331.xsd#lly_OutsideUSAndJapanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7e99053f-d29b-4a58-a922-cfe3b240b86f" xlink:to="loc_lly_OutsideUSAndJapanMember_70dc0c76-363d-48f3-ad3b-33546f5e28b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_12695ed7-d0e9-4717-abe6-9b2360826548" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7e99053f-d29b-4a58-a922-cfe3b240b86f" xlink:to="loc_us-gaap_NonUsMember_12695ed7-d0e9-4717-abe6-9b2360826548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6e65f6a9-f294-4e46-b55e-4a7d2788b454" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9108bbe7-6c7a-4e3c-8894-020414f27b68" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6e65f6a9-f294-4e46-b55e-4a7d2788b454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5f47c961-0710-4699-95e9-77e9306f4e50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6e65f6a9-f294-4e46-b55e-4a7d2788b454" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5f47c961-0710-4699-95e9-77e9306f4e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JunshiBiosciencesMember_6c4f40eb-f8dd-405f-a97f-fb5db40e89b8" xlink:href="lly-20210331.xsd#lly_JunshiBiosciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5f47c961-0710-4699-95e9-77e9306f4e50" xlink:to="loc_lly_JunshiBiosciencesMember_6c4f40eb-f8dd-405f-a97f-fb5db40e89b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8ba266dc-a562-40d2-a9f0-02d3f054e568" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9108bbe7-6c7a-4e3c-8894-020414f27b68" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8ba266dc-a562-40d2-a9f0-02d3f054e568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_7bcdc5cd-3abf-4e97-b4bf-26f5490cbe20" xlink:href="lly-20210331.xsd#lly_CollaborativeArrangementRightsAndObligationsRightsObligations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8ba266dc-a562-40d2-a9f0-02d3f054e568" xlink:to="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_7bcdc5cd-3abf-4e97-b4bf-26f5490cbe20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_18e7e3a4-411b-45cc-8d48-60e059a90d44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8ba266dc-a562-40d2-a9f0-02d3f054e568" xlink:to="loc_us-gaap_Revenues_18e7e3a4-411b-45cc-8d48-60e059a90d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsPercent_13ad70d0-40bb-4f42-9820-e5c575396640" xlink:href="lly-20210331.xsd#lly_CollaborativeArrangementRightsAndObligationsPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8ba266dc-a562-40d2-a9f0-02d3f054e568" xlink:to="loc_lly_CollaborativeArrangementRightsAndObligationsPercent_13ad70d0-40bb-4f42-9820-e5c575396640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold_da4c0b8e-1385-40c7-b02f-2dfa668ef107" xlink:href="lly-20210331.xsd#lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8ba266dc-a562-40d2-a9f0-02d3f054e568" xlink:to="loc_lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold_da4c0b8e-1385-40c7-b02f-2dfa668ef107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_f2a87e65-fdde-4575-b243-3f2372d3c006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8ba266dc-a562-40d2-a9f0-02d3f054e568" xlink:to="loc_us-gaap_ContractWithCustomerLiability_f2a87e65-fdde-4575-b243-3f2372d3c006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges" xlink:type="simple" xlink:href="lly-20210331.xsd#AssetImpairmentRestructuringandOtherSpecialCharges"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6989606b-b9e9-4253-b475-29593b3e0821" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_9c102607-6311-4b4d-afaa-a4cb6e109b1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6989606b-b9e9-4253-b475-29593b3e0821" xlink:to="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_9c102607-6311-4b4d-afaa-a4cb6e109b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables" xlink:type="simple" xlink:href="lly-20210331.xsd#AssetImpairmentRestructuringandOtherSpecialChargesTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5d7cc32e-feee-4bbd-9bb7-7c8fcf2d8d24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_cc3e9950-ee2c-4d2b-a8a0-f94bd1769fc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5d7cc32e-feee-4bbd-9bb7-7c8fcf2d8d24" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_cc3e9950-ee2c-4d2b-a8a0-f94bd1769fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#AssetImpairmentRestructuringandOtherSpecialChargesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3dde0504-f581-4351-98f9-70d29ec0ade8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_8c60a170-f119-49a9-a207-95b10282421c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3dde0504-f581-4351-98f9-70d29ec0ade8" xlink:to="loc_us-gaap_SeveranceCosts1_8c60a170-f119-49a9-a207-95b10282421c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_c22148cb-9bf7-4dbd-812c-0fc80168a377" xlink:href="lly-20210331.xsd#lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3dde0504-f581-4351-98f9-70d29ec0ade8" xlink:to="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_c22148cb-9bf7-4dbd-812c-0fc80168a377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_ddeca764-b20b-4ae8-a8ae-ae35de4a311d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringSettlementAndImpairmentProvisions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3dde0504-f581-4351-98f9-70d29ec0ade8" xlink:to="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_ddeca764-b20b-4ae8-a8ae-ae35de4a311d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_8b9960c4-74d8-44fd-adb9-3f5ab3680218" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3dde0504-f581-4351-98f9-70d29ec0ade8" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_8b9960c4-74d8-44fd-adb9-3f5ab3680218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstruments" xlink:type="simple" xlink:href="lly-20210331.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a6af321d-1a68-4932-a3a9-e651bd93125a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_ad6c9d5d-f4ed-4d0d-a826-7daab886f608" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a6af321d-1a68-4932-a3a9-e651bd93125a" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_ad6c9d5d-f4ed-4d0d-a826-7daab886f608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="lly-20210331.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_61888fbf-d7d1-4fa2-a0dc-0007bd76a1ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_576bba92-4fbb-49d7-aaed-f991ee975515" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_61888fbf-d7d1-4fa2-a0dc-0007bd76a1ef" xlink:to="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_576bba92-4fbb-49d7-aaed-f991ee975515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_fc444044-5357-4d80-ad54-40be8990b537" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_61888fbf-d7d1-4fa2-a0dc-0007bd76a1ef" xlink:to="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_fc444044-5357-4d80-ad54-40be8990b537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_44cd2fce-eaf5-4f18-bb3d-4d6f9aa03d90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_61888fbf-d7d1-4fa2-a0dc-0007bd76a1ef" xlink:to="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_44cd2fce-eaf5-4f18-bb3d-4d6f9aa03d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_52aba5bb-b913-497d-8e78-81795cd26213" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_61888fbf-d7d1-4fa2-a0dc-0007bd76a1ef" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_52aba5bb-b913-497d-8e78-81795cd26213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_a21c381c-e060-4dab-8873-fcce8e012db3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_61888fbf-d7d1-4fa2-a0dc-0007bd76a1ef" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_a21c381c-e060-4dab-8873-fcce8e012db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_0e2db613-b46e-425f-ab21-98be87d7ab90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_61888fbf-d7d1-4fa2-a0dc-0007bd76a1ef" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_0e2db613-b46e-425f-ab21-98be87d7ab90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_ac478eb3-0f7e-460c-a3ac-40d3d4915681" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_61888fbf-d7d1-4fa2-a0dc-0007bd76a1ef" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_ac478eb3-0f7e-460c-a3ac-40d3d4915681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_10aed2bb-a92e-4a9d-a6b3-f841399435bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_61888fbf-d7d1-4fa2-a0dc-0007bd76a1ef" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_10aed2bb-a92e-4a9d-a6b3-f841399435bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock_faf1e3a2-4e86-4021-be60-429896776bd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_61888fbf-d7d1-4fa2-a0dc-0007bd76a1ef" xlink:to="loc_us-gaap_GainLossOnInvestmentsTextBlock_faf1e3a2-4e86-4021-be60-429896776bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d3453dc5-77ea-4b1c-bd26-daf0319ae207" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0952f4ef-4999-4e4e-a1e8-220c29e0f460" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d3453dc5-77ea-4b1c-bd26-daf0319ae207" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0952f4ef-4999-4e4e-a1e8-220c29e0f460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_8dee71d3-f937-43aa-883a-dd90fae5ed98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0952f4ef-4999-4e4e-a1e8-220c29e0f460" xlink:to="loc_us-gaap_HedgingDesignationAxis_8dee71d3-f937-43aa-883a-dd90fae5ed98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_07bf97ec-b7d3-48c3-bfa0-cbe623731068" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_8dee71d3-f937-43aa-883a-dd90fae5ed98" xlink:to="loc_us-gaap_HedgingDesignationDomain_07bf97ec-b7d3-48c3-bfa0-cbe623731068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_a08e7ebe-5de0-45e4-882e-af9ceb0aca1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_07bf97ec-b7d3-48c3-bfa0-cbe623731068" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_a08e7ebe-5de0-45e4-882e-af9ceb0aca1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_423a7b5a-a398-40a2-9d8a-d627b67a8cad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0952f4ef-4999-4e4e-a1e8-220c29e0f460" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_423a7b5a-a398-40a2-9d8a-d627b67a8cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_770d76dd-09de-4fb4-913d-de7bd24457a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_423a7b5a-a398-40a2-9d8a-d627b67a8cad" xlink:to="loc_us-gaap_HedgingRelationshipDomain_770d76dd-09de-4fb4-913d-de7bd24457a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_21073233-95ad-43c1-af5c-977bbb54b632" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_770d76dd-09de-4fb4-913d-de7bd24457a8" xlink:to="loc_us-gaap_CashFlowHedgingMember_21073233-95ad-43c1-af5c-977bbb54b632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ea62c3d1-d9f5-4860-8662-321db5a51f5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0952f4ef-4999-4e4e-a1e8-220c29e0f460" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ea62c3d1-d9f5-4860-8662-321db5a51f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_dae11b78-d395-4819-83b4-edf555e99417" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ea62c3d1-d9f5-4860-8662-321db5a51f5a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_dae11b78-d395-4819-83b4-edf555e99417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForeignCurrencyDenominatedDebtMember_3cc9ae74-805b-4994-bfb0-f09093dd5edd" xlink:href="lly-20210331.xsd#lly_ForeignCurrencyDenominatedDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dae11b78-d395-4819-83b4-edf555e99417" xlink:to="loc_lly_ForeignCurrencyDenominatedDebtMember_3cc9ae74-805b-4994-bfb0-f09093dd5edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_1791c2d4-2357-4fba-b35f-83dbbad7e108" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0952f4ef-4999-4e4e-a1e8-220c29e0f460" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_1791c2d4-2357-4fba-b35f-83dbbad7e108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6f4fb931-b5f7-44c0-98de-50c34fb5b800" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1791c2d4-2357-4fba-b35f-83dbbad7e108" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6f4fb931-b5f7-44c0-98de-50c34fb5b800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUsDollarSellEuroMember_cbf5d153-eee5-4996-9970-5f1a44ce92d8" xlink:href="lly-20210331.xsd#lly_BuyUsDollarSellEuroMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6f4fb931-b5f7-44c0-98de-50c34fb5b800" xlink:to="loc_lly_BuyUsDollarSellEuroMember_cbf5d153-eee5-4996-9970-5f1a44ce92d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyEuroSellUsDollarMember_11c933a8-7e88-4288-b38d-c2b3358c6490" xlink:href="lly-20210331.xsd#lly_BuyEuroSellUsDollarMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6f4fb931-b5f7-44c0-98de-50c34fb5b800" xlink:to="loc_lly_BuyEuroSellUsDollarMember_11c933a8-7e88-4288-b38d-c2b3358c6490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUSdollarSellJapaneseYenMember_db170a53-0dd8-44ff-b659-b848543ebca4" xlink:href="lly-20210331.xsd#lly_BuyUSdollarSellJapaneseYenMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6f4fb931-b5f7-44c0-98de-50c34fb5b800" xlink:to="loc_lly_BuyUSdollarSellJapaneseYenMember_db170a53-0dd8-44ff-b659-b848543ebca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyBritishPoundandSellUSDollarsMember_37fe1cda-a25a-4782-8dac-78077da9b879" xlink:href="lly-20210331.xsd#lly_BuyBritishPoundandSellUSDollarsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6f4fb931-b5f7-44c0-98de-50c34fb5b800" xlink:to="loc_lly_BuyBritishPoundandSellUSDollarsMember_37fe1cda-a25a-4782-8dac-78077da9b879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SwapU.S.DollarsToEuroMember_e5d52aa1-bb8e-4e80-996e-fde665f5d23f" xlink:href="lly-20210331.xsd#lly_SwapU.S.DollarsToEuroMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6f4fb931-b5f7-44c0-98de-50c34fb5b800" xlink:to="loc_lly_SwapU.S.DollarsToEuroMember_e5d52aa1-bb8e-4e80-996e-fde665f5d23f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SwapSwissFrancsToU.S.DollarsMember_b0993be3-dc81-4c96-a9e3-66df5297362e" xlink:href="lly-20210331.xsd#lly_SwapSwissFrancsToU.S.DollarsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6f4fb931-b5f7-44c0-98de-50c34fb5b800" xlink:to="loc_lly_SwapSwissFrancsToU.S.DollarsMember_b0993be3-dc81-4c96-a9e3-66df5297362e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_5c5e81a8-a9ba-4f7c-8839-20164480ac43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6f4fb931-b5f7-44c0-98de-50c34fb5b800" xlink:to="loc_us-gaap_InterestRateSwapMember_5c5e81a8-a9ba-4f7c-8839-20164480ac43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_adf35fd9-8721-4921-a3b8-3d73e3766db0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0952f4ef-4999-4e4e-a1e8-220c29e0f460" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_adf35fd9-8721-4921-a3b8-3d73e3766db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_08310bd9-74f0-4e29-b51c-5f14efbc635b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_adf35fd9-8721-4921-a3b8-3d73e3766db0" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_08310bd9-74f0-4e29-b51c-5f14efbc635b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_0344dabb-5113-4c05-a6bf-323090449236" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_adf35fd9-8721-4921-a3b8-3d73e3766db0" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_0344dabb-5113-4c05-a6bf-323090449236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_ffddbf03-975a-4101-8efb-d5055a1c77c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_adf35fd9-8721-4921-a3b8-3d73e3766db0" xlink:to="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_ffddbf03-975a-4101-8efb-d5055a1c77c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_ef57d127-ec25-4d4f-ad5c-54f4c2667444" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_adf35fd9-8721-4921-a3b8-3d73e3766db0" xlink:to="loc_us-gaap_LongTermDebt_ef57d127-ec25-4d4f-ad5c-54f4c2667444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax_53e9cecf-04e7-4e34-a5ab-dfb6b6c10b5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_adf35fd9-8721-4921-a3b8-3d73e3766db0" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax_53e9cecf-04e7-4e34-a5ab-dfb6b6c10b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_4b4757cf-1032-4913-b428-f92b2f041944" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_adf35fd9-8721-4921-a3b8-3d73e3766db0" xlink:to="loc_us-gaap_DerivativeNotionalAmount_4b4757cf-1032-4913-b428-f92b2f041944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DescriptionOfDerivativeActivityVolumePercent_f8a43af8-cfc2-47bb-a7b4-66a581231149" xlink:href="lly-20210331.xsd#lly_DescriptionOfDerivativeActivityVolumePercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_adf35fd9-8721-4921-a3b8-3d73e3766db0" xlink:to="loc_lly_DescriptionOfDerivativeActivityVolumePercent_f8a43af8-cfc2-47bb-a7b4-66a581231149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_440e4849-b883-496f-aa4d-26c64fe5adca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_adf35fd9-8721-4921-a3b8-3d73e3766db0" xlink:to="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_440e4849-b883-496f-aa4d-26c64fe5adca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_69be14c0-d348-460b-bd82-85d0dcc9ec2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_adf35fd9-8721-4921-a3b8-3d73e3766db0" xlink:to="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_69be14c0-d348-460b-bd82-85d0dcc9ec2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_13c37c4c-ef02-4f6c-bc53-bbbba3bc43a4" xlink:href="lly-20210331.xsd#lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_adf35fd9-8721-4921-a3b8-3d73e3766db0" xlink:to="loc_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_13c37c4c-ef02-4f6c-bc53-bbbba3bc43a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_7a5dc759-0964-4d30-81c6-e35aff2e61a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_adf35fd9-8721-4921-a3b8-3d73e3766db0" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_7a5dc759-0964-4d30-81c6-e35aff2e61a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets_ef2971c1-2f93-449b-8d32-930365ae20c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_adf35fd9-8721-4921-a3b8-3d73e3766db0" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets_ef2971c1-2f93-449b-8d32-930365ae20c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_f95a8d85-9f5f-45fb-8a12-5303971acab9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_adf35fd9-8721-4921-a3b8-3d73e3766db0" xlink:to="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_f95a8d85-9f5f-45fb-8a12-5303971acab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#FinancialInstrumentsEffectofRiskManagementInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_819e218d-eb86-4460-99d6-ee7de9a4fcd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_997ff6ed-b042-4553-886e-48bbb85ce8db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_819e218d-eb86-4460-99d6-ee7de9a4fcd2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_997ff6ed-b042-4553-886e-48bbb85ce8db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_e828de25-5da9-4944-86f7-fda3525d1ba7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_997ff6ed-b042-4553-886e-48bbb85ce8db" xlink:to="loc_us-gaap_HedgingDesignationAxis_e828de25-5da9-4944-86f7-fda3525d1ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_34045ce0-6015-4a23-a117-e3ee4df03538" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_e828de25-5da9-4944-86f7-fda3525d1ba7" xlink:to="loc_us-gaap_HedgingDesignationDomain_34045ce0-6015-4a23-a117-e3ee4df03538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_254112f0-0c20-43eb-a00a-52745c97770b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_34045ce0-6015-4a23-a117-e3ee4df03538" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_254112f0-0c20-43eb-a00a-52745c97770b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_1a71fdc5-6f9b-406d-be2e-cd104bc8d8bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_34045ce0-6015-4a23-a117-e3ee4df03538" xlink:to="loc_us-gaap_NondesignatedMember_1a71fdc5-6f9b-406d-be2e-cd104bc8d8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_15e43493-595d-4823-a2a6-33fa9e211247" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_997ff6ed-b042-4553-886e-48bbb85ce8db" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_15e43493-595d-4823-a2a6-33fa9e211247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0ed43062-ed06-42d5-82b4-29f37df6b540" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_15e43493-595d-4823-a2a6-33fa9e211247" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0ed43062-ed06-42d5-82b4-29f37df6b540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HedgedFixedRateDebtMember_f9c115bb-42b7-4bca-9b77-96ab83989b1f" xlink:href="lly-20210331.xsd#lly_HedgedFixedRateDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0ed43062-ed06-42d5-82b4-29f37df6b540" xlink:to="loc_lly_HedgedFixedRateDebtMember_f9c115bb-42b7-4bca-9b77-96ab83989b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_9424e183-2ce9-4d7e-8f26-7e8283368bc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0ed43062-ed06-42d5-82b4-29f37df6b540" xlink:to="loc_us-gaap_InterestRateContractMember_9424e183-2ce9-4d7e-8f26-7e8283368bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_ac5f6dd5-8591-46a8-b2e9-50db83d6f4f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0ed43062-ed06-42d5-82b4-29f37df6b540" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_ac5f6dd5-8591-46a8-b2e9-50db83d6f4f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_9e8e9937-242e-4dd1-b943-93bfec695a13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0ed43062-ed06-42d5-82b4-29f37df6b540" xlink:to="loc_us-gaap_ForeignExchangeContractMember_9e8e9937-242e-4dd1-b943-93bfec695a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_50963c55-6742-4a9b-ae54-2eff15f09264" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0ed43062-ed06-42d5-82b4-29f37df6b540" xlink:to="loc_us-gaap_InterestRateSwapMember_50963c55-6742-4a9b-ae54-2eff15f09264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_751158da-2edf-41e1-801c-69d1f7b7942c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_997ff6ed-b042-4553-886e-48bbb85ce8db" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_751158da-2edf-41e1-801c-69d1f7b7942c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FairValueHedgeAbstract_ca8b6826-155f-4d3a-ac0f-b96297dd885d" xlink:href="lly-20210331.xsd#lly_FairValueHedgeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_751158da-2edf-41e1-801c-69d1f7b7942c" xlink:to="loc_lly_FairValueHedgeAbstract_ca8b6826-155f-4d3a-ac0f-b96297dd885d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_01f6dc3c-c929-4212-94d5-ed3376432d9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_FairValueHedgeAbstract_ca8b6826-155f-4d3a-ac0f-b96297dd885d" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_01f6dc3c-c929-4212-94d5-ed3376432d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_c85f6e8f-85f9-428a-a1d4-6a46710fee07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_FairValueHedgeAbstract_ca8b6826-155f-4d3a-ac0f-b96297dd885d" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_c85f6e8f-85f9-428a-a1d4-6a46710fee07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CashFlowHedgeAbstract_d570c496-78a1-4935-88a6-cee0ced01526" xlink:href="lly-20210331.xsd#lly_CashFlowHedgeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_751158da-2edf-41e1-801c-69d1f7b7942c" xlink:to="loc_lly_CashFlowHedgeAbstract_d570c496-78a1-4935-88a6-cee0ced01526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_ffdd1598-5555-4286-9d65-31ce64226bee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_CashFlowHedgeAbstract_d570c496-78a1-4935-88a6-cee0ced01526" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_ffdd1598-5555-4286-9d65-31ce64226bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_88e46833-9710-4a69-a75f-0f25814f28a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_751158da-2edf-41e1-801c-69d1f7b7942c" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_88e46833-9710-4a69-a75f-0f25814f28a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DerivativeInstrumentsGainLossRecognized_7c7a2106-fdea-4e59-a7f1-d3d353d5ae25" xlink:href="lly-20210331.xsd#lly_DerivativeInstrumentsGainLossRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_751158da-2edf-41e1-801c-69d1f7b7942c" xlink:to="loc_lly_DerivativeInstrumentsGainLossRecognized_7c7a2106-fdea-4e59-a7f1-d3d353d5ae25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_96b757a5-dfd5-4239-a52e-884e5a2a47d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_751158da-2edf-41e1-801c-69d1f7b7942c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_96b757a5-dfd5-4239-a52e-884e5a2a47d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_fb53b156-29d3-476d-9c7c-c5c11d17c333" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_751158da-2edf-41e1-801c-69d1f7b7942c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_fb53b156-29d3-476d-9c7c-c5c11d17c333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#FinancialInstrumentsFairValueofFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9023fdd9-0619-4dff-b4f6-24d7d2ed2cb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4ec1a449-c378-4bcd-9622-8eef40b3d9a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9023fdd9-0619-4dff-b4f6-24d7d2ed2cb6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4ec1a449-c378-4bcd-9622-8eef40b3d9a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_3e9aba55-53c5-4f32-95e6-2df6252cddb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4ec1a449-c378-4bcd-9622-8eef40b3d9a7" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_3e9aba55-53c5-4f32-95e6-2df6252cddb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_bcfdc6b5-0291-4de2-995c-89ee0e9498ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_3e9aba55-53c5-4f32-95e6-2df6252cddb7" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_bcfdc6b5-0291-4de2-995c-89ee0e9498ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2f66fc76-3552-4fdf-b14b-beff8364ff59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_bcfdc6b5-0291-4de2-995c-89ee0e9498ff" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2f66fc76-3552-4fdf-b14b-beff8364ff59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_302c0b02-51af-475a-97ae-09bc44688432" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_bcfdc6b5-0291-4de2-995c-89ee0e9498ff" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_302c0b02-51af-475a-97ae-09bc44688432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_d645404d-ae5b-4d40-8512-204caa983496" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_bcfdc6b5-0291-4de2-995c-89ee0e9498ff" xlink:to="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_d645404d-ae5b-4d40-8512-204caa983496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_2d50943e-b0df-4ae4-8175-aa380a7b47ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_bcfdc6b5-0291-4de2-995c-89ee0e9498ff" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_2d50943e-b0df-4ae4-8175-aa380a7b47ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2c57234e-d1e5-4e0b-96f9-5285bf082961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4ec1a449-c378-4bcd-9622-8eef40b3d9a7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2c57234e-d1e5-4e0b-96f9-5285bf082961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a59e4711-669f-4f80-ab63-6964d1e58964" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2c57234e-d1e5-4e0b-96f9-5285bf082961" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a59e4711-669f-4f80-ab63-6964d1e58964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_b50301d6-29c1-4f5f-b92a-491d074225c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a59e4711-669f-4f80-ab63-6964d1e58964" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_b50301d6-29c1-4f5f-b92a-491d074225c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_7ce01efb-8498-4cd5-9d3c-4326d419469d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a59e4711-669f-4f80-ab63-6964d1e58964" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_7ce01efb-8498-4cd5-9d3c-4326d419469d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_4dab4092-528b-4531-b0a4-01d5b00807cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a59e4711-669f-4f80-ab63-6964d1e58964" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_4dab4092-528b-4531-b0a4-01d5b00807cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_548ce93f-a5b9-4748-a071-4ea44e1dbbde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a59e4711-669f-4f80-ab63-6964d1e58964" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_548ce93f-a5b9-4748-a071-4ea44e1dbbde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember_6d5c1de5-d194-4419-9e0b-2d2b9b0d6f61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a59e4711-669f-4f80-ab63-6964d1e58964" xlink:to="loc_us-gaap_MortgageBackedSecuritiesMember_6d5c1de5-d194-4419-9e0b-2d2b9b0d6f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherEquitySecuritiesMember_0a8f3f5a-5e56-4c55-aba7-e230d8e5d121" xlink:href="lly-20210331.xsd#lly_OtherEquitySecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a59e4711-669f-4f80-ab63-6964d1e58964" xlink:to="loc_lly_OtherEquitySecuritiesMember_0a8f3f5a-5e56-4c55-aba7-e230d8e5d121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MarketableSecuritiesMember_933cf1fb-2282-43a9-a838-4f3b4bed7e12" xlink:href="lly-20210331.xsd#lly_MarketableSecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a59e4711-669f-4f80-ab63-6964d1e58964" xlink:to="loc_lly_MarketableSecuritiesMember_933cf1fb-2282-43a9-a838-4f3b4bed7e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EquityMethodAndOtherInvestmentsMember_17468f6a-4484-40c8-a41c-37e886879ed1" xlink:href="lly-20210331.xsd#lly_EquityMethodAndOtherInvestmentsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a59e4711-669f-4f80-ab63-6964d1e58964" xlink:to="loc_lly_EquityMethodAndOtherInvestmentsMember_17468f6a-4484-40c8-a41c-37e886879ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d9d3de97-30ef-4403-9a6b-c6e20fe78d51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4ec1a449-c378-4bcd-9622-8eef40b3d9a7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d9d3de97-30ef-4403-9a6b-c6e20fe78d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c671464c-fb14-4c02-8aad-521243a471f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d9d3de97-30ef-4403-9a6b-c6e20fe78d51" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c671464c-fb14-4c02-8aad-521243a471f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_188c3e47-fe6d-4a13-83d7-0cbf2e769353" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c671464c-fb14-4c02-8aad-521243a471f1" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_188c3e47-fe6d-4a13-83d7-0cbf2e769353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_409053de-e74c-4355-acf2-fc8792174c78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c671464c-fb14-4c02-8aad-521243a471f1" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_409053de-e74c-4355-acf2-fc8792174c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_cb7bd515-6103-4023-b385-1057c9b4f0da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c671464c-fb14-4c02-8aad-521243a471f1" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_cb7bd515-6103-4023-b385-1057c9b4f0da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_28d6da0a-02a7-4d74-9839-219eebd30e2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4ec1a449-c378-4bcd-9622-8eef40b3d9a7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_28d6da0a-02a7-4d74-9839-219eebd30e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_693130d3-7a0f-4554-87ed-c13edfaff0a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_28d6da0a-02a7-4d74-9839-219eebd30e2b" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_693130d3-7a0f-4554-87ed-c13edfaff0a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c02d8608-cc73-460e-af46-a2914187f0b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_28d6da0a-02a7-4d74-9839-219eebd30e2b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c02d8608-cc73-460e-af46-a2914187f0b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_a9c0b173-5240-4b25-a84b-077f7824175e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_28d6da0a-02a7-4d74-9839-219eebd30e2b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_a9c0b173-5240-4b25-a84b-077f7824175e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_24d9731d-d466-41a7-b356-d48c9df84404" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_28d6da0a-02a7-4d74-9839-219eebd30e2b" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_24d9731d-d466-41a7-b356-d48c9df84404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_c2b6e0c3-8e12-46ca-8710-945060bd0b9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_28d6da0a-02a7-4d74-9839-219eebd30e2b" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_c2b6e0c3-8e12-46ca-8710-945060bd0b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_d2a3db5f-4a6b-4c41-b18d-34d0f1afce33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_28d6da0a-02a7-4d74-9839-219eebd30e2b" xlink:to="loc_us-gaap_OtherLongTermInvestments_d2a3db5f-4a6b-4c41-b18d-34d0f1afce33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_39e36a4f-9a69-48b3-8a18-77b33203a822" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_28d6da0a-02a7-4d74-9839-219eebd30e2b" xlink:to="loc_us-gaap_LongTermInvestments_39e36a4f-9a69-48b3-8a18-77b33203a822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_f3b20649-bfe3-414a-b2aa-3f9b8526e6a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_28d6da0a-02a7-4d74-9839-219eebd30e2b" xlink:to="loc_us-gaap_LongTermDebt_f3b20649-bfe3-414a-b2aa-3f9b8526e6a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#FinancialInstrumentsRiskManagementInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_23a57fbb-c192-42d0-8d0e-32f0ef9ac194" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3e9cc9a7-b812-4b78-a2d3-850334831b53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_23a57fbb-c192-42d0-8d0e-32f0ef9ac194" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3e9cc9a7-b812-4b78-a2d3-850334831b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_99ec58d6-5144-4623-898a-b24ea527cfbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3e9cc9a7-b812-4b78-a2d3-850334831b53" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_99ec58d6-5144-4623-898a-b24ea527cfbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_19179d7d-33d4-460e-bb18-c2e1094ce2ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_99ec58d6-5144-4623-898a-b24ea527cfbf" xlink:to="loc_us-gaap_HedgingRelationshipDomain_19179d7d-33d4-460e-bb18-c2e1094ce2ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_3734f44a-7d1c-4dde-85fe-88ea34f242bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_19179d7d-33d4-460e-bb18-c2e1094ce2ef" xlink:to="loc_us-gaap_FairValueHedgingMember_3734f44a-7d1c-4dde-85fe-88ea34f242bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_01b99251-5e6f-4b9d-8619-103bc04b0075" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_19179d7d-33d4-460e-bb18-c2e1094ce2ef" xlink:to="loc_us-gaap_CashFlowHedgingMember_01b99251-5e6f-4b9d-8619-103bc04b0075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_990e469c-18a7-4934-9562-ed167eaa20c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_19179d7d-33d4-460e-bb18-c2e1094ce2ef" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_990e469c-18a7-4934-9562-ed167eaa20c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_9b99d27c-3317-4534-b284-f3049397b869" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3e9cc9a7-b812-4b78-a2d3-850334831b53" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_9b99d27c-3317-4534-b284-f3049397b869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_baef8bbe-5459-4f8b-be56-ece89566a3f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_9b99d27c-3317-4534-b284-f3049397b869" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_baef8bbe-5459-4f8b-be56-ece89566a3f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c79fd35a-1937-4688-9345-11aa8398f329" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_baef8bbe-5459-4f8b-be56-ece89566a3f6" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c79fd35a-1937-4688-9345-11aa8398f329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_ac40e24e-5d79-4986-b324-ce236ecbd52d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_baef8bbe-5459-4f8b-be56-ece89566a3f6" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_ac40e24e-5d79-4986-b324-ce236ecbd52d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_03cfc68d-d8c7-4283-980a-538099dd6088" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_baef8bbe-5459-4f8b-be56-ece89566a3f6" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_03cfc68d-d8c7-4283-980a-538099dd6088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_00efe8ac-5fcd-441e-84f1-2c61fcdd7b1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3e9cc9a7-b812-4b78-a2d3-850334831b53" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_00efe8ac-5fcd-441e-84f1-2c61fcdd7b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e3a5be5e-6de2-499d-8014-829d395cd471" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_00efe8ac-5fcd-441e-84f1-2c61fcdd7b1c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e3a5be5e-6de2-499d-8014-829d395cd471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_d70ae6a0-275d-470b-b557-997c23452fbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e3a5be5e-6de2-499d-8014-829d395cd471" xlink:to="loc_us-gaap_InterestRateContractMember_d70ae6a0-275d-470b-b557-997c23452fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_34fa3446-ebd7-496b-b961-665bf78be575" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e3a5be5e-6de2-499d-8014-829d395cd471" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_34fa3446-ebd7-496b-b961-665bf78be575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_ae1fb8f3-7002-4906-b10e-fdd5403597e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e3a5be5e-6de2-499d-8014-829d395cd471" xlink:to="loc_us-gaap_ForeignExchangeContractMember_ae1fb8f3-7002-4906-b10e-fdd5403597e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_6f314b97-0850-47d4-944e-b19c0614ec7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3e9cc9a7-b812-4b78-a2d3-850334831b53" xlink:to="loc_us-gaap_HedgingDesignationAxis_6f314b97-0850-47d4-944e-b19c0614ec7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_0cc375ae-96ce-436d-8cab-4af1bccfc8c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_6f314b97-0850-47d4-944e-b19c0614ec7f" xlink:to="loc_us-gaap_HedgingDesignationDomain_0cc375ae-96ce-436d-8cab-4af1bccfc8c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_4f5bd4a0-f13b-4ac0-aa57-29bbd69f940c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_0cc375ae-96ce-436d-8cab-4af1bccfc8c3" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_4f5bd4a0-f13b-4ac0-aa57-29bbd69f940c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_a23fc233-57e4-4218-8791-4f1a04dd62d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_0cc375ae-96ce-436d-8cab-4af1bccfc8c3" xlink:to="loc_us-gaap_NondesignatedMember_a23fc233-57e4-4218-8791-4f1a04dd62d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_79aa4a9b-8b06-4b77-82b9-50c1a7686c2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3e9cc9a7-b812-4b78-a2d3-850334831b53" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_79aa4a9b-8b06-4b77-82b9-50c1a7686c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6b7f395a-2277-4275-b3ae-3c1b6a157104" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_79aa4a9b-8b06-4b77-82b9-50c1a7686c2e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6b7f395a-2277-4275-b3ae-3c1b6a157104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_0dee082a-ff55-4eee-b9ea-218bb670a8ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6b7f395a-2277-4275-b3ae-3c1b6a157104" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_0dee082a-ff55-4eee-b9ea-218bb670a8ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_caa3ff3f-97d9-42c4-adc3-e083727a6040" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6b7f395a-2277-4275-b3ae-3c1b6a157104" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_caa3ff3f-97d9-42c4-adc3-e083727a6040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_801ce60c-62fb-453b-afe1-3ae79c7ac917" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6b7f395a-2277-4275-b3ae-3c1b6a157104" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_801ce60c-62fb-453b-afe1-3ae79c7ac917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_df0fb750-4678-48ca-9506-73808304bb41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3e9cc9a7-b812-4b78-a2d3-850334831b53" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_df0fb750-4678-48ca-9506-73808304bb41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_8b1c270b-b9f0-430a-845c-e3b009e3cf28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_df0fb750-4678-48ca-9506-73808304bb41" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_8b1c270b-b9f0-430a-845c-e3b009e3cf28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_a3cd5699-df0b-425a-a178-df54a7d14ff0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_df0fb750-4678-48ca-9506-73808304bb41" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_a3cd5699-df0b-425a-a178-df54a7d14ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_05a1f91b-f1ee-45d7-a78e-a5ac0df78c57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_df0fb750-4678-48ca-9506-73808304bb41" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_05a1f91b-f1ee-45d7-a78e-a5ac0df78c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_55752126-f23c-4d42-b0bc-fabf77c2d13e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_df0fb750-4678-48ca-9506-73808304bb41" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_55752126-f23c-4d42-b0bc-fabf77c2d13e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4cc4ea6e-2fdf-4d4f-bcc6-613b0559015e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_df0fb750-4678-48ca-9506-73808304bb41" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4cc4ea6e-2fdf-4d4f-bcc6-613b0559015e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#FinancialInstrumentsContractualMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_185543c7-1adc-4254-bfb8-d2a02342cf47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c30280be-4768-459a-8893-088a9373b8dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_185543c7-1adc-4254-bfb8-d2a02342cf47" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c30280be-4768-459a-8893-088a9373b8dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6da1bdab-75b5-4f42-9071-c24d99ad07b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_185543c7-1adc-4254-bfb8-d2a02342cf47" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6da1bdab-75b5-4f42-9071-c24d99ad07b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_d860772d-7400-4fd2-93b1-a055ca5352c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_185543c7-1adc-4254-bfb8-d2a02342cf47" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_d860772d-7400-4fd2-93b1-a055ca5352c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_ff6dc2f9-aa63-4dda-aa71-cec9349b983d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_185543c7-1adc-4254-bfb8-d2a02342cf47" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_ff6dc2f9-aa63-4dda-aa71-cec9349b983d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_47338210-3373-4c6b-8c1d-ff84a6099ce2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_185543c7-1adc-4254-bfb8-d2a02342cf47" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_47338210-3373-4c6b-8c1d-ff84a6099ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#FinancialInstrumentsUnrealizedGainsandLossesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6e4f7d5d-d2cc-428e-a72f-e553eb406c72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f7227482-bd18-48d6-8808-732ffd0f7ba7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6e4f7d5d-d2cc-428e-a72f-e553eb406c72" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f7227482-bd18-48d6-8808-732ffd0f7ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_695e9f2f-a5f2-40be-86b3-d39e6003df8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6e4f7d5d-d2cc-428e-a72f-e553eb406c72" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_695e9f2f-a5f2-40be-86b3-d39e6003df8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition_4a0e8d70-5b1b-48f4-81be-630ea1034013" xlink:href="lly-20210331.xsd#lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6e4f7d5d-d2cc-428e-a72f-e553eb406c72" xlink:to="loc_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition_4a0e8d70-5b1b-48f4-81be-630ea1034013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_b2bee072-d21c-449c-a1a9-bbd427b3ff31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6e4f7d5d-d2cc-428e-a72f-e553eb406c72" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_b2bee072-d21c-449c-a1a9-bbd427b3ff31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#FinancialInstrumentsRealizedGainsandLossesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_00f45d3f-c564-4590-bc98-f8cef6d80fda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities_47858fc1-9419-4f1f-aa96-c271a6ca5b63" xlink:href="lly-20210331.xsd#lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_00f45d3f-c564-4590-bc98-f8cef6d80fda" xlink:to="loc_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities_47858fc1-9419-4f1f-aa96-c271a6ca5b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain_ef34c5e3-188f-4077-a7f8-aa6e261d92e2" xlink:href="lly-20210331.xsd#lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_00f45d3f-c564-4590-bc98-f8cef6d80fda" xlink:to="loc_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain_ef34c5e3-188f-4077-a7f8-aa6e261d92e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss_2bd1789c-bcdf-4f61-a8f1-44be06e8478a" xlink:href="lly-20210331.xsd#lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_00f45d3f-c564-4590-bc98-f8cef6d80fda" xlink:to="loc_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss_2bd1789c-bcdf-4f61-a8f1-44be06e8478a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxes" xlink:type="simple" xlink:href="lly-20210331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_366ea26b-f55e-4082-bea0-dcc774a2da5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_9f520125-1e4c-495f-87b3-421243e8c170" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_366ea26b-f55e-4082-bea0-dcc774a2da5e" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_9f520125-1e4c-495f-87b3-421243e8c170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d6e54df4-e44a-485f-b611-e8c362f3dac2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1031d54e-cef4-4da4-9402-6234122d055a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d6e54df4-e44a-485f-b611-e8c362f3dac2" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1031d54e-cef4-4da4-9402-6234122d055a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefits" xlink:type="simple" xlink:href="lly-20210331.xsd#RetirementBenefits"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RetirementBenefits" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_739cccfb-916d-4fcc-9c3a-cb3d3d888aa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_6338d879-4837-4bef-ae63-3840c3bd1cad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_739cccfb-916d-4fcc-9c3a-cb3d3d888aa3" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_6338d879-4837-4bef-ae63-3840c3bd1cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsTables" xlink:type="simple" xlink:href="lly-20210331.xsd#RetirementBenefitsTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_b6eb7995-f420-4508-a140-abd14ff59a46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_6227b656-e77f-4594-a533-f409efe95b94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_b6eb7995-f420-4508-a140-abd14ff59a46" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_6227b656-e77f-4594-a533-f409efe95b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_db6c3467-7d36-4a66-bf35-fee56a4b1e19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_d514aff9-3811-4ff4-853f-01bf17752bd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_db6c3467-7d36-4a66-bf35-fee56a4b1e19" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_d514aff9-3811-4ff4-853f-01bf17752bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_592468eb-fff3-4fd6-bdca-65eb76307c28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_d514aff9-3811-4ff4-853f-01bf17752bd0" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_592468eb-fff3-4fd6-bdca-65eb76307c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_478a992f-d488-4ba2-8308-c0657f651b04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_592468eb-fff3-4fd6-bdca-65eb76307c28" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_478a992f-d488-4ba2-8308-c0657f651b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_a91ee94d-2b73-4bef-9520-231144f155a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_478a992f-d488-4ba2-8308-c0657f651b04" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_a91ee94d-2b73-4bef-9520-231144f155a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_8804a6fb-b015-40b4-89b4-b48107476e0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_478a992f-d488-4ba2-8308-c0657f651b04" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_8804a6fb-b015-40b4-89b4-b48107476e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1dab591e-fb3b-4188-a3a0-15d75d41ca08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_d514aff9-3811-4ff4-853f-01bf17752bd0" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1dab591e-fb3b-4188-a3a0-15d75d41ca08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_1b9aa6cb-92cd-4120-bb59-59a63460e8c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1dab591e-fb3b-4188-a3a0-15d75d41ca08" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_1b9aa6cb-92cd-4120-bb59-59a63460e8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_60d5477a-c0b1-4373-8961-b9ef3bdd8e0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1dab591e-fb3b-4188-a3a0-15d75d41ca08" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_60d5477a-c0b1-4373-8961-b9ef3bdd8e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_f2f86b67-b0da-4d18-9efc-f2e4ffb47b0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1dab591e-fb3b-4188-a3a0-15d75d41ca08" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_f2f86b67-b0da-4d18-9efc-f2e4ffb47b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_8594142d-9346-467b-aafc-7207526db8fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1dab591e-fb3b-4188-a3a0-15d75d41ca08" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_8594142d-9346-467b-aafc-7207526db8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_213b7f76-36f9-406f-9c15-6cc0901ffc41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1dab591e-fb3b-4188-a3a0-15d75d41ca08" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_213b7f76-36f9-406f-9c15-6cc0901ffc41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_cd3531e7-7e7b-4a7c-a6ef-03dc14099710" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1dab591e-fb3b-4188-a3a0-15d75d41ca08" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_cd3531e7-7e7b-4a7c-a6ef-03dc14099710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsNarrativeDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#RetirementBenefitsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_aa71f1d7-c133-4724-8d31-f82fc67b639b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionContributions_1bdcd672-9611-487e-aaae-8e9f92ef24c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionContributions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_aa71f1d7-c133-4724-8d31-f82fc67b639b" xlink:to="loc_us-gaap_PensionContributions_1bdcd672-9611-487e-aaae-8e9f92ef24c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PaymentforPensionBenefitsAdditionalDiscretionaryFunding_f199ad10-161d-4029-af44-f9c1c8c12e44" xlink:href="lly-20210331.xsd#lly_PaymentforPensionBenefitsAdditionalDiscretionaryFunding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_aa71f1d7-c133-4724-8d31-f82fc67b639b" xlink:to="loc_lly_PaymentforPensionBenefitsAdditionalDiscretionaryFunding_f199ad10-161d-4029-af44-f9c1c8c12e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear_c885573b-65ba-4875-9608-bf10bef583f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_aa71f1d7-c133-4724-8d31-f82fc67b639b" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear_c885573b-65ba-4875-9608-bf10bef583f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/Contingencies" xlink:type="simple" xlink:href="lly-20210331.xsd#Contingencies"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/Contingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_918305e1-1499-4aaa-9640-fd13a8fd761b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c365256b-9c84-4403-9dce-b2346a27795c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_918305e1-1499-4aaa-9640-fd13a8fd761b" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c365256b-9c84-4403-9dce-b2346a27795c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ContingenciesDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#ContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5ead372b-7bf8-4bf4-aa2a-8abb6b0bf8c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_32801a9b-7f49-4ae8-86e3-43e7a9f683ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5ead372b-7bf8-4bf4-aa2a-8abb6b0bf8c2" xlink:to="loc_us-gaap_LossContingenciesTable_32801a9b-7f49-4ae8-86e3-43e7a9f683ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_504673ca-35d6-404e-80fe-c13c0ee6cb57" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_32801a9b-7f49-4ae8-86e3-43e7a9f683ba" xlink:to="loc_srt_StatementGeographicalAxis_504673ca-35d6-404e-80fe-c13c0ee6cb57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6d542446-be73-4280-a7dc-5dac1cb59f99" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_504673ca-35d6-404e-80fe-c13c0ee6cb57" xlink:to="loc_srt_SegmentGeographicalDomain_6d542446-be73-4280-a7dc-5dac1cb59f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_BR_527888fb-9c02-4905-80ec-020cf82b46ff" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_BR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6d542446-be73-4280-a7dc-5dac1cb59f99" xlink:to="loc_country_BR_527888fb-9c02-4905-80ec-020cf82b46ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_90a72255-ff94-4bab-a089-8f5f61b9e308" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_32801a9b-7f49-4ae8-86e3-43e7a9f683ba" xlink:to="loc_srt_LitigationCaseAxis_90a72255-ff94-4bab-a089-8f5f61b9e308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_eea9a6e5-001d-4c4b-a864-ffc579b9229e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_90a72255-ff94-4bab-a089-8f5f61b9e308" xlink:to="loc_srt_LitigationCaseTypeDomain_eea9a6e5-001d-4c4b-a864-ffc579b9229e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DrReddysLabMember_3f7ac731-3584-424c-b4fb-0f94c851ff82" xlink:href="lly-20210331.xsd#lly_DrReddysLabMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_eea9a6e5-001d-4c4b-a864-ffc579b9229e" xlink:to="loc_lly_DrReddysLabMember_3f7ac731-3584-424c-b4fb-0f94c851ff82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmgalityPatentLitigationMember_22190af3-20e2-4d5e-9bbc-017e675c4c64" xlink:href="lly-20210331.xsd#lly_EmgalityPatentLitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_eea9a6e5-001d-4c4b-a864-ffc579b9229e" xlink:to="loc_lly_EmgalityPatentLitigationMember_22190af3-20e2-4d5e-9bbc-017e675c4c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember_23658d9b-a486-4381-a341-38eb6bfc4c89" xlink:href="lly-20210331.xsd#lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_eea9a6e5-001d-4c4b-a864-ffc579b9229e" xlink:to="loc_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember_23658d9b-a486-4381-a341-38eb6bfc4c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_WhyteEtAlVEliLillyEtAlMember_1941f3f7-bc8b-4d47-895e-cce57026be54" xlink:href="lly-20210331.xsd#lly_WhyteEtAlVEliLillyEtAlMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_eea9a6e5-001d-4c4b-a864-ffc579b9229e" xlink:to="loc_lly_WhyteEtAlVEliLillyEtAlMember_1941f3f7-bc8b-4d47-895e-cce57026be54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_WeilerVTakedaCanadaIncEtAlMember_f1cf096f-addd-4b21-8f5b-681abc31cb7c" xlink:href="lly-20210331.xsd#lly_WeilerVTakedaCanadaIncEtAlMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_eea9a6e5-001d-4c4b-a864-ffc579b9229e" xlink:to="loc_lly_WeilerVTakedaCanadaIncEtAlMember_f1cf096f-addd-4b21-8f5b-681abc31cb7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EppVTakedaCanadaIncEtAlMember_9dac1693-b208-4d60-9dfc-75d7afe7725b" xlink:href="lly-20210331.xsd#lly_EppVTakedaCanadaIncEtAlMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_eea9a6e5-001d-4c4b-a864-ffc579b9229e" xlink:to="loc_lly_EppVTakedaCanadaIncEtAlMember_9dac1693-b208-4d60-9dfc-75d7afe7725b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmployeeLitigationMember_51a3b154-0b64-4b63-a94c-80361cf23af9" xlink:href="lly-20210331.xsd#lly_EmployeeLitigationMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_eea9a6e5-001d-4c4b-a864-ffc579b9229e" xlink:to="loc_lly_EmployeeLitigationMember_51a3b154-0b64-4b63-a94c-80361cf23af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a97e5bcd-6f53-4aa6-8686-cb09e1b3c132" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_32801a9b-7f49-4ae8-86e3-43e7a9f683ba" xlink:to="loc_srt_ProductOrServiceAxis_a97e5bcd-6f53-4aa6-8686-cb09e1b3c132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_78e90a10-87bf-4bb7-a994-31a1a1a047ca" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a97e5bcd-6f53-4aa6-8686-cb09e1b3c132" xlink:to="loc_srt_ProductsAndServicesDomain_78e90a10-87bf-4bb7-a994-31a1a1a047ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ActosMember_f905f210-7d52-4085-accd-975cad08a771" xlink:href="lly-20210331.xsd#lly_ActosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_78e90a10-87bf-4bb7-a994-31a1a1a047ca" xlink:to="loc_lly_ActosMember_f905f210-7d52-4085-accd-975cad08a771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ByettaMember_14ad7ce6-4eef-43cd-94a0-5a40e82254cb" xlink:href="lly-20210331.xsd#lly_ByettaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_78e90a10-87bf-4bb7-a994-31a1a1a047ca" xlink:to="loc_lly_ByettaMember_14ad7ce6-4eef-43cd-94a0-5a40e82254cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CialisMember_c93734f3-b7f7-4743-aa14-29b4ebcd6f0f" xlink:href="lly-20210331.xsd#lly_CialisMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_78e90a10-87bf-4bb7-a994-31a1a1a047ca" xlink:to="loc_lly_CialisMember_c93734f3-b7f7-4743-aa14-29b4ebcd6f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_7db32335-45b0-43e1-b1e7-ee0986318e3b" xlink:href="lly-20210331.xsd#lly_JardianceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_78e90a10-87bf-4bb7-a994-31a1a1a047ca" xlink:to="loc_lly_JardianceMember_7db32335-45b0-43e1-b1e7-ee0986318e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumalogHumulinAndForteoMember_09de4c8d-50c6-475a-a838-a82e67c91134" xlink:href="lly-20210331.xsd#lly_HumalogHumulinAndForteoMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_78e90a10-87bf-4bb7-a994-31a1a1a047ca" xlink:to="loc_lly_HumalogHumulinAndForteoMember_09de4c8d-50c6-475a-a838-a82e67c91134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DomicileOfLitigationAxis_69052e37-5c07-47b8-b457-a2d3f9c6cc20" xlink:href="lly-20210331.xsd#lly_DomicileOfLitigationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_32801a9b-7f49-4ae8-86e3-43e7a9f683ba" xlink:to="loc_lly_DomicileOfLitigationAxis_69052e37-5c07-47b8-b457-a2d3f9c6cc20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DomicileOfLitigationDomain_305eba41-58c9-43de-b751-a940cf83abd7" xlink:href="lly-20210331.xsd#lly_DomicileOfLitigationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DomicileOfLitigationAxis_69052e37-5c07-47b8-b457-a2d3f9c6cc20" xlink:to="loc_lly_DomicileOfLitigationDomain_305eba41-58c9-43de-b751-a940cf83abd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LosAngelesMember_07c535c4-8502-48f4-acd3-31f45ff1a138" xlink:href="lly-20210331.xsd#lly_LosAngelesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DomicileOfLitigationDomain_305eba41-58c9-43de-b751-a940cf83abd7" xlink:to="loc_lly_LosAngelesMember_07c535c4-8502-48f4-acd3-31f45ff1a138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SouthernDistrictOfCaliforniaMember_32376e5c-1b3c-437a-8527-cca6ffa15bbf" xlink:href="lly-20210331.xsd#lly_SouthernDistrictOfCaliforniaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DomicileOfLitigationDomain_305eba41-58c9-43de-b751-a940cf83abd7" xlink:to="loc_lly_SouthernDistrictOfCaliforniaMember_32376e5c-1b3c-437a-8527-cca6ffa15bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_VariousStateDomicilesMember_7218acad-e8a5-43df-b36e-1dd8d30ccdff" xlink:href="lly-20210331.xsd#lly_VariousStateDomicilesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DomicileOfLitigationDomain_305eba41-58c9-43de-b751-a940cf83abd7" xlink:to="loc_lly_VariousStateDomicilesMember_7218acad-e8a5-43df-b36e-1dd8d30ccdff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PlaintiffAllegationsAxis_213af3f3-bacc-4528-87c1-f51a6b0f2877" xlink:href="lly-20210331.xsd#lly_PlaintiffAllegationsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_32801a9b-7f49-4ae8-86e3-43e7a9f683ba" xlink:to="loc_lly_PlaintiffAllegationsAxis_213af3f3-bacc-4528-87c1-f51a6b0f2877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PlaintiffAllegationsDomain_e04e1079-7014-4f02-8908-873ea2f652c9" xlink:href="lly-20210331.xsd#lly_PlaintiffAllegationsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_PlaintiffAllegationsAxis_213af3f3-bacc-4528-87c1-f51a6b0f2877" xlink:to="loc_lly_PlaintiffAllegationsDomain_e04e1079-7014-4f02-8908-873ea2f652c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PancreaticCancerOrThyroidCancerMember_d7bf04a2-1b19-4a32-a89d-2fd3ee588867" xlink:href="lly-20210331.xsd#lly_PancreaticCancerOrThyroidCancerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_PlaintiffAllegationsDomain_e04e1079-7014-4f02-8908-873ea2f652c9" xlink:to="loc_lly_PancreaticCancerOrThyroidCancerMember_d7bf04a2-1b19-4a32-a89d-2fd3ee588867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PancreatitisMember_2719cedb-8cb1-45c5-87bb-55ac585976f1" xlink:href="lly-20210331.xsd#lly_PancreatitisMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_PlaintiffAllegationsDomain_e04e1079-7014-4f02-8908-873ea2f652c9" xlink:to="loc_lly_PancreatitisMember_2719cedb-8cb1-45c5-87bb-55ac585976f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AmpullaryCancerMember_a58e0560-66ea-4d52-9955-ac27aeeb3336" xlink:href="lly-20210331.xsd#lly_AmpullaryCancerMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_PlaintiffAllegationsDomain_e04e1079-7014-4f02-8908-873ea2f652c9" xlink:to="loc_lly_AmpullaryCancerMember_a58e0560-66ea-4d52-9955-ac27aeeb3336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6b2ca16d-f79e-4f24-962c-a8c48ee9957f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_32801a9b-7f49-4ae8-86e3-43e7a9f683ba" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6b2ca16d-f79e-4f24-962c-a8c48ee9957f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_7763ad7f-2a12-46b4-99b2-4344935466a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6b2ca16d-f79e-4f24-962c-a8c48ee9957f" xlink:to="loc_us-gaap_LossContingencyNatureDomain_7763ad7f-2a12-46b4-99b2-4344935466a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProductLiabilityMember_3a3d5f91-4d14-4231-aeb5-9bb075daf08b" xlink:href="lly-20210331.xsd#lly_ProductLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_7763ad7f-2a12-46b4-99b2-4344935466a0" xlink:to="loc_lly_ProductLiabilityMember_3a3d5f91-4d14-4231-aeb5-9bb075daf08b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember_6cee22dc-ad47-4e07-bfac-03131b58fc66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnfavorableRegulatoryActionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_7763ad7f-2a12-46b4-99b2-4344935466a0" xlink:to="loc_us-gaap_UnfavorableRegulatoryActionMember_6cee22dc-ad47-4e07-bfac-03131b58fc66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_1c690e1e-d660-4b29-a761-7057c7c7d980" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_32801a9b-7f49-4ae8-86e3-43e7a9f683ba" xlink:to="loc_us-gaap_LossContingenciesLineItems_1c690e1e-d660-4b29-a761-7057c7c7d980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm_38dd3512-3aeb-40c5-b74e-9024878db664" xlink:href="lly-20210331.xsd#lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1c690e1e-d660-4b29-a761-7057c7c7d980" xlink:to="loc_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm_38dd3512-3aeb-40c5-b74e-9024878db664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfPatents_913fe99d-a65f-46e4-b948-f635b36d35d4" xlink:href="lly-20210331.xsd#lly_LossContingencyNumberOfPatents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1c690e1e-d660-4b29-a761-7057c7c7d980" xlink:to="loc_lly_LossContingencyNumberOfPatents_913fe99d-a65f-46e4-b948-f635b36d35d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfPatentsClaimsDismissed_177b45b3-1633-46db-9108-15f5648c6a44" xlink:href="lly-20210331.xsd#lly_LossContingencyNumberOfPatentsClaimsDismissed"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1c690e1e-d660-4b29-a761-7057c7c7d980" xlink:to="loc_lly_LossContingencyNumberOfPatentsClaimsDismissed_177b45b3-1633-46db-9108-15f5648c6a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfPatentsRuledUnpatentable_a11815d7-51f4-4d13-9cae-1f1fedc54d75" xlink:href="lly-20210331.xsd#lly_LossContingencyNumberOfPatentsRuledUnpatentable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1c690e1e-d660-4b29-a761-7057c7c7d980" xlink:to="loc_lly_LossContingencyNumberOfPatentsRuledUnpatentable_a11815d7-51f4-4d13-9cae-1f1fedc54d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_59857b25-100e-4442-827b-79dfe1dbc59f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1c690e1e-d660-4b29-a761-7057c7c7d980" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_59857b25-100e-4442-827b-79dfe1dbc59f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_2ea176b6-f116-4418-8f13-06c66b315a07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1c690e1e-d660-4b29-a761-7057c7c7d980" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_2ea176b6-f116-4418-8f13-06c66b315a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfClaimants_6400ac1c-6b68-419d-8138-4922277b69da" xlink:href="lly-20210331.xsd#lly_LossContingencyNumberOfClaimants"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1c690e1e-d660-4b29-a761-7057c7c7d980" xlink:to="loc_lly_LossContingencyNumberOfClaimants_6400ac1c-6b68-419d-8138-4922277b69da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup_f5ce0bcf-3451-411c-bd45-343a27b925b9" xlink:href="lly-20210331.xsd#lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1c690e1e-d660-4b29-a761-7057c7c7d980" xlink:to="loc_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup_f5ce0bcf-3451-411c-bd45-343a27b925b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_fce23ba8-cd65-4fb4-b1b6-48b4a7720af4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1c690e1e-d660-4b29-a761-7057c7c7d980" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_fce23ba8-cd65-4fb4-b1b6-48b4a7720af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfRequestsForInformation_531a286a-d31b-4607-8e89-bf210960d65c" xlink:href="lly-20210331.xsd#lly_LossContingencyNumberOfRequestsForInformation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1c690e1e-d660-4b29-a761-7057c7c7d980" xlink:to="loc_lly_LossContingencyNumberOfRequestsForInformation_531a286a-d31b-4607-8e89-bf210960d65c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLoss" xlink:type="simple" xlink:href="lly-20210331.xsd#OtherComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7205429a-7c74-4fbf-89a8-aa385f3c00e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_50ab3518-39ad-4b5b-8c5f-c65646d3a6c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7205429a-7c74-4fbf-89a8-aa385f3c00e1" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_50ab3518-39ad-4b5b-8c5f-c65646d3a6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="lly-20210331.xsd#OtherComprehensiveIncomeLossTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_25fea77e-14a2-4476-97b7-5366a9b9fa1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_3c83c381-ba18-401a-9d40-1e9c242dce95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_25fea77e-14a2-4476-97b7-5366a9b9fa1e" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_3c83c381-ba18-401a-9d40-1e9c242dce95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_9bf9d82d-fa22-4c90-9e07-5df883f50dc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_25fea77e-14a2-4476-97b7-5366a9b9fa1e" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_9bf9d82d-fa22-4c90-9e07-5df883f50dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#OtherComprehensiveIncomeLossAOCIDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_aff014e5-4d94-4ea1-abd1-50d2d8cd9dc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c3b4d31c-fbf7-4c7a-8a56-7b22ae189416" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_aff014e5-4d94-4ea1-abd1-50d2d8cd9dc5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c3b4d31c-fbf7-4c7a-8a56-7b22ae189416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fba13d9b-fd68-4bc3-9960-f905a5f1b3df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c3b4d31c-fbf7-4c7a-8a56-7b22ae189416" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fba13d9b-fd68-4bc3-9960-f905a5f1b3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f9f86046-f80c-4218-91ac-42c4db742087" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fba13d9b-fd68-4bc3-9960-f905a5f1b3df" xlink:to="loc_us-gaap_EquityComponentDomain_f9f86046-f80c-4218-91ac-42c4db742087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_73f5a2b9-3627-4795-aecb-115b0f76fa78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f9f86046-f80c-4218-91ac-42c4db742087" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_73f5a2b9-3627-4795-aecb-115b0f76fa78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_f8585906-e79e-4c83-be4e-d21f96661921" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_73f5a2b9-3627-4795-aecb-115b0f76fa78" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_f8585906-e79e-4c83-be4e-d21f96661921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_9070b67d-d95d-42f2-ac0a-55a3b7c5510d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_73f5a2b9-3627-4795-aecb-115b0f76fa78" xlink:to="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_9070b67d-d95d-42f2-ac0a-55a3b7c5510d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_008c0fc2-fb57-47d9-ab42-62352dd489cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_73f5a2b9-3627-4795-aecb-115b0f76fa78" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_008c0fc2-fb57-47d9-ab42-62352dd489cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_9ecd6ff4-c79f-43f1-976c-d5abcd09ed25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_73f5a2b9-3627-4795-aecb-115b0f76fa78" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_9ecd6ff4-c79f-43f1-976c-d5abcd09ed25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_08c75747-b4d3-427f-855d-e4101af34c5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c3b4d31c-fbf7-4c7a-8a56-7b22ae189416" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_08c75747-b4d3-427f-855d-e4101af34c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_03d31278-524c-486b-8ce6-d1552472491a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_08c75747-b4d3-427f-855d-e4101af34c5f" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_03d31278-524c-486b-8ce6-d1552472491a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_25052755-b188-46e4-9514-219182165982" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_03d31278-524c-486b-8ce6-d1552472491a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_25052755-b188-46e4-9514-219182165982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_2a5ce90a-ca77-424d-90d8-89f10ec4d8f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_03d31278-524c-486b-8ce6-d1552472491a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_2a5ce90a-ca77-424d-90d8-89f10ec4d8f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_ea10d205-0c88-4c99-88a7-63faac6da2bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_03d31278-524c-486b-8ce6-d1552472491a" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_ea10d205-0c88-4c99-88a7-63faac6da2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d2c830f7-44cd-47e8-a7a6-26e411c32b80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_03d31278-524c-486b-8ce6-d1552472491a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d2c830f7-44cd-47e8-a7a6-26e411c32b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a24c9a78-ef97-4362-a108-927d2b8b1cc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_03d31278-524c-486b-8ce6-d1552472491a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a24c9a78-ef97-4362-a108-927d2b8b1cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#OtherComprehensiveIncomeLossTaxEffectDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_29aa8d21-1e92-40d5-9663-dd74e2753bf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_76f32386-7c71-4555-b9eb-03fbe825c6e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_29aa8d21-1e92-40d5-9663-dd74e2753bf0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_76f32386-7c71-4555-b9eb-03fbe825c6e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_aff16e8c-d1c4-47db-b86c-9a15b6cf5ce0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_76f32386-7c71-4555-b9eb-03fbe825c6e9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_aff16e8c-d1c4-47db-b86c-9a15b6cf5ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_83a56c8f-8df1-43cd-b15a-b2df1de09b2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_aff16e8c-d1c4-47db-b86c-9a15b6cf5ce0" xlink:to="loc_us-gaap_EquityComponentDomain_83a56c8f-8df1-43cd-b15a-b2df1de09b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_ac593ded-b7c8-4349-8fc3-b2de5c155498" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_83a56c8f-8df1-43cd-b15a-b2df1de09b2e" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_ac593ded-b7c8-4349-8fc3-b2de5c155498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_b849982d-bbd7-4cec-b18d-65678f85a313" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_83a56c8f-8df1-43cd-b15a-b2df1de09b2e" xlink:to="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_b849982d-bbd7-4cec-b18d-65678f85a313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_9fb76a3f-967d-4378-9305-e9ccb997f884" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_83a56c8f-8df1-43cd-b15a-b2df1de09b2e" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_9fb76a3f-967d-4378-9305-e9ccb997f884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_23f102ad-7df1-4d9b-b613-899fdc5c2aa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_83a56c8f-8df1-43cd-b15a-b2df1de09b2e" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_23f102ad-7df1-4d9b-b613-899fdc5c2aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_10a420f0-ce6c-4316-8f9c-ed1b43eb58a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_76f32386-7c71-4555-b9eb-03fbe825c6e9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_10a420f0-ce6c-4316-8f9c-ed1b43eb58a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_4f229a7c-a65e-4224-95bd-a97100f1a5e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_10a420f0-ce6c-4316-8f9c-ed1b43eb58a4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_4f229a7c-a65e-4224-95bd-a97100f1a5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#OtherComprehensiveIncomeLossReclassificationDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a8ac225a-b942-40c5-9b0a-7ce4ee451d55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_64390716-4879-4936-bceb-89067c1dcff0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a8ac225a-b942-40c5-9b0a-7ce4ee451d55" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_64390716-4879-4936-bceb-89067c1dcff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b17d9bc9-63bb-4497-afdd-8cb21da5517b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_64390716-4879-4936-bceb-89067c1dcff0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b17d9bc9-63bb-4497-afdd-8cb21da5517b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8ffd8d6f-f291-43fe-af82-8e6b2a6a63f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b17d9bc9-63bb-4497-afdd-8cb21da5517b" xlink:to="loc_us-gaap_EquityComponentDomain_8ffd8d6f-f291-43fe-af82-8e6b2a6a63f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_6499782e-9935-45c7-8bc4-8d362634abb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8ffd8d6f-f291-43fe-af82-8e6b2a6a63f0" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_6499782e-9935-45c7-8bc4-8d362634abb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember_fbe90100-2c31-41d7-9542-fe98d8747f1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_6499782e-9935-45c7-8bc4-8d362634abb5" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember_fbe90100-2c31-41d7-9542-fe98d8747f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_a9ae762a-8e00-48de-a6fd-e148db0e0915" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_6499782e-9935-45c7-8bc4-8d362634abb5" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_a9ae762a-8e00-48de-a6fd-e148db0e0915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_f818948d-4393-41d5-a56f-401fb7aa5261" xlink:href="lly-20210331.xsd#lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8ffd8d6f-f291-43fe-af82-8e6b2a6a63f0" xlink:to="loc_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_f818948d-4393-41d5-a56f-401fb7aa5261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_990ef70f-b05f-41cc-900d-2c3ab6476d7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_64390716-4879-4936-bceb-89067c1dcff0" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_990ef70f-b05f-41cc-900d-2c3ab6476d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_0e363c4b-b945-4132-8138-962adc6a205c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_990ef70f-b05f-41cc-900d-2c3ab6476d7b" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_0e363c4b-b945-4132-8138-962adc6a205c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_6e1e7394-6568-4cc8-9d6a-e97d39cb3523" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_0e363c4b-b945-4132-8138-962adc6a205c" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_6e1e7394-6568-4cc8-9d6a-e97d39cb3523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_6fefcdb2-f731-4b8a-a6fa-dc917897776c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_64390716-4879-4936-bceb-89067c1dcff0" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_6fefcdb2-f731-4b8a-a6fa-dc917897776c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_fec53d9a-126b-4720-913e-ceff713c1387" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_6fefcdb2-f731-4b8a-a6fa-dc917897776c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_fec53d9a-126b-4720-913e-ceff713c1387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d82703a0-4b93-4e22-9fb2-a20fefa155f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_6fefcdb2-f731-4b8a-a6fa-dc917897776c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d82703a0-4b93-4e22-9fb2-a20fefa155f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f36dda22-3dba-480c-a689-53e176ecf261" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_6fefcdb2-f731-4b8a-a6fa-dc917897776c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f36dda22-3dba-480c-a689-53e176ecf261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e6143cf2-bb72-41dd-a185-31047c6ff952" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_6fefcdb2-f731-4b8a-a6fa-dc917897776c" xlink:to="loc_us-gaap_ProfitLoss_e6143cf2-bb72-41dd-a185-31047c6ff952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherNetIncomeExpense" xlink:type="simple" xlink:href="lly-20210331.xsd#OtherNetIncomeExpense"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherNetIncomeExpense" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d80bb2da-ba9d-49b5-8c7d-4ba68e0ab254" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_b8ea59a5-c878-4454-bdd4-a1b1aef20dcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d80bb2da-ba9d-49b5-8c7d-4ba68e0ab254" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_b8ea59a5-c878-4454-bdd4-a1b1aef20dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherNetIncomeExpenseTables" xlink:type="simple" xlink:href="lly-20210331.xsd#OtherNetIncomeExpenseTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherNetIncomeExpenseTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_edb7f961-cbb2-40f6-b364-c1b372fc33e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_bb666067-9f06-471a-a0a6-2473616184e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_edb7f961-cbb2-40f6-b364-c1b372fc33e4" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_bb666067-9f06-471a-a0a6-2473616184e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherNetIncomeExpenseDetails" xlink:type="simple" xlink:href="lly-20210331.xsd#OtherNetIncomeExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherNetIncomeExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_117037f6-49bc-475c-b390-802c440f8ada" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_bf13f451-7f42-4b12-b63b-6ddcfba8ef5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_117037f6-49bc-475c-b390-802c440f8ada" xlink:to="loc_us-gaap_InterestExpense_bf13f451-7f42-4b12-b63b-6ddcfba8ef5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_b8dc39d2-e541-403f-bf01-84cf1a5b0e01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_117037f6-49bc-475c-b390-802c440f8ada" xlink:to="loc_us-gaap_InvestmentIncomeInterest_b8dc39d2-e541-403f-bf01-84cf1a5b0e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_78640638-fd2f-4062-b8a5-2307b7e955d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_117037f6-49bc-475c-b390-802c440f8ada" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_78640638-fd2f-4062-b8a5-2307b7e955d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_d1d6edd6-32ff-405f-a676-5afb10b3eba1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_117037f6-49bc-475c-b390-802c440f8ada" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_d1d6edd6-32ff-405f-a676-5afb10b3eba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a238186d-c61b-489c-a770-c343737a6fd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_117037f6-49bc-475c-b390-802c440f8ada" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a238186d-c61b-489c-a770-c343737a6fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_a287dcf7-7729-42b3-935d-0252f6d80972" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_117037f6-49bc-475c-b390-802c440f8ada" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_a287dcf7-7729-42b3-935d-0252f6d80972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>lly-20210331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:lly="http://www.lilly.com/20210331"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lly-20210331.xsd" xlink:type="simple"/>
    <context id="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib6bc00b2d2b24b739475df069c617a03_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic3e378dfd41341fb9e60b25e358c23ef_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.000NotesDueJune22022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i44103ce383994d74a3ab84ed4f5b4a46_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A718NotesDueJune12025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i086dc0b8a28b43438b0ec2d949452e3e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.625NotesDueJune22026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1ffb83ec38e84898b6c89250d5c39070_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A2.125NotesDueJune32030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if8ceb4ed9fcd4e6e8a65b6d5a85314e7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A625Notesdue2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i996950b9da7c4950a18ada582b1fc257_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A6.77NotesDueJanuary12036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if8debecbe586414a933f775ea52cd38e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.700Notesdue2049Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8777fbeb1d88449d8d60f606fd5c2c77_I20210427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2021-04-27</instant>
        </period>
    </context>
    <context id="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie5f8381a63d1432f9f9dae6e35adb977_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic0cb0d0f80df4940b8645cfac86c2594_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5bce3a2756434f739e7c3845a02a47cf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3ffc5bab7133436682aff62ddec1e376_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i957ad33ccc1240e3948e9f141963844f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7f3109e398cb4ebe87fb955a863b8ede_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i46e5e55c87bf4c9285d8bfe7ce6fd6d3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i932abea342a94c46a25f33f1c8acc500_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifdecec535fa14d78b9ef123144efa368_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic7db1dc190e2453aba10749ea47cfdb0_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2eee151cb0194a7c9d3cdf6eaece9015_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ibcf85b46974c4de78d45cca588cdb257_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4f89a4953ed54302a07fe2fd0dc4e36b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i610527f799c444f999e77fc61f00e502_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i86f7f5436d51421a8501779a09dd82ab_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id525ea543ffc4ac699696ae6133c1a3f_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ie25f9462d4864ec48a45f240362e710e_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i3e1e492a833a4874b74b3fb0b7f96fa5_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id163dac405614d4ab0aab11d9539c9a8_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ife78f2b5881b4ab594c089c77d07dfdd_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i4a5e6fba402d49eda6d65097c72bd64e_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i1a2504bfe86b4fe3905a4c1dd6e8a31a_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ib44d59353e664823911abf62eca2a0ec_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icc56172f5f014bb48f88ac5499c1c0c8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i60d84be3db5c4d85abc4b594cd075e4e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idcdf0da7a8b34a378831b2abf856ab11_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0582a765e6944e928d84c3bf2f09767c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaaf707b56bb5401397f3d1be8be7a6da_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia85d98868ecb4c1d9f33581b32035094_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i002f042f1d494e298177c727853e4883_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie0d38013f7a5421cab5b95d3ca766cc6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie6e502d3f77649d3b4966205297947db_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5aa2dbcea11b45b1bc31588610d72e1a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if2c1d39a9337457d82ae76c6cc3e027a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic2d8de6d89ca4b36831a2fad2f21e997_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i717123173f4f4d45a26fc171fcef135f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i19ffbb6496914f979518c442d56ddfdc_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia95ec94014ed412d9ddf912309b31906_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i336e60271cdd431887ad40e2953cb881_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iaf8fa9dfe55240c8904822bb89d5d580_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia54f7cb622be43a6a63855f304e93c8a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9b0151dc1fa445c680975efcbdc26506_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ice5b008047fc4f969d378bc0e8f5337b_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="iea0fcbeedbfb4018b173fba695dd9fc7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9dd152b8ae7b497f800f65a679736686_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i1b961987b212484fba2e55e3f8599292_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i00e2ad623e9f4f09a525954c7be34a38_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib696b72b79fd4a64a05a14552524fd57_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia9bcfbde64cf4e6885eff068fd1c0181_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i3a64fdc1a7fc44278f9cf486b1d6c7cf_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i38bd7b2a836c4d14abc0e95512ba56c5_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i0b2a402409bd47ceb3efc76f535f0984_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iec6120b958de4ece8b0bb1b2c92eb827_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i14a1f7c9c8094a24b89b05adbfa13722_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1da1bf79aee54038ab5fb824f0b5459c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7879b1c8e8154d82951f06d7277606ca_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib22403656ba044288e3a7c9bd076149a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie60de7ffff384040bda8a7073de65757_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i35e2453e887841ba845624286f429037_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iac9fe39efa6e493c8fc3b5a5cb61875a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i12fc66e4003b4a108dafd95f3f948eae_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iaf36848406364477a5b09c68263549c0_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i0cec2d3e8980474dba0ccd4ba2f4be53_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i7ac183bd15654d9ea8bfb79ecfdabc21_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5d5411d889ea4b0c92badda1ff003164_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i80b19d05555b462299ff41542279ba37_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib8ce72672e984dc38dbee5c4872a819f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4bd74f7f91ca4076b9bc23d4ac7407c8_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie6cacb66e50b43a29e19d4cc6a18b475_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i82b9a6cc26eb4896a200c5b2d5ee6aa5_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i23a99b86356248b7a363e089040850b1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1c94039dc776423e982d5e1215b9f0e7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if95072ac7b3c4004b82c2aac605e5d70_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i57d3bc0a03b5400f848a8a445a06af73_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5c9abc35851840cd80b9598eb84e59be_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i65808f9c08a34e2fbb20de15f09d6663_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i68c425bf807b4ecfb4bfc4e63113b9a5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i991e0184719242bb9681a766c00e183e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6308d09ed16f45708083f216e5eb9053_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9ad3a54cc6da48c7aabdfbd4ce0fd7d8_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i97e8d103205d4d8a8ddce47720e2b0df_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9b572a7d820847f2b77197f14a7598e9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i37a9f92fe3be4a59bd100214c32741d5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iab3763aca7de40e3bd3755d4afdf8ddd_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i08fa42e2b3004f2c8d8c3d2949a77b62_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if05b79fd4afb4b3b85e0170d60701765_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i53e1ac90f1794867bdc0e1208a22454d_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie5488586d175451ea3762d3e3427d7fb_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6655e736bfc145ae9b61bcbd43ca3775_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i95a511f3e56540efaf67326c58f115f8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3a8600a4d0ae48ac8eb847f76d72fb39_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5d683e3edb3b47769c30eadb5fc443db_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia92a87d280ea46c88caa7e96c7a0c2c6_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i3dc1168de1ac4bd892f4336105fe8d34_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib1eb5c54ee4f4ffd849c70b74454938b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i99351a29767e4c33b139db7c60592e0c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8c035a4a36d1475c87f42c50e4fe5b66_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ica6ff26a8f5c493bb678f8b8bdd2f5d0_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9a84f264bd5f43d18f95d6449dbfd211_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i3ad5e6e9c6b04e0ca3a23762ff4389d4_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia3895e84ece4456f9fd7475f8330b5e2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4bf54072320b4a95bcc03ebf93fd790b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1a64b17a7372474b936176a48e73353e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id1ca44d898d14b6ba06c659cc8685067_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iaec1b41e2f1c429990d5463381ccb5b2_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic305b0216fae4bc4be68a9c14511b14b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ifc30d8c3304846bf98d3aff4faa90db6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i301b5063b45f4c778fa6be355225f1d2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6ac8015a990a47ac84766a6b061f5c80_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ice0f65e55bc14fb4a8b9c74295879c9f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iabd56efbd9ee475196495211900a4916_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib4990ade4fb749c5becfec40f273af6a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="idc1ec2db8e1b4baa971e09c08d4342fd_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i699a1a79461d4373af3cf037c5ca77a1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="icbf8577a767f4b6fa45fbea9fc0008e8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9a65c960be0f46ebaab122d5eb8f5e3c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib410c05551594d84936a917166832ea9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i8d36ff64df614dd2a64ea2e3cb167f9b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="if30239ae11764340af612d6d0acb2802_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i55a39c6d0d9146729c9cbfd483622222_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i10cbac4f340148c58e34434fbbf2a27f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5a346e0ad24144caac752ea7f4355d34_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i37c6a808e0e24c1f8e75607e3a823271_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia3156015f19b4add93eceadb6f839944_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i16d7bf43c3214967ae1523ebc568940c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1a1925d8bba04bf5a88ae7c5a2c5a30e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i65134b9feaf3468bae4f56eb446cc39b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6b08818da51f405ab315d6a7b99fcdb8_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9f8df345856f4facb882054634c50249_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6b44fc5413ea4394a3af4e9ae8cc9357_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic6c1690f2a1044549cd196b5d0d49bad_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5f2094304a9b41efa6498348dc920bd5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iccb5bb5fcf05439eafdaafbbf45b94dc_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if46aa3d35d9f4f9e9f98c940d7063f27_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i27ef923c97994ad09a5131b38a10eff2_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i22ac5026b0df4c01a41cbb9fd7bf0ed4_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1e7b860d15e24b6d8a4c42caa07a07e9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic9d2acfb73014f21b93868d591ba0055_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic86716e51463478c9178d57dbc0df5e9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1eca7f391c9c4eb4bf1be4d2f78c64f1_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i23a06e4fd12547b68a8c1fa847a573cd_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2cdd8652ee714626a6ac6694e023589f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ibe710610bc2745d6b62b94d3e5a59c49_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib5195f2602fa4de78f56cde487a199e9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id181bab5e80145f7b4aac52329fa68c0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8e4a642cedfe46019dbf6bdbe6fbe49e_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i82c451df337849a9aa0ebbd6efa659e5_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6c5697fd7da74cdbb6d77c6a62017381_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id5d69a9f098946b99fd0dc8d1e98e66a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9d569029e59948f09619b73bf0efdca2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8ec2c9c0bb35428e84cb57a3987f75e0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ida0989eec65245df9b1682cf38ed4bd2_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i3bc0464b0bdb43f5a8e902cdb4b263da_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia8cb347768764c2b955eac4a8f4a17ad_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i98c884b95b7b4a8493c13f83a7b6caa7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5c53c31a3a5c43e680ca9bf03cd18bab_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9f23306ae00143a6a4003c6797529b59_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if6964e815afd40a1a706fd094d27e141_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9ff073cd832f489a918e71ed9f2bc601_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="icaab0628ba61471db8a691d30a7a5ae6_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie6540e5cb4f94023bd8a1a99cae7dd50_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if0244d48c6684b1d90aaffa07334e12c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3a035aacb6aa496e9aacfa82670a5f77_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2126f23f1b6c45da8eda485ea4fb0ffd_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i476ff2f62e6e4dcd89e4d0e6f6e2e23a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="icd995ff940774cf9958d9496ccefdd49_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i91bb5aef62c64ba6b7374026ad6cb167_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibc1a4bfd08874c51bd52ae124d146ed1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1d060a91a83540adba28a86e89f8a0a9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7ead156d8e30415e96ef9f5d2ae30817_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1019c9ffdc464664a457a1558f80f5c1_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1d28979d157949e8beda765ff3ebba18_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i59a5e3ece3b2457d9dc9503670f62a19_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="idcb95436aea141439b320a672d06798b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibbdb540b92834be9a1952a6988efe111_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id5ec8f6c1a2745b6aef8220c52179da0_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ifdac2859144646f497bdee29d8f1077c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6ecf74960c9f4004bfb28db9ceeee105_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ibe3a395375b74608adcd0dcb2511ccb6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4e845118c19743509f235e3de1249c91_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i956b8eaf8bcc48e18a6392d104e3f82f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7f802e7b0b4c462498edd33fe1a08df8_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i41bf8c2f57c2453187f38f71658035fd_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iccd1e7bf99a04464a2be5ae2844e93c3_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i3a96f967a3e14ccfbf1709108752b15a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5e1de888a7434a7d8901d5d91e9a5662_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i805e06baf0334dd2a9272620abb71ef1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7bf6f39de92a477295091f337c5f246d_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i87c3683c282e4dcab93976f033317191_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib781ea03fa4343ea9f43fe30bf85eaff_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib9004a4576d54acdab802ba18e5954b5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5b813d4b7f6a4ba8ab05eb62fa8c0d7e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1e2d53c2e70b4fa7b373f89ff566d337_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie6e00607e2514771bb461112b624c3c8_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i678860fa552c43d4b4fcb6cefb64112a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i009fa3f9194b481097ec59ef54e9398c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic91d06961c624604bf888bc77f143328_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1a70d046e3e04fe8814a35c37222c987_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5a1a9bda61764661a686cd2e6cdf4353_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2f37eacef6da488b9411e64b1e6f9bf8_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i46371b039efc4855ab60d1a0cfdee9ef_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iae0c3902df5443afaa207966c3c336ae_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i01ed93e108f540d895209d6cd63a4196_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i02826dfbba6c48f19cdc43d704001dbe_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0da8ce69328d41578d3e52a25ef5c637_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="icf3afa843ed74fd3a1dccd7d9a340f73_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="icdbb2ee92d984ead82d0bfe89b0b7e67_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5b635789ef4a4a3ea608c5ece8aad1d5_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia0503e2189e0437c94e4365e2f5e1a42_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if7a3d52cbc5f4c36913820afde8b5ce0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i29a85ee0346840baa3213980b51c8392_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i48278fe6c84a480c993daadca8e14bec_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id2da738de9a9496d82ebcd1ed1dfc349_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i72d5f436073e4013afbbcd703dec4745_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i3f47b5c8b6e647f7a98ae58501327a48_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7ba01d74fb2f4bc0a8c1b64e3b1eef96_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i91fdfa6c20d94c5db431e71629735e62_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3bdeb0b05ca8485aae2687a910e899e8_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ibf27f4b868ff4ca6852de83fc00626db_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i725c25318b374568a7f6a1c522f751f5_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iddbce9adb77b4313a6ec25296cfc82c6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic8f05f60f5234be3b895a985508995c8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i35174116703c48a1ba3d71d19b34d188_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iecc41b1e93894363b921a691b8c9ad5f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1a8c46f072984025becf4f91f04a0ad4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i53a4c1fd0f0e411bbd983b92368c6662_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia8476fa283c5420a8c1cb44bf1886c3e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8a141f4168094f93bc307eb5ebbf7392_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iaf7492d96a0b4f29b67c7ffc8e4fc10e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2d6aaabb8fc4471fb4d955cbdc949682_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1d1b2d8fe9744bfb992ea8ca03c8de17_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7fb432a8a93945a68250848e46684f98_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia3e93321ddf644359c1906deaf4915d8_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrevailTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="if8e0d422156841d5ad8a9105568a5622_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrevailTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="icbcb632a5c694ec29deb85ebe3a2a2e9_D20200201-20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:DermiraInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="i532d485d20654594a8b1a96d44626d00_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:DermiraInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="i1a359ced678146c9b9d8f9eb94adc1f8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:DermiraInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if0a60d23094d4089a16f414a2eb40222_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrecisionBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="ib490931de5a249db92647a2ab94af9ad_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:MerusNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="ie1c5831cc7174801a03a8b0a2fd91a4b_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:AsahiKaseiPharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="id6460ea51b114fd5952c6937cbc22e89_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:RigelPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if871b5e2a0ea46059a74abfa4e82d02d_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:SitryxTherapeuticsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5c7fcc42f3b34de0bb6bf706fa7541fa_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:AbCelleraBiologicsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i7cfe3973fd10441580375afacb0b0090_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:AbCelleraBiologicsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i787debb10db9449ebf355978b2cac4c9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1d95635b39cc445ebd68b8eaacc4cf49_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8356c279b93c42829023f67b564fd0f1_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7898c22d6db548ba8e625e7b4cb51b1c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie49f3b9fa84949058c66e2ccc6f1bafe_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iecf3e061ab6a44e0b3e95b09ceec5863_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iabb0222b012c480fa8a4b4033fb1c3b4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i50e1340911c44726ba35205e9879816a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i661524a58a1c40ec97906a968e6f6aca_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id9bf6a3d44b2458aabd053d1804a3283_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsCapitalizedAsIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i64aadc652c4343c1bcd2bfc5b72d6158_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3343c905d8554be69ab7b345fa893082_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3ec641d1b0e0486dba0286bc54d9f28f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:JunshiBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsCapitalizedAsIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9cadf4d9d0bd4bf6b1d1bd9d0dc96dee_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:JunshiBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSuccessBasedRegulatoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i44a54fd999064e8484fd5ca2af4dcc17_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:JunshiBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ied018ff88f6646e88340a81a87e88722_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:NonCHINAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:InnoventBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2d761f2cc36e4a03b6ad57e5ab13c540_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:InnoventBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia32a56f35ba84943ac17a6ae53d314e0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TanezumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OutsideUSAndJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i24615d347773426cb44faa02b5f3a282_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TanezumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3b6de8f942f44cf0aced4adc5181105e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TanezumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4ee311292e604c2ba36873038aa0d41a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2e55c79531a045a4849418d1e780b569_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1bd3d506e737426ca9f7d5071e2fe975_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia6017620bc984fc3b23178c68fc11436_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5c39357db5cc4a9cbcfd00adcb81f908_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6fea589edc3e4ab08f9ed7052aad2e59_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if8fd6ec70f034998b9025e47bf69042a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyUsDollarSellEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iacc428f5b7444f79a59f33bd449c5b64_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyEuroSellUsDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i53cacc69bc7f436e8384c8ab4a5a9044_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyUSdollarSellJapaneseYenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i196a382db4dd474f9215758c00592480_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyBritishPoundandSellUSDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i790e81260a954cde9599960f6c59fcd6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iee91d9656eb3472e8cf1ac38a3807882_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifca25d1668f0447a8c0fb8e92c444a46_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:SwapU.S.DollarsToEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="icd062c4f7c644c92a3bd0c5fc8d3cd2c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:SwapSwissFrancsToU.S.DollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i08261dc843c546e282dc7746c9935f3a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i40ae6e16034149ffab19351331c55b6a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5bc95e47cf6e4f3da137f20ede5e2282_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i02b03c88c1f84031a54577f36537d1bb_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5492a540a4eb4396826f07e4a6429720_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2e9ced055f4647d1b7ac5f1b13d3dcdb_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0675cae41ecf4fad80226860b67627c8_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5cc6b325c96343679b6ae5ded2b4017a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1ebf8484d97442a79f3fb0056a0a0636_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i48597227bfbf4037b23b06218e7f576b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i733a2380e7734f87b92e3f8aed9fe6ac_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib4ed115b785a4ad9a93f7287cb139b8e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6d351595dea941808d14c80b2e44c3b3_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie02bf6e1811a43e7a3d115fc98ca56c9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic8a0cc4c13104fccbd1c69dcb601af62_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i0468ac52ec0a40758c116186c956d819_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i259ea4a4728c4829bf5a1d53b88fe316_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i379b7bdd53b04924a6915f7b6f539ae9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i502fd03d8e8b42f384a0637943ac9227_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i110e7dd739b14882b203dd13e31a425d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1b1fc639100545e8b40e4cfd5886def1_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i50db401e52d34c6bbb22d8b87c712ee3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9d9b74593ec94447a6448aee79dc1a4f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i11210e6bf5044a31804dbf8297477c5b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1f4fe1622f184cf9a797fcf2b732d7fe_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3c35346f0f3b44448000e57b1d0d71cf_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8e2ffab98d7f45a0a3b806e73e461745_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iab695d20c84c457e96ce06476d8e182f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2c6474daeefd44828fcb9effa40e0c54_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7e03a9ef9cef4a99bcd45329382a4b01_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib6f572bcda8c4de4b675b9afeb36f32c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5321b80fe49f4dc4a8096c02973ab7ab_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5b5fc37a695a4b88b864b0b0f8a57e93_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i94d22e93a3ad41848489c4810cedd352_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id8aef2fe7df7413a99dc9b367490fdba_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i21ff33225cde42d38dd508e225243ffe_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i094cfa08457b4639b53077e02b7b579b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i39943827be2c4f9ea50a2cdfca84df2b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="idaeb507e6d804976ad515b86786c2663_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="idd103e4954f440de8adec2b901b7d26f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2765888bb9a44e86856eb0e40a7a95a1_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i937ee9f927b84aafaa8fd46c3071e390_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5623a1b5a79348899d40b0b51b54335e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i273c3175cdf54c6d9bd6414b446f3ab2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib521cd4c99774b97881a80a2a1c9c35d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i49b67199341a409fb3c610a89020e4e4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8d997ddd2afa4e4aa435ed61a0039a79_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i162abcddb00540a6b88917d1b8c94bc8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i70666e8c06ae4150b3d53ba8f358e55b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0b8e28324e994e5a9e7af4dd5abbfa4b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9cef5c921b4d4a13aa14e51caae1e54c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i45eb28a2afb843b5a7599d09796ba47a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8c96a7e6ebdb4b5894e42f4f674afc2f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i35a6dbafa15745eabd7e346fc0404f3c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie03e1c230dbe49b5b1a23948beb4fdf8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic4814dc5f3094945b14b09c32634e414_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5428a6a7e77a4afc87dbec371aa0e81b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5b460fcffdff4102b1a5f350e775eb50_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i68b41c9f5b24461e99ffaf90ae7df35e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i07692a7baeb34e989f264a119af0c6a3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6cc36d48d552416e883d9009bfca5133_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id251b7aadbd741c38319af027dda2015_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie57e8b8550a94ed3a3001f7258f40509_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie22efb639d76469d92d9d05b55c13b2e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:EquityMethodAndOtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie5244871105b411bba98a34bdca3bb0f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id7364db11b9f4acc956a7d2db362e700_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icc89d6e873484ce2a724580ab1fb0293_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib227796e6d934483a3898110d9a529dd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic99278c5824b4d0d9f4dabbc783d760a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i173d02bf976949bb9c2fff706b29e7c8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaca67a3e336f480dbf5c62f2d4887602_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2385ee7845f44db9928643d251ba010f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia2a7caef4a994ecfa2504a1f8fab161d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i674d272a65ea4e939a918cbd40640fad_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia5ba42bd6f784aae8d55cfe3e64aaebb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iea8e950975814a17bb0570d6ed036339_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iab6a22cd5a3647489cfa1868842fce27_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id94556bfa50648c6896a229ad967ebdb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5ba9c3716f03494583ac46573df6d898_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if3f1ae733c62431ea7747e533857a063_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8e05c6e58a3e45f9bbc6bfe65eb5fb24_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i15f60e22ff78453692beb5eecfca6ffc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifd7549721eee45bb8a3527258d461fd4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3f9525a450be44ef9048544d4294da74_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i65bf701b377c4beda33939db2d2f21ff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i55aec24c88d44f4fa43277cc7538aab2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i34a3b14dc8874f0c86a0d3eb37f253a0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i853e5949474b4d67b1db52061559bac8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieb0f7206c077458c83a576a665d51173_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieb18caa1f88e42d389a9b17c85b0d9bd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i43215dcd05be459096efcec752179430_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i54c52e457bd4422ca65d6e22cb0ade48_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1389fc9ec68d4b2db27d6a8e3bbd4bf1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib3c4f4f185ab4ad881bcc56455b80c21_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i79853a9b5da14a6fac53703381e9a418_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i33320e06f4274ef9845c5efab8d73bb1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2b2eb8a9c98a498ca9bf40a99de8f49a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib04cc817383740faa1e617ece927631a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id384954fa3fa4e6095584ab30e130a4e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic8955bee463a4261b77faca6da120420_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3e8796c582de405f85453b6be2e3dc09_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if57b6463cf5a4132bbba6db81c527ec0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i65887bb8147d4233b2936ee964d36760_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i45624739b2404896b6fe384552b5797f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i18bd77315f3640e2b75151bd1a403bd6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i095078139e5147baa3f7c5a93913c9f2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i41723e47817543c98de3be1e9ac4e77b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ide25b210128b49279f9dcc009920c562_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2ed173a5c7554ed8a6efa974dce7de56_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8841002a34004d4d894ac4dd47bba8cf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifd5d2cfe7b1c4e6293342168871eb584_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1862e16eb5894cbb872c6ebca5ff8dda_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2a8f781677394edcb970a7db2a230211_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:EquityMethodAndOtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib0320b4ac23843468622fdd30e513355_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id725308cf9eb4e51afe628b2f6dd2bfa_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9df56ec982804883a504fffec19bec2b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i818be88d8b754d358fa8f0f48530989d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie4605596f0c549af8b2aa8ac2b0821f7_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iff50ed7383624a5dabf03016acb58cb4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic22a911ebb564c3e8e5e11aebe36daf2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3791d236011c495c9a6bc09f31e0e651_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1eef9a676fef442f8cc0df6224b88661_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7f4f985dfc4c4913b6b477e42c5b7abf_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i97f888ed727b47c4969964bbc26cee74_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibb9cad6e8ee145a28421160b0fd93ac8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibc00ea5651d44a68866912b87e772f32_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9728137c063040fdb217c0c575d24e90_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia5691e9a962e48b9bab39a38eebafc58_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib8f794d05abe4bb88fcbc982b4151ef0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i083270152267493cab8ef4a98752605d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="idb4db963049a418ebc24c7b6962c9c42_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2df54907b9c740578baa39b1f16db346_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9868066d4bf64c67b21b80f50a543d09_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id3477ea907754af1b237c11ecd845a8c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5579461ee30641f5866f90f7f973fc2d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0c522dc4d3644e6b89e1c04ae748b784_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4028304ed5344f378d4d8453889c1244_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6c3b7e0e20ce4aa79064e5c448631a6e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i835b04928dc34e3d9eb5b6a882d6a434_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i59341bae0f284bb79a7771c86ff861f4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i253bfddb6f414fe3a582437856252d99_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icd815ed694bb4b1da50025622caa47df_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie39cd3b104234bdfbcbaedb52a41b15c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i94f25e4c5e4b42cca659ef04248013aa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1893ad6b0e8c4f9d9ce45848acc79e12_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i541afb2da75d43639f7fec2ae5748d7f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i014bd38c39aa4b1895340e1de5390e79_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i79425d230e734042bd4df00c16901373_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2553d800f08240b1b782fd37f8f03377_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icdf6391061294c348287bce4418a7767_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i326c763bfd9e49bdb908141c5104c4c6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if72250a4fe7543458ef88e49f913f39a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i53ee22718d2249e6932918034d9479f7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i11784cd0180b4240bfe628b8a935091b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id2b7165b4f9f4b159f2f118447ef21b2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3c9d21e349b44826bb9ff73def0b0f9b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i492cf935c87d44ea908c1584da4f932b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i86f5f0213b924cf4a2443b1755e0e558_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie913be1662fb496dadd88c102ecc6d7f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5133f4445b424b37b5a24aee0f8c8ad5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icb9d49fc86e54fa4aef040dc305765cc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i34c34c5498af462390f43272c1214aad_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i80e1536360e0467e919e75a282b9c273_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1d9dae1aca8e45a9bd0624944e8a56ca_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5e38511a533b4a35afcd45b88276b271_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic4b0ceabb1674432983305cc3a962999_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="idf4e9376f20b4a76a67b9874281b82b7_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9472948bb7f947afa49886afa824b300_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7408050434b1433f9057403b967bc044_D20200201-20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="i1dfd4b4b1d2a4b459b67e2e9c72eac8d_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="ie6e455b81cdd4b63a8577a6c3f916221_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i19d9bfc8635f470e9a7adb121100256d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4fbb93a5eb8140d2b2faeef2de2e7c59_I20111231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2011-12-31</instant>
        </period>
    </context>
    <context id="i9877de074e3b4cd68f3e14e738b53b96_I20120731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:WhyteEtAlVEliLillyEtAlMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-07-31</instant>
        </period>
    </context>
    <context id="idac89cba080843258ae570efc0620a18_I20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:WeilerVTakedaCanadaIncEtAlMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-30</instant>
        </period>
    </context>
    <context id="iad757e1928624ece99a2023c2b06db4a_I20130131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EppVTakedaCanadaIncEtAlMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-01-31</instant>
        </period>
    </context>
    <context id="ic92b96cca8ef435288a260a7692a4296_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i87320df79b3f461da082a107fa7a8e57_D20090301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i15f9ce4e2e9f47789b45d86896781f54_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:LosAngelesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6776f7310a5341a3b3f6bfdef846dfea_D20090301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:LosAngelesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib44052b397dc4098a69265e6060b79a8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:SouthernDistrictOfCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i121dcf9b52ce46eead9ac16494dd1642_D20090301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:SouthernDistrictOfCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib73e27481f2e44bcb74fda4f3cecf682_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:VariousStateDomicilesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2fa2b0f3392543f2b160709e35c124d7_D20090301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:VariousStateDomicilesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9b029559694b48b08c94d12ad381445e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:PlaintiffAllegationsAxis">lly:PancreaticCancerOrThyroidCancerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if02307f1292e42dd8aa0a8c7f88d014f_D20090301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:PlaintiffAllegationsAxis">lly:PancreaticCancerOrThyroidCancerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7ccdd965fb0d44ed8eaa51cd4f6af3a8_D20090301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:PlaintiffAllegationsAxis">lly:PancreatitisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id5a9904ee8fe4ee9900bba9f1c855eb9_D20090301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:PlaintiffAllegationsAxis">lly:AmpullaryCancerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0ac86530d3c243cca63aa23529e06624_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9f7430fd06b947ef84b255b6fb8aee26_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ida0a952118b340e6ba680f7df96d7075_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib5001859aff84e2dbe43c4543f7e5dbc_D20180701-20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="ieb85b610e8d84b4788f9a42c2d175b66_D20210331-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i877919e055e34b8eb3844514babacc6f_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="iaa67ffc334f74fdd88aeff3e17eb06fd_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i69f451428d3e45a3a75cd744529fea05_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogHumulinAndForteoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i08bd92534c0942898d7deffdcc7f9938_D20191201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:DrReddysLabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6b10da171de74c8882000a2f696152fd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5614d38977b64c168c1b9fc251c757ca_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iffd75cb32c5543a891d689e8933d4949_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icaa91bb6c1a24ffcb202a27011d73dd0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2845560a0ba2491a904c84ba82f35819_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i743947277250425485ee1e0a26d90120_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i205a56c975a443f7b7c7708eb29b679c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0ebbc7661fa041f1ba2dd368ac1ee896_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5c5b25a00f1643c98078aba97cc80b62_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9655bade5b00400dba7752533cb6743c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i577b7fef6c2c49bf87fe8cb8121248ce_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie23fc76e1a5a432a8db78dd624ef5cc1_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7caab5ff3a4d4ca8a64128cbbeb05cdd_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7b8b459cd1fc47f6baa6f11b48145ac4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic1eeb66393264479aecf1f1d2fcd51b1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1cc74d110d0145598aeabdd970d87f17_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iaa58ad2146314403b3eff9eaf3e10324_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6ebe01e7039a44a4888856db6e4a7d39_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iffabc6d5c4614780a93ce1b21d701159_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i96ce660d25654b37a7243b236eca576b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i55b8fd6090834514913a2977fd43623e_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i17796a268f3742fda454ebd20b70ba1d_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9bc687d07e3f4ff4bcb96e53bc8d83ec_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="icd5fe3b1199247e6a91eb8d01efc2392_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i41d912b5241343a9b988106cef8e0215_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i33afbb7d73484c0a83d56114c6756d5c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i194e7735259d438eb363e7d9f3ae1523_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i986fb3e559c0490ca09848e9ac9bf901_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ibf742f7aff334b05a91842e894677604_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i02045ea33c7d43d4a34c42a37721b125_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="if48b9be7413d42df903afc9bf15c3c13_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i492583e2c9b044f29ac4a51092ddfbe8_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ibfdc30c8362d4397a4020c9b938662fa_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2917edad81e5463e9d61cceea8f62ea4_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="if82cce099c354dd78182619455a05af1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i25e6d224ac334db98fbf37d17ced616d_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i191727da20c34eae98d4dbc93f0337fe_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9638221883d14af2935d735e8cc9a360_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i37bfd76d6ecb46708142e81e2d19a33c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9c0ff30fbf7f474f9b43c59d3bc7e538_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="right">
        <measure>lly:right</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="jpy">
        <measure>iso4217:JPY</measure>
    </unit>
    <unit id="gbp">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="patent">
        <measure>lly:patent</measure>
    </unit>
    <unit id="lawsuit">
        <measure>lly:lawsuit</measure>
    </unit>
    <unit id="plaintiff">
        <measure>lly:plaintiff</measure>
    </unit>
    <unit id="claimant">
        <measure>lly:claimant</measure>
    </unit>
    <unit id="site">
        <measure>lly:site</measure>
    </unit>
    <unit id="brl">
        <measure>iso4217:BRL</measure>
    </unit>
    <unit id="request">
        <measure>lly:request</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80L2ZyYWc6ZjRiODc0YWZjODYyNDM4NmE1YWUzNWM2ZmY0NzAzMzgvdGFibGU6YWMzNjM5ZGQ5MDljNGM1ZTllMzFlNTI3ZTNlYmY3YjQvdGFibGVyYW5nZTphYzM2MzlkZDkwOWM0YzVlOWUzMWU1MjdlM2ViZjdiNF81LTEtMS0xLTA_25bd029b-d269-4078-ade8-49a8fde5e6ab">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80L2ZyYWc6ZjRiODc0YWZjODYyNDM4NmE1YWUzNWM2ZmY0NzAzMzgvdGFibGU6YWMzNjM5ZGQ5MDljNGM1ZTllMzFlNTI3ZTNlYmY3YjQvdGFibGVyYW5nZTphYzM2MzlkZDkwOWM0YzVlOWUzMWU1MjdlM2ViZjdiNF82LTEtMS0xLTA_470931e9-72e7-4323-abab-91652d95fd9d">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80L2ZyYWc6ZjRiODc0YWZjODYyNDM4NmE1YWUzNWM2ZmY0NzAzMzgvdGFibGU6YWMzNjM5ZGQ5MDljNGM1ZTllMzFlNTI3ZTNlYmY3YjQvdGFibGVyYW5nZTphYzM2MzlkZDkwOWM0YzVlOWUzMWU1MjdlM2ViZjdiNF83LTEtMS0xLTA_dce5736d-1265-4056-b3ef-e0c487ee4dd8">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80L2ZyYWc6ZjRiODc0YWZjODYyNDM4NmE1YWUzNWM2ZmY0NzAzMzgvdGFibGU6YWMzNjM5ZGQ5MDljNGM1ZTllMzFlNTI3ZTNlYmY3YjQvdGFibGVyYW5nZTphYzM2MzlkZDkwOWM0YzVlOWUzMWU1MjdlM2ViZjdiNF84LTEtMS0xLTA_189acf29-f303-4b2d-952f-fafdaaf432ca">0000059478</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80L2ZyYWc6ZjRiODc0YWZjODYyNDM4NmE1YWUzNWM2ZmY0NzAzMzgvdGFibGU6YWMzNjM5ZGQ5MDljNGM1ZTllMzFlNTI3ZTNlYmY3YjQvdGFibGVyYW5nZTphYzM2MzlkZDkwOWM0YzVlOWUzMWU1MjdlM2ViZjdiNF85LTEtMS0xLTA_4fd04c6a-744f-4599-a012-ab066e0193a6">--12-31</dei:CurrentFiscalYearEndDate>
    <lly:LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm
      contextRef="i08bd92534c0942898d7deffdcc7f9938_D20191201-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83My9mcmFnOmZjYWU3NTY3YWMyYTQ0NDliN2YxYjJiNjQ1YzI3Zjg3L3RleHRyZWdpb246ZmNhZTc1NjdhYzJhNDQ0OWI3ZjFiMmI2NDVjMjdmODdfNTA3_7b495efd-4927-4cb8-a7c3-719b42e6dcac">P21D</lly:LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm>
    <dei:DocumentType
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl8yMDMx_c2b9ed78-63cc-4402-9b93-0d368b9aa5bf">10-Q</dei:DocumentType>
    <dei:DocumentTransitionReport
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl80OTQ3ODAyMzI3MDg3_50524f91-7466-4ed1-8a0e-4ce3dec76b0b">false</dei:DocumentTransitionReport>
    <dei:DocumentQuarterlyReport
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl80OTQ3ODAyMzI3MDg3_ed6a6b1d-7d90-4454-9a97-2f44f6fac31d">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl8yMDU_54d3768c-fcb0-4dfe-a940-17fc80e0a257">2021-03-31</dei:DocumentPeriodEndDate>
    <dei:EntityFileNumber
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl8yMDM3_941c6df3-644e-4aee-a032-e86c79125d81">001-6351</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl8yMDMy_eafa7129-abe9-4396-85ac-0509a8a791db">ELI LILLY AND COMPANY</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6MTMzMGExNWNjZmMwNDI3NmE0NjU5NzBiMzgxZDlmMmEvdGFibGVyYW5nZToxMzMwYTE1Y2NmYzA0Mjc2YTQ2NTk3MGIzODFkOWYyYV8wLTAtMS0xLTA_5ba4d629-ef82-4d8c-9fcf-ff68042ea2ae">IN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6MTMzMGExNWNjZmMwNDI3NmE0NjU5NzBiMzgxZDlmMmEvdGFibGVyYW5nZToxMzMwYTE1Y2NmYzA0Mjc2YTQ2NTk3MGIzODFkOWYyYV8wLTItMS0xLTA_d4bbb31a-df75-48cd-b8b9-306cf3d83247">35-0470950</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl8yMDMz_27dbb615-7f0c-415d-99ef-cb4d12b161b0">Lilly Corporate Center</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl8yMDM4_477fb1e2-e68e-4a77-8667-f1aaeb4f6608">Indianapolis</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl8yMDM0_1d8d3687-6efb-46f3-a252-33f8569fffb0">IN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl8yMDI5_67048238-f05e-46fa-94fb-89c7384b062a">46285</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl8yMDM5_0f54f8d1-891a-4573-93cf-0745c6d91461">317</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl8yMDMw_73cce34b-600d-420a-9c6b-b59b8b5171a1">276-2000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ib6bc00b2d2b24b739475df069c617a03_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl8xLTAtMS0xLTA_5852ea3e-abe5-46df-8885-e1ff73dd97c9">Common Stock (no par value)</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ib6bc00b2d2b24b739475df069c617a03_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl8xLTEtMS0xLTA_32af1ca8-ec20-4bb1-b2a7-3b7a3b6ec007">LLY</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ib6bc00b2d2b24b739475df069c617a03_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl8xLTItMS0xLTA_a6e4c6d9-81fc-4c24-8399-e83077bae5fd">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ic3e378dfd41341fb9e60b25e358c23ef_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl8yLTAtMS0xLTA_02a9f67b-f920-46ba-bedd-a609ff4ba425">1.000% Notes due 2022</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ic3e378dfd41341fb9e60b25e358c23ef_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl8yLTEtMS0xLTA_55876694-6a66-457e-8c0c-11de8b5f3b9d">LLY22</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ic3e378dfd41341fb9e60b25e358c23ef_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl8yLTItMS0xLTA_eb74693f-0c5a-446c-b927-bc5be1003f72">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i44103ce383994d74a3ab84ed4f5b4a46_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl8zLTAtMS0xLTA_d8b50eae-ed90-4d86-a091-ff0573a57d9a">7 1/8% Notes due 2025</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i44103ce383994d74a3ab84ed4f5b4a46_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl8zLTEtMS0xLTA_01faa47f-63d7-46ec-ad8d-321e3e04bada">LLY25</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i44103ce383994d74a3ab84ed4f5b4a46_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl8zLTItMS0xLTA_5be754f0-9d9d-404c-8baf-9f91d7df91f8">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i086dc0b8a28b43438b0ec2d949452e3e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl80LTAtMS0xLTA_62ccd249-293e-4394-a1ee-2ff65d4a3668">1.625% Notes due 2026</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i086dc0b8a28b43438b0ec2d949452e3e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl80LTEtMS0xLTA_d649d9e3-810f-4f88-b11c-5af5437046c5">LLY26</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i086dc0b8a28b43438b0ec2d949452e3e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl80LTItMS0xLTA_31e4cd36-ac40-4fbe-b189-c65c92f1feeb">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i1ffb83ec38e84898b6c89250d5c39070_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl81LTAtMS0xLTA_0d331ad7-b4c1-48a5-81e0-23cd986ebe3c">2.125% Notes due 2030</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i1ffb83ec38e84898b6c89250d5c39070_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl81LTEtMS0xLTA_647c3c2d-dd00-4092-b7ba-12447200608b">LLY30</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i1ffb83ec38e84898b6c89250d5c39070_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl81LTItMS0xLTA_f67af9d2-a1a2-45b9-99c8-68565551dddc">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="if8ceb4ed9fcd4e6e8a65b6d5a85314e7_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl82LTAtMS0xLTA_1af55436-1efb-4d22-add3-749d55e1acd1">0.625% Notes due 2031</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="if8ceb4ed9fcd4e6e8a65b6d5a85314e7_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl82LTEtMS0xLTA_8c5d9633-0fbc-44ba-95ea-bfd8bec2c49d">LLY31</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="if8ceb4ed9fcd4e6e8a65b6d5a85314e7_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl82LTItMS0xLTA_6906eeb0-ca8f-46e1-8a49-0e2b75ab686f">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i996950b9da7c4950a18ada582b1fc257_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl83LTAtMS0xLTA_bfd3ae83-1f34-4d48-b4c7-3ceff96c5453">6.77%&#160;Notes due 2036</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i996950b9da7c4950a18ada582b1fc257_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl83LTEtMS0xLTA_ac233df6-c8ae-4368-9082-b9bd752f8f97">LLY36</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i996950b9da7c4950a18ada582b1fc257_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl83LTItMS0xLTA_d3dc6bff-572e-4d8a-9f9b-203d8eb0d68f">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="if8debecbe586414a933f775ea52cd38e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl84LTAtMS0xLTA_cc65f1d5-af80-44f1-b7d9-7c97935d37cd">1.700% Notes due 2049</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="if8debecbe586414a933f775ea52cd38e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl84LTEtMS0xLTA_994a0125-366c-4068-abb3-25aba8111495">LLY49A</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="if8debecbe586414a933f775ea52cd38e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6YTFhOGNlYjg5MmE0NDk3Mjg4NWVmNTQzNjI2ZDJkNWIvdGFibGVyYW5nZTphMWE4Y2ViODkyYTQ0OTcyODg1ZWY1NDM2MjZkMmQ1Yl84LTItMS0xLTA_03a472e8-842f-426c-99e2-543f449c964e">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl8yMDQw_8316d960-0856-4a7e-8b1d-ee51109c64fb">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl8yMDM1_c638c031-3805-48a3-9c9f-ad1df8425815">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6Yzk4ZGM0MmNmMjBiNGQyODhiYTJkMzUzYTRjZDljZWUvdGFibGVyYW5nZTpjOThkYzQyY2YyMGI0ZDI4OGJhMmQzNTNhNGNkOWNlZV8wLTAtMS0xLTA_6fcdb110-1ea5-4f3f-9769-81e29600c2ad">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6Yzk4ZGM0MmNmMjBiNGQyODhiYTJkMzUzYTRjZDljZWUvdGFibGVyYW5nZTpjOThkYzQyY2YyMGI0ZDI4OGJhMmQzNTNhNGNkOWNlZV8xLTctMS0xLTA_26fe7f6e-5b13-4a6e-aa31-43601438e047">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6Yzk4ZGM0MmNmMjBiNGQyODhiYTJkMzUzYTRjZDljZWUvdGFibGVyYW5nZTpjOThkYzQyY2YyMGI0ZDI4OGJhMmQzNTNhNGNkOWNlZV8yLTctMS0xLTA_5943a540-b02b-47db-ae6c-851d80537700">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGV4dHJlZ2lvbjpjOTZiZmRiYmUzN2E0YWNkOWZiYzkzMjkwZmY2YzdiMl8yMDM2_55615946-59d6-4dae-b2f9-bc6a2db335fc">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i8777fbeb1d88449d8d60f606fd5c2c77_I20210427"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xL2ZyYWc6Yzk2YmZkYmJlMzdhNGFjZDlmYmM5MzI5MGZmNmM3YjIvdGFibGU6ZGQ4N2E0ZWZkOWUyNDA4Y2I3ZTM2YTgzOTYxZGUxMmIvdGFibGVyYW5nZTpkZDg3YTRlZmQ5ZTI0MDhjYjdlMzZhODM5NjFkZTEyYl8xLTItMS0xLTA_2e4c175a-d277-48bd-9ae6-fd9d9db41429"
      unitRef="shares">959025446</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Revenues
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMi0xLTEtMS0w_cdc049d5-2d49-4700-9596-113c5a6bdda8"
      unitRef="usd">6805600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMi0zLTEtMS0w_dacb8a1f-5e19-46c6-9a11-2a2c57bae91d"
      unitRef="usd">5859800000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfNC0xLTEtMS0w_9ba2fceb-ee49-4a8b-8346-76e081a31a3f"
      unitRef="usd">1878600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfNC0zLTEtMS0w_87ad829e-e05d-41bd-ae98-2f91a74a2b62"
      unitRef="usd">1215100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfNS0xLTEtMS0w_f8b4cd4a-2076-4e6b-8580-772d97f02af6"
      unitRef="usd">1684800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfNS0zLTEtMS0w_025feed4-c178-4e39-ab60-2494910cdcd0"
      unitRef="usd">1392100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfNi0xLTEtMS0w_e9da96b3-fff1-4c26-be72-dc12179ab88b"
      unitRef="usd">1576000000.0</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfNi0zLTEtMS0w_da1c1dee-53f6-481d-bfa1-65b9d3399c1f"
      unitRef="usd">1549600000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <lly:AcquiredInProcessResearchAndDevelopment
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfNy0xLTEtMS0w_f22b0665-a414-427f-a392-d550ff6a24db"
      unitRef="usd">299300000</lly:AcquiredInProcessResearchAndDevelopment>
    <lly:AcquiredInProcessResearchAndDevelopment
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfNy0zLTEtMS0w_e596da16-5335-4bd7-a836-7c3abf06b559"
      unitRef="usd">52300000</lly:AcquiredInProcessResearchAndDevelopment>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfOC0xLTEtMS0w_867dc0f3-4934-4403-bb1c-95f003c7ea49"
      unitRef="usd">211600000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfOC0zLTEtMS0w_61e9d0f7-00f1-4631-bc7a-178c42842cd9"
      unitRef="usd">59900000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfOS0xLTEtMS0w_49172d7c-4713-4a2f-973b-380bc431025b"
      unitRef="usd">321100000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfOS0zLTEtMS0w_db66b2b8-dfdf-4080-ba6b-e3e254491d0a"
      unitRef="usd">89100000</us-gaap:NonoperatingIncomeExpense>
    <lly:CostOfSalesOperatingExpensesAndOtherNet
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMTAtMS0xLTEtMA_d0032acc-81f7-437b-ba30-aedbaaa5b406"
      unitRef="usd">5329200000</lly:CostOfSalesOperatingExpensesAndOtherNet>
    <lly:CostOfSalesOperatingExpensesAndOtherNet
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMTAtMy0xLTEtMA_070ba26f-5648-4913-b04c-09e4be48ac68"
      unitRef="usd">4179900000</lly:CostOfSalesOperatingExpensesAndOtherNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMTEtMS0xLTEtMA_dd4bee67-0886-4a2a-9b4a-487c6a1d8f0c"
      unitRef="usd">1476400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMTEtMy0xLTEtMA_2a049c13-51fa-4014-b603-b30c60c21d65"
      unitRef="usd">1679900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMTItMS0xLTEtMA_939aec93-1f5e-428f-84e7-ca213f434238"
      unitRef="usd">121100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMTItMy0xLTEtMA_f7a2b37d-1475-4fc4-9d8c-34d43b09a8fe"
      unitRef="usd">223400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMTMtMS0xLTEtMA_cc339fb1-a3d8-40fe-bd5a-d7d496f2ee0b"
      unitRef="usd">1355300000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMTMtMy0xLTEtMA_be444e07-fef8-45e6-aa2a-4663cf497616"
      unitRef="usd">1456500000</us-gaap:ProfitLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMTgtMS0xLTEtMA_6dae2d9a-054e-4ba3-a878-91126bff5d82"
      unitRef="usdPerShare">1.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMTgtMy0xLTEtMA_a412d89f-0c49-4153-b210-3917b8f07278"
      unitRef="usdPerShare">1.60</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMjItMS0xLTEtMA_abf07fd6-089c-478d-86a2-347b71efc313"
      unitRef="usdPerShare">1.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMjItMy0xLTEtMA_03a4aa9a-eba9-4fea-8fbb-7fe5d08add7a"
      unitRef="usdPerShare">1.60</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMjctMS0xLTEtMA_3c35c5a9-73e4-4f0c-ac6d-e930b74dc741"
      unitRef="shares">908800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMjctMy0xLTEtMA_895ee77e-373c-4d4b-a6e4-f46c3819ee3f"
      unitRef="shares">908200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMjgtMS0xLTEtMA_da1d0de4-5bcc-447d-8960-719067847d15"
      unitRef="shares">912400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8xOS9mcmFnOmMzMmMyOTVkM2I1MTRiMzE4ZDEyMWU1NDc1NmJhNjdmL3RhYmxlOmQ4NzExMjU3OTU5NzRjZDc5MzA4YTgwN2FiOWZhMTE1L3RhYmxlcmFuZ2U6ZDg3MTEyNTc5NTk3NGNkNzkzMDhhODA3YWI5ZmExMTVfMjgtMy0xLTEtMA_4c301199-0d52-4f7f-b99d-f82add56f70d"
      unitRef="shares">911700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yMi9mcmFnOmE1NTQ0ZjAwNjk4NDQ0Njg4MjYzMzE3YWVkNzYwNzdjL3RhYmxlOjI1MjFlNjExZTdhMDQ0NmU5ZGY4NjNiMDI5NzJmZTM0L3RhYmxlcmFuZ2U6MjUyMWU2MTFlN2EwNDQ2ZTlkZjg2M2IwMjk3MmZlMzRfMi0xLTEtMS0w_cc339fb1-a3d8-40fe-bd5a-d7d496f2ee0b"
      unitRef="usd">1355300000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yMi9mcmFnOmE1NTQ0ZjAwNjk4NDQ0Njg4MjYzMzE3YWVkNzYwNzdjL3RhYmxlOjI1MjFlNjExZTdhMDQ0NmU5ZGY4NjNiMDI5NzJmZTM0L3RhYmxlcmFuZ2U6MjUyMWU2MTFlN2EwNDQ2ZTlkZjg2M2IwMjk3MmZlMzRfMi0zLTEtMS0w_be444e07-fef8-45e6-aa2a-4663cf497616"
      unitRef="usd">1456500000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yMi9mcmFnOmE1NTQ0ZjAwNjk4NDQ0Njg4MjYzMzE3YWVkNzYwNzdjL3RhYmxlOjI1MjFlNjExZTdhMDQ0NmU5ZGY4NjNiMDI5NzJmZTM0L3RhYmxlcmFuZ2U6MjUyMWU2MTFlN2EwNDQ2ZTlkZjg2M2IwMjk3MmZlMzRfNS0xLTEtMS0w_a79a99fe-4b1e-44a8-a984-c93057b5c890"
      unitRef="usd">100800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yMi9mcmFnOmE1NTQ0ZjAwNjk4NDQ0Njg4MjYzMzE3YWVkNzYwNzdjL3RhYmxlOjI1MjFlNjExZTdhMDQ0NmU5ZGY4NjNiMDI5NzJmZTM0L3RhYmxlcmFuZ2U6MjUyMWU2MTFlN2EwNDQ2ZTlkZjg2M2IwMjk3MmZlMzRfNS0zLTEtMS0w_82ff9c03-fc22-4abb-93c4-d85c797465a2"
      unitRef="usd">-362300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yMi9mcmFnOmE1NTQ0ZjAwNjk4NDQ0Njg4MjYzMzE3YWVkNzYwNzdjL3RhYmxlOjI1MjFlNjExZTdhMDQ0NmU5ZGY4NjNiMDI5NzJmZTM0L3RhYmxlcmFuZ2U6MjUyMWU2MTFlN2EwNDQ2ZTlkZjg2M2IwMjk3MmZlMzRfNi0xLTEtMS0w_897f99ac-b4ae-4368-95aa-9a941897260c"
      unitRef="usd">1456100000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yMi9mcmFnOmE1NTQ0ZjAwNjk4NDQ0Njg4MjYzMzE3YWVkNzYwNzdjL3RhYmxlOjI1MjFlNjExZTdhMDQ0NmU5ZGY4NjNiMDI5NzJmZTM0L3RhYmxlcmFuZ2U6MjUyMWU2MTFlN2EwNDQ2ZTlkZjg2M2IwMjk3MmZlMzRfNi0zLTEtMS0w_09eecf62-c95e-4973-9cf2-1ac3c1956e81"
      unitRef="usd">1094200000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMy0xLTEtMS0w_034f9e93-900e-4fb4-8ad3-cdd9bf5ecf03"
      unitRef="usd">3002400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMy0zLTEtMS0w_69ace194-1e38-44a0-b337-1996cc5d86d1"
      unitRef="usd">3657100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNC0xLTEtMS0w_442e9d67-69bf-4e3f-b9b1-29d1fded794e"
      unitRef="usd">49000000.0</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNC0zLTEtMS0w_34125e58-651a-4c6a-a066-f4d405257885"
      unitRef="usd">24200000</us-gaap:ShortTermInvestments>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNS0wLTEtMS0wL3RleHRyZWdpb246NDZjNmI0Y2EzOTJhNGRmZTlmNzdkNDhkY2ZmMDA1ZmRfNDc_1d325f81-0281-4300-a333-ff1fee095d03"
      unitRef="usd">23900000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNS0wLTEtMS0wL3RleHRyZWdpb246NDZjNmI0Y2EzOTJhNGRmZTlmNzdkNDhkY2ZmMDA1ZmRfNjE_d50d661c-f008-4799-96a3-ec599f5664ad"
      unitRef="usd">25900000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNS0xLTEtMS0w_8346b42f-e329-40c0-9f85-47311fed5b74"
      unitRef="usd">5592800000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNS0zLTEtMS0w_a524cd36-3168-4ddd-8cd1-0c45e977037a"
      unitRef="usd">5875300000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNi0xLTEtMS0w_24df703d-80b8-4e64-8cd0-0061c234dcf7"
      unitRef="usd">1065800000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNi0zLTEtMS0w_9201bac2-3ffc-4783-9889-ed9d7c50d6dc"
      unitRef="usd">1053700000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNy0xLTEtMS0w_cec099a5-ce58-44a8-9836-a02f318df379"
      unitRef="usd">3660800000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNy0zLTEtMS0w_a92ddf93-bb71-42ea-a458-397c3cf21504"
      unitRef="usd">3980300000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfOC0xLTEtMS0w_7bb5cdcc-af37-403a-be67-49a7c67fa27a"
      unitRef="usd">3233700000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfOC0zLTEtMS0w_2e14d297-3829-42da-b5e0-6b89a044d785"
      unitRef="usd">2871500000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfOS0xLTEtMS0w_ff560519-b78c-4506-b7a1-6cd75bcae2af"
      unitRef="usd">16604500000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfOS0zLTEtMS0w_3b9e257c-b4f0-4a4a-bec1-01e6d8166461"
      unitRef="usd">17462100000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTAtMS0xLTEtMA_5f709141-2822-4a7b-a241-db41dd0c099e"
      unitRef="usd">3232400000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTAtMy0xLTEtMA_a767f40c-70db-4008-ae4b-88d702843af9"
      unitRef="usd">2966800000</us-gaap:LongTermInvestments>
    <us-gaap:Goodwill
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTEtMS0xLTEtMA_c58376a8-4d20-456d-9a96-b1e3957cd079"
      unitRef="usd">3877400000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTEtMy0xLTEtMA_313289d1-34ef-44cd-978b-7bf1803a0e60"
      unitRef="usd">3766500000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTItMS0xLTEtMA_67c308b5-6d09-4964-b9f7-964f3c398e1e"
      unitRef="usd">8087800000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTItMy0xLTEtMA_1cfc3905-b15c-4fb3-a57d-c193a31ee036"
      unitRef="usd">7450000000.0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTMtMS0xLTEtMA_8a0dc432-cf32-41f7-8eb6-b34f6d40d71d"
      unitRef="usd">2649900000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTMtMy0xLTEtMA_1283a6f0-fec8-4a79-a915-738152bf6282"
      unitRef="usd">2830400000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTQtMC0xLTEtMC90ZXh0cmVnaW9uOjQyMjA2NmYwNDMyMjRhZDVhOWM3Mjc3NDAzMzdkYjdjXzYz_05ccbfcf-5761-451b-b76d-3d7b3f4f7208"
      unitRef="usd">9643400000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTQtMC0xLTEtMC90ZXh0cmVnaW9uOjQyMjA2NmYwNDMyMjRhZDVhOWM3Mjc3NDAzMzdkYjdjXzc3_d952a318-4574-4d1b-b8d7-88ede913ff9e"
      unitRef="usd">9570700000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTQtMS0xLTEtMA_dc5ec02b-146f-455d-914c-ab68f74ce807"
      unitRef="usd">8630100000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTQtMy0xLTEtMA_490bad88-3732-458b-8c7e-c6e65c4a5008"
      unitRef="usd">8681900000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTUtMS0xLTEtMA_75703814-703c-468f-8d09-98d359c7c032"
      unitRef="usd">3756200000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTUtMy0xLTEtMA_d89b4823-f88e-49cd-93d5-c8a9b8d12ded"
      unitRef="usd">3475400000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTYtMS0xLTEtMA_0415647e-435e-4299-b5e2-0d4829261b63"
      unitRef="usd">46838300000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTYtMy0xLTEtMA_d6978284-b968-4dc4-86fc-9b1b71a4db78"
      unitRef="usd">46633100000</us-gaap:Assets>
    <us-gaap:DebtCurrent
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTktMS0xLTEtMA_23f4c3fe-b9f1-4774-a007-033a7e650e04"
      unitRef="usd">4900000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMTktMy0xLTEtMA_a6a294f9-36eb-461a-ab90-21ea90d5c4f0"
      unitRef="usd">8700000</us-gaap:DebtCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjAtMS0xLTEtMA_1e429c67-bd7e-4ccc-a1d2-d28302ce40fa"
      unitRef="usd">1639600000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjAtMy0xLTEtMA_12ae1353-3677-49be-9afa-862ba08f4f67"
      unitRef="usd">1606700000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjEtMS0xLTEtMA_2ebde5b6-8fef-47d4-b426-b626cf00e0e2"
      unitRef="usd">649900000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjEtMy0xLTEtMA_67faf49b-20c0-422c-837d-a608fd8e6372"
      unitRef="usd">997200000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <lly:SalesRebatesAndDiscounts
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjItMS0xLTEtMA_d9ca682d-9455-4e50-aa36-c0693e6fb6d5"
      unitRef="usd">5821400000</lly:SalesRebatesAndDiscounts>
    <lly:SalesRebatesAndDiscounts
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjItMy0xLTEtMA_57d73291-4974-4d25-a5bd-bf6a59492e91"
      unitRef="usd">5853000000.0</lly:SalesRebatesAndDiscounts>
    <us-gaap:DividendsPayableCurrent
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjMtMS0xLTEtMA_78b8a931-1340-4301-b518-97e4aff9487d"
      unitRef="usd">0</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjMtMy0xLTEtMA_89812fa7-98c8-4285-a6e3-db0a3caeeed5"
      unitRef="usd">770600000</us-gaap:DividendsPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjQtMS0xLTEtMA_8bd63a24-fe57-4d97-97e0-8207844b9a1a"
      unitRef="usd">791600000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjQtMy0xLTEtMA_770468c6-042d-45d4-be29-cb09bf822891"
      unitRef="usd">495100000</us-gaap:TaxesPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjUtMS0xLTEtMA_d0b1c191-bbed-4c21-a776-bed48a1ad5df"
      unitRef="usd">2806800000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjUtMy0xLTEtMA_766a78e7-cc0e-492f-8039-ceabf5bf8511"
      unitRef="usd">2750300000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjYtMS0xLTEtMA_e8d21695-899b-4c59-aee6-c79d52de7d6f"
      unitRef="usd">11714200000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjYtMy0xLTEtMA_b1eb52d3-b3d5-41f3-82fe-054caa817bfa"
      unitRef="usd">12481600000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjgtMS0xLTEtMA_71fb1798-e563-4adc-88f4-30795d1922db"
      unitRef="usd">16199600000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjgtMy0xLTEtMA_3c04221c-244c-4a10-b24b-169f3b87da89"
      unitRef="usd">16586600000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjktMS0xLTEtMA_fcb2b670-6441-4559-a93a-6d562cc2d101"
      unitRef="usd">3969800000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMjktMy0xLTEtMA_fad1d723-a179-43d5-88a2-b43d1d27d780"
      unitRef="usd">4094500000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzAtMS0xLTEtMA_0a5a8745-70ba-4e14-9918-027ef227844e"
      unitRef="usd">3917500000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzAtMy0xLTEtMA_27ab968b-a764-46a9-84ea-7ba8970b5da1"
      unitRef="usd">3837800000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzEtMS0xLTEtMA_b9915539-b00c-4b33-8344-1677059b5e1e"
      unitRef="usd">2200600000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzEtMy0xLTEtMA_d4d13d47-c4bf-40ac-9893-703717bdc702"
      unitRef="usd">2099900000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzItMS0xLTEtMA_79aa0d32-c818-4dcd-bfb8-a4a0cc7972b8"
      unitRef="usd">1737300000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzItMy0xLTEtMA_bfa0f893-cffa-4109-b416-2724a56acf68"
      unitRef="usd">1707500000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzMtMS0xLTEtMA_0de7255c-da6a-4975-95e5-55546a09e56e"
      unitRef="usd">28024800000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzMtMy0xLTEtMA_ce3d877d-8429-4ba7-8393-9248fa26e178"
      unitRef="usd">28326300000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzQtMS0xLTEtMA_1430d540-ea80-491d-af71-87513bb9824a"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzQtMy0xLTEtMA_cff7caa8-a783-4578-a425-3a848eece547"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzYtMS0xLTEtMA_7f7c3cad-f765-439b-9b92-3ae56712ddfc"
      unitRef="usd">599700000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzYtMy0xLTEtMA_d1dedd7b-9125-43e6-9ce7-608d90369ecf"
      unitRef="usd">598200000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzctMS0xLTEtMA_1afeeafb-607b-4647-b92f-ea8716703329"
      unitRef="usd">6579200000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzctMy0xLTEtMA_a5015b02-4133-489e-98ae-1d2672f0b72c"
      unitRef="usd">6778500000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzgtMS0xLTEtMA_f281b49e-e72a-4036-b9fe-592174303a44"
      unitRef="usd">9181300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzgtMy0xLTEtMA_c961505c-154a-4637-a02b-f51dac7f9cf5"
      unitRef="usd">7830200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CommonStockSharesHeldInEmployeeTrust
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzktMS0xLTEtMA_5dd4d647-217d-4ab7-90f0-28a13d698817"
      unitRef="usd">3013200000</us-gaap:CommonStockSharesHeldInEmployeeTrust>
    <us-gaap:CommonStockSharesHeldInEmployeeTrust
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfMzktMy0xLTEtMA_51734cc1-6ea5-4bf0-8e2a-398e9ea3e162"
      unitRef="usd">3013200000</us-gaap:CommonStockSharesHeldInEmployeeTrust>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNDAtMS0xLTEtMA_639e9003-c830-4c07-883f-c0597984374d"
      unitRef="usd">-6395600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNDAtMy0xLTEtMA_1e77ebaa-a100-4485-9488-6819d91787fd"
      unitRef="usd">-6496400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockValue
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNDEtMS0xLTEtMA_0f1a838d-bd9d-48a6-b7a1-9e46b3cdd4cd"
      unitRef="usd">52700000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNDEtMy0xLTEtMA_8589a315-f65e-405a-909b-10c9fad292f9"
      unitRef="usd">55700000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNDItMS0xLTEtMA_0f8ec0ee-a6bf-4170-a295-ea85a65cb488"
      unitRef="usd">6898700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNDItMy0xLTEtMA_d4ec8dd4-0412-45cf-8201-dd528b951a6d"
      unitRef="usd">5641600000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNDMtMS0xLTEtMA_dc16b1c7-7859-4e91-a67f-e58e294a4258"
      unitRef="usd">200600000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNDMtMy0xLTEtMA_cbdaf687-1576-471b-958f-67f5516ee4dc"
      unitRef="usd">183600000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNDQtMS0xLTEtMA_c5cec4f2-e4e6-46f5-beae-1a937d9b975d"
      unitRef="usd">7099300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNDQtMy0xLTEtMA_a6649690-4901-4147-a160-beffc79b0ae0"
      unitRef="usd">5825200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNDUtMS0xLTEtMA_30ec29c8-6ed0-4486-9a97-10ec81476ee2"
      unitRef="usd">46838300000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yNS9mcmFnOjhjZmJkODY1ZDMxMzRjYjNiNzUxMTU1YTk3MzZiYTQ4L3RhYmxlOmE2MmEzNDdhYzY5NzQ1MzU4OGMxNjViNzg4ZWZjNTc2L3RhYmxlcmFuZ2U6YTYyYTM0N2FjNjk3NDUzNTg4YzE2NWI3ODhlZmM1NzZfNDUtMy0xLTEtMA_8391f9c8-ea95-4c2b-8afc-3442797380ac"
      unitRef="usd">46633100000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i5bce3a2756434f739e7c3845a02a47cf_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMy0xLTEtMS0w_9c1b04ea-872d-4a06-afe7-fc4e379fe744"
      unitRef="shares">958056000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5bce3a2756434f739e7c3845a02a47cf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMy0zLTEtMS0w_5ce40ca3-4adf-41de-ba30-eff791195989"
      unitRef="usd">598800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3ffc5bab7133436682aff62ddec1e376_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMy01LTEtMS0w_8b4ed52b-d8a9-4996-bce0-f6f74f0c4b93"
      unitRef="usd">6685300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i957ad33ccc1240e3948e9f141963844f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMy03LTEtMS0w_e445cf97-c62d-41ac-9b33-3826bbed0dc9"
      unitRef="usd">4920400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7f3109e398cb4ebe87fb955a863b8ede_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMy05LTEtMS0w_fb52eddc-d19f-499d-a27e-fe55841bf227"
      unitRef="usd">-3013200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i46e5e55c87bf4c9285d8bfe7ce6fd6d3_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMy0xMS0xLTEtMA_c9b95bb8-785b-4ce8-85b2-2e7ef11d1695"
      unitRef="usd">-6523600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i932abea342a94c46a25f33f1c8acc500_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMy0xMy0xLTEtMA_7e73863e-9cb2-4626-b057-57e3085d9eb7"
      unitRef="shares">530000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i932abea342a94c46a25f33f1c8acc500_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMy0xNS0xLTEtMA_896c20ea-1137-46b1-b06d-3cfc73c9a19c"
      unitRef="usd">-60800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifdecec535fa14d78b9ef123144efa368_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMy0xNy0xLTEtMA_4020e14d-dd44-48ad-a24c-18016e40e376"
      unitRef="usd">92200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ic7db1dc190e2453aba10749ea47cfdb0_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfNC03LTEtMS0w_061c9e8d-e6f4-4340-af12-8f82b634b072"
      unitRef="usd">1456500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2eee151cb0194a7c9d3cdf6eaece9015_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfNC0xNy0xLTEtMA_f6557702-9e71-4c8e-9da5-1296046877ca"
      unitRef="usd">26200000</us-gaap:ProfitLoss>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibcf85b46974c4de78d45cca588cdb257_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfNS0xMS0xLTEtMA_98ca8388-f71b-4f97-8a7a-32a63cd7130c"
      unitRef="usd">-362300000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="i4f89a4953ed54302a07fe2fd0dc4e36b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfNy0xLTEtMS0w_8bab93fd-bc14-4b2f-8243-0d9167876dd8"
      unitRef="shares">3627000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i4f89a4953ed54302a07fe2fd0dc4e36b_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfNy0zLTEtMS0w_6bb74d66-56d6-4e79-83ed-019a0b014199"
      unitRef="usd">2300000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ic7db1dc190e2453aba10749ea47cfdb0_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfNy03LTEtMS0w_145a0233-bcbf-4f90-baaa-f63a1c879372"
      unitRef="usd">497700000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="i610527f799c444f999e77fc61f00e502_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfNy0xMy0xLTEtMA_fa34a8c6-acd0-4dd6-b1f0-f8bf46aa4b63"
      unitRef="shares">3627000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i610527f799c444f999e77fc61f00e502_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfNy0xNS0xLTEtMA_588282b7-d96e-49e6-b9b3-6a61a0e391a6"
      unitRef="usd">-500000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i610527f799c444f999e77fc61f00e502_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfOC0xMy0xLTEtMA_76263621-d7db-43c7-9a4b-2c8ce236b352"
      unitRef="shares">3627000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i610527f799c444f999e77fc61f00e502_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfOC0xNS0xLTEtMA_cb394133-c64f-4a76-8f37-d79b3621fe3c"
      unitRef="usd">500000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i4f89a4953ed54302a07fe2fd0dc4e36b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfOS0xLTEtMS0w_f1ee94fa-5aa6-4b96-b149-edd2ede0336e"
      unitRef="shares">2500000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i4f89a4953ed54302a07fe2fd0dc4e36b_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfOS0zLTEtMS0w_ccf810f7-601c-4236-8d4c-f9e538d5295e"
      unitRef="usd">1600000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i86f7f5436d51421a8501779a09dd82ab_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfOS01LTEtMS0w_d3f2ec52-6485-44cd-94ad-82147ff606fd"
      unitRef="usd">-201000000.0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i610527f799c444f999e77fc61f00e502_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfOS0xMy0xLTEtMA_c510d9f3-bc28-4070-8865-f7a0fe2dbd73"
      unitRef="shares">-43000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i610527f799c444f999e77fc61f00e502_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfOS0xNS0xLTEtMA_062c3330-5553-4be1-aa49-20efe7e43411"
      unitRef="usd">5100000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i86f7f5436d51421a8501779a09dd82ab_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTAtNS0xLTEtMA_7c1614b3-2d10-46d8-91e3-2c010e71c751"
      unitRef="usd">71800000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockholdersEquityOther
      contextRef="ic7db1dc190e2453aba10749ea47cfdb0_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTMtNy0xLTEtMA_2c25eb19-bad4-4277-b227-e28d5d92621e"
      unitRef="usd">-200000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i2eee151cb0194a7c9d3cdf6eaece9015_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTMtMTctMS0xLTA_e7d28129-b3a8-47dc-8c13-25ab5d8ee729"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesIssued
      contextRef="id525ea543ffc4ac699696ae6133c1a3f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTQtMS0xLTEtMA_a1efb309-54ae-4022-9d60-41ba30c599be"
      unitRef="shares">956929000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id525ea543ffc4ac699696ae6133c1a3f_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTQtMy0xLTEtMA_6aefc5f1-297a-4155-978b-c3f81077f45e"
      unitRef="usd">598100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie25f9462d4864ec48a45f240362e710e_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTQtNS0xLTEtMA_1fc861ef-e719-4608-a8e6-5d9b97a44c4a"
      unitRef="usd">6556100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3e1e492a833a4874b74b3fb0b7f96fa5_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTQtNy0xLTEtMA_98830ab4-71fb-407f-8cde-864d345bb8cf"
      unitRef="usd">5879400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id163dac405614d4ab0aab11d9539c9a8_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTQtOS0xLTEtMA_a167bd24-69ba-41ba-afda-bbf93b82b7c1"
      unitRef="usd">-3013200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ife78f2b5881b4ab594c089c77d07dfdd_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTQtMTEtMS0xLTA_e882d840-3e3b-4741-99e8-066e76382c23"
      unitRef="usd">-6885900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i4a5e6fba402d49eda6d65097c72bd64e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTQtMTMtMS0xLTA_60b33594-c5f1-4c72-8b2c-f2c91e7eae87"
      unitRef="shares">487000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4a5e6fba402d49eda6d65097c72bd64e_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTQtMTUtMS0xLTA_02e5eef2-b0a6-47ee-8ec3-455237f458df"
      unitRef="usd">-55700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1a2504bfe86b4fe3905a4c1dd6e8a31a_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTQtMTctMS0xLTA_264fb1be-6682-4895-850f-737d7443e544"
      unitRef="usd">118400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="ib44d59353e664823911abf62eca2a0ec_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTYtMS0xLTEtMA_6364214a-064b-4e14-8ea5-e4ab5d6cbeca"
      unitRef="shares">957077000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib44d59353e664823911abf62eca2a0ec_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTYtMy0xLTEtMA_43ea76a6-364f-4f91-809d-4562c757f477"
      unitRef="usd">598200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icc56172f5f014bb48f88ac5499c1c0c8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTYtNS0xLTEtMA_336e9203-62f3-4643-bbf0-064f47f20caf"
      unitRef="usd">6778500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i60d84be3db5c4d85abc4b594cd075e4e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTYtNy0xLTEtMA_7abb21c8-7bf3-4214-ac06-b9f071dac6ce"
      unitRef="usd">7830200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idcdf0da7a8b34a378831b2abf856ab11_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTYtOS0xLTEtMA_0fde597f-1d4e-459a-9cc4-bf63677962e4"
      unitRef="usd">-3013200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0582a765e6944e928d84c3bf2f09767c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTYtMTEtMS0xLTA_eaf3c92a-ed87-4dac-a63f-6b53a6e6d2a2"
      unitRef="usd">-6496400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="iaaf707b56bb5401397f3d1be8be7a6da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTYtMTMtMS0xLTA_75b3c8b2-21ed-4ad7-aabc-e741d28250b3"
      unitRef="shares">487000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaaf707b56bb5401397f3d1be8be7a6da_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTYtMTUtMS0xLTA_ff57fea3-796e-44c4-89ea-0f44504b2776"
      unitRef="usd">-55700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia85d98868ecb4c1d9f33581b32035094_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTYtMTctMS0xLTA_d30ea7f3-281c-4efb-9ba2-b0809b98bdd1"
      unitRef="usd">183600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i002f042f1d494e298177c727853e4883_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTctNy0xLTEtMA_883c9ba3-03f2-4b07-9836-0f25eff17743"
      unitRef="usd">1355300000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie0d38013f7a5421cab5b95d3ca766cc6_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTctMTctMS0xLTA_9349dda0-e39a-4217-b527-76e1dc5b4888"
      unitRef="usd">16400000</us-gaap:ProfitLoss>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie6e502d3f77649d3b4966205297947db_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMTgtMTEtMS0xLTA_6acfa60a-464f-4735-8c2b-559ac2392fd9"
      unitRef="usd">100800000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i5aa2dbcea11b45b1bc31588610d72e1a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjItMS0xLTEtMA_6b4a8131-b98e-4717-be4d-30549319d681"
      unitRef="shares">2405000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i5aa2dbcea11b45b1bc31588610d72e1a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjItMy0xLTEtMA_a5b62b9c-0d44-4684-aa93-f61bc6c852af"
      unitRef="usd">1500000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="if2c1d39a9337457d82ae76c6cc3e027a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjItNS0xLTEtMA_fe592fd7-c0d6-4ac8-bac4-daecc8749730"
      unitRef="usd">-283900000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ic2d8de6d89ca4b36831a2fad2f21e997_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjItMTMtMS0xLTA_ed2669e1-f56f-4a0f-90c2-8b8e603ce075"
      unitRef="shares">-24000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ic2d8de6d89ca4b36831a2fad2f21e997_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjItMTUtMS0xLTA_750ec208-8831-46fe-ab4b-fd9f77971ab1"
      unitRef="usd">3000000.0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if2c1d39a9337457d82ae76c6cc3e027a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjMtNS0xLTEtMA_a9ae4bd5-d1d0-4fcf-b7d4-7d1732ea9fc4"
      unitRef="usd">85500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockholdersEquityOther
      contextRef="if2c1d39a9337457d82ae76c6cc3e027a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjQtNS0xLTEtMA_eff4418b-9f6e-4bea-97c2-66bc61fbb52c"
      unitRef="usd">900000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i002f042f1d494e298177c727853e4883_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjQtNy0xLTEtMA_153cde31-f440-455a-9b6e-dd4598b71513"
      unitRef="usd">4200000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ie0d38013f7a5421cab5b95d3ca766cc6_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjQtMTctMS0xLTA_146a58fe-01e5-40bd-9725-d358cf6e8aa6"
      unitRef="usd">-600000</us-gaap:StockholdersEquityOther>
    <us-gaap:SharesIssued
      contextRef="i717123173f4f4d45a26fc171fcef135f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjUtMS0xLTEtMA_0519d9a4-9de4-43ca-b1e8-17e424dc890c"
      unitRef="shares">959482000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i717123173f4f4d45a26fc171fcef135f_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjUtMy0xLTEtMA_9e192271-604d-4b0f-bcd8-5fee2a23d64b"
      unitRef="usd">599700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i19ffbb6496914f979518c442d56ddfdc_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjUtNS0xLTEtMA_a5912e6a-35a9-44fc-b9e9-96d1b1b8ce8c"
      unitRef="usd">6579200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia95ec94014ed412d9ddf912309b31906_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjUtNy0xLTEtMA_e098123b-d178-4987-bbdc-250e984fa2de"
      unitRef="usd">9181300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i336e60271cdd431887ad40e2953cb881_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjUtOS0xLTEtMA_c9d9f0ed-8cbc-4642-92a2-33f72e9abcd3"
      unitRef="usd">-3013200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaf8fa9dfe55240c8904822bb89d5d580_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjUtMTEtMS0xLTA_62f91c8d-d804-4763-890d-d11c3067fc2b"
      unitRef="usd">-6395600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="ia54f7cb622be43a6a63855f304e93c8a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjUtMTMtMS0xLTA_85488785-e26b-45f8-b3c8-8d6b78d135e6"
      unitRef="shares">463000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia54f7cb622be43a6a63855f304e93c8a_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjUtMTUtMS0xLTA_e46dcc18-cf01-4074-9b97-4f814d5cf7f1"
      unitRef="usd">-52700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9b0151dc1fa445c680975efcbdc26506_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RhYmxlOjZhMmJkYTAxYWE0YjQ2ZDE4YjgwNzQzY2IxNTgyMTdjL3RhYmxlcmFuZ2U6NmEyYmRhMDFhYTRiNDZkMThiODA3NDNjYjE1ODIxN2NfMjUtMTctMS0xLTA_b204493d-1f36-497c-9d6b-8cfe503871da"
      unitRef="usd">200600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RleHRyZWdpb246YTMwNDZiY2ZiZjAyNDg5N2FmN2ViMWVmZmE2NzMzMmZfMTI3_f031e19e-8127-4a8f-8d2a-c700b0d97016"
      unitRef="usd">1000000000.00</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="ice5b008047fc4f969d378bc0e8f5337b_I20180630"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8yOC9mcmFnOmEzMDQ2YmNmYmYwMjQ4OTdhZjdlYjFlZmZhNjczMzJmL3RleHRyZWdpb246YTMwNDZiY2ZiZjAyNDg5N2FmN2ViMWVmZmE2NzMzMmZfMTUw_d403757c-0ecd-4915-a9d9-f760002d89a4"
      unitRef="usd">8000000000.00</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:NetIncomeLoss
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMy0xLTEtMS0w_ae7ee78c-bc2a-4a56-8162-6b0384fdf98f"
      unitRef="usd">1355300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMy0zLTEtMS0w_f158bb6a-1289-4b50-9341-e6fd06c0b0c5"
      unitRef="usd">1456500000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfNi0xLTEtMS0w_899d8243-13d3-49a8-baab-59805438dc16"
      unitRef="usd">350300000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfNi0zLTEtMS0w_45fb5017-a964-4749-b022-4336855051c5"
      unitRef="usd">273600000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfNy0xLTEtMS0w_c5a37435-e612-4242-a7d3-6fda0e8ea615"
      unitRef="usd">119100000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfNy0zLTEtMS0w_44d0fa7a-9262-4e7a-8b74-2c1d160feb2e"
      unitRef="usd">-11200000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:ShareBasedCompensation
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfOS0xLTEtMS0w_289e0aec-9861-46d1-854a-c93c7a316019"
      unitRef="usd">85500000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfOS0zLTEtMS0w_3928ef4b-17e2-4e5d-a12c-2653d5e524a7"
      unitRef="usd">71800000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnInvestments
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTEtMS0xLTEtMA_6c502d6e-b3e4-45a6-93c5-b341df7383e2"
      unitRef="usd">302200000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTEtMy0xLTEtMA_27208db8-e473-4ff6-9fad-e29823183e0b"
      unitRef="usd">186700000</us-gaap:GainLossOnInvestments>
    <lly:AcquiredInProcessResearchAndDevelopment
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTItMS0xLTEtMA_d69046f9-685d-4939-9370-816b77c86a76"
      unitRef="usd">299300000</lly:AcquiredInProcessResearchAndDevelopment>
    <lly:AcquiredInProcessResearchAndDevelopment
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTItMy0xLTEtMA_5da87cc2-3e07-4dac-8cb3-0ca427a092cf"
      unitRef="usd">52300000</lly:AcquiredInProcessResearchAndDevelopment>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTMtMS0xLTEtMA_edd17af3-f84f-4e30-8c38-95163872eeeb"
      unitRef="usd">102800000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTMtMy0xLTEtMA_353f55d6-c299-4b0e-b96c-7ae59d5fc2df"
      unitRef="usd">1408100000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTQtMS0xLTEtMA_2206b6ad-6444-4caf-b752-c62fcac9b413"
      unitRef="usd">131100000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTQtMy0xLTEtMA_f015a202-6238-41b2-90ac-d8cf5a56bf5e"
      unitRef="usd">111800000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTUtMS0xLTEtMA_9871c9fb-7ff5-4e79-9516-056db5f18943"
      unitRef="usd">1697400000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTUtMy0xLTEtMA_02557f3b-a2d5-4f74-967a-7cda6a90d707"
      unitRef="usd">382400000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTctMS0xLTEtMA_ea76a953-9d1b-4e58-9ab4-894286ac61cf"
      unitRef="usd">300300000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTctMy0xLTEtMA_862e91fe-247d-4537-ac49-1f418013ad0a"
      unitRef="usd">258300000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTgtMS0xLTEtMA_0c2b1814-56c6-49a6-bb3a-b300096af45f"
      unitRef="usd">4000000.0</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTgtMy0xLTEtMA_f50132f9-410a-4b26-bac0-6925aea9f013"
      unitRef="usd">36800000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTktMS0xLTEtMA_d4860695-0b8e-4d98-821b-0da7602614c4"
      unitRef="usd">19400000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMTktMy0xLTEtMA_fd3db003-2441-4469-8ee0-aa4025160ec0"
      unitRef="usd">0</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfLongtermInvestments
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjAtMS0xLTEtMA_a2daba93-2536-49c9-8501-8081497c690e"
      unitRef="usd">284800000</us-gaap:ProceedsFromSaleOfLongtermInvestments>
    <us-gaap:ProceedsFromSaleOfLongtermInvestments
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjAtMy0xLTEtMA_9656bcf8-0fed-41e7-9d33-192783cb3f99"
      unitRef="usd">54500000</us-gaap:ProceedsFromSaleOfLongtermInvestments>
    <us-gaap:PaymentsToAcquireLongtermInvestments
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjEtMS0xLTEtMA_ad1fdbe8-fdf7-48fa-bbb0-b37192a6622d"
      unitRef="usd">291500000</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:PaymentsToAcquireLongtermInvestments
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjEtMy0xLTEtMA_ad5b0792-48d0-4aa0-bb2a-9a58065a35d0"
      unitRef="usd">83000000.0</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjItMS0xLTEtMA_71e42b07-63bf-494b-a7b6-8b25546e0d90"
      unitRef="usd">747400000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjItMy0xLTEtMA_35952610-324c-45b7-9ca4-89e51ef4a9ab"
      unitRef="usd">849300000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <lly:PurchasedInProcessResearchAndDevelopment
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjQtMS0xLTEtMA_dd3195b0-1a74-4524-a625-ce8f9e25d894"
      unitRef="usd">191800000</lly:PurchasedInProcessResearchAndDevelopment>
    <lly:PurchasedInProcessResearchAndDevelopment
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjQtMy0xLTEtMA_87988fb2-237a-459a-9868-912b8de8e45c"
      unitRef="usd">13000000.0</lly:PurchasedInProcessResearchAndDevelopment>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjUtMS0xLTEtMA_d577ec7a-7cd0-4309-8d48-15dcc3ea5846"
      unitRef="usd">21900000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjUtMy0xLTEtMA_9f7f2452-e907-4ea4-974b-1cc804a04046"
      unitRef="usd">-51400000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjYtMS0xLTEtMA_db111105-b95e-4418-a567-252f99a4f5ae"
      unitRef="usd">-1283500000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjYtMy0xLTEtMA_e8baff8e-15f8-470c-b669-fab0965698e1"
      unitRef="usd">-1060900000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfDividends
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjgtMS0xLTEtMA_d3e8f006-e6c5-439e-a21c-6a2f1dbf2f41"
      unitRef="usd">774800000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjgtMy0xLTEtMA_7eac4258-65f4-477c-b3d2-5e9c0ad9d66e"
      unitRef="usd">671300000</us-gaap:PaymentsOfDividends>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjktMS0xLTEtMA_ff8f3835-9afd-4747-abdf-43eb11be0a69"
      unitRef="usd">3700000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMjktMy0xLTEtMA_980128f1-cb67-42c3-8f93-236c77fce4d6"
      unitRef="usd">1748700000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMzEtMS0xLTEtMA_252516be-9ad6-4b33-a9a3-6115af6854be"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMzEtMy0xLTEtMA_715cab77-5188-4b46-b3d5-2254e2ccccca"
      unitRef="usd">276300000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMzItMS0xLTEtMA_0bcaec84-4534-4129-a36d-8248dbd3df6e"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMzItMy0xLTEtMA_75c398ce-1ad4-4696-9a32-dd934c3f96cc"
      unitRef="usd">500000000.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMzQtMS0xLTEtMA_b265bb6b-3b03-4af4-ab0f-15918d9f82d9"
      unitRef="usd">-279900000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMzQtMy0xLTEtMA_d2fb53c3-da61-44ef-bc78-e7ae3b2216ce"
      unitRef="usd">-194400000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMzUtMS0xLTEtMA_768671b4-a1cf-4af2-9214-71dfa20f6d83"
      unitRef="usd">-1058400000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMzUtMy0xLTEtMA_c5fa09a2-23af-4249-93b2-899c00bbfdc0"
      unitRef="usd">106700000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMzYtMS0xLTEtMA_3d063542-ea23-41b9-89b3-79d7274c33bb"
      unitRef="usd">-10200000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMzYtMy0xLTEtMA_204c10d1-cb08-417a-a74d-f1229c65e219"
      unitRef="usd">-66700000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMzgtMS0xLTEtMA_0804902c-2f69-4417-a853-8139e4858909"
      unitRef="usd">-654700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMzgtMy0xLTEtMA_1d836a92-775c-47fe-820f-039a1cfacaa7"
      unitRef="usd">-638500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMzktMS0xLTEtMA_aee31920-0162-4fa0-aed1-d404307d4974"
      unitRef="usd">3657100000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="iea0fcbeedbfb4018b173fba695dd9fc7_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfMzktMy0xLTEtMA_10ae2936-d0bb-453f-861d-9b269eaf4005"
      unitRef="usd">2337500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfNDAtMS0xLTEtMA_3b4ae334-c242-4ec8-a83a-e7d10052e40b"
      unitRef="usd">3002400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i9dd152b8ae7b497f800f65a679736686_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zMS9mcmFnOjNiNWQ5M2U0OTgyZjRhYWJhOTVjZjg5ODNhNzdhOWI0L3RhYmxlOmYzMjFiY2VlMDM2MzRjMGY4ZjIyNmM4ZWFmNzZjMzhjL3RhYmxlcmFuZ2U6ZjMyMWJjZWUwMzYzNGMwZjhmMjI2YzhlYWY3NmMzOGNfNDAtMy0xLTEtMA_d7f7f66a-9b33-44ab-9a42-55af35b3a70c"
      unitRef="usd">1699000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV8zNy9mcmFnOmViNDAyMmNkMGRiMTQ3MGY4MDYyMThhNzc2ODBmMjBlL3RleHRyZWdpb246ZWI0MDIyY2QwZGIxNDcwZjgwNjIxOGE3NzY4MGYyMGVfMjc1Mw_3fb1f345-b9e4-4a93-9eba-3c4a64f1819f">Basis of Presentation &lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have prepared the accompanying unaudited consolidated condensed financial statements in accordance with the requirements of Form 10-Q and, therefore, they do not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). In our opinion, the consolidated condensed financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for a fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our consolidated financial statements and accompanying notes included in our Annual Report on &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231.htm" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Form 10-K&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the year ended December&#160;31, 2020. We issue our financial statements by filing them with the Securities and Exchange Commission and have evaluated subsequent events up to the time of the filing of this Quarterly Report on Form 10-Q.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis, that is, based on the weighted-average number of common shares outstanding plus the effect of incremental shares from our stock-based compensation programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide. A global research and development organization and a supply chain organization are responsible for the discovery, development, manufacturing, and supply of our products. Regional commercial organizations market, distribute, and sell the products. The business is also supported by global corporate staff functions. Our determination that we operate as a single segment is consistent with the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RleHRyZWdpb246ZTYyZjZlZTEwMTg1NGZhN2IxN2NjNWZjNDU1ZjVhNGRfMzM4MA_cc163449-fa82-412a-bdac-5ea120741e96">Revenue&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our revenue recognized in our consolidated condensed statements of operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,320.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,403.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration and other revenue &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;485.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;456.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,805.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,859.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Collaboration and other revenue associated with prior period transfers of intellectual property was $43.0 million and $35.4 million during the three months ended March&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements includes our share of profits from the collaboration, as well as royalties, upfront and milestone payments we receive under these types of contracts. See Note 4 for additional information related to certain of our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue from the Jardiance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trajenta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; families of products resulting from our collaboration with Boehringer Ingelheim discussed in Note 4. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Adjustments to Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adjustments to increase revenue recognized as a result of changes in estimates for our most significant United States (U.S.) sales returns, rebates, and discounts liability balances for products shipped in previous periods were less than 2 percent of U.S. revenue during the three months ended March&#160;31, 2021 and 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Contract Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contract liabilities result from arrangements where we have received payment in advance of performance under the contract and do not include sales returns, rebates, and discounts. Changes in contract liabilities are generally due to either receipt of additional advance payments or our performance under the contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract liability balances:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.276%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;346.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2021 and 2020, revenue recognized from contract liabilities as of the beginning of the respective year was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Disaggregation of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenue by product for the three months ended March 31, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.699%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outside U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outside U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&#x2014;to unaffiliated customers:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diabetes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Trulicity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,116.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;335.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,452.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;929.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,229.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Humalog&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;332.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;284.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;617.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Humulin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;219.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;102.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;321.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Jardiance &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;151.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;160.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;312.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;175.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;71.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;246.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;66.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;94.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;161.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,061.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,049.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,111.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,991.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;977.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,968.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oncology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Alimta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;261.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;297.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;559.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Verzenio&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;172.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;96.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;269.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cyramza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;80.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;160.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;240.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Erbitux&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;107.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;122.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Tyvyt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;109.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;109.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;51.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;71.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;642.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;729.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,372.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;657.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,201.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Immunology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Taltz&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;249.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;153.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;403.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;443.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Olumiant&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;24.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;169.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;193.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;284.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;329.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;613.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;585.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neuroscience:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cymbalta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;165.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;176.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Emgality&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;101.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;119.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Zyprexa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;88.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;95.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;51.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;73.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;141.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;323.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;465.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;COVID-19 Antibodies &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;650.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;159.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;810.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Forteo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;97.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;100.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;198.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cialis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;118.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;126.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;54.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;53.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;107.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;811.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;431.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,242.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;640.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,941.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,864.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,805.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,328.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,531.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,859.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Numbers may not add due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Humalog revenue includes insulin lispro.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Jardiance revenue includes Glyxambi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Synjardy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;and Trijardy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; XR.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to Emergency Use Authorizations (EUAs). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenue by geographical area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.461%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&#x2014;to unaffiliated customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,941.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,328.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,321.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,061.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;571.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;592.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;362.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other foreign countries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;609.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;610.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,805.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,859.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Numbers may not add due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Revenue is attributed to the countries based on the location of the customer.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RleHRyZWdpb246ZTYyZjZlZTEwMTg1NGZhN2IxN2NjNWZjNDU1ZjVhNGRfMzM3OA_298eb2a7-7132-4b14-92b7-0934812fbef6">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our revenue recognized in our consolidated condensed statements of operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,320.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,403.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration and other revenue &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;485.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;456.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,805.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,859.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Collaboration and other revenue associated with prior period transfers of intellectual property was $43.0 million and $35.4 million during the three months ended March&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenue by product for the three months ended March 31, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.699%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outside U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outside U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&#x2014;to unaffiliated customers:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diabetes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Trulicity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,116.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;335.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,452.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;929.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,229.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Humalog&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;332.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;284.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;617.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Humulin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;219.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;102.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;321.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Jardiance &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;151.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;160.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;312.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;175.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;71.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;246.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;66.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;94.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;161.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,061.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,049.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,111.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,991.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;977.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,968.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oncology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Alimta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;261.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;297.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;559.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Verzenio&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;172.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;96.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;269.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cyramza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;80.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;160.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;240.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Erbitux&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;107.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;122.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Tyvyt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;109.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;109.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;51.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;71.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;642.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;729.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,372.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;657.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,201.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Immunology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Taltz&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;249.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;153.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;403.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;443.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Olumiant&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;24.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;169.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;193.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;284.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;329.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;613.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;585.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neuroscience:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cymbalta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;165.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;176.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Emgality&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;101.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;119.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Zyprexa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;88.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;95.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;51.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;73.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;141.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;323.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;465.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;COVID-19 Antibodies &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;650.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;159.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;810.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Forteo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;97.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;100.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;198.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cialis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;118.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;126.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;54.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;53.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;107.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;811.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;431.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,242.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;640.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,941.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,864.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,805.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,328.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,531.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,859.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Numbers may not add due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Humalog revenue includes insulin lispro.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Jardiance revenue includes Glyxambi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Synjardy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;and Trijardy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; XR.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to Emergency Use Authorizations (EUAs). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenue by geographical area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.461%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&#x2014;to unaffiliated customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,941.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,328.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,321.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,061.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;571.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;592.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;362.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other foreign countries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;609.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;610.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,805.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,859.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Numbers may not add due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Revenue is attributed to the countries based on the location of the customer.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="i1b961987b212484fba2e55e3f8599292_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjRmMmJmMTRjYjNkMTRmYzlhOTMyMTdkYjIzMWFhNzk5L3RhYmxlcmFuZ2U6NGYyYmYxNGNiM2QxNGZjOWE5MzIxN2RiMjMxYWE3OTlfMi0xLTEtMS0w_03785b25-56a0-4de7-9429-0c09b0fe5ab5"
      unitRef="usd">6320000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i00e2ad623e9f4f09a525954c7be34a38_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjRmMmJmMTRjYjNkMTRmYzlhOTMyMTdkYjIzMWFhNzk5L3RhYmxlcmFuZ2U6NGYyYmYxNGNiM2QxNGZjOWE5MzIxN2RiMjMxYWE3OTlfMi0zLTEtMS0w_933928b0-4b7d-46c5-8150-d6ada1d5d9e1"
      unitRef="usd">5403500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib696b72b79fd4a64a05a14552524fd57_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjRmMmJmMTRjYjNkMTRmYzlhOTMyMTdkYjIzMWFhNzk5L3RhYmxlcmFuZ2U6NGYyYmYxNGNiM2QxNGZjOWE5MzIxN2RiMjMxYWE3OTlfMy0xLTEtMS0w_abeffc77-ed9f-49a2-921b-99f934035343"
      unitRef="usd">485600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia9bcfbde64cf4e6885eff068fd1c0181_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjRmMmJmMTRjYjNkMTRmYzlhOTMyMTdkYjIzMWFhNzk5L3RhYmxlcmFuZ2U6NGYyYmYxNGNiM2QxNGZjOWE5MzIxN2RiMjMxYWE3OTlfMy0zLTEtMS0w_b5f92ba6-f837-44bb-af82-4c369008a91e"
      unitRef="usd">456300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjRmMmJmMTRjYjNkMTRmYzlhOTMyMTdkYjIzMWFhNzk5L3RhYmxlcmFuZ2U6NGYyYmYxNGNiM2QxNGZjOWE5MzIxN2RiMjMxYWE3OTlfNC0xLTEtMS0w_e2466254-4b1c-42d5-84e3-adb2cd00661d"
      unitRef="usd">6805600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjRmMmJmMTRjYjNkMTRmYzlhOTMyMTdkYjIzMWFhNzk5L3RhYmxlcmFuZ2U6NGYyYmYxNGNiM2QxNGZjOWE5MzIxN2RiMjMxYWE3OTlfNC0zLTEtMS0w_346c0333-f621-411c-8941-80d8dc8eb8a3"
      unitRef="usd">5859800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3a64fdc1a7fc44278f9cf486b1d6c7cf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RleHRyZWdpb246ZTYyZjZlZTEwMTg1NGZhN2IxN2NjNWZjNDU1ZjVhNGRfMjM4_5b90024e-dd78-49cb-b2a9-0cdd52c79720"
      unitRef="usd">43000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i38bd7b2a836c4d14abc0e95512ba56c5_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RleHRyZWdpb246ZTYyZjZlZTEwMTg1NGZhN2IxN2NjNWZjNDU1ZjVhNGRfMjQ1_a2540f76-d446-46f1-bec0-a2e20ace801d"
      unitRef="usd">35400000</us-gaap:Revenues>
    <lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent
      contextRef="i0b2a402409bd47ceb3efc76f535f0984_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RleHRyZWdpb246ZTYyZjZlZTEwMTg1NGZhN2IxN2NjNWZjNDU1ZjVhNGRfMTA5OTUxMTYzMjUyNQ_64f45f88-44e1-419f-b95c-9b78b4662655"
      unitRef="number">0.02</lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RleHRyZWdpb246ZTYyZjZlZTEwMTg1NGZhN2IxN2NjNWZjNDU1ZjVhNGRfMzM5Mg_a20590c0-f11a-4876-b466-d92fce9f433f">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract liability balances:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.276%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;346.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjI0ZTcwNzA2YTA0MjQxM2E4YTE4Njc5ZjI2NGU4M2ExL3RhYmxlcmFuZ2U6MjRlNzA3MDZhMDQyNDEzYThhMTg2NzlmMjY0ZTgzYTFfMS0xLTEtMS0w_98e0a090-0409-41a6-9ae9-98b31c749fcc"
      unitRef="usd">346600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjI0ZTcwNzA2YTA0MjQxM2E4YTE4Njc5ZjI2NGU4M2ExL3RhYmxlcmFuZ2U6MjRlNzA3MDZhMDQyNDEzYThhMTg2NzlmMjY0ZTgzYTFfMS0zLTEtMS0w_52b8aa3b-2191-40f4-9407-b94416773d3a"
      unitRef="usd">276800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:Revenues
      contextRef="iec6120b958de4ece8b0bb1b2c92eb827_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNS0xLTEtMS0w_4f66f567-9c0a-4c9f-8128-b5251d29f0a3"
      unitRef="usd">1116800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i14a1f7c9c8094a24b89b05adbfa13722_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNS0yLTEtMS0w_7955e0e6-4e9f-4dd0-bb80-8c03f038c307"
      unitRef="usd">335700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1da1bf79aee54038ab5fb824f0b5459c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNS0zLTEtMS0w_8319a666-4a1c-4502-ad7e-5a9199b95737"
      unitRef="usd">1452400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7879b1c8e8154d82951f06d7277606ca_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNS01LTEtMS0w_86ab1026-90ea-489b-ab46-db48ee563ba7"
      unitRef="usd">929500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib22403656ba044288e3a7c9bd076149a_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNS02LTEtMS0w_c26c050d-7c65-480c-8c0e-573b699cc69c"
      unitRef="usd">299900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie60de7ffff384040bda8a7073de65757_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNS03LTEtMS0w_04113082-064a-4a2a-ba83-375e8581eb8a"
      unitRef="usd">1229400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i35e2453e887841ba845624286f429037_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNi0xLTEtMS0w_f5e08274-e4f7-4510-a9ef-38d7e3057cf0"
      unitRef="usd">332700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iac9fe39efa6e493c8fc3b5a5cb61875a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNi0yLTEtMS0w_b6bf08c3-968a-49da-8052-b0501f0f2d42"
      unitRef="usd">284400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i12fc66e4003b4a108dafd95f3f948eae_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNi0zLTEtMS0w_020d842b-3727-431f-b1f6-39468a0b167f"
      unitRef="usd">617000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaf36848406364477a5b09c68263549c0_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNi01LTEtMS0w_90d63d05-c14a-456f-a582-b94fc4e7c615"
      unitRef="usd">398600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0cec2d3e8980474dba0ccd4ba2f4be53_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNi02LTEtMS0w_bb8211b0-a021-49bc-b488-f459ea381b90"
      unitRef="usd">297200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7ac183bd15654d9ea8bfb79ecfdabc21_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNi03LTEtMS0w_17472488-fa01-4361-8d8d-547d412c09d4"
      unitRef="usd">695800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5d5411d889ea4b0c92badda1ff003164_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNy0xLTEtMS0zNjMx_65f93c6d-1cca-49e3-9f59-332ada8a4fd7"
      unitRef="usd">219000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i80b19d05555b462299ff41542279ba37_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNy0yLTEtMS0zNjMx_03770a81-b3dc-4328-9a11-75daa539f75d"
      unitRef="usd">102700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib8ce72672e984dc38dbee5c4872a819f_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNy0zLTEtMS0zNjMx_eeffdfe7-4d39-4737-bf1e-abd17ef8ff56"
      unitRef="usd">321700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4bd74f7f91ca4076b9bc23d4ac7407c8_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNy01LTEtMS0zNjMx_75182754-2b34-4afa-ac3b-d49eec86db1b"
      unitRef="usd">214100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie6cacb66e50b43a29e19d4cc6a18b475_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNy02LTEtMS0zNjMx_0d67ab58-520f-4f65-b075-84220d858c05"
      unitRef="usd">101500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i82b9a6cc26eb4896a200c5b2d5ee6aa5_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNy03LTEtMS0zNjMx_14e7bcee-661d-4c56-bb6e-36f9a1c31d5d"
      unitRef="usd">315700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i23a99b86356248b7a363e089040850b1_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNy0xLTEtMS0w_96876aeb-d36d-454b-b8bc-814dcc1ed10f"
      unitRef="usd">151200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1c94039dc776423e982d5e1215b9f0e7_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNy0yLTEtMS0w_07a03a6f-447b-4c2b-95b8-6761e349e362"
      unitRef="usd">160800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if95072ac7b3c4004b82c2aac605e5d70_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNy0zLTEtMS0w_aafa8472-ae8a-4bc6-80be-9b15648fda23"
      unitRef="usd">312000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i57d3bc0a03b5400f848a8a445a06af73_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNy01LTEtMS0w_d8e2c058-6d7d-4c3c-b864-5ea1a7228f6a"
      unitRef="usd">144600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5c9abc35851840cd80b9598eb84e59be_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNy02LTEtMS0w_4cae0cc0-9247-471f-8a9d-4804c0607ac4"
      unitRef="usd">122900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i65808f9c08a34e2fbb20de15f09d6663_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNy03LTEtMS0w_5bd7fdb7-0e99-4719-bc21-00d331b9d6a9"
      unitRef="usd">267500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i68c425bf807b4ecfb4bfc4e63113b9a5_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfOS0xLTEtMS0w_33595673-891d-46f9-a7c4-70bd0b328ad7"
      unitRef="usd">175200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i991e0184719242bb9681a766c00e183e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfOS0yLTEtMS0w_f47ed12a-e32e-4385-a129-f72d431ed912"
      unitRef="usd">71400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6308d09ed16f45708083f216e5eb9053_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfOS0zLTEtMS0w_dbc0725d-fc85-44cd-9fd8-4b1bfe2430d3"
      unitRef="usd">246600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9ad3a54cc6da48c7aabdfbd4ce0fd7d8_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfOS01LTEtMS0w_52650033-a694-4c97-aa1b-ef47a2b5083c"
      unitRef="usd">230400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i97e8d103205d4d8a8ddce47720e2b0df_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfOS02LTEtMS0w_32b5f669-6b71-4b03-bec4-11314720cbfb"
      unitRef="usd">73300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9b572a7d820847f2b77197f14a7598e9_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfOS03LTEtMS0w_5b2e845f-3e4b-4b3a-86bc-2680bbf4e4bd"
      unitRef="usd">303700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i37a9f92fe3be4a59bd100214c32741d5_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTEtMS0xLTEtMA_926932e5-593e-4b7f-b823-28104204d1bd"
      unitRef="usd">66300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iab3763aca7de40e3bd3755d4afdf8ddd_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTEtMi0xLTEtMA_57fb056b-d37f-459c-8d2f-448d9d609137"
      unitRef="usd">94900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i08fa42e2b3004f2c8d8c3d2949a77b62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTEtMy0xLTEtMA_6f77ea1f-35a9-42dd-aafa-c90a65001536"
      unitRef="usd">161400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if05b79fd4afb4b3b85e0170d60701765_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTEtNS0xLTEtMA_12938704-05e5-4c98-9b39-5e62117d230b"
      unitRef="usd">74000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i53e1ac90f1794867bdc0e1208a22454d_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTEtNi0xLTEtMA_d2cfea7b-68a1-43ab-b710-c91e566eb514"
      unitRef="usd">82900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie5488586d175451ea3762d3e3427d7fb_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTEtNy0xLTEtMA_d64b51de-c125-4335-afca-9fc26f294da5"
      unitRef="usd">156800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6655e736bfc145ae9b61bcbd43ca3775_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTItMS0xLTEtMA_a02eec77-6333-40c3-86c9-18c580b355f8"
      unitRef="usd">2061200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i95a511f3e56540efaf67326c58f115f8_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTItMi0xLTEtMA_0cbab2a4-4c15-4df7-a6fa-de79571bfb40"
      unitRef="usd">1049900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3a8600a4d0ae48ac8eb847f76d72fb39_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTItMy0xLTEtMA_c9234a1f-32e5-46f7-ae41-27f7c3d56ef9"
      unitRef="usd">3111100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5d683e3edb3b47769c30eadb5fc443db_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTItNS0xLTEtMA_cfe347ee-828c-4227-839b-c1b12f726954"
      unitRef="usd">1991200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia92a87d280ea46c88caa7e96c7a0c2c6_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTItNi0xLTEtMA_bc717e06-5720-43cf-9d94-671003e27840"
      unitRef="usd">977700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3dc1168de1ac4bd892f4336105fe8d34_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTItNy0xLTEtMA_c51ffb0f-c259-462a-897b-e047713186c8"
      unitRef="usd">2968900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib1eb5c54ee4f4ffd849c70b74454938b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTUtMS0xLTEtMA_4b9d1937-f406-4ef4-8362-b4ad3878c888"
      unitRef="usd">261100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i99351a29767e4c33b139db7c60592e0c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTUtMi0xLTEtMA_b041014b-b937-4571-9868-935fd56a1d3b"
      unitRef="usd">297800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8c035a4a36d1475c87f42c50e4fe5b66_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTUtMy0xLTEtMA_a19d5740-7f55-4a7e-bc3f-fa40b87c9d93"
      unitRef="usd">559000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ica6ff26a8f5c493bb678f8b8bdd2f5d0_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTUtNS0xLTEtMA_f47b8149-c703-46a3-97e1-7fdb4d02eb89"
      unitRef="usd">324200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9a84f264bd5f43d18f95d6449dbfd211_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTUtNi0xLTEtMA_caf6095c-800d-4aa0-a54e-53f03654fec4"
      unitRef="usd">235800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3ad5e6e9c6b04e0ca3a23762ff4389d4_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTUtNy0xLTEtMA_53dc05fd-0e58-4197-968b-174390ecfd61"
      unitRef="usd">560100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia3895e84ece4456f9fd7475f8330b5e2_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTUtMS0xLTEtMzYzOQ_6fb149a7-b32e-4029-b23c-d8c65860c785"
      unitRef="usd">172800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4bf54072320b4a95bcc03ebf93fd790b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTUtMi0xLTEtMzYzOQ_fe82de4d-d533-424e-ac03-4488aa9147dd"
      unitRef="usd">96200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1a64b17a7372474b936176a48e73353e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTUtMy0xLTEtMzYzOQ_2fe831bf-95a2-4b0c-874e-ee25f4ee2298"
      unitRef="usd">269000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id1ca44d898d14b6ba06c659cc8685067_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTUtNS0xLTEtMzYzOQ_586f8119-f23d-411e-bab7-3690733e6087"
      unitRef="usd">129400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaec1b41e2f1c429990d5463381ccb5b2_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTUtNi0xLTEtMzYzOQ_07bd4b8c-c15d-47f9-8ee8-c3829c8fd847"
      unitRef="usd">58600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic305b0216fae4bc4be68a9c14511b14b_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTUtNy0xLTEtMzYzOQ_25753e2f-fb7f-44d6-9469-a4a5740f2c55"
      unitRef="usd">188000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifc30d8c3304846bf98d3aff4faa90db6_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTYtMS0xLTEtMA_a1e43dcf-daab-480b-933e-b8858367c67f"
      unitRef="usd">80200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i301b5063b45f4c778fa6be355225f1d2_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTYtMi0xLTEtMA_44f909dc-bded-4dc4-90af-62e00831ff0f"
      unitRef="usd">160300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6ac8015a990a47ac84766a6b061f5c80_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTYtMy0xLTEtMA_124c656e-0fa3-46fd-9d3e-eb02c58aaa83"
      unitRef="usd">240500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ice0f65e55bc14fb4a8b9c74295879c9f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTYtNS0xLTEtMA_b08dd4d2-5cfa-4138-ac24-923a056cdf49"
      unitRef="usd">89100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iabd56efbd9ee475196495211900a4916_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTYtNi0xLTEtMA_25477350-7944-4a5f-9201-dab4b3849e69"
      unitRef="usd">149900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib4990ade4fb749c5becfec40f273af6a_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTYtNy0xLTEtMA_f0514538-f30a-4f4f-9e66-d9386fe75291"
      unitRef="usd">239000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idc1ec2db8e1b4baa971e09c08d4342fd_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTgtMS0xLTEtMA_e892bae4-aaab-4387-b900-f69a86cfd6ad"
      unitRef="usd">107900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i699a1a79461d4373af3cf037c5ca77a1_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTgtMi0xLTEtMA_ec723406-69a8-450e-8401-daca49d88901"
      unitRef="usd">14400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icbf8577a767f4b6fa45fbea9fc0008e8_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTgtMy0xLTEtMA_5a2d0784-2491-4bd5-99e3-5f2db37cda1f"
      unitRef="usd">122400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9a65c960be0f46ebaab122d5eb8f5e3c_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTgtNS0xLTEtMA_8c37255d-902f-4885-9e28-ea339b8abaa1"
      unitRef="usd">117800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib410c05551594d84936a917166832ea9_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTgtNi0xLTEtMA_c758f8ee-e6a5-4cec-81cf-4977fdd964fa"
      unitRef="usd">13000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8d36ff64df614dd2a64ea2e3cb167f9b_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTgtNy0xLTEtMA_80b4b6c3-fc00-479b-8587-88f6ed1636ed"
      unitRef="usd">130800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if30239ae11764340af612d6d0acb2802_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTgtMS0xLTEtNTkwOQ_dd13c573-a839-4cdf-be82-18ed024672d9"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i55a39c6d0d9146729c9cbfd483622222_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTgtMi0xLTEtNTkwOQ_b1fa3217-3b4b-4488-be3c-9a95a7c78d93"
      unitRef="usd">109700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i10cbac4f340148c58e34434fbbf2a27f_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTgtMy0xLTEtNTkwOQ_1494f895-e1dc-4797-a905-5c54a4bd2f9a"
      unitRef="usd">109700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5a346e0ad24144caac752ea7f4355d34_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTgtNS0xLTEtNTkxMg_730ab310-6c00-4dda-a369-75dc317202d0"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i37c6a808e0e24c1f8e75607e3a823271_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTgtNi0xLTEtNTkxMg_0f70f948-9ad1-4927-a458-413ccdf9f113"
      unitRef="usd">57400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia3156015f19b4add93eceadb6f839944_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTgtNy0xLTEtNTkxMg_c2095b64-e688-40c2-a2c4-425ccf0506cd"
      unitRef="usd">57400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i16d7bf43c3214967ae1523ebc568940c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTktMS0xLTEtMA_e3821a8e-0522-4d9c-ae02-c470701ee86e"
      unitRef="usd">20500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1a1925d8bba04bf5a88ae7c5a2c5a30e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTktMi0xLTEtMA_4a13c13b-011a-4f81-9958-3b706f8fa620"
      unitRef="usd">51300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i65134b9feaf3468bae4f56eb446cc39b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTktMy0xLTEtMA_6d72189b-6ae0-4552-b604-9c3ac0ade6dd"
      unitRef="usd">71600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6b08818da51f405ab315d6a7b99fcdb8_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTktNS0xLTEtMA_021d56da-a8f7-4857-853c-7f4c7b0b1cf6"
      unitRef="usd">-2600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9f8df345856f4facb882054634c50249_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTktNi0xLTEtMA_3ca7b4cd-f2dd-4e26-bc4c-ff99aa9515b4"
      unitRef="usd">28900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6b44fc5413ea4394a3af4e9ae8cc9357_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMTktNy0xLTEtMA_45bd42f8-67c4-4009-8b9b-79362f426b07"
      unitRef="usd">26200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic6c1690f2a1044549cd196b5d0d49bad_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjAtMS0xLTEtMA_d62dbc9b-63d6-40ef-bd33-d5d6b43d7120"
      unitRef="usd">642500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5f2094304a9b41efa6498348dc920bd5_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjAtMi0xLTEtMA_f39017a6-86f6-4f77-96b8-54b72a79a22e"
      unitRef="usd">729700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iccb5bb5fcf05439eafdaafbbf45b94dc_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjAtMy0xLTEtMA_3efabe92-683f-4d77-9f06-5ece818aca4c"
      unitRef="usd">1372200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if46aa3d35d9f4f9e9f98c940d7063f27_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjAtNS0xLTEtMA_207a841e-6a29-493c-a10c-a6be02b90d7d"
      unitRef="usd">657900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i27ef923c97994ad09a5131b38a10eff2_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjAtNi0xLTEtMA_48fb196d-b7f8-4e0b-921a-7be87b6aba7b"
      unitRef="usd">543600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i22ac5026b0df4c01a41cbb9fd7bf0ed4_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjAtNy0xLTEtMA_556d4b96-7732-49d7-9eb3-9eb503c906a7"
      unitRef="usd">1201500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1e7b860d15e24b6d8a4c42caa07a07e9_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjMtMS0xLTEtMA_821a1405-f33e-438a-875c-db72c58fbc51"
      unitRef="usd">249600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic9d2acfb73014f21b93868d591ba0055_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjMtMi0xLTEtMA_9a1ade00-ee6a-4490-b4ff-cc840a222285"
      unitRef="usd">153600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic86716e51463478c9178d57dbc0df5e9_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjMtMy0xLTEtMA_7b833611-ad34-40b6-8565-e2cc8bcc0cea"
      unitRef="usd">403200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1eca7f391c9c4eb4bf1be4d2f78c64f1_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjMtNS0xLTEtMA_e245bfb9-d929-4354-9bd7-1d42774957d0"
      unitRef="usd">327500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i23a06e4fd12547b68a8c1fa847a573cd_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjMtNi0xLTEtMA_b28c6d9c-c21c-41dc-b5d0-47a2ba434d18"
      unitRef="usd">116000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2cdd8652ee714626a6ac6694e023589f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjMtNy0xLTEtMA_ab1185d0-0961-41f9-8a95-52888c0756cc"
      unitRef="usd">443500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibe710610bc2745d6b62b94d3e5a59c49_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjQtMS0xLTEtMA_9e543814-3451-44fb-973b-c0ed60e63dd6"
      unitRef="usd">24700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib5195f2602fa4de78f56cde487a199e9_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjQtMi0xLTEtMA_4d810de1-2f5f-42f5-bcb4-a82d890e20a8"
      unitRef="usd">169100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id181bab5e80145f7b4aac52329fa68c0_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjQtMy0xLTEtMA_43dfdcb5-e735-4121-ad47-147da4f5a662"
      unitRef="usd">193800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id181bab5e80145f7b4aac52329fa68c0_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjQtMy0xLTEtMA_ba60441b-b236-48e2-9d7f-ff80305eb163"
      unitRef="usd">193800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8e4a642cedfe46019dbf6bdbe6fbe49e_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjQtNS0xLTEtMA_1f7cad31-7de3-4f61-b43b-386a96321e7a"
      unitRef="usd">11300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i82c451df337849a9aa0ebbd6efa659e5_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjQtNi0xLTEtMA_5f9beb2b-cffd-4dae-996d-bcb53c4c5b86"
      unitRef="usd">128400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6c5697fd7da74cdbb6d77c6a62017381_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjQtNy0xLTEtMA_72d5363b-b180-417d-b6c7-91b3343689d9"
      unitRef="usd">139700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6c5697fd7da74cdbb6d77c6a62017381_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjQtNy0xLTEtMA_eff31ee2-fe9a-417e-9b48-e79b1e0348ce"
      unitRef="usd">139700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id5d69a9f098946b99fd0dc8d1e98e66a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjUtMS0xLTEtMA_8daf5991-22ef-48a0-8471-ffc68d24bec8"
      unitRef="usd">10500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9d569029e59948f09619b73bf0efdca2_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjUtMi0xLTEtMA_0e64a3b5-21ed-4a2f-91d5-028001e680d8"
      unitRef="usd">6400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8ec2c9c0bb35428e84cb57a3987f75e0_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjUtMy0xLTEtMA_d88ee19d-b17a-440c-8274-0c2591d1119e"
      unitRef="usd">16900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ida0989eec65245df9b1682cf38ed4bd2_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjUtNS0xLTEtMA_eb9d6fc3-bed2-4a79-aa4e-e45e895a4220"
      unitRef="usd">2600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3bc0464b0bdb43f5a8e902cdb4b263da_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjUtNi0xLTEtMA_92a84263-a5df-46e5-b0d4-a8947cea3aaf"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia8cb347768764c2b955eac4a8f4a17ad_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjUtNy0xLTEtMA_2eff3293-2a61-4971-b25a-9166f6b56ee3"
      unitRef="usd">2600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i98c884b95b7b4a8493c13f83a7b6caa7_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjYtMS0xLTEtMA_6d5b2d5f-8334-4484-bc00-1cb47c3576b1"
      unitRef="usd">284800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5c53c31a3a5c43e680ca9bf03cd18bab_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjYtMi0xLTEtMA_2bb5d873-800b-403d-972c-86c6d680cbb5"
      unitRef="usd">329100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9f23306ae00143a6a4003c6797529b59_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjYtMy0xLTEtMA_a395506b-e34e-4b22-9107-01577b0a6eca"
      unitRef="usd">613900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if6964e815afd40a1a706fd094d27e141_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjYtNS0xLTEtMA_c96d7e64-4aff-40cb-9424-c6a24499364f"
      unitRef="usd">341400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9ff073cd832f489a918e71ed9f2bc601_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjYtNi0xLTEtMA_92e8db33-91f8-4811-80dc-660bcc762e95"
      unitRef="usd">244400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icaab0628ba61471db8a691d30a7a5ae6_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjYtNy0xLTEtMA_03583474-a9e5-4836-9303-3471aeae8d96"
      unitRef="usd">585800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie6540e5cb4f94023bd8a1a99cae7dd50_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjktMS0xLTEtMA_1709741e-a5c7-437c-8cbf-9812972e95e5"
      unitRef="usd">11000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if0244d48c6684b1d90aaffa07334e12c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjktMi0xLTEtMA_377c945d-0c51-402b-b471-64631d0eb054"
      unitRef="usd">165700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3a035aacb6aa496e9aacfa82670a5f77_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjktMy0xLTEtMA_aa7d3802-acbb-4c50-a36d-8ff9f7c90599"
      unitRef="usd">176600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2126f23f1b6c45da8eda485ea4fb0ffd_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjktNS0xLTEtMA_9e1e9b22-fda7-475e-8582-e40580488905"
      unitRef="usd">11600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i476ff2f62e6e4dcd89e4d0e6f6e2e23a_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjktNi0xLTEtMA_e81f2805-12ac-457f-9502-c33d3bd09114"
      unitRef="usd">198800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icd995ff940774cf9958d9496ccefdd49_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjktNy0xLTEtMA_1c33885e-dfd8-4327-b85a-47194c584e1c"
      unitRef="usd">210400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i91bb5aef62c64ba6b7374026ad6cb167_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjktMS0xLTEtMzY0Nw_a7e20e58-02e0-478e-8040-b75b11d1b42d"
      unitRef="usd">101500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibc1a4bfd08874c51bd52ae124d146ed1_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjktMi0xLTEtMzY0Nw_fdc60b3a-825d-416c-a68c-2e28976a2af1"
      unitRef="usd">18000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1d060a91a83540adba28a86e89f8a0a9_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjktMy0xLTEtMzY0Nw_87d3660d-5c73-4ab8-af0c-4b9e97561451"
      unitRef="usd">119500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7ead156d8e30415e96ef9f5d2ae30817_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjktNS0xLTEtMzY0Nw_468e6097-73e2-485f-962f-e485d6fc19a4"
      unitRef="usd">67300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7ead156d8e30415e96ef9f5d2ae30817_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjktNS0xLTEtMzY0Nw_ec2bdabf-07de-46f0-9126-e195a820151c"
      unitRef="usd">67300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1019c9ffdc464664a457a1558f80f5c1_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjktNi0xLTEtMzY0Nw_68cc054c-472c-4e86-ba72-7d30c5262036"
      unitRef="usd">6700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1019c9ffdc464664a457a1558f80f5c1_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjktNi0xLTEtMzY0Nw_de70a077-08ed-49c6-9944-08a28e4fbe48"
      unitRef="usd">6700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1d28979d157949e8beda765ff3ebba18_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMjktNy0xLTEtMzY0Nw_5cb3666b-706e-4437-b613-183f14e15ba5"
      unitRef="usd">74000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i59a5e3ece3b2457d9dc9503670f62a19_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzAtMS0xLTEtMA_14b3a014-62b6-4f30-824c-3281b096a49b"
      unitRef="usd">6900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idcb95436aea141439b320a672d06798b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzAtMi0xLTEtMA_6556d913-23e3-4039-a647-94131b19b45b"
      unitRef="usd">88900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibbdb540b92834be9a1952a6988efe111_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzAtMy0xLTEtMA_537d2206-f07a-4fd0-b455-5b4712c4a9fe"
      unitRef="usd">95800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id5ec8f6c1a2745b6aef8220c52179da0_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzAtNS0xLTEtMA_2a898070-554b-49a4-90a7-8834f3abfb70"
      unitRef="usd">11200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifdac2859144646f497bdee29d8f1077c_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzAtNi0xLTEtMA_5965c6b7-a80d-49f5-8169-b104d98022f3"
      unitRef="usd">87200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6ecf74960c9f4004bfb28db9ceeee105_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzAtNy0xLTEtMA_d1286232-001d-496d-9ea9-184f578d75e9"
      unitRef="usd">98400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibe3a395375b74608adcd0dcb2511ccb6_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzMtMS0xLTEtMA_cabd0fa4-bc12-40c0-8aad-b0de68273fde"
      unitRef="usd">22300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4e845118c19743509f235e3de1249c91_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzMtMi0xLTEtMA_2507100c-1886-4840-b16d-183d3cbc4541"
      unitRef="usd">51100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i956b8eaf8bcc48e18a6392d104e3f82f_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzMtMy0xLTEtMA_fc8b4dd9-aaba-4637-b01d-dc14a57f26fe"
      unitRef="usd">73500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7f802e7b0b4c462498edd33fe1a08df8_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzMtNS0xLTEtMA_d5c8f589-9d63-468f-93bd-a9f31322c4dc"
      unitRef="usd">20200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i41bf8c2f57c2453187f38f71658035fd_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzMtNi0xLTEtMA_ecec1dcc-bca2-4e5b-9fdc-44e0c771ae8d"
      unitRef="usd">60500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iccd1e7bf99a04464a2be5ae2844e93c3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzMtNy0xLTEtMA_57a1733f-5d72-416c-90bc-68dee9467df1"
      unitRef="usd">80700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3a96f967a3e14ccfbf1709108752b15a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzQtMS0xLTEtMA_58db5dec-c3f2-4bad-8685-0ea3321bfae2"
      unitRef="usd">141700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5e1de888a7434a7d8901d5d91e9a5662_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzQtMi0xLTEtMA_4d506696-6955-48af-915e-59f46f157a3d"
      unitRef="usd">323700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i805e06baf0334dd2a9272620abb71ef1_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzQtMy0xLTEtMA_9f3ccbbb-3813-44ba-8bee-2d93c852fce5"
      unitRef="usd">465400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7bf6f39de92a477295091f337c5f246d_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzQtNS0xLTEtMA_cf22b358-6e57-40ed-ae3f-80ca874dcfc7"
      unitRef="usd">110300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i87c3683c282e4dcab93976f033317191_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzQtNi0xLTEtMA_6fc5e62a-736f-4ac8-8130-e838a28f1eae"
      unitRef="usd">353200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib781ea03fa4343ea9f43fe30bf85eaff_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzQtNy0xLTEtMA_d950276b-5811-44d1-b69a-755d4eac702f"
      unitRef="usd">463500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib9004a4576d54acdab802ba18e5954b5_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzgtMS0xLTEtMzYwOA_60affd60-a097-4595-a747-dca3ae7397ff"
      unitRef="usd">650600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5b813d4b7f6a4ba8ab05eb62fa8c0d7e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzgtMi0xLTEtMzYwOA_0b8eaeaf-9a60-4300-a57f-19f1e07bf504"
      unitRef="usd">159500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1e2d53c2e70b4fa7b373f89ff566d337_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzgtMy0xLTEtMzYwOA_287208df-52a7-4065-8892-5d3b6e35705c"
      unitRef="usd">810100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie6e00607e2514771bb461112b624c3c8_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzgtNS0xLTEtMzYwOA_0e2cae64-98d9-4c66-9bb1-587c5733f421"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i678860fa552c43d4b4fcb6cefb64112a_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzgtNi0xLTEtMzYwOA_0bbff655-0788-4ea7-aeff-9125460078e1"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i009fa3f9194b481097ec59ef54e9398c_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzgtNy0xLTEtMzYwOA_fb8da522-d627-4243-b500-71cfb89b670e"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic91d06961c624604bf888bc77f143328_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzgtMS0xLTEtMA_cb3102df-a6bc-41e5-9ce5-708bc2e1baca"
      unitRef="usd">97700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1a70d046e3e04fe8814a35c37222c987_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzgtMi0xLTEtMA_1de89ddf-6d15-49b9-b555-98ad2189865c"
      unitRef="usd">100800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5a1a9bda61764661a686cd2e6cdf4353_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzgtMy0xLTEtMA_25e677b0-e5e0-4d99-8fcf-71b705d40801"
      unitRef="usd">198500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2f37eacef6da488b9411e64b1e6f9bf8_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzgtNS0xLTEtMA_71290bb5-bbc1-4c1f-a640-45a4f20217fd"
      unitRef="usd">122500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i46371b039efc4855ab60d1a0cfdee9ef_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzgtNi0xLTEtMA_8dbcb534-f565-4a67-9347-d19780bcb521"
      unitRef="usd">149800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iae0c3902df5443afaa207966c3c336ae_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzgtNy0xLTEtMA_f3925561-5ba8-440f-af56-e8792f167a71"
      unitRef="usd">272400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i01ed93e108f540d895209d6cd63a4196_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzktMS0xLTEtMA_8c8f637a-c30a-4af6-b994-a67ea3fbec43"
      unitRef="usd">8600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i02826dfbba6c48f19cdc43d704001dbe_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzktMi0xLTEtMA_a78c5581-be87-4fde-9d0f-5a606d50cfc3"
      unitRef="usd">118100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0da8ce69328d41578d3e52a25ef5c637_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzktMy0xLTEtMA_0755f358-1bb3-4252-bffc-88acdde89d9b"
      unitRef="usd">126800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icf3afa843ed74fd3a1dccd7d9a340f73_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzktNS0xLTEtMA_96ed555a-4c5e-4106-b682-d783869558c4"
      unitRef="usd">26100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icdbb2ee92d984ead82d0bfe89b0b7e67_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzktNi0xLTEtMA_aa6ed3e0-ada1-4fe7-865a-183e48ce5e3c"
      unitRef="usd">167000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5b635789ef4a4a3ea608c5ece8aad1d5_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfMzktNy0xLTEtMA_5bf6594a-65ef-47d8-b9c7-2c89179a8b68"
      unitRef="usd">193000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia0503e2189e0437c94e4365e2f5e1a42_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDAtMS0xLTEtMA_897b229e-37a9-4f90-a795-2c16677de794"
      unitRef="usd">54200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if7a3d52cbc5f4c36913820afde8b5ce0_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDAtMi0xLTEtMA_dec1123b-9fb4-46f3-ada1-71582f018212"
      unitRef="usd">53400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i29a85ee0346840baa3213980b51c8392_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDAtMy0xLTEtMA_33338d0c-7c8e-44b5-9399-dca215404a26"
      unitRef="usd">107500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i48278fe6c84a480c993daadca8e14bec_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDAtNS0xLTEtMA_830f38e5-eeb1-4afe-9399-d429ef2187bc"
      unitRef="usd">79400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id2da738de9a9496d82ebcd1ed1dfc349_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDAtNi0xLTEtMA_c2893e08-2554-4cc8-b63d-a99cc13b006a"
      unitRef="usd">95300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i72d5f436073e4013afbbcd703dec4745_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDAtNy0xLTEtMA_62f00c01-f336-45d3-943c-79ee36be5b52"
      unitRef="usd">174700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3f47b5c8b6e647f7a98ae58501327a48_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDEtMS0xLTEtMA_d12c39f3-2f9b-4c52-ad42-8c3411ea8d51"
      unitRef="usd">811100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7ba01d74fb2f4bc0a8c1b64e3b1eef96_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDEtMi0xLTEtMA_88f090ca-62a0-45f3-924a-f8e7d8e9c86c"
      unitRef="usd">431800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i91fdfa6c20d94c5db431e71629735e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDEtMy0xLTEtMA_944790e6-c38b-470e-97fb-b50bfa9b7ebe"
      unitRef="usd">1242900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3bdeb0b05ca8485aae2687a910e899e8_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDEtNS0xLTEtMA_1b32ac05-2480-4752-9b92-d3e2ac19eb5f"
      unitRef="usd">228000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibf27f4b868ff4ca6852de83fc00626db_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDEtNi0xLTEtMA_92b1a8b2-2227-40d8-8085-82c004008439"
      unitRef="usd">412100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i725c25318b374568a7f6a1c522f751f5_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDEtNy0xLTEtMA_bd1638e2-761f-4aea-9948-a760e4bddf72"
      unitRef="usd">640100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iddbce9adb77b4313a6ec25296cfc82c6_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDItMS0xLTEtMA_a1d0804d-182d-4dbf-8f9c-6e154fa32ebd"
      unitRef="usd">3941300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic8f05f60f5234be3b895a985508995c8_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDItMi0xLTEtMA_adc413f7-cec7-400f-8bf3-e5dc03a65a66"
      unitRef="usd">2864300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDItMy0xLTEtMA_4b6e8fa4-7d70-4f2a-a5d4-22aff23211dc"
      unitRef="usd">6805600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i35174116703c48a1ba3d71d19b34d188_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDItNS0xLTEtMA_0d977cc7-613d-4854-ba8d-997ae56f3841"
      unitRef="usd">3328800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iecc41b1e93894363b921a691b8c9ad5f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDItNi0xLTEtMA_0cb0ffd8-9857-458f-91c2-2c0c8b2646b5"
      unitRef="usd">2531000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOmIzZmE0MTFhNDU1ODRmODdhNjlmZDhmNWE3ZGViNTUzL3RhYmxlcmFuZ2U6YjNmYTQxMWE0NTU4NGY4N2E2OWZkOGY1YTdkZWI1NTNfNDItNy0xLTEtMA_63f76030-5ba4-4b9c-8f25-fa75b15dd0b4"
      unitRef="usd">5859800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iddbce9adb77b4313a6ec25296cfc82c6_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjljY2I1MjY1NWJlMjQ5YjA4MmJhZjMwYzQ2NzAwMGY3L3RhYmxlcmFuZ2U6OWNjYjUyNjU1YmUyNDliMDgyYmFmMzBjNDY3MDAwZjdfMy0xLTEtMS0w_69d784ca-1c74-435b-be92-ca91c961dd02"
      unitRef="usd">3941300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i35174116703c48a1ba3d71d19b34d188_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjljY2I1MjY1NWJlMjQ5YjA4MmJhZjMwYzQ2NzAwMGY3L3RhYmxlcmFuZ2U6OWNjYjUyNjU1YmUyNDliMDgyYmFmMzBjNDY3MDAwZjdfMy0zLTEtMS0w_9c7065da-483f-4a4e-8fb6-5b4c4b4435d3"
      unitRef="usd">3328800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1a8c46f072984025becf4f91f04a0ad4_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjljY2I1MjY1NWJlMjQ5YjA4MmJhZjMwYzQ2NzAwMGY3L3RhYmxlcmFuZ2U6OWNjYjUyNjU1YmUyNDliMDgyYmFmMzBjNDY3MDAwZjdfNC0xLTEtMS0w_10d6e43d-1d95-492a-bf90-8939490e3bc5"
      unitRef="usd">1321200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i53a4c1fd0f0e411bbd983b92368c6662_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjljY2I1MjY1NWJlMjQ5YjA4MmJhZjMwYzQ2NzAwMGY3L3RhYmxlcmFuZ2U6OWNjYjUyNjU1YmUyNDliMDgyYmFmMzBjNDY3MDAwZjdfNC0zLTEtMS0w_b23a1060-ce44-49f1-bd3c-1e9e1f9894d0"
      unitRef="usd">1061000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia8476fa283c5420a8c1cb44bf1886c3e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjljY2I1MjY1NWJlMjQ5YjA4MmJhZjMwYzQ2NzAwMGY3L3RhYmxlcmFuZ2U6OWNjYjUyNjU1YmUyNDliMDgyYmFmMzBjNDY3MDAwZjdfNS0xLTEtMS0w_f038800b-140c-4413-b5e0-80017bbf49c4"
      unitRef="usd">571800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8a141f4168094f93bc307eb5ebbf7392_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjljY2I1MjY1NWJlMjQ5YjA4MmJhZjMwYzQ2NzAwMGY3L3RhYmxlcmFuZ2U6OWNjYjUyNjU1YmUyNDliMDgyYmFmMzBjNDY3MDAwZjdfNS0zLTEtMS0w_67bb26be-6ac7-4e3a-89b1-6557422ddefe"
      unitRef="usd">592300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaf7492d96a0b4f29b67c7ffc8e4fc10e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjljY2I1MjY1NWJlMjQ5YjA4MmJhZjMwYzQ2NzAwMGY3L3RhYmxlcmFuZ2U6OWNjYjUyNjU1YmUyNDliMDgyYmFmMzBjNDY3MDAwZjdfNi0xLTEtMS0w_5309b16d-74d1-4958-85e6-5d89bef7fff1"
      unitRef="usd">362200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2d6aaabb8fc4471fb4d955cbdc949682_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjljY2I1MjY1NWJlMjQ5YjA4MmJhZjMwYzQ2NzAwMGY3L3RhYmxlcmFuZ2U6OWNjYjUyNjU1YmUyNDliMDgyYmFmMzBjNDY3MDAwZjdfNi0zLTEtMS0w_76331d3d-5faa-4c9e-baf4-2981aa689a53"
      unitRef="usd">267300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1d1b2d8fe9744bfb992ea8ca03c8de17_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjljY2I1MjY1NWJlMjQ5YjA4MmJhZjMwYzQ2NzAwMGY3L3RhYmxlcmFuZ2U6OWNjYjUyNjU1YmUyNDliMDgyYmFmMzBjNDY3MDAwZjdfNy0xLTEtMS0w_69443a3e-aac5-40d3-b5a6-025df928ff3e"
      unitRef="usd">609100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7fb432a8a93945a68250848e46684f98_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjljY2I1MjY1NWJlMjQ5YjA4MmJhZjMwYzQ2NzAwMGY3L3RhYmxlcmFuZ2U6OWNjYjUyNjU1YmUyNDliMDgyYmFmMzBjNDY3MDAwZjdfNy0zLTEtMS0w_3c591930-d0c1-4d95-95b1-67a6d9a848b2"
      unitRef="usd">610400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjljY2I1MjY1NWJlMjQ5YjA4MmJhZjMwYzQ2NzAwMGY3L3RhYmxlcmFuZ2U6OWNjYjUyNjU1YmUyNDliMDgyYmFmMzBjNDY3MDAwZjdfOC0xLTEtMS0w_8090a2ef-b28f-4707-a0ab-9ca08a41ba3a"
      unitRef="usd">6805600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80MC9mcmFnOmU2MmY2ZWUxMDE4NTRmYTdiMTdjYzVmYzQ1NWY1YTRkL3RhYmxlOjljY2I1MjY1NWJlMjQ5YjA4MmJhZjMwYzQ2NzAwMGY3L3RhYmxlcmFuZ2U6OWNjYjUyNjU1YmUyNDliMDgyYmFmMzBjNDY3MDAwZjdfOC0zLTEtMS0w_8d0e9611-a5e6-4efb-8ef5-5fba0c98e408"
      unitRef="usd">5859800000</us-gaap:Revenues>
    <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfNzI5Mw_65c4c3c3-765a-4151-ac9a-b89405a6752d">Acquisitions&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021 and February 2020, we completed the acquisitions of Prevail Therapeutics Inc. (Prevail) and Dermira, Inc. (Dermira), respectively. These transactions, as further discussed in this note below in Acquisitions of Businesses, were accounted for as business combinations under the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions are included in our consolidated condensed financial statements from the date of acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also acquired assets in development which are further discussed in this note below in Asset Acquisitions. Upon each acquisition, the cost allocated to acquired in-process research and development (IPR&amp;amp;D) was immediately expensed because the compound had no alternative future use. We recognized $299.3 million and $52.3 &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of acquired IPR&amp;amp;D charges for the three months ended March&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisitions of Businesses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Prevail Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Overview of Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, we acquired all shares of Prevail for a purchase price that included $22.50 per share in cash (or an aggregate of $747.4 million, net of cash acquired) plus one non-tradable contingent value right (CVR) per share. The CVR entitles Prevail stockholders to up to an additional $4.00 per share in cash (or an aggregate of approximately $160&#160;million) payable, subject to certain terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom, Germany, France, Italy or Spain. To achieve the full value of the CVR, such regulatory approval must occur by December 31, 2024. If such regulatory approval occurs after December 31, 2024, the value of the CVR will be reduced by approximately 8.3 cents per month until December 1, 2028, at which point the CVR will expire.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prevail is a biotechnology company developing potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The acquisition establishes a new modality for drug discovery and development, extending our research efforts through the creation of a gene therapy program that will be anchored by Prevail&#x2019;s portfolio of assets. Prevail&#x2019;s lead gene therapies in clinical development are PR001 for patients with Parkinson&#x2019;s disease with GBA1 mutations and neuronopathic Gaucher disease and PR006 for patients with frontotemporal dementia with GRN mutations. Both PR001 and PR006 were granted Fast Track designation from the U.S. Food and Drug Administration (FDA). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets Acquired and Liabilities Assumed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our access to Prevail information was limited prior to the acquisition. As a consequence, we are in the process of determining fair values and tax bases of a significant portion of the assets acquired and liabilities assumed, including the identification and valuation of intangible assets and tax exposures. The final determination of these amounts will be completed as soon as possible but no later than one year from the acquisition date. The final determination may result in asset and liability fair values and tax bases that differ from the preliminary estimates and require changes to the preliminary amounts recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.016%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value at January 22, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;834.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition date fair value of consideration transferred &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Fair value of CVR liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Acquired IPR&amp;amp;D intangibles primarily relate to PR001.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The goodwill recognized from this acquisition is not deductible for tax purposes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;See Note 6 for a discussion on the estimation of the CVR liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pro forma information has not been included as this acquisition did not have a material impact on our consolidated condensed statements of operations for the three months ended March 31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Dermira Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Overview of Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020, we acquired all shares of Dermira for a purchase price of approximately $849.3 million, net of cash acquired. Under the terms of the agreement, we acquired lebrikizumab, a novel, investigational, monoclonal antibody being evaluated for the treatment of moderate-to-severe atopic dermatitis. Lebrikizumab was granted Fast Track designation from the FDA. We also acquired Qbrexza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (glycopyrronium) cloth, a medicated cloth approved by the FDA for the topical treatment of primary axillary hyperhidrosis (uncontrolled excessive underarm sweating). During the three months ended March&#160;31, 2021, we decided to sell the rights to Qbrexza. See Note 5 for additional information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets Acquired and Liabilities Assumed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values recognized related to the assets acquired and liabilities assumed in this acquisition included goodwill of $86.8 million, other intangibles of $1.20 billion primarily related to lebrikizumab, deferred income tax liabilities of $49.5 million, and long-term debt of $375.5 million. After the acquisition, we repaid $276.2 million of long-term debt assumed as part of our acquisition of Dermira.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Asset Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our asset acquisitions during the three months ended March&#160;31, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.916%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Counterparty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Compound(s) or Therapy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquisition Month&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Phase of Development &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquired IPR&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Precision Biosciences, Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development of potential in vivo therapies for genetic disorders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;107.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Merus N.V. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CD3-engaging T-cell re-directing bispecific antibodies for the potential treatment of cancer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;46.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asahi Kasei Pharma Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AK1780, an orally bioavailable P2X7 receptor antagonist for the potential treatment of chronic pain conditions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phase I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rigel Pharmaceuticals, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the potential treatment of autoimmune and inflammatory diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phase I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;125.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sitryx Therapeutics Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical targets that could lead to potential new medicines for autoimmune diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AbCellera Biologics Inc. (AbCellera)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neutralizing antibodies for the treatment and prevention of COVID-19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; We recognized an acquired IPR&amp;amp;D expense of $25.0 million in May 2020 upon closing of the transaction. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with these arrangements, our partners may be entitled to future royalties and/or commercial milestones based on sales should products be approved for commercialization and/or milestones based on the successful progress of compounds through the development process.&lt;/span&gt;&lt;/div&gt;</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfNzI5NQ_660d065c-49eb-43df-b468-9119d86187ab">Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions are included in our consolidated condensed financial statements from the date of acquisition.Upon each acquisition, the cost allocated to acquired in-process research and development (IPR&amp;amp;D) was immediately expensed because the compound had no alternative future use.</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfMTA5OTUxMTYzNTI5Nw_c1726182-6323-41a7-ab12-320e1c94ecf2"
      unitRef="usd">299300000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfMTM4Mg_9587bc0b-3486-4772-9d87-da9a861caf6c"
      unitRef="usd">52300000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="ia3e93321ddf644359c1906deaf4915d8_I20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfNDk0NzgwMjM1ODc0MQ_adf8230b-a63f-438d-b5ac-4ebef0d49e25"
      unitRef="usdPerShare">22.50</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="if8e0d422156841d5ad8a9105568a5622_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfMTA5OTUxMTY2MDY3NQ_e1639a03-a0de-40c9-a68a-914a2f8fc235"
      unitRef="usd">747400000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <lly:BusinessCombinationConsiderationTransferredNumberOfContingentValueRights
      contextRef="if8e0d422156841d5ad8a9105568a5622_D20210101-20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfNDk0NzgwMjM1MDQ1Mw_99f2580c-5b75-4669-ae75-fe6a66c34996"
      unitRef="right">1</lly:BusinessCombinationConsiderationTransferredNumberOfContingentValueRights>
    <lly:BusinessAcquisitionContingentValueRightAdditionalPricePerShare
      contextRef="ia3e93321ddf644359c1906deaf4915d8_I20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfNDk0NzgwMjM1ODc1NQ_ef6771c6-8094-469d-8e1f-805780b3eff2"
      unitRef="usdPerShare">4.00</lly:BusinessAcquisitionContingentValueRightAdditionalPricePerShare>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="ia3e93321ddf644359c1906deaf4915d8_I20210131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfNDk0NzgwMjM1ODc2Mg_2c276e04-a8b7-48f7-83a8-98f44af3801e"
      unitRef="usd">160000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <lly:BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction
      contextRef="ia3e93321ddf644359c1906deaf4915d8_I20210131"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfNDk0NzgwMjM2MDkwMQ_6bb9b1e9-c864-4b6b-937f-92d3fda3b645"
      unitRef="usdPerShare">0.083</lly:BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfNDk0NzgwMjM2MDkwMg_12b29c0d-c796-4cad-ac1e-0b6dc66c5370">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.016%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value at January 22, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;834.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition date fair value of consideration transferred &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Fair value of CVR liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Acquired IPR&amp;amp;D intangibles primarily relate to PR001.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The goodwill recognized from this acquisition is not deductible for tax purposes. &lt;/span&gt;&lt;/div&gt;(3) See Note 6 for a discussion on the estimation of the CVR liability.</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="ia3e93321ddf644359c1906deaf4915d8_I20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOjVlYTMzNGZkODY1ZDRlOGJhNDY0OGFhNzJjNTViOGI1L3RhYmxlcmFuZ2U6NWVhMzM0ZmQ4NjVkNGU4YmE0NjQ4YWE3MmM1NWI4YjVfMS0xLTEtMS03OTc2_86525dbf-0f39-4901-98f3-0e12836ff32e"
      unitRef="usd">90500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="ia3e93321ddf644359c1906deaf4915d8_I20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOjVlYTMzNGZkODY1ZDRlOGJhNDY0OGFhNzJjNTViOGI1L3RhYmxlcmFuZ2U6NWVhMzM0ZmQ4NjVkNGU4YmE0NjQ4YWE3MmM1NWI4YjVfMi0xLTEtMS03OTk1_701e81f5-27d8-4080-8673-4f3ee872dc74"
      unitRef="usd">834000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:Goodwill
      contextRef="ia3e93321ddf644359c1906deaf4915d8_I20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOjVlYTMzNGZkODY1ZDRlOGJhNDY0OGFhNzJjNTViOGI1L3RhYmxlcmFuZ2U6NWVhMzM0ZmQ4NjVkNGU4YmE0NjQ4YWE3MmM1NWI4YjVfMy0xLTEtMS04MDAx_90f88061-c9e8-41e1-913f-e84fd79313d7"
      unitRef="usd">111000000.0</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="ia3e93321ddf644359c1906deaf4915d8_I20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOjVlYTMzNGZkODY1ZDRlOGJhNDY0OGFhNzJjNTViOGI1L3RhYmxlcmFuZ2U6NWVhMzM0ZmQ4NjVkNGU4YmE0NjQ4YWE3MmM1NWI4YjVfNC0xLTEtMS04MDEw_81132a22-3980-4ff0-8605-f81c8cf743d2"
      unitRef="usd">100200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <lly:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet
      contextRef="ia3e93321ddf644359c1906deaf4915d8_I20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOjVlYTMzNGZkODY1ZDRlOGJhNDY0OGFhNzJjNTViOGI1L3RhYmxlcmFuZ2U6NWVhMzM0ZmQ4NjVkNGU4YmE0NjQ4YWE3MmM1NWI4YjVfNS0xLTEtMS04MDE3_7e868679-3ce8-4652-9c4a-7882cec79228"
      unitRef="usd">-31500000</lly:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="ia3e93321ddf644359c1906deaf4915d8_I20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOjVlYTMzNGZkODY1ZDRlOGJhNDY0OGFhNzJjNTViOGI1L3RhYmxlcmFuZ2U6NWVhMzM0ZmQ4NjVkNGU4YmE0NjQ4YWE3MmM1NWI4YjVfNi0xLTEtMS04NTc4_c951eb16-7415-40e3-aa4d-1ad3581787b0"
      unitRef="usd">903800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="if8e0d422156841d5ad8a9105568a5622_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOjVlYTMzNGZkODY1ZDRlOGJhNDY0OGFhNzJjNTViOGI1L3RhYmxlcmFuZ2U6NWVhMzM0ZmQ4NjVkNGU4YmE0NjQ4YWE3MmM1NWI4YjVfOC0xLTEtMS04MDQw_fc9e256c-cb16-4390-a5d1-60ae62329edf"
      unitRef="usd">90500000</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability
      contextRef="ia3e93321ddf644359c1906deaf4915d8_I20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOjVlYTMzNGZkODY1ZDRlOGJhNDY0OGFhNzJjNTViOGI1L3RhYmxlcmFuZ2U6NWVhMzM0ZmQ4NjVkNGU4YmE0NjQ4YWE3MmM1NWI4YjVfOS0xLTEtMS04MDM1_96c4f215-44a6-4c2d-bf12-5dfff74a99ef"
      unitRef="usd">65900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="if8e0d422156841d5ad8a9105568a5622_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOjVlYTMzNGZkODY1ZDRlOGJhNDY0OGFhNzJjNTViOGI1L3RhYmxlcmFuZ2U6NWVhMzM0ZmQ4NjVkNGU4YmE0NjQ4YWE3MmM1NWI4YjVfMTAtMS0xLTEtODU4MQ_4a3f43de-e613-4b73-9f48-465c4eabae38"
      unitRef="usd">747400000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="icbcb632a5c694ec29deb85ebe3a2a2e9_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfMTY1NQ_6ff5a115-2354-408c-aebb-1be9fe7fb083"
      unitRef="usd">849300000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:Goodwill
      contextRef="i532d485d20654594a8b1a96d44626d00_I20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfMjkwNg_f7a3f23a-fc30-42eb-a690-c30dba993546"
      unitRef="usd">86800000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i532d485d20654594a8b1a96d44626d00_I20200229"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfMjkzMQ_5a6fb229-69c3-4faa-bdf9-212dc068ac1d"
      unitRef="usd">1200000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i532d485d20654594a8b1a96d44626d00_I20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfMzAwNA_b5d48ad5-ba9f-4645-b4fa-f9fba4a6e252"
      unitRef="usd">49500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt
      contextRef="i532d485d20654594a8b1a96d44626d00_I20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfMzAzMA_1f0fda30-5c03-42dd-bac4-4d3bf04004a7"
      unitRef="usd">375500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i1a359ced678146c9b9d8f9eb94adc1f8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfMzA2Nw_bdb3a1e3-da09-4039-80d6-6775cc221b40"
      unitRef="usd">276200000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfNzI4NA_696c362c-47d4-4f87-a851-b553d2a25903">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our asset acquisitions during the three months ended March&#160;31, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.916%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Counterparty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Compound(s) or Therapy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquisition Month&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Phase of Development &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquired IPR&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Precision Biosciences, Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development of potential in vivo therapies for genetic disorders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;107.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Merus N.V. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CD3-engaging T-cell re-directing bispecific antibodies for the potential treatment of cancer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;46.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asahi Kasei Pharma Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AK1780, an orally bioavailable P2X7 receptor antagonist for the potential treatment of chronic pain conditions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phase I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rigel Pharmaceuticals, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the potential treatment of autoimmune and inflammatory diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phase I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;125.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sitryx Therapeutics Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical targets that could lead to potential new medicines for autoimmune diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AbCellera Biologics Inc. (AbCellera)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neutralizing antibodies for the treatment and prevention of COVID-19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable. &lt;/span&gt;&lt;/div&gt;(2) We recognized an acquired IPR&amp;amp;D expense of $25.0 million in May 2020 upon closing of the transaction.</us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="if0a60d23094d4089a16f414a2eb40222_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOmExNWQ0NmZiOGFhZDQwMTBiNWQ2ZDMyNjQ2MTFkM2Y5L3RhYmxlcmFuZ2U6YTE1ZDQ2ZmI4YWFkNDAxMGI1ZDZkMzI2NDYxMWQzZjlfMS02LTEtMS0xNzg0_23bcdc46-58f6-4403-9f71-8c36c4ce8bda"
      unitRef="usd">107800000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ib490931de5a249db92647a2ab94af9ad_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOmExNWQ0NmZiOGFhZDQwMTBiNWQ2ZDMyNjQ2MTFkM2Y5L3RhYmxlcmFuZ2U6YTE1ZDQ2ZmI4YWFkNDAxMGI1ZDZkMzI2NDYxMWQzZjlfMi02LTEtMS0xNzcz_8a893286-42d6-4b00-bd50-3e730c38bb2c"
      unitRef="usd">46500000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ie1c5831cc7174801a03a8b0a2fd91a4b_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOmExNWQ0NmZiOGFhZDQwMTBiNWQ2ZDMyNjQ2MTFkM2Y5L3RhYmxlcmFuZ2U6YTE1ZDQ2ZmI4YWFkNDAxMGI1ZDZkMzI2NDYxMWQzZjlfMy02LTEtMS0xNzY4_c441e7e6-126d-45cd-af5b-57d921f6a5a4"
      unitRef="usd">20000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="id6460ea51b114fd5952c6937cbc22e89_D20210301-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOmExNWQ0NmZiOGFhZDQwMTBiNWQ2ZDMyNjQ2MTFkM2Y5L3RhYmxlcmFuZ2U6YTE1ZDQ2ZmI4YWFkNDAxMGI1ZDZkMzI2NDYxMWQzZjlfNC02LTEtMS0xNzk4_ef3cb04d-7268-4d7a-b416-4422385a8966"
      unitRef="usd">125000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="if871b5e2a0ea46059a74abfa4e82d02d_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOmExNWQ0NmZiOGFhZDQwMTBiNWQ2ZDMyNjQ2MTFkM2Y5L3RhYmxlcmFuZ2U6YTE1ZDQ2ZmI4YWFkNDAxMGI1ZDZkMzI2NDYxMWQzZjlfMS02LTEtMS0w_4717fb67-fdcd-4428-af0d-f26f1e352184"
      unitRef="usd">52300000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i5c7fcc42f3b34de0bb6bf706fa7541fa_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RhYmxlOmExNWQ0NmZiOGFhZDQwMTBiNWQ2ZDMyNjQ2MTFkM2Y5L3RhYmxlcmFuZ2U6YTE1ZDQ2ZmI4YWFkNDAxMGI1ZDZkMzI2NDYxMWQzZjlfMi02LTEtMS0w_20723a11-eb11-4077-85b0-91f946b85d1c"
      unitRef="usd">25000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i7cfe3973fd10441580375afacb0b0090_D20200501-20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80Ni9mcmFnOmUyN2U1ZjYyYWU3NzQzMjZhNzM5MGE2YWZhYTZmOGRhL3RleHRyZWdpb246ZTI3ZTVmNjJhZTc3NDMyNmE3MzkwYTZhZmFhNmY4ZGFfNTI2MA_6fa1f3b0-daa4-4b87-88af-0fef5b91a60e"
      unitRef="usd">25000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfMTAwODk_99ca6efb-3712-4f6c-b910-5f4d58db5b43">Collaborations and Other Arrangements&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We often enter into collaborative and other similar arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These arrangements often require milestone as well as royalty or profit-share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements from or payments to the collaboration partner. See Note 2 for amounts of collaboration and other revenue recognized from these types of arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Each collaboration is unique in nature, and our more significant arrangements are discussed below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Boehringer Ingelheim Diabetes Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We and Boehringer Ingelheim have a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Currently included in the collaboration are Boehringer Ingelheim&#x2019;s oral diabetes products: Jardiance,  Glyxambi, Synjardy, Trijardy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; XR, Trajenta, and Jentadueto&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as well as our basal insulin, Basaglar. Glyxambi, Synjardy, and Trijardy XR are included in the Jardiance product family. Jentadueto is included in the Trajenta product family. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the net amount of significant milestones (deferred) capitalized at March 31, 2021 and December 31, 2020 for the compounds included in this collaboration: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Milestones (Deferred) Capitalized &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;as of:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Product Family&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jardiance &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;151.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trajenta &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;108.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(163.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(168.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In connection with the regulatory approvals of Basaglar in the U.S., Europe, and Japan, milestone payments received were recorded as contract liabilities and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. In connection with the regulatory approvals of Jardiance and Trajenta, milestone payments made were capitalized as intangible assets and are being amortized to cost of sales through the term of the collaboration. This represents the amounts that have been (deferred) or capitalized from the start of this collaboration through the end of the reporting period, net of amount amortized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The collaboration agreement with Boehringer Ingelheim for Jardiance ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The collaboration agreement with Boehringer Ingelheim for Trajenta ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the Jardiance product family, we and Boehringer Ingelheim share equally the ongoing development and commercialization costs in the most significant markets, and we record our portion of the development and commercialization costs as research and development expense and marketing, selling, and administrative expense, respectively. We receive a royalty on net sales of Boehringer Ingelheim's products in the most significant markets and recognize the royalty as collaboration and other revenue.  Boehringer Ingelheim is entitled to potential performance payments depending on the net sales of the Jardiance product family; therefore, our reported revenue for Jardiance may be reduced by any potential performance payments we make related to this product family. Beginning January 1, 2021, the royalty received by us related to the Jardiance product family may also be increased or decreased depending on whether net sales for this product family exceed or fall below certain thresholds. We pay to Boehringer Ingelheim a royalty on net sales for Basaglar in the U.S. We record our sales of Basaglar to third parties as net product revenue with the royalty payments made to Boehringer Ingelheim recorded as cost of sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our net product revenue recognized with respect to Basaglar and collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Product Family&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jardiance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;312.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;246.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trajenta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;94.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Olumiant&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a worldwide license and collaboration agreement with Incyte Corporation (Incyte), which provides us the development and commercialization rights to its Janus tyrosine kinase (JAK) inhibitor compound, now known as Olumiant (baricitinib), and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases. Incyte has the right to receive tiered, double digit royalty payments on global net sales with rates ranging up to 20 percent. The agreement calls for payments by us to Incyte associated with certain development, success-based regulatory, and sales-based milestones. In 2020, the agreement was amended to include the treatment of COVID-19, with Incyte obtaining the right to receive an additional royalty ranging up to the low teens on global net sales for the treatment of COVID-19 that exceed a specified aggregate global net sales threshold. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the regulatory approvals of Olumiant in the U.S., Europe, and Japan, milestone payments of $210.0 million were capitalized as intangible assets as of March 31, 2021 and December 31, 2020 and are being amortized to cost of sales through the term of the collaboration. This represents the cumulative amounts that have been capitalized from the start of this collaboration through the end of each reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021, Incyte is eligible to receive up to $100.0 million of additional payments from us contingent upon certain success-based regulatory milestones. Incyte is also eligible to receive up to $150.0 million of potential sales-based milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record our sales of Olumiant to third parties as net product revenue with the royalty payments made to Incyte recorded as cost of sales. The following table summarizes our net product revenue recognized with respect to Olumiant:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Olumiant&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;193.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;COVID-19 antibodies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, we entered into a worldwide license and collaboration agreement with AbCellera to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including bamlanivimab, for which we hold development and commercialization rights. AbCellera has the right to receive tiered royalty payments on global net sales of bamlanivimab with percentages ranging in the mid-teens to mid-twenties. Royalty payments made to AbCellera are recorded as cost of sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, we entered into a license and collaboration agreement with Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences) to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including etesevimab, for which we hold development and commercialization rights outside of Greater China (which includes mainland China, Hong Kong and Macau Special Administrative Regions and Taiwan) and for which Junshi Biosciences maintains all rights in Greater China. Junshi Biosciences has the right to receive royalty payments in the mid-teens on our net sales of etesevimab. Junshi Biosciences also has the right to receive certain development, success-based regulatory and sales-based milestones. In connection with the regulatory authorizations of etesevimab (for administration with bamlanivimab) in the U.S. and Europe, milestone payments of $60.0 million were capitalized as intangible assets as of March&#160;31, 2021 and are being amortized to cost of sales over the estimated useful life of etesevimab. As of March&#160;31, 2021, Junshi Biosciences is eligible to receive up to $15.0 million of additional payments contingent upon certain success-based regulatory milestones and up to $120.0 million of potential sales-based milestones. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to EUAs, we recognized $810.1 million of net product revenue associated with our sales of our COVID-19 antibodies during the three months ended March&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Tyvyt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a collaboration agreement with Innovent Biologics, Inc. (Innovent) to jointly develop and commercialize Tyvyt (sintilimab injection) in China. In 2019, we and Innovent began co-commercializing Tyvyt in China. We record our sales of Tyvyt to third parties as revenue, with payments made to Innovent for its portion of the gross margin reported as cost of sales. We also report as revenue our portion of the gross margin for Tyvyt sales made by Innovent to third parties. Our Tyvyt revenue in China, which is primarily recorded as net product revenue, was $109.7 million and $57.4 million during the three months ended March 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, we obtained an exclusive license for Tyvyt from Innovent for geographies outside of China. Innovent, with collaboration from us, will pursue the initial registration of Tyvyt in the U.S., and we will pursue initial registration of Tyvyt in other markets and all other subsequent registrations of Tyvyt. We have exclusive commercialization rights outside of China.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021, Innovent is eligible to receive up to $825.0 million for geographies outside of China and up to $235.0 million in China in success-based regulatory and sales-based milestones. Innovent is also eligible to receive tiered double digit royalties on net sales for geographies outside of China. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Tanezumab&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a collaboration agreement with Pfizer Inc. (Pfizer) to jointly develop and globally commercialize tanezumab for the treatment of osteoarthritis pain and cancer pain. The companies equally share the ongoing development costs and, if successful, in the U.S. will co-commercialize and equally share in gross margin and certain commercialization expenses. As a result of an amendment to the agreement in 2020, Pfizer will be responsible for commercialization activities and costs outside the U.S., and we have the right to receive tiered royalties in percentages from the high teens to mid-twenties for net sales in Japan as well as low double digit royalties on annual net sales greater than $150.0&#160;million in all other territories outside of the U.S. and Japan. As of March&#160;31, 2021, Pfizer is eligible to receive up to $147.5 million in success-based regulatory milestones based on current development plans and up to $1.23 billion in a series of sales-based milestones, contingent upon the commercial success of tanezumab.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Lebrikizumab&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of our acquisition of Dermira, we have a worldwide licensing agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. (collectively Roche), which provides us the global development and commercialization rights to lebrikizumab. Roche has the right to receive tiered royalty payments on future global net sales ranging in percentages from high single digits to high teens if the product is successfully commercialized. As of March&#160;31, 2021, Roche is eligible to receive up to $180.0 million of payments from us contingent upon the achievement of success-based regulatory milestones and up to $1.03 billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of our acquisition of Dermira, we have a license agreement with Almirall, S.A. (Almirall), under which Almirall licensed the rights to develop and commercialize lebrikizumab for the treatment or prevention of dermatology indications, including, but not limited to, atopic dermatitis in Europe. We have the right to receive tiered royalty payments on future net sales in Europe ranging in percentages from low double digits to low twenties if the product is successfully commercialized. As of March&#160;31, 2021, we are eligible to receive additional payments of $85.0 million from Almirall contingent upon the achievement of success-based regulatory milestones and up to $1.25 billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab.&lt;/span&gt;&lt;/div&gt;As of March&#160;31, 2021 and December 31, 2020, $23.3 million and $29.7 million, respectively, were recorded as contract liabilities on the consolidated condensed balance sheet and are expected to be recognized as collaboration and other revenue over the remaining Phase III development period. During the three months ended March&#160;31, 2021 and 2020, milestones received and collaboration and other revenue recognized were not material.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfMTAwOTM_5e29e693-ec19-4791-803c-fad41b8c15bc">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the net amount of significant milestones (deferred) capitalized at March 31, 2021 and December 31, 2020 for the compounds included in this collaboration: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Milestones (Deferred) Capitalized &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;as of:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Product Family&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jardiance &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;151.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trajenta &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;108.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(163.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(168.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In connection with the regulatory approvals of Basaglar in the U.S., Europe, and Japan, milestone payments received were recorded as contract liabilities and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. In connection with the regulatory approvals of Jardiance and Trajenta, milestone payments made were capitalized as intangible assets and are being amortized to cost of sales through the term of the collaboration. This represents the amounts that have been (deferred) or capitalized from the start of this collaboration through the end of the reporting period, net of amount amortized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The collaboration agreement with Boehringer Ingelheim for Jardiance ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The collaboration agreement with Boehringer Ingelheim for Trajenta ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our net product revenue recognized with respect to Basaglar and collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Product Family&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jardiance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;312.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;246.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trajenta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;94.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The following table summarizes our net product revenue recognized with respect to Olumiant:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Olumiant&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;193.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i787debb10db9449ebf355978b2cac4c9_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOjY1NDkzNjUxYTQ5ZDQ3Njc4ZDZkM2Q3ZDhhNDUwMmI1L3RhYmxlcmFuZ2U6NjU0OTM2NTFhNDlkNDc2NzhkNmQzZDdkOGE0NTAyYjVfMi0xLTEtMS04MzEx_0361397f-01c7-4de2-997a-88e0ac9ad3ab"
      unitRef="usd">151200000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i1d95635b39cc445ebd68b8eaacc4cf49_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOjY1NDkzNjUxYTQ5ZDQ3Njc4ZDZkM2Q3ZDhhNDUwMmI1L3RhYmxlcmFuZ2U6NjU0OTM2NTFhNDlkNDc2NzhkNmQzZDdkOGE0NTAyYjVfMi0yLTEtMS04MzEx_aa18fde8-72f4-43c2-9573-2aae2451a8a8"
      unitRef="usd">156200000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i8356c279b93c42829023f67b564fd0f1_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOjY1NDkzNjUxYTQ5ZDQ3Njc4ZDZkM2Q3ZDhhNDUwMmI1L3RhYmxlcmFuZ2U6NjU0OTM2NTFhNDlkNDc2NzhkNmQzZDdkOGE0NTAyYjVfMi0xLTEtMS01MDM3_ca961c16-e81e-499a-b1c0-581a629f4d8a"
      unitRef="usd">108100000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i7898c22d6db548ba8e625e7b4cb51b1c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOjY1NDkzNjUxYTQ5ZDQ3Njc4ZDZkM2Q3ZDhhNDUwMmI1L3RhYmxlcmFuZ2U6NjU0OTM2NTFhNDlkNDc2NzhkNmQzZDdkOGE0NTAyYjVfMS0yLTEtMS0w_4fb1a185-7395-46e9-9cd4-35d8b9a2d5b2"
      unitRef="usd">114600000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="ie49f3b9fa84949058c66e2ccc6f1bafe_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOjY1NDkzNjUxYTQ5ZDQ3Njc4ZDZkM2Q3ZDhhNDUwMmI1L3RhYmxlcmFuZ2U6NjU0OTM2NTFhNDlkNDc2NzhkNmQzZDdkOGE0NTAyYjVfNC0xLTEtMS01MDM3_f2921045-378c-4d32-90a1-ff887f74aac6"
      unitRef="usd">-163300000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="iecf3e061ab6a44e0b3e95b09ceec5863_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOjY1NDkzNjUxYTQ5ZDQ3Njc4ZDZkM2Q3ZDhhNDUwMmI1L3RhYmxlcmFuZ2U6NjU0OTM2NTFhNDlkNDc2NzhkNmQzZDdkOGE0NTAyYjVfMy0yLTEtMS0w_f32badb5-5d80-47b8-8642-20f7ef2b9441"
      unitRef="usd">-168000000.0</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <us-gaap:Revenues
      contextRef="if95072ac7b3c4004b82c2aac605e5d70_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOjBmOTdhOTVjZTgyMTRlNzQ5Nzg0MjdhZGUzNGExZDcxL3RhYmxlcmFuZ2U6MGY5N2E5NWNlODIxNGU3NDk3ODQyN2FkZTM0YTFkNzFfMi0xLTEtMS04MzMz_aafa8472-ae8a-4bc6-80be-9b15648fda23"
      unitRef="usd">312000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i65808f9c08a34e2fbb20de15f09d6663_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOjBmOTdhOTVjZTgyMTRlNzQ5Nzg0MjdhZGUzNGExZDcxL3RhYmxlcmFuZ2U6MGY5N2E5NWNlODIxNGU3NDk3ODQyN2FkZTM0YTFkNzFfMi0zLTEtMS04MzMz_5bd7fdb7-0e99-4719-bc21-00d331b9d6a9"
      unitRef="usd">267500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6308d09ed16f45708083f216e5eb9053_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOjBmOTdhOTVjZTgyMTRlNzQ5Nzg0MjdhZGUzNGExZDcxL3RhYmxlcmFuZ2U6MGY5N2E5NWNlODIxNGU3NDk3ODQyN2FkZTM0YTFkNzFfMi0xLTEtMS0w_dbc0725d-fc85-44cd-9fd8-4b1bfe2430d3"
      unitRef="usd">246600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9b572a7d820847f2b77197f14a7598e9_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOjBmOTdhOTVjZTgyMTRlNzQ5Nzg0MjdhZGUzNGExZDcxL3RhYmxlcmFuZ2U6MGY5N2E5NWNlODIxNGU3NDk3ODQyN2FkZTM0YTFkNzFfMi0zLTEtMS0w_5b2e845f-3e4b-4b3a-86bc-2680bbf4e4bd"
      unitRef="usd">303700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iabb0222b012c480fa8a4b4033fb1c3b4_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOjBmOTdhOTVjZTgyMTRlNzQ5Nzg0MjdhZGUzNGExZDcxL3RhYmxlcmFuZ2U6MGY5N2E5NWNlODIxNGU3NDk3ODQyN2FkZTM0YTFkNzFfNC0xLTEtMS0w_7ef61ed1-ad75-442b-b0da-806f8d9af6df"
      unitRef="usd">94600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i50e1340911c44726ba35205e9879816a_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOjBmOTdhOTVjZTgyMTRlNzQ5Nzg0MjdhZGUzNGExZDcxL3RhYmxlcmFuZ2U6MGY5N2E5NWNlODIxNGU3NDk3ODQyN2FkZTM0YTFkNzFfNC0zLTEtMS0w_60603f4f-6ee6-4292-a88f-0de106a7fe4d"
      unitRef="usd">93200000</us-gaap:Revenues>
    <lly:CollaborativeArrangementRightsAndObligationsPercent
      contextRef="i661524a58a1c40ec97906a968e6f6aca_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNjI1Mw_971163d5-a212-4916-9914-af3cd3cf4e56"
      unitRef="number">0.20</lly:CollaborativeArrangementRightsAndObligationsPercent>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="id9bf6a3d44b2458aabd053d1804a3283_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNjUwOA_75191053-25b1-4459-ad43-6db8ad11885e"
      unitRef="usd">210000000.0</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i64aadc652c4343c1bcd2bfc5b72d6158_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNjgxOQ_0dcae872-c3af-42fb-a209-7c7c28c86e6b"
      unitRef="usd">100000000.0</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i3343c905d8554be69ab7b345fa893082_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNjk3MQ_19489ce0-3fb9-4522-910f-6b707b34fd61"
      unitRef="usd">150000000.0</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <us-gaap:Revenues
      contextRef="id181bab5e80145f7b4aac52329fa68c0_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOmRjNDUxOWUxYjhlYzRjZDE5YThiZDc0OTM5NjAzNGU4L3RhYmxlcmFuZ2U6ZGM0NTE5ZTFiOGVjNGNkMTlhOGJkNzQ5Mzk2MDM0ZThfMi0xLTEtMS0w_43dfdcb5-e735-4121-ad47-147da4f5a662"
      unitRef="usd">193800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id181bab5e80145f7b4aac52329fa68c0_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOmRjNDUxOWUxYjhlYzRjZDE5YThiZDc0OTM5NjAzNGU4L3RhYmxlcmFuZ2U6ZGM0NTE5ZTFiOGVjNGNkMTlhOGJkNzQ5Mzk2MDM0ZThfMi0xLTEtMS0w_ba60441b-b236-48e2-9d7f-ff80305eb163"
      unitRef="usd">193800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6c5697fd7da74cdbb6d77c6a62017381_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOmRjNDUxOWUxYjhlYzRjZDE5YThiZDc0OTM5NjAzNGU4L3RhYmxlcmFuZ2U6ZGM0NTE5ZTFiOGVjNGNkMTlhOGJkNzQ5Mzk2MDM0ZThfMi0zLTEtMS0w_72d5363b-b180-417d-b6c7-91b3343689d9"
      unitRef="usd">139700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6c5697fd7da74cdbb6d77c6a62017381_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RhYmxlOmRjNDUxOWUxYjhlYzRjZDE5YThiZDc0OTM5NjAzNGU4L3RhYmxlcmFuZ2U6ZGM0NTE5ZTFiOGVjNGNkMTlhOGJkNzQ5Mzk2MDM0ZThfMi0zLTEtMS0w_eff31ee2-fe9a-417e-9b48-e79b1e0348ce"
      unitRef="usd">139700000</us-gaap:Revenues>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i3ec641d1b0e0486dba0286bc54d9f28f_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNTQ5NzU1ODE1NDg3OA_e328a81f-6023-4d4c-bb97-f9359f674143"
      unitRef="usd">60000000.0</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i9cadf4d9d0bd4bf6b1d1bd9d0dc96dee_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNTQ5NzU1ODE1NDg2NA_71ed43c5-b39e-42f9-bb9e-f1dd1d8becd4"
      unitRef="usd">15000000.0</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i44a54fd999064e8484fd5ca2af4dcc17_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNTQ5NzU1ODE1NDg2OQ_6bfe2c41-a48d-4c7b-a34a-dae460326a01"
      unitRef="usd">120000000.0</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <us-gaap:Revenues
      contextRef="i1e2d53c2e70b4fa7b373f89ff566d337_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNTQ5NzU1ODE1OTk2NQ_287208df-52a7-4065-8892-5d3b6e35705c"
      unitRef="usd">810100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i55a39c6d0d9146729c9cbfd483622222_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNTQ5NzU1ODE1OTY4Nw_b1fa3217-3b4b-4488-be3c-9a95a7c78d93"
      unitRef="usd">109700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i37c6a808e0e24c1f8e75607e3a823271_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNTQ5NzU1ODE1OTY3MQ_f9954cb6-a22d-425c-a088-134ad2d685fd"
      unitRef="usd">57400000</us-gaap:Revenues>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="ied018ff88f6646e88340a81a87e88722_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNTQ5NzU1ODE1NDg4OA_ad2281d6-a9e6-4001-a984-47b8469128ee"
      unitRef="usd">825000000.0</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i2d761f2cc36e4a03b6ad57e5ab13c540_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNTQ5NzU1ODE1NDg5Mw_a1337b91-4c92-4b78-ad4f-890665ad5b1f"
      unitRef="usd">235000000.0</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold
      contextRef="ia32a56f35ba84943ac17a6ae53d314e0_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNDk0NzgwMjM0NTYzOQ_8a0e07cc-289f-43d3-ab41-e429dd02c103"
      unitRef="usd">150000000.0</lly:CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i24615d347773426cb44faa02b5f3a282_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfODA5Mw_7a5b96ac-6595-439e-885b-4f61c456cfdb"
      unitRef="usd">147500000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i3b6de8f942f44cf0aced4adc5181105e_I20210331"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfODE4MA_4992ab14-7f3e-4803-8581-3143b6bf1ec9"
      unitRef="usd">1230000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i4ee311292e604c2ba36873038aa0d41a_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfODc2NQ_2197898d-1c35-48a0-86c8-40da352577c1"
      unitRef="usd">180000000.0</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i2e55c79531a045a4849418d1e780b569_I20210331"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfODg3MA_77e1fb01-e28e-493e-9d42-c474a09ec427"
      unitRef="usd">1030000000.00</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i1bd3d506e737426ca9f7d5071e2fe975_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfOTUyNg_db3476fb-d847-445a-8fc5-f48a832c7a6d"
      unitRef="usd">85000000.0</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="ia6017620bc984fc3b23178c68fc11436_I20210331"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfOTYyNA_4372d029-f890-4b0d-a4d3-7784585ca72a"
      unitRef="usd">1250000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i5c39357db5cc4a9cbcfd00adcb81f908_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNTQ5NzU1ODE1NDkwMw_46e412e0-d89f-4983-86aa-a650444a5dae"
      unitRef="usd">23300000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i6fea589edc3e4ab08f9ed7052aad2e59_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV80OS9mcmFnOjdlNjFhMTRjNmRmYzQ1ZjZhMmEwMTcxMDU1NDQ2NDVhL3RleHRyZWdpb246N2U2MWExNGM2ZGZjNDVmNmEyYTAxNzEwNTU0NDY0NWFfNTQ5NzU1ODE1ODY3NA_820362df-11ab-42bc-915e-58e9962906ba"
      unitRef="usd">29700000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV81OC9mcmFnOmFmMzJlNjhkYWFlMTQ3NTliYjY1ZjRhZjVlZWFhMmY4L3RleHRyZWdpb246YWYzMmU2OGRhYWUxNDc1OWJiNjVmNGFmNWVlYWEyZjhfNzc4_36abbb79-574f-414e-b791-2864374b5292">Asset Impairment, Restructuring, and Other Special Charges&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated condensed statements of operations are described below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset impairment and other special charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;200.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total asset impairment, restructuring, and other special charges&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;211.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Asset impairment, restructuring, and other special charges recognized during the three months ended March&#160;31, 2021 were primarily related to an intangible asset impairment of $108.1&#160;million resulting from the decision to sell the rights to Qbrexza, as well as acquisition and integration costs associated with the acquisition of Prevail. During the three months ended March&#160;31, 2021, we entered into an agreement to sell our rights to Qbrexza, subject to closing conditions which are expected to be completed in the second quarter of 2021. The assets associated with Qbrexza were written down to fair value less cost to sell, which were determined based upon a discounted cash flow valuation. The remaining book value of assets associated with Qbrexza subsequent to the impairment charge is not material.&lt;/span&gt;&lt;/div&gt;Asset impairment, restructuring, and other special charges recognized during the three months ended March&#160;31, 2020 were primarily related to acquisition and integration costs associated with the acquisition of Dermira.</us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV81OC9mcmFnOmFmMzJlNjhkYWFlMTQ3NTliYjY1ZjRhZjVlZWFhMmY4L3RleHRyZWdpb246YWYzMmU2OGRhYWUxNDc1OWJiNjVmNGFmNWVlYWEyZjhfNzg1_d9ee5252-7669-466e-beb3-eda60f33990a">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated condensed statements of operations are described below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset impairment and other special charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;200.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total asset impairment, restructuring, and other special charges&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;211.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:SeveranceCosts1
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV81OC9mcmFnOmFmMzJlNjhkYWFlMTQ3NTliYjY1ZjRhZjVlZWFhMmY4L3RhYmxlOjRlMzhjNTNiNWY1NjQ0N2ViNWIzM2RhODFhZTFlZmZjL3RhYmxlcmFuZ2U6NGUzOGM1M2I1ZjU2NDQ3ZWI1YjMzZGE4MWFlMWVmZmNfMi0xLTEtMS0w_6d174d88-bd85-4952-b4cc-f3df9bff93b9"
      unitRef="usd">11500000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV81OC9mcmFnOmFmMzJlNjhkYWFlMTQ3NTliYjY1ZjRhZjVlZWFhMmY4L3RhYmxlOjRlMzhjNTNiNWY1NjQ0N2ViNWIzM2RhODFhZTFlZmZjL3RhYmxlcmFuZ2U6NGUzOGM1M2I1ZjU2NDQ3ZWI1YjMzZGE4MWFlMWVmZmNfMi0zLTEtMS0w_b4e78399-dba1-4aae-8ccc-3528e952767e"
      unitRef="usd">9800000</us-gaap:SeveranceCosts1>
    <lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV81OC9mcmFnOmFmMzJlNjhkYWFlMTQ3NTliYjY1ZjRhZjVlZWFhMmY4L3RhYmxlOjRlMzhjNTNiNWY1NjQ0N2ViNWIzM2RhODFhZTFlZmZjL3RhYmxlcmFuZ2U6NGUzOGM1M2I1ZjU2NDQ3ZWI1YjMzZGE4MWFlMWVmZmNfMy0xLTEtMS0w_0987e5e5-2fc3-494a-8f25-22f0cd050e33"
      unitRef="usd">200100000</lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges>
    <lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV81OC9mcmFnOmFmMzJlNjhkYWFlMTQ3NTliYjY1ZjRhZjVlZWFhMmY4L3RhYmxlOjRlMzhjNTNiNWY1NjQ0N2ViNWIzM2RhODFhZTFlZmZjL3RhYmxlcmFuZ2U6NGUzOGM1M2I1ZjU2NDQ3ZWI1YjMzZGE4MWFlMWVmZmNfMy0zLTEtMS0w_26bb8512-cc99-4be1-aa04-8de2e2d65491"
      unitRef="usd">50100000</lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV81OC9mcmFnOmFmMzJlNjhkYWFlMTQ3NTliYjY1ZjRhZjVlZWFhMmY4L3RhYmxlOjRlMzhjNTNiNWY1NjQ0N2ViNWIzM2RhODFhZTFlZmZjL3RhYmxlcmFuZ2U6NGUzOGM1M2I1ZjU2NDQ3ZWI1YjMzZGE4MWFlMWVmZmNfNC0xLTEtMS0w_867dc0f3-4934-4403-bb1c-95f003c7ea49"
      unitRef="usd">211600000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV81OC9mcmFnOmFmMzJlNjhkYWFlMTQ3NTliYjY1ZjRhZjVlZWFhMmY4L3RhYmxlOjRlMzhjNTNiNWY1NjQ0N2ViNWIzM2RhODFhZTFlZmZjL3RhYmxlcmFuZ2U6NGUzOGM1M2I1ZjU2NDQ3ZWI1YjMzZGE4MWFlMWVmZmNfNC0zLTEtMS0w_61e9d0f7-00f1-4631-bc7a-178c42842cd9"
      unitRef="usd">59900000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV81OC9mcmFnOmFmMzJlNjhkYWFlMTQ3NTliYjY1ZjRhZjVlZWFhMmY4L3RleHRyZWdpb246YWYzMmU2OGRhYWUxNDc1OWJiNjVmNGFmNWVlYWEyZjhfNDk0NzgwMjMzMTA1NQ_ab77e7a4-3bae-4da2-9fc0-bb1eeb0c06f9"
      unitRef="usd">108100000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTQ4OTg_77a10609-7cb8-4d05-9dde-2c32f7d2eea0">Financial InstrumentsFinancial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life science products account for a substantial portion of our trade receivables; collateral is generally not required. We seek to mitigate the risk associated with this concentration through our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions. We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings.&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our equity investments are accounted for using three different methods depending on the type of equity investment:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We review equity investments other than public equity investments for indications of impairment and observable price changes on a regular basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market, with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, and Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other&#x2013;net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months. At March&#160;31, 2021, we had outstanding foreign currency forward commitments to purchase 1.11 billion U.S. dollars and sell 941.7 million euro, commitments to purchase 4.19 billion euro and sell 4.98 billion U.S. dollars, commitments to purchase 140.7 million U.S. dollars and sell 15.47 billion Japanese yen, and commitments to purchase 285.2 million British pounds and sell 396.5 million U.S. dollars, which all settled within 30 days.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign currency exchange risk is also managed through the use of foreign currency debt and cross-currency interest rate swaps. Our foreign currency-denominated notes had carrying amounts of $5.72 billion and $6.02 billion as of March&#160;31, 2021 and December&#160;31, 2020, respectively, of which $4.30 billion and $4.50 billion have been designated as, and are effective as, economic hedges of net investments in certain of our euro-denominated foreign operations as of March&#160;31, 2021 and December&#160;31, 2020, respectively. At March&#160;31, 2021, we had outstanding cross currency swaps with notional amounts of $3.79 billion swapping U.S. dollars to euro and $1.00 billion swapping Swiss francs to U.S. dollars which have settlement dates ranging through 2028. Our cross-currency interest rate swaps, for which a majority convert a portion of our U.S. dollar-denominated fixed-rate debt to foreign-denominated fixed-rate debt, have also been designated as, and are effective as, economic hedges of net investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated condensed statements of cash flows. At March&#160;31, 2021, substantially all of our total long-term debt is at a fixed rate. We have converted approximately 13 percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. The change in fair value of these instruments is recorded as part of other comprehensive income (loss), and upon completion of a debt issuance and termination of the swap, is amortized to interest expense over the life of the underlying debt. As of March 31, 2021, the total notional amounts of forward-starting interest rate contracts in designated cash flow hedging instruments were $1.75 billion, which have settlement dates ranging between 2023 and 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Effect of Risk-Management Instruments on the Consolidated Condensed Statements of Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following effects of risk-management instruments were recognized in other&#x2013;net, (income) expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect from hedged fixed-rate debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(81.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect from interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;81.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(117.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;71.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;133.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;208.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2021 and 2020, the amortization of losses related to the portion of our risk management hedging instruments, fair value hedges, and cash flow hedges that was excluded from the assessment of effectiveness was not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Effect of Risk-Management Instruments on Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Foreign currency-denominated notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;207.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;150.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Forward-starting interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;295.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(369.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;26.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the next 12&#160;months, we expect to reclassify $16.9&#160;million of pretax net losses on cash flow hedges from accumulated other comprehensive loss to other&#x2013;net, (income) expense. During the three months ended March&#160;31, 2021 and 2020, the amounts excluded from the assessment of hedge effectiveness recognized in other comprehensive income (loss) were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize certain fair value information at March&#160;31, 2021 and December&#160;31, 2020 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other&lt;br/&gt;Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,554.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,554.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,554.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,554.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;20.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;20.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;20.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;20.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;18.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;18.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;18.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;18.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;49.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;109.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;108.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;109.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;109.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;177.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;175.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;177.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;177.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;102.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;99.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;102.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;102.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;23.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;23.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;23.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;23.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;110.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;30.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;110.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;110.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,645.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;386.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,645.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,645.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity investments without readily determinable fair values &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;384.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity method investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;679.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,232.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,097.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,097.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,097.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,097.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;126.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,664.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;311.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,664.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,664.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity investments without readily determinable fair values &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;373.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity method investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;471.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,966.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments.&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.916%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Long-term debt, including current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(16,204.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(17,462.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(17,462.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,595.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,038.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,038.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-management instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;87.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;87.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;87.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;235.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;235.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;235.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;39.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;39.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;39.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(45.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(45.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(45.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(19.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(19.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(19.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(16.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(16.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(16.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(66.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(66.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(66.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration liability:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(71.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(71.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(71.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-management instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-management instruments above are disclosed on a gross basis. There are various rights of setoff associated with certain of the risk-management instruments above that are subject to enforceable master netting arrangements or similar agreements. Although various rights of setoff and master netting arrangements or similar agreements may exist with the individual counterparties to the risk-management instruments above, individually, these financial rights are not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine our Level 1 and Level 2 fair value measurements based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. Level 3 fair value measurements for other investment securities are determined using unobservable inputs, including the investments' cost adjusted for impairments and price changes from orderly transactions. The fair values of equity method investments and investments measured under the measurement alternative for equity investments that do not have readily determinable fair values are not readily available. As of March 31, 2021, we had approximately $736 million of unfunded commitments to invest in venture capital funds, which we anticipate will be paid over a period of up to 10 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration liability relates to our liability arising in connection with the CVR issued as a result of the Prevail acquisition. The fair value of the CVR liability was estimated using a discounted cash flow analysis and Level 3 inputs, including projections representative of a market participant's view of the expected cash payment associated with the first potential regulatory approval of a Prevail compound in the applicable countries based on probabilities of technical success, timing of the potential approval events for the compounds, and an estimated discount rate. See Note 3 for additional information related to the CVR arrangement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of March&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturities by Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less&#160;Than&lt;br/&gt;1 Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1-5&lt;br/&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6-10&lt;br/&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;More&#160;Than&lt;br/&gt;10 Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;443.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net gains recognized in our consolidated condensed statements of operations for equity securities were $301.5&#160;million and $186.6 million for the three months ended March&#160;31, 2021 and 2020, respectively. The net gains/losses recognized during the three months ended March&#160;31, 2021 and 2020 on equity securities sold during the respective periods were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We adjust our equity investments without readily determinable fair values based upon changes in the equity instruments' values resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Downward adjustments resulting from an impairment are recorded based upon impairment considerations, including the financial condition and near term prospects of the issuer, general market conditions, and industry specific factors. Adjustments recorded during the three months ended March&#160;31, 2021 and 2020 were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the fair value of available-for-sale securities in an unrealized gain or loss position and the amount of unrealized gains and losses in accumulated other comprehensive loss follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gross gains&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gross losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of securities in an unrealized gain position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;273.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of securities in an unrealized loss position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;170.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We periodically assess our investment in available-for-sale securities for impairment losses and credit losses. The amount of credit losses are determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration. Impairment and credit losses related to available-for-sale securities were not material in the three months ended March&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021, the available-for-sale securities in an unrealized loss position include primarily fixed-rate debt securities of varying maturities, which are sensitive to changes in the yield curve and other market conditions. Approximately 94 percent&#160;of the fixed-rate debt securities in a loss position are investment-grade debt securities. As of March&#160;31, 2021, we do not intend to sell, and it is not more likely than not that we will be required to sell, the securities in a loss position before the market values recover or the underlying cash flows have been received, and there is no indication of default on interest or principal payments for any of our debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity related to our available-for-sale securities was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;43.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized gross gains on sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized gross losses on sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized gains and losses on sales of available-for-sale investments are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts Receivable Factoring Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into accounts receivable factoring agreements with financial institutions to sell certain of our non-U.S. accounts receivable. These transactions are accounted for as sales and result in a reduction in accounts receivable because the agreements transfer effective control over and, risk related to, the receivables to the buyers. Our factoring agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. We derecognized $637.8 million and $754.9 million&#160;of accounts receivable as of March&#160;31, 2021 and December 31, 2020, respectively, under these factoring arrangements. The costs of factoring such accounts receivable on our consolidated condensed results of operations for the three months ended March&#160;31, 2021 and 2020&#160;were&#160;not material.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTQ4Mjk_40b19818-1fc9-4819-a30b-6ed9b2b414d2">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market, with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.&lt;/span&gt;&lt;/div&gt;We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, and Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other&#x2013;net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months.</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="if8fd6ec70f034998b9025e47bf69042a_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNDMwNw_8be969a2-8fe0-4880-82ff-1005831944be"
      unitRef="usd">1110000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="if8fd6ec70f034998b9025e47bf69042a_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNDMzMg_6a7555b9-1f54-4db3-aaf1-3f84d1eea9c9"
      unitRef="eur">941700000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="iacc428f5b7444f79a59f33bd449c5b64_I20210331"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNDM2NQ_67d67f1b-3a87-44dc-be01-d12b6a1e0b21"
      unitRef="eur">4190000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="iacc428f5b7444f79a59f33bd449c5b64_I20210331"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNDM4Mg_fd0805d8-975b-40fb-acc4-d9fe68fdb67a"
      unitRef="usd">4980000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i53cacc69bc7f436e8384c8ab4a5a9044_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNDQyMw_76a0d582-3444-414c-9051-da55b8a5f3b9"
      unitRef="usd">140700000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i53cacc69bc7f436e8384c8ab4a5a9044_I20210331"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNDQ0OA_cf717cae-fa36-4235-8b99-b2d2cd207e92"
      unitRef="jpy">15470000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i196a382db4dd474f9215758c00592480_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNDQ5Mw_40187227-e041-4000-b2c6-4cfa926f665a"
      unitRef="gbp">285200000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i196a382db4dd474f9215758c00592480_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNDUyMA_863c582d-9f72-44fe-9a20-9f8c8ec2e42e"
      unitRef="usd">396500000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNDU2Ng_69718dcf-f14e-4ae0-8b38-43c80559d386">P30D</us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1>
    <us-gaap:LongTermDebt
      contextRef="i790e81260a954cde9599960f6c59fcd6_I20210331"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNDc2MQ_7c437e4b-194d-43d8-ad4a-9e541eac160d"
      unitRef="usd">5720000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="iee91d9656eb3472e8cf1ac38a3807882_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNDc2OA_fe04fae3-298e-4961-a3d7-a00e04179265"
      unitRef="usd">6020000000.00</us-gaap:LongTermDebt>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNDgxMQ_d228b96e-a9fd-481d-afe9-265751887a71"
      unitRef="usd">4300000000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNDgxOA_7cacecac-dad8-4076-969e-14cb318f9f66"
      unitRef="usd">4500000000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ifca25d1668f0447a8c0fb8e92c444a46_I20210331"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNTA2MA_f68a4f95-40c5-4b24-a7bf-2b2bda01656b"
      unitRef="usd">3790000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="icd062c4f7c644c92a3bd0c5fc8d3cd2c_I20210331"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNTA5Nw_f783611f-44ac-4387-acda-a0a0b17e922f"
      unitRef="usd">1000000000.00</us-gaap:DerivativeNotionalAmount>
    <lly:DescriptionOfDerivativeActivityVolumePercent
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNjg4MA_c0501b28-d2d1-4e34-84c7-4030225792fb"
      unitRef="number">0.13</lly:DescriptionOfDerivativeActivityVolumePercent>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i08261dc843c546e282dc7746c9935f3a_I20210331"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfNzYwMQ_264bf1da-2105-4b73-a0bc-69c24b6fc7ed"
      unitRef="usd">1750000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTQ4MzA_a9f88747-6636-408d-abdd-7e994387c2e3">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following effects of risk-management instruments were recognized in other&#x2013;net, (income) expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect from hedged fixed-rate debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(81.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect from interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;81.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(117.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;71.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;133.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;208.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="i40ae6e16034149ffab19351331c55b6a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM3MjY4OGZhODliZDQ3ZTE4MjM2ZTg1NjY0NTU5Y2YyL3RhYmxlcmFuZ2U6YzcyNjg4ZmE4OWJkNDdlMTgyMzZlODU2NjQ1NTljZjJfMy0xLTEtMS0w_091d97c9-6ec4-4d84-b4c8-e69aed54569e"
      unitRef="usd">81500000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="i5bc95e47cf6e4f3da137f20ede5e2282_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM3MjY4OGZhODliZDQ3ZTE4MjM2ZTg1NjY0NTU5Y2YyL3RhYmxlcmFuZ2U6YzcyNjg4ZmE4OWJkNDdlMTgyMzZlODU2NjQ1NTljZjJfMy0zLTEtMS0w_91b5e364-0421-4d52-bdce-b7bfd05366e5"
      unitRef="usd">-117300000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i02b03c88c1f84031a54577f36537d1bb_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM3MjY4OGZhODliZDQ3ZTE4MjM2ZTg1NjY0NTU5Y2YyL3RhYmxlcmFuZ2U6YzcyNjg4ZmE4OWJkNDdlMTgyMzZlODU2NjQ1NTljZjJfNC0xLTEtMS0w_e8d47989-4b87-453f-8cb5-d018ce9c4ce9"
      unitRef="usd">-81500000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i5492a540a4eb4396826f07e4a6429720_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM3MjY4OGZhODliZDQ3ZTE4MjM2ZTg1NjY0NTU5Y2YyL3RhYmxlcmFuZ2U6YzcyNjg4ZmE4OWJkNDdlMTgyMzZlODU2NjQ1NTljZjJfNC0zLTEtMS0w_e09c8394-16c2-4554-b58e-7187a7bc84eb"
      unitRef="usd">117300000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i02b03c88c1f84031a54577f36537d1bb_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM3MjY4OGZhODliZDQ3ZTE4MjM2ZTg1NjY0NTU5Y2YyL3RhYmxlcmFuZ2U6YzcyNjg4ZmE4OWJkNDdlMTgyMzZlODU2NjQ1NTljZjJfNi0xLTEtMS0w_ecb3f3e2-92a4-44b0-8e06-cc815d661450"
      unitRef="usd">4100000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i5492a540a4eb4396826f07e4a6429720_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM3MjY4OGZhODliZDQ3ZTE4MjM2ZTg1NjY0NTU5Y2YyL3RhYmxlcmFuZ2U6YzcyNjg4ZmE4OWJkNDdlMTgyMzZlODU2NjQ1NTljZjJfNi0zLTEtMS0w_d91e23e2-1e04-4c14-a32c-97c35600eeb4"
      unitRef="usd">4000000.0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i2e9ced055f4647d1b7ac5f1b13d3dcdb_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM3MjY4OGZhODliZDQ3ZTE4MjM2ZTg1NjY0NTU5Y2YyL3RhYmxlcmFuZ2U6YzcyNjg4ZmE4OWJkNDdlMTgyMzZlODU2NjQ1NTljZjJfNy0xLTEtMS0w_ab927ed0-044d-41d0-988f-11ddc7f04ed3"
      unitRef="usd">71500000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i0675cae41ecf4fad80226860b67627c8_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM3MjY4OGZhODliZDQ3ZTE4MjM2ZTg1NjY0NTU5Y2YyL3RhYmxlcmFuZ2U6YzcyNjg4ZmE4OWJkNDdlMTgyMzZlODU2NjQ1NTljZjJfNy0zLTEtMS0w_43004df9-1d6f-4c61-8d58-ab58bd2c47cb"
      unitRef="usd">-12900000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="i5cc6b325c96343679b6ae5ded2b4017a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM3MjY4OGZhODliZDQ3ZTE4MjM2ZTg1NjY0NTU5Y2YyL3RhYmxlcmFuZ2U6YzcyNjg4ZmE4OWJkNDdlMTgyMzZlODU2NjQ1NTljZjJfOC0xLTEtMS0w_929d33de-317f-4130-bb31-cac405be335f"
      unitRef="usd">-133000000.0</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="i1ebf8484d97442a79f3fb0056a0a0636_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM3MjY4OGZhODliZDQ3ZTE4MjM2ZTg1NjY0NTU5Y2YyL3RhYmxlcmFuZ2U6YzcyNjg4ZmE4OWJkNDdlMTgyMzZlODU2NjQ1NTljZjJfOC0zLTEtMS0w_13bee5ee-39f7-4f2f-a482-8de94bd1039a"
      unitRef="usd">5700000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <lly:DerivativeInstrumentsGainLossRecognized
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM3MjY4OGZhODliZDQ3ZTE4MjM2ZTg1NjY0NTU5Y2YyL3RhYmxlcmFuZ2U6YzcyNjg4ZmE4OWJkNDdlMTgyMzZlODU2NjQ1NTljZjJfOS0xLTEtMS0w_51e24626-faf7-4389-b313-c1588fa23c2d"
      unitRef="usd">-208600000</lly:DerivativeInstrumentsGainLossRecognized>
    <lly:DerivativeInstrumentsGainLossRecognized
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM3MjY4OGZhODliZDQ3ZTE4MjM2ZTg1NjY0NTU5Y2YyL3RhYmxlcmFuZ2U6YzcyNjg4ZmE4OWJkNDdlMTgyMzZlODU2NjQ1NTljZjJfOS0zLTEtMS0w_568c8bdc-9a39-492c-9d09-e2ca30f6d94a"
      unitRef="usd">14600000</lly:DerivativeInstrumentsGainLossRecognized>
    <us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTQ4MjM_d444bfe7-d7a5-45b7-8f18-91271a909470">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Foreign currency-denominated notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;207.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;150.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Forward-starting interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;295.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(369.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;26.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTQ4NTU_f2563394-95a8-40f8-960d-2c2f01b65ead">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Foreign currency-denominated notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;207.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;150.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Forward-starting interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;295.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(369.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;26.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i48597227bfbf4037b23b06218e7f576b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmNkOGI2OTVlYTY0NjQxODVhYTZlNzFhNGMzZmY4MzMxL3RhYmxlcmFuZ2U6Y2Q4YjY5NWVhNjQ2NDE4NWFhNmU3MWE0YzNmZjgzMzFfMy0xLTEtMS0w_4cf4ac8e-05de-4dc8-b6e4-a163850f5cc9"
      unitRef="usd">207700000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i733a2380e7734f87b92e3f8aed9fe6ac_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmNkOGI2OTVlYTY0NjQxODVhYTZlNzFhNGMzZmY4MzMxL3RhYmxlcmFuZ2U6Y2Q4YjY5NWVhNjQ2NDE4NWFhNmU3MWE0YzNmZjgzMzFfMy0zLTEtMS0w_79c330e7-f109-4bd0-90e2-6e13af8dd268"
      unitRef="usd">67400000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ib4ed115b785a4ad9a93f7287cb139b8e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmNkOGI2OTVlYTY0NjQxODVhYTZlNzFhNGMzZmY4MzMxL3RhYmxlcmFuZ2U6Y2Q4YjY5NWVhNjQ2NDE4NWFhNmU3MWE0YzNmZjgzMzFfNC0xLTEtMS0w_2a1dcbdd-bcdb-45b8-afcb-ab620dc55d96"
      unitRef="usd">150600000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i6d351595dea941808d14c80b2e44c3b3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmNkOGI2OTVlYTY0NjQxODVhYTZlNzFhNGMzZmY4MzMxL3RhYmxlcmFuZ2U6Y2Q4YjY5NWVhNjQ2NDE4NWFhNmU3MWE0YzNmZjgzMzFfNC0zLTEtMS0w_b99945b8-2f81-42cf-8481-656b648458f8"
      unitRef="usd">115800000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ie02bf6e1811a43e7a3d115fc98ca56c9_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmNkOGI2OTVlYTY0NjQxODVhYTZlNzFhNGMzZmY4MzMxL3RhYmxlcmFuZ2U6Y2Q4YjY5NWVhNjQ2NDE4NWFhNmU3MWE0YzNmZjgzMzFfNy0xLTEtMS0w_7fcba855-c0d2-4984-8c93-0329ffa7b396"
      unitRef="usd">295100000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ic8a0cc4c13104fccbd1c69dcb601af62_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmNkOGI2OTVlYTY0NjQxODVhYTZlNzFhNGMzZmY4MzMxL3RhYmxlcmFuZ2U6Y2Q4YjY5NWVhNjQ2NDE4NWFhNmU3MWE0YzNmZjgzMzFfNy0zLTEtMS0w_bca4f9a9-69af-400f-9a10-1b14d65eab4a"
      unitRef="usd">-369800000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ib4ed115b785a4ad9a93f7287cb139b8e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmNkOGI2OTVlYTY0NjQxODVhYTZlNzFhNGMzZmY4MzMxL3RhYmxlcmFuZ2U6Y2Q4YjY5NWVhNjQ2NDE4NWFhNmU3MWE0YzNmZjgzMzFfOC0xLTEtMS0w_08a7ac18-daff-4724-af5d-f2f5ee314191"
      unitRef="usd">26300000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i6d351595dea941808d14c80b2e44c3b3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmNkOGI2OTVlYTY0NjQxODVhYTZlNzFhNGMzZmY4MzMxL3RhYmxlcmFuZ2U6Y2Q4YjY5NWVhNjQ2NDE4NWFhNmU3MWE0YzNmZjgzMzFfOC0zLTEtMS0w_0c7b6d49-b939-41ca-834c-3fa2dfabac83"
      unitRef="usd">-69800000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfODkyOQ_e4ca65fe-9ca3-488e-9af9-b7ce78764d0b"
      unitRef="usd">-16900000</us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTQ4NTA_b38730a1-9e8f-499a-98d2-1a61a5fc301a">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize certain fair value information at March&#160;31, 2021 and December&#160;31, 2020 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other&lt;br/&gt;Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,554.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,554.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,554.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,554.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;20.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;20.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;20.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;20.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;18.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;18.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;18.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;18.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;49.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;109.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;108.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;109.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;109.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;177.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;175.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;177.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;177.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;102.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;99.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;102.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;102.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;23.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;23.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;23.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;23.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;110.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;30.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;110.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;110.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,645.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;386.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,645.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,645.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity investments without readily determinable fair values &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;384.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity method investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;679.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,232.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,097.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,097.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,097.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,097.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;126.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,664.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;311.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,664.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,664.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity investments without readily determinable fair values &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;373.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity method investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;471.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,966.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0468ac52ec0a40758c116186c956d819_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMy0xLTEtMS0w_305307bc-3e5e-4f81-b0d7-b14e9cbf2786"
      unitRef="usd">1554500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i259ea4a4728c4829bf5a1d53b88fe316_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMy0zLTEtMS0w_ab5c1787-e111-481f-bcde-2c43c950ce72"
      unitRef="usd">1554500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i379b7bdd53b04924a6915f7b6f539ae9_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMy01LTEtMS0w_1b44dc38-278c-4fe2-8504-843ff8eea6f0"
      unitRef="usd">1554500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i502fd03d8e8b42f384a0637943ac9227_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMy03LTEtMS0w_cee65b4d-1992-489d-9d97-c6341118c48a"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i110e7dd739b14882b203dd13e31a425d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMy05LTEtMS0w_d8363081-4d3d-4407-b24c-e15a832e8561"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1b1fc639100545e8b40e4cfd5886def1_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMy0xMS0xLTEtMA_08e0db31-f09c-4ade-8fcf-8f9a05fa040d"
      unitRef="usd">1554500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i50db401e52d34c6bbb22d8b87c712ee3_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNi0xLTEtMS0w_5001c7cf-479f-444f-b868-632ccefc2172"
      unitRef="usd">20900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i9d9b74593ec94447a6448aee79dc1a4f_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNi0zLTEtMS0w_a4d29ff9-e3db-4b60-b4b3-54987a8e32ef"
      unitRef="usd">20800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i11210e6bf5044a31804dbf8297477c5b_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNi01LTEtMS0w_444894d1-5db3-48c5-82fa-3d9b9aa7991d"
      unitRef="usd">20900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i1f4fe1622f184cf9a797fcf2b732d7fe_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNi03LTEtMS0w_76e9970c-c30a-43d0-bcd5-c8b234d4587a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i3c35346f0f3b44448000e57b1d0d71cf_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNi05LTEtMS0w_c17ed7a8-d156-4aef-a74e-0d0ee0287a21"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i8e2ffab98d7f45a0a3b806e73e461745_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNi0xMS0xLTEtMA_8b507bd8-f009-49db-b88e-19e4e97d7bf3"
      unitRef="usd">20900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iab695d20c84c457e96ce06476d8e182f_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfOC0xLTEtMS0w_c8f0cd03-6171-40cf-b0c7-f313ac338a91"
      unitRef="usd">7600000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i2c6474daeefd44828fcb9effa40e0c54_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfOC0zLTEtMS0w_c3ae9805-60a7-4394-b476-49532a51b9d0"
      unitRef="usd">7500000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i7e03a9ef9cef4a99bcd45329382a4b01_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfOC01LTEtMS0w_8296b48b-6da1-4553-a42d-848fdf9cb558"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ib6f572bcda8c4de4b675b9afeb36f32c_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfOC03LTEtMS0w_3f38441b-e0db-4fb3-ae63-5e5a49bdfbba"
      unitRef="usd">7600000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i5321b80fe49f4dc4a8096c02973ab7ab_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfOC05LTEtMS0w_4a8c1046-4ad0-4750-b68d-8f5cdc53ba84"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i5b5fc37a695a4b88b864b0b0f8a57e93_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfOC0xMS0xLTEtMA_75316296-594f-49e9-a6ac-8bbb3472b260"
      unitRef="usd">7600000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i94d22e93a3ad41848489c4810cedd352_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfOS0xLTEtMS0w_43e593c4-52ad-404c-b177-c95af62823a8"
      unitRef="usd">2300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="id8aef2fe7df7413a99dc9b367490fdba_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfOS0zLTEtMS0w_0e339da6-ca0f-48eb-b0ec-2056d473139f"
      unitRef="usd">2200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i21ff33225cde42d38dd508e225243ffe_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfOS01LTEtMS0w_0eec8368-0515-4fd7-b894-e33dc599f5cd"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i094cfa08457b4639b53077e02b7b579b_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfOS03LTEtMS0w_85db2fa0-f1da-4d49-b36f-768b89c1fd1f"
      unitRef="usd">2300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i39943827be2c4f9ea50a2cdfca84df2b_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfOS05LTEtMS0w_bbb57532-4d72-404e-bbec-f1c1bddc89b8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="idaeb507e6d804976ad515b86786c2663_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfOS0xMS0xLTEtMA_cc18196e-23a7-4093-a913-1255b3415609"
      unitRef="usd">2300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="idd103e4954f440de8adec2b901b7d26f_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTAtMS0xLTEtMA_6c33b19e-dd1f-4f0f-8059-e24d5ef0cf39"
      unitRef="usd">18200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i2765888bb9a44e86856eb0e40a7a95a1_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTAtMy0xLTEtMA_bdae86e9-270f-4789-a4ed-dab0c91d6798"
      unitRef="usd">18200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i937ee9f927b84aafaa8fd46c3071e390_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTAtNS0xLTEtMA_bf96ca64-0d7f-4879-bde3-a724ef9f18f9"
      unitRef="usd">18200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i5623a1b5a79348899d40b0b51b54335e_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTAtNy0xLTEtMA_915ac37f-a9eb-4127-89a9-b8d8593ed452"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i273c3175cdf54c6d9bd6414b446f3ab2_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTAtOS0xLTEtMA_2b2a6575-0455-4d5d-8faf-bfbfef2418bd"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ib521cd4c99774b97881a80a2a1c9c35d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTAtMTEtMS0xLTA_af9df4bd-b40e-44d8-b1e0-3c4751883e4e"
      unitRef="usd">18200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i0468ac52ec0a40758c116186c956d819_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTItMS0xLTEtMA_630e609a-c67e-43e4-8681-b578671c2d0f"
      unitRef="usd">49000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i50db401e52d34c6bbb22d8b87c712ee3_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTUtMS0xLTEtMA_c657e494-da39-4bde-b0b5-93f55008ebbc"
      unitRef="usd">109100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i9d9b74593ec94447a6448aee79dc1a4f_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTUtMy0xLTEtMA_8415a7c8-5d4b-4a15-aeba-12171ebb931b"
      unitRef="usd">108800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i11210e6bf5044a31804dbf8297477c5b_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTUtNS0xLTEtMA_7985bec2-d53e-409e-bdd5-e5ff093e49f9"
      unitRef="usd">109100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i1f4fe1622f184cf9a797fcf2b732d7fe_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTUtNy0xLTEtMA_09b1cbda-25b9-4e55-a37f-c9bd524ceea4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i3c35346f0f3b44448000e57b1d0d71cf_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTUtOS0xLTEtMA_5fe18368-4f6e-45c8-b4d5-fc68bfcff512"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i8e2ffab98d7f45a0a3b806e73e461745_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTUtMTEtMS0xLTA_48baff9d-d3eb-48ac-8702-c7ab12810e14"
      unitRef="usd">109100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="iab695d20c84c457e96ce06476d8e182f_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTctMS0xLTEtMA_4455579c-d0ca-446f-8732-328ba91caa80"
      unitRef="usd">177800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i2c6474daeefd44828fcb9effa40e0c54_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTctMy0xLTEtMA_ee61749e-aebf-4e38-a1db-3315c64b67d7"
      unitRef="usd">175500000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i7e03a9ef9cef4a99bcd45329382a4b01_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTctNS0xLTEtMA_a2867d81-a71e-4476-9c72-ec2b236370bc"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ib6f572bcda8c4de4b675b9afeb36f32c_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTctNy0xLTEtMA_086816f0-0921-49ff-8a89-8b39908b22d3"
      unitRef="usd">177800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i5321b80fe49f4dc4a8096c02973ab7ab_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTctOS0xLTEtMA_67dbe50e-b0cd-4afe-8fae-7efc580d6b21"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i5b5fc37a695a4b88b864b0b0f8a57e93_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTctMTEtMS0xLTA_e922801e-bc1e-41bf-832c-09ace39ebae4"
      unitRef="usd">177800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i49b67199341a409fb3c610a89020e4e4_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTgtMS0xLTEtMA_ddf23040-3a23-4b79-99c5-a7c7c082f80f"
      unitRef="usd">102300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i8d997ddd2afa4e4aa435ed61a0039a79_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTgtMy0xLTEtMA_6071b5fd-2d65-425a-896e-273ed0c73de8"
      unitRef="usd">99700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i162abcddb00540a6b88917d1b8c94bc8_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTgtNS0xLTEtMA_7470e1a4-f8f9-4699-84a6-0f4ac50e5781"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i70666e8c06ae4150b3d53ba8f358e55b_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTgtNy0xLTEtMA_18179c9f-996f-459c-bbea-6c05c4013ad7"
      unitRef="usd">102300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i0b8e28324e994e5a9e7af4dd5abbfa4b_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTgtOS0xLTEtMA_a14ff7dd-d173-4ddb-ab67-e7956567f0b6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i9cef5c921b4d4a13aa14e51caae1e54c_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTgtMTEtMS0xLTA_683cab71-6b95-4d41-8aca-b124efc7afad"
      unitRef="usd">102300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i94d22e93a3ad41848489c4810cedd352_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTktMS0xLTEtMA_eeba3c59-197e-4460-bb85-361047755a32"
      unitRef="usd">23800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="id8aef2fe7df7413a99dc9b367490fdba_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTktMy0xLTEtMA_6585d34d-02aa-4827-b473-a3aaf46b2244"
      unitRef="usd">23500000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i21ff33225cde42d38dd508e225243ffe_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTktNS0xLTEtMA_e3300b37-d303-4379-b4f0-7271b1e31a99"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i094cfa08457b4639b53077e02b7b579b_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTktNy0xLTEtMA_d8efcf92-3bc8-4a66-9568-5f3838c7ff76"
      unitRef="usd">23800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i39943827be2c4f9ea50a2cdfca84df2b_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTktOS0xLTEtMA_7c511fbe-9544-4989-a4d6-335e365268fe"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="idaeb507e6d804976ad515b86786c2663_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMTktMTEtMS0xLTA_f0af32d1-6642-442b-b28f-ef8b20323e6c"
      unitRef="usd">23800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i45eb28a2afb843b5a7599d09796ba47a_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjAtMS0xLTEtMA_f1f2a827-a7bd-4404-bca9-071a301ee27c"
      unitRef="usd">110300000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i8c96a7e6ebdb4b5894e42f4f674afc2f_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjAtMy0xLTEtMA_2155c07a-ee33-440a-a18a-bb40e3ca9646"
      unitRef="usd">30100000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i35a6dbafa15745eabd7e346fc0404f3c_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjAtNS0xLTEtMA_02a4de54-2cfa-433c-a29c-2382746976fa"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ie03e1c230dbe49b5b1a23948beb4fdf8_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjAtNy0xLTEtMA_9466ec16-967b-4045-9b07-5d3b6007219e"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ic4814dc5f3094945b14b09c32634e414_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjAtOS0xLTEtMA_79bf8922-6baa-476b-be66-90b689dedf0c"
      unitRef="usd">110300000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i5428a6a7e77a4afc87dbec371aa0e81b_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjAtMTEtMS0xLTA_182e5dd5-b07f-41ca-a545-889c72e4a758"
      unitRef="usd">110300000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i5b460fcffdff4102b1a5f350e775eb50_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjEtMS0xLTEtMA_d80e48d9-7dae-4684-8ec8-fbaffad9d186"
      unitRef="usd">1645500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i68b41c9f5b24461e99ffaf90ae7df35e_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjEtMy0xLTEtMA_3c94ee45-f007-4d98-a54b-6e2ec1433d83"
      unitRef="usd">386100000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i07692a7baeb34e989f264a119af0c6a3_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjEtNS0xLTEtMA_8e82fbd1-fac4-4a1e-98ce-ff673eb202fa"
      unitRef="usd">1645500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6cc36d48d552416e883d9009bfca5133_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjEtNy0xLTEtMA_6b6c4f8e-5b17-4f54-be54-44653ac9a75f"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="id251b7aadbd741c38319af027dda2015_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjEtOS0xLTEtMA_9dfa2938-0e29-4296-9b4e-d6b31c7aef7a"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ie57e8b8550a94ed3a3001f7258f40509_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjEtMTEtMS0xLTA_d47ab838-3910-4a6a-9cb9-766161dfde1a"
      unitRef="usd">1645500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i0468ac52ec0a40758c116186c956d819_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjItMS0xLTEtMA_56f5323f-f7a3-4992-9b64-853bb18725c7"
      unitRef="usd">384300000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:OtherLongTermInvestments
      contextRef="ie22efb639d76469d92d9d05b55c13b2e_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjMtMS0xLTEtMA_570f0405-9674-4d15-a351-e7db8b3fec1f"
      unitRef="usd">679300000</us-gaap:OtherLongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i0468ac52ec0a40758c116186c956d819_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjQtMS0xLTEtMA_b1f7147f-a7af-4e0a-a124-f6b449bc6db0"
      unitRef="usd">3232400000</us-gaap:LongTermInvestments>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie5244871105b411bba98a34bdca3bb0f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjctMS0xLTEtMA_3b56f49c-2559-4d49-9964-c155d7dd316e"
      unitRef="usd">2097900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id7364db11b9f4acc956a7d2db362e700_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjctMy0xLTEtMA_a72d586c-c4e3-42de-924c-16a634e54c58"
      unitRef="usd">2097900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="icc89d6e873484ce2a724580ab1fb0293_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjctNS0xLTEtMA_d84f1b00-8057-4800-b5b0-f119a95d2b53"
      unitRef="usd">2097900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib227796e6d934483a3898110d9a529dd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjctNy0xLTEtMA_cf853136-5202-4e92-8fe8-393a021304b8"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic99278c5824b4d0d9f4dabbc783d760a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjctOS0xLTEtMA_674c70b6-6f9f-4672-8e60-fe4493994ed6"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i173d02bf976949bb9c2fff706b29e7c8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMjctMTEtMS0xLTA_bbbc985b-9e6b-4a70-9356-3b886ad1dcab"
      unitRef="usd">2097900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iaca67a3e336f480dbf5c62f2d4887602_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzAtMS0xLTEtMA_e605251d-cf6a-4e6f-86b3-df45b2fdf25d"
      unitRef="usd">9900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i2385ee7845f44db9928643d251ba010f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzAtMy0xLTEtMA_b7ba7d81-4620-4df7-928c-f9edd416d250"
      unitRef="usd">9900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ia2a7caef4a994ecfa2504a1f8fab161d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzAtNS0xLTEtMA_61e620d8-c63b-4de4-a787-10963787c0bb"
      unitRef="usd">9900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i674d272a65ea4e939a918cbd40640fad_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzAtNy0xLTEtMA_d82a5741-bc5a-4e1e-b28e-6b3bf2ad2155"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ia5ba42bd6f784aae8d55cfe3e64aaebb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzAtOS0xLTEtMA_5f750a51-2f0b-4418-aeff-f726d04329d2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iea8e950975814a17bb0570d6ed036339_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzAtMTEtMS0xLTA_988f0318-c280-4e45-8a18-105c6049bdfd"
      unitRef="usd">9900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iab6a22cd5a3647489cfa1868842fce27_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzEtMS0xLTEtMA_9520042f-813a-4413-a18a-6d8abe4e6a1c"
      unitRef="usd">2800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="id94556bfa50648c6896a229ad967ebdb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzEtMy0xLTEtMA_392b6ac7-c081-480c-a4c7-cdc70f32f2a5"
      unitRef="usd">2800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i5ba9c3716f03494583ac46573df6d898_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzEtNS0xLTEtMA_8f224b66-824e-49ba-ab34-d1cf93893309"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="if3f1ae733c62431ea7747e533857a063_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzEtNy0xLTEtMA_7b1fbba1-1785-46be-b96a-15d1ee3d4663"
      unitRef="usd">2800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i8e05c6e58a3e45f9bbc6bfe65eb5fb24_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzEtOS0xLTEtMA_80d8ce9d-0064-4469-9b23-9ac8477ab784"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i15f60e22ff78453692beb5eecfca6ffc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzEtMTEtMS0xLTA_854c0199-4848-4295-bcc9-29505a7b4a36"
      unitRef="usd">2800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ifd7549721eee45bb8a3527258d461fd4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzItMS0xLTEtMA_6dcfd230-d788-4d0a-bccb-44788dc5f576"
      unitRef="usd">1200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i3f9525a450be44ef9048544d4294da74_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzItMy0xLTEtMA_445a44a8-1d00-488a-bd4c-5fc40974eda7"
      unitRef="usd">1200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i65bf701b377c4beda33939db2d2f21ff_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzItNS0xLTEtMA_480fc4bb-7966-45db-b254-21bee997941d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i55aec24c88d44f4fa43277cc7538aab2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzItNy0xLTEtMA_484e2818-3659-4d91-b278-43f536981550"
      unitRef="usd">1200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i34a3b14dc8874f0c86a0d3eb37f253a0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzItOS0xLTEtMA_d7d89220-7dd7-4451-94d1-3d7069b0d618"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i853e5949474b4d67b1db52061559bac8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzItMTEtMS0xLTA_8a3f7853-de78-481c-8005-40e968e76b64"
      unitRef="usd">1200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ieb0f7206c077458c83a576a665d51173_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzMtMS0xLTEtMA_210b37b2-fa22-4b66-b53d-1047e827621a"
      unitRef="usd">10300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ieb18caa1f88e42d389a9b17c85b0d9bd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzMtMy0xLTEtMA_1e950c07-af93-4ae2-8003-f7fd961ce22b"
      unitRef="usd">10300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i43215dcd05be459096efcec752179430_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzMtNS0xLTEtMA_8269aa0f-7754-44e4-ab90-173d93e2bba2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i54c52e457bd4422ca65d6e22cb0ade48_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzMtNy0xLTEtMA_06f65f5d-505e-4cda-9379-b69c6c9f2b27"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i1389fc9ec68d4b2db27d6a8e3bbd4bf1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzMtOS0xLTEtMA_9c8fba3a-50aa-47a6-819c-c5e0928d3482"
      unitRef="usd">10300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ib3c4f4f185ab4ad881bcc56455b80c21_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzMtMTEtMS0xLTA_34f80914-83a2-4238-bab2-fcc13ae39c16"
      unitRef="usd">10300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ie5244871105b411bba98a34bdca3bb0f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzUtMS0xLTEtMA_bef91bd3-e4cb-472c-b643-99379d7b920c"
      unitRef="usd">24200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="iaca67a3e336f480dbf5c62f2d4887602_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzgtMS0xLTEtMA_970a8ca8-e7c3-49b1-9245-4b59c910a902"
      unitRef="usd">78700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i2385ee7845f44db9928643d251ba010f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzgtMy0xLTEtMA_b932469e-39b9-4ccd-b808-f2f64898e09b"
      unitRef="usd">74300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ia2a7caef4a994ecfa2504a1f8fab161d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzgtNS0xLTEtMA_ba5ad492-fefe-4689-9d01-deeb83bdeef9"
      unitRef="usd">78700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i674d272a65ea4e939a918cbd40640fad_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzgtNy0xLTEtMA_bf664bef-9459-4093-b1a3-20c667ae9267"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ia5ba42bd6f784aae8d55cfe3e64aaebb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzgtOS0xLTEtMA_ef1d6cb6-756c-406b-85a1-b21bcfc17fa4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="iea8e950975814a17bb0570d6ed036339_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzgtMTEtMS0xLTA_d821f161-d7aa-4c96-abad-d77974949bb1"
      unitRef="usd">78700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="iab6a22cd5a3647489cfa1868842fce27_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzktMS0xLTEtMA_5199021c-b611-47f7-b995-fab6c6b6910f"
      unitRef="usd">137000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="id94556bfa50648c6896a229ad967ebdb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzktMy0xLTEtMA_d9cea973-06e8-446f-b32b-726e052a891e"
      unitRef="usd">126800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i5ba9c3716f03494583ac46573df6d898_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzktNS0xLTEtMA_eea61346-585c-4b51-80ad-17bad380ec69"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="if3f1ae733c62431ea7747e533857a063_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzktNy0xLTEtMA_6474128e-b873-4556-8c5e-5b5174ee949f"
      unitRef="usd">137000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i8e05c6e58a3e45f9bbc6bfe65eb5fb24_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzktOS0xLTEtMA_302433ad-7cce-44ab-9380-1c14040bd15f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i15f60e22ff78453692beb5eecfca6ffc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfMzktMTEtMS0xLTA_aea5a02e-4edf-4c31-9a42-c2b6654c03f5"
      unitRef="usd">137000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i79853a9b5da14a6fac53703381e9a418_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDAtMS0xLTEtMA_cbc05334-f109-40c1-8b9c-d08705942e39"
      unitRef="usd">106400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i33320e06f4274ef9845c5efab8d73bb1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDAtMy0xLTEtMA_1ab017d1-c28c-42c5-a265-21a9f55d7122"
      unitRef="usd">101400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i2b2eb8a9c98a498ca9bf40a99de8f49a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDAtNS0xLTEtMA_64851bc3-1a16-4d34-9feb-6c08dd391cad"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ib04cc817383740faa1e617ece927631a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDAtNy0xLTEtMA_1dde1e21-4f0f-41c4-8356-7daa8dd30677"
      unitRef="usd">106400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="id384954fa3fa4e6095584ab30e130a4e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDAtOS0xLTEtMA_da4e22fd-ec6f-4dc1-ada8-6d9f95497cf4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ic8955bee463a4261b77faca6da120420_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDAtMTEtMS0xLTA_fc1dde88-c332-419a-9986-c8a188e08c25"
      unitRef="usd">106400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ifd7549721eee45bb8a3527258d461fd4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDEtMS0xLTEtMA_f22b66ff-3ad3-41b2-8c58-42eb20000f72"
      unitRef="usd">24300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i3f9525a450be44ef9048544d4294da74_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDEtMy0xLTEtMA_f142f20d-8cee-40d4-be59-ba554646d9a7"
      unitRef="usd">23700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i65bf701b377c4beda33939db2d2f21ff_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDEtNS0xLTEtMA_ac588570-9bae-4a63-a80d-a011e15d99d5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i55aec24c88d44f4fa43277cc7538aab2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDEtNy0xLTEtMA_d7b59a16-ef0c-4904-9023-c9ee619fda65"
      unitRef="usd">24300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i34a3b14dc8874f0c86a0d3eb37f253a0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDEtOS0xLTEtMA_2bee3c94-7f9a-4c29-a422-7ed2451318c4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i853e5949474b4d67b1db52061559bac8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDEtMTEtMS0xLTA_b2cce36a-89d0-4ef6-8d26-a56b8220f244"
      unitRef="usd">24300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i3e8796c582de405f85453b6be2e3dc09_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDItMS0xLTEtMA_47f0261e-1a0f-46d6-acd6-58796897fb68"
      unitRef="usd">110500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if57b6463cf5a4132bbba6db81c527ec0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDItMy0xLTEtMA_fe9a1c65-048a-4007-ac7f-8d9410ab9f7a"
      unitRef="usd">31800000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i65887bb8147d4233b2936ee964d36760_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDItNS0xLTEtMA_117ec505-425a-492a-add4-be46679dee5d"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i45624739b2404896b6fe384552b5797f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDItNy0xLTEtMA_42eb1b7c-3056-4b85-a1b9-1cbd6c785c47"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i18bd77315f3640e2b75151bd1a403bd6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDItOS0xLTEtMA_2bbcb288-22d1-4837-9f97-259a30ab10a0"
      unitRef="usd">110500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i095078139e5147baa3f7c5a93913c9f2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDItMTEtMS0xLTA_da18f102-f9a8-45c3-9b19-6c518346062c"
      unitRef="usd">110500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i41723e47817543c98de3be1e9ac4e77b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDMtMS0xLTEtMA_97a97ecc-1927-4a58-8fef-0003df5cd589"
      unitRef="usd">1664200000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ide25b210128b49279f9dcc009920c562_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDMtMy0xLTEtMA_07c1d570-71a7-43ea-96cf-b19e5fdbe5f1"
      unitRef="usd">311600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i2ed173a5c7554ed8a6efa974dce7de56_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDMtNS0xLTEtMA_99f26ccd-48ba-478f-b792-d0265d6e6810"
      unitRef="usd">1664200000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i8841002a34004d4d894ac4dd47bba8cf_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDMtNy0xLTEtMA_f0fdfca5-b7e7-4449-a26f-bdd29661abc8"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ifd5d2cfe7b1c4e6293342168871eb584_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDMtOS0xLTEtMA_e9097022-477c-4449-a44b-6a43697da0d7"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i1862e16eb5894cbb872c6ebca5ff8dda_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDMtMTEtMS0xLTA_bc6bc761-a47b-4980-8b13-89cd76a2f9d7"
      unitRef="usd">1664200000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="ie5244871105b411bba98a34bdca3bb0f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDQtMS0xLTEtMA_b55220ed-5538-4faa-89d3-ab7ab161c67c"
      unitRef="usd">373900000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:OtherLongTermInvestments
      contextRef="i2a8f781677394edcb970a7db2a230211_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDUtMS0xLTEtMA_86d1ff83-be72-44a8-b004-7431f6cce0b5"
      unitRef="usd">471800000</us-gaap:OtherLongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="ie5244871105b411bba98a34bdca3bb0f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmM5MGQwZmNiNWI2ODRkYTRiY2FlNzA5OTJhOTQ1ZGM0L3RhYmxlcmFuZ2U6YzkwZDBmY2I1YjY4NGRhNGJjYWU3MDk5MmE5NDVkYzRfNDYtMS0xLTEtMA_ab120fab-f284-4bb7-8a70-307bb77701ff"
      unitRef="usd">2966800000</us-gaap:LongTermInvestments>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTQ4ODY_62bbef02-549b-410e-ab88-b58c8704c202">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.916%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Long-term debt, including current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(16,204.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(17,462.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(17,462.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,595.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,038.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,038.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:LongTermDebt
      contextRef="i0468ac52ec0a40758c116186c956d819_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjU3NDI3NzkxMTg2NzRmNDJhZjQ5MWU2YzhkM2UyNTlmL3RhYmxlcmFuZ2U6NTc0Mjc3OTExODY3NGY0MmFmNDkxZTZjOGQzZTI1OWZfNi0xLTEtMS0w_aa7ed7bc-3614-499b-8c28-8aae4291562d"
      unitRef="usd">16204500000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i379b7bdd53b04924a6915f7b6f539ae9_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjU3NDI3NzkxMTg2NzRmNDJhZjQ5MWU2YzhkM2UyNTlmL3RhYmxlcmFuZ2U6NTc0Mjc3OTExODY3NGY0MmFmNDkxZTZjOGQzZTI1OWZfNi0zLTEtMS0w_677ab780-b0ce-4862-835a-8c58a0af7c19"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i502fd03d8e8b42f384a0637943ac9227_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjU3NDI3NzkxMTg2NzRmNDJhZjQ5MWU2YzhkM2UyNTlmL3RhYmxlcmFuZ2U6NTc0Mjc3OTExODY3NGY0MmFmNDkxZTZjOGQzZTI1OWZfNi01LTEtMS0w_bafb101a-287a-44d9-baa5-549e58618d49"
      unitRef="usd">17462600000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i110e7dd739b14882b203dd13e31a425d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjU3NDI3NzkxMTg2NzRmNDJhZjQ5MWU2YzhkM2UyNTlmL3RhYmxlcmFuZ2U6NTc0Mjc3OTExODY3NGY0MmFmNDkxZTZjOGQzZTI1OWZfNi03LTEtMS0w_31d6fce1-e1a8-4a28-baca-203f72940ff7"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i1b1fc639100545e8b40e4cfd5886def1_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjU3NDI3NzkxMTg2NzRmNDJhZjQ5MWU2YzhkM2UyNTlmL3RhYmxlcmFuZ2U6NTc0Mjc3OTExODY3NGY0MmFmNDkxZTZjOGQzZTI1OWZfNi05LTEtMS0w_b0708977-c750-4bda-904f-fa1cd373b3f4"
      unitRef="usd">17462600000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ie5244871105b411bba98a34bdca3bb0f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjU3NDI3NzkxMTg2NzRmNDJhZjQ5MWU2YzhkM2UyNTlmL3RhYmxlcmFuZ2U6NTc0Mjc3OTExODY3NGY0MmFmNDkxZTZjOGQzZTI1OWZfNy0xLTEtMS0w_fba37efc-19b8-4f59-bf1c-a01c094ecf7b"
      unitRef="usd">16595300000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="icc89d6e873484ce2a724580ab1fb0293_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjU3NDI3NzkxMTg2NzRmNDJhZjQ5MWU2YzhkM2UyNTlmL3RhYmxlcmFuZ2U6NTc0Mjc3OTExODY3NGY0MmFmNDkxZTZjOGQzZTI1OWZfNy0zLTEtMS0w_e63b4510-a86e-49de-b880-36904010d300"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ib227796e6d934483a3898110d9a529dd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjU3NDI3NzkxMTg2NzRmNDJhZjQ5MWU2YzhkM2UyNTlmL3RhYmxlcmFuZ2U6NTc0Mjc3OTExODY3NGY0MmFmNDkxZTZjOGQzZTI1OWZfNy01LTEtMS0w_6a0437b5-45cd-4060-8b06-1e25e901bf7c"
      unitRef="usd">19038900000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ic99278c5824b4d0d9f4dabbc783d760a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjU3NDI3NzkxMTg2NzRmNDJhZjQ5MWU2YzhkM2UyNTlmL3RhYmxlcmFuZ2U6NTc0Mjc3OTExODY3NGY0MmFmNDkxZTZjOGQzZTI1OWZfNy03LTEtMS0w_0bf073e6-1fe1-4ec1-83fc-8989bb1ec36c"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i173d02bf976949bb9c2fff706b29e7c8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjU3NDI3NzkxMTg2NzRmNDJhZjQ5MWU2YzhkM2UyNTlmL3RhYmxlcmFuZ2U6NTc0Mjc3OTExODY3NGY0MmFmNDkxZTZjOGQzZTI1OWZfNy05LTEtMS0w_74eb80c7-fae0-4ebb-89a0-45fea65cc1dd"
      unitRef="usd">19038900000</us-gaap:LongTermDebt>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTQ4NTI_418f5d28-67f4-4993-b6f1-46d1bb1738db">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-management instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;87.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;87.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;87.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;235.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;235.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;235.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;39.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;39.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;39.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(45.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(45.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(45.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(19.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(19.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(19.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(16.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(16.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(16.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(66.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(66.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(66.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration liability:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(71.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(71.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(71.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-management instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ib0320b4ac23843468622fdd30e513355_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNi0xLTEtMS0w_1c36095a-1ac3-4f2a-a70e-72eeaa7ab1ac"
      unitRef="usd">87200000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="id725308cf9eb4e51afe628b2f6dd2bfa_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNi0zLTEtMS0w_953271b3-eadf-4b6d-82c0-198ee835ab6c"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i9df56ec982804883a504fffec19bec2b_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNi01LTEtMS0w_06874db9-8311-429a-a113-a993e69c65bf"
      unitRef="usd">87200000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i818be88d8b754d358fa8f0f48530989d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNi03LTEtMS0w_6b1beb08-608e-480e-8932-e14e458b0c22"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ie4605596f0c549af8b2aa8ac2b0821f7_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNi05LTEtMS0w_8f699b1d-ebaa-4357-928d-7104912569f5"
      unitRef="usd">87200000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ib0320b4ac23843468622fdd30e513355_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfOC0xLTEtMS0w_7dbae019-a024-4457-9032-74013df60bea"
      unitRef="usd">9900000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="id725308cf9eb4e51afe628b2f6dd2bfa_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfOC0zLTEtMS0w_afa251bd-85f0-4975-a2e8-7bef580087ab"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i9df56ec982804883a504fffec19bec2b_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfOC01LTEtMS0w_6df1c79f-3d4f-4d12-8939-708bd7d328bd"
      unitRef="usd">9900000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i818be88d8b754d358fa8f0f48530989d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfOC03LTEtMS0w_f7676b95-0f38-4b50-9af3-42b7a6b2d014"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ie4605596f0c549af8b2aa8ac2b0821f7_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfOC05LTEtMS0w_38e13996-c331-4a63-a093-6f59891567e6"
      unitRef="usd">9900000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="iff50ed7383624a5dabf03016acb58cb4_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTItMS0xLTEtMA_c6f712b5-13b0-4388-83e7-f024dd5a290b"
      unitRef="usd">235400000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ic22a911ebb564c3e8e5e11aebe36daf2_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTItMy0xLTEtMA_b826fac3-2586-4cc5-b4fc-7219e12cb2c7"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i3791d236011c495c9a6bc09f31e0e651_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTItNS0xLTEtMA_f826691c-1c93-4c8a-99dc-5d57c016feff"
      unitRef="usd">235400000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i1eef9a676fef442f8cc0df6224b88661_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTItNy0xLTEtMA_851f1258-42b6-45ea-ab20-a7663f61b7eb"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i7f4f985dfc4c4913b6b477e42c5b7abf_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTItOS0xLTEtMA_340bc596-6b1e-409a-ae23-498108bcacff"
      unitRef="usd">235400000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i97f888ed727b47c4969964bbc26cee74_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTUtMS0xLTEtMA_a94e044c-d8a7-433a-b313-294d535a3f0e"
      unitRef="usd">12700000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ibb9cad6e8ee145a28421160b0fd93ac8_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTUtMy0xLTEtMA_d79d385a-bb9b-42b4-a79f-0eaf18c9c894"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ibc00ea5651d44a68866912b87e772f32_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTUtNS0xLTEtMA_eadd6b5a-c837-4f1c-b569-cfa6257ae56a"
      unitRef="usd">12700000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i9728137c063040fdb217c0c575d24e90_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTUtNy0xLTEtMA_1999e081-f4af-4b86-9aab-16c129289bfa"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ia5691e9a962e48b9bab39a38eebafc58_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTUtOS0xLTEtMA_b21aadb2-0bfd-4b1c-ac59-c6532071e6d2"
      unitRef="usd">12700000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i97f888ed727b47c4969964bbc26cee74_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTYtMS0xLTEtMA_f07fc2c8-4da0-40d8-a700-691bb87b77e3"
      unitRef="usd">39400000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ibb9cad6e8ee145a28421160b0fd93ac8_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTYtMy0xLTEtMA_f1715ef5-1023-40e4-926d-45e0d19c41da"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ibc00ea5651d44a68866912b87e772f32_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTYtNS0xLTEtMA_e38d1b8c-18fd-46a2-a975-2d578d822fc6"
      unitRef="usd">39400000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i9728137c063040fdb217c0c575d24e90_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTYtNy0xLTEtMA_5631ebc0-d01d-4225-96f7-f2d6fd6ea0d0"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ia5691e9a962e48b9bab39a38eebafc58_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTYtOS0xLTEtMA_5cb98137-7c44-43f5-a6d6-f72d893c2777"
      unitRef="usd">39400000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i97f888ed727b47c4969964bbc26cee74_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTctMS0xLTEtMA_87e2c300-8796-4e2d-9969-d2722bdd4ba9"
      unitRef="usd">45500000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="ibb9cad6e8ee145a28421160b0fd93ac8_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTctMy0xLTEtMA_faaeb623-8962-4d77-a897-228e0bd658eb"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="ibc00ea5651d44a68866912b87e772f32_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTctNS0xLTEtMA_16cf1f95-ca19-47e0-a2e1-e5cbfab5f8dc"
      unitRef="usd">45500000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i9728137c063040fdb217c0c575d24e90_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTctNy0xLTEtMA_d0e8946d-f687-43c7-8f68-1ab6df90d93a"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="ia5691e9a962e48b9bab39a38eebafc58_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTctOS0xLTEtMA_60c5d0a2-9886-48a7-90b6-79e016fe84f6"
      unitRef="usd">45500000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i97f888ed727b47c4969964bbc26cee74_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTgtMS0xLTEtMA_42beaf6d-45c1-4c25-83be-788d38339c67"
      unitRef="usd">19100000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ibb9cad6e8ee145a28421160b0fd93ac8_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTgtMy0xLTEtMA_1d5dd257-81af-4633-abbd-6f02e83788c7"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ibc00ea5651d44a68866912b87e772f32_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTgtNS0xLTEtMA_daa52edc-3907-4a79-b637-09161544f8a5"
      unitRef="usd">19100000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i9728137c063040fdb217c0c575d24e90_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTgtNy0xLTEtMA_1abec63d-78ce-42a5-84a9-0e93cc5f8654"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ia5691e9a962e48b9bab39a38eebafc58_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMTgtOS0xLTEtMA_442b2f8c-b002-4e46-8e2f-43de3868dd1b"
      unitRef="usd">19100000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ib8f794d05abe4bb88fcbc982b4151ef0_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjAtMS0xLTEtMA_f5ffaa5c-bd09-4305-80b1-15f790dd40e0"
      unitRef="usd">3000000.0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i083270152267493cab8ef4a98752605d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjAtMy0xLTEtMzI4Mg_f788c07e-0e7d-4472-836e-025b0261a946"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="idb4db963049a418ebc24c7b6962c9c42_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjAtNS0xLTEtMA_92692327-e6a7-4b60-8662-9b8d499d7bee"
      unitRef="usd">3000000.0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i2df54907b9c740578baa39b1f16db346_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjAtNy0xLTEtMzI4Mg_7e5fd5db-0b26-4043-ba61-c251ecb7fc72"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i9868066d4bf64c67b21b80f50a543d09_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjAtOS0xLTEtMA_42ded5ab-0eba-423b-a190-8ceb2ff7c96b"
      unitRef="usd">3000000.0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ib8f794d05abe4bb88fcbc982b4151ef0_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjEtMS0xLTEtMA_826331c7-e264-447d-82c4-f5853f31a466"
      unitRef="usd">16800000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i083270152267493cab8ef4a98752605d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjEtMy0xLTEtMA_ae2c15e2-becb-475b-bbeb-f8880c0cae45"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="idb4db963049a418ebc24c7b6962c9c42_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjEtNS0xLTEtMA_dcddb1e6-27cb-4854-961f-da0ef48f179b"
      unitRef="usd">16800000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i2df54907b9c740578baa39b1f16db346_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjEtNy0xLTEtMA_6979ccf7-670d-4e36-8852-1b32798acc4e"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i9868066d4bf64c67b21b80f50a543d09_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjEtOS0xLTEtMA_1324c55e-9db6-419a-bbfa-1e59f2e6c675"
      unitRef="usd">16800000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="id3477ea907754af1b237c11ecd845a8c_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjMtMS0xLTEtMA_3dadf9e3-90e2-4eca-bb48-bf31562f2835"
      unitRef="usd">14800000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i5579461ee30641f5866f90f7f973fc2d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjMtMy0xLTEtMA_28ebe9b2-fc77-49a0-96cf-3e46e08c0a0b"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i0c522dc4d3644e6b89e1c04ae748b784_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjMtNS0xLTEtMA_72da6b88-ecce-41bc-acfc-775a3d774f59"
      unitRef="usd">14800000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i4028304ed5344f378d4d8453889c1244_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjMtNy0xLTEtMA_cb1e3809-7c08-41cc-beca-4c5cd19e4c32"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i6c3b7e0e20ce4aa79064e5c448631a6e_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjMtOS0xLTEtMA_c7d668d3-e879-4b6d-ab8e-6f5f82677006"
      unitRef="usd">14800000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="id3477ea907754af1b237c11ecd845a8c_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjQtMS0xLTEtMA_2b6834f0-7d7c-4ec1-b624-b1c8221ea16a"
      unitRef="usd">66200000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i5579461ee30641f5866f90f7f973fc2d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjQtMy0xLTEtMA_ec9a237e-9be6-43f1-aa89-0db903fbcf66"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i0c522dc4d3644e6b89e1c04ae748b784_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjQtNS0xLTEtMA_7ebba9a8-6f27-44c4-9b48-655920986ed5"
      unitRef="usd">66200000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i4028304ed5344f378d4d8453889c1244_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjQtNy0xLTEtMA_a1e101b8-427b-4d43-9725-a45a66ffefb4"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i6c3b7e0e20ce4aa79064e5c448631a6e_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjQtOS0xLTEtMA_675cf999-46bd-4391-9fc5-03ff0d642205"
      unitRef="usd">66200000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i0468ac52ec0a40758c116186c956d819_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjktMS0xLTEtNzY4NQ_84da6db7-cdbb-4006-a62c-9962566b886d"
      unitRef="usd">71100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i379b7bdd53b04924a6915f7b6f539ae9_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjktMy0xLTEtNzY4NQ_4cb0aa99-ee22-4980-8fdb-e634405a4abe"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i502fd03d8e8b42f384a0637943ac9227_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjktNS0xLTEtNzY4NQ_1cfa9373-5edd-4bbf-a7ed-f90d9bcbd758"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i110e7dd739b14882b203dd13e31a425d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjktNy0xLTEtNzY4NQ_ba6bdddb-8fd6-4353-897c-ab0885682359"
      unitRef="usd">71100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i1b1fc639100545e8b40e4cfd5886def1_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMjktOS0xLTEtNzY4NQ_ba0c4b2c-2d34-4d66-98cb-f43c116ae983"
      unitRef="usd">71100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i835b04928dc34e3d9eb5b6a882d6a434_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMzUtMS0xLTEtMA_7462ab78-c251-4a85-8c1b-064be14e96cd"
      unitRef="usd">158900000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i59341bae0f284bb79a7771c86ff861f4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMzUtMy0xLTEtMA_52a151a4-bca3-4334-bbe0-22ef4d0b3aa4"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i253bfddb6f414fe3a582437856252d99_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMzUtNS0xLTEtMA_32e2bb8c-d58b-41f6-8069-d3ebf953b843"
      unitRef="usd">158900000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="icd815ed694bb4b1da50025622caa47df_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMzUtNy0xLTEtMA_eeef826e-c79c-4769-9135-3ac87867518a"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ie39cd3b104234bdfbcbaedb52a41b15c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMzUtOS0xLTEtMA_372bcab0-0e55-4d66-97d0-d0bb8a0be136"
      unitRef="usd">158900000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i94f25e4c5e4b42cca659ef04248013aa_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMzktMS0xLTEtMA_f0965049-e4be-4f0e-9c68-ea23d3510745"
      unitRef="usd">38100000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i1893ad6b0e8c4f9d9ce45848acc79e12_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMzktMy0xLTEtMA_c646d7cc-a4ed-4d7e-9ec0-b12dce3d3dc4"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i541afb2da75d43639f7fec2ae5748d7f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMzktNS0xLTEtMA_786d6733-2a45-41c5-9fba-28eb2a6223c8"
      unitRef="usd">38100000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i014bd38c39aa4b1895340e1de5390e79_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMzktNy0xLTEtMA_da61d7da-2328-467a-be32-3d43211ca3c0"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i79425d230e734042bd4df00c16901373_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfMzktOS0xLTEtMA_ad139b9e-e51d-40a5-88a5-7aaae14db0a6"
      unitRef="usd">38100000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i94f25e4c5e4b42cca659ef04248013aa_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDAtMS0xLTEtNTQ1Nw_24f78da9-27cd-47e5-a7b9-a94d064d6ca8"
      unitRef="usd">97800000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i1893ad6b0e8c4f9d9ce45848acc79e12_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDAtMy0xLTEtNTQ1Nw_7f405576-7e71-4676-923f-9304bb35d1fc"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i541afb2da75d43639f7fec2ae5748d7f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDAtNS0xLTEtNTQ1Nw_bef65268-7a52-42aa-ba56-48878e6ae59b"
      unitRef="usd">97800000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i014bd38c39aa4b1895340e1de5390e79_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDAtNy0xLTEtNTQ1Nw_c496a71f-34ab-4c86-ae11-12e0cb6a4426"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i79425d230e734042bd4df00c16901373_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDAtOS0xLTEtNTQ1Nw_c06cbc78-c248-47f0-ab6e-9cb276e795d6"
      unitRef="usd">97800000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i2553d800f08240b1b782fd37f8f03377_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDMtMS0xLTEtMA_5b1c93cf-c133-47bd-9a3d-d5c537c1c107"
      unitRef="usd">92600000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="icdf6391061294c348287bce4418a7767_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDMtMy0xLTEtMA_4591e762-167e-45bf-91ab-a1a3b69a03a9"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i326c763bfd9e49bdb908141c5104c4c6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDMtNS0xLTEtMA_8ce13888-830e-43b6-ac05-3e6d1a40ebea"
      unitRef="usd">92600000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="if72250a4fe7543458ef88e49f913f39a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDMtNy0xLTEtMA_0ebd982c-b3b0-446a-ad3a-5cc9e6b88620"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i53ee22718d2249e6932918034d9479f7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDMtOS0xLTEtMA_e2ef42d6-e39d-472e-9a5e-6fbe3a885160"
      unitRef="usd">92600000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i2553d800f08240b1b782fd37f8f03377_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDQtMS0xLTEtMA_8739e0bd-701a-498a-be78-7702ac7f2bf2"
      unitRef="usd">97200000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="icdf6391061294c348287bce4418a7767_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDQtMy0xLTEtMA_bead6971-afb8-454c-b2cb-12c627ec6f42"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i326c763bfd9e49bdb908141c5104c4c6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDQtNS0xLTEtMA_4107cc8e-ded8-49e8-8e22-fe4e0788aa3b"
      unitRef="usd">97200000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="if72250a4fe7543458ef88e49f913f39a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDQtNy0xLTEtMA_18dcc2ba-1c9c-4232-bcb5-e521ab9b92e8"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i53ee22718d2249e6932918034d9479f7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDQtOS0xLTEtMA_bd2fa48f-21f3-4f56-bca1-02c13ca20b19"
      unitRef="usd">97200000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i11784cd0180b4240bfe628b8a935091b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDYtMS0xLTEtMA_4d0231af-1c84-41fd-9169-202558746e6c"
      unitRef="usd">34400000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="id2b7165b4f9f4b159f2f118447ef21b2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDYtMy0xLTEtMA_a9a33290-14b2-409c-a41a-cd02e1b57508"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i3c9d21e349b44826bb9ff73def0b0f9b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDYtNS0xLTEtMA_bd4a307e-0928-4ddc-8c12-376d4be1b443"
      unitRef="usd">34400000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i492cf935c87d44ea908c1584da4f932b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDYtNy0xLTEtMA_5dcc239c-0df9-4aa0-ad0d-e55f9aca31ae"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i86f5f0213b924cf4a2443b1755e0e558_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDYtOS0xLTEtMA_975d87f5-8649-45d9-be8e-b0009b9a0627"
      unitRef="usd">34400000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i11784cd0180b4240bfe628b8a935091b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDctMS0xLTEtMA_6481c109-1f96-4b51-9540-0c638b2ca246"
      unitRef="usd">2900000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="id2b7165b4f9f4b159f2f118447ef21b2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDctMy0xLTEtMA_82dec22c-a8c9-48ba-b590-12020a9ee4a1"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i3c9d21e349b44826bb9ff73def0b0f9b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDctNS0xLTEtMA_250ca144-49b4-4358-9be8-060016628308"
      unitRef="usd">2900000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i492cf935c87d44ea908c1584da4f932b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDctNy0xLTEtMA_c3e0882a-374d-441d-b15c-58d2f8f332fe"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i86f5f0213b924cf4a2443b1755e0e558_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDctOS0xLTEtMA_1d8d58ba-6e27-43a4-8af8-b36234c8f98f"
      unitRef="usd">2900000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ie913be1662fb496dadd88c102ecc6d7f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDktMS0xLTEtMA_6a691c2f-3202-4546-ac4b-9bd2e95eb6af"
      unitRef="usd">41100000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i5133f4445b424b37b5a24aee0f8c8ad5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDktMy0xLTEtMA_87cf09b7-f212-4109-a345-5bf081725e9a"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="icb9d49fc86e54fa4aef040dc305765cc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDktNS0xLTEtMA_07d14ea2-d573-48c1-9f2d-72646e032788"
      unitRef="usd">41100000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i34c34c5498af462390f43272c1214aad_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDktNy0xLTEtMA_b5fb6dfc-3cc8-405f-a471-ca33fa834e6b"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i80e1536360e0467e919e75a282b9c273_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNDktOS0xLTEtMA_1fb0670a-7226-4a2c-9df2-e9074c274f7a"
      unitRef="usd">41100000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="ie913be1662fb496dadd88c102ecc6d7f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNTAtMS0xLTEtMA_ce6759fe-4323-4a88-8ecc-1af9cf7c75de"
      unitRef="usd">15200000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i5133f4445b424b37b5a24aee0f8c8ad5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNTAtMy0xLTEtMA_28e08b7e-a601-431a-aaa9-209b90426601"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="icb9d49fc86e54fa4aef040dc305765cc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNTAtNS0xLTEtMA_7409c232-216a-4746-833c-c0bcdf9b1aa1"
      unitRef="usd">15200000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i34c34c5498af462390f43272c1214aad_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNTAtNy0xLTEtMA_e372d0a3-ff66-404c-944e-73466e950505"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i80e1536360e0467e919e75a282b9c273_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOmJjNDQzNzZiMTY0OTRjMjVhYTdjYmZlNzJkN2VlMzNiL3RhYmxlcmFuZ2U6YmM0NDM3NmIxNjQ5NGMyNWFhN2NiZmU3MmQ3ZWUzM2JfNTAtOS0xLTEtMA_95c96cce-077d-4bb8-b73d-32de64188eda"
      unitRef="usd">15200000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTA5MzM_fb644623-add0-4654-8be0-42bdd5349919"
      unitRef="usd">736000000</us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments>
    <lly:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTEwNTI_43edea2e-b25d-473c-9111-73de4e6f9de9">P10Y</lly:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTQ4Nzc_fe6c1cc3-3eca-4d12-b6f8-b31c0fffae99">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of March&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturities by Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less&#160;Than&lt;br/&gt;1 Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1-5&lt;br/&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6-10&lt;br/&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;More&#160;Than&lt;br/&gt;10 Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;443.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjcyNmI3YWIwNTg3NTRlOWNiMjY2MGRlOTQwMmQ2ZGQ3L3RhYmxlcmFuZ2U6NzI2YjdhYjA1ODc1NGU5Y2IyNjYwZGU5NDAyZDZkZDdfMi0xLTEtMS0w_a0c8f488-046b-493d-876b-a5c521fadae2"
      unitRef="usd">443700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjcyNmI3YWIwNTg3NTRlOWNiMjY2MGRlOTQwMmQ2ZGQ3L3RhYmxlcmFuZ2U6NzI2YjdhYjA1ODc1NGU5Y2IyNjYwZGU5NDAyZDZkZDdfMi0zLTEtMS0w_2c57ac94-4f9f-471c-89e9-d2c9da62c2fa"
      unitRef="usd">30800000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjcyNmI3YWIwNTg3NTRlOWNiMjY2MGRlOTQwMmQ2ZGQ3L3RhYmxlcmFuZ2U6NzI2YjdhYjA1ODc1NGU5Y2IyNjYwZGU5NDAyZDZkZDdfMi01LTEtMS0w_3f5447fb-617a-4b03-bbf1-03ac0c5ecefc"
      unitRef="usd">147800000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjcyNmI3YWIwNTg3NTRlOWNiMjY2MGRlOTQwMmQ2ZGQ3L3RhYmxlcmFuZ2U6NzI2YjdhYjA1ODc1NGU5Y2IyNjYwZGU5NDAyZDZkZDdfMi03LTEtMS0w_c1db2b5b-dbb9-4339-bd85-e3b90188c587"
      unitRef="usd">125200000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjcyNmI3YWIwNTg3NTRlOWNiMjY2MGRlOTQwMmQ2ZGQ3L3RhYmxlcmFuZ2U6NzI2YjdhYjA1ODc1NGU5Y2IyNjYwZGU5NDAyZDZkZDdfMi05LTEtMS0w_fd035206-29a3-45ed-87fb-80d8f75d9c17"
      unitRef="usd">139900000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTEyOTM_1603b77d-5a4a-4a3e-8cc3-1d7d6863f508"
      unitRef="usd">301500000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTEzMDA_87075633-ef07-464b-b626-2e752c780cc0"
      unitRef="usd">186600000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTQ4MzM_e76ecccd-0895-4923-939d-4c2beb6e2beb">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the fair value of available-for-sale securities in an unrealized gain or loss position and the amount of unrealized gains and losses in accumulated other comprehensive loss follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gross gains&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gross losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of securities in an unrealized gain position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;273.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of securities in an unrealized loss position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;170.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjlkNGFlNGFhNTNiOTRmMWQ4YzcwNzQ0M2VjN2E0MzVlL3RhYmxlcmFuZ2U6OWQ0YWU0YWE1M2I5NGYxZDhjNzA3NDQzZWM3YTQzNWVfMS0xLTEtMS0w_eb255352-fa6a-4c64-a225-8e62a4dcd83c"
      unitRef="usd">12000000.0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjlkNGFlNGFhNTNiOTRmMWQ4YzcwNzQ0M2VjN2E0MzVlL3RhYmxlcmFuZ2U6OWQ0YWU0YWE1M2I5NGYxZDhjNzA3NDQzZWM3YTQzNWVfMS0zLTEtMS0w_f369aa22-544a-4427-8e14-70d740fd8b57"
      unitRef="usd">20900000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjlkNGFlNGFhNTNiOTRmMWQ4YzcwNzQ0M2VjN2E0MzVlL3RhYmxlcmFuZ2U6OWQ0YWU0YWE1M2I5NGYxZDhjNzA3NDQzZWM3YTQzNWVfMi0xLTEtMS0w_c0915cec-1b69-4c8a-a618-1a69bb19e2ea"
      unitRef="usd">6300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjlkNGFlNGFhNTNiOTRmMWQ4YzcwNzQ0M2VjN2E0MzVlL3RhYmxlcmFuZ2U6OWQ0YWU0YWE1M2I5NGYxZDhjNzA3NDQzZWM3YTQzNWVfMi0zLTEtMS0w_b73a4321-d243-49ea-a565-f3e11d1da308"
      unitRef="usd">500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjlkNGFlNGFhNTNiOTRmMWQ4YzcwNzQ0M2VjN2E0MzVlL3RhYmxlcmFuZ2U6OWQ0YWU0YWE1M2I5NGYxZDhjNzA3NDQzZWM3YTQzNWVfMy0xLTEtMS0w_bb6ad23a-2187-4cbf-af30-90c366edb8c6"
      unitRef="usd">273600000</lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition>
    <lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjlkNGFlNGFhNTNiOTRmMWQ4YzcwNzQ0M2VjN2E0MzVlL3RhYmxlcmFuZ2U6OWQ0YWU0YWE1M2I5NGYxZDhjNzA3NDQzZWM3YTQzNWVfMy0zLTEtMS0w_c077b1a3-8626-446e-b83d-8c2b073a1f10"
      unitRef="usd">348900000</lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjlkNGFlNGFhNTNiOTRmMWQ4YzcwNzQ0M2VjN2E0MzVlL3RhYmxlcmFuZ2U6OWQ0YWU0YWE1M2I5NGYxZDhjNzA3NDQzZWM3YTQzNWVfNC0xLTEtMS0w_a59137b2-2304-4833-9ff7-ecf499863d91"
      unitRef="usd">170100000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjlkNGFlNGFhNTNiOTRmMWQ4YzcwNzQ0M2VjN2E0MzVlL3RhYmxlcmFuZ2U6OWQ0YWU0YWE1M2I5NGYxZDhjNzA3NDQzZWM3YTQzNWVfNC0zLTEtMS0w_327a8289-f28a-4d10-8cd6-795132a6c38e"
      unitRef="usd">11400000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTMyNTY_6b9c8d39-fdea-48e5-afa2-2fa95285814f"
      unitRef="number">0.94</us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets>
    <us-gaap:GainLossOnInvestmentsTextBlock
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTQ4NzE_a9839108-e652-4358-9573-53d2df9f6f11">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity related to our available-for-sale securities was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;43.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized gross gains on sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized gross losses on sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GainLossOnInvestmentsTextBlock>
    <lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjQyZWFmZDVlMzBjNzQ2YzY4NmJmYjcyNzI3ZDc1NDI3L3RhYmxlcmFuZ2U6NDJlYWZkNWUzMGM3NDZjNjg2YmZiNzI3MjdkNzU0MjdfMi0xLTEtMS0w_bd13b639-b34e-4f9d-8c65-fecbc648f30a"
      unitRef="usd">43300000</lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities>
    <lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjQyZWFmZDVlMzBjNzQ2YzY4NmJmYjcyNzI3ZDc1NDI3L3RhYmxlcmFuZ2U6NDJlYWZkNWUzMGM3NDZjNjg2YmZiNzI3MjdkNzU0MjdfMi0zLTEtMS0w_51bf6c4b-aa29-420c-8eec-0747e7429ade"
      unitRef="usd">38000000.0</lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities>
    <lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjQyZWFmZDVlMzBjNzQ2YzY4NmJmYjcyNzI3ZDc1NDI3L3RhYmxlcmFuZ2U6NDJlYWZkNWUzMGM3NDZjNjg2YmZiNzI3MjdkNzU0MjdfMy0xLTEtMS0w_040ad5a7-692f-4540-b5be-9523369e19e0"
      unitRef="usd">1100000</lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain>
    <lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjQyZWFmZDVlMzBjNzQ2YzY4NmJmYjcyNzI3ZDc1NDI3L3RhYmxlcmFuZ2U6NDJlYWZkNWUzMGM3NDZjNjg2YmZiNzI3MjdkNzU0MjdfMy0zLTEtMS0w_1e653ddc-ff54-4c93-96a1-4537196160e8"
      unitRef="usd">900000</lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain>
    <lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjQyZWFmZDVlMzBjNzQ2YzY4NmJmYjcyNzI3ZDc1NDI3L3RhYmxlcmFuZ2U6NDJlYWZkNWUzMGM3NDZjNjg2YmZiNzI3MjdkNzU0MjdfNC0xLTEtMS0w_ce19e297-533d-413d-941d-046530b9e687"
      unitRef="usd">400000</lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss>
    <lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RhYmxlOjQyZWFmZDVlMzBjNzQ2YzY4NmJmYjcyNzI3ZDc1NDI3L3RhYmxlcmFuZ2U6NDJlYWZkNWUzMGM3NDZjNjg2YmZiNzI3MjdkNzU0MjdfNC0zLTEtMS0w_0e4a31a8-7d95-4afe-ad61-d332c6113e29"
      unitRef="usd">800000</lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss>
    <us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTQ1NTM_822085b7-de69-4f12-9fcc-f4f09f0b1a9e"
      unitRef="usd">637800000</us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized>
    <us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized
      contextRef="ic0cb0d0f80df4940b8645cfac86c2594_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82MS9mcmFnOjE5YTMwZTllMzQxYzQ4NjNiMzQxNmI1ZWExZmUyNGNjL3RleHRyZWdpb246MTlhMzBlOWUzNDFjNDg2M2IzNDE2YjVlYTFmZTI0Y2NfMTQ1NjA_a48ab26b-779b-4f99-a61f-9aa4caaccad6"
      unitRef="usd">754900000</us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82NC9mcmFnOjZjMGVjOWIwOWYwZDQ1ZWI5ODU3MTJhMmFhY2Y2YzRlL3RleHRyZWdpb246NmMwZWM5YjA5ZjBkNDVlYjk4NTcxMmEyYWFjZjZjNGVfNzUw_734b6905-09e7-46b9-b56e-c95a9f489cad">Income Taxes &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective tax rate was 8.2 percent for the three months ended March&#160;31, 2021, compared with 13.3 percent for the three months ended March 31, 2020. The effective tax rates for both periods were reduced by net discrete tax benefits, with a larger net discrete tax benefit reflected for the three months ended March&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The U.S. examination of tax years 2016-2018 began in the fourth quarter of 2019 and remains ongoing; therefore, the resolution of this audit period will likely extend beyond the next 12 months.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82NC9mcmFnOjZjMGVjOWIwOWYwZDQ1ZWI5ODU3MTJhMmFhY2Y2YzRlL3RleHRyZWdpb246NmMwZWM5YjA5ZjBkNDVlYjk4NTcxMmEyYWFjZjZjNGVfNTQ_8b9ec730-8fe7-4646-93eb-2dd09797521a"
      unitRef="number">0.082</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82NC9mcmFnOjZjMGVjOWIwOWYwZDQ1ZWI5ODU3MTJhMmFhY2Y2YzRlL3RleHRyZWdpb246NmMwZWM5YjA5ZjBkNDVlYjk4NTcxMmEyYWFjZjZjNGVfMTAy_d13e69a1-1cfe-478e-bff8-2abee110c4fe"
      unitRef="number">0.133</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RleHRyZWdpb246MDRjZmJhNmZlZTM1NGY1OGE1MWIwYjc4NTgzOTM0OWRfMTM3MQ_caa192cb-ee93-4553-aef9-ddbce1695e61">Retirement Benefits&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net pension and retiree health benefit (income) cost included the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of net periodic benefit cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;92.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;84.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(238.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(221.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;121.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;61.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Retiree Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of net periodic benefit income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(36.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(30.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We contributed approximately $15 million to satisfy minimum funding requirements to our defined benefit pension and retiree health benefit plans during the three months ended March&#160;31, 2021. We contributed approximately $10 million in discretionary funding during the three months ended March&#160;31, 2021. During the remainder of 2021, we expect to make contributions of approximately $20 million to our defined benefit pension and retiree health plans to satisfy minimum funding requirements.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RleHRyZWdpb246MDRjZmJhNmZlZTM1NGY1OGE1MWIwYjc4NTgzOTM0OWRfMTM3OQ_cf41afce-f762-4aa3-8f6f-81e7433c79b9">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net pension and retiree health benefit (income) cost included the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of net periodic benefit cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;92.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;84.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(238.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(221.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;121.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;61.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Retiree Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of net periodic benefit income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(36.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(30.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i1d9dae1aca8e45a9bd0624944e8a56ca_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmQ3YWVjZjVjNzdkNjQxNThhMGUyNjgzZjliMTk3NzYzL3RhYmxlcmFuZ2U6ZDdhZWNmNWM3N2Q2NDE1OGEwZTI2ODNmOWIxOTc3NjNfNC0xLTEtMS0w_c749ef18-861e-4463-8169-6b7321b9482f"
      unitRef="usd">92000000.0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i5e38511a533b4a35afcd45b88276b271_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmQ3YWVjZjVjNzdkNjQxNThhMGUyNjgzZjliMTk3NzYzL3RhYmxlcmFuZ2U6ZDdhZWNmNWM3N2Q2NDE1OGEwZTI2ODNmOWIxOTc3NjNfNC0zLTEtMS0w_66c9e723-0d24-4c12-b562-f9b4fe13e8b4"
      unitRef="usd">78700000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i1d9dae1aca8e45a9bd0624944e8a56ca_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmQ3YWVjZjVjNzdkNjQxNThhMGUyNjgzZjliMTk3NzYzL3RhYmxlcmFuZ2U6ZDdhZWNmNWM3N2Q2NDE1OGEwZTI2ODNmOWIxOTc3NjNfNS0xLTEtMS0w_4160c028-e794-43a7-b407-2ab58f1cfd97"
      unitRef="usd">84300000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i5e38511a533b4a35afcd45b88276b271_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmQ3YWVjZjVjNzdkNjQxNThhMGUyNjgzZjliMTk3NzYzL3RhYmxlcmFuZ2U6ZDdhZWNmNWM3N2Q2NDE1OGEwZTI2ODNmOWIxOTc3NjNfNS0zLTEtMS0w_6fab79d3-3582-4597-8fc6-c9c63d6aae5b"
      unitRef="usd">105000000.0</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i1d9dae1aca8e45a9bd0624944e8a56ca_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmQ3YWVjZjVjNzdkNjQxNThhMGUyNjgzZjliMTk3NzYzL3RhYmxlcmFuZ2U6ZDdhZWNmNWM3N2Q2NDE1OGEwZTI2ODNmOWIxOTc3NjNfNi0xLTEtMS0w_75b99afd-39d5-4de9-b5dd-a9422b47c1ca"
      unitRef="usd">238000000.0</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i5e38511a533b4a35afcd45b88276b271_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmQ3YWVjZjVjNzdkNjQxNThhMGUyNjgzZjliMTk3NzYzL3RhYmxlcmFuZ2U6ZDdhZWNmNWM3N2Q2NDE1OGEwZTI2ODNmOWIxOTc3NjNfNi0zLTEtMS0w_a0507bf2-b131-42f0-9a2e-d4c6ccb73012"
      unitRef="usd">221200000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i1d9dae1aca8e45a9bd0624944e8a56ca_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmQ3YWVjZjVjNzdkNjQxNThhMGUyNjgzZjliMTk3NzYzL3RhYmxlcmFuZ2U6ZDdhZWNmNWM3N2Q2NDE1OGEwZTI2ODNmOWIxOTc3NjNfNy0xLTEtMS0w_1f3eb112-d031-4e42-9398-91a0920ea90f"
      unitRef="usd">1100000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i5e38511a533b4a35afcd45b88276b271_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmQ3YWVjZjVjNzdkNjQxNThhMGUyNjgzZjliMTk3NzYzL3RhYmxlcmFuZ2U6ZDdhZWNmNWM3N2Q2NDE1OGEwZTI2ODNmOWIxOTc3NjNfNy0zLTEtMS0w_ff144d49-c207-48bb-a801-2cde463b6744"
      unitRef="usd">1100000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit
      contextRef="i1d9dae1aca8e45a9bd0624944e8a56ca_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmQ3YWVjZjVjNzdkNjQxNThhMGUyNjgzZjliMTk3NzYzL3RhYmxlcmFuZ2U6ZDdhZWNmNWM3N2Q2NDE1OGEwZTI2ODNmOWIxOTc3NjNfOC0xLTEtMS0w_f72501ab-f6b2-4260-8d28-e6536ac33f37"
      unitRef="usd">-121800000</us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit>
    <us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit
      contextRef="i5e38511a533b4a35afcd45b88276b271_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmQ3YWVjZjVjNzdkNjQxNThhMGUyNjgzZjliMTk3NzYzL3RhYmxlcmFuZ2U6ZDdhZWNmNWM3N2Q2NDE1OGEwZTI2ODNmOWIxOTc3NjNfOC0zLTEtMS0w_f9a3aa4e-371f-498b-8324-5addef9c1b42"
      unitRef="usd">-111000000.0</us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i1d9dae1aca8e45a9bd0624944e8a56ca_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmQ3YWVjZjVjNzdkNjQxNThhMGUyNjgzZjliMTk3NzYzL3RhYmxlcmFuZ2U6ZDdhZWNmNWM3N2Q2NDE1OGEwZTI2ODNmOWIxOTc3NjNfMTAtMS0xLTEtMA_1b1ca009-20c4-46d2-9fbf-310b18bd0525"
      unitRef="usd">61200000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i5e38511a533b4a35afcd45b88276b271_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmQ3YWVjZjVjNzdkNjQxNThhMGUyNjgzZjliMTk3NzYzL3RhYmxlcmFuZ2U6ZDdhZWNmNWM3N2Q2NDE1OGEwZTI2ODNmOWIxOTc3NjNfMTAtMy0xLTEtMA_6d29c3a4-449b-4d8f-afa5-a32acc199740"
      unitRef="usd">74600000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ic4b0ceabb1674432983305cc3a962999_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmRkNjFmYjAxNDc3ZDQ2NDU4YWY0NzJhZjA3NmJjYzg4L3RhYmxlcmFuZ2U6ZGQ2MWZiMDE0NzdkNDY0NThhZjQ3MmFmMDc2YmNjODhfNC0xLTEtMS0w_4b78ce6c-5dcf-422e-93d6-5d7495f3e7dc"
      unitRef="usd">11700000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="idf4e9376f20b4a76a67b9874281b82b7_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmRkNjFmYjAxNDc3ZDQ2NDU4YWY0NzJhZjA3NmJjYzg4L3RhYmxlcmFuZ2U6ZGQ2MWZiMDE0NzdkNDY0NThhZjQ3MmFmMDc2YmNjODhfNC0zLTEtMS0w_1ac7dda9-eaa5-4e32-a706-962f1d76fc41"
      unitRef="usd">9800000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ic4b0ceabb1674432983305cc3a962999_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmRkNjFmYjAxNDc3ZDQ2NDU4YWY0NzJhZjA3NmJjYzg4L3RhYmxlcmFuZ2U6ZGQ2MWZiMDE0NzdkNDY0NThhZjQ3MmFmMDc2YmNjODhfNS0xLTEtMS0w_88391b3c-4df5-48fb-bb30-56dff9c9101c"
      unitRef="usd">8100000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="idf4e9376f20b4a76a67b9874281b82b7_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmRkNjFmYjAxNDc3ZDQ2NDU4YWY0NzJhZjA3NmJjYzg4L3RhYmxlcmFuZ2U6ZGQ2MWZiMDE0NzdkNDY0NThhZjQ3MmFmMDc2YmNjODhfNS0zLTEtMS0w_d99f1b0f-9a0c-4406-9d96-439b6f0e583e"
      unitRef="usd">11000000.0</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ic4b0ceabb1674432983305cc3a962999_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmRkNjFmYjAxNDc3ZDQ2NDU4YWY0NzJhZjA3NmJjYzg4L3RhYmxlcmFuZ2U6ZGQ2MWZiMDE0NzdkNDY0NThhZjQ3MmFmMDc2YmNjODhfNi0xLTEtMS0w_90809314-5d2b-4b89-a8d2-40ca87064ecb"
      unitRef="usd">36600000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="idf4e9376f20b4a76a67b9874281b82b7_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmRkNjFmYjAxNDc3ZDQ2NDU4YWY0NzJhZjA3NmJjYzg4L3RhYmxlcmFuZ2U6ZGQ2MWZiMDE0NzdkNDY0NThhZjQ3MmFmMDc2YmNjODhfNi0zLTEtMS0w_48cede54-448f-4596-91c2-cc8a1506d172"
      unitRef="usd">37400000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ic4b0ceabb1674432983305cc3a962999_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmRkNjFmYjAxNDc3ZDQ2NDU4YWY0NzJhZjA3NmJjYzg4L3RhYmxlcmFuZ2U6ZGQ2MWZiMDE0NzdkNDY0NThhZjQ3MmFmMDc2YmNjODhfNy0xLTEtMS0w_17f324ef-efcd-4ef1-8486-e02d323f3abc"
      unitRef="usd">-14900000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="idf4e9376f20b4a76a67b9874281b82b7_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmRkNjFmYjAxNDc3ZDQ2NDU4YWY0NzJhZjA3NmJjYzg4L3RhYmxlcmFuZ2U6ZGQ2MWZiMDE0NzdkNDY0NThhZjQ3MmFmMDc2YmNjODhfNy0zLTEtMS0w_2db2b24c-ce8a-40bf-89f3-8e807f16ee3b"
      unitRef="usd">-14900000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit
      contextRef="ic4b0ceabb1674432983305cc3a962999_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmRkNjFmYjAxNDc3ZDQ2NDU4YWY0NzJhZjA3NmJjYzg4L3RhYmxlcmFuZ2U6ZGQ2MWZiMDE0NzdkNDY0NThhZjQ3MmFmMDc2YmNjODhfOC0xLTEtMS0w_21906c70-f75e-4962-ba14-09758e501411"
      unitRef="usd">-800000</us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit>
    <us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit
      contextRef="idf4e9376f20b4a76a67b9874281b82b7_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmRkNjFmYjAxNDc3ZDQ2NDU4YWY0NzJhZjA3NmJjYzg4L3RhYmxlcmFuZ2U6ZGQ2MWZiMDE0NzdkNDY0NThhZjQ3MmFmMDc2YmNjODhfOC0zLTEtMS0w_6b2f4ab4-968e-4cf1-b85f-55497ae88986"
      unitRef="usd">-800000</us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ic4b0ceabb1674432983305cc3a962999_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmRkNjFmYjAxNDc3ZDQ2NDU4YWY0NzJhZjA3NmJjYzg4L3RhYmxlcmFuZ2U6ZGQ2MWZiMDE0NzdkNDY0NThhZjQ3MmFmMDc2YmNjODhfMTAtMS0xLTEtMA_b3623aaa-13f1-42ae-82d2-678517f5ee5a"
      unitRef="usd">-30900000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="idf4e9376f20b4a76a67b9874281b82b7_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RhYmxlOmRkNjFmYjAxNDc3ZDQ2NDU4YWY0NzJhZjA3NmJjYzg4L3RhYmxlcmFuZ2U6ZGQ2MWZiMDE0NzdkNDY0NThhZjQ3MmFmMDc2YmNjODhfMTAtMy0xLTEtMA_19889fc8-568c-45d2-be18-99802445b28f"
      unitRef="usd">-30700000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:PensionContributions
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RleHRyZWdpb246MDRjZmJhNmZlZTM1NGY1OGE1MWIwYjc4NTgzOTM0OWRfMTU1_458f3c34-cdc8-4ba2-900f-20f868f7c017"
      unitRef="usd">15000000</us-gaap:PensionContributions>
    <lly:PaymentforPensionBenefitsAdditionalDiscretionaryFunding
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RleHRyZWdpb246MDRjZmJhNmZlZTM1NGY1OGE1MWIwYjc4NTgzOTM0OWRfMjk1_90cd8118-d75c-44f5-91cc-b4c455bcc489"
      unitRef="usd">10000000</lly:PaymentforPensionBenefitsAdditionalDiscretionaryFunding>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV82Ny9mcmFnOjA0Y2ZiYTZmZWUzNTRmNThhNTFiMGI3ODU4MzkzNDlkL3RleHRyZWdpb246MDRjZmJhNmZlZTM1NGY1OGE1MWIwYjc4NTgzOTM0OWRfNDE4_fd66c107-99d1-4312-bd66-ec6a72109add"
      unitRef="usd">20000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTY4NTU_3e47f319-aeb5-4506-bae7-0def76065ce3">Contingencies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are involved in various lawsuits, claims, government investigations and other legal proceedings that arise in the ordinary course of business. These claims or proceedings can involve various types of parties, including governments, competitors, customers, suppliers, service providers, licensees, employees, or shareholders, among others. These matters may involve patent infringement, antitrust, securities, pricing, sales and marketing practices, environmental, commercial, contractual rights, licensing obligations, health and safety matters, consumer fraud, employment matters, product liability and insurance coverage, among others. The resolution of these matters often develops over a long period of time and expectations can change as a result of new findings, rulings, appeals or settlement arrangements. Legal proceedings that are significant or that we believe could become significant or material are described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We believe the legal proceedings in which we are named as defendants are without merit and we are defending against them vigorously. It is not possible to determine the outcome of these matters, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated condensed balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of additional product liability and related claims in the future. Due to a very restrictive market for product liability insurance, we are self-insured for product liability losses for all our currently and previously marketed products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Alimta Patent Litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A number of manufacturers are seeking approvals in the U.S. and a number of countries in Europe to market generic forms of Alimta prior to the expiration of our vitamin regimen patents, alleging that those patents are invalid, not infringed, or both. We believe our Alimta vitamin regimen patents are valid and enforceable against these generic manufacturers.&#160;However, it is not possible to determine the ultimate outcome of the proceedings, and accordingly, we can provide no assurance that we will prevail.&#160;The loss of exclusivity in the U.S. could have a material adverse impact on our future consolidated results of operations and cash flows and would result in a rapid and severe decline in future revenue for the product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Alimta (pemetrexed) is protected by a vitamin regimen patent until 2021, plus pediatric exclusivity through May 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2017, we filed a lawsuit in the U.S. District Court for the Southern District of Indiana against Apotex Inc. (Apotex) alleging infringement of Alimta's vitamin regimen patent for its application to market a pemetrexed product. In December 2019, the U.S. District Court for the Southern District of Indiana granted our motion for summary judgment of infringement, and in December 2020, the U.S. Court of Appeals for the Federal Circuit affirmed that ruling. Apotex did not request reconsideration or a rehearing of that ruling. However, Apotex could petition the U.S. Supreme Court to review the case. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, we settled a lawsuit we filed against Eagle Pharmaceuticals, Inc. (Eagle) in response to its application to market a product using an alternative form of pemetrexed. Per the settlement agreement, Eagle has a limited initial entry into the market with its product starting February 2022 (up to an approximate three-week supply) and subsequent unlimited entry starting April 2022.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;European Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In Europe, Alimta (pemetrexed) is prot&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ected by the vitamin regimen patent through June of 2021. Notwithstanding the existence of our vitamin regimen patent, several companies launched generic pemetrexed products at risk in France, Germany, and the Netherlands but those products were subsequently removed from those markets as a consequence of patent infringement actions brought by us. In many cases, those patent infringement actions are subject to appeals filed by the generic manufacturer. In March 2021, we entered into a settlement agreement with Fresenius Kabi Aktienngesellschaft that discontinued all pending European patent litigation involving the Fresenius Kabi group of companies including that between us and Fresenius Kabi France and Fresenius Kabi Groupe France.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Legal proceedings are ongoing regarding &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;our Alimta patents in various national courts throughout Europe. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We will continue to seek to remove any generic pemetrexed products launched at risk in other European markets, seek damages with respect to such launches, and defend our patents against validity challenges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Emgality Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2018, we were&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; named as a defendant in litigation filed by Teva Pharmaceuticals International GMBH and Teva Pharmaceuticals USA, Inc. (collectively, Teva) in the U.S. District Court for the District of Massachusetts seeking a ruling that various claims in nine differ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ent Teva patents would be infringed by our launch and continued sales of Emgality for the prevention of migraine in adults. Trial is expected in February 2022. Separately, the U.S. Patent and Trademark Office (USPTO) granted our request to initiate an&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;inter partes review&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;(IPR) to reexamine the validity of the nine Teva patents asserted against us in the litigation. In February 2020, the USPTO ruled in our favor and found that the claims asserted against us in six of Teva's nine patents were invalid. In March 2020, the USPTO ruled against us on the remaining three Teva patents, finding that we failed to show that the remaining three patents were unpatentable based on the subset of invalidity arguments available in an IPR proceeding. In April 2020, we appealed the USPTO&#x2019;s March 2020 ruling, and Teva appealed the USPTO&#x2019;s February 2020 ruling to the U.S. Court of Appeals for the Federal Circuit. The district court litigation will proceed in parallel with the IPR appeals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Jardiance Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, Boehringer Ingelheim (BI), our partner in marketing and development of Jardiance, initiated U.S. patent litigation in the U.S. District Court of Delaware alleging infringement arising from Alkem Laboratories Ltd.'s (Alkem) and Ascend Laboratories, LLC's (Ascend) submissions of Abbreviated New Drug Applications (ANDA) seeking approval to market generic versions of Jardiance, Glyxambi, and Synjardy in accordance with the procedures set out in the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). Particularly with respect to Jardiance, Alkem's and Ascend's ANDAs seek approval to market generic versions of Jardiance prior to the expiration of the relevant patents, and allege that certain patents, including in some allegations the compound patent, are invalid or would not be infringed. We are not a party to this litigation. Trial is scheduled for September 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Taltz Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, we petitioned the High Court of Ireland to declare invalid the patent that Novartis Pharma AG (Novartis) purchased from Genentech, Inc. in 2020. Novartis responded by filing a claim against us alleging patent infringement related to our commercialization of Taltz and seeking damages for past infringement and an injunction against future infringement. This matter is ongoing. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Zyprexa Canada Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in the mid-2000&#x2019;s, several generic companies in Canada challenged the validity of our Zyprexa compound patent. In 2012, the Canadian Federal Court of Appeals denied our appeal of a lower court's decision that certain patent claims were invalid for lack of utility. In 2013, Apotex Inc. and Apotex Pharmachem Inc. (collectively, Apotex) brought claims against us in the Ontario Superior Court of Justice at Toronto for damages related to our enforcement of the Zyprexa compound patent under Canadian regulations governing patented drugs. Apotex seeks compensation based on novel legal theories under the Statute of Monopolies, Trade-Mark Act, and common law. In March 2021, the Ontario Superior Court granted our motion for summary judgement, thereby dismissing Apotex&#x2019;s case. Apotex appealed that ruling to the Court of Appeal for Ontario in April 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Liability Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Actos&#xae;  Product Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are named along with Takeda Chemical Industries, Ltd. and Takeda affiliates (collectively, Takeda) as a defendant in four purported product liability class actions in Canada related to Actos, which we commercialized with Takeda in Canada until 2009, including one in Ontario filed December 2011 (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Casseres et al. v. Takeda Pharmaceutical North America, Inc., et al.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), one in Quebec filed July 2012 (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Whyte et al. v. Eli Lilly et al.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), one in Saskatchewan filed November 2017 (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Weiler v. Takeda Canada Inc. et al.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), and one in Alberta filed January 2013 (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Epp v. Takeda Canada Inc. et al.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). In general, plaintiffs in these actions alleged that Actos caused or contributed to their bladder cancer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Byetta&#xae; Product Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;First initiated in March 2009, we are named as a defendant in approximately 570 Byetta product liability lawsuits in the U.S. involving approximately 810 plaintiffs. Approximately 55 of these lawsuits, covering about 285 plaintiffs, are filed in California state court and coordinated in a Los Angeles Superior Court. Approximately 515 of the lawsuits, covering about 515 plaintiffs, are filed in federal court, the majority of which are coordinated in a multi-district litigation (MDL) in the U.S. District Court for the Southern District of California. Three lawsuits, representing approximately four plaintiffs, have also been filed in various state courts. Approximately 565 of the lawsuits, involving approximately 800 plaintiffs, contain allegations that Byetta caused or contributed to the plaintiffs' cancer (primarily pancreatic cancer or thyroid cancer); while six plaintiffs allege Byetta caused or contributed to pancreatitis. In addition, one case alleges that Byetta caused or contributed to ampullary cancer. The federal and state trial courts granted summary judgment in favor of us and our co-defendants on the claims alleging pancreatic cancer. The plaintiffs appealed those rulings. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2017, the U.S. Court of Appeals for the Ninth Circuit reversed the U.S. District Court for the Southern District of California's grant of summary judgment in the MDL based on that court's discovery rulings and remanded the cases back to the U.S. District Court for further proceedings. In March 2021, the U.S. District Court granted summary judgment for the defendants and in April 2021, the plaintiffs filed a notice of appeal to the U.S. Court of Appeals for the Ninth Circuit. In the state court actions, in November 2018, the California Court of Appeal reversed the Los Angeles County Superior Court of California&#x2019;s grant of summary judgment based on that court's discovery rulings and remanded for further proceedings. In April 2021, the Los Angeles County Superior Court of California granted summary judgment for the defendants.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are aware of approximately 20 additional claimants who have not yet filed suit. These additional claims allege damages for pancreatic cancer or thyroid cancer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Cialis Product Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;First initiated in August 2015, we are named as a defendant in approximately 350 Cialis product liability lawsuits in the U.S. These cases, many of which were originally filed in various federal courts, contain allegations that Cialis caused or contributed to the plaintiffs' cancer (melanoma). In December 2016, the Judicial Panel on Multidistrict Litigation (JPML) granted the plaintiffs' petition to have filed cases and an unspecified number of future cases coordinated into a federal multidistrict litigation (MDL) in the U.S. District Court for the Northern District of California, alongside an existing coordinated proceeding involving Viagra&#xae;. The JPML ordered the transfer of the existing cases to the now-renamed MDL &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re: Viagra (Sildenafil Citrate) and Cialis (Tadalafil) Products Liability Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In April 2020, the MDL court granted summary judgment to the defendants on all of the claims brought against them by the plaintiffs. In May 2020, plaintiffs filed an appeal in the U.S. Court of Appeals for the Ninth Circuit. The plaintiffs&#x2019; appeal has been administratively closed until August 2021 pending completion of a procedure to resolve the claims in this litigation.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Jardiance Product Liability &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;First initiated in January 2019, we and Boehringer Ingelheim Pharmaceuticals, Inc., a subsidiary of BI, have been named as a defendant in approximately 95 product liability lawsuits in the U.S., mostly in Stamford Superior Court in Connecticut, alleging that Jardiance caused or contributed to plaintiffs&#x2019; Fournier&#x2019;s gangrene.  Our agreement with BI calls for BI to defend and indemnify us against any damages, costs, expenses, and certain other losses with respect to product liability claims in accordance with the terms of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Environmental Proceedings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as "Superfund," we have been designated as one of several potentially responsible parties with respect to the cleanup of fewer than 10 sites. Under Superfund, each responsible party may be jointly and severally liable for the entire amount of the cleanup.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;340B Litigation and Investigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are the plaintiff in a lawsuit filed in January 2021 in the U.S. District Court for the Southern District of Indiana against the U.S. Department of Health and Human Services (HHS), the Secretary of HHS, the Health Resources and Services Administration (HRSA), and the Administrator of HRSA. The lawsuit challenges the HHS's December 30, 2020 advisory opinion stating that drug manufacturers are required to deliver discounts under the 340B program to all contract pharmacies. We seek a declaratory judgment that the defendants violated the Administrative Procedures Act and the U.S. Constitution, a preliminary injunction enjoining implementation of the administrative dispute resolution process created by defendants and, with it, their application of the advisory opinion, and other related relief. In March 2021, the court entered an order preliminarily enjoining the government&#x2019;s enforcement of the administrative dispute resolution process against Lilly. The matter is ongoing. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In January 2021, we, along with other pharmaceutical manufacturers, were named as a defendant in a petition currently pending before the HHS Administration Dispute Resolution Panel. Petitioner seeks declaratory and other injunctive relief related to the 340B program. As described above, the U.S. District Court for the Southern District of Indiana has entered a preliminary injunction enjoining the government&#x2019;s enforcement of this administrative dispute resolution process against us.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In February 2021, we received a civil investigative subpoena from the Office of the Attorney General for the State of Vermont relating to the sale of pharmaceutical products to Vermont covered entities under the 340B program. We are cooperating with this subpoena. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Brazil Litigation &#x2013; Cosmopolis Facility &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Labor Attorney Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;First initiated in 2008, our subsidiary in Brazil, Eli Lilly do Brasil Limitada (Lilly Brasil), is named in a lawsuit brought by the Labor Attorney for the 15th Region in the Labor Court of Paulinia, State of Sao Paulo, Brazil, alleging possible harm to employees and former employees caused by exposure to heavy metals at a former Lilly Brasil manufacturing facility in Cosmopolis, Brazil, operated by the company between 1977 and 2003. In May 2014, the labor court judge ruled against Lilly Brasil, ordering it to undertake several actions of unspecified financial impact, including paying lifetime health coverage for the employees and contractors who worked at the Cosmopolis facility more than six months during the affected years and their children born during and after this period. We appealed this decision. In July 2018, the appeals court affirmed the labor court's ruling with a liquidated award of&#160;300&#160;million&#160;Brazilian real (for moral damages, donation of equipment, and creation of a foundation) which, adjusted for inflation and interest using the current Central Bank of Brazil's special system of clearance and custody rate (SELIC), is approximately 950&#160;million Brazilian real (approximately $165&#160;million as of March 31, 2021). The appeals court restricted the broad health coverage awarded by the labor court to health problems that claimants could show arose from exposure to the alleged contamination. In August 2019, Lilly Brasil filed an appeal to the superior labor court. In September 2019, the appeals court stayed a number of elements of its prior decision, including the obligation to provide health coverage for contractors, their children, and children of employees who worked at the Cosmopolis facility, pending the determination of Lilly Brasil&#x2019;s appeal to the superior labor court. The cost of any such health coverage has not been determined.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2019, the Labor Attorney filed an application in the labor court for enforcement of the healthcare coverage granted by the appeals court in its July 2018 ruling and requested restrictions on Lilly Brasil&#x2019;s assets in Brazil. In July 2019, the labor court issued a ruling requiring either a freeze of Lilly Brasil&#x2019;s immovable property or, alternatively, a security deposit of 500 million Brazilian real. Lilly Brasil filed a writ of mandamus challenging this ruling&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; but the court has stayed its decision on this writ and instead directed the parties to attend conciliation hearings, a process that concluded unsuccessfully in September 2020. Consequently, the partial stay of the proceedings relating to Lilly Brasil's application to appeal in the main proceedings has been lifted. In addition, the Labor Attorney's application for preliminary enforcement of the July 2018 healthcare coverage ruling was granted. As the conciliation hearings have been unsuccessful, we have filed a brief to strike the Labor Attorney&#x2019;s application to enforce the previous healthcare coverage. Lilly Brasil is currently awaiting a determination as to whether its application seeking leave to appeal to the superior labor court has been successful.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Individual Former Employee Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are also named in approximately 30&#160;lawsuits filed in the same labor court by individual former employees making similar claims. These lawsuits are each at various stages in the litigation process, with judgments being handed down in approximately half of the lawsuits, nearly all of which are on appeal in the labor courts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;China NDRC Antitrust Matter&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The competition authority in China has investigated our distributor pricing practices in China in connection with a broader inquiry into pharmaceutical industry pricing. We have cooperated with this investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Eastern District of Pennsylvania Pricing (Average Manufacturer Price) Inquiry&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2014, we, along with another pharmaceutical manufacturer, are named as co-defendants in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;United States et al. ex rel. Streck v. Takeda Pharm. Am., Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which was filed in November 2014 and unsealed in the U.S. District Court for the Northern District of Illinois. The complaint alleges that the defendants should have treated certain credits from distributors as retroactive price increases and included such increases in calculating average manufacturer prices. Trial is scheduled for February 2022.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Health Choice Alliance &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are named as a defendant in a lawsuit filed in June 2017 in the U.S. District Court for the Eastern District of Texas seeking damages under the federal anti-kickback statute and state and federal false claims acts for certain patient support programs related to our products Humalog, Humulin, and Forteo. In September 2019, the U.S. District Court granted the U.S. Department of Justice&#x2019;s motion to dismiss the relator&#x2019;s second amended complaint. In January 2020, the relator appealed the District Court&#x2019;s dismissal to the U.S. Court of Appeals for the Fifth Circuit. We are also named as a defendant in two similar lawsuits filed in Texas and New Jersey state courts in October 2019 seeking damages under the Texas Medicaid Fraud Prevention Act and New Jersey Medicaid False Claims Act, respectively. In November 2020, the Texas state court action was stayed pending a decision by the U.S. Court of Appeals for the Fifth Circuit on the aforementioned District Court appeal. In April 2021, the New Jersey state court action was dismissed with prejudice.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Pricing Litigation, Investigations, and Inquiries&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2017, we, along with Sanofi-Aventis U.S. LLC (Sanofi) and Novo Nordisk, Inc. (Novo Nordisk) were named as defendants in a consolidated purported class action lawsuit,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re. Insulin Pricing Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in the U.S. District Court for the District of New Jersey relating to insulin pricing seeking damages under various state consumer protection laws and the Federal Racketeer Influenced and Corrupt Organization Act (federal RICO Act). Separately, in February 2018, we, along with Sanofi and Novo Nordisk, were named as defendants in&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;MSP Recovery Claims, Series, LLC et al. v. Sanofi Aventis U.S. LLC et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in the same court, seeking damages under various state consumer protection laws, common law fraud, unjust enrichment, and the federal RICO Act. In both&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; In re. Insulin Pricing Litigation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; MSP Recovery Claims&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; litigation, the court dismissed claims under the federal RICO Act and certain state laws. Also, filed in the same court in November 2020, we, along with Sanofi, Novo Nordisk, CVS, Express Scripts, and Optum, have been sued in a purported class action, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;FWK Holdings, LLC v. Novo Nordisk Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for alleged violations of the federal RICO Act as well as the New Jersey RICO Act and anti-trust law. That same group of defendants, along with Medco Health and United Health Group, also have been sued in other purported class actions in the same court, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rochester Drug Co-Operative Inc. v. Eli Lilly &amp;amp; Co. et al. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Value Drug Co. v. Eli Lilly &amp;amp; Co. et al. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;both initiated in March 2020, for alleged violations of the federal RICO Act. In September 2020, the U.S. District Court for the District of New Jersey granted plaintiffs&#x2019; motion to consolidate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;FWK Holdings, LLC v. Novo Nordisk Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rochester Drug Co-Operative Inc. v. Eli Lilly &amp;amp; Co. et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Value Drug Co. v. Eli Lilly &amp;amp; Co. et al.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Minnesota Attorney General&#x2019;s Office initiated litigation against us, Sanofi, and Novo Nordisk,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;State of Minnesota v. Sanofi-Aventis U.S. LLC et al.,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;in the U.S. District Court for the District of New Jersey, alleging unjust enrichment, violations of various Minnesota state consumer protection laws, and the federal RICO Act. In March 2021, the U.S. District Court for the District of New Jersey dismissed with prejudice the Minnesota Attorney General&#x2019;s federal RICO claims and false advertising claims under state law; the consumer fraud and other related state law claims remain ongoing. Additionally, in May 2019, the Kentucky Attorney General&#x2019;s Office filed a complaint against us, Sanofi, and Novo Nordisk,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Commonwealth of Kentucky v. Novo Nordisk, Inc. et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in Kentucky state court, alleging violations of the Kentucky consumer protection law, false advertising, and unjust enrichment. In November 2019, Harris County in Texas initiated litigation against us, Sanofi, Novo Nordisk, Express Scripts, CVS, Optum, and Aetna, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;County of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Harris Texas v. Eli Lilly &amp;amp; Co., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in federal court in the Southern District of Texas alleging violations of the federal RICO Act, federal and state antitrust law, and the state deceptive trade practices-consumer protection act. Harris County also alleges common law claims such as fraud, unjust enrichment, and civil conspiracy. This lawsuit relates to our insulin products as well as Trulicity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investigations, Subpoenas, and Inquiries&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We received a subpoena from the New York a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nd Vermont Attorney General Offices and civil investigative demands from the Washington, New Mexico, and Colorado Attorney General Offices relating to the pricing and sale of our insulin products. The Offices of the Attorney General in Mississippi, Washington D.C., California, Florida, Hawaii, and Nevada have requested information relating to the pricing and sale of our insulin products. We also received interrogatories and a subpoena from the California Attorney General's Office regarding our competition in the long-acting insulin market. We received two&#160;requests from the House of Representatives&#x2019; Committee on Energy and Commerce and a request from the Senate&#x2019;s Committee on Health, Education, Labor, and Pensions seeking certain information related to the pricing of insulin products, among other issues. We also received requests from the House of Representatives&#x2019; Committee on Oversight and Reform and the Senate&#x2019;s Committee on Finance, which seek detailed commercial information and business records. In January 2021, the Senate&#x2019;s Committee on Finance released a report summarizing the findings of its investigation. We are cooperating with all of these aforementioned investigations, subpoenas, and inquiries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Research Corporation Technologies, Inc. &lt;/span&gt;&lt;/div&gt;In April 2016, we were named as a defendant in litigation filed by Research Corporation Technologies, Inc. (RCT) in the U.S. District Court for the District of Arizona. RCT is seeking damages for breach of contract, unjust enrichment, and conversion related to processes used to manufacture certain products, including Humalog and Humulin. A trial date has not been set.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <lly:LossContingencyNumberOfPatents
      contextRef="i9472948bb7f947afa49886afa824b300_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY2MzQwMQ_d819cedb-081b-42e5-82ad-0618fa7ebdb1"
      unitRef="patent">9</lly:LossContingencyNumberOfPatents>
    <lly:LossContingencyNumberOfPatents
      contextRef="i9472948bb7f947afa49886afa824b300_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY2MzcyMg_d819cedb-081b-42e5-82ad-0618fa7ebdb1"
      unitRef="patent">9</lly:LossContingencyNumberOfPatents>
    <lly:LossContingencyNumberOfPatentsClaimsDismissed
      contextRef="i7408050434b1433f9057403b967bc044_D20200201-20200229"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY2Mzg3NA_d1b46b31-11b8-410b-97f0-7baa102975c3"
      unitRef="patent">6</lly:LossContingencyNumberOfPatentsClaimsDismissed>
    <lly:LossContingencyNumberOfPatents
      contextRef="i1dfd4b4b1d2a4b459b67e2e9c72eac8d_I20200229"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY2Mzg4OA_f9a97bbf-14fe-48fd-9c9e-d7a2414e5d7a"
      unitRef="patent">9</lly:LossContingencyNumberOfPatents>
    <lly:LossContingencyNumberOfPatentsRuledUnpatentable
      contextRef="ie6e455b81cdd4b63a8577a6c3f916221_D20200301-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY2Mzk3Mw_b26ab727-7d6e-48ea-8ac3-d0257fc5b729"
      unitRef="patent">3</lly:LossContingencyNumberOfPatentsRuledUnpatentable>
    <lly:LossContingencyNumberOfPatentsRuledUnpatentable
      contextRef="ie6e455b81cdd4b63a8577a6c3f916221_D20200301-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY2NDA0MQ_f841c985-1711-4e5b-8ad4-45b8745cc52e"
      unitRef="patent">3</lly:LossContingencyNumberOfPatentsRuledUnpatentable>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i19d9bfc8635f470e9a7adb121100256d_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MDIyMg_fd9f7f9e-96ce-44ba-aeb1-732170eed896"
      unitRef="lawsuit">4</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i4fbb93a5eb8140d2b2faeef2de2e7c59_I20111231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MDM2NA_5dc345bd-832d-4e39-a834-aab4b34a17eb"
      unitRef="lawsuit">1</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i9877de074e3b4cd68f3e14e738b53b96_I20120731"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MDQ3MQ_8300ea75-acf6-4387-9ce4-b79101fdfa15"
      unitRef="lawsuit">1</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="idac89cba080843258ae570efc0620a18_I20171130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MDUzNw_8c08b91c-fe40-417a-857a-4fd8f7da97a7"
      unitRef="lawsuit">1</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="iad757e1928624ece99a2023c2b06db4a_I20130131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MDYyMA_f2e89a15-0906-40b6-a1af-a626faf6b9c1"
      unitRef="lawsuit">1</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ic92b96cca8ef435288a260a7692a4296_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MDk2MA_bc860445-55e5-40b4-8741-58b5d2212caa"
      unitRef="lawsuit">570</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i87320df79b3f461da082a107fa7a8e57_D20090301-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MTAzNA_86b8f62f-945f-4edb-a91b-1038d1e3f232"
      unitRef="plaintiff">810</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i15f9ce4e2e9f47789b45d86896781f54_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MTA2NA_15aedd19-9c24-4fe8-9599-8945a8a4bd62"
      unitRef="lawsuit">55</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i6776f7310a5341a3b3f6bfdef846dfea_D20090301-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MTEwMg_89f54836-76a3-49aa-8e0d-532932ad120f"
      unitRef="plaintiff">285</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ib44052b397dc4098a69265e6060b79a8_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MTIxNw_45d66bec-80bd-4d70-b314-6702de437aa8"
      unitRef="lawsuit">515</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i121dcf9b52ce46eead9ac16494dd1642_D20090301-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MTI1Mw_acb14dce-f1d9-4125-8b14-f74d953212ef"
      unitRef="plaintiff">515</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ib73e27481f2e44bcb74fda4f3cecf682_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MTQ0MA_2b62ad20-83f9-4943-94f7-10b6ae9e0435"
      unitRef="lawsuit">3</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i2fa2b0f3392543f2b160709e35c124d7_D20090301-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MTQ4MQ_a7e9b17c-d70e-48bc-a6c0-1a80cecaaaeb"
      unitRef="plaintiff">4</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i9b029559694b48b08c94d12ad381445e_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MTU1Nw_cd332168-7b7e-4def-969e-33524d253994"
      unitRef="lawsuit">565</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="if02307f1292e42dd8aa0a8c7f88d014f_D20090301-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MTYwMg_fa925bbc-0fe5-4176-8cf1-192d4bbac2a7"
      unitRef="plaintiff">800</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i7ccdd965fb0d44ed8eaa51cd4f6af3a8_D20090301-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MTc1Mw_0eaf45c3-96d4-42d7-9040-09a345f22958"
      unitRef="plaintiff">6</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="id5a9904ee8fe4ee9900bba9f1c855eb9_D20090301-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MTgzNA_18fae89c-55a5-4de4-9f71-64269e4be7c3"
      unitRef="plaintiff">1</us-gaap:LossContingencyNumberOfPlaintiffs>
    <lly:LossContingencyNumberOfClaimants
      contextRef="ic92b96cca8ef435288a260a7692a4296_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MjUwOQ_b0c3cb9e-0d42-4405-8c75-73d4627b2cc5"
      unitRef="claimant">20</lly:LossContingencyNumberOfClaimants>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i0ac86530d3c243cca63aa23529e06624_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3MjgwMg_512f4d10-9cb5-4101-8426-0383a09ea45a"
      unitRef="lawsuit">350</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i9f7430fd06b947ef84b255b6fb8aee26_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3Mzk3Mw_f463ff8b-9fc9-4e1e-ac4e-f170e34292e2"
      unitRef="lawsuit">95</us-gaap:LossContingencyPendingClaimsNumber>
    <lly:LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup
      contextRef="ida0a952118b340e6ba680f7df96d7075_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfNDk0NzgwMjM5OTk4OQ_906b66e0-190e-4cf0-968b-6c4dd4326930"
      unitRef="site">10</lly:LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="ib5001859aff84e2dbe43c4543f7e5dbc_D20180701-20180731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfNDk0NzgwMjM5MDc3NA_6857a45c-3819-4d34-970a-cb762631fb45"
      unitRef="brl">300000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="ieb85b610e8d84b4788f9a42c2d175b66_D20210331-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfNDk0NzgwMjM5MDc0Nw_e2d789bf-3bcd-4fca-8f7a-2d820feb62ea"
      unitRef="brl">950000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="ieb85b610e8d84b4788f9a42c2d175b66_D20210331-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfNDk0NzgwMjM5MDg1Mw_c4220554-edd4-46b2-b093-463ecdb9076e"
      unitRef="usd">165000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i877919e055e34b8eb3844514babacc6f_D20190701-20190731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY3OTIwOQ_90f3f437-1fd7-4da5-8caa-7ed08056a46b"
      unitRef="brl">500000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="iaa67ffc334f74fdd88aeff3e17eb06fd_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTE4NDY_e4ab0d19-3135-4405-b46c-585670ed37e7"
      unitRef="lawsuit">30</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i69f451428d3e45a3a75cd744529fea05_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY4MzcyMw_41ae0345-139e-4f6a-becd-690569738367"
      unitRef="lawsuit">2</us-gaap:LossContingencyPendingClaimsNumber>
    <lly:LossContingencyNumberOfRequestsForInformation
      contextRef="ie5f8381a63d1432f9f9dae6e35adb977_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83MC9mcmFnOjQzZTcwOTJmNmFmZjQ3OWNiNDc3NzgxOTBiZmMyZWE0L3RleHRyZWdpb246NDNlNzA5MmY2YWZmNDc5Y2I0Nzc3ODE5MGJmYzJlYTRfMTA5OTUxMTY5MTkyOQ_3fb9f236-ddf0-4450-a1cd-db4abbe7ce3b"
      unitRef="request">2</lly:LossContingencyNumberOfRequestsForInformation>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RleHRyZWdpb246YTcwNmY0MTNhNTkyNDdiOGI4ZmM0NDJjZjA4ZjE2NGVfMTQ3NQ_9cce71f0-5a2e-4a07-9024-04767baba9c5">Other Comprehensive Income (Loss)&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the activity related to each component of other comprehensive income (loss) during the three months ended March&#160;31, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Amounts presented net of taxes)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Gains&#160;(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Net Gains (Losses) on&#160;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension and Retiree&#160;Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Effective Portion of Cash&#160;Flow Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,427.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,751.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(332.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6,496.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(249.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(10.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;252.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;85.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;89.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(249.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(10.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;104.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;256.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;100.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,677.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,646.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(76.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6,395.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Amounts presented net of taxes)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Gains&#160;(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Net Gains (Losses) on&#160;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension and Retiree&#160;Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Effective Portion of Cash&#160;Flow Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,678.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,638.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(211.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,523.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(348.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(442.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(345.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(362.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,804.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,530.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(556.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,885.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax effects on the net activity related to each component of other comprehensive income (loss) were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Tax benefit (expense) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation gains/losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(75.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized net gains/losses on securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Defined benefit pension and retiree health benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(31.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective portion of cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(68.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit (provision) for income taxes allocated to other comprehensive income (loss) items&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(170.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Except for the tax effects of foreign currency translation gains and losses related to our foreign currency-denominated notes, cross-currency interest rate swaps, and other foreign currency exchange contracts designated as net investment hedges (see Note 6), income taxes were not provided for foreign currency translation. Generally, the assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows; therefore, resulting translation adjustments are made in shareholders' equity rather than in the consolidated condensed statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reclassifications out of accumulated other comprehensive loss were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:11pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.552%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Details about Accumulated Other Comprehensive Loss Components&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Affected Line Item in the Consolidated Condensed Statements of Operations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="30" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of retirement benefit items:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior service benefits, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(13.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2013;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial losses, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;122.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2013;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;108.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(22.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;85.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2013;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;89.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RleHRyZWdpb246YTcwNmY0MTNhNTkyNDdiOGI4ZmM0NDJjZjA4ZjE2NGVfMTQ5MA_f78d9883-ca92-4385-aa58-9aa0f82dde75">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the activity related to each component of other comprehensive income (loss) during the three months ended March&#160;31, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Amounts presented net of taxes)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Gains&#160;(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Net Gains (Losses) on&#160;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension and Retiree&#160;Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Effective Portion of Cash&#160;Flow Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,427.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,751.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(332.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6,496.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(249.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(10.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;252.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;85.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;89.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(249.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(10.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;104.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;256.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;100.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,677.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,646.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(76.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6,395.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Amounts presented net of taxes)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Gains&#160;(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Net Gains (Losses) on&#160;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension and Retiree&#160;Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Effective Portion of Cash&#160;Flow Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,678.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,638.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(211.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,523.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(348.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(442.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(345.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(362.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,804.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,530.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(556.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,885.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax effects on the net activity related to each component of other comprehensive income (loss) were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Tax benefit (expense) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation gains/losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(75.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized net gains/losses on securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Defined benefit pension and retiree health benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(31.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective portion of cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(68.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit (provision) for income taxes allocated to other comprehensive income (loss) items&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(170.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6b10da171de74c8882000a2f696152fd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfMi0xLTEtMS0w_78a39739-9b63-41a4-acd4-d7c83d35e235"
      unitRef="usd">-1427500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5614d38977b64c168c1b9fc251c757ca_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfMi0zLTEtMS0w_1df9d921-1253-48a6-b48e-07878593c7f5"
      unitRef="usd">14800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iffd75cb32c5543a891d689e8933d4949_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfMi01LTEtMS0w_a3ac93ca-4247-4c91-9f58-db825ba70e44"
      unitRef="usd">-4751000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icaa91bb6c1a24ffcb202a27011d73dd0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfMi03LTEtMS0w_0e08d2f4-cfbc-4fbc-8196-9a9e6d373397"
      unitRef="usd">-332700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2845560a0ba2491a904c84ba82f35819_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfMi0xMS0xLTEtMA_b95c5add-ec2e-4b00-8bc4-f85b5201cc4c"
      unitRef="usd">-6496400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i743947277250425485ee1e0a26d90120_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNC0xLTEtMS0w_c0ab2da5-9e0d-4189-aeee-e08fdd18f3c7"
      unitRef="usd">-249700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i205a56c975a443f7b7c7708eb29b679c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNC0zLTEtMS0w_3d827e58-00b2-4ae4-b8b7-dfb7d50de94d"
      unitRef="usd">-10800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i0ebbc7661fa041f1ba2dd368ac1ee896_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNC01LTEtMS0w_5c8b798f-9924-483e-b1ca-c4f4bc08608f"
      unitRef="usd">18800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i5c5b25a00f1643c98078aba97cc80b62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNC03LTEtMS0w_21befebb-4339-4a0a-bc26-9c2d3b91f906"
      unitRef="usd">252800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNC0xMS0xLTEtMA_95d4a7dd-f9c6-4ba6-9915-9437f2213d69"
      unitRef="usd">11100000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i743947277250425485ee1e0a26d90120_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNS0xLTEtMS0w_6d6a1854-f0e0-42f9-a898-8c64ceb85f5d"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i205a56c975a443f7b7c7708eb29b679c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNS0zLTEtMS0w_320fb153-f84f-4e11-b2f9-96c16696c0fe"
      unitRef="usd">-500000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i0ebbc7661fa041f1ba2dd368ac1ee896_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNS01LTEtMS0w_0ec7980a-a4bb-45d8-8dc8-2a226dcc585b"
      unitRef="usd">-85900000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i5c5b25a00f1643c98078aba97cc80b62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNS03LTEtMS0w_03c419d7-967c-4b5d-aa6a-e34325e5373d"
      unitRef="usd">-3300000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNS0xMS0xLTEtMA_e6d33f7c-83e3-4e2e-9756-f17f22ca71bb"
      unitRef="usd">-89700000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i743947277250425485ee1e0a26d90120_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNi0xLTEtMS0w_6e4c48a7-6803-4fc6-9fd5-dadab0c4f22b"
      unitRef="usd">-249700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i205a56c975a443f7b7c7708eb29b679c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNi0zLTEtMS0w_2949c66b-7f13-435d-b171-a8739189b485"
      unitRef="usd">-10300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0ebbc7661fa041f1ba2dd368ac1ee896_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNi01LTEtMS0w_2ba96491-feb1-4e5b-9958-10acda5f8691"
      unitRef="usd">104700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i5c5b25a00f1643c98078aba97cc80b62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNi03LTEtMS0w_960576ee-c2bf-49ad-8a55-17240931e525"
      unitRef="usd">256100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfNi0xMS0xLTEtMA_ab0fd064-1948-434c-8075-bd0ee7ba1e42"
      unitRef="usd">100800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9655bade5b00400dba7752533cb6743c_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfOC0xLTEtMS0w_f72807ab-04e3-42f3-9b91-5ac517970c4d"
      unitRef="usd">-1677200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i577b7fef6c2c49bf87fe8cb8121248ce_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfOC0zLTEtMS0w_d9518527-dcd6-45b9-8d95-a00451ca25f9"
      unitRef="usd">4500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie23fc76e1a5a432a8db78dd624ef5cc1_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfOC01LTEtMS0w_d5cae3be-3e8e-4950-b836-c1394a1d646f"
      unitRef="usd">-4646300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7caab5ff3a4d4ca8a64128cbbeb05cdd_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfOC03LTEtMS0w_923b98dd-798d-4af2-9f50-195d791242ea"
      unitRef="usd">-76600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7b8b459cd1fc47f6baa6f11b48145ac4_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjIzN2U1ODZmYWFlZDRjYWI5YWM3OTY5NjU0MTJlYjJmL3RhYmxlcmFuZ2U6MjM3ZTU4NmZhYWVkNGNhYjlhYzc5Njk2NTQxMmViMmZfOC0xMS0xLTEtMA_2dc7c19e-1afa-4059-9cd7-5948bdeb4517"
      unitRef="usd">-6395600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic1eeb66393264479aecf1f1d2fcd51b1_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfMi0xLTEtMS0w_a3e188dd-4ba7-4572-a5c9-8b781fb445ad"
      unitRef="usd">-1678000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1cc74d110d0145598aeabdd970d87f17_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfMi0zLTEtMS0w_80d6720d-cdfb-4179-832f-a38f54409d00"
      unitRef="usd">4900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaa58ad2146314403b3eff9eaf3e10324_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfMi01LTEtMS0w_a124b393-22dd-4e3f-a5ca-f5c3e8f20a93"
      unitRef="usd">-4638600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6ebe01e7039a44a4888856db6e4a7d39_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfMi03LTEtMS0w_838cd285-3c6f-4681-9151-2c31d5065336"
      unitRef="usd">-211900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iffabc6d5c4614780a93ce1b21d701159_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfMi0xMS0xLTEtMA_e7a45a8e-ea31-4d72-9553-4f33caf001e9"
      unitRef="usd">-6523600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i96ce660d25654b37a7243b236eca576b_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNC0xLTEtMS0w_5ee49e98-0d2b-45a4-8ee5-13478ae20a40"
      unitRef="usd">-126500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i55b8fd6090834514913a2977fd43623e_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNC0zLTEtMS0w_8b90cd77-a86d-4854-b65e-dca8a0514fd3"
      unitRef="usd">1000000.0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i17796a268f3742fda454ebd20b70ba1d_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNC01LTEtMS0w_3d06fc95-dea7-4d75-86d2-8bc01b238856"
      unitRef="usd">30900000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i9bc687d07e3f4ff4bcb96e53bc8d83ec_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNC03LTEtMS0w_1fa5f343-0920-4563-90c5-f00ef034fcd7"
      unitRef="usd">-348200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNC0xMS0xLTEtMA_fe43ed8f-5010-43a9-a55d-f8e75257b4ff"
      unitRef="usd">-442800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i96ce660d25654b37a7243b236eca576b_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNS0xLTEtMS0w_0c56285c-7dd2-4c09-b312-7ca3dd62a9cf"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i55b8fd6090834514913a2977fd43623e_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNS0zLTEtMS0w_6553ead3-dd79-41e2-9687-66065dd392e2"
      unitRef="usd">100000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i17796a268f3742fda454ebd20b70ba1d_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNS01LTEtMS0w_e1810fab-5447-4173-b344-778a15891af0"
      unitRef="usd">-77400000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i9bc687d07e3f4ff4bcb96e53bc8d83ec_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNS03LTEtMS0w_3f86e489-453d-4c01-b65e-4a57c7e0b7ae"
      unitRef="usd">-3200000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNS0xMS0xLTEtMA_e9dfd8fb-e550-4868-8161-5f36488a7c1c"
      unitRef="usd">-80500000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i96ce660d25654b37a7243b236eca576b_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNi0xLTEtMS0w_ffc7465a-49cb-43c3-bd78-576a1c44556c"
      unitRef="usd">-126500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i55b8fd6090834514913a2977fd43623e_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNi0zLTEtMS0w_f03f954a-abd8-4f7a-9c83-be3e7b43e1eb"
      unitRef="usd">900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i17796a268f3742fda454ebd20b70ba1d_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNi01LTEtMS0w_947d3455-091a-41bc-bea4-c4d115fa53aa"
      unitRef="usd">108300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9bc687d07e3f4ff4bcb96e53bc8d83ec_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNi03LTEtMS0w_2ed5dc6e-1c4d-405e-b8b4-d1e51d7e649e"
      unitRef="usd">-345000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfNi0xMS0xLTEtMA_9440ac46-1488-4f69-b265-56aa4318bfdd"
      unitRef="usd">-362300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icd5fe3b1199247e6a91eb8d01efc2392_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfOC0xLTEtMS0w_4a0538de-b7d1-4273-b463-848b2baa3e91"
      unitRef="usd">-1804500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i41d912b5241343a9b988106cef8e0215_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfOC0zLTEtMS0w_3bdd29a2-6af8-4a51-b9c7-c593b6190737"
      unitRef="usd">5800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i33afbb7d73484c0a83d56114c6756d5c_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfOC01LTEtMS0w_8cd48e6f-77a1-4bdf-9521-23fc0923036a"
      unitRef="usd">-4530300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i194e7735259d438eb363e7d9f3ae1523_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfOC03LTEtMS0w_8d439137-8e26-47ea-97b2-cae09bb23921"
      unitRef="usd">-556900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i986fb3e559c0490ca09848e9ac9bf901_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmU0OWJkZmFlZTQyNTQ0YWRhZGQ0NjFkMWMwNzY1NTFiL3RhYmxlcmFuZ2U6ZTQ5YmRmYWVlNDI1NDRhZGFkZDQ2MWQxYzA3NjU1MWJfOC0xMS0xLTEtMA_b5ca2f5c-ab0e-4270-bff9-174d4ab913b6"
      unitRef="usd">-6885900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i743947277250425485ee1e0a26d90120_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjE1ZjMxMTEyNjliMTRlNThiZDRiODVlYjRjMDcxY2ZhL3RhYmxlcmFuZ2U6MTVmMzExMTI2OWIxNGU1OGJkNGI4NWViNGMwNzFjZmFfMi0xLTEtMS0w_4f5cb6fd-9422-448f-8f98-77ac4555bbd0"
      unitRef="usd">75300000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i96ce660d25654b37a7243b236eca576b_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjE1ZjMxMTEyNjliMTRlNThiZDRiODVlYjRjMDcxY2ZhL3RhYmxlcmFuZ2U6MTVmMzExMTI2OWIxNGU1OGJkNGI4NWViNGMwNzFjZmFfMi0zLTEtMS0w_f525edf9-0348-4d1b-82bb-51f0e93b9789"
      unitRef="usd">38500000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i205a56c975a443f7b7c7708eb29b679c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjE1ZjMxMTEyNjliMTRlNThiZDRiODVlYjRjMDcxY2ZhL3RhYmxlcmFuZ2U6MTVmMzExMTI2OWIxNGU1OGJkNGI4NWViNGMwNzFjZmFfMy0xLTEtMS0w_883bddba-fea5-4f3a-ad3f-6474fe6f4a7b"
      unitRef="usd">-4400000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i55b8fd6090834514913a2977fd43623e_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjE1ZjMxMTEyNjliMTRlNThiZDRiODVlYjRjMDcxY2ZhL3RhYmxlcmFuZ2U6MTVmMzExMTI2OWIxNGU1OGJkNGI4NWViNGMwNzFjZmFfMy0zLTEtMS0w_c16ca3f2-ba44-4e24-8ac9-1945561dbe1f"
      unitRef="usd">300000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i0ebbc7661fa041f1ba2dd368ac1ee896_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjE1ZjMxMTEyNjliMTRlNThiZDRiODVlYjRjMDcxY2ZhL3RhYmxlcmFuZ2U6MTVmMzExMTI2OWIxNGU1OGJkNGI4NWViNGMwNzFjZmFfNC0xLTEtMS0w_bce29064-79f1-400a-a8e5-459edad3293d"
      unitRef="usd">31300000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i17796a268f3742fda454ebd20b70ba1d_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjE1ZjMxMTEyNjliMTRlNThiZDRiODVlYjRjMDcxY2ZhL3RhYmxlcmFuZ2U6MTVmMzExMTI2OWIxNGU1OGJkNGI4NWViNGMwNzFjZmFfNC0zLTEtMS0w_0ebd877e-b1a4-4431-8f1b-6210cf69c41f"
      unitRef="usd">25700000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="ibf742f7aff334b05a91842e894677604_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjE1ZjMxMTEyNjliMTRlNThiZDRiODVlYjRjMDcxY2ZhL3RhYmxlcmFuZ2U6MTVmMzExMTI2OWIxNGU1OGJkNGI4NWViNGMwNzFjZmFfNS0xLTEtMS0w_c9ddf321-9843-49d2-aa1b-6fb091d5962a"
      unitRef="usd">68100000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i02045ea33c7d43d4a34c42a37721b125_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjE1ZjMxMTEyNjliMTRlNThiZDRiODVlYjRjMDcxY2ZhL3RhYmxlcmFuZ2U6MTVmMzExMTI2OWIxNGU1OGJkNGI4NWViNGMwNzFjZmFfNS0zLTEtMS0w_d2f63020-8259-4d96-81c1-8d60430234ee"
      unitRef="usd">-91700000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjE1ZjMxMTEyNjliMTRlNThiZDRiODVlYjRjMDcxY2ZhL3RhYmxlcmFuZ2U6MTVmMzExMTI2OWIxNGU1OGJkNGI4NWViNGMwNzFjZmFfNi0xLTEtMS0w_258adb7c-aaf1-4b6a-b1e6-9ecb832080fd"
      unitRef="usd">170300000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOjE1ZjMxMTEyNjliMTRlNThiZDRiODVlYjRjMDcxY2ZhL3RhYmxlcmFuZ2U6MTVmMzExMTI2OWIxNGU1OGJkNGI4NWViNGMwNzFjZmFfNi0zLTEtMS0w_801435d4-4ca8-4021-81d8-6449d5486f99"
      unitRef="usd">-27200000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RleHRyZWdpb246YTcwNmY0MTNhNTkyNDdiOGI4ZmM0NDJjZjA4ZjE2NGVfMTQ4NQ_f66e70a5-a9cd-4fa5-a881-07c935aacb9e">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reclassifications out of accumulated other comprehensive loss were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:11pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.552%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Details about Accumulated Other Comprehensive Loss Components&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Affected Line Item in the Consolidated Condensed Statements of Operations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="30" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of retirement benefit items:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior service benefits, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(13.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2013;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial losses, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;122.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2013;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;108.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(22.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;85.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2013;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;89.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if48b9be7413d42df903afc9bf15c3c13_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmYxMjU5ZDQ5Y2YwMTQ1ZWU5ODBkMzE4ZWI0ZWZkZTJhL3RhYmxlcmFuZ2U6ZjEyNTlkNDljZjAxNDVlZTk4MGQzMThlYjRlZmRlMmFfNC0yLTEtMS0w_5a2a977e-38e5-4ebe-958c-f7d3077840f8"
      unitRef="usd">-13800000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i492583e2c9b044f29ac4a51092ddfbe8_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmYxMjU5ZDQ5Y2YwMTQ1ZWU5ODBkMzE4ZWI0ZWZkZTJhL3RhYmxlcmFuZ2U6ZjEyNTlkNDljZjAxNDVlZTk4MGQzMThlYjRlZmRlMmFfNC00LTEtMS0w_0d6a518d-7b11-4826-b884-532e1d038418"
      unitRef="usd">-13800000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ibfdc30c8362d4397a4020c9b938662fa_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmYxMjU5ZDQ5Y2YwMTQ1ZWU5ODBkMzE4ZWI0ZWZkZTJhL3RhYmxlcmFuZ2U6ZjEyNTlkNDljZjAxNDVlZTk4MGQzMThlYjRlZmRlMmFfNS0yLTEtMS0w_d158155b-030d-4959-b25c-888722621ea5"
      unitRef="usd">122600000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2917edad81e5463e9d61cceea8f62ea4_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmYxMjU5ZDQ5Y2YwMTQ1ZWU5ODBkMzE4ZWI0ZWZkZTJhL3RhYmxlcmFuZ2U6ZjEyNTlkNDljZjAxNDVlZTk4MGQzMThlYjRlZmRlMmFfNS00LTEtMS0w_c8129a61-84b9-4a70-9a92-383fb30d61df"
      unitRef="usd">111800000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if82cce099c354dd78182619455a05af1_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmYxMjU5ZDQ5Y2YwMTQ1ZWU5ODBkMzE4ZWI0ZWZkZTJhL3RhYmxlcmFuZ2U6ZjEyNTlkNDljZjAxNDVlZTk4MGQzMThlYjRlZmRlMmFfNi0yLTEtMS0w_efccc077-c89d-4b27-9b85-b8fa673d1071"
      unitRef="usd">108800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i25e6d224ac334db98fbf37d17ced616d_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmYxMjU5ZDQ5Y2YwMTQ1ZWU5ODBkMzE4ZWI0ZWZkZTJhL3RhYmxlcmFuZ2U6ZjEyNTlkNDljZjAxNDVlZTk4MGQzMThlYjRlZmRlMmFfNi00LTEtMS0w_1e6b4d10-6706-4d86-b337-2e9eab37f7bf"
      unitRef="usd">98000000.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if82cce099c354dd78182619455a05af1_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmYxMjU5ZDQ5Y2YwMTQ1ZWU5ODBkMzE4ZWI0ZWZkZTJhL3RhYmxlcmFuZ2U6ZjEyNTlkNDljZjAxNDVlZTk4MGQzMThlYjRlZmRlMmFfNy0yLTEtMS0w_c580848a-e94a-41cd-8dfa-878e0b170f9f"
      unitRef="usd">22900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i25e6d224ac334db98fbf37d17ced616d_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmYxMjU5ZDQ5Y2YwMTQ1ZWU5ODBkMzE4ZWI0ZWZkZTJhL3RhYmxlcmFuZ2U6ZjEyNTlkNDljZjAxNDVlZTk4MGQzMThlYjRlZmRlMmFfNy00LTEtMS0w_8d83bd4a-1aa4-4939-aa2a-bbeb5c9d3091"
      unitRef="usd">20600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="if82cce099c354dd78182619455a05af1_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmYxMjU5ZDQ5Y2YwMTQ1ZWU5ODBkMzE4ZWI0ZWZkZTJhL3RhYmxlcmFuZ2U6ZjEyNTlkNDljZjAxNDVlZTk4MGQzMThlYjRlZmRlMmFfOC0yLTEtMS0w_3e0d06c5-6706-4bd4-bbb5-a1eba33a5fb8"
      unitRef="usd">85900000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i25e6d224ac334db98fbf37d17ced616d_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmYxMjU5ZDQ5Y2YwMTQ1ZWU5ODBkMzE4ZWI0ZWZkZTJhL3RhYmxlcmFuZ2U6ZjEyNTlkNDljZjAxNDVlZTk4MGQzMThlYjRlZmRlMmFfOC00LTEtMS0w_4031e400-0895-4917-9390-56bd30269776"
      unitRef="usd">77400000</us-gaap:ProfitLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i191727da20c34eae98d4dbc93f0337fe_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmYxMjU5ZDQ5Y2YwMTQ1ZWU5ODBkMzE4ZWI0ZWZkZTJhL3RhYmxlcmFuZ2U6ZjEyNTlkNDljZjAxNDVlZTk4MGQzMThlYjRlZmRlMmFfMTAtMi0xLTEtMA_4e04b0d9-6b5b-4808-aaa3-80bea98b8414"
      unitRef="usd">3800000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9638221883d14af2935d735e8cc9a360_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmYxMjU5ZDQ5Y2YwMTQ1ZWU5ODBkMzE4ZWI0ZWZkZTJhL3RhYmxlcmFuZ2U6ZjEyNTlkNDljZjAxNDVlZTk4MGQzMThlYjRlZmRlMmFfMTAtNC0xLTEtMA_c04baaf6-8fd1-40e6-ab09-fb6107dcd0fa"
      unitRef="usd">3100000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:ProfitLoss
      contextRef="i37bfd76d6ecb46708142e81e2d19a33c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmYxMjU5ZDQ5Y2YwMTQ1ZWU5ODBkMzE4ZWI0ZWZkZTJhL3RhYmxlcmFuZ2U6ZjEyNTlkNDljZjAxNDVlZTk4MGQzMThlYjRlZmRlMmFfMTMtMi0xLTEtMA_85064f7a-6b84-4c31-8ac4-ac975595f81f"
      unitRef="usd">89700000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i9c0ff30fbf7f474f9b43c59d3bc7e538_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV83Ni9mcmFnOmE3MDZmNDEzYTU5MjQ3YjhiOGZjNDQyY2YwOGYxNjRlL3RhYmxlOmYxMjU5ZDQ5Y2YwMTQ1ZWU5ODBkMzE4ZWI0ZWZkZTJhL3RhYmxlcmFuZ2U6ZjEyNTlkNDljZjAxNDVlZTk4MGQzMThlYjRlZmRlMmFfMTMtNC0xLTEtMA_f1a4b31d-bd84-436e-bb67-660bbc26f190"
      unitRef="usd">80500000</us-gaap:ProfitLoss>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV84Mi9mcmFnOmVlYWM2MTIyMDVhYjRjYzhhMmZmY2VkYmMzYjk1NzFiL3RleHRyZWdpb246ZWVhYzYxMjIwNWFiNGNjOGEyZmZjZWRiYzNiOTU3MWJfMjMy_1a318be7-1d3c-48ef-806e-69be3396eac0">Other&#x2013;Net, (Income) Expense&lt;div style="margin-bottom:12pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&#x2013;net, (income) expense consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;87.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(5.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment gains on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(301.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(186.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retirement benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(73.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (income) expense &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(28.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2013;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(321.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(89.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV84Mi9mcmFnOmVlYWM2MTIyMDVhYjRjYzhhMmZmY2VkYmMzYjk1NzFiL3RleHRyZWdpb246ZWVhYzYxMjIwNWFiNGNjOGEyZmZjZWRiYzNiOTU3MWJfMjM1_d4756328-bc79-42ca-8998-9b628fa1d557">&lt;div style="margin-bottom:12pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&#x2013;net, (income) expense consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;87.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(5.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment gains on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(301.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(186.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retirement benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(73.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (income) expense &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(28.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2013;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(321.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(89.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InterestExpense
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV84Mi9mcmFnOmVlYWM2MTIyMDVhYjRjYzhhMmZmY2VkYmMzYjk1NzFiL3RhYmxlOjQ0MTRmMmZlZjcyYzRhZTZhZDVmZjI2ZjhjN2M5MTU3L3RhYmxlcmFuZ2U6NDQxNGYyZmVmNzJjNGFlNmFkNWZmMjZmOGM3YzkxNTdfMi0xLTEtMS0w_0682fe7c-5a78-4669-a10b-d87c3985d48a"
      unitRef="usd">87800000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV84Mi9mcmFnOmVlYWM2MTIyMDVhYjRjYzhhMmZmY2VkYmMzYjk1NzFiL3RhYmxlOjQ0MTRmMmZlZjcyYzRhZTZhZDVmZjI2ZjhjN2M5MTU3L3RhYmxlcmFuZ2U6NDQxNGYyZmVmNzJjNGFlNmFkNWZmMjZmOGM3YzkxNTdfMi0zLTEtMS0w_fab98565-94d1-4ace-87fa-9bae2aaa930d"
      unitRef="usd">92500000</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV84Mi9mcmFnOmVlYWM2MTIyMDVhYjRjYzhhMmZmY2VkYmMzYjk1NzFiL3RhYmxlOjQ0MTRmMmZlZjcyYzRhZTZhZDVmZjI2ZjhjN2M5MTU3L3RhYmxlcmFuZ2U6NDQxNGYyZmVmNzJjNGFlNmFkNWZmMjZmOGM3YzkxNTdfMy0xLTEtMS0w_3e1a5b04-1acf-471e-b99e-009bc4001da6"
      unitRef="usd">5500000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV84Mi9mcmFnOmVlYWM2MTIyMDVhYjRjYzhhMmZmY2VkYmMzYjk1NzFiL3RhYmxlOjQ0MTRmMmZlZjcyYzRhZTZhZDVmZjI2ZjhjN2M5MTU3L3RhYmxlcmFuZ2U6NDQxNGYyZmVmNzJjNGFlNmFkNWZmMjZmOGM3YzkxNTdfMy0zLTEtMS0w_b492304a-08d1-4b0a-8050-87077da727db"
      unitRef="usd">14300000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV84Mi9mcmFnOmVlYWM2MTIyMDVhYjRjYzhhMmZmY2VkYmMzYjk1NzFiL3RhYmxlOjQ0MTRmMmZlZjcyYzRhZTZhZDVmZjI2ZjhjN2M5MTU3L3RhYmxlcmFuZ2U6NDQxNGYyZmVmNzJjNGFlNmFkNWZmMjZmOGM3YzkxNTdfNC0xLTEtMS04Mzgx_db9b03ee-c25d-4f68-bfc5-7cd3e608f98c"
      unitRef="usd">301500000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV84Mi9mcmFnOmVlYWM2MTIyMDVhYjRjYzhhMmZmY2VkYmMzYjk1NzFiL3RhYmxlOjQ0MTRmMmZlZjcyYzRhZTZhZDVmZjI2ZjhjN2M5MTU3L3RhYmxlcmFuZ2U6NDQxNGYyZmVmNzJjNGFlNmFkNWZmMjZmOGM3YzkxNTdfNC0zLTEtMS04NDA5_84491e38-880a-484c-a954-d38d6bfae84e"
      unitRef="usd">186600000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV84Mi9mcmFnOmVlYWM2MTIyMDVhYjRjYzhhMmZmY2VkYmMzYjk1NzFiL3RhYmxlOjQ0MTRmMmZlZjcyYzRhZTZhZDVmZjI2ZjhjN2M5MTU3L3RhYmxlcmFuZ2U6NDQxNGYyZmVmNzJjNGFlNmFkNWZmMjZmOGM3YzkxNTdfNC0xLTEtMS0w_096ee406-ccac-4068-814f-d35a09b6962c"
      unitRef="usd">-73400000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV84Mi9mcmFnOmVlYWM2MTIyMDVhYjRjYzhhMmZmY2VkYmMzYjk1NzFiL3RhYmxlOjQ0MTRmMmZlZjcyYzRhZTZhZDVmZjI2ZjhjN2M5MTU3L3RhYmxlcmFuZ2U6NDQxNGYyZmVmNzJjNGFlNmFkNWZmMjZmOGM3YzkxNTdfNC0zLTEtMS0w_3b90c007-552a-4def-ae05-14cf9e733cb5"
      unitRef="usd">-44600000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV84Mi9mcmFnOmVlYWM2MTIyMDVhYjRjYzhhMmZmY2VkYmMzYjk1NzFiL3RhYmxlOjQ0MTRmMmZlZjcyYzRhZTZhZDVmZjI2ZjhjN2M5MTU3L3RhYmxlcmFuZ2U6NDQxNGYyZmVmNzJjNGFlNmFkNWZmMjZmOGM3YzkxNTdfNS0xLTEtMS0w_5752735c-e01b-4f10-b8ef-54d6f0e747f0"
      unitRef="usd">28500000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV84Mi9mcmFnOmVlYWM2MTIyMDVhYjRjYzhhMmZmY2VkYmMzYjk1NzFiL3RhYmxlOjQ0MTRmMmZlZjcyYzRhZTZhZDVmZjI2ZjhjN2M5MTU3L3RhYmxlcmFuZ2U6NDQxNGYyZmVmNzJjNGFlNmFkNWZmMjZmOGM3YzkxNTdfNS0zLTEtMS0w_24c35329-0d10-4a2f-98ce-dd071e05f304"
      unitRef="usd">-63900000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV84Mi9mcmFnOmVlYWM2MTIyMDVhYjRjYzhhMmZmY2VkYmMzYjk1NzFiL3RhYmxlOjQ0MTRmMmZlZjcyYzRhZTZhZDVmZjI2ZjhjN2M5MTU3L3RhYmxlcmFuZ2U6NDQxNGYyZmVmNzJjNGFlNmFkNWZmMjZmOGM3YzkxNTdfNi0xLTEtMS0w_8c109cd8-0fc7-4fc2-8165-adb4a3c3602d"
      unitRef="usd">321100000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ie4be1cc0c2ce4c74b99934fe8b9fecb3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjZDE1MWI1ZDgzMjQ2YTk4YjBlMGVmNGE5ZmViMjY5L3NlYzozY2QxNTFiNWQ4MzI0NmE5OGIwZTBlZjRhOWZlYjI2OV84Mi9mcmFnOmVlYWM2MTIyMDVhYjRjYzhhMmZmY2VkYmMzYjk1NzFiL3RhYmxlOjQ0MTRmMmZlZjcyYzRhZTZhZDVmZjI2ZjhjN2M5MTU3L3RhYmxlcmFuZ2U6NDQxNGYyZmVmNzJjNGFlNmFkNWZmMjZmOGM3YzkxNTdfNi0zLTEtMS0w_001f4e46-c11f-44a8-8d7f-1c46208bf7eb"
      unitRef="usd">89100000</us-gaap:NonoperatingIncomeExpense>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356210406168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Apr. 27, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000059478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-6351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ELI LILLY AND COMPANY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">IN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">35-0470950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Lilly Corporate Center<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Indianapolis<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">46285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">276-2000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">959,025,446<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Stock (no par value)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock (no par value)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1.000NotesDueJune22022Member', window );">1.000% Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.000% Notes due 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member', window );">7 1/8% Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">7 1/8% Notes due 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member', window );">1.625% Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.625% Notes due 2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member', window );">2.125% Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.125% Notes due 2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member', window );">0.625% Notes due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.625% Notes due 2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member', window );">6.77%&#160;Notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">6.77%&#160;Notes due 2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member', window );">1.700% Notes due 2049</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.700% Notes due 2049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY49A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1.000NotesDueJune22022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1.000NotesDueJune22022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356211058232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Condensed Statements of Operations - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue (Note 2)</a></td>
<td class="nump">$ 6,805.6<span></span>
</td>
<td class="nump">$ 5,859.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs, expenses, and other:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">1,878.6<span></span>
</td>
<td class="nump">1,215.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,684.8<span></span>
</td>
<td class="nump">1,392.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Marketing, selling, and administrative</a></td>
<td class="nump">1,576.0<span></span>
</td>
<td class="nump">1,549.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development (Note 3)</a></td>
<td class="nump">299.3<span></span>
</td>
<td class="nump">52.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringSettlementAndImpairmentProvisions', window );">Asset impairment, restructuring, and other special charges (Note 5)</a></td>
<td class="nump">211.6<span></span>
</td>
<td class="nump">59.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other&#8211;net, (income) expense (Note 11)</a></td>
<td class="num">(321.1)<span></span>
</td>
<td class="num">(89.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CostOfSalesOperatingExpensesAndOtherNet', window );">Costs, expenses, and other</a></td>
<td class="nump">5,329.2<span></span>
</td>
<td class="nump">4,179.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">1,476.4<span></span>
</td>
<td class="nump">1,679.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes (Note 7)</a></td>
<td class="nump">121.1<span></span>
</td>
<td class="nump">223.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 1,355.3<span></span>
</td>
<td class="nump">$ 1,456.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in usd per share)</a></td>
<td class="nump">$ 1.49<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in usd per share)</a></td>
<td class="nump">$ 1.49<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Shares used in calculation of earnings per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">908.8<span></span>
</td>
<td class="nump">908.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">912.4<span></span>
</td>
<td class="nump">911.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of EXPENSE related to research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore written off in the period of acquisition (INCOME STATEMENT)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_CostOfSalesOperatingExpensesAndOtherNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of sales, operating expenses, and other-net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_CostOfSalesOperatingExpensesAndOtherNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringSettlementAndImpairmentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of restructuring charges, remediation cost, and asset impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringSettlementAndImpairmentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356135857512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Condensed Statements of Comprehensive Income (Loss) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 1,355.3<span></span>
</td>
<td class="nump">$ 1,456.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax (Note 10)</a></td>
<td class="nump">100.8<span></span>
</td>
<td class="num">(362.3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 1,456.1<span></span>
</td>
<td class="nump">$ 1,094.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356210413208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Condensed Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents (Note 6)</a></td>
<td class="nump">$ 3,002.4<span></span>
</td>
<td class="nump">$ 3,657.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments (Note 6)</a></td>
<td class="nump">49.0<span></span>
</td>
<td class="nump">24.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowances of $23.9 (2021) and $25.9 (2020)</a></td>
<td class="nump">5,592.8<span></span>
</td>
<td class="nump">5,875.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">1,065.8<span></span>
</td>
<td class="nump">1,053.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">3,660.8<span></span>
</td>
<td class="nump">3,980.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">3,233.7<span></span>
</td>
<td class="nump">2,871.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">16,604.5<span></span>
</td>
<td class="nump">17,462.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investments (Note 6)</a></td>
<td class="nump">3,232.4<span></span>
</td>
<td class="nump">2,966.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">3,877.4<span></span>
</td>
<td class="nump">3,766.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">8,087.8<span></span>
</td>
<td class="nump">7,450.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">2,649.9<span></span>
</td>
<td class="nump">2,830.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation of $9,643.4 (2021) and $9,570.7 (2020)</a></td>
<td class="nump">8,630.1<span></span>
</td>
<td class="nump">8,681.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">3,756.2<span></span>
</td>
<td class="nump">3,475.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">46,838.3<span></span>
</td>
<td class="nump">46,633.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Short-term borrowings and current maturities of long-term debt</a></td>
<td class="nump">4.9<span></span>
</td>
<td class="nump">8.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,639.6<span></span>
</td>
<td class="nump">1,606.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation</a></td>
<td class="nump">649.9<span></span>
</td>
<td class="nump">997.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_SalesRebatesAndDiscounts', window );">Sales rebates and discounts</a></td>
<td class="nump">5,821.4<span></span>
</td>
<td class="nump">5,853.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividends payable</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">770.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income taxes payable</a></td>
<td class="nump">791.6<span></span>
</td>
<td class="nump">495.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">2,806.8<span></span>
</td>
<td class="nump">2,750.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">11,714.2<span></span>
</td>
<td class="nump">12,481.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Other Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">16,199.6<span></span>
</td>
<td class="nump">16,586.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Accrued retirement benefits (Note 8)</a></td>
<td class="nump">3,969.8<span></span>
</td>
<td class="nump">4,094.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Long-term income taxes payable</a></td>
<td class="nump">3,917.5<span></span>
</td>
<td class="nump">3,837.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="nump">2,200.6<span></span>
</td>
<td class="nump">2,099.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">1,737.3<span></span>
</td>
<td class="nump">1,707.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total other liabilities</a></td>
<td class="nump">28,024.8<span></span>
</td>
<td class="nump">28,326.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Eli Lilly and Company Shareholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">599.7<span></span>
</td>
<td class="nump">598.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">6,579.2<span></span>
</td>
<td class="nump">6,778.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">9,181.3<span></span>
</td>
<td class="nump">7,830.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesHeldInEmployeeTrust', window );">Employee benefit trust</a></td>
<td class="num">(3,013.2)<span></span>
</td>
<td class="num">(3,013.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss (Note 10)</a></td>
<td class="num">(6,395.6)<span></span>
</td>
<td class="num">(6,496.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Cost of common stock in treasury</a></td>
<td class="num">(52.7)<span></span>
</td>
<td class="num">(55.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Eli Lilly and Company shareholders&#8217; equity</a></td>
<td class="nump">6,898.7<span></span>
</td>
<td class="nump">5,641.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">200.6<span></span>
</td>
<td class="nump">183.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">7,099.3<span></span>
</td>
<td class="nump">5,825.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 46,838.3<span></span>
</td>
<td class="nump">$ 46,633.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_SalesRebatesAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales rebates and discounts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_SalesRebatesAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesHeldInEmployeeTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of common stock issued to a trust (for example, but not limited to, rabbi trust) set up specifically to accumulate stock for the sole purpose of distribution to participating employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesHeldInEmployeeTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1731-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356215092968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Condensed Balance Sheets (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrentAbstract', window );"><strong>Receivables, Net, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowances for doubtful accounts</a></td>
<td class="nump">$ 23.9<span></span>
</td>
<td class="nump">$ 25.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Property and equipment, accumulated depreciation</a></td>
<td class="nump">$ 9,643.4<span></span>
</td>
<td class="nump">$ 9,570.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356215397288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Condensed Statements of Equity - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Employee Benefit Trust</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Common Stock in Treasury</div></th>
<th class="th"><div>Noncontrolling Interests</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">958,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 598.8<span></span>
</td>
<td class="nump">$ 6,685.3<span></span>
</td>
<td class="nump">$ 4,920.4<span></span>
</td>
<td class="num">$ (3,013.2)<span></span>
</td>
<td class="num">$ (6,523.6)<span></span>
</td>
<td class="num">$ (60.8)<span></span>
</td>
<td class="nump">$ 92.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 1,456.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,456.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(362.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,627)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,627)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(497.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (500.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock under employee stock plans, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock under employee stock plans, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="num">(201.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">956,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 598.1<span></span>
</td>
<td class="nump">6,556.1<span></span>
</td>
<td class="nump">5,879.4<span></span>
</td>
<td class="num">(3,013.2)<span></span>
</td>
<td class="num">(6,885.9)<span></span>
</td>
<td class="num">$ (55.7)<span></span>
</td>
<td class="nump">118.4<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">957,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">5,825.2<span></span>
</td>
<td class="nump">$ 598.2<span></span>
</td>
<td class="nump">6,778.5<span></span>
</td>
<td class="nump">7,830.2<span></span>
</td>
<td class="num">(3,013.2)<span></span>
</td>
<td class="num">(6,496.4)<span></span>
</td>
<td class="num">$ (55.7)<span></span>
</td>
<td class="nump">183.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,355.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,355.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock under employee stock plans, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock under employee stock plans, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="num">(283.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
<td class="num">(4.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">959,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">$ 7,099.3<span></span>
</td>
<td class="nump">$ 599.7<span></span>
</td>
<td class="nump">$ 6,579.2<span></span>
</td>
<td class="nump">$ 9,181.3<span></span>
</td>
<td class="num">$ (3,013.2)<span></span>
</td>
<td class="num">$ (6,395.6)<span></span>
</td>
<td class="num">$ (52.7)<span></span>
</td>
<td class="nump">$ 200.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredCostMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredCostMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesRetired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common and preferred stock retired from treasury during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesRetired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356211117736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Condensed Statements of Equity (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Remaining authorized repurchase amount</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356211551672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Condensed Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 1,355.3<span></span>
</td>
<td class="nump">$ 1,456.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">350.3<span></span>
</td>
<td class="nump">273.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Change in deferred income taxes</a></td>
<td class="num">(119.1)<span></span>
</td>
<td class="nump">11.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">85.5<span></span>
</td>
<td class="nump">71.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Net investment gains</a></td>
<td class="num">(302.2)<span></span>
</td>
<td class="num">(186.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development (Note 3)</a></td>
<td class="nump">299.3<span></span>
</td>
<td class="nump">52.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other changes in operating assets and liabilities, net of acquisitions and divestitures</a></td>
<td class="num">(102.8)<span></span>
</td>
<td class="num">(1,408.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other non-cash operating activities, net</a></td>
<td class="nump">131.1<span></span>
</td>
<td class="nump">111.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by Operating Activities</a></td>
<td class="nump">1,697.4<span></span>
</td>
<td class="nump">382.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Net purchases of property and equipment</a></td>
<td class="num">(300.3)<span></span>
</td>
<td class="num">(258.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Proceeds from sales and maturities of short-term investments</a></td>
<td class="nump">4.0<span></span>
</td>
<td class="nump">36.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of short-term investments</a></td>
<td class="num">(19.4)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfLongtermInvestments', window );">Proceeds from sales of noncurrent investments</a></td>
<td class="nump">284.8<span></span>
</td>
<td class="nump">54.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLongtermInvestments', window );">Purchases of noncurrent investments</a></td>
<td class="num">(291.5)<span></span>
</td>
<td class="num">(83.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid for acquisitions, net of cash acquired (Note 3)</a></td>
<td class="num">(747.4)<span></span>
</td>
<td class="num">(849.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_PurchasedInProcessResearchAndDevelopment', window );">Purchases of in-process research and development</a></td>
<td class="num">(191.8)<span></span>
</td>
<td class="num">(13.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other investing activities, net</a></td>
<td class="num">(21.9)<span></span>
</td>
<td class="nump">51.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used for Investing Activities</a></td>
<td class="num">(1,283.5)<span></span>
</td>
<td class="num">(1,060.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Dividends paid</a></td>
<td class="num">(774.8)<span></span>
</td>
<td class="num">(671.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Net change in short-term borrowings</a></td>
<td class="num">(3.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Net change in short-term borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,748.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(276.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of common stock</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(500.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other financing activities, net</a></td>
<td class="num">(279.9)<span></span>
</td>
<td class="num">(194.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash (Used for) Provided by Financing Activities</a></td>
<td class="num">(1,058.4)<span></span>
</td>
<td class="nump">106.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(10.2)<span></span>
</td>
<td class="num">(66.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(654.7)<span></span>
</td>
<td class="num">(638.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at January&#160;1</a></td>
<td class="nump">3,657.1<span></span>
</td>
<td class="nump">2,337.5<span></span>
</td>
<td class="nump">$ 2,337.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and Cash Equivalents at March 31</a></td>
<td class="nump">$ 3,002.4<span></span>
</td>
<td class="nump">$ 1,699.0<span></span>
</td>
<td class="nump">$ 3,657.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of EXPENSE related to research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore written off in the period of acquisition (INCOME STATEMENT)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_PurchasedInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of CASH paid for research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore, written off in the period of acquisition (CASH FLOWS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_PurchasedInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireLongtermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireLongtermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfLongtermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, beyond the current operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfLongtermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356136061176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have prepared the accompanying unaudited consolidated condensed financial statements in accordance with the requirements of Form 10-Q and, therefore, they do not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). In our opinion, the consolidated condensed financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for a fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our consolidated financial statements and accompanying notes included in our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231.htm" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2020. We issue our financial statements by filing them with the Securities and Exchange Commission and have evaluated subsequent events up to the time of the filing of this Quarterly Report on Form 10-Q.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis, that is, based on the weighted-average number of common shares outstanding plus the effect of incremental shares from our stock-based compensation programs.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide. A global research and development organization and a supply chain organization are responsible for the discovery, development, manufacturing, and supply of our products. Regional commercial organizations market, distribute, and sell the products. The business is also supported by global corporate staff functions. Our determination that we operate as a single segment is consistent with the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356135004264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text">Revenue<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue recognized in our consolidated condensed statements of operations:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.712%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,320.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,403.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration and other revenue </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">485.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,805.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,859.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Collaboration and other revenue associated with prior period transfers of intellectual property was $43.0 million and $35.4 million during the three months ended March&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements includes our share of profits from the collaboration, as well as royalties, upfront and milestone payments we receive under these types of contracts. See Note 4 for additional information related to certain of our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue from the Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trajenta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> families of products resulting from our collaboration with Boehringer Ingelheim discussed in Note 4. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Adjustments to Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to increase revenue recognized as a result of changes in estimates for our most significant United States (U.S.) sales returns, rebates, and discounts liability balances for products shipped in previous periods were less than 2 percent of U.S. revenue during the three months ended March&#160;31, 2021 and 2020. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contract Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract liabilities result from arrangements where we have received payment in advance of performance under the contract and do not include sales returns, rebates, and discounts. Changes in contract liabilities are generally due to either receipt of additional advance payments or our performance under the contract. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract liability balances:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">346.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021 and 2020, revenue recognized from contract liabilities as of the beginning of the respective year was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Disaggregation of Revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by product for the three months ended March 31, 2021 and 2020:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.699%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trulicity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,116.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">335.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,452.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">929.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,229.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">332.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">284.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">617.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humulin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">219.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">102.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">321.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Jardiance </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">151.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">160.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">312.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Basaglar</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">175.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">71.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">246.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Diabetes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">66.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">94.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">161.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Diabetes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,061.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,049.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,111.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,991.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">977.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,968.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Alimta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">261.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">297.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">559.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Verzenio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">172.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">96.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">269.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cyramza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">80.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">160.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">240.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Erbitux</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">107.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">122.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Tyvyt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">109.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">109.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Oncology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">71.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Oncology</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">642.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">729.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,372.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,201.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunology:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Taltz</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">249.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">153.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">403.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Olumiant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">169.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">193.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Immunology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Immunology</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">284.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">329.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">613.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cymbalta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">165.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">176.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Emgality</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">101.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">119.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Zyprexa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">88.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">95.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Neuroscience</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Neuroscience</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">141.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">323.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">465.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">COVID-19 Antibodies </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">650.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">159.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">810.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Forteo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">97.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">198.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cialis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">118.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">126.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">53.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">107.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Other</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">811.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">431.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,242.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,941.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,864.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,805.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,328.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,531.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,859.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Humalog revenue includes insulin lispro.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Jardiance revenue includes Glyxambi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Synjardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and Trijardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> XR.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)   </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to Emergency Use Authorizations (EUAs). </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by geographical area:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.461%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,941.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,328.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,321.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,061.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">571.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">592.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">362.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other foreign countries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">609.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,805.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,859.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenue is attributed to the countries based on the location of the customer.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356206901544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">Acquisitions</a></td>
<td class="text">Acquisitions<div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021 and February 2020, we completed the acquisitions of Prevail Therapeutics Inc. (Prevail) and Dermira, Inc. (Dermira), respectively. These transactions, as further discussed in this note below in Acquisitions of Businesses, were accounted for as business combinations under the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions are included in our consolidated condensed financial statements from the date of acquisition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also acquired assets in development which are further discussed in this note below in Asset Acquisitions. Upon each acquisition, the cost allocated to acquired in-process research and development (IPR&amp;D) was immediately expensed because the compound had no alternative future use. We recognized $299.3 million and $52.3 </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of acquired IPR&amp;D charges for the three months ended March&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions of Businesses</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Prevail Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Transaction</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we acquired all shares of Prevail for a purchase price that included $22.50 per share in cash (or an aggregate of $747.4 million, net of cash acquired) plus one non-tradable contingent value right (CVR) per share. The CVR entitles Prevail stockholders to up to an additional $4.00 per share in cash (or an aggregate of approximately $160&#160;million) payable, subject to certain terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom, Germany, France, Italy or Spain. To achieve the full value of the CVR, such regulatory approval must occur by December 31, 2024. If such regulatory approval occurs after December 31, 2024, the value of the CVR will be reduced by approximately 8.3 cents per month until December 1, 2028, at which point the CVR will expire.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prevail is a biotechnology company developing potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The acquisition establishes a new modality for drug discovery and development, extending our research efforts through the creation of a gene therapy program that will be anchored by Prevail&#8217;s portfolio of assets. Prevail&#8217;s lead gene therapies in clinical development are PR001 for patients with Parkinson&#8217;s disease with GBA1 mutations and neuronopathic Gaucher disease and PR006 for patients with frontotemporal dementia with GRN mutations. Both PR001 and PR006 were granted Fast Track designation from the U.S. Food and Drug Administration (FDA). </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our access to Prevail information was limited prior to the acquisition. As a consequence, we are in the process of determining fair values and tax bases of a significant portion of the assets acquired and liabilities assumed, including the identification and valuation of intangible assets and tax exposures. The final determination of these amounts will be completed as soon as possible but no later than one year from the acquisition date. The final determination may result in asset and liability fair values and tax bases that differ from the preliminary estimates and require changes to the preliminary amounts recognized.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at January 22, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition date fair value of consideration transferred </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Fair value of CVR liability</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid, net of cash acquired</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquired IPR&amp;D intangibles primarily relate to PR001.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The goodwill recognized from this acquisition is not deductible for tax purposes. </span></div><div style="margin-bottom:6pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Note 6 for a discussion on the estimation of the CVR liability. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma information has not been included as this acquisition did not have a material impact on our consolidated condensed statements of operations for the three months ended March 31, 2021 and 2020.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Dermira Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Transaction</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we acquired all shares of Dermira for a purchase price of approximately $849.3 million, net of cash acquired. Under the terms of the agreement, we acquired lebrikizumab, a novel, investigational, monoclonal antibody being evaluated for the treatment of moderate-to-severe atopic dermatitis. Lebrikizumab was granted Fast Track designation from the FDA. We also acquired Qbrexza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (glycopyrronium) cloth, a medicated cloth approved by the FDA for the topical treatment of primary axillary hyperhidrosis (uncontrolled excessive underarm sweating). During the three months ended March&#160;31, 2021, we decided to sell the rights to Qbrexza. See Note 5 for additional information. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values recognized related to the assets acquired and liabilities assumed in this acquisition included goodwill of $86.8 million, other intangibles of $1.20 billion primarily related to lebrikizumab, deferred income tax liabilities of $49.5 million, and long-term debt of $375.5 million. After the acquisition, we repaid $276.2 million of long-term debt assumed as part of our acquisition of Dermira.</span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Acquisitions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our asset acquisitions during the three months ended March&#160;31, 2021 and 2020:</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.916%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Counterparty</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compound(s) or Therapy</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition Month</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase of Development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired IPR&amp;D Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Precision Biosciences, Inc. </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development of potential in vivo therapies for genetic disorders</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">107.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merus N.V. </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CD3-engaging T-cell re-directing bispecific antibodies for the potential treatment of cancer</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asahi Kasei Pharma Corporation</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AK1780, an orally bioavailable P2X7 receptor antagonist for the potential treatment of chronic pain conditions</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rigel Pharmaceuticals, Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the potential treatment of autoimmune and inflammatory diseases</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">125.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sitryx Therapeutics Limited</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new medicines for autoimmune diseases</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.3&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbCellera Biologics Inc. (AbCellera)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neutralizing antibodies for the treatment and prevention of COVID-19</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2020</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable. </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> We recognized an acquired IPR&amp;D expense of $25.0 million in May 2020 upon closing of the transaction. </span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with these arrangements, our partners may be entitled to future royalties and/or commercial milestones based on sales should products be approved for commercialization and/or milestones based on the successful progress of compounds through the development process.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures.  This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356136163576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations and Other Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborations and Other Arrangements</a></td>
<td class="text">Collaborations and Other Arrangements<div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We often enter into collaborative and other similar arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These arrangements often require milestone as well as royalty or profit-share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements from or payments to the collaboration partner. See Note 2 for amounts of collaboration and other revenue recognized from these types of arrangements. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Each collaboration is unique in nature, and our more significant arrangements are discussed below. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Boehringer Ingelheim Diabetes Collaboration</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Boehringer Ingelheim have a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Currently included in the collaboration are Boehringer Ingelheim&#8217;s oral diabetes products: Jardiance,  Glyxambi, Synjardy, Trijardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> XR, Trajenta, and Jentadueto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as our basal insulin, Basaglar. Glyxambi, Synjardy, and Trijardy XR are included in the Jardiance product family. Jentadueto is included in the Trajenta product family. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the net amount of significant milestones (deferred) capitalized at March 31, 2021 and December 31, 2020 for the compounds included in this collaboration: </span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Milestones (Deferred) Capitalized </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">as of:</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product Family</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">151.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(163.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In connection with the regulatory approvals of Basaglar in the U.S., Europe, and Japan, milestone payments received were recorded as contract liabilities and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. In connection with the regulatory approvals of Jardiance and Trajenta, milestone payments made were capitalized as intangible assets and are being amortized to cost of sales through the term of the collaboration. This represents the amounts that have been (deferred) or capitalized from the start of this collaboration through the end of the reporting period, net of amount amortized. </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The collaboration agreement with Boehringer Ingelheim for Jardiance ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The collaboration agreement with Boehringer Ingelheim for Trajenta ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Jardiance product family, we and Boehringer Ingelheim share equally the ongoing development and commercialization costs in the most significant markets, and we record our portion of the development and commercialization costs as research and development expense and marketing, selling, and administrative expense, respectively. We receive a royalty on net sales of Boehringer Ingelheim's products in the most significant markets and recognize the royalty as collaboration and other revenue.  Boehringer Ingelheim is entitled to potential performance payments depending on the net sales of the Jardiance product family; therefore, our reported revenue for Jardiance may be reduced by any potential performance payments we make related to this product family. Beginning January 1, 2021, the royalty received by us related to the Jardiance product family may also be increased or decreased depending on whether net sales for this product family exceed or fall below certain thresholds. We pay to Boehringer Ingelheim a royalty on net sales for Basaglar in the U.S. We record our sales of Basaglar to third parties as net product revenue with the royalty payments made to Boehringer Ingelheim recorded as cost of sales.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our net product revenue recognized with respect to Basaglar and collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product Family</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">312.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">246.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">94.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Olumiant</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a worldwide license and collaboration agreement with Incyte Corporation (Incyte), which provides us the development and commercialization rights to its Janus tyrosine kinase (JAK) inhibitor compound, now known as Olumiant (baricitinib), and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases. Incyte has the right to receive tiered, double digit royalty payments on global net sales with rates ranging up to 20 percent. The agreement calls for payments by us to Incyte associated with certain development, success-based regulatory, and sales-based milestones. In 2020, the agreement was amended to include the treatment of COVID-19, with Incyte obtaining the right to receive an additional royalty ranging up to the low teens on global net sales for the treatment of COVID-19 that exceed a specified aggregate global net sales threshold. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the regulatory approvals of Olumiant in the U.S., Europe, and Japan, milestone payments of $210.0 million were capitalized as intangible assets as of March 31, 2021 and December 31, 2020 and are being amortized to cost of sales through the term of the collaboration. This represents the cumulative amounts that have been capitalized from the start of this collaboration through the end of each reporting period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, Incyte is eligible to receive up to $100.0 million of additional payments from us contingent upon certain success-based regulatory milestones. Incyte is also eligible to receive up to $150.0 million of potential sales-based milestones.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record our sales of Olumiant to third parties as net product revenue with the royalty payments made to Incyte recorded as cost of sales. The following table summarizes our net product revenue recognized with respect to Olumiant:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olumiant</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">193.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 antibodies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we entered into a worldwide license and collaboration agreement with AbCellera to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including bamlanivimab, for which we hold development and commercialization rights. AbCellera has the right to receive tiered royalty payments on global net sales of bamlanivimab with percentages ranging in the mid-teens to mid-twenties. Royalty payments made to AbCellera are recorded as cost of sales.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we entered into a license and collaboration agreement with Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences) to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including etesevimab, for which we hold development and commercialization rights outside of Greater China (which includes mainland China, Hong Kong and Macau Special Administrative Regions and Taiwan) and for which Junshi Biosciences maintains all rights in Greater China. Junshi Biosciences has the right to receive royalty payments in the mid-teens on our net sales of etesevimab. Junshi Biosciences also has the right to receive certain development, success-based regulatory and sales-based milestones. In connection with the regulatory authorizations of etesevimab (for administration with bamlanivimab) in the U.S. and Europe, milestone payments of $60.0 million were capitalized as intangible assets as of March&#160;31, 2021 and are being amortized to cost of sales over the estimated useful life of etesevimab. As of March&#160;31, 2021, Junshi Biosciences is eligible to receive up to $15.0 million of additional payments contingent upon certain success-based regulatory milestones and up to $120.0 million of potential sales-based milestones. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to EUAs, we recognized $810.1 million of net product revenue associated with our sales of our COVID-19 antibodies during the three months ended March&#160;31, 2021. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tyvyt</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Innovent Biologics, Inc. (Innovent) to jointly develop and commercialize Tyvyt (sintilimab injection) in China. In 2019, we and Innovent began co-commercializing Tyvyt in China. We record our sales of Tyvyt to third parties as revenue, with payments made to Innovent for its portion of the gross margin reported as cost of sales. We also report as revenue our portion of the gross margin for Tyvyt sales made by Innovent to third parties. Our Tyvyt revenue in China, which is primarily recorded as net product revenue, was $109.7 million and $57.4 million during the three months ended March 31, 2021 and 2020, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we obtained an exclusive license for Tyvyt from Innovent for geographies outside of China. Innovent, with collaboration from us, will pursue the initial registration of Tyvyt in the U.S., and we will pursue initial registration of Tyvyt in other markets and all other subsequent registrations of Tyvyt. We have exclusive commercialization rights outside of China.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, Innovent is eligible to receive up to $825.0 million for geographies outside of China and up to $235.0 million in China in success-based regulatory and sales-based milestones. Innovent is also eligible to receive tiered double digit royalties on net sales for geographies outside of China. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tanezumab</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Pfizer Inc. (Pfizer) to jointly develop and globally commercialize tanezumab for the treatment of osteoarthritis pain and cancer pain. The companies equally share the ongoing development costs and, if successful, in the U.S. will co-commercialize and equally share in gross margin and certain commercialization expenses. As a result of an amendment to the agreement in 2020, Pfizer will be responsible for commercialization activities and costs outside the U.S., and we have the right to receive tiered royalties in percentages from the high teens to mid-twenties for net sales in Japan as well as low double digit royalties on annual net sales greater than $150.0&#160;million in all other territories outside of the U.S. and Japan. As of March&#160;31, 2021, Pfizer is eligible to receive up to $147.5 million in success-based regulatory milestones based on current development plans and up to $1.23 billion in a series of sales-based milestones, contingent upon the commercial success of tanezumab.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lebrikizumab</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Dermira, we have a worldwide licensing agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. (collectively Roche), which provides us the global development and commercialization rights to lebrikizumab. Roche has the right to receive tiered royalty payments on future global net sales ranging in percentages from high single digits to high teens if the product is successfully commercialized. As of March&#160;31, 2021, Roche is eligible to receive up to $180.0 million of payments from us contingent upon the achievement of success-based regulatory milestones and up to $1.03 billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Dermira, we have a license agreement with Almirall, S.A. (Almirall), under which Almirall licensed the rights to develop and commercialize lebrikizumab for the treatment or prevention of dermatology indications, including, but not limited to, atopic dermatitis in Europe. We have the right to receive tiered royalty payments on future net sales in Europe ranging in percentages from low double digits to low twenties if the product is successfully commercialized. As of March&#160;31, 2021, we are eligible to receive additional payments of $85.0 million from Almirall contingent upon the achievement of success-based regulatory milestones and up to $1.25 billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab.</span></div>As of March&#160;31, 2021 and December 31, 2020, $23.3 million and $29.7 million, respectively, were recorded as contract liabilities on the consolidated condensed balance sheet and are expected to be recognized as collaboration and other revenue over the remaining Phase III development period. During the three months ended March&#160;31, 2021 and 2020, milestones received and collaboration and other revenue recognized were not material.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356136064280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Impairment, Restructuring, and Other Special Charges<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock', window );">Asset Impairment, Restructuring, and Other Special Charges</a></td>
<td class="text">Asset Impairment, Restructuring, and Other Special Charges<div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated condensed statements of operations are described below. </span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.192%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.036%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment and other special charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">200.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total asset impairment, restructuring, and other special charges</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">211.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairment, restructuring, and other special charges recognized during the three months ended March&#160;31, 2021 were primarily related to an intangible asset impairment of $108.1&#160;million resulting from the decision to sell the rights to Qbrexza, as well as acquisition and integration costs associated with the acquisition of Prevail. During the three months ended March&#160;31, 2021, we entered into an agreement to sell our rights to Qbrexza, subject to closing conditions which are expected to be completed in the second quarter of 2021. The assets associated with Qbrexza were written down to fair value less cost to sell, which were determined based upon a discounted cash flow valuation. The remaining book value of assets associated with Qbrexza subsequent to the impairment charge is not material.</span></div>Asset impairment, restructuring, and other special charges recognized during the three months ended March&#160;31, 2020 were primarily related to acquisition and integration costs associated with the acquisition of Dermira.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356136099624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Financial Instruments</a></td>
<td class="text">Financial InstrumentsFinancial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life science products account for a substantial portion of our trade receivables; collateral is generally not required. We seek to mitigate the risk associated with this concentration through our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions. We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings.<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our equity investments are accounted for using three different methods depending on the type of equity investment:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review equity investments other than public equity investments for indications of impairment and observable price changes on a regular basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market, with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, and Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other&#8211;net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months. At March&#160;31, 2021, we had outstanding foreign currency forward commitments to purchase 1.11 billion U.S. dollars and sell 941.7 million euro, commitments to purchase 4.19 billion euro and sell 4.98 billion U.S. dollars, commitments to purchase 140.7 million U.S. dollars and sell 15.47 billion Japanese yen, and commitments to purchase 285.2 million British pounds and sell 396.5 million U.S. dollars, which all settled within 30 days.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency exchange risk is also managed through the use of foreign currency debt and cross-currency interest rate swaps. Our foreign currency-denominated notes had carrying amounts of $5.72 billion and $6.02 billion as of March&#160;31, 2021 and December&#160;31, 2020, respectively, of which $4.30 billion and $4.50 billion have been designated as, and are effective as, economic hedges of net investments in certain of our euro-denominated foreign operations as of March&#160;31, 2021 and December&#160;31, 2020, respectively. At March&#160;31, 2021, we had outstanding cross currency swaps with notional amounts of $3.79 billion swapping U.S. dollars to euro and $1.00 billion swapping Swiss francs to U.S. dollars which have settlement dates ranging through 2028. Our cross-currency interest rate swaps, for which a majority convert a portion of our U.S. dollar-denominated fixed-rate debt to foreign-denominated fixed-rate debt, have also been designated as, and are effective as, economic hedges of net investments.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated condensed statements of cash flows. At March&#160;31, 2021, substantially all of our total long-term debt is at a fixed rate. We have converted approximately 13 percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. The change in fair value of these instruments is recorded as part of other comprehensive income (loss), and upon completion of a debt issuance and termination of the swap, is amortized to interest expense over the life of the underlying debt. As of March 31, 2021, the total notional amounts of forward-starting interest rate contracts in designated cash flow hedging instruments were $1.75 billion, which have settlement dates ranging between 2023 and 2025.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Effect of Risk-Management Instruments on the Consolidated Condensed Statements of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following effects of risk-management instruments were recognized in other&#8211;net, (income) expense:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from hedged fixed-rate debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(81.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from interest rate contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">81.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">71.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">133.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">208.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.6)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021 and 2020, the amortization of losses related to the portion of our risk management hedging instruments, fair value hedges, and cash flow hedges that was excluded from the assessment of effectiveness was not material.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Effect of Risk-Management Instruments on Other Comprehensive Income (Loss)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Foreign currency-denominated notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">207.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">150.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Forward-starting interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">295.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(369.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the next 12&#160;months, we expect to reclassify $16.9&#160;million of pretax net losses on cash flow hedges from accumulated other comprehensive loss to other&#8211;net, (income) expense. During the three months ended March&#160;31, 2021 and 2020, the amounts excluded from the assessment of hedge effectiveness recognized in other comprehensive income (loss) were not material.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize certain fair value information at March&#160;31, 2021 and December&#160;31, 2020 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:34.624%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other<br/>Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,554.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,554.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,554.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,554.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">20.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">20.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">20.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">20.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">18.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">18.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">18.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">18.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">49.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">109.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">108.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">109.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">109.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">177.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">175.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">177.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">177.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">102.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">99.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">102.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">102.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">23.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">23.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">23.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">23.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">110.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">30.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">110.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">110.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,645.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">386.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,645.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,645.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">384.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">679.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,232.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,097.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,097.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,097.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,097.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,664.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">311.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,664.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,664.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">373.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">471.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,966.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments.</span></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:38.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.916%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt, including current portion</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(16,204.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(17,462.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(17,462.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,595.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,038.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,038.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.981%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.679%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-management instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">87.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">87.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">87.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">235.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">235.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">235.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(45.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(45.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(45.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(19.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(19.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(19.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(16.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(16.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(16.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(66.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(66.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(66.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liability:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(71.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(71.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(71.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-management instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-management instruments above are disclosed on a gross basis. There are various rights of setoff associated with certain of the risk-management instruments above that are subject to enforceable master netting arrangements or similar agreements. Although various rights of setoff and master netting arrangements or similar agreements may exist with the individual counterparties to the risk-management instruments above, individually, these financial rights are not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine our Level 1 and Level 2 fair value measurements based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. Level 3 fair value measurements for other investment securities are determined using unobservable inputs, including the investments' cost adjusted for impairments and price changes from orderly transactions. The fair values of equity method investments and investments measured under the measurement alternative for equity investments that do not have readily determinable fair values are not readily available. As of March 31, 2021, we had approximately $736 million of unfunded commitments to invest in venture capital funds, which we anticipate will be paid over a period of up to 10 years. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration liability relates to our liability arising in connection with the CVR issued as a result of the Prevail acquisition. The fair value of the CVR liability was estimated using a discounted cash flow analysis and Level 3 inputs, including projections representative of a market participant's view of the expected cash payment associated with the first potential regulatory approval of a Prevail compound in the applicable countries based on probabilities of technical success, timing of the potential approval events for the compounds, and an estimated discount rate. See Note 3 for additional information related to the CVR arrangement. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of March&#160;31, 2021:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:40.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturities by Period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less&#160;Than<br/>1 Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1-5<br/>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6-10<br/>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More&#160;Than<br/>10 Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net gains recognized in our consolidated condensed statements of operations for equity securities were $301.5&#160;million and $186.6 million for the three months ended March&#160;31, 2021 and 2020, respectively. The net gains/losses recognized during the three months ended March&#160;31, 2021 and 2020 on equity securities sold during the respective periods were not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adjust our equity investments without readily determinable fair values based upon changes in the equity instruments' values resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Downward adjustments resulting from an impairment are recorded based upon impairment considerations, including the financial condition and near term prospects of the issuer, general market conditions, and industry specific factors. Adjustments recorded during the three months ended March&#160;31, 2021 and 2020 were not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value of available-for-sale securities in an unrealized gain or loss position and the amount of unrealized gains and losses in accumulated other comprehensive loss follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.249%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.860%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross gains</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized gain position</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">273.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized loss position</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">170.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically assess our investment in available-for-sale securities for impairment losses and credit losses. The amount of credit losses are determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration. Impairment and credit losses related to available-for-sale securities were not material in the three months ended March&#160;31, 2021 and 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, the available-for-sale securities in an unrealized loss position include primarily fixed-rate debt securities of varying maturities, which are sensitive to changes in the yield curve and other market conditions. Approximately 94 percent&#160;of the fixed-rate debt securities in a loss position are investment-grade debt securities. As of March&#160;31, 2021, we do not intend to sell, and it is not more likely than not that we will be required to sell, the securities in a loss position before the market values recover or the underlying cash flows have been received, and there is no indication of default on interest or principal payments for any of our debt securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity related to our available-for-sale securities was as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">43.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross gains on sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross losses on sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on sales of available-for-sale investments are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable Factoring Arrangements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into accounts receivable factoring agreements with financial institutions to sell certain of our non-U.S. accounts receivable. These transactions are accounted for as sales and result in a reduction in accounts receivable because the agreements transfer effective control over and, risk related to, the receivables to the buyers. Our factoring agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. We derecognized $637.8 million and $754.9 million&#160;of accounts receivable as of March&#160;31, 2021 and December 31, 2020, respectively, under these factoring arrangements. The costs of factoring such accounts receivable on our consolidated condensed results of operations for the three months ended March&#160;31, 2021 and 2020&#160;were&#160;not material.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356207380008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate was 8.2 percent for the three months ended March&#160;31, 2021, compared with 13.3 percent for the three months ended March 31, 2020. The effective tax rates for both periods were reduced by net discrete tax benefits, with a larger net discrete tax benefit reflected for the three months ended March&#160;31, 2021. </span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. examination of tax years 2016-2018 began in the fourth quarter of 2019 and remains ongoing; therefore, the resolution of this audit period will likely extend beyond the next 12 months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356225075576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefits<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Retirement Benefits</a></td>
<td class="text">Retirement Benefits<div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net pension and retiree health benefit (income) cost included the following components:</span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Pension Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of net periodic benefit cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">92.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">84.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(238.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">121.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">61.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of net periodic benefit income:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(36.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(14.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit income</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(30.9)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.7)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We contributed approximately $15 million to satisfy minimum funding requirements to our defined benefit pension and retiree health benefit plans during the three months ended March&#160;31, 2021. We contributed approximately $10 million in discretionary funding during the three months ended March&#160;31, 2021. During the remainder of 2021, we expect to make contributions of approximately $20 million to our defined benefit pension and retiree health plans to satisfy minimum funding requirements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356206786280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies</a></td>
<td class="text">Contingencies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in various lawsuits, claims, government investigations and other legal proceedings that arise in the ordinary course of business. These claims or proceedings can involve various types of parties, including governments, competitors, customers, suppliers, service providers, licensees, employees, or shareholders, among others. These matters may involve patent infringement, antitrust, securities, pricing, sales and marketing practices, environmental, commercial, contractual rights, licensing obligations, health and safety matters, consumer fraud, employment matters, product liability and insurance coverage, among others. The resolution of these matters often develops over a long period of time and expectations can change as a result of new findings, rulings, appeals or settlement arrangements. Legal proceedings that are significant or that we believe could become significant or material are described below.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the legal proceedings in which we are named as defendants are without merit and we are defending against them vigorously. It is not possible to determine the outcome of these matters, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated condensed balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of additional product liability and related claims in the future. Due to a very restrictive market for product liability insurance, we are self-insured for product liability losses for all our currently and previously marketed products. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Alimta Patent Litigation </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of manufacturers are seeking approvals in the U.S. and a number of countries in Europe to market generic forms of Alimta prior to the expiration of our vitamin regimen patents, alleging that those patents are invalid, not infringed, or both. We believe our Alimta vitamin regimen patents are valid and enforceable against these generic manufacturers.&#160;However, it is not possible to determine the ultimate outcome of the proceedings, and accordingly, we can provide no assurance that we will prevail.&#160;The loss of exclusivity in the U.S. could have a material adverse impact on our future consolidated results of operations and cash flows and would result in a rapid and severe decline in future revenue for the product.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alimta (pemetrexed) is protected by a vitamin regimen patent until 2021, plus pediatric exclusivity through May 2022. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2017, we filed a lawsuit in the U.S. District Court for the Southern District of Indiana against Apotex Inc. (Apotex) alleging infringement of Alimta's vitamin regimen patent for its application to market a pemetrexed product. In December 2019, the U.S. District Court for the Southern District of Indiana granted our motion for summary judgment of infringement, and in December 2020, the U.S. Court of Appeals for the Federal Circuit affirmed that ruling. Apotex did not request reconsideration or a rehearing of that ruling. However, Apotex could petition the U.S. Supreme Court to review the case. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we settled a lawsuit we filed against Eagle Pharmaceuticals, Inc. (Eagle) in response to its application to market a product using an alternative form of pemetrexed. Per the settlement agreement, Eagle has a limited initial entry into the market with its product starting February 2022 (up to an approximate three-week supply) and subsequent unlimited entry starting April 2022.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Patent Litigation</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, Alimta (pemetrexed) is prot</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ected by the vitamin regimen patent through June of 2021. Notwithstanding the existence of our vitamin regimen patent, several companies launched generic pemetrexed products at risk in France, Germany, and the Netherlands but those products were subsequently removed from those markets as a consequence of patent infringement actions brought by us. In many cases, those patent infringement actions are subject to appeals filed by the generic manufacturer. In March 2021, we entered into a settlement agreement with Fresenius Kabi Aktienngesellschaft that discontinued all pending European patent litigation involving the Fresenius Kabi group of companies including that between us and Fresenius Kabi France and Fresenius Kabi Groupe France.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal proceedings are ongoing regarding </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our Alimta patents in various national courts throughout Europe. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to seek to remove any generic pemetrexed products launched at risk in other European markets, seek damages with respect to such launches, and defend our patents against validity challenges.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Emgality Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, we were</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> named as a defendant in litigation filed by Teva Pharmaceuticals International GMBH and Teva Pharmaceuticals USA, Inc. (collectively, Teva) in the U.S. District Court for the District of Massachusetts seeking a ruling that various claims in nine differ</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ent Teva patents would be infringed by our launch and continued sales of Emgality for the prevention of migraine in adults. Trial is expected in February 2022. Separately, the U.S. Patent and Trademark Office (USPTO) granted our request to initiate an&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes review</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(IPR) to reexamine the validity of the nine Teva patents asserted against us in the litigation. In February 2020, the USPTO ruled in our favor and found that the claims asserted against us in six of Teva's nine patents were invalid. In March 2020, the USPTO ruled against us on the remaining three Teva patents, finding that we failed to show that the remaining three patents were unpatentable based on the subset of invalidity arguments available in an IPR proceeding. In April 2020, we appealed the USPTO&#8217;s March 2020 ruling, and Teva appealed the USPTO&#8217;s February 2020 ruling to the U.S. Court of Appeals for the Federal Circuit. The district court litigation will proceed in parallel with the IPR appeals.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Jardiance Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, Boehringer Ingelheim (BI), our partner in marketing and development of Jardiance, initiated U.S. patent litigation in the U.S. District Court of Delaware alleging infringement arising from Alkem Laboratories Ltd.'s (Alkem) and Ascend Laboratories, LLC's (Ascend) submissions of Abbreviated New Drug Applications (ANDA) seeking approval to market generic versions of Jardiance, Glyxambi, and Synjardy in accordance with the procedures set out in the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). Particularly with respect to Jardiance, Alkem's and Ascend's ANDAs seek approval to market generic versions of Jardiance prior to the expiration of the relevant patents, and allege that certain patents, including in some allegations the compound patent, are invalid or would not be infringed. We are not a party to this litigation. Trial is scheduled for September 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Taltz Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, we petitioned the High Court of Ireland to declare invalid the patent that Novartis Pharma AG (Novartis) purchased from Genentech, Inc. in 2020. Novartis responded by filing a claim against us alleging patent infringement related to our commercialization of Taltz and seeking damages for past infringement and an injunction against future infringement. This matter is ongoing. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Zyprexa Canada Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the mid-2000&#8217;s, several generic companies in Canada challenged the validity of our Zyprexa compound patent. In 2012, the Canadian Federal Court of Appeals denied our appeal of a lower court's decision that certain patent claims were invalid for lack of utility. In 2013, Apotex Inc. and Apotex Pharmachem Inc. (collectively, Apotex) brought claims against us in the Ontario Superior Court of Justice at Toronto for damages related to our enforcement of the Zyprexa compound patent under Canadian regulations governing patented drugs. Apotex seeks compensation based on novel legal theories under the Statute of Monopolies, Trade-Mark Act, and common law. In March 2021, the Ontario Superior Court granted our motion for summary judgement, thereby dismissing Apotex&#8217;s case. Apotex appealed that ruling to the Court of Appeal for Ontario in April 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Actos&#174;  Product Liability</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are named along with Takeda Chemical Industries, Ltd. and Takeda affiliates (collectively, Takeda) as a defendant in four purported product liability class actions in Canada related to Actos, which we commercialized with Takeda in Canada until 2009, including one in Ontario filed December 2011 (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Casseres et al. v. Takeda Pharmaceutical North America, Inc., et al.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), one in Quebec filed July 2012 (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Whyte et al. v. Eli Lilly et al.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), one in Saskatchewan filed November 2017 (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Weiler v. Takeda Canada Inc. et al.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), and one in Alberta filed January 2013 (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Epp v. Takeda Canada Inc. et al.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). In general, plaintiffs in these actions alleged that Actos caused or contributed to their bladder cancer. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Byetta&#174; Product Liability</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First initiated in March 2009, we are named as a defendant in approximately 570 Byetta product liability lawsuits in the U.S. involving approximately 810 plaintiffs. Approximately 55 of these lawsuits, covering about 285 plaintiffs, are filed in California state court and coordinated in a Los Angeles Superior Court. Approximately 515 of the lawsuits, covering about 515 plaintiffs, are filed in federal court, the majority of which are coordinated in a multi-district litigation (MDL) in the U.S. District Court for the Southern District of California. Three lawsuits, representing approximately four plaintiffs, have also been filed in various state courts. Approximately 565 of the lawsuits, involving approximately 800 plaintiffs, contain allegations that Byetta caused or contributed to the plaintiffs' cancer (primarily pancreatic cancer or thyroid cancer); while six plaintiffs allege Byetta caused or contributed to pancreatitis. In addition, one case alleges that Byetta caused or contributed to ampullary cancer. The federal and state trial courts granted summary judgment in favor of us and our co-defendants on the claims alleging pancreatic cancer. The plaintiffs appealed those rulings. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, the U.S. Court of Appeals for the Ninth Circuit reversed the U.S. District Court for the Southern District of California's grant of summary judgment in the MDL based on that court's discovery rulings and remanded the cases back to the U.S. District Court for further proceedings. In March 2021, the U.S. District Court granted summary judgment for the defendants and in April 2021, the plaintiffs filed a notice of appeal to the U.S. Court of Appeals for the Ninth Circuit. In the state court actions, in November 2018, the California Court of Appeal reversed the Los Angeles County Superior Court of California&#8217;s grant of summary judgment based on that court's discovery rulings and remanded for further proceedings. In April 2021, the Los Angeles County Superior Court of California granted summary judgment for the defendants.   </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of approximately 20 additional claimants who have not yet filed suit. These additional claims allege damages for pancreatic cancer or thyroid cancer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cialis Product Liability</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First initiated in August 2015, we are named as a defendant in approximately 350 Cialis product liability lawsuits in the U.S. These cases, many of which were originally filed in various federal courts, contain allegations that Cialis caused or contributed to the plaintiffs' cancer (melanoma). In December 2016, the Judicial Panel on Multidistrict Litigation (JPML) granted the plaintiffs' petition to have filed cases and an unspecified number of future cases coordinated into a federal multidistrict litigation (MDL) in the U.S. District Court for the Northern District of California, alongside an existing coordinated proceeding involving Viagra&#174;. The JPML ordered the transfer of the existing cases to the now-renamed MDL </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Viagra (Sildenafil Citrate) and Cialis (Tadalafil) Products Liability Litigation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In April 2020, the MDL court granted summary judgment to the defendants on all of the claims brought against them by the plaintiffs. In May 2020, plaintiffs filed an appeal in the U.S. Court of Appeals for the Ninth Circuit. The plaintiffs&#8217; appeal has been administratively closed until August 2021 pending completion of a procedure to resolve the claims in this litigation.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Jardiance Product Liability </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First initiated in January 2019, we and Boehringer Ingelheim Pharmaceuticals, Inc., a subsidiary of BI, have been named as a defendant in approximately 95 product liability lawsuits in the U.S., mostly in Stamford Superior Court in Connecticut, alleging that Jardiance caused or contributed to plaintiffs&#8217; Fournier&#8217;s gangrene.  Our agreement with BI calls for BI to defend and indemnify us against any damages, costs, expenses, and certain other losses with respect to product liability claims in accordance with the terms of the agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Proceedings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as "Superfund," we have been designated as one of several potentially responsible parties with respect to the cleanup of fewer than 10 sites. Under Superfund, each responsible party may be jointly and severally liable for the entire amount of the cleanup.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">340B Litigation and Investigations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the plaintiff in a lawsuit filed in January 2021 in the U.S. District Court for the Southern District of Indiana against the U.S. Department of Health and Human Services (HHS), the Secretary of HHS, the Health Resources and Services Administration (HRSA), and the Administrator of HRSA. The lawsuit challenges the HHS's December 30, 2020 advisory opinion stating that drug manufacturers are required to deliver discounts under the 340B program to all contract pharmacies. We seek a declaratory judgment that the defendants violated the Administrative Procedures Act and the U.S. Constitution, a preliminary injunction enjoining implementation of the administrative dispute resolution process created by defendants and, with it, their application of the advisory opinion, and other related relief. In March 2021, the court entered an order preliminarily enjoining the government&#8217;s enforcement of the administrative dispute resolution process against Lilly. The matter is ongoing. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2021, we, along with other pharmaceutical manufacturers, were named as a defendant in a petition currently pending before the HHS Administration Dispute Resolution Panel. Petitioner seeks declaratory and other injunctive relief related to the 340B program. As described above, the U.S. District Court for the Southern District of Indiana has entered a preliminary injunction enjoining the government&#8217;s enforcement of this administrative dispute resolution process against us.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2021, we received a civil investigative subpoena from the Office of the Attorney General for the State of Vermont relating to the sale of pharmaceutical products to Vermont covered entities under the 340B program. We are cooperating with this subpoena. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Brazil Litigation &#8211; Cosmopolis Facility </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Labor Attorney Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First initiated in 2008, our subsidiary in Brazil, Eli Lilly do Brasil Limitada (Lilly Brasil), is named in a lawsuit brought by the Labor Attorney for the 15th Region in the Labor Court of Paulinia, State of Sao Paulo, Brazil, alleging possible harm to employees and former employees caused by exposure to heavy metals at a former Lilly Brasil manufacturing facility in Cosmopolis, Brazil, operated by the company between 1977 and 2003. In May 2014, the labor court judge ruled against Lilly Brasil, ordering it to undertake several actions of unspecified financial impact, including paying lifetime health coverage for the employees and contractors who worked at the Cosmopolis facility more than six months during the affected years and their children born during and after this period. We appealed this decision. In July 2018, the appeals court affirmed the labor court's ruling with a liquidated award of&#160;300&#160;million&#160;Brazilian real (for moral damages, donation of equipment, and creation of a foundation) which, adjusted for inflation and interest using the current Central Bank of Brazil's special system of clearance and custody rate (SELIC), is approximately 950&#160;million Brazilian real (approximately $165&#160;million as of March 31, 2021). The appeals court restricted the broad health coverage awarded by the labor court to health problems that claimants could show arose from exposure to the alleged contamination. In August 2019, Lilly Brasil filed an appeal to the superior labor court. In September 2019, the appeals court stayed a number of elements of its prior decision, including the obligation to provide health coverage for contractors, their children, and children of employees who worked at the Cosmopolis facility, pending the determination of Lilly Brasil&#8217;s appeal to the superior labor court. The cost of any such health coverage has not been determined.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the Labor Attorney filed an application in the labor court for enforcement of the healthcare coverage granted by the appeals court in its July 2018 ruling and requested restrictions on Lilly Brasil&#8217;s assets in Brazil. In July 2019, the labor court issued a ruling requiring either a freeze of Lilly Brasil&#8217;s immovable property or, alternatively, a security deposit of 500 million Brazilian real. Lilly Brasil filed a writ of mandamus challenging this ruling</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> but the court has stayed its decision on this writ and instead directed the parties to attend conciliation hearings, a process that concluded unsuccessfully in September 2020. Consequently, the partial stay of the proceedings relating to Lilly Brasil's application to appeal in the main proceedings has been lifted. In addition, the Labor Attorney's application for preliminary enforcement of the July 2018 healthcare coverage ruling was granted. As the conciliation hearings have been unsuccessful, we have filed a brief to strike the Labor Attorney&#8217;s application to enforce the previous healthcare coverage. Lilly Brasil is currently awaiting a determination as to whether its application seeking leave to appeal to the superior labor court has been successful.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Individual Former Employee Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also named in approximately 30&#160;lawsuits filed in the same labor court by individual former employees making similar claims. These lawsuits are each at various stages in the litigation process, with judgments being handed down in approximately half of the lawsuits, nearly all of which are on appeal in the labor courts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">China NDRC Antitrust Matter</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The competition authority in China has investigated our distributor pricing practices in China in connection with a broader inquiry into pharmaceutical industry pricing. We have cooperated with this investigation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Eastern District of Pennsylvania Pricing (Average Manufacturer Price) Inquiry</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2014, we, along with another pharmaceutical manufacturer, are named as co-defendants in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States et al. ex rel. Streck v. Takeda Pharm. Am., Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was filed in November 2014 and unsealed in the U.S. District Court for the Northern District of Illinois. The complaint alleges that the defendants should have treated certain credits from distributors as retroactive price increases and included such increases in calculating average manufacturer prices. Trial is scheduled for February 2022.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Health Choice Alliance </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are named as a defendant in a lawsuit filed in June 2017 in the U.S. District Court for the Eastern District of Texas seeking damages under the federal anti-kickback statute and state and federal false claims acts for certain patient support programs related to our products Humalog, Humulin, and Forteo. In September 2019, the U.S. District Court granted the U.S. Department of Justice&#8217;s motion to dismiss the relator&#8217;s second amended complaint. In January 2020, the relator appealed the District Court&#8217;s dismissal to the U.S. Court of Appeals for the Fifth Circuit. We are also named as a defendant in two similar lawsuits filed in Texas and New Jersey state courts in October 2019 seeking damages under the Texas Medicaid Fraud Prevention Act and New Jersey Medicaid False Claims Act, respectively. In November 2020, the Texas state court action was stayed pending a decision by the U.S. Court of Appeals for the Fifth Circuit on the aforementioned District Court appeal. In April 2021, the New Jersey state court action was dismissed with prejudice.   </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Pricing Litigation, Investigations, and Inquiries</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we, along with Sanofi-Aventis U.S. LLC (Sanofi) and Novo Nordisk, Inc. (Novo Nordisk) were named as defendants in a consolidated purported class action lawsuit,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re. Insulin Pricing Litigation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the U.S. District Court for the District of New Jersey relating to insulin pricing seeking damages under various state consumer protection laws and the Federal Racketeer Influenced and Corrupt Organization Act (federal RICO Act). Separately, in February 2018, we, along with Sanofi and Novo Nordisk, were named as defendants in&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MSP Recovery Claims, Series, LLC et al. v. Sanofi Aventis U.S. LLC et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the same court, seeking damages under various state consumer protection laws, common law fraud, unjust enrichment, and the federal RICO Act. In both</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> In re. Insulin Pricing Litigation </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> MSP Recovery Claims</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> litigation, the court dismissed claims under the federal RICO Act and certain state laws. Also, filed in the same court in November 2020, we, along with Sanofi, Novo Nordisk, CVS, Express Scripts, and Optum, have been sued in a purported class action, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FWK Holdings, LLC v. Novo Nordisk Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for alleged violations of the federal RICO Act as well as the New Jersey RICO Act and anti-trust law. That same group of defendants, along with Medco Health and United Health Group, also have been sued in other purported class actions in the same court, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rochester Drug Co-Operative Inc. v. Eli Lilly &amp; Co. et al. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Value Drug Co. v. Eli Lilly &amp; Co. et al. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">both initiated in March 2020, for alleged violations of the federal RICO Act. In September 2020, the U.S. District Court for the District of New Jersey granted plaintiffs&#8217; motion to consolidate </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FWK Holdings, LLC v. Novo Nordisk Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rochester Drug Co-Operative Inc. v. Eli Lilly &amp; Co. et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Value Drug Co. v. Eli Lilly &amp; Co. et al.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Minnesota Attorney General&#8217;s Office initiated litigation against us, Sanofi, and Novo Nordisk,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">State of Minnesota v. Sanofi-Aventis U.S. LLC et al.,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;in the U.S. District Court for the District of New Jersey, alleging unjust enrichment, violations of various Minnesota state consumer protection laws, and the federal RICO Act. In March 2021, the U.S. District Court for the District of New Jersey dismissed with prejudice the Minnesota Attorney General&#8217;s federal RICO claims and false advertising claims under state law; the consumer fraud and other related state law claims remain ongoing. Additionally, in May 2019, the Kentucky Attorney General&#8217;s Office filed a complaint against us, Sanofi, and Novo Nordisk,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commonwealth of Kentucky v. Novo Nordisk, Inc. et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in Kentucky state court, alleging violations of the Kentucky consumer protection law, false advertising, and unjust enrichment. In November 2019, Harris County in Texas initiated litigation against us, Sanofi, Novo Nordisk, Express Scripts, CVS, Optum, and Aetna, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">County of</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Harris Texas v. Eli Lilly &amp; Co., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in federal court in the Southern District of Texas alleging violations of the federal RICO Act, federal and state antitrust law, and the state deceptive trade practices-consumer protection act. Harris County also alleges common law claims such as fraud, unjust enrichment, and civil conspiracy. This lawsuit relates to our insulin products as well as Trulicity. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigations, Subpoenas, and Inquiries</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received a subpoena from the New York a</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd Vermont Attorney General Offices and civil investigative demands from the Washington, New Mexico, and Colorado Attorney General Offices relating to the pricing and sale of our insulin products. The Offices of the Attorney General in Mississippi, Washington D.C., California, Florida, Hawaii, and Nevada have requested information relating to the pricing and sale of our insulin products. We also received interrogatories and a subpoena from the California Attorney General's Office regarding our competition in the long-acting insulin market. We received two&#160;requests from the House of Representatives&#8217; Committee on Energy and Commerce and a request from the Senate&#8217;s Committee on Health, Education, Labor, and Pensions seeking certain information related to the pricing of insulin products, among other issues. We also received requests from the House of Representatives&#8217; Committee on Oversight and Reform and the Senate&#8217;s Committee on Finance, which seek detailed commercial information and business records. In January 2021, the Senate&#8217;s Committee on Finance released a report summarizing the findings of its investigation. We are cooperating with all of these aforementioned investigations, subpoenas, and inquiries.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Research Corporation Technologies, Inc. </span></div>In April 2016, we were named as a defendant in litigation filed by Research Corporation Technologies, Inc. (RCT) in the U.S. District Court for the District of Arizona. RCT is seeking damages for breach of contract, unjust enrichment, and conversion related to processes used to manufacture certain products, including Humalog and Humulin. A trial date has not been set.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356206900984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Other Comprehensive Income (Loss)</a></td>
<td class="text">Other Comprehensive Income (Loss)<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the activity related to each component of other comprehensive income (loss) during the three months ended March&#160;31, 2021 and 2020:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&#160;Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&#160;Flow Hedges</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,427.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,751.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(332.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,496.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(249.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">252.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">85.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">89.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(249.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">104.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">256.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,677.2)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,646.3)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(76.6)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,395.6)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.455%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&#160;Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&#160;Flow Hedges</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2020</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,678.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,638.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,523.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(348.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(442.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(345.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(362.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,804.5)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,530.3)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(556.9)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,885.9)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects on the net activity related to each component of other comprehensive income (loss) were as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.683%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tax benefit (expense) </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation gains/losses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(75.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized net gains/losses on securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit pension and retiree health benefit plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(31.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of cash flow hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(68.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit (provision) for income taxes allocated to other comprehensive income (loss) items</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(170.3)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for the tax effects of foreign currency translation gains and losses related to our foreign currency-denominated notes, cross-currency interest rate swaps, and other foreign currency exchange contracts designated as net investment hedges (see Note 6), income taxes were not provided for foreign currency translation. Generally, the assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows; therefore, resulting translation adjustments are made in shareholders' equity rather than in the consolidated condensed statements of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassifications out of accumulated other comprehensive loss were as follows:</span></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:33.552%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Details about Accumulated Other Comprehensive Loss Components</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Affected Line Item in the Consolidated Condensed Statements of Operations</span></td></tr><tr style="height:6pt"><td colspan="30" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of retirement benefit items:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service benefits, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(13.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial losses, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">122.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(22.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">85.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net of tax</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">89.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI http://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356136122008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other&#8211;Net, (Income) Expense<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Nonoperating Income (Expense) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">Other&#8211;Net, (Income) Expense</a></td>
<td class="text">Other&#8211;Net, (Income) Expense<div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other&#8211;net, (income) expense consisted of the following:</span></div><div style="margin-bottom:12pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">87.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment gains on equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(301.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(186.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement benefit plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(73.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(28.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(321.1)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89.1)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -URI http://asc.fasb.org/topic&amp;trid=2122503<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 610<br> -URI http://asc.fasb.org/topic&amp;trid=49130413<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356224815800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations Policy</a></td>
<td class="text">Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions are included in our consolidated condensed financial statements from the date of acquisition.Upon each acquisition, the cost allocated to acquired in-process research and development (IPR&amp;D) was immediately expensed because the compound had no alternative future use.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Description of Derivative Risk Management Policy</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market, with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.</span></div>We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, and Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other&#8211;net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41638-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41675-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356136115544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of disaggregation of revenue</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue recognized in our consolidated condensed statements of operations:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.712%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,320.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,403.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration and other revenue </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">485.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,805.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,859.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Collaboration and other revenue associated with prior period transfers of intellectual property was $43.0 million and $35.4 million during the three months ended March&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by product for the three months ended March 31, 2021 and 2020:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.699%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trulicity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,116.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">335.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,452.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">929.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,229.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">332.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">284.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">617.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humulin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">219.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">102.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">321.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Jardiance </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">151.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">160.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">312.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Basaglar</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">175.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">71.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">246.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Diabetes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">66.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">94.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">161.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Diabetes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,061.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,049.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,111.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,991.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">977.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,968.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Alimta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">261.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">297.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">559.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Verzenio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">172.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">96.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">269.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cyramza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">80.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">160.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">240.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Erbitux</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">107.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">122.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Tyvyt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">109.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">109.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Oncology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">71.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Oncology</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">642.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">729.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,372.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,201.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunology:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Taltz</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">249.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">153.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">403.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Olumiant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">169.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">193.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Immunology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Immunology</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">284.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">329.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">613.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cymbalta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">165.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">176.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Emgality</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">101.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">119.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Zyprexa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">88.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">95.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Neuroscience</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Neuroscience</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">141.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">323.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">465.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">COVID-19 Antibodies </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">650.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">159.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">810.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Forteo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">97.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">198.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cialis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">118.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">126.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">53.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">107.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Other</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">811.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">431.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,242.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,941.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,864.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,805.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,328.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,531.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,859.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Humalog revenue includes insulin lispro.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Jardiance revenue includes Glyxambi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Synjardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and Trijardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> XR.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)   </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to Emergency Use Authorizations (EUAs). </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by geographical area:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.461%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,941.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,328.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,321.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,061.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">571.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">592.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">362.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other foreign countries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">609.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,805.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,859.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenue is attributed to the countries based on the location of the customer.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of amounts recorded for contract liabilities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract liability balances:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">346.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356207378888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of the amounts recognized for assets acquired and liabilities assumed</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at January 22, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition date fair value of consideration transferred </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Fair value of CVR liability</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid, net of cash acquired</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquired IPR&amp;D intangibles primarily relate to PR001.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The goodwill recognized from this acquisition is not deductible for tax purposes. </span></div>(3) See Note 6 for a discussion on the estimation of the CVR liability.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock', window );">Schedule of asset acquisitions</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our asset acquisitions during the three months ended March&#160;31, 2021 and 2020:</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.916%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Counterparty</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compound(s) or Therapy</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition Month</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase of Development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired IPR&amp;D Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Precision Biosciences, Inc. </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development of potential in vivo therapies for genetic disorders</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">107.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merus N.V. </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CD3-engaging T-cell re-directing bispecific antibodies for the potential treatment of cancer</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asahi Kasei Pharma Corporation</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AK1780, an orally bioavailable P2X7 receptor antagonist for the potential treatment of chronic pain conditions</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rigel Pharmaceuticals, Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the potential treatment of autoimmune and inflammatory diseases</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">125.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sitryx Therapeutics Limited</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new medicines for autoimmune diseases</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.3&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbCellera Biologics Inc. (AbCellera)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neutralizing antibodies for the treatment and prevention of COVID-19</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2020</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable. </span></div>(2) We recognized an acquired IPR&amp;D expense of $25.0 million in May 2020 upon closing of the transaction.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature and amounts of capitalized costs of a research and development nature that were acquired in a transaction other than a business combination, the amount of such assets charged to expense during the period, and identification of the income statement caption in which the charges are included.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356206797048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations and Other Arrangements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of significant milestones and revenue recognized</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the net amount of significant milestones (deferred) capitalized at March 31, 2021 and December 31, 2020 for the compounds included in this collaboration: </span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Milestones (Deferred) Capitalized </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">as of:</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product Family</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">151.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(163.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In connection with the regulatory approvals of Basaglar in the U.S., Europe, and Japan, milestone payments received were recorded as contract liabilities and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. In connection with the regulatory approvals of Jardiance and Trajenta, milestone payments made were capitalized as intangible assets and are being amortized to cost of sales through the term of the collaboration. This represents the amounts that have been (deferred) or capitalized from the start of this collaboration through the end of the reporting period, net of amount amortized. </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The collaboration agreement with Boehringer Ingelheim for Jardiance ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The collaboration agreement with Boehringer Ingelheim for Trajenta ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our net product revenue recognized with respect to Basaglar and collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product Family</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">312.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">246.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">94.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>The following table summarizes our net product revenue recognized with respect to Olumiant:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olumiant</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">193.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356136225848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Impairment, Restructuring, and Other Special Charges (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">The components of the charges included in asset impairment, restructuring, and other special charges</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated condensed statements of operations are described below. </span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.192%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.036%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment and other special charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">200.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total asset impairment, restructuring, and other special charges</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">211.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356227598120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of effects of risk-management instruments were recognized in other&#8211;net, (income) expense</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following effects of risk-management instruments were recognized in other&#8211;net, (income) expense:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from hedged fixed-rate debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(81.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from interest rate contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">81.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">71.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">133.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">208.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.6)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of effective portion of risk-management instruments that was recognized in other comprehensive income (loss), net investment hedges</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Foreign currency-denominated notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">207.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">150.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Forward-starting interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">295.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(369.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of effective portion of risk-management instruments that was recognized in other comprehensive income (loss), cash flow hedges</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Foreign currency-denominated notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">207.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">150.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Forward-starting interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">295.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(369.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Summary certain fair value information</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize certain fair value information at March&#160;31, 2021 and December&#160;31, 2020 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:34.624%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other<br/>Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,554.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,554.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,554.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,554.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">20.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">20.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">20.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">20.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">18.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">18.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">18.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">18.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">49.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">109.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">108.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">109.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">109.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">177.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">175.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">177.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">177.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">102.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">99.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">102.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">102.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">23.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">23.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">23.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">23.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">110.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">30.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">110.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">110.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,645.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">386.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,645.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,645.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">384.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">679.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,232.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,097.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,097.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,097.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,097.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,664.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">311.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,664.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,664.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">373.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">471.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,966.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Summary certain fair value information, liabilities</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:38.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.916%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt, including current portion</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(16,204.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(17,462.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(17,462.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,595.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,038.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,038.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Fair value, by balance sheet grouping</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.981%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.679%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-management instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">87.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">87.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">87.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">235.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">235.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">235.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(45.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(45.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(45.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(19.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(19.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(19.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(16.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(16.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(16.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(66.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(66.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(66.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liability:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(71.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(71.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(71.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-management instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary the contractual maturities of our investments in debt securities measured at fair value</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of March&#160;31, 2021:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:40.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturities by Period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less&#160;Than<br/>1 Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1-5<br/>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6-10<br/>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More&#160;Than<br/>10 Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock', window );">Summary of the fair value of available-for-sale securities in an unrealized gain or loss position</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value of available-for-sale securities in an unrealized gain or loss position and the amount of unrealized gains and losses in accumulated other comprehensive loss follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.249%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.860%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross gains</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized gain position</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">273.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized loss position</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">170.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestmentsTextBlock', window );">Activity related to our available-for-sale securities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity related to our available-for-sale securities was as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">43.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross gains on sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross losses on sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized and unrealized gain (loss) on investment in security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrealized gains and losses on investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356137424472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefits (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Schedule of net pension and retiree health benefit (income) cost</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net pension and retiree health benefit (income) cost included the following components:</span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Pension Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of net periodic benefit cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">92.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">84.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(238.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">121.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">61.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of net periodic benefit income:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(36.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(14.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit income</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(30.9)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.7)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356206858536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of components of other comprehensive income (loss)</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the activity related to each component of other comprehensive income (loss) during the three months ended March&#160;31, 2021 and 2020:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&#160;Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&#160;Flow Hedges</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,427.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,751.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(332.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,496.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(249.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">252.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">85.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">89.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(249.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">104.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">256.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,677.2)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,646.3)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(76.6)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,395.6)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.455%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&#160;Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&#160;Flow Hedges</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2020</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,678.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,638.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,523.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(348.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(442.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(345.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(362.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,804.5)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,530.3)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(556.9)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,885.9)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects on the net activity related to each component of other comprehensive income (loss) were as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.683%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tax benefit (expense) </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation gains/losses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(75.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized net gains/losses on securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit pension and retiree health benefit plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(31.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of cash flow hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(68.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit (provision) for income taxes allocated to other comprehensive income (loss) items</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(170.3)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock', window );">Schedule of reclassifications out of accumulated other comprehensive loss</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassifications out of accumulated other comprehensive loss were as follows:</span></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:33.552%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Details about Accumulated Other Comprehensive Loss Components</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Affected Line Item in the Consolidated Condensed Statements of Operations</span></td></tr><tr style="height:6pt"><td colspan="30" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of retirement benefit items:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service benefits, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(13.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial losses, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">122.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(22.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">85.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net of tax</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">89.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356136073736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other&#8211;Net, (Income) Expense (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Nonoperating Income (Expense) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of other&#8211;net, (income) expense</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other&#8211;net, (income) expense consisted of the following:</span></div><div style="margin-bottom:12pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">87.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment gains on equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(301.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(186.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement benefit plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(73.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(28.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(321.1)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89.1)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356211091464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Summary of Revenue Recognized) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 6,805.6<span></span>
</td>
<td class="nump">$ 5,859.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">6,320.0<span></span>
</td>
<td class="nump">5,403.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CollaborationandOtherRevenueMember', window );">Collaboration and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">485.6<span></span>
</td>
<td class="nump">456.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Collaboration and other revenue associated with prior period transfers of intellectual property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 43.0<span></span>
</td>
<td class="nump">$ 35.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_CollaborationandOtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_CollaborationandOtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356136055992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Adjustments to Revenue) (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. | Sales returns, rebates, and discounts</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Change in Accounting Estimate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent', window );">Revenue, information used to determine revenue recognized, change in accounting estimate, percent (less than)</a></td>
<td class="nump">2.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=us-gaap_SalesReturnsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateByTypeAxis=us-gaap_SalesReturnsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356207428632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue (Contract Liabilities) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">$ 346.6<span></span>
</td>
<td class="nump">$ 276.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356209944120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Disaggregation of Revenue by Product) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 6,805.6<span></span>
</td>
<td class="nump">$ 5,859.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">3,941.3<span></span>
</td>
<td class="nump">3,328.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">2,864.3<span></span>
</td>
<td class="nump">2,531.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_DiabetesMember', window );">Diabetes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">3,111.1<span></span>
</td>
<td class="nump">2,968.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_DiabetesMember', window );">Diabetes | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">2,061.2<span></span>
</td>
<td class="nump">1,991.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_DiabetesMember', window );">Diabetes | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,049.9<span></span>
</td>
<td class="nump">977.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TrulicityMemberMember', window );">Trulicity&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,452.4<span></span>
</td>
<td class="nump">1,229.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TrulicityMemberMember', window );">Trulicity&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,116.8<span></span>
</td>
<td class="nump">929.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TrulicityMemberMember', window );">Trulicity&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">335.7<span></span>
</td>
<td class="nump">299.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumalogMember', window );">Humalog&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">617.0<span></span>
</td>
<td class="nump">695.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumalogMember', window );">Humalog&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">332.7<span></span>
</td>
<td class="nump">398.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumalogMember', window );">Humalog&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">284.4<span></span>
</td>
<td class="nump">297.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumulinMember', window );">Humulin&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">321.7<span></span>
</td>
<td class="nump">315.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumulinMember', window );">Humulin&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">219.0<span></span>
</td>
<td class="nump">214.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumulinMember', window );">Humulin&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">102.7<span></span>
</td>
<td class="nump">101.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_JardianceMember', window );">Jardiance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">312.0<span></span>
</td>
<td class="nump">267.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_JardianceMember', window );">Jardiance | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">151.2<span></span>
</td>
<td class="nump">144.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_JardianceMember', window );">Jardiance | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">160.8<span></span>
</td>
<td class="nump">122.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_BasaglarMember', window );">Basaglar&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">246.6<span></span>
</td>
<td class="nump">303.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_BasaglarMember', window );">Basaglar&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">175.2<span></span>
</td>
<td class="nump">230.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_BasaglarMember', window );">Basaglar&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">71.4<span></span>
</td>
<td class="nump">73.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherDiabetesMember', window );">Other Diabetes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">161.4<span></span>
</td>
<td class="nump">156.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherDiabetesMember', window );">Other Diabetes | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">66.3<span></span>
</td>
<td class="nump">74.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherDiabetesMember', window );">Other Diabetes | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">94.9<span></span>
</td>
<td class="nump">82.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OncologyMember', window );">Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,372.2<span></span>
</td>
<td class="nump">1,201.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OncologyMember', window );">Oncology | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">642.5<span></span>
</td>
<td class="nump">657.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OncologyMember', window );">Oncology | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">729.7<span></span>
</td>
<td class="nump">543.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_AlimtaMember', window );">Alimta&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">559.0<span></span>
</td>
<td class="nump">560.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_AlimtaMember', window );">Alimta&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">261.1<span></span>
</td>
<td class="nump">324.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_AlimtaMember', window );">Alimta&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">297.8<span></span>
</td>
<td class="nump">235.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_VerzenioMember', window );">Verzenio&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">269.0<span></span>
</td>
<td class="nump">188.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_VerzenioMember', window );">Verzenio&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">172.8<span></span>
</td>
<td class="nump">129.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_VerzenioMember', window );">Verzenio&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">96.2<span></span>
</td>
<td class="nump">58.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CyramzaMember', window );">Cyramza&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">240.5<span></span>
</td>
<td class="nump">239.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CyramzaMember', window );">Cyramza&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">80.2<span></span>
</td>
<td class="nump">89.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CyramzaMember', window );">Cyramza&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">160.3<span></span>
</td>
<td class="nump">149.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ErbituxMember', window );">Erbitux&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">122.4<span></span>
</td>
<td class="nump">130.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ErbituxMember', window );">Erbitux&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">107.9<span></span>
</td>
<td class="nump">117.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ErbituxMember', window );">Erbitux&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">14.4<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TYVYTMember', window );">Tyvyt&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">109.7<span></span>
</td>
<td class="nump">57.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TYVYTMember', window );">Tyvyt&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TYVYTMember', window );">Tyvyt&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">109.7<span></span>
</td>
<td class="nump">57.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherOncologyMember', window );">Other Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">71.6<span></span>
</td>
<td class="nump">26.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherOncologyMember', window );">Other Oncology | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">20.5<span></span>
</td>
<td class="num">(2.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherOncologyMember', window );">Other Oncology | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">51.3<span></span>
</td>
<td class="nump">28.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ImmunologyMember', window );">Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">613.9<span></span>
</td>
<td class="nump">585.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ImmunologyMember', window );">Immunology | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">284.8<span></span>
</td>
<td class="nump">341.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ImmunologyMember', window );">Immunology | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">329.1<span></span>
</td>
<td class="nump">244.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TaltzMember', window );">Taltz&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">403.2<span></span>
</td>
<td class="nump">443.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TaltzMember', window );">Taltz&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">249.6<span></span>
</td>
<td class="nump">327.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TaltzMember', window );">Taltz&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">153.6<span></span>
</td>
<td class="nump">116.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">193.8<span></span>
</td>
<td class="nump">139.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">24.7<span></span>
</td>
<td class="nump">11.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">169.1<span></span>
</td>
<td class="nump">128.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherImmunologyMember', window );">Other Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">16.9<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherImmunologyMember', window );">Other Immunology | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">10.5<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherImmunologyMember', window );">Other Immunology | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">6.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_NeuroscienceMember', window );">Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">465.4<span></span>
</td>
<td class="nump">463.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_NeuroscienceMember', window );">Neuroscience | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">141.7<span></span>
</td>
<td class="nump">110.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_NeuroscienceMember', window );">Neuroscience | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">323.7<span></span>
</td>
<td class="nump">353.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CymbaltaMember', window );">Cymbalta&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">176.6<span></span>
</td>
<td class="nump">210.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CymbaltaMember', window );">Cymbalta&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">11.0<span></span>
</td>
<td class="nump">11.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CymbaltaMember', window );">Cymbalta&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">165.7<span></span>
</td>
<td class="nump">198.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_EmgalityMember', window );">Emgality&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">119.5<span></span>
</td>
<td class="nump">74.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_EmgalityMember', window );">Emgality&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">101.5<span></span>
</td>
<td class="nump">67.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_EmgalityMember', window );">Emgality&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">18.0<span></span>
</td>
<td class="nump">6.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ZyprexaMember', window );">Zyprexa&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">95.8<span></span>
</td>
<td class="nump">98.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ZyprexaMember', window );">Zyprexa&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">6.9<span></span>
</td>
<td class="nump">11.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ZyprexaMember', window );">Zyprexa&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">88.9<span></span>
</td>
<td class="nump">87.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherNeuroscienceMember', window );">Other Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">73.5<span></span>
</td>
<td class="nump">80.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherNeuroscienceMember', window );">Other Neuroscience | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">22.3<span></span>
</td>
<td class="nump">20.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherNeuroscienceMember', window );">Other Neuroscience | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">51.1<span></span>
</td>
<td class="nump">60.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherProductTotalMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,242.9<span></span>
</td>
<td class="nump">640.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherProductTotalMember', window );">Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">811.1<span></span>
</td>
<td class="nump">228.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherProductTotalMember', window );">Other | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">431.8<span></span>
</td>
<td class="nump">412.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember', window );">COVID-19 Antibodies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">810.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember', window );">COVID-19 Antibodies | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">650.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember', window );">COVID-19 Antibodies | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">159.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ForteoMember', window );">Forteo&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">198.5<span></span>
</td>
<td class="nump">272.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ForteoMember', window );">Forteo&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">97.7<span></span>
</td>
<td class="nump">122.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ForteoMember', window );">Forteo&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">100.8<span></span>
</td>
<td class="nump">149.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CialisMember', window );">Cialis&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">126.8<span></span>
</td>
<td class="nump">193.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CialisMember', window );">Cialis&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">8.6<span></span>
</td>
<td class="nump">26.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CialisMember', window );">Cialis&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">118.1<span></span>
</td>
<td class="nump">167.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherProductMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">107.5<span></span>
</td>
<td class="nump">174.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherProductMember', window );">Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">54.2<span></span>
</td>
<td class="nump">79.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherProductMember', window );">Other | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 53.4<span></span>
</td>
<td class="nump">$ 95.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_DiabetesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_DiabetesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_TrulicityMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_TrulicityMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_HumalogMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_HumalogMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_HumulinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_HumulinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_JardianceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_JardianceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_BasaglarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_BasaglarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OtherDiabetesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OtherDiabetesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_AlimtaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_AlimtaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_VerzenioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_VerzenioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_CyramzaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_CyramzaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_ErbituxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_ErbituxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_TYVYTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_TYVYTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OtherOncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OtherOncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_ImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_ImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_TaltzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_TaltzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OlumiantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OlumiantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OtherImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OtherImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_NeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_NeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_CymbaltaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_CymbaltaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_EmgalityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_EmgalityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_ZyprexaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_ZyprexaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OtherNeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OtherNeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OtherProductTotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OtherProductTotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_ForteoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_ForteoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_CialisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_CialisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OtherProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OtherProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356210816920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Disaggregation of Revenue by Geographical Area) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 6,805.6<span></span>
</td>
<td class="nump">$ 5,859.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">3,941.3<span></span>
</td>
<td class="nump">3,328.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,321.2<span></span>
</td>
<td class="nump">1,061.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">571.8<span></span>
</td>
<td class="nump">592.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">362.2<span></span>
</td>
<td class="nump">267.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=lly_OtherForeignCountriesMember', window );">Other foreign countries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 609.1<span></span>
</td>
<td class="nump">$ 610.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=lly_OtherForeignCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=lly_OtherForeignCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356211341656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Narrative) (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($) </div>
<div>right </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 299.3<span></span>
</td>
<td class="nump">$ 52.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">747.4<span></span>
</td>
<td class="nump">849.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,877.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,766.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 276.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_PrevailTherapeuticsIncMember', window );">Prevail Therapeutics Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business acquisition, share price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 22.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid, net of cash acquired</a></td>
<td class="nump">$ 747.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights', window );">Consideration transferred, number of contingent value rights | right</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare', window );">Contingent value right, additional price per share (up to) (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Contingent value right, additional price per share, aggregate amount</a></td>
<td class="nump">$ 160.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction', window );">Contingent value right, monthly reduction (in cents per share) | $ / shares</a></td>
<td class="nump">$ 0.083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 111.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquired IPR&amp;D</a></td>
<td class="nump">834.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income taxes assumed</a></td>
<td class="nump">$ 100.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_DermiraInc.Member', window );">Dermira</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 849.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income taxes assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt', window );">Long-term debt assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 375.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 276.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Contingent Value Right, Additional Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Contingent Value Right, Covenant, Regulatory Approval Occurs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Number Of Contingent Value Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_PrevailTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_PrevailTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_DermiraInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_DermiraInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356211371016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Assets Acquired and Liabilities Assumed) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,877.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,766.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 747.4<span></span>
</td>
<td class="nump">$ 849.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_PrevailTherapeuticsIncMember', window );">Prevail Therapeutics Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="nump">$ 90.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquired IPR&amp;D</a></td>
<td class="nump">834.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">111.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(100.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet', window );">Other assets and liabilities, net</a></td>
<td class="num">(31.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Acquisition date fair value of consideration transferred</a></td>
<td class="nump">903.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash acquired</a></td>
<td class="num">(90.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability', window );">Fair value of CVR liability</a></td>
<td class="num">(65.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid, net of cash acquired</a></td>
<td class="nump">$ 747.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_PrevailTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_PrevailTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356211618472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Asset Acquisitions) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 299.3<span></span>
</td>
<td class="nump">$ 52.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_PrecisionBiosciencesIncMember', window );">Precision Biosciences, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_MerusNVMember', window );">Merus N.V.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_AsahiKaseiPharmaCorporationMember', window );">Asahi Kasei Pharma Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_RigelPharmaceuticalsIncMember', window );">Rigel Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D Expense</a></td>
<td class="nump">$ 125.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_SitryxTherapeuticsLimitedMember', window );">Sitryx Therapeutics Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_AbCelleraBiologicsInc.Member', window );">AbCellera Biologics Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_PrecisionBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_PrecisionBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_MerusNVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_MerusNVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_AsahiKaseiPharmaCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_AsahiKaseiPharmaCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_RigelPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_RigelPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_SitryxTherapeuticsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_SitryxTherapeuticsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_AbCelleraBiologicsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_AbCelleraBiologicsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356210742568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations and Other Arrangements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 6,805.6<span></span>
</td>
<td class="nump">$ 5,859.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">346.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 276.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">362.2<span></span>
</td>
<td class="nump">267.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">2,864.3<span></span>
</td>
<td class="nump">2,531.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_JardianceMember', window );">Jardiance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">312.0<span></span>
</td>
<td class="nump">267.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_JardianceMember', window );">Jardiance | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">160.8<span></span>
</td>
<td class="nump">122.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TrajentaBIMember', window );">Trajenta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">94.6<span></span>
</td>
<td class="nump">93.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_BasaglarMember', window );">Basaglar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">246.6<span></span>
</td>
<td class="nump">303.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_BasaglarMember', window );">Basaglar | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">71.4<span></span>
</td>
<td class="nump">73.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">193.8<span></span>
</td>
<td class="nump">139.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">169.1<span></span>
</td>
<td class="nump">128.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember', window );">COVID-19 Antibodies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">810.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember', window );">COVID-19 Antibodies | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">159.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TYVYTMember', window );">Tyvyt&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">109.7<span></span>
</td>
<td class="nump">57.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TYVYTMember', window );">Tyvyt&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">109.7<span></span>
</td>
<td class="nump">$ 57.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TanezumabMember', window );">Tanezumab | Outside US And Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold', window );">Collaborative arrangement, rights and obligations, terms, annual net sales threshold (up to)</a></td>
<td class="nump">150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_LebrikizumabMember', window );">Lebrikizumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">23.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember', window );">Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative | Jardiance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones capitalized</a></td>
<td class="nump">151.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember', window );">Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative | Trajenta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones capitalized</a></td>
<td class="nump">108.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember', window );">Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative | Basaglar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones capitalized</a></td>
<td class="num">$ (163.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (168.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_RoyaltyAgreementTermsMember', window );">Royalty Agreement Terms | Olumiant&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsPercent', window );">Collaborative arrangement, rights and obligations, percentage (up to)</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember', window );">Milestone Payments, Capitalized as Intangible Assets | Shanghai Junshi Biosciences Co., Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones capitalized</a></td>
<td class="nump">$ 60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember', window );">Milestone Payments, Capitalized as Intangible Assets | Olumiant&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones capitalized</a></td>
<td class="nump">210.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentAndRegulatoryMember', window );">Milestone Payments, Development and Regulatory | Olumiant&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones capitalized</a></td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentAndRegulatoryMember', window );">Milestone Payments, Development and Regulatory | Tanezumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones capitalized</a></td>
<td class="nump">147.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentAndRegulatoryMember', window );">Milestone Payments, Development and Regulatory | Lebrikizumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones capitalized</a></td>
<td class="nump">85.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSalesBasedMember', window );">Milestone Payments, Sales-based | Shanghai Junshi Biosciences Co., Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones capitalized</a></td>
<td class="nump">120.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSalesBasedMember', window );">Milestone Payments, Sales-based | Olumiant&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones capitalized</a></td>
<td class="nump">150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSalesBasedMember', window );">Milestone Payments, Sales-based | Tanezumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones capitalized</a></td>
<td class="nump">1,230.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSalesBasedMember', window );">Milestone Payments, Sales-based | Lebrikizumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones capitalized</a></td>
<td class="nump">1,250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSuccessBasedRegulatoryMember', window );">Milestone Payments, Success-based Regulatory | Shanghai Junshi Biosciences Co., Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones capitalized</a></td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=lly_InnoventBiologicsIncMember', window );">Innovent Biologics, Inc. | Milestone Payments, Success-based Regulatory and Sales-based | Tyvyt&#174; | Non-CHINA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones capitalized</a></td>
<td class="nump">825.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=lly_InnoventBiologicsIncMember', window );">Innovent Biologics, Inc. | Milestone Payments, Success-based Regulatory and Sales-based | Tyvyt&#174; | China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones capitalized</a></td>
<td class="nump">235.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=lly_RocheMember', window );">Roche | Milestone Payments, Development and Regulatory | Lebrikizumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones capitalized</a></td>
<td class="nump">180.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=lly_RocheMember', window );">Roche | Milestone Payments, Sales-based | Lebrikizumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Milestones capitalized</a></td>
<td class="nump">$ 1,030.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_CollaborativeArrangementRightsAndObligationsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of rights and obligations under the collaborative arrangements, including but not limited to - percent share in various revenues and costs, percent interest earned on related party notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_CollaborativeArrangementRightsAndObligationsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Terms or rights and obligations under collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_CollaborativeArrangementRightsAndObligationsRightsObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Terms, Annual Net Sales Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_JardianceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_JardianceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_TrajentaBIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_TrajentaBIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_BasaglarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_BasaglarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OlumiantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OlumiantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_TYVYTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_TYVYTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_TanezumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_TanezumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=lly_OutsideUSAndJapanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=lly_OutsideUSAndJapanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_LebrikizumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_LebrikizumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_RoyaltyAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_RoyaltyAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_JunshiBiosciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_JunshiBiosciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentAndRegulatoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentAndRegulatoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSalesBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSalesBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSuccessBasedRegulatoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSuccessBasedRegulatoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=lly_InnoventBiologicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=lly_InnoventBiologicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=lly_NonCHINAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=lly_NonCHINAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=lly_RocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=lly_RocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356212515288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Impairment, Restructuring, and Other Special Charges (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance</a></td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="nump">$ 9.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges', window );">Asset impairment and other special charges</a></td>
<td class="nump">200.1<span></span>
</td>
<td class="nump">50.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringSettlementAndImpairmentProvisions', window );">Total asset impairment, restructuring, and other special charges</a></td>
<td class="nump">211.6<span></span>
</td>
<td class="nump">$ 59.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Intangible asset impairment</a></td>
<td class="nump">$ 108.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Impairment Charges (Recoveries) And Other Special Charges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringSettlementAndImpairmentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of restructuring charges, remediation cost, and asset impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringSettlementAndImpairmentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356208406184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Narrative) (Details)<br> &#8364; in Millions, &#165; in Millions, &#163; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>JPY (&#165;)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1', window );">Maximum remaining maturity of foreign currency derivatives</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax', window );">Derivatives used in net investment hedge, net of tax</a></td>
<td class="nump">$ 4,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DescriptionOfDerivativeActivityVolumePercent', window );">Percentage of long-term fixed-rate notes to floating rates through the use of interest rate swaps converted</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet', window );">Pretax net losses on cash flow hedges expected to be reclassified during the next 12 months</a></td>
<td class="nump">$ 16.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments', window );">Alternative investments, unfunded commitments</a></td>
<td class="nump">$ 736.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod', window );">Alternative investments, unfunded commitments, payment period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Equity securities, net unrealized gains</a></td>
<td class="nump">$ 301.5<span></span>
</td>
<td class="nump">$ 186.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets', window );">Available-for-sale, percentage of nonperforming assets</a></td>
<td class="nump">94.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized', window );">Amount of receivable derecognized</a></td>
<td class="nump">$ 637.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">754.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUsDollarSellEuroMember', window );">Buy U.S. Dollars Sell Euros</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount</a></td>
<td class="nump">1,110.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 941.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyEuroSellUsDollarMember', window );">Buy Euros Sell U.S. Dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,190.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="nump">4,980.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUSdollarSellJapaneseYenMember', window );">Buy U.S. Dollars Sell Japanese Yen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount</a></td>
<td class="nump">140.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 15,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyBritishPoundandSellUSDollarsMember', window );">Buy British Pounds and Sell U.S. Dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 285.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="nump">396.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_SwapU.S.DollarsToEuroMember', window );">Swap U.S. Dollars to Euro</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">3,790.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_SwapSwissFrancsToU.S.DollarsMember', window );">Swap Swiss Francs to U.S. Dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember', window );">Foreign Currency Denominated Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, including current portion</a></td>
<td class="nump">5,720.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,020.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Cash Flow Hedging | Forward-starting interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">$ 1,750.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DescriptionOfDerivativeActivityVolumePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Label: Description of Derivative Activity Volume Element ID: us-gaap_DescriptionOfDerivativeActivityVolume Balance Type: na Data Type: PERCENT Period Type: duration --------------------------------------------------------------------- Definition: Information that would enable users to understand the volume of the entity's derivative activity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 133 -Paragraph 44 -Subparagraph 2</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DescriptionOfDerivativeActivityVolumePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the percentage of nonperforming assets that the underlying assets in the security represent and which were considered as one of the potential factors in reaching a conclusion that the available-for-sale investments are not other-than-temporarily impaired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of unfunded commitments for which the entity is obligated, to those certain investments for which net asset value per share is calculated (including by unit, membership interest, or other equity (ownership interest) unit measure) (alternative investments).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=SL6742756-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of time remaining before foreign currency exchange rate derivatives mature or expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction, at the date of derecognition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of cumulative translation adjustment attributable to gain (loss) on foreign currency derivatives that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUsDollarSellEuroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUsDollarSellEuroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyEuroSellUsDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_BuyEuroSellUsDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUSdollarSellJapaneseYenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUSdollarSellJapaneseYenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyBritishPoundandSellUSDollarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_BuyBritishPoundandSellUSDollarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_SwapU.S.DollarsToEuroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_SwapU.S.DollarsToEuroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_SwapSwissFrancsToU.S.DollarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_SwapSwissFrancsToU.S.DollarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356211153752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Effect of Risk-Management Instruments) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DerivativeInstrumentsGainLossRecognized', window );">Total</a></td>
<td class="nump">$ 208.6<span></span>
</td>
<td class="num">$ (14.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_HedgedFixedRateDebtMember', window );">Foreign currency-denominated notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss), net investment hedges</a></td>
<td class="nump">207.7<span></span>
</td>
<td class="nump">67.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember', window );">Cross-currency interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss), net investment hedges</a></td>
<td class="nump">150.6<span></span>
</td>
<td class="nump">115.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss), cash flow hedges</a></td>
<td class="nump">26.3<span></span>
</td>
<td class="num">(69.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Forward-starting interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss), cash flow hedges</a></td>
<td class="nump">295.1<span></span>
</td>
<td class="num">(369.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Foreign currency-denominated notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_FairValueHedgeAbstract', window );"><strong>Fair value hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1', window );">Effect from hedged fixed-rate debt</a></td>
<td class="num">(81.5)<span></span>
</td>
<td class="nump">117.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Interest rate contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_FairValueHedgeAbstract', window );"><strong>Fair value hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1', window );">Effect from interest rate contracts</a></td>
<td class="nump">81.5<span></span>
</td>
<td class="num">(117.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">4.1<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Cross-currency interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">71.5<span></span>
</td>
<td class="num">(12.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument | Foreign currency exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments</a></td>
<td class="nump">$ 133.0<span></span>
</td>
<td class="num">$ (5.7)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_CashFlowHedgeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Flow Hedge [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_CashFlowHedgeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DerivativeInstrumentsGainLossRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative Instruments, Gain (Loss) Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DerivativeInstrumentsGainLossRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_FairValueHedgeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Hedge [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_FairValueHedgeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_HedgedFixedRateDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_HedgedFixedRateDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356210290856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Fair Value of Financial Instruments) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Noncurrent investments</a></td>
<td class="nump">$ 3,232.4<span></span>
</td>
<td class="nump">$ 2,966.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,554.5<span></span>
</td>
<td class="nump">2,097.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">49.0<span></span>
</td>
<td class="nump">24.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity investments without readily determinable fair values</a></td>
<td class="nump">384.3<span></span>
</td>
<td class="nump">373.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Noncurrent investments</a></td>
<td class="nump">3,232.4<span></span>
</td>
<td class="nump">2,966.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, including current portion</a></td>
<td class="num">(16,204.5)<span></span>
</td>
<td class="num">(16,595.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">20.9<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">109.1<span></span>
</td>
<td class="nump">78.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">7.6<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">177.8<span></span>
</td>
<td class="nump">137.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">23.8<span></span>
</td>
<td class="nump">24.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Other securities, current investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">18.2<span></span>
</td>
<td class="nump">10.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">102.3<span></span>
</td>
<td class="nump">106.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Other securities, noncurrent investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">110.3<span></span>
</td>
<td class="nump">110.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">1,645.5<span></span>
</td>
<td class="nump">1,664.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Equity method investments</a></td>
<td class="nump">679.3<span></span>
</td>
<td class="nump">471.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,554.5<span></span>
</td>
<td class="nump">2,097.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Cost | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">20.8<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">108.8<span></span>
</td>
<td class="nump">74.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Cost | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">7.5<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">175.5<span></span>
</td>
<td class="nump">126.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Cost | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">23.5<span></span>
</td>
<td class="nump">23.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Cost | Other securities, current investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">18.2<span></span>
</td>
<td class="nump">10.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Cost | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">99.7<span></span>
</td>
<td class="nump">101.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Cost | Other securities, noncurrent investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">30.1<span></span>
</td>
<td class="nump">31.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Cost | Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">386.1<span></span>
</td>
<td class="nump">311.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,554.5<span></span>
</td>
<td class="nump">2,097.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, including current portion</a></td>
<td class="num">(17,462.6)<span></span>
</td>
<td class="num">(19,038.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,554.5<span></span>
</td>
<td class="nump">2,097.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, including current portion</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, including current portion</a></td>
<td class="num">(17,462.6)<span></span>
</td>
<td class="num">(19,038.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, including current portion</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">20.9<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">109.1<span></span>
</td>
<td class="nump">78.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | U.S. government and agency securities | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">20.9<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">109.1<span></span>
</td>
<td class="nump">78.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | U.S. government and agency securities | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | U.S. government and agency securities | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">7.6<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">177.8<span></span>
</td>
<td class="nump">137.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Corporate debt securities | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Corporate debt securities | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">7.6<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">177.8<span></span>
</td>
<td class="nump">137.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Corporate debt securities | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">23.8<span></span>
</td>
<td class="nump">24.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Asset-backed securities | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Asset-backed securities | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">23.8<span></span>
</td>
<td class="nump">24.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Asset-backed securities | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Other securities, current investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">18.2<span></span>
</td>
<td class="nump">10.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Other securities, current investments | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">18.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Other securities, current investments | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Other securities, current investments | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">10.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">102.3<span></span>
</td>
<td class="nump">106.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Mortgage-backed securities | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Mortgage-backed securities | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">102.3<span></span>
</td>
<td class="nump">106.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Mortgage-backed securities | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Other securities, noncurrent investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">110.3<span></span>
</td>
<td class="nump">110.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Other securities, noncurrent investments | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Other securities, noncurrent investments | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Other securities, noncurrent investments | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">110.3<span></span>
</td>
<td class="nump">110.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">1,645.5<span></span>
</td>
<td class="nump">1,664.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Marketable equity securities | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">1,645.5<span></span>
</td>
<td class="nump">1,664.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Marketable equity securities | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Marketable equity securities | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=lly_OtherEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=lly_OtherEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=lly_MarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=lly_MarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=lly_EquityMethodAndOtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=lly_EquityMethodAndOtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356209745768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Risk Management Instruments) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability, other noncurrent liabilities</a></td>
<td class="num">$ (71.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">14.8<span></span>
</td>
<td class="nump">$ 41.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(66.2)<span></span>
</td>
<td class="num">(15.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability, other noncurrent liabilities</a></td>
<td class="num">(71.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability, other noncurrent liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability, other noncurrent liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability, other noncurrent liabilities</a></td>
<td class="num">(71.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">14.8<span></span>
</td>
<td class="nump">41.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(66.2)<span></span>
</td>
<td class="num">(15.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Foreign currency exchange contracts | Not Designated as Hedging Instrument | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Foreign currency exchange contracts | Not Designated as Hedging Instrument | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">14.8<span></span>
</td>
<td class="nump">41.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(66.2)<span></span>
</td>
<td class="num">(15.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Foreign currency exchange contracts | Not Designated as Hedging Instrument | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Carrying Amount | Interest rate contracts | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">87.2<span></span>
</td>
<td class="nump">158.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(9.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Estimate of Fair Value Measurement | Interest rate contracts | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">87.2<span></span>
</td>
<td class="nump">158.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(9.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Estimate of Fair Value Measurement | Interest rate contracts | Designated as Hedging Instrument | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Estimate of Fair Value Measurement | Interest rate contracts | Designated as Hedging Instrument | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">87.2<span></span>
</td>
<td class="nump">158.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(9.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Estimate of Fair Value Measurement | Interest rate contracts | Designated as Hedging Instrument | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Carrying Amount | Interest rate contracts | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">235.4<span></span>
</td>
<td class="nump">38.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(97.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Carrying Amount | Cross-currency interest rate swaps | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">34.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(16.8)<span></span>
</td>
<td class="num">(2.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Estimate of Fair Value Measurement | Interest rate contracts | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">235.4<span></span>
</td>
<td class="nump">38.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(97.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Estimate of Fair Value Measurement | Interest rate contracts | Designated as Hedging Instrument | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Estimate of Fair Value Measurement | Interest rate contracts | Designated as Hedging Instrument | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">235.4<span></span>
</td>
<td class="nump">38.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(97.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Estimate of Fair Value Measurement | Interest rate contracts | Designated as Hedging Instrument | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">34.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(16.8)<span></span>
</td>
<td class="num">(2.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">34.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(16.8)<span></span>
</td>
<td class="num">(2.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net investment hedges | Carrying Amount | Cross-currency interest rate swaps | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">39.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">12.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(45.5)<span></span>
</td>
<td class="num">(92.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(19.1)<span></span>
</td>
<td class="num">(97.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net investment hedges | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">39.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">12.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(45.5)<span></span>
</td>
<td class="num">(92.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(19.1)<span></span>
</td>
<td class="num">(97.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net investment hedges | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net investment hedges | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">39.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">12.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(45.5)<span></span>
</td>
<td class="num">(92.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(19.1)<span></span>
</td>
<td class="num">(97.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net investment hedges | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356135945768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Contractual Maturities) (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">$ 443.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Less&#160;Than 1 Year</a></td>
<td class="nump">30.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">1-5 Years</a></td>
<td class="nump">147.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">6-10 Years</a></td>
<td class="nump">125.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue', window );">More&#160;Than 10 Years</a></td>
<td class="nump">$ 139.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356215093528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Unrealized Gains and Losses) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gross gains</a></td>
<td class="nump">$ 12.0<span></span>
</td>
<td class="nump">$ 20.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized gross losses</a></td>
<td class="nump">6.3<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition', window );">Fair value of securities in an unrealized gain position</a></td>
<td class="nump">273.6<span></span>
</td>
<td class="nump">348.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair value of securities in an unrealized loss position</a></td>
<td class="nump">$ 170.1<span></span>
</td>
<td class="nump">$ 11.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale, Unrealized Gain Position</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356206795224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Realized Gains and Losses) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities', window );">Proceeds from sales</a></td>
<td class="nump">$ 43.3<span></span>
</td>
<td class="nump">$ 38.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain', window );">Realized gross gains on sales</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss', window );">Realized gross losses on sales</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available for Sale Securities and Equity Securities, FV-NI, Realized Gain</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available for sale Securities and Equity Securities, FV-NI, Realized Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Sale of Equity and Available for Sale Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356206754776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate, percentage</a></td>
<td class="nump">8.20%<span></span>
</td>
<td class="nump">13.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356212349944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefits (Components of Net Periodic Benefit Cost) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">$ 92.0<span></span>
</td>
<td class="nump">$ 78.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">84.3<span></span>
</td>
<td class="nump">105.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(238.0)<span></span>
</td>
<td class="num">(221.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service cost</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit', window );">Recognized actuarial loss</a></td>
<td class="nump">121.8<span></span>
</td>
<td class="nump">111.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="nump">61.2<span></span>
</td>
<td class="nump">74.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">11.7<span></span>
</td>
<td class="nump">9.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">8.1<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(36.6)<span></span>
</td>
<td class="num">(37.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service cost</a></td>
<td class="num">(14.9)<span></span>
</td>
<td class="num">(14.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit', window );">Recognized actuarial loss</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="num">$ (30.9)<span></span>
</td>
<td class="num">$ (30.7)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss), recognized immediately as component of net periodic benefit (cost) credit, for change in value of benefit obligation or plan assets from experience different from that assumed, change in actuarial assumption, or consequence of temporarily deviating from substantive plan. Includes, but is not limited to, amount in excess of ten percent of greater of fair value of plan assets or benefit obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356206760920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefits (Narrative) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionContributions', window );">Pension contributions</a></td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_PaymentforPensionBenefitsAdditionalDiscretionaryFunding', window );">Payment for additional discretionary funding</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear', window );">Estimated future employer contributions in current fiscal year</a></td>
<td class="nump">$ 20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_PaymentforPensionBenefitsAdditionalDiscretionaryFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment for Pension Benefits, Additional Discretionary Funding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_PaymentforPensionBenefitsAdditionalDiscretionaryFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution expected to be received by defined benefit plan from employer in remainder of current fiscal year. Excludes contribution previously paid by employer in current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356208263592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies (Details)<br> R$ in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1">145 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>BRL (R$) </div>
<div>lawsuit </div>
<div>request </div>
<div>claimant </div>
<div>patent </div>
<div>site</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>lawsuit </div>
<div>request </div>
<div>claimant </div>
<div>patent </div>
<div>site</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>patent</div>
</th>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>patent</div>
</th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>BRL (R$)</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>BRL (R$)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>request </div>
<div>lawsuit </div>
<div>claimant </div>
<div>plaintiff </div>
<div>patent </div>
<div>site</div>
</th>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Jan. 31, 2013 </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Jul. 31, 2012 </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Dec. 31, 2011 </div>
<div>lawsuit</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_LossContingencyNumberOfRequestsForInformation', window );">Number of requests for information | request</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_UnfavorableRegulatoryActionMember', window );">Unfavorable Regulatory Action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup', window );">Number of sites jointly and severally liable for cleanup (fewer than) | site</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ActosMember', window );">Actos | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ByettaMember', window );">Byetta | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="nump">570<span></span>
</td>
<td class="nump">570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_LossContingencyNumberOfClaimants', window );">Number of claimants | claimant</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ByettaMember', window );">Byetta | Pancreatic Cancer or Thyroid Cancer | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="nump">565<span></span>
</td>
<td class="nump">565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ByettaMember', window );">Byetta | Pancreatitis | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ByettaMember', window );">Byetta | Ampullary Cancer | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ByettaMember', window );">Byetta | Los Angeles | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ByettaMember', window );">Byetta | Southern District of California | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="nump">515<span></span>
</td>
<td class="nump">515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ByettaMember', window );">Byetta | Various State Domiciles | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CialisMember', window );">Cialis&#174; | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="nump">350<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_JardianceMember', window );">Jardiance | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumalogHumulinAndForteoMember', window );">Humalog, Humulin and Forteo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=lly_DrReddysLabMember', window );">Dr Reddy's Lab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm', window );">Limited initial market entry, supply term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=lly_EmgalityPatentLitigationMember', window );">Emgality Patent Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_LossContingencyNumberOfPatents', window );">Number of patents | patent</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_LossContingencyNumberOfPatentsClaimsDismissed', window );">Number of patents, claims dismissed | patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_LossContingencyNumberOfPatentsRuledUnpatentable', window );">Number of patents ruled unpatentable | patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember', window );">Casseres et al. v. Takeda Pharmaceutical North America, Inc., et al. | Actos | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=lly_WhyteEtAlVEliLillyEtAlMember', window );">Weiler v. Takeda Canada Inc. et al. | Actos | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=lly_WeilerVTakedaCanadaIncEtAlMember', window );">Weiler v. Takeda Canada Inc. et al. | Actos | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=lly_EppVTakedaCanadaIncEtAlMember', window );">Epp v. Takeda Canada Inc. et al. | Actos | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_BR', window );">Brazil | Employee Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded, value</a></td>
<td class="nump">R$ 950<span></span>
</td>
<td class="nump">$ 165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">R$ 500<span></span>
</td>
<td class="nump">R$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Claims Settled And Dismissed, Limited Initial Market Entry, Supply Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_LossContingencyNumberOfClaimants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Claimants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_LossContingencyNumberOfClaimants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_LossContingencyNumberOfPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Patents</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_LossContingencyNumberOfPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_LossContingencyNumberOfPatentsClaimsDismissed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Patents, Claims Dismissed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_LossContingencyNumberOfPatentsClaimsDismissed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_LossContingencyNumberOfPatentsRuledUnpatentable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Patents Ruled Unpatentable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_LossContingencyNumberOfPatentsRuledUnpatentable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_LossContingencyNumberOfRequestsForInformation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Requests For Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_LossContingencyNumberOfRequestsForInformation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of plaintiffs that have filed claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_UnfavorableRegulatoryActionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_UnfavorableRegulatoryActionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_ActosMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_ActosMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=lly_ProductLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=lly_ProductLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_ByettaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_ByettaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_PlaintiffAllegationsAxis=lly_PancreaticCancerOrThyroidCancerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_PlaintiffAllegationsAxis=lly_PancreaticCancerOrThyroidCancerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_PlaintiffAllegationsAxis=lly_PancreatitisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_PlaintiffAllegationsAxis=lly_PancreatitisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_PlaintiffAllegationsAxis=lly_AmpullaryCancerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_PlaintiffAllegationsAxis=lly_AmpullaryCancerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DomicileOfLitigationAxis=lly_LosAngelesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DomicileOfLitigationAxis=lly_LosAngelesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DomicileOfLitigationAxis=lly_SouthernDistrictOfCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DomicileOfLitigationAxis=lly_SouthernDistrictOfCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DomicileOfLitigationAxis=lly_VariousStateDomicilesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DomicileOfLitigationAxis=lly_VariousStateDomicilesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_CialisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_CialisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_JardianceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_JardianceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_HumalogHumulinAndForteoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_HumalogHumulinAndForteoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lly_DrReddysLabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lly_DrReddysLabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lly_EmgalityPatentLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lly_EmgalityPatentLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lly_WhyteEtAlVEliLillyEtAlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lly_WhyteEtAlVEliLillyEtAlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lly_WeilerVTakedaCanadaIncEtAlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lly_WeilerVTakedaCanadaIncEtAlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lly_EppVTakedaCanadaIncEtAlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lly_EppVTakedaCanadaIncEtAlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lly_EmployeeLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lly_EmployeeLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356215719864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss) (AOCI) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">$ 5,825.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">11.1<span></span>
</td>
<td class="num">$ (442.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amount reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">89.7<span></span>
</td>
<td class="nump">80.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="nump">100.8<span></span>
</td>
<td class="num">(362.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">7,099.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(6,496.4)<span></span>
</td>
<td class="num">(6,523.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(6,395.6)<span></span>
</td>
<td class="num">(6,885.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Foreign Currency Translation Gains&#160;(Losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(1,427.5)<span></span>
</td>
<td class="num">(1,678.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(249.7)<span></span>
</td>
<td class="num">(126.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amount reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="num">(249.7)<span></span>
</td>
<td class="num">(126.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(1,677.2)<span></span>
</td>
<td class="num">(1,804.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember', window );">Unrealized Net Gains (Losses) on&#160;Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">14.8<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(10.8)<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amount reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="num">(10.3)<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">4.5<span></span>
</td>
<td class="nump">5.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(4,751.0)<span></span>
</td>
<td class="num">(4,638.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">18.8<span></span>
</td>
<td class="nump">30.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amount reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">85.9<span></span>
</td>
<td class="nump">77.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="nump">104.7<span></span>
</td>
<td class="nump">108.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(4,646.3)<span></span>
</td>
<td class="num">(4,530.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember', window );">Effective Portion of Cash&#160;Flow Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(332.7)<span></span>
</td>
<td class="num">(211.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">252.8<span></span>
</td>
<td class="num">(348.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amount reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="nump">256.1<span></span>
</td>
<td class="num">(345.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">$ (76.6)<span></span>
</td>
<td class="num">$ (556.9)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17B<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL34724394-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356211612440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss) (Tax Effect) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Benefit (provision) for income taxes allocated to other comprehensive income (loss) items</a></td>
<td class="num">$ (170.3)<span></span>
</td>
<td class="nump">$ 27.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Foreign Currency Translation Gains&#160;(Losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Benefit (provision) for income taxes allocated to other comprehensive income (loss) items</a></td>
<td class="num">(75.3)<span></span>
</td>
<td class="num">(38.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember', window );">Unrealized net gains/losses on securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Benefit (provision) for income taxes allocated to other comprehensive income (loss) items</a></td>
<td class="nump">4.4<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Benefit (provision) for income taxes allocated to other comprehensive income (loss) items</a></td>
<td class="num">(31.3)<span></span>
</td>
<td class="num">(25.7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember', window );">Effective portion of cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Benefit (provision) for income taxes allocated to other comprehensive income (loss) items</a></td>
<td class="num">$ (68.1)<span></span>
</td>
<td class="nump">$ 91.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e39076-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356212391432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss) (Reclassification) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other&#8211;net, (income) expense</a></td>
<td class="nump">$ 28.5<span></span>
</td>
<td class="num">$ (63.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Total before tax</a></td>
<td class="nump">1,476.4<span></span>
</td>
<td class="nump">1,679.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax benefit</a></td>
<td class="num">(121.1)<span></span>
</td>
<td class="num">(223.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Total reclassifications, net of tax</a></td>
<td class="nump">1,355.3<span></span>
</td>
<td class="nump">1,456.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Total reclassifications, net of tax</a></td>
<td class="nump">89.7<span></span>
</td>
<td class="nump">80.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Defined Benefit Pension and Retiree&#160;Health Benefit Plans | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Total before tax</a></td>
<td class="nump">108.8<span></span>
</td>
<td class="nump">98.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax benefit</a></td>
<td class="num">(22.9)<span></span>
</td>
<td class="num">(20.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Total reclassifications, net of tax</a></td>
<td class="nump">85.9<span></span>
</td>
<td class="nump">77.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember', window );">Prior service benefits, net | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other&#8211;net, (income) expense</a></td>
<td class="num">(13.8)<span></span>
</td>
<td class="num">(13.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember', window );">Actuarial losses, net | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other&#8211;net, (income) expense</a></td>
<td class="nump">122.6<span></span>
</td>
<td class="nump">111.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Other, net of tax | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other&#8211;net, (income) expense</a></td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="nump">$ 3.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140356210111624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other&#8211;Net, (Income) Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Nonoperating Income (Expense) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">$ 87.8<span></span>
</td>
<td class="nump">$ 92.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">(5.5)<span></span>
</td>
<td class="num">(14.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net investment gains</a></td>
<td class="num">(301.5)<span></span>
</td>
<td class="num">(186.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent', window );">Retirement benefit plans</a></td>
<td class="num">(73.4)<span></span>
</td>
<td class="num">(44.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense</a></td>
<td class="num">(28.5)<span></span>
</td>
<td class="nump">63.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other&#8211;net, (income) expense</a></td>
<td class="num">$ (321.1)<span></span>
</td>
<td class="num">$ (89.1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>66
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M$H: _EL):!'0"8A:,03T]T5 BY E 0-#P  G(#URU\/N80O4P! P.!P! T/
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MW'/N.=?F,MI*]:9+ $-V%1=Z[)7&K&Z#0.<E5%3[<@4"GRRDJJC!K5H&>J6
M%@Y4\2 *PS2H*!->-G*Q9Y6-Y-IP)N!9$;VN*JI^3X#+[=@;>.^!%[8LC0T$
MV6A%ES #\[IZ5K@+6I:"52 TDX(H6(R]N\'M-+7Y+N$;@ZWNK(EU,I?RS6X>
MBK$76D' (3>6@>+?!J; N25"&;\:3J\M:8'=]3O[)^<=O<RIAJGDWUEARK%W
MXY$"%G3-S8O<?H;&3V+Y<LFU^R7;)C?T2+[61E8-&!543-3_=-?TH0- GGY
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MS>6:Q3"0) "^O^5</-W(%Q6'UW>S?P%02P,$%     @ [TJ>4ER6]^M% @
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M ?Q](V$[7O_0#VB^Q%W\!U!+ P04    " #O2IY2VVDL2O(%  #W#0  &
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MNBT1<839)69I" !I!@L<+3DXL?:6W]/ 9&$M1__1"8\BE*B>_'AV=O%TH=X
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M*4"!#?">&\YVP!M,WWJG?P)02P,$%     @ [TJ>4G<*Y]'L"0  _Q<  !D
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MBI%^RTT!T'04:TW-$0<3LXP]AQ3:/D@F3ST,TM^:.\8<!-SV]&C2'@SVR%7
M!=?,_XN;)$VILEY2W@#T DA1$NM8:QI*$X8@;9$54-,4TAM<%NO!D5EG=QH\
MRYK4,SA4'5HM#++I%FX27"8L\/ZY^))\2L:X^UK"Y5\J3;GV%FLR4X[%&U@C
MJ]58O$:HI+#XTDL<!^?]5,-:^).R,M?(NZ"A0:0,$!+.IG,BDA\RN@2U$R9-
M 6#S%8IQJLHYW!N#_B 1EXO'-_,^^&H!G]W?&T!DTQ9!B(NTAT XB!!@M7%5
M)\C=E&&2+IHS4E!-+=8J@H:3,97% (.UT94?Z@#&:(JX]DH AU+,-1 QS2M3
MF.6*$0?>;6&++J;&>RA#PJT(3Q42:[<TF5ZLZ.WIZ==GN\2^,X%09Y>#W>B(
M(S6PB@V_U;"Y4@V"0-$Z&T LRHLEKU^H41T1D!K\F8RL@ [0*<$(5BPXL\V2
MT9TJX6H3:<<X*HS.R$"J1!TBJP4VPQQ@FVF6>0!9M$QM09?]0ZPH9I=6E@%!
MVFM"U.7&AGN*GOSM;R>SZ?'ON!](1TAKP\*X2"7W%A5HT3:=17D+!HKJ7 Q*
M!N7TU?5D,GW G5?2?M,HL54G.;HSO'YS=CI%-/M8M\E%? &5@1B$B'@C$<:A
M2/(N6D&ZCA[0A?I<>00"ZI%E$TN.B:CI^L-:42+.#!G'1J]%,GF#,YE1OI;(
M,4!]^@V2B!.%"^A(  & > TR$@@QW?5I!N*EJ3G@I:/7%Z<[2:C?+E23ECJ^
MZU''TT@=/R((P$2I.@/8NOBO0N], JD>%[IDK$'9H!IH-MDCZ4.($*\!QU.,
M/E23 NXR38L4 +??DD6*P0$OA8E>WG''ZD+,]5DA15 ,QE_@QN-8WT@9;=,9
M70^)]"T%(/5=G ,:9+745*9:#=$L8(1Q(!8Q)8FL%?>);V2 )6&VZS)CW?_
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M9'2X!@AOX<9)<H3OR=U[R9U6D,G)74# XZ/CY%[+PWV"A?>/ 1I?YW6A*<O
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MF 5$+O'4,?33G)[*JB9KPB$DBFE %4.R$CR4\<-/1/6Q>DO<;%L8LGW (H
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MH_W4KK'!M4!^>Z)"+@&QM/;%;@\(@,L1LR X"7G?KL[<PPP8Y2UF)LH;/"J
M,\X$ )\0Q>#'C%GYBRV?O,?RL%>C]?;$C8V[]37_UFK^AT#S?W>QST>JDN6
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MM'V7IA3SU/)?+Y^GOO_O7)Q@&#BDL0=B[^4M  A X+OF^ >GZF:F0P\M@U7
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M-TD'^><":+Q4RAXZ+L'P?;7\ 5!+ P04    " #O2IY22WH^@T,C  "7;
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M?5R"4IT23XZ&*DSM20UD]ILUUH$AUJ;ML:0<3Q350"\D!-,JFM7:]JYO6OK
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M&VHJ5^*IDG0/1D$/8QE.IH#K=/\>7 G3R>$.>]477><&],4IP/B=,46[F0&
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M::S[QO4&P9,TGC)418?D:"L$>2).HU'3>>C8>;QNX =S-F</)DO&I:2C(\A
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M,\_G$@HJ:/W? R("(SLDCJ7U3JQED(#$L>5L<C$>)7@%'4[Q+*7@KDDTXG*
MS<(/"-&0 +E_)&CT ,S(3G']UFJ&EJI9U#S5EU?F"A[H8A1SX5Q$?_C'PXSU
MHELWA"@P]YT*$= (APU8<06/@>!.<9(\/T?XH#4P42M<3Y/)J]:J#(6Z):>F
M4%4G,-I)VH-80ZY*(X>2P"B&*/24=#W5/$#,:SL'>F_%)K.#8<W1O);8]MG#
M,TS]\!913TH>FT-Q/\.\(P&S#_!TR/QA^%/$L4KM76(?QMYU0.<^,N9W^:(L
M."-:VA[C]'[FYZ'F"$&.:9;]TO3$ ] ER:I$51@6 \@[@VHN?I:09P._7E,D
MK\Q0%TO0XN/:KLE#.-!HUUV3HKQ6K/,3PAFRJI@/_6+)QI&$E!V#; W8?HA;
M\N^1SQ4AK%5#Y;9%VZST:9%Q)Z4*,C1^6)8U437B.C1%FSDSJB=^4FX &1!M
M;#E=/H(.T^^;=H0L?0U$+$F%-!7W>:IWID5*+%$#YH=QK8!O!I-3>B]*_)K*
MD;5#F/D78&%V>HW\KP9E@(]55RS-HA=?4KI.(#E!<$*+:RU3!"W4I551"Z74
MYM5C:R9DGS .QG->"V*YD*><VQXV4H.9+-ZM]T4%IG[YB4:V^L!4G8@8W=17
M#<T44YP$G7DTEM1@:Z.@GBJE?>?-@FHXP@%&>@Q\/)](B 1MQ9.2FG$%X"X5
M#W:0Z+I4<P.;53MS&;HT*R1DG<@R2;2Y0**C*8J3RA(O,Z!-=<^,.#E/75(0
M)_'#O:S -_IRTKU<VG4?XL"WK'-L7*'@96+)BU:1J$50Z(\ B-M! 6.K*V=N
M__3NQ1NF?O+97R]/?1 IFJJ*50IZ^O ^:"?% N\ 9$VQ',A8NIB4:!@5G?3J
M$).WFJ!BZ18+L(+8Q(1Z!M]JUA@S UHWB4!D(P@UV)64ET%*X'U$G 1!?<:R
M<L K"E%-2< 7*)L1LTOR</*3:32:D= ,( .S*'!&Q<M,;DUI2<&R]X CL*Z#
M7R\O/KX_',$C#T(H1G.0I!(%&3ODQJ5_+$&!P\'YQ8=#47_[V83$(ZB;S\KI
MAQ'?)@I 7II1D=COI2OTP(MH)JD)#SAE,#=<>J1,>*C+6%I4.>Z9KW.?B48B
M#>B5R0R2M3'Y&SO@"2J2415OP1_@*U$K,&>T^MQ7Q$,^M3"^3M0MF]NT,#H>
M943<4,O'W9(6!T#%LD$6IKT:=%<M5+FX9IE!B(G[E#S#PY CJ3=PJ+)E7/C?
M__;MR?&S[[J$+6I'>33G.UX;B3588//UP%K2S]*;.7OOU!EIJLJKH_62@<"3
M5.)1:4!:OL;B6?8S!0L./)->\1<X^<0IOFCLDLV^Q8]7MEI:M\H.7IP?YNJ&
MVQZQ@*:-VTGBJGF3Q6<<8=(\6%PI7)B*N7M]'D9Z:0'1N9@VF:O1WB!]R6#H
MM+JVJ^RMF3=P&0T77-[VY0R&<, _"6@][0J**NEC>?;V[1D_QK\=DKZM7-<Q
MR"&)S>?D'W@5O\!+O&P' K8!ZM.;O[P\/=RI"TV4>:@^X,=-V/13M8&_F3M1
MMLM-_3M^XXJ#U#)8@D'"+/Z2"\=L%T-(E)FTBY9<X9EN6G(=&(.J_#\"@68?
M+%53-?>78'+\_-LGV0&-\<;TQ?+A)_,9F(U^/227"S1?#)5I@4"W0W>R#.;S
M-UW":'P@WDAX^FK&W%4%T]T$V"4594/YJRY%5[2X$TK<_H&(V<A?4A6)'U=!
MLHL%X]CI>OB?E,TH<Y482>EM&B=G?D.<?C!L*ALAW'6C&!#B'K6WE.QNR16D
M^(02EH]($?^8-MK@S 0Z>RFK7WKCD/P$ SJGZFU=2C$-P2-9"FN2SYG *O@"
M$G.GJ"4[_2D[\-\=9NL!?I&=,AO;3Q ; FBQ5#P#9I+GF\51)#<N!4$ 0@DV
MX?B5QI=@V%.9AB\]AUTKOS_M_@AZ((R2<IB8G\>87$0VW7;V0AI"?N=W !JQ
M#J5&BV?IT^2-7:<[=R0TA>&S[+\W@#B?379F:E-.E9!?T+)J531.Q5WY\.3H
MZ,C'C)A7>AM(,PL_<$"XY0X4(99X,K:4EH,>?/J)Q'8>"Q85@\UV-"J1CRA>
MDMC!6P-9U2 T2Q#ZAAXJ7"<5F!W3\L@DQ1DL@<H4US08,# A1$_9XWQ4E&./
M(9\5--,N\A14]M4[G[UZ1+0#O-X#2L!]4)7(LAL)B_YYZ*@!@I*6CTW;4,I)
ME'J]V=(Z+6K[X$9#[^$Z( S8&[F-7(UVQ-BS2$-)5'2,7\)9=Z%F1MK;2:M)
MW8D*!1!4X^5*=^\QOP0WF8PKA;WI!]EB>]?4S;JI.*HQ.G[XCN QW'BNV'VU
MPH"(JCM9^!T\NT>U44M3E/M9&#P #(=0+@'1^@)2DL*<+CI!5*'^Y]W]EH[R
MC)X^EWI!Q">M:KT-6T5I<;OHF^[O?SM^]N2[B0<_C?H>N#N$ ]Q'<VUA?F=0
M0]YP.Z_+H>L5+@!6""J4AZ@66A$^Z';R.G[@<"*_7#"@&MIUTR:[5.,MV*X+
MM9;H$!+MY)7EL8$C]8^T\9BL([[OR_5'S]-@V$ARYODK*6]:.CW.#C "I1U8
M)14UJUEV,_/#CQ-=!($64Y]2LTAA)$+D_B7"DC+9?PYV;@N=Z^>AVK#'PCR?
MEAMH<YSD5>4@L8IV2K?'N#3=->$5>VM\HIYBVF<TFL77;4*L,H*=2QR0&]%D
MT--J3K[-4V9J1?;'CS'<J_7Z"V.Q9;%/IT:J-?P36+Y8>,?4V5A!8Z2BVL_2
MS'C[EW$&=V"Y^="''7?79O/*E&3V!<&C=I:]V"#Y-WNU^[5K.?YY$.ZBR1\]
MSW>:?K9T-*D!@_=/GQWI=%-;L]KR-\+SL9XV'NG;XZ.$+>0,1O,\C?TV22<A
M^4\>:DYX]^3;I\D0@M%$7*SIE8.WJ)VA0G1O-8L2_R<MA,H,D[T%ST\IUX%:
MC[W>#EW'GK#]9-$S>\E::/!E:G(MS_\.9R[A7,S8\$[A%I$KVOI\&)+")'TZ
M>/?R[;T*1Y.[29%1!'0H(X\K:RUW?DK;SUA^XKN29<H^:-51(X6MXXI]]2F1
MPJZX_S'!UKV:<W0TFIALA##(&,/#F%11[[*F9*!OU)ZR@]AT B16M!9C%OY'
MYN2F;5RIWQQ^1T*K+-==$CO7!.1+-(09 )?99_A6#/%N%"AUJ'LNRJS60U5Q
M>ZRZ!ZHE>+5CB,R"Z#D%T<*PC^T[6X>DL5R&(O"FC;H,PA\FO8%:H?$@+(+Y
M+>8)*2F/8N2G?0;MI)QM%R6>W6=O\A<,N@P[DU1Y;#M?I?GS)O&-\H:^G6(.
M#0'K2TM5IH]8F?8?I"=&EJ:]-$BJ2Z6--UKP>G$]JA1-4+O /ZBHGFP*3,*W
MJ??WRM>S(>WTE,WA-,$<&TK8H$>6ZV2'2=.%>]6Z1H+B%7!Y+_71A385NYWB
ME"0RP;-OP\.1V%.O?D;]-YN)-" .%L#I?H'_*2G?);MM)G\ER5\CUU";D%J:
M""WQJB=':1<8VS*KP^VR$==.-8V-]>U_G2]3DG_:>B\XOW$2_D57"J4AV-K=
M#\/$MI&G7PEB'C\]\C/=$\3HJ0+9%%UI-["'W-Q>[.#R#*'3G;@WBOAWA2LE
MZ:O#U8JJ.\W*'.ZT.OQ#M.IGP'MN%[XP-5)(Z.\[PA(!2B1YTL'/%^_>QJV3
M[2EC^X4JA:Q6G)@658::JH)N0:6$V #G^Y_XR3&VX<U>SZ75B+(_ W(X[]CO
MT7-)\*@1A:CE_7^*5BE-T4P3$/*;,V"+H&R)9,0K.HW"F]8T=0^V=0M9<&@N
MX,%YV2K#NKE]V%I158H=YU0D^*>.GQU<NJK$K^ L-**GG2\I6JMZ''Q$KE'1
MSX?>3KKIG'=GT\,'J^+NF*!DC@,\]UHNTCCO:R^CEG_=\4^!/8<HO]6U&T5J
M'SQ2T=XW>(SQA'IP/R#UQC 4->4*GH/.54E*GM%I*\PM67#P(R?'H3^ *C"5
M#<W[L=@N^X(='\9)>,&T;]5XDUV7^[BS),/4I PRG]R+F>Q(RJEA8IA#K1V-
M JI?G"LF9Q[<SS,^?WI/CP@OV'34BD+I=V]6D$^Y':HH"=,>ZF+HM[M2(WOV
M8^,=R;[&P+6S;8S5IKZ"+=E9]IZJEN,VD1?G&+M2[<$'KG]S/X%@G-*N:K?8
M,+!5)2;7KE$KEQ;Q/+2D:_%,*YYZ7DVZD;>W0^YHII_<S*$.U\[;5UC%+'LU
M.DQQD;2#_!H*?[3'0VUT=4>-9.,W/FAO6BX[05I3E(5$;>3"H!0%(=%K^*>:
M-.4!RW,QU&7^(!QD8&4J+37#L^::CO,40DM:R ZG;[A1B>?G5EX]8+?#*S$C
M"_7GSIJ%O>6%P3$<'R&IZJFM0U8;Z<FL*98[HV_XK-S<9K\W+K2#*UGX1,*H
M8C\L$4EPB(_[1-_&A$"=6+SO]+3.XR='+T;'73#P^?@,HZ*KD?>3Q-TW& 9D
M$$T=+N?_J[LU#D+]$KVO5+^)Y_+>#+29=RF'%!%(WKRY/)2@<&D!S7KU&_A:
MOM57H4.@IM  'UX_39PJA><W'RY/#V-/6_*S9(_TN[95*S]BWXY,]^828#K
ME\='N>RCF_+&=0W1ML:(F(I2A>!&J'X^T9U/_1ZNM;KG53DZ]\<XG8]VQ:HY
M"Q;6BF"XXNQ96Z'HU*,_;N&L@&?9O=0M-%I6&C-]=T,2-6]<HU7:,3_(3"_B
M[BWMO7JN:?"#/%T_J*E2&PTU5O*1UV3'RM:DYHQ1*%BQQ:?[HN.H1ZM?T_Y
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MX,A!S_QD:![#P:.?42Z-<GR:MB<A@&$[8$JQ**N65P,X\6:DN\XDX*XW!F<
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M8W17,?%##'T.58L:5WTP%2E_*T1.(WX0+9MW:)R%VKG:MLR=[GLD3J\MS17
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M?Q$8B=DO72TKLQJ4$"6B2$!8Y#$^ISQ#ZJ(B!W%$D06"I44"$Q"#^680$[S
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M6IJ [TMCW/!"!L:?+^?_!U!+ P04    " #O2IY2B!+@)9X%  #;#   &0
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MS:Y'HZ;8="E<3J_H.(XF--UXO)[=_"#*ZL<KZB<#.AH?1#'];$RV5D5!_=&
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MQN,R'!YSL$-:%L#WA0%'VA=VT/T_<_XW4$L#!!0    ( .]*GE+5$=@0OP0
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MVDP31;917W@]9$61)>IV+0+DJ=0!SY<9CL,E01-4W_Q=_Q=02P,$%     @
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M7"G@:0"Z?1':@56UOX77RM*=[KMTV K4SH#6-TK9_< %Z)_E^2]02P,$%
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MQ/QT<.X?7\0\WT[XLQ1KO3,FCF0FY2=^N,I/!QX#$I7(#%M(\>]>7(JJ8D.
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M#>Z!=H@^E0O%$_!]+J7I']C!YBI_]A]02P,$%     @ [TJ>4@O6S\NL @
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M7(A,UCB$;\_T\!IA<,\6%>KA-# 4SZ*"K.,^:[GC'=P)7$IA2@W?1([Y6WQ
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M5]: P^TL69Q=+B]"? SXJG#G#VP(E6RL?0S.K9PE61"$-184$ 3_GO *ZSH
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M-1M_8$FNF]+.(=O$R=A8XCF+9L4/&[H0P/M;:VGO!(+AJ9S_ U!+ P04
M" #O2IY2),1=_ T"  "!!   &0   'AL+W=O<FMS:&5E=',O<VAE970S,2YX
M;6R-5$UOVS ,_2N"T4,*;)%CIVY1. 9:!\,&K$"0H-MAV$%QZ%BH/CR)B;M_
M/TEVO QKNUUL4N)[))\HY9TV3[8!0/(LA;*+J$%L;RFU50.2V:EN0;F=6AO)
MT+EF3VUK@.T"2 J:Q'%&)>,J*O*PMC)%K@\HN(*5(?8@)3,_[T'H;A'-HM/"
MFN\;] NTR%NVAPW@8[LRSJ,CRXY+4)9K10S4B^AN=ENF/CX$?.'0V3.;^$ZV
M6C]YY]-N$<6^(!!0H6=@[G>$$H3P1*Z,'P-G-*;TP'/[Q/XA].YZV3(+I19?
M^0Z;1703D1W4["!PK;N/,/1SY?DJ+6SXDJZ/S:XB4ATL:CF 7062J_[/G@<=
MS@"S^2N 9  D_PM(!T!0CO:5A;:6#%F1&]T1XZ,=FS>"-@'MNN'*G^(&C=OE
M#H?%&HZ@#D FI59HG*CD,V=;+CARL)=DL@1D7#CK/7G<+,GDXI)<$*[( Q?"
M'8/-*;HJ/!>MAHSW?<;DE8P/S$Q).GM'DCB9O0 OWX8OH1KA\9]PZGH?!4A&
M 9+ E_Y#@-IH2481.HX-*8/\8,BWNZT-Z]_?2)B."=.0</Y*PC&'^"WT2RKV
M+%E@\7?Q6*3S;)KE]'@NUM]1R74VO1FC^A+IV8#XR^G.8,^5)0)JAXNGUVZ<
M33_PO8.Z#3.SU>@D"&;CW@@P/L#MUUKCR?%C.+XZQ2]02P,$%     @ [TJ>
M4G50+5YK#P  ,7P  !D   !X;"]W;W)K<VAE971S+W-H965T,S(N>&ULM9UK
M;QRW%8;_RD(-B@1H5CR'EQFFM@%;3A 7=6W$20JTZ(>5-)86V8NS.[*MH#^^
MLU>>&1Z24QKT!UN7P]'LJ_&[?,EGSCSYM-[\MKUOFG;R>;E8;9]>W+?MA^\N
M+[<W]\URMIVN/S2K[COOUYOEK.T^W=Q=;C]LFMGM?M!R<8E"F,OE;+ZZ>/9D
M_[6WFV=/U@_M8KYJWFXFVX?E<K9Y?-$LUI^>7L#%Z0L_S>_NV]T7+I\]^3"[
M:]XU[2\?WFZZSR[/1[F=+YO5=KY>33;-^Z<7S^&[*S2X&[$O^77>?-J2CR>[
MUW*]7O^V^^35[=,+L3NE9M'<M+MCS+I_/C97S6*Q.U1W(K\?CWIQ_J&[@?3C
MT]%_V+_Z[M5<S[;-U7KQS_EM>__THKZ8W#;O9P^+]J?UIQ^;XRO2N^/=K!?;
M_=^33\=:<3&Y>=BVZ^5Q<'<&R_GJ\._L\U$),J [#C\ CP-P.$ %!LCC +E_
MH8<SV[^LE[-V]NS)9OUILME5=T?;?;#79C^Z>S7SU>[W^*[==-^==^/:9S\U
M'YO50S/Y^N5\.[N[VS1WL[V\Z_>3T[>N'R=O-^O;AYOVFZZL:6?SQ?:;R;>3
M7]Z]G'S]U3>3KR;SU>3U?+'HQFV?7+;=6>V.?7ES/(,7AS/ P!G(R>OUJKW?
M3KY?W3:W_?&7W:LYOR0\O:07&#W@Z]EF.I'PEPD*!.9\KL8/%Y'3D6>%Y?YX
M,G"\L+#__GM7.GG5-LOM?R(_2)U_D-K_(!7_57*_@<- LQ^X^Y_]\9FIA9Z:
M)Y<?J3!^F:ZUG=;GLMYYZ?-YZ>AY_3)]-XV\/',^C"FK8W7^056NCH>!%1%(
M6@53.="1*9-8AW2LS^=51\_KS4.[G=\VDX2>]GPX6U9/$,YC1*ZBQY%4*ZR-
M\B0]UFE:IR7PB@)Q/XB>V<OY[+IIFVWL9:([&!96U'D*R&Q%I7_U < 4AHKZ
M=6A-/;4!39T-0=R'3II._INZ5,%9".C"TCJ; 9,MK?$E$P:F.)36KP-K:5W_
MW)PS0=R:B+0CW0"<NT!=6&+G/&"S);:^=$)9<E4>)?;K;%5-*UYA=%:%<:OZ
M>?.PF-_,V\<__PDJ]=?8=,29#$)99=%9$&*NLL>1/665QJD:*,O5(5I2US\W
MYUD8]ZR!M&E[0&<YJ HK[)P(X[.9F,+:5P[ D/?]H\)^G>T$U@&!G7-AW+E\
M@4>:!#H#PJJPT,Z/,#[=B0E=,Q,L3?[S'W7VR]#:T!L<.OO"N'W]^+"<+=9W
M28>0SG6D*"NK=&8DXS.>B*S'D72.96 HZK&(BFJL#LUMI7,N&7>NGJAI;Y D
M?A7.7]+9D,Q.8,>1@TS@7;)<F:U)4.N?F7,M&7>MH;HCC4$Z[Y&%TYET'B2S
M\YGTDQ?6RGN+X\IL%9J>26=9,FY9G<J= Z_2QN"L1A8.:<IYD,H.:<H/:1+!
MNWBY,M"A.9EREJ7BEM63-6T-RGF.*AS8E',AE1W8CB-[T1:&\UW%I#50TT
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MW,R6?Z0G#2 (%BE*<Y&"@)$BGXP4S"::$MZ$]U37<Q(9XB(% 2-%W+QZXH[
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M!'4^$'ETLRKB1W7I]$=H<JCSTU_-I3KIB\W5:1E<NB< .B0(]*O'Y747 $=
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M7U]C4;:+Y43QI>VXIESI_LT.,]UB$V$"]/Z"<[6=F /JIGWT#U!+ P04
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M>0/Y_X<D$2]O\B^HSMI>_0-02P,$%     @ [TJ>4M'0"&3$ @  3 <  !D
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ML@:XOY;2'"8V0/6 CO\!4$L#!!0    ( .]*GE*<^3"-S@8  ((=   9
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M_5J9&1G">   "<:VU/5C]/FD?"!LM;-2_P3 G,"8_@GZF^YDV5)BILB6P)W
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M\]@*P8P=X45CQTKT8$=XQ]@Q!I]=5[KS6WBCV-'AR^C\[M]&5,UOX7UA1T=
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M:P/^]YN"K\?;+W7!T'V%V(O_ 5!+ P04    " #O2IY2;UN&$E@"  "^!0
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MD]3&NX!G1C>ZMP:K9";EB]W<EF,OM(0HIX6Q&0C>UG1".;>)D,:O-J?7E;3
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M1^B%:F9DLS%RY<;,3!H<6FZYQ-\*538 W\^E-.\;.[FZ'U7^!U!+ P04
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M$+F$0$*.CH'3[R>L0$I'1&G\&#B#,:0#'LL']@^^=JIERRVLM/PJ"JSFP6W
M"BAY*_%)=Q]AJ.>MX\NUM/[+NMXW(>>\M:CK 4P9U$+U?[X?^G $()[S@'@
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M6Q0)D$@B94MR:ANPG0T-T*!&TFX?AGU@I+/-51(]DGX9L!\_ZL62+,M*VL&
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M<F]P<R]A<' N>&UL4$L! A0#%     @ [TJ>4LXSRN3O    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ [TJ>
M4IE<G",0!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " #O2IY233?5I^ &  #/)P  &
M@($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ [TJ>
M4BL/2Q>@!    !   !@              ("!) \  'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    ( .]*GE*T13$=F@(  )\&   8
M      " @?H3  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M" #O2IY2](7YP*@'    (   &               @('*%@  >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ [TJ>4A=5?M9C @  6@4  !@
M             ("!J!X  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    ( .]*GE)AG(8T6@8  ,H;   8              " @4$A  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " #O2IY27);WZT4"   0
M!0  &               @('1)P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ [TJ>4B*F:?3&!@  E1L  !@              ("!3"H
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( .]*GE+;:2Q*
M\@4  /<-   8              " @4@Q  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    " #O2IY2=PKGT>P)  #_%P  &0
M@(%P-P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( .]*
MGE(=S1/O)PT  &(A   9              " @9-!  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ [TJ>4HB/>I9<#P  A30  !D
M         ("!\4X  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    " #O2IY2M?XI=MD#  !X"0  &0              @(&$7@  >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( .]*GE+6J):6MQ@  +96
M   9              " @91B  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ [TJ>4O(6'NR\ @  3P8  !D              ("!@GL
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " #O2IY244.F
M@J@#  !K"0  &0              @(%U?@  >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    ( .]*GE)+>CZ#0R,  )=L   9
M  " @52"  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
M[TJ>4F@5[BB9!@  JA$  !D              ("!SJ4  'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    " #O2IY2$X!W\Y@"  #F!0  &0
M            @(&>K   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    ( .]*GE+4-S-M004  /T,   9              " @6VO  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ [TJ>4F+]L96^!P
MB!$  !D              ("!Y;0  'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    " #O2IY2B!+@)9X%  #;#   &0              @(':
MO   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( .]*GE+5
M$=@0OP0  *X+   9              " @:_"  !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @ [TJ>4IWY\LRN @  808  !D
M     ("!I<<  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .]*GE)G_-!F P,  'L)   9              "
M@=#@  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ [TJ>
M4HAW<'Y7 @  -@4  !D              ("!"N0  'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6Q02P$"% ,4    " #O2IY2),1=_ T"  "!!   &0
M        @(&8Y@  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0
M   ( .]*GE)U4"U>:P\  #%\   9              " @=SH  !X;"]W;W)K
M<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ [TJ>4F".(^4H P  P L
M !D              ("!?O@  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q0
M2P$"% ,4    " #O2IY2Q'!^.NX$   D$P  &0              @('=^P
M>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( .]*GE)AEA P
MK@,  %H,   9              " @0(! 0!X;"]W;W)K<VAE971S+W-H965T
M,S4N>&UL4$L! A0#%     @ [TJ>4H\<B=:F P  _@X  !D
M ("!YP0! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " #O
M2IY2\S@S<YH(  !W.P  &0              @('$" $ >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( .]*GE+1T ADQ (  $P'   9
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M970T,BYX;6Q02P$"% ,4    " #O2IY2;UN&$E@"  "^!0  &0
M    @(';-@$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (
M .]*GE+3W9Y_D@(  +0&   9              " @6HY 0!X;"]W;W)K<VAE
M971S+W-H965T-#0N>&UL4$L! A0#%     @ [TJ>4CB"K?V2 @  =P8  !D
M             ("!,SP! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"
M% ,4    " #O2IY24)9PO2 "   A!0  &0              @('\/@$ >&PO
M=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( .]*GE*9OUI4W ,
M +@-   9              " @5-! 0!X;"]W;W)K<VAE971S+W-H965T-#<N
M>&UL4$L! A0#%     @ [TJ>4G[?N$F' @  S@4  !D              ("!
M9D4! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " #O2IY2
MZ](A\L,'  #.+   &0              @($D2 $ >&PO=V]R:W-H965T<R]S
M:&5E=#0Y+GAM;%!+ 0(4 Q0    ( .]*GE(IIBE6] 4  "X=   9
M      " @1Y0 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%
M  @ [TJ>4M^G$V2) P  _PP  !D              ("!258! 'AL+W=O<FMS
M:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " #O2IY2A+'=02H$  !5$@
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M+G)E;'-02P$"% ,4    " #O2IY2?YGQ3%X$  !A(P  #P
M@ $79@$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ [TJ>4GQ^Z1O4 0
MQA\  !H              ( !HFH! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L! A0#%     @ [TJ>4BIDTJ;* 0  FQ\  !,              ( !
MKFP! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #T /0"B$   J6X!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>526</ContextCount>
  <ElementCount>318</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>138</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>15</UnitCount>
  <MyReports>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Condensed Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations</Role>
      <ShortName>Consolidated Condensed Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Condensed Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Condensed Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Condensed Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets</Role>
      <ShortName>Consolidated Condensed Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Consolidated Condensed Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedCondensedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Condensed Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Condensed Statements of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity</Role>
      <ShortName>Consolidated Condensed Statements of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Consolidated Condensed Statements of Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquityParenthetical</Role>
      <ShortName>Consolidated Condensed Statements of Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - Consolidated Condensed Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows</Role>
      <ShortName>Consolidated Condensed Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/BasisofPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2110103 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2115104 - Disclosure - Collaborations and Other Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CollaborationsandOtherArrangements</Role>
      <ShortName>Collaborations and Other Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2118105 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges</Role>
      <ShortName>Asset Impairment, Restructuring, and Other Special Charges</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2121106 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2130107 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2132108 - Disclosure - Retirement Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RetirementBenefits</Role>
      <ShortName>Retirement Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2136109 - Disclosure - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/Contingencies</Role>
      <ShortName>Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2138110 - Disclosure - Other Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherComprehensiveIncomeLoss</Role>
      <ShortName>Other Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2143111 - Disclosure - Other???Net, (Income) Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherNetIncomeExpense</Role>
      <ShortName>Other???Net, (Income) Expense</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/BasisofPresentationPolicies</Role>
      <ShortName>Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/Revenue</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - Acquisitions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AcquisitionsTables</Role>
      <ShortName>Acquisitions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/Acquisitions</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2316303 - Disclosure - Collaborations and Other Arrangements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CollaborationsandOtherArrangementsTables</Role>
      <ShortName>Collaborations and Other Arrangements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/CollaborationsandOtherArrangements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2319304 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables</Role>
      <ShortName>Asset Impairment, Restructuring, and Other Special Charges (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2322305 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstruments</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2333306 - Disclosure - Retirement Benefits (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RetirementBenefitsTables</Role>
      <ShortName>Retirement Benefits (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RetirementBenefits</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2339307 - Disclosure - Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherComprehensiveIncomeLossTables</Role>
      <ShortName>Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/OtherComprehensiveIncomeLoss</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2344308 - Disclosure - Other???Net, (Income) Expense (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherNetIncomeExpenseTables</Role>
      <ShortName>Other???Net, (Income) Expense (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/OtherNetIncomeExpense</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2405401 - Disclosure - Revenue (Summary of Revenue Recognized) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails</Role>
      <ShortName>Revenue (Summary of Revenue Recognized) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RevenueTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Revenue (Adjustments to Revenue) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails</Role>
      <ShortName>Revenue (Adjustments to Revenue) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RevenueTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Revenue (Contract Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RevenueContractLiabilitiesDetails</Role>
      <ShortName>Revenue (Contract Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RevenueTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Revenue (Disaggregation of Revenue by Product) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails</Role>
      <ShortName>Revenue (Disaggregation of Revenue by Product) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RevenueTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Revenue (Disaggregation of Revenue by Geographical Area) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails</Role>
      <ShortName>Revenue (Disaggregation of Revenue by Geographical Area) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RevenueTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Acquisitions (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AcquisitionsNarrativeDetails</Role>
      <ShortName>Acquisitions (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/AcquisitionsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Acquisitions (Assets Acquired and Liabilities Assumed) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>Acquisitions (Assets Acquired and Liabilities Assumed) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/AcquisitionsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2414408 - Disclosure - Acquisitions (Asset Acquisitions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails</Role>
      <ShortName>Acquisitions (Asset Acquisitions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/AcquisitionsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2417409 - Disclosure - Collaborations and Other Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails</Role>
      <ShortName>Collaborations and Other Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/CollaborationsandOtherArrangementsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails</Role>
      <ShortName>Asset Impairment, Restructuring, and Other Special Charges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2423411 - Disclosure - Financial Instruments (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Financial Instruments (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2424412 - Disclosure - Financial Instruments (Effect of Risk-Management Instruments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Effect of Risk-Management Instruments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2425413 - Disclosure - Financial Instruments (Fair Value of Financial Instruments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Fair Value of Financial Instruments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2426414 - Disclosure - Financial Instruments (Risk Management Instruments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Risk Management Instruments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2427415 - Disclosure - Financial Instruments (Contractual Maturities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails</Role>
      <ShortName>Financial Instruments (Contractual Maturities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2428416 - Disclosure - Financial Instruments (Unrealized Gains and Losses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails</Role>
      <ShortName>Financial Instruments (Unrealized Gains and Losses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2429417 - Disclosure - Financial Instruments (Realized Gains and Losses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails</Role>
      <ShortName>Financial Instruments (Realized Gains and Losses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2431418 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/IncomeTaxes</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2434419 - Disclosure - Retirement Benefits (Components of Net Periodic Benefit Cost) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails</Role>
      <ShortName>Retirement Benefits (Components of Net Periodic Benefit Cost) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RetirementBenefitsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2435420 - Disclosure - Retirement Benefits (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RetirementBenefitsNarrativeDetails</Role>
      <ShortName>Retirement Benefits (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RetirementBenefitsTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2437421 - Disclosure - Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ContingenciesDetails</Role>
      <ShortName>Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/Contingencies</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2440422 - Disclosure - Other Comprehensive Income (Loss) (AOCI) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails</Role>
      <ShortName>Other Comprehensive Income (Loss) (AOCI) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/OtherComprehensiveIncomeLossTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2441423 - Disclosure - Other Comprehensive Income (Loss) (Tax Effect) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails</Role>
      <ShortName>Other Comprehensive Income (Loss) (Tax Effect) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/OtherComprehensiveIncomeLossTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2442424 - Disclosure - Other Comprehensive Income (Loss) (Reclassification) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails</Role>
      <ShortName>Other Comprehensive Income (Loss) (Reclassification) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/OtherComprehensiveIncomeLossTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="lly-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2445425 - Disclosure - Other???Net, (Income) Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherNetIncomeExpenseDetails</Role>
      <ShortName>Other???Net, (Income) Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/OtherNetIncomeExpenseTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="lly-20210331.htm">lly-20210331.htm</File>
    <File>lly-20210331.xsd</File>
    <File>lly-20210331_cal.xml</File>
    <File>lly-20210331_def.xml</File>
    <File>lly-20210331_lab.xml</File>
    <File>lly-20210331_pre.xml</File>
    <File>lly-3312021x10qxexhibit101.htm</File>
    <File>lly-3312021x10qxexhibit102.htm</File>
    <File>lly-3312021x10qxexhibit311.htm</File>
    <File>lly-3312021x10qxexhibit312.htm</File>
    <File>lly-3312021x10qxexhibit32.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>72
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "lly-20210331.htm": {
   "axisCustom": 2,
   "axisStandard": 19,
   "contextCount": 526,
   "dts": {
    "calculationLink": {
     "local": [
      "lly-20210331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lly-20210331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "lly-20210331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lly-20210331_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lly-20210331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "lly-20210331.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 489,
   "entityCount": 1,
   "hidden": {
    "http://www.lilly.com/20210331": 1,
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 6
   },
   "keyCustom": 28,
   "keyStandard": 290,
   "memberCustom": 88,
   "memberStandard": 50,
   "nsprefix": "lly",
   "nsuri": "http://www.lilly.com/20210331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "dei:DocumentTransitionReport",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentQuarterlyReport",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.lilly.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "dei:DocumentTransitionReport",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentQuarterlyReport",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Revenue",
     "role": "http://www.lilly.com/role/Revenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110103 - Disclosure - Acquisitions",
     "role": "http://www.lilly.com/role/Acquisitions",
     "shortName": "Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115104 - Disclosure - Collaborations and Other Arrangements",
     "role": "http://www.lilly.com/role/CollaborationsandOtherArrangements",
     "shortName": "Collaborations and Other Arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118105 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges",
     "role": "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges",
     "shortName": "Asset Impairment, Restructuring, and Other Special Charges",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121106 - Disclosure - Financial Instruments",
     "role": "http://www.lilly.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130107 - Disclosure - Income Taxes",
     "role": "http://www.lilly.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132108 - Disclosure - Retirement Benefits",
     "role": "http://www.lilly.com/role/RetirementBenefits",
     "shortName": "Retirement Benefits",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136109 - Disclosure - Contingencies",
     "role": "http://www.lilly.com/role/Contingencies",
     "shortName": "Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2138110 - Disclosure - Other Comprehensive Income (Loss)",
     "role": "http://www.lilly.com/role/OtherComprehensiveIncomeLoss",
     "shortName": "Other Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143111 - Disclosure - Other\u2013Net, (Income) Expense",
     "role": "http://www.lilly.com/role/OtherNetIncomeExpense",
     "shortName": "Other\u2013Net, (Income) Expense",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Condensed Statements of Operations",
     "role": "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations",
     "shortName": "Consolidated Condensed Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationsPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Basis of Presentation (Policies)",
     "role": "http://www.lilly.com/role/BasisofPresentationPolicies",
     "shortName": "Basis of Presentation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationsPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - Revenue (Tables)",
     "role": "http://www.lilly.com/role/RevenueTables",
     "shortName": "Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - Acquisitions (Tables)",
     "role": "http://www.lilly.com/role/AcquisitionsTables",
     "shortName": "Acquisitions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316303 - Disclosure - Collaborations and Other Arrangements (Tables)",
     "role": "http://www.lilly.com/role/CollaborationsandOtherArrangementsTables",
     "shortName": "Collaborations and Other Arrangements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319304 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Tables)",
     "role": "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables",
     "shortName": "Asset Impairment, Restructuring, and Other Special Charges (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322305 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.lilly.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333306 - Disclosure - Retirement Benefits (Tables)",
     "role": "http://www.lilly.com/role/RetirementBenefitsTables",
     "shortName": "Retirement Benefits (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2339307 - Disclosure - Other Comprehensive Income (Loss) (Tables)",
     "role": "http://www.lilly.com/role/OtherComprehensiveIncomeLossTables",
     "shortName": "Other Comprehensive Income (Loss) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2344308 - Disclosure - Other\u2013Net, (Income) Expense (Tables)",
     "role": "http://www.lilly.com/role/OtherNetIncomeExpenseTables",
     "shortName": "Other\u2013Net, (Income) Expense (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405401 - Disclosure - Revenue (Summary of Revenue Recognized) (Details)",
     "role": "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails",
     "shortName": "Revenue (Summary of Revenue Recognized) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i1b961987b212484fba2e55e3f8599292_D20210101-20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Condensed Statements of Comprehensive Income (Loss)",
     "role": "http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeLoss",
     "shortName": "Consolidated Condensed Statements of Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i0b2a402409bd47ceb3efc76f535f0984_D20200101-20200331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Revenue (Adjustments to Revenue) (Details)",
     "role": "http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails",
     "shortName": "Revenue (Adjustments to Revenue) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i0b2a402409bd47ceb3efc76f535f0984_D20200101-20200331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "ie5f8381a63d1432f9f9dae6e35adb977_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Revenue (Contract Liabilities) (Details)",
     "role": "http://www.lilly.com/role/RevenueContractLiabilitiesDetails",
     "shortName": "Revenue (Contract Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Revenue (Disaggregation of Revenue by Product) (Details)",
     "role": "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
     "shortName": "Revenue (Disaggregation of Revenue by Product) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i3a8600a4d0ae48ac8eb847f76d72fb39_D20210101-20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Revenue (Disaggregation of Revenue by Geographical Area) (Details)",
     "role": "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
     "shortName": "Revenue (Disaggregation of Revenue by Geographical Area) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i1a8c46f072984025becf4f91f04a0ad4_D20210101-20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Acquisitions (Narrative) (Details)",
     "role": "http://www.lilly.com/role/AcquisitionsNarrativeDetails",
     "shortName": "Acquisitions (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "ia3e93321ddf644359c1906deaf4915d8_I20210131",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionSharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "ie5f8381a63d1432f9f9dae6e35adb977_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - Acquisitions (Assets Acquired and Liabilities Assumed) (Details)",
     "role": "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
     "shortName": "Acquisitions (Assets Acquired and Liabilities Assumed) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "ia3e93321ddf644359c1906deaf4915d8_I20210131",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414408 - Disclosure - Acquisitions (Asset Acquisitions) (Details)",
     "role": "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails",
     "shortName": "Acquisitions (Asset Acquisitions) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "if0a60d23094d4089a16f414a2eb40222_D20210101-20210131",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417409 - Disclosure - Collaborations and Other Arrangements (Details)",
     "role": "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails",
     "shortName": "Collaborations and Other Arrangements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "iabb0222b012c480fa8a4b4033fb1c3b4_D20210101-20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Details)",
     "role": "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails",
     "shortName": "Asset Impairment, Restructuring, and Other Special Charges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423411 - Disclosure - Financial Instruments (Narrative) (Details)",
     "role": "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
     "shortName": "Financial Instruments (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "ie5f8381a63d1432f9f9dae6e35adb977_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Condensed Balance Sheets",
     "role": "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets",
     "shortName": "Consolidated Condensed Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "ie5f8381a63d1432f9f9dae6e35adb977_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:DerivativeInstrumentsGainLossRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424412 - Disclosure - Financial Instruments (Effect of Risk-Management Instruments) (Details)",
     "role": "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails",
     "shortName": "Financial Instruments (Effect of Risk-Management Instruments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:DerivativeInstrumentsGainLossRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "ie5f8381a63d1432f9f9dae6e35adb977_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425413 - Disclosure - Financial Instruments (Fair Value of Financial Instruments) (Details)",
     "role": "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails",
     "shortName": "Financial Instruments (Fair Value of Financial Instruments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i0468ac52ec0a40758c116186c956d819_I20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i0468ac52ec0a40758c116186c956d819_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426414 - Disclosure - Financial Instruments (Risk Management Instruments) (Details)",
     "role": "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails",
     "shortName": "Financial Instruments (Risk Management Instruments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i0468ac52ec0a40758c116186c956d819_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "ie5f8381a63d1432f9f9dae6e35adb977_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427415 - Disclosure - Financial Instruments (Contractual Maturities) (Details)",
     "role": "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails",
     "shortName": "Financial Instruments (Contractual Maturities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "ie5f8381a63d1432f9f9dae6e35adb977_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "ie5f8381a63d1432f9f9dae6e35adb977_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428416 - Disclosure - Financial Instruments (Unrealized Gains and Losses) (Details)",
     "role": "http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails",
     "shortName": "Financial Instruments (Unrealized Gains and Losses) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "ie5f8381a63d1432f9f9dae6e35adb977_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:GainLossOnInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429417 - Disclosure - Financial Instruments (Realized Gains and Losses) (Details)",
     "role": "http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails",
     "shortName": "Financial Instruments (Realized Gains and Losses) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:GainLossOnInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431418 - Disclosure - Income Taxes (Details)",
     "role": "http://www.lilly.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i1d9dae1aca8e45a9bd0624944e8a56ca_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434419 - Disclosure - Retirement Benefits (Components of Net Periodic Benefit Cost) (Details)",
     "role": "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails",
     "shortName": "Retirement Benefits (Components of Net Periodic Benefit Cost) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i1d9dae1aca8e45a9bd0624944e8a56ca_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionContributions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435420 - Disclosure - Retirement Benefits (Narrative) (Details)",
     "role": "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails",
     "shortName": "Retirement Benefits (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionContributions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "ie5f8381a63d1432f9f9dae6e35adb977_I20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "lly:LossContingencyNumberOfRequestsForInformation",
      "reportCount": 1,
      "unitRef": "request",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437421 - Disclosure - Contingencies (Details)",
     "role": "http://www.lilly.com/role/ContingenciesDetails",
     "shortName": "Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i87320df79b3f461da082a107fa7a8e57_D20090301-20210331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:LossContingencyNumberOfPlaintiffs",
      "reportCount": 1,
      "unique": true,
      "unitRef": "plaintiff",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "ie5f8381a63d1432f9f9dae6e35adb977_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Consolidated Condensed Balance Sheets (Parenthetical)",
     "role": "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheetsParenthetical",
     "shortName": "Consolidated Condensed Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "ie5f8381a63d1432f9f9dae6e35adb977_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "ic0cb0d0f80df4940b8645cfac86c2594_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440422 - Disclosure - Other Comprehensive Income (Loss) (AOCI) (Details)",
     "role": "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails",
     "shortName": "Other Comprehensive Income (Loss) (AOCI) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441423 - Disclosure - Other Comprehensive Income (Loss) (Tax Effect) (Details)",
     "role": "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails",
     "shortName": "Other Comprehensive Income (Loss) (Tax Effect) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherNonoperatingIncomeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442424 - Disclosure - Other Comprehensive Income (Loss) (Reclassification) (Details)",
     "role": "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails",
     "shortName": "Other Comprehensive Income (Loss) (Reclassification) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i37bfd76d6ecb46708142e81e2d19a33c_D20210101-20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445425 - Disclosure - Other\u2013Net, (Income) Expense (Details)",
     "role": "http://www.lilly.com/role/OtherNetIncomeExpenseDetails",
     "shortName": "Other\u2013Net, (Income) Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i5bce3a2756434f739e7c3845a02a47cf_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Condensed Statements of Equity",
     "role": "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity",
     "shortName": "Consolidated Condensed Statements of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i5bce3a2756434f739e7c3845a02a47cf_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "link:footnote",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "ie5f8381a63d1432f9f9dae6e35adb977_I20210331",
      "decimals": "-7",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Consolidated Condensed Statements of Equity (Parenthetical)",
     "role": "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquityParenthetical",
     "shortName": "Consolidated Condensed Statements of Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "link:footnote",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "ie5f8381a63d1432f9f9dae6e35adb977_I20210331",
      "decimals": "-7",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - Consolidated Condensed Statements of Cash Flows",
     "role": "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows",
     "shortName": "Consolidated Condensed Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Basis of Presentation",
     "role": "http://www.lilly.com/role/BasisofPresentation",
     "shortName": "Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210331.htm",
      "contextRef": "i8310eb65428c41a3a7adc7a8db17092b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 138,
   "tag": {
    "country_BR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BRAZIL",
        "terseLabel": "Brazil"
       }
      }
     },
     "localname": "BR",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA",
        "terseLabel": "China"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "lly_A1.000NotesDueJune22022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.000% Notes Due June 2, 2022 [Member]",
        "label": "1.000% Notes Due June 2, 2022 [Member]",
        "terseLabel": "1.000% Notes due 2022"
       }
      }
     },
     "localname": "A1.000NotesDueJune22022Member",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1.625NotesDueJune22026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.625% Notes Due June 2, 2026 [Member]",
        "label": "1.625% Notes Due June 2, 2026 [Member]",
        "terseLabel": "1.625% Notes due 2026"
       }
      }
     },
     "localname": "A1.625NotesDueJune22026Member",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1.700Notesdue2049Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.700% Notes due 2049 [Member]",
        "label": "1.700% Notes due 2049 [Member]",
        "terseLabel": "1.700% Notes due 2049"
       }
      }
     },
     "localname": "A1.700Notesdue2049Member",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A2.125NotesDueJune32030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.125% Notes Due June 3, 2030 [Member]",
        "label": "2.125% Notes Due June 3, 2030 [Member]",
        "terseLabel": "2.125% Notes due 2030"
       }
      }
     },
     "localname": "A2.125NotesDueJune32030Member",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A6.77NotesDueJanuary12036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.77%\u00a0Notes Due January\u00a01, 2036 [Member]",
        "label": "6.77%\u00a0Notes Due January\u00a01, 2036 [Member]",
        "terseLabel": "6.77%\u00a0Notes due 2036"
       }
      }
     },
     "localname": "A6.77NotesDueJanuary12036Member",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A625Notesdue2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": ".625% Notes due 2031 [Member]",
        "label": ".625% Notes due 2031 [Member]",
        "terseLabel": "0.625% Notes due 2031"
       }
      }
     },
     "localname": "A625Notesdue2031Member",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A718NotesDueJune12025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "7 1/8% Notes Due June\u00a01, 2025 [Member]",
        "label": "7 1/8% Notes Due June\u00a01, 2025 [Member]",
        "terseLabel": "7 1/8% Notes due 2025"
       }
      }
     },
     "localname": "A718NotesDueJune12025Member",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AbCelleraBiologicsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AbCellera Biologics Inc. [Member]",
        "label": "AbCellera Biologics Inc. [Member]",
        "terseLabel": "AbCellera Biologics Inc."
       }
      }
     },
     "localname": "AbCelleraBiologicsInc.Member",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated Gain (Loss), Net, Cash Flow Hedge And Foreign Currency Adjustment, Including Portion Attributable To Noncontrolling Interest",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge And Foreign Currency Adjustment, Including Portion Attributable To Noncontrolling Interest [Member]",
        "terseLabel": "Other, net of tax"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AcquiredInProcessResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of EXPENSE related to research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore written off in the period of acquisition (INCOME STATEMENT)",
        "label": "Acquired in-process research and development",
        "terseLabel": "Acquired in-process research and development (Note 3)"
       }
      }
     },
     "localname": "AcquiredInProcessResearchAndDevelopment",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows",
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_ActosMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Actos",
        "label": "Actos [Member]",
        "terseLabel": "Actos"
       }
      }
     },
     "localname": "ActosMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AlimtaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alimta [Member]",
        "label": "Alimta [Member]",
        "terseLabel": "Alimta\u00ae"
       }
      }
     },
     "localname": "AlimtaMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AmpullaryCancerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ampullary Cancer",
        "label": "Ampullary Cancer [Member]",
        "terseLabel": "Ampullary Cancer"
       }
      }
     },
     "localname": "AmpullaryCancerMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AsahiKaseiPharmaCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asahi Kasei Pharma Corporation",
        "label": "Asahi Kasei Pharma Corporation [Member]",
        "terseLabel": "Asahi Kasei Pharma Corporation"
       }
      }
     },
     "localname": "AsahiKaseiPharmaCorporationMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Impairment Charges (Recoveries) And Other Special Charges",
        "label": "Asset Impairment Charges (Recoveries) And Other Special Charges",
        "terseLabel": "Asset impairment and other special charges"
       }
      }
     },
     "localname": "AssetImpairmentChargesRecoveriesAndOtherSpecialCharges",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for Sale Securities and Equity Securities, FV-NI, Realized Gain",
        "label": "Available for Sale Securities and Equity Securities, FV-NI, Realized Gain",
        "terseLabel": "Realized gross gains on sales"
       }
      }
     },
     "localname": "AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for sale Securities and Equity Securities, FV-NI, Realized Loss",
        "label": "Available for sale Securities and Equity Securities, FV-NI, Realized Loss",
        "terseLabel": "Realized gross losses on sales"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_BasaglarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basaglar [Member]",
        "label": "Basaglar [Member]",
        "terseLabel": "Basaglar\u00ae",
        "verboseLabel": "Basaglar"
       }
      }
     },
     "localname": "BasaglarMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Contingent Value Right, Additional Price Per Share",
        "label": "Business Acquisition, Contingent Value Right, Additional Price Per Share",
        "terseLabel": "Contingent value right, additional price per share (up to) (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentValueRightAdditionalPricePerShare",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Contingent Value Right, Covenant, Regulatory Approval Occurs",
        "label": "Business Acquisition, Contingent Value Right, Regulatory Approval Delay, Monthly Reduction",
        "terseLabel": "Contingent value right, monthly reduction (in cents per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Number Of Contingent Value Rights",
        "label": "Business Combination, Consideration Transferred, Number Of Contingent Value Rights",
        "terseLabel": "Consideration transferred, number of contingent value rights"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredNumberOfContingentValueRights",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net",
        "terseLabel": "Other assets and liabilities, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_BuyBritishPoundandSellUSDollarsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Buy British Pound and Sell US Dollars [Member]",
        "label": "Buy British Pound and Sell US Dollars [Member]",
        "terseLabel": "Buy British Pounds and Sell U.S. Dollars"
       }
      }
     },
     "localname": "BuyBritishPoundandSellUSDollarsMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_BuyEuroSellUsDollarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Currency Forward Commitment to Buy euro Sell US dollar",
        "label": "Buy Euro Sell Us Dollar [Member]",
        "terseLabel": "Buy Euros Sell U.S. Dollars"
       }
      }
     },
     "localname": "BuyEuroSellUsDollarMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_BuyUSdollarSellJapaneseYenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Buy US dollar Sell Japanese Yen [Member]",
        "label": "Buy US dollar Sell Japanese Yen [Member]",
        "terseLabel": "Buy U.S. Dollars Sell Japanese Yen"
       }
      }
     },
     "localname": "BuyUSdollarSellJapaneseYenMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_BuyUsDollarSellEuroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Currency Forward commitment to Buy US dollar Sell euro",
        "label": "Buy Us Dollar Sell Euro [Member]",
        "terseLabel": "Buy U.S. Dollars Sell Euros"
       }
      }
     },
     "localname": "BuyUsDollarSellEuroMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ByettaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Byetta",
        "label": "Byetta [Member]",
        "terseLabel": "Byetta"
       }
      }
     },
     "localname": "ByettaMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_COVID19AntibodiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19 Antibodies",
        "label": "COVID-19 Antibodies [Member]",
        "terseLabel": "COVID-19 Antibodies"
       }
      }
     },
     "localname": "COVID19AntibodiesMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_CashFlowHedgeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Flow Hedge [Abstract]",
        "label": "Cash Flow Hedge [Abstract]",
        "terseLabel": "Cash flow hedges:"
       }
      }
     },
     "localname": "CashFlowHedgeAbstract",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Casseres Et Al. V. Takeda Pharmaceutical North America, Inc., Et Al.",
        "label": "Casseres Et Al. V. Takeda Pharmaceutical North America, Inc., Et Al. [Member]",
        "terseLabel": "Casseres et al. v. Takeda Pharmaceutical North America, Inc., et al."
       }
      }
     },
     "localname": "CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_CialisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cialis [Member]",
        "label": "Cialis [Member]",
        "terseLabel": "Cialis\u00ae"
       }
      }
     },
     "localname": "CialisMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_CollaborationandOtherRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and Other Revenue [Member]",
        "label": "Collaboration and Other Revenue [Member]",
        "verboseLabel": "Collaboration and other revenue"
       }
      }
     },
     "localname": "CollaborationandOtherRevenueMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_CollaborativeArrangementRightsAndObligationsPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of rights and obligations under the collaborative arrangements, including but not limited to - percent share in various revenues and costs, percent interest earned on related party notes.",
        "label": "Collaborative Arrangement, Rights and Obligations Percent",
        "terseLabel": "Collaborative arrangement, rights and obligations, percentage (up to)"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsPercent",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lly_CollaborativeArrangementRightsAndObligationsRightsObligations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms or rights and obligations under collaborative arrangements.",
        "label": "Collaborative Arrangement, Rights and Obligations, Rights (Obligations)",
        "terseLabel": "Milestones capitalized"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsRightsObligations",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Terms, Annual Net Sales Threshold",
        "label": "Collaborative Arrangement, Rights and Obligations, Terms, Annual Net Sales Threshold",
        "terseLabel": "Collaborative arrangement, rights and obligations, terms, annual net sales threshold (up to)"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsTermsAnnualNetSalesThreshold",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_CostOfSalesOperatingExpensesAndOtherNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of sales, operating expenses, and other-net",
        "label": "Cost of sales, operating expenses, and other-net",
        "totalLabel": "Costs, expenses, and other"
       }
      }
     },
     "localname": "CostOfSalesOperatingExpensesAndOtherNet",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_CymbaltaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cymbalta [Member]",
        "label": "Cymbalta [Member]",
        "terseLabel": "Cymbalta\u00ae"
       }
      }
     },
     "localname": "CymbaltaMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_CyramzaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cyramza [Member]",
        "label": "Cyramza [Member]",
        "terseLabel": "Cyramza\u00ae"
       }
      }
     },
     "localname": "CyramzaMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-sale, Unrealized Gain Position",
        "label": "Debt Securities, Available-for-sale, Unrealized Gain Position",
        "terseLabel": "Fair value of securities in an unrealized gain position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableforsaleUnrealizedGainPosition",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_DerivativeInstrumentsGainLossRecognized": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Instruments, Gain (Loss) Recognized",
        "label": "Derivative Instruments, Gain (Loss) Recognized",
        "negatedTotalLabel": "Total"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossRecognized",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_DermiraInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dermira, Inc. [Member]",
        "label": "Dermira, Inc. [Member]",
        "terseLabel": "Dermira"
       }
      }
     },
     "localname": "DermiraInc.Member",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_DescriptionOfDerivativeActivityVolumePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Label: Description of Derivative Activity Volume Element ID: us-gaap_DescriptionOfDerivativeActivityVolume Balance Type: na Data Type: PERCENT Period Type: duration --------------------------------------------------------------------- Definition: Information that would enable users to understand the volume of the entity's derivative activity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 133 -Paragraph 44 -Subparagraph 2",
        "label": "Description of Derivative Activity Volume Percent",
        "terseLabel": "Percentage of long-term fixed-rate notes to floating rates through the use of interest rate swaps converted"
       }
      }
     },
     "localname": "DescriptionOfDerivativeActivityVolumePercent",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lly_DiabetesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Diabetes [Member]",
        "label": "Diabetes [Member]",
        "terseLabel": "Diabetes"
       }
      }
     },
     "localname": "DiabetesMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_DomicileOfLitigationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Domicile Of Litigation",
        "label": "Domicile Of Litigation [Axis]",
        "terseLabel": "Domicile of Litigation [Axis]"
       }
      }
     },
     "localname": "DomicileOfLitigationAxis",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lly_DomicileOfLitigationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Domicile Of Litigation",
        "label": "Domicile Of Litigation [Domain]",
        "terseLabel": "Domicile of Litigation [Domain]"
       }
      }
     },
     "localname": "DomicileOfLitigationDomain",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_DrReddysLabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dr Reddy's Lab [Member]",
        "label": "Dr Reddy's Lab [Member]",
        "terseLabel": "Dr Reddy's Lab"
       }
      }
     },
     "localname": "DrReddysLabMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_EmgalityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emgality [Member]",
        "label": "Emgality [Member]",
        "terseLabel": "Emgality\u00ae"
       }
      }
     },
     "localname": "EmgalityMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_EmgalityPatentLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emgality Patent Litigation [Member]",
        "label": "Emgality Patent Litigation [Member]",
        "terseLabel": "Emgality Patent Litigation"
       }
      }
     },
     "localname": "EmgalityPatentLitigationMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_EmployeeLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Litigation [Member]",
        "label": "Employee Litigation [Member]",
        "terseLabel": "Employee Litigation"
       }
      }
     },
     "localname": "EmployeeLitigationMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_EppVTakedaCanadaIncEtAlMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Epp V. Takeda Canada Inc. Et Al.",
        "label": "Epp V. Takeda Canada Inc. Et Al. [Member]",
        "terseLabel": "Epp v. Takeda Canada Inc. et al."
       }
      }
     },
     "localname": "EppVTakedaCanadaIncEtAlMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_EquityMethodAndOtherInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method and Other Investments [Member]",
        "label": "Equity Method And Other Investments [Member]",
        "verboseLabel": "Equity method investments"
       }
      }
     },
     "localname": "EquityMethodAndOtherInvestmentsMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ErbituxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Erbitux [Member]",
        "label": "Erbitux [Member]",
        "terseLabel": "Erbitux\u00ae"
       }
      }
     },
     "localname": "ErbituxMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_FairValueHedgeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Hedge [Abstract]",
        "label": "Fair Value Hedge [Abstract]",
        "terseLabel": "Fair value hedges:"
       }
      }
     },
     "localname": "FairValueHedgeAbstract",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period",
        "label": "Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period",
        "terseLabel": "Alternative investments, unfunded commitments, payment period"
       }
      }
     },
     "localname": "FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lly_ForeignCurrencyDenominatedDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Currency Denominated Debt [Member]",
        "label": "Foreign Currency Denominated Debt [Member]",
        "terseLabel": "Foreign Currency Denominated Debt"
       }
      }
     },
     "localname": "ForeignCurrencyDenominatedDebtMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ForteoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forteo [Member]",
        "label": "Forteo [Member]",
        "terseLabel": "Forteo\u00ae"
       }
      }
     },
     "localname": "ForteoMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_HedgedFixedRateDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedged Fixed-Rate Debt [Member]",
        "label": "Hedged Fixed Rate Debt [Member]",
        "terseLabel": "Foreign currency-denominated notes"
       }
      }
     },
     "localname": "HedgedFixedRateDebtMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_HumalogHumulinAndForteoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Humalog, Humulin, And Forteo",
        "label": "Humalog, Humulin, And Forteo [Member]",
        "terseLabel": "Humalog, Humulin and Forteo"
       }
      }
     },
     "localname": "HumalogHumulinAndForteoMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_HumalogMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Humalog [Member]",
        "label": "Humalog [Member]",
        "terseLabel": "Humalog\u00ae"
       }
      }
     },
     "localname": "HumalogMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_HumulinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Humulin [Member]",
        "label": "Humulin [Member]",
        "terseLabel": "Humulin\u00ae"
       }
      }
     },
     "localname": "HumulinMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ImmunologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immunology [Member]",
        "label": "Immunology [Member]",
        "terseLabel": "Immunology"
       }
      }
     },
     "localname": "ImmunologyMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_InnoventBiologicsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Innovent Biologics, Inc.",
        "label": "Innovent Biologics, Inc. [Member]",
        "terseLabel": "Innovent Biologics, Inc."
       }
      }
     },
     "localname": "InnoventBiologicsIncMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_JardianceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jardiance [Member]",
        "label": "Jardiance [Member]",
        "terseLabel": "Jardiance"
       }
      }
     },
     "localname": "JardianceMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.lilly.com/role/ContingenciesDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_JunshiBiosciencesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Junshi Biosciences",
        "label": "Junshi Biosciences [Member]",
        "terseLabel": "Shanghai Junshi Biosciences Co., Ltd."
       }
      }
     },
     "localname": "JunshiBiosciencesMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_LebrikizumabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lebrikizumab [Member]",
        "label": "Lebrikizumab [Member]",
        "terseLabel": "Lebrikizumab"
       }
      }
     },
     "localname": "LebrikizumabMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_LosAngelesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Los Angeles",
        "label": "Los Angeles [Member]",
        "terseLabel": "Los Angeles"
       }
      }
     },
     "localname": "LosAngelesMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Claims Settled And Dismissed, Limited Initial Market Entry, Supply Term",
        "label": "Loss Contingency, Claims Settled And Dismissed, Limited Initial Market Entry, Supply Term",
        "terseLabel": "Limited initial market entry, supply term"
       }
      }
     },
     "localname": "LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lly_LossContingencyNumberOfClaimants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Claimants",
        "label": "Loss Contingency, Number Of Claimants",
        "terseLabel": "Number of claimants"
       }
      }
     },
     "localname": "LossContingencyNumberOfClaimants",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lly_LossContingencyNumberOfPatents": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Patents",
        "label": "Loss Contingency, Number Of Patents",
        "terseLabel": "Number of patents"
       }
      }
     },
     "localname": "LossContingencyNumberOfPatents",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lly_LossContingencyNumberOfPatentsClaimsDismissed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Patents, Claims Dismissed",
        "label": "Loss Contingency, Number Of Patents, Claims Dismissed",
        "terseLabel": "Number of patents, claims dismissed"
       }
      }
     },
     "localname": "LossContingencyNumberOfPatentsClaimsDismissed",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lly_LossContingencyNumberOfPatentsRuledUnpatentable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Patents Ruled Unpatentable",
        "label": "Loss Contingency, Number Of Patents Ruled Unpatentable",
        "terseLabel": "Number of patents ruled unpatentable"
       }
      }
     },
     "localname": "LossContingencyNumberOfPatentsRuledUnpatentable",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lly_LossContingencyNumberOfRequestsForInformation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Requests For Information",
        "label": "Loss Contingency, Number Of Requests For Information",
        "terseLabel": "Number of requests for information"
       }
      }
     },
     "localname": "LossContingencyNumberOfRequestsForInformation",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup",
        "label": "Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup",
        "terseLabel": "Number of sites jointly and severally liable for cleanup (fewer than)"
       }
      }
     },
     "localname": "LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lly_MarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities [Member]",
        "label": "Marketable Securities [Member]",
        "terseLabel": "Marketable equity securities"
       }
      }
     },
     "localname": "MarketableSecuritiesMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MerusNVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merus N.V.",
        "label": "Merus N.V. [Member]",
        "terseLabel": "Merus N.V."
       }
      }
     },
     "localname": "MerusNVMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Capitalized As Intangible Assets",
        "label": "Milestone Payments, Capitalized As Intangible Assets [Member]",
        "terseLabel": "Milestone Payments, Capitalized as Intangible Assets"
       }
      }
     },
     "localname": "MilestonePaymentsCapitalizedAsIntangibleAssetsMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MilestonePaymentsDevelopmentAndRegulatoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Development and Regulatory [Member]",
        "label": "Milestone Payments, Development and Regulatory [Member]",
        "terseLabel": "Milestone Payments, Development and Regulatory"
       }
      }
     },
     "localname": "MilestonePaymentsDevelopmentAndRegulatoryMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member]",
        "label": "Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative [Member]",
        "terseLabel": "Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative"
       }
      }
     },
     "localname": "MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MilestonePaymentsSalesBasedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Sales-based [Member]",
        "label": "Milestone Payments, Sales-based [Member]",
        "terseLabel": "Milestone Payments, Sales-based"
       }
      }
     },
     "localname": "MilestonePaymentsSalesBasedMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Success-based Regulatory And Sales-based",
        "label": "Milestone Payments, Success-based Regulatory And Sales-based [Member]",
        "terseLabel": "Milestone Payments, Success-based Regulatory and Sales-based"
       }
      }
     },
     "localname": "MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MilestonePaymentsSuccessBasedRegulatoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Success-based Regulatory",
        "label": "Milestone Payments, Success-based Regulatory [Member]",
        "terseLabel": "Milestone Payments, Success-based Regulatory"
       }
      }
     },
     "localname": "MilestonePaymentsSuccessBasedRegulatoryMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_NeuroscienceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue to unaffiliated customers, Neuroscience",
        "label": "Neuroscience [Member]",
        "terseLabel": "Neuroscience"
       }
      }
     },
     "localname": "NeuroscienceMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_NonCHINAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-CHINA",
        "label": "Non-CHINA [Member]",
        "terseLabel": "Non-CHINA"
       }
      }
     },
     "localname": "NonCHINAMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OlumiantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Olumiant [Member]",
        "label": "Olumiant [Member]",
        "terseLabel": "Olumiant\u00ae"
       }
      }
     },
     "localname": "OlumiantMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue to unaffiliated customers, Oncology",
        "label": "Oncology [Member]",
        "terseLabel": "Oncology"
       }
      }
     },
     "localname": "OncologyMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherDiabetesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Diabetes [Member]",
        "label": "Other Diabetes [Member]",
        "terseLabel": "Other Diabetes"
       }
      }
     },
     "localname": "OtherDiabetesMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherEquitySecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Equity Securities [Member]",
        "label": "Other Equity Securities [Member]",
        "terseLabel": "Other securities, noncurrent investments"
       }
      }
     },
     "localname": "OtherEquitySecuritiesMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherForeignCountriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Foreign Countries [Member]",
        "label": "Other Foreign Countries [Member]",
        "terseLabel": "Other foreign countries"
       }
      }
     },
     "localname": "OtherForeignCountriesMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherImmunologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Immunology [Member]",
        "label": "Other Immunology [Member]",
        "terseLabel": "Other Immunology"
       }
      }
     },
     "localname": "OtherImmunologyMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherNeuroscienceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Neuroscience [Member]",
        "label": "Other Neuroscience [Member]",
        "terseLabel": "Other Neuroscience"
       }
      }
     },
     "localname": "OtherNeuroscienceMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherOncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Oncology [Member]",
        "label": "Other Oncology [Member]",
        "terseLabel": "Other Oncology"
       }
      }
     },
     "localname": "OtherOncologyMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Product [Member]",
        "label": "Other Product [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherProductMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherProductTotalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Product, Total [Member]",
        "label": "Other Product, Total [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherProductTotalMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OutsideUSAndJapanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outside US And Japan",
        "label": "Outside US And Japan [Member]",
        "terseLabel": "Outside US And Japan"
       }
      }
     },
     "localname": "OutsideUSAndJapanMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_PancreaticCancerOrThyroidCancerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pancreatic Cancer Or Thyroid Cancer",
        "label": "Pancreatic Cancer Or Thyroid Cancer [Member]",
        "terseLabel": "Pancreatic Cancer or Thyroid Cancer"
       }
      }
     },
     "localname": "PancreaticCancerOrThyroidCancerMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_PancreatitisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pancreatitis",
        "label": "Pancreatitis [Member]",
        "terseLabel": "Pancreatitis"
       }
      }
     },
     "localname": "PancreatitisMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_PaymentforPensionBenefitsAdditionalDiscretionaryFunding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment for Pension Benefits, Additional Discretionary Funding",
        "label": "Payment for Pension Benefits, Additional Discretionary Funding",
        "terseLabel": "Payment for additional discretionary funding"
       }
      }
     },
     "localname": "PaymentforPensionBenefitsAdditionalDiscretionaryFunding",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_PlaintiffAllegationsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plaintiff Allegations",
        "label": "Plaintiff Allegations [Axis]",
        "terseLabel": "Plaintiff Allegations [Axis]"
       }
      }
     },
     "localname": "PlaintiffAllegationsAxis",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lly_PlaintiffAllegationsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plaintiff Allegations",
        "label": "Plaintiff Allegations [Domain]",
        "terseLabel": "Plaintiff Allegations [Domain]"
       }
      }
     },
     "localname": "PlaintiffAllegationsDomain",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_PrecisionBiosciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Precision Biosciences, Inc.",
        "label": "Precision Biosciences, Inc. [Member]",
        "terseLabel": "Precision Biosciences, Inc."
       }
      }
     },
     "localname": "PrecisionBiosciencesIncMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_PrevailTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prevail Therapeutics Inc.",
        "label": "Prevail Therapeutics Inc. [Member]",
        "terseLabel": "Prevail Therapeutics Inc."
       }
      }
     },
     "localname": "PrevailTherapeuticsIncMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Sale of Equity and Available for Sale Securities",
        "label": "Proceeds from Sale of Equity and Available for Sale Securities",
        "terseLabel": "Proceeds from sales"
       }
      }
     },
     "localname": "ProceedsfromSaleofEquityandAvailableforSaleSecurities",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_ProductLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Liability",
        "label": "Product Liability [Member]",
        "terseLabel": "Product Liability"
       }
      }
     },
     "localname": "ProductLiabilityMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_PurchasedInProcessResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of CASH paid for research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore, written off in the period of acquisition (CASH FLOWS).",
        "label": "Purchased in-process research and development",
        "negatedTerseLabel": "Purchases of in-process research and development"
       }
      }
     },
     "localname": "PurchasedInProcessResearchAndDevelopment",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent",
        "label": "Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent",
        "terseLabel": "Revenue, information used to determine revenue recognized, change in accounting estimate, percent (less than)"
       }
      }
     },
     "localname": "RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lly_RigelPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rigel Pharmaceuticals, Inc.",
        "label": "Rigel Pharmaceuticals, Inc. [Member]",
        "terseLabel": "Rigel Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "RigelPharmaceuticalsIncMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_RocheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Roche [Member]",
        "label": "Roche [Member]",
        "terseLabel": "Roche"
       }
      }
     },
     "localname": "RocheMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_SalesRebatesAndDiscounts": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales rebates and discounts",
        "label": "Sales rebates and discounts",
        "terseLabel": "Sales rebates and discounts"
       }
      }
     },
     "localname": "SalesRebatesAndDiscounts",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_SitryxTherapeuticsLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sitryx Therapeutics Limited [Member]",
        "label": "Sitryx Therapeutics Limited [Member]",
        "terseLabel": "Sitryx Therapeutics Limited"
       }
      }
     },
     "localname": "SitryxTherapeuticsLimitedMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_SouthernDistrictOfCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Southern District Of California",
        "label": "Southern District Of California [Member]",
        "terseLabel": "Southern District of California"
       }
      }
     },
     "localname": "SouthernDistrictOfCaliforniaMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_SwapSwissFrancsToU.S.DollarsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Swap Swiss Francs To U.S. Dollars [Member]",
        "label": "Swap Swiss Francs To U.S. Dollars [Member]",
        "terseLabel": "Swap Swiss Francs to U.S. Dollars"
       }
      }
     },
     "localname": "SwapSwissFrancsToU.S.DollarsMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_SwapU.S.DollarsToEuroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Swap U.S. Dollars To Euro [Member]",
        "label": "Swap U.S. Dollars To Euro [Member]",
        "terseLabel": "Swap U.S. Dollars to Euro"
       }
      }
     },
     "localname": "SwapU.S.DollarsToEuroMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_TYVYTMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TYVYT",
        "label": "TYVYT [Member]",
        "terseLabel": "Tyvyt\u00ae"
       }
      }
     },
     "localname": "TYVYTMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_TaltzMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Taltz [Member]",
        "label": "Taltz [Member]",
        "terseLabel": "Taltz\u00ae"
       }
      }
     },
     "localname": "TaltzMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_TanezumabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tanezumab [Member]",
        "label": "Tanezumab [Member]",
        "terseLabel": "Tanezumab"
       }
      }
     },
     "localname": "TanezumabMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_TrajentaBIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trajenta (BI) [Member]",
        "label": "Trajenta (BI) [Member]",
        "terseLabel": "Trajenta"
       }
      }
     },
     "localname": "TrajentaBIMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_TrulicityMemberMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trulicity [Member] [Member]",
        "label": "Trulicity [Member] [Member]",
        "terseLabel": "Trulicity\u00ae"
       }
      }
     },
     "localname": "TrulicityMemberMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_VariousStateDomicilesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Various State Domiciles",
        "label": "Various State Domiciles [Member]",
        "terseLabel": "Various State Domiciles"
       }
      }
     },
     "localname": "VariousStateDomicilesMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_VerzenioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Verzenio [Member]",
        "label": "Verzenio [Member]",
        "terseLabel": "Verzenio\u00ae"
       }
      }
     },
     "localname": "VerzenioMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_WeilerVTakedaCanadaIncEtAlMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weiler V. Takeda Canada Inc. Et Al.",
        "label": "Weiler V. Takeda Canada Inc. Et Al. [Member]",
        "terseLabel": "Weiler v. Takeda Canada Inc. et al."
       }
      }
     },
     "localname": "WeilerVTakedaCanadaIncEtAlMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_WhyteEtAlVEliLillyEtAlMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Whyte Et Al. V. Eli Lilly Et Al.",
        "label": "Whyte Et Al. V. Eli Lilly Et Al. [Member]",
        "terseLabel": "Weiler v. Takeda Canada Inc. et al."
       }
      }
     },
     "localname": "WhyteEtAlVEliLillyEtAlMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ZyprexaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zyprexa [Member]",
        "label": "Zyprexa [Member]",
        "terseLabel": "Zyprexa\u00ae"
       }
      }
     },
     "localname": "ZyprexaMember",
     "nsuri": "http://www.lilly.com/20210331",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case Type [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r158",
      "r249",
      "r252",
      "r495",
      "r538",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.lilly.com/role/ContingenciesDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r158",
      "r249",
      "r252",
      "r495",
      "r538",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.lilly.com/role/ContingenciesDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r159",
      "r160",
      "r249",
      "r253",
      "r540",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.lilly.com/role/ContingenciesDetails",
      "http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r159",
      "r160",
      "r249",
      "r253",
      "r540",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.lilly.com/role/ContingenciesDetails",
      "http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r5",
      "r25",
      "r162",
      "r163"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net of allowances of $23.9 (2021) and $25.9 (2020)"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "auth_ref": [
      "r21",
      "r499",
      "r522"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.",
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Long-term income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r56",
      "r62",
      "r64",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Defined Benefit Pension and Retiree\u00a0Health Benefit Plans"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r55",
      "r62",
      "r64",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) related to gain (loss) component of defined benefit plans including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Actuarial losses, net"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r57",
      "r62",
      "r64",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to prior service cost (credit) component of defined benefit plans including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Defined Benefit Plans Adjustment, Net Prior Service Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Prior service benefits, net"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r35",
      "r209"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment, accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r50",
      "r62",
      "r64",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Foreign Currency Translation Gains\u00a0(Losses)"
       }
      }
     },
     "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember": {
     "auth_ref": [
      "r62",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, including portion attributable to noncontrolling interest.",
        "label": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]",
        "terseLabel": "Effective portion of cash flow hedges"
       }
      }
     },
     "localname": "AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r51",
      "r62",
      "r64",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges, including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Effective Portion of Cash\u00a0Flow Hedges"
       }
      }
     },
     "localname": "AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r52",
      "r53",
      "r54",
      "r62",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), including portion attributable to noncontrolling interest.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Including Noncontrolling Interest [Member]",
        "terseLabel": "Unrealized net gains/losses on securities",
        "verboseLabel": "Unrealized Net Gains (Losses) on\u00a0Securities"
       }
      }
     },
     "localname": "AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r28",
      "r59",
      "r61",
      "r62",
      "r524",
      "r545",
      "r546"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss (Note 10)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r58",
      "r62",
      "r64",
      "r113",
      "r114",
      "r115",
      "r402",
      "r541",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r350",
      "r351",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r32",
      "r164",
      "r188"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Allowances for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r58",
      "r62",
      "r64",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r178",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r109",
      "r148",
      "r151",
      "r156",
      "r186",
      "r397",
      "r403",
      "r450",
      "r498",
      "r521"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r7",
      "r9",
      "r48",
      "r109",
      "r186",
      "r397",
      "r403",
      "r450"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current Assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r171"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized gross gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r172"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "terseLabel": "Unrealized gross losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": {
     "auth_ref": [
      "r173",
      "r176",
      "r518"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "6-10 Years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r173",
      "r175",
      "r517"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "1-5 Years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue": {
     "auth_ref": [
      "r173",
      "r177",
      "r519"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10",
        "terseLabel": "More\u00a0Than 10 Years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r173",
      "r174",
      "r516"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Less\u00a0Than 1 Year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r166",
      "r170",
      "r194",
      "r505"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r167",
      "r194"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "verboseLabel": "Short-term investments, debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r167",
      "r194"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "verboseLabel": "Noncurrent investments, debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the percentage of nonperforming assets that the underlying assets in the security represent and which were considered as one of the potential factors in reaching a conclusion that the available-for-sale investments are not other-than-temporarily impaired.",
        "label": "Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Other, Percentage of Nonperforming Assets",
        "terseLabel": "Available-for-sale, percentage of nonperforming assets"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r339",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails",
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r339",
      "r343",
      "r377",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails",
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails",
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Business acquisition, share price (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r383",
      "r384",
      "r386"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Purchase price"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "auth_ref": [
      "r388"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.",
        "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "terseLabel": "Contingent value right, additional price per share, aggregate amount"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r382",
      "r385",
      "r387"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "negatedLabel": "Contingent consideration liability, other noncurrent liabilities"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r380"
     ],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability": {
     "auth_ref": [
      "r379",
      "r380"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability",
        "negatedTerseLabel": "Fair value of CVR liability"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r380"
     ],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedTerseLabel": "Deferred tax liabilities",
        "terseLabel": "Deferred income taxes assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r380"
     ],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Acquired IPR&amp;D"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": {
     "auth_ref": [
      "r380"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt",
        "terseLabel": "Long-term debt assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r380"
     ],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Acquisition date fair value of consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r107",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations Policy"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r448",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Amount"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).",
        "label": "Cash Acquired from Acquisition",
        "negatedTerseLabel": "Cash acquired"
       }
      }
     },
     "localname": "CashAcquiredFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r33",
      "r105"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents (Note 6)"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r99",
      "r105",
      "r106"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash and Cash Equivalents at March 31",
        "periodStartLabel": "Cash and cash equivalents at January\u00a01"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r99",
      "r451"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInAccountingEstimateByTypeAxis": {
     "auth_ref": [
      "r121",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of change in accounting estimate.",
        "label": "Change in Accounting Estimate by Type [Axis]",
        "terseLabel": "Change in Accounting Estimate by Type [Axis]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingEstimateLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Change in Accounting Estimate [Line Items]",
        "terseLabel": "Change in Accounting Estimate [Line Items]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingEstimateTypeDomain": {
     "auth_ref": [
      "r121",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities.",
        "label": "Change in Accounting Estimate, Type [Domain]",
        "terseLabel": "Change in Accounting Estimate, Type [Domain]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": {
     "auth_ref": [
      "r436"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails": {
       "order": 3.0,
       "parentTag": "lly_DerivativeInstrumentsGainLossRecognized",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments",
        "negatedLabel": "Effect from interest rate contracts"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": {
     "auth_ref": [
      "r436"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails": {
       "order": 4.0,
       "parentTag": "lly_DerivativeInstrumentsGainLossRecognized",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge",
        "negatedLabel": "Effect from hedged fixed-rate debt"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r108",
      "r109",
      "r128",
      "r129",
      "r130",
      "r132",
      "r134",
      "r139",
      "r140",
      "r141",
      "r186",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r390",
      "r391",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborations and Other Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r43",
      "r220",
      "r506",
      "r529"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies (Note 9)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/Contingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Common Stock (no par value)"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r113",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockSharesHeldInEmployeeTrust": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of common stock issued to a trust (for example, but not limited to, rabbi trust) set up specifically to accumulate stock for the sole purpose of distribution to participating employees.",
        "label": "Common Stock, Shares Held in Employee Trust",
        "negatedLabel": "Employee benefit trust"
       }
      }
     },
     "localname": "CommonStockSharesHeldInEmployeeTrust",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r67",
      "r69",
      "r70",
      "r78",
      "r511",
      "r534"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r67",
      "r69",
      "r77",
      "r396",
      "r407",
      "r510",
      "r533"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r76",
      "r87",
      "r509",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of amounts recorded for contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r239",
      "r240",
      "r250"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "verboseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.lilly.com/role/RevenueContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r288",
      "r333",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r80",
      "r495"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs, expenses, and other:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CrossCurrencyInterestRateContractMember": {
     "auth_ref": [
      "r288",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates.",
        "label": "Cross Currency Interest Rate Contract [Member]",
        "terseLabel": "Cross-currency interest rate swaps"
       }
      }
     },
     "localname": "CrossCurrencyInterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.",
        "label": "Debt, Current",
        "terseLabel": "Short-term borrowings and current maturities of long-term debt"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Summary the contractual maturities of our investments in debt securities measured at fair value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r181",
      "r196",
      "r200"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
        "terseLabel": "Fair value of securities in an unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r358",
      "r359"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "verboseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r358",
      "r359"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit": {
     "auth_ref": [
      "r265",
      "r303",
      "r327"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss), recognized immediately as component of net periodic benefit (cost) credit, for change in value of benefit obligation or plan assets from experience different from that assumed, change in actuarial assumption, or consequence of temporarily deviating from substantive plan. Includes, but is not limited to, amount in excess of ten percent of greater of fair value of plan assets or benefit obligation.",
        "label": "Defined Benefit Plan, Actuarial Gain (Loss), Immediate Recognition as Component in Net Periodic Benefit (Cost) Credit",
        "negatedLabel": "Recognized actuarial loss"
       }
      }
     },
     "localname": "DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r265",
      "r304",
      "r328",
      "r333",
      "r334"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "terseLabel": "Amortization of prior service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear": {
     "auth_ref": [
      "r331",
      "r334"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution expected to be received by defined benefit plan from employer in remainder of current fiscal year. Excludes contribution previously paid by employer in current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Employer Contributions, Remainder of Fiscal Year",
        "terseLabel": "Estimated future employer contributions in current fiscal year"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r265",
      "r302",
      "r326",
      "r333",
      "r334"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r265",
      "r269",
      "r301",
      "r325",
      "r333",
      "r334"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "terseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r299",
      "r323",
      "r333",
      "r334"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "totalLabel": "Net periodic benefit cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r267",
      "r300",
      "r324",
      "r333",
      "r334"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "terseLabel": "Service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]",
        "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r103",
      "r146"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetNotionalAmount": {
     "auth_ref": [
      "r410",
      "r411",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payments on the derivative asset.",
        "label": "Derivative Asset, Notional Amount",
        "terseLabel": "Derivative asset, notional amount"
       }
      }
     },
     "localname": "DerivativeAssetNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsCurrent": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "DerivativeAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsNoncurrent": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset, Noncurrent",
        "terseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "DerivativeAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r419",
      "r422",
      "r426",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r417",
      "r419",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Current",
        "negatedTerseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Noncurrent",
        "negatedTerseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityNotionalAmount": {
     "auth_ref": [
      "r410",
      "r411",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payments on the derivative liability.",
        "label": "Derivative Liability, Notional Amount",
        "terseLabel": "Derivative liability, notional amount"
       }
      }
     },
     "localname": "DerivativeLiabilityNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r411",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative, notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r107",
      "r111",
      "r409",
      "r412",
      "r417",
      "r418",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Description of Derivative Risk Management Policy"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r249",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of disaggregation of revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DividendsPayableCurrent": {
     "auth_ref": [
      "r12",
      "r39"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Dividends Payable, Current",
        "terseLabel": "Dividends payable"
       }
      }
     },
     "localname": "DividendsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r79",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r126",
      "r128",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r512",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r79",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r128",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r512",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate, percentage"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r117",
      "r123",
      "r125",
      "r138",
      "r187",
      "r234",
      "r235",
      "r350",
      "r351",
      "r352",
      "r365",
      "r366",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r458",
      "r541",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r445"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "auth_ref": [
      "r185"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "negatedLabel": "Net investment gains",
        "terseLabel": "Equity securities, net unrealized gains"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r184"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Equity investments without readily determinable fair values"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Estimate of Fair Value Measurement"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r438",
      "r439",
      "r440",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r438",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary certain fair value information"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r438",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Fair value, by balance sheet grouping"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r288",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r333",
      "r439",
      "r467",
      "r468",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r438",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueHedgingMember": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.",
        "label": "Fair Value Hedging [Member]",
        "terseLabel": "Fair Value Hedging"
       }
      }
     },
     "localname": "FairValueHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r288",
      "r290",
      "r295",
      "r333",
      "r439",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r288",
      "r290",
      "r295",
      "r333",
      "r439",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r288",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r333",
      "r439",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments": {
     "auth_ref": [
      "r444"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of unfunded commitments for which the entity is obligated, to those certain investments for which net asset value per share is calculated (including by unit, membership interest, or other equity (ownership interest) unit measure) (alternative investments).",
        "label": "Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unfunded Commitments",
        "terseLabel": "Alternative investments, unfunded commitments"
       }
      }
     },
     "localname": "FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r438",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary certain fair value information, liabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r288",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r333",
      "r467",
      "r468",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r178",
      "r179",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r197",
      "r198",
      "r199",
      "r200",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r288",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign currency exchange contracts"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": {
     "auth_ref": [
      "r419",
      "r425"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "lly_DerivativeInstrumentsGainLossRecognized",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.",
        "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments",
        "negatedLabel": "Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments"
       }
      }
     },
     "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r84",
      "r103",
      "r168"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Gain (Loss) on Investments",
        "negatedLabel": "Net investment gains"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security.",
        "label": "Gain (Loss) on Securities [Table Text Block]",
        "terseLabel": "Activity related to our available-for-sale securities"
       }
      }
     },
     "localname": "GainLossOnInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r203",
      "r204",
      "r497"
     ],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails",
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r417",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r103",
      "r208"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)",
        "terseLabel": "Intangible asset impairment"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r74",
      "r148",
      "r150",
      "r152",
      "r155",
      "r157",
      "r496",
      "r507",
      "r514",
      "r536"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Total before tax",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r362",
      "r363",
      "r364",
      "r367",
      "r369",
      "r373",
      "r374",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r110",
      "r124",
      "r125",
      "r147",
      "r360",
      "r368",
      "r371",
      "r537"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedNetLabel": "Tax benefit",
        "terseLabel": "Income taxes (Note 7)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedTerseLabel": "Change in deferred income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedTerseLabel": "Other changes in operating assets and liabilities, net of acquisitions and divestitures"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Shareholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r205",
      "r207"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Other intangibles, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r72",
      "r145",
      "r459",
      "r460",
      "r513"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": {
     "auth_ref": [
      "r437"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.",
        "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net",
        "negatedLabel": "Pretax net losses on cash flow hedges expected to be reclassified during the next 12 months"
       }
      }
     },
     "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateContractMember": {
     "auth_ref": [
      "r288",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.",
        "label": "Interest Rate Contract [Member]",
        "terseLabel": "Interest rate contracts"
       }
      }
     },
     "localname": "InterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Forward-starting interest rate swaps"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r4",
      "r47"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r83",
      "r144"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "negatedLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r31",
      "r109",
      "r186",
      "r450",
      "r502",
      "r527"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r40",
      "r109",
      "r186",
      "r398",
      "r403",
      "r404",
      "r450"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r19",
      "r20",
      "r109",
      "r186",
      "r398",
      "r403",
      "r404",
      "r450"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total other liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Other Liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r19",
      "r233",
      "r500",
      "r523"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "negatedTerseLabel": "Long-term debt, including current portion",
        "terseLabel": "Long-term debt, including current portion"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-term Investments",
        "terseLabel": "Investments (Note 6)",
        "totalLabel": "Noncurrent investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets",
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r41",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r228",
      "r230",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r228",
      "r230",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyDamagesAwardedValue": {
     "auth_ref": [
      "r220",
      "r223",
      "r227"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of damages awarded to the plaintiff in the legal matter.",
        "label": "Loss Contingency, Damages Awarded, Value",
        "terseLabel": "Damages awarded, value"
       }
      }
     },
     "localname": "LossContingencyDamagesAwardedValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r228",
      "r230",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyNumberOfPlaintiffs": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Number of Plaintiffs",
        "terseLabel": "Number of plaintiffs"
       }
      }
     },
     "localname": "LossContingencyNumberOfPlaintiffs",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Number of pending lawsuits"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of time remaining before foreign currency exchange rate derivatives mature or expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Maximum Remaining Maturity of Foreign Currency Derivatives",
        "terseLabel": "Maximum remaining maturity of foreign currency derivatives"
       }
      }
     },
     "localname": "MaximumRemainingMaturityOfForeignCurrencyDerivatives1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": {
     "auth_ref": [
      "r1",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures.  This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.",
        "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/Acquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r46",
      "r109",
      "r186",
      "r450",
      "r501",
      "r526"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MortgageBackedSecuritiesMember": {
     "auth_ref": [
      "r169",
      "r288",
      "r290",
      "r333",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities collateralized by mortgage loans.",
        "label": "Collateralized Mortgage Backed Securities [Member]",
        "terseLabel": "Mortgage-backed securities"
       }
      }
     },
     "localname": "MortgageBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net Cash (Used for) Provided by Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows from Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net Cash Used for Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows from Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r99",
      "r101",
      "r104"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net Cash Provided by Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows from Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r65",
      "r68",
      "r75",
      "r104",
      "r109",
      "r116",
      "r118",
      "r119",
      "r120",
      "r121",
      "r124",
      "r125",
      "r131",
      "r148",
      "r150",
      "r152",
      "r155",
      "r157",
      "r186",
      "r450",
      "r508",
      "r531"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net investment hedges"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.",
        "label": "Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component",
        "terseLabel": "Retirement benefit plans"
       }
      }
     },
     "localname": "NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Outside U.S."
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r235",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations": {
       "order": 6.0,
       "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet",
       "weight": -1.0
      },
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "negatedLabel": "Other\u2013net, (income) expense (Note 11)",
        "negatedTotalLabel": "Other\u2013net, (income) expense"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations",
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/BasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r62",
      "r71",
      "r452",
      "r454",
      "r458"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "terseLabel": "Other comprehensive income (loss) before reclassifications"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r51",
      "r59",
      "r420",
      "r423",
      "r435"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Effective portion of risk-management instruments that was recognized in other comprehensive income (loss), cash flow hedges"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r59",
      "r63",
      "r424"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails": {
       "order": 2.0,
       "parentTag": "lly_DerivativeInstrumentsGainLossRecognized",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "terseLabel": "Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r427"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Effective portion of risk-management instruments that was recognized in other comprehensive income (loss), net investment hedges"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r66",
      "r69",
      "r71",
      "r76",
      "r234",
      "r452",
      "r457",
      "r458",
      "r509",
      "r532"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss), net of tax (Note 10)",
        "totalLabel": "Net other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeLoss",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTax": {
     "auth_ref": [
      "r60",
      "r76",
      "r360",
      "r370",
      "r372",
      "r452",
      "r455",
      "r458",
      "r509",
      "r532"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Tax",
        "negatedTerseLabel": "Benefit (provision) for income taxes allocated to other comprehensive income (loss) items"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherDebtSecuritiesMember": {
     "auth_ref": [
      "r180",
      "r195",
      "r288",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in debt securities classified as other.",
        "label": "Other Debt Obligations [Member]",
        "terseLabel": "Other securities, current investments"
       }
      }
     },
     "localname": "OtherDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "auth_ref": [
      "r260",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.",
        "label": "Other Income and Other Expense Disclosure [Text Block]",
        "terseLabel": "Other\u2013Net, (Income) Expense"
       }
      }
     },
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherNetIncomeExpense"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r39"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLongTermInvestments": {
     "auth_ref": [
      "r34",
      "r530"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term investments classified as other.",
        "label": "Other Long-term Investments",
        "verboseLabel": "Equity method investments"
       }
      }
     },
     "localname": "OtherLongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other (income) expense",
        "terseLabel": "Other\u2013net, (income) expense"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails",
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other non-cash operating activities, net"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "auth_ref": [
      "r262",
      "r263",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r316",
      "r320",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
        "label": "Other Postretirement Benefits Plan [Member]",
        "terseLabel": "Retiree Health Benefit Plans"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r89",
      "r92",
      "r112"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other investing activities, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Purchases of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividends": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.",
        "label": "Payments of Dividends",
        "negatedLabel": "Dividends paid"
       }
      }
     },
     "localname": "PaymentsOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Cash paid for acquisitions, net of cash acquired (Note 3)",
        "terseLabel": "Cash paid, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails",
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r91"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "terseLabel": "Acquired IPR&amp;D Expense"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails",
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireLongtermInvestments": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.",
        "label": "Payments to Acquire Long-term Investments",
        "negatedTerseLabel": "Purchases of noncurrent investments"
       }
      }
     },
     "localname": "PaymentsToAcquireLongtermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "negatedLabel": "Net purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-term Investments",
        "negatedTerseLabel": "Purchases of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r287",
      "r289",
      "r295",
      "r312",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r333",
      "r335",
      "r336",
      "r337",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Retirement Benefits"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefits"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": {
     "auth_ref": [
      "r21",
      "r263",
      "r264",
      "r286",
      "r333"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.",
        "label": "Liability, Defined Benefit Plan, Noncurrent",
        "terseLabel": "Accrued retirement benefits (Note 8)"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionContributions": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit.",
        "label": "Payment for Pension Benefits",
        "terseLabel": "Pension contributions"
       }
      }
     },
     "localname": "PensionContributions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r261",
      "r263",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r316",
      "r320",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r337",
      "r338",
      "r343",
      "r344",
      "r345",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "verboseLabel": "Defined Benefit Pension Plans"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement [Member]"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Not measured at fair value.",
        "label": "Portion at Other than Fair Value Measurement [Member]",
        "terseLabel": "Cost"
       }
      }
     },
     "localname": "PortionAtOtherThanFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r6",
      "r8",
      "r201",
      "r202"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r94",
      "r97",
      "r112"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other financing activities, net"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfLongtermInvestments": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, beyond the current operating cycle.",
        "label": "Proceeds from Sale of Long-term Investments",
        "terseLabel": "Proceeds from sales of noncurrent investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfLongtermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale of Short-term Investments",
        "terseLabel": "Proceeds from sales and maturities of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from Short-term Debt",
        "terseLabel": "Net change in short-term borrowings"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Net product revenue"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r65",
      "r68",
      "r98",
      "r109",
      "r116",
      "r124",
      "r125",
      "r148",
      "r150",
      "r152",
      "r155",
      "r157",
      "r186",
      "r396",
      "r399",
      "r400",
      "r406",
      "r407",
      "r450",
      "r514"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Total reclassifications, net of tax"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeLoss",
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity",
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r16",
      "r17",
      "r210",
      "r528"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net of accumulated depreciation of $9,643.4 (2021) and $9,570.7 (2020)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesNetCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables, Net, Current [Abstract]",
        "terseLabel": "Receivables, Net, Current [Abstract]"
       }
      }
     },
     "localname": "ReceivablesNetCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]",
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r62",
      "r64",
      "r71",
      "r452",
      "r456",
      "r458"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "negatedTerseLabel": "Net amount reclassified from accumulated other comprehensive loss"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]",
        "terseLabel": "Schedule of reclassifications out of accumulated other comprehensive loss"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Repayments of long-term debt",
        "terseLabel": "Repayments of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails",
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-term Debt",
        "negatedTerseLabel": "Net change in short-term borrowings"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r355",
      "r558"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring, Impairment, and Other Activities Disclosure [Text Block]",
        "terseLabel": "Asset Impairment, Restructuring, and Other Special Charges"
       }
      }
     },
     "localname": "RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringSettlementAndImpairmentProvisions": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of restructuring charges, remediation cost, and asset impairment loss.",
        "label": "Restructuring, Settlement and Impairment Provisions",
        "terseLabel": "Asset impairment, restructuring, and other special charges (Note 5)",
        "totalLabel": "Total asset impairment, restructuring, and other special charges"
       }
      }
     },
     "localname": "RestructuringSettlementAndImpairmentProvisions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails",
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r27",
      "r235",
      "r353",
      "r525",
      "r544",
      "r546"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r117",
      "r123",
      "r125",
      "r187",
      "r350",
      "r351",
      "r352",
      "r365",
      "r366",
      "r541",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r316",
      "r320",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r316",
      "r320",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r251",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/Revenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r73",
      "r109",
      "r142",
      "r143",
      "r149",
      "r153",
      "r154",
      "r158",
      "r159",
      "r161",
      "r186",
      "r450",
      "r514"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenue",
        "verboseLabel": "Revenue (Note 2)"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyAgreementTermsMember": {
     "auth_ref": [
      "r356",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of the royalty agreement under research and development arrangements.",
        "label": "Royalty Agreement Terms [Member]",
        "terseLabel": "Royalty Agreement Terms"
       }
      }
     },
     "localname": "RoyaltyAgreementTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Collaboration and other revenue associated with prior period transfers of intellectual property"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesReturnsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A revision in the estimated reserve needed for product returns and price or other concessions granted to customers.",
        "label": "Sales Returns and Allowances [Member]",
        "terseLabel": "Sales returns, rebates, and discounts"
       }
      }
     },
     "localname": "SalesReturnsAndAllowancesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r62",
      "r457",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of components of other comprehensive income (loss)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r377",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails",
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.",
        "label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of effective portion of risk-management instruments that was recognized in other comprehensive income (loss), cash flow hedges"
       }
      }
     },
     "localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfChangeInAccountingEstimateTable": {
     "auth_ref": [
      "r121",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A summarization of the nature of changes in accounting estimates, including changes that occur in interim periods. Changes in accounting estimate have the effect of adjusting the carrying amounts of existing assets or liabilities or altering the subsequent accounting for existing or future assets or liabilities. Changes in accounting estimates are a necessary consequence of assessments, in conjunction with the periodic presentation of financial statements, of the present status and expected future benefits and obligations associated with assets and liabilities. Changes in accounting estimates result from new or better information. Examples of items for which estimates are necessary are uncollectible receivables, inventory obsolescence, service lives and salvage values of depreciable assets, warranty obligations, and regulatory reviews.",
        "label": "Schedule of Change in Accounting Estimate [Table]",
        "terseLabel": "Schedule of Change in Accounting Estimate [Table]"
       }
      }
     },
     "localname": "ScheduleOfChangeInAccountingEstimateTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Schedule of significant milestones and revenue recognized"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r319",
      "r320",
      "r321",
      "r322",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans.  Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Schedule of effects of risk-management instruments were recognized in other\u2013net, (income) expense"
       }
      }
     },
     "localname": "ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "terseLabel": "Schedule of net pension and retiree health benefit (income) cost"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.",
        "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of effective portion of risk-management instruments that was recognized in other comprehensive income (loss), net investment hedges"
       }
      }
     },
     "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "terseLabel": "Schedule of other\u2013net, (income) expense"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherNetIncomeExpenseTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of the amounts recognized for assets acquired and liabilities assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature and amounts of capitalized costs of a research and development nature that were acquired in a transaction other than a business combination, the amount of such assets charged to expense during the period, and identification of the income statement caption in which the charges are included.",
        "label": "Schedule of Research and Development Assets Acquired Other than Through Business Combination [Table Text Block]",
        "terseLabel": "Schedule of asset acquisitions"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r212",
      "r213",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "The components of the charges included in asset impairment, restructuring, and other special charges"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Marketing, selling, and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r103",
      "r211",
      "r214",
      "r216"
     ],
     "calculation": {
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "terseLabel": "Severance"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r18",
      "r503",
      "r504",
      "r520"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments (Note 6)"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r22",
      "r23",
      "r24",
      "r108",
      "r109",
      "r128",
      "r129",
      "r130",
      "r132",
      "r134",
      "r139",
      "r140",
      "r141",
      "r186",
      "r234",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r45",
      "r113",
      "r114",
      "r115",
      "r117",
      "r123",
      "r125",
      "r138",
      "r187",
      "r234",
      "r235",
      "r350",
      "r351",
      "r352",
      "r365",
      "r366",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r458",
      "r541",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r138",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r23",
      "r24",
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of stock under employee stock plans, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r23",
      "r24",
      "r234",
      "r235"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of stock under employee stock plans, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r23",
      "r24",
      "r235",
      "r348",
      "r349"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock repurchase program, authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Remaining authorized repurchase amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r24",
      "r29",
      "r30",
      "r109",
      "r165",
      "r186",
      "r450"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Eli Lilly and Company shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r109",
      "r113",
      "r114",
      "r115",
      "r117",
      "r123",
      "r186",
      "r187",
      "r235",
      "r350",
      "r351",
      "r352",
      "r365",
      "r366",
      "r394",
      "r395",
      "r405",
      "r450",
      "r452",
      "r453",
      "r458",
      "r542",
      "r543"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets",
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Eli Lilly and Company Shareholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized": {
     "auth_ref": [
      "r477"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction, at the date of derecognition.",
        "label": "Transfer of Financial Assets Accounted for as Sales, Amount Derecognized",
        "terseLabel": "Amount of receivable derecognized"
       }
      }
     },
     "localname": "TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r178",
      "r179",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax": {
     "auth_ref": [
      "r453"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of cumulative translation adjustment attributable to gain (loss) on foreign currency derivatives that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.",
        "label": "Derivatives used in Net Investment Hedge, Net of Tax",
        "terseLabel": "Derivatives used in net investment hedge, net of tax"
       }
      }
     },
     "localname": "TranslationAdjustmentForNetInvestmentHedgeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r44",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Common Stock in Treasury"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockRetiredCostMethodAmount": {
     "auth_ref": [
      "r24",
      "r234",
      "r236"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.",
        "label": "Treasury Stock, Retired, Cost Method, Amount",
        "negatedTerseLabel": "Retirement of treasury shares"
       }
      }
     },
     "localname": "TreasuryStockRetiredCostMethodAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r24",
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "terseLabel": "Purchase of treasury shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesRetired": {
     "auth_ref": [
      "r24",
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common and preferred stock retired from treasury during the period.",
        "label": "Treasury Stock, Shares, Retired",
        "negatedTerseLabel": "Retirement of treasury shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesRetired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r44",
      "r237",
      "r238"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Cost of common stock in treasury"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r234",
      "r235",
      "r237"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Purchase of treasury shares"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TrustForBenefitOfEmployeesMember": {
     "auth_ref": [
      "r313",
      "r461",
      "r462",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trust created by the entity that exists for the benefit of its employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management.",
        "label": "Trust for Benefit of Employees [Member]",
        "terseLabel": "Employee Benefit Trust"
       }
      }
     },
     "localname": "TrustForBenefitOfEmployeesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangements [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r288",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. government and agency securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnfavorableRegulatoryActionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A enacted or proposed action, ruling or regulation that is likely to or possibly will have an adverse effect on the entity's financial position or results of operations, excluding tax matters.",
        "label": "Unfavorable Regulatory Action [Member]",
        "terseLabel": "Unfavorable Regulatory Action"
       }
      }
     },
     "localname": "UnfavorableRegulatoryActionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of unrealized gains and losses on investments.",
        "label": "Unrealized Gain (Loss) on Investments [Table Text Block]",
        "terseLabel": "Summary of the fair value of available-for-sale securities in an unrealized gain or loss position"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r127",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Shares used in calculation of earnings per share:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r126",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 15
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e777-108305"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27405-111563"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL6283291-111563"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117539-209714"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117546-209714"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "610",
   "URI": "http://asc.fasb.org/topic&trid=49130413"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1731-114919"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=SL108413299-114919"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2410-114920"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2439-114920"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2919-114920"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4587-114921"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "720",
   "URI": "http://asc.fasb.org/topic&trid=2122503"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e39076-109324"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(i)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998896-113959"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998896-113959"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(6)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41675-113959"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(d)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r559": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r560": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r561": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r562": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r563": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r564": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e689-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "http://asc.fasb.org/topic&trid=2134417"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>73
<FILENAME>0000059478-21-000122-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000059478-21-000122-xbrl.zip
M4$L#!!0    ( .]*GE(P A9-%I4" !0W'P 0    ;&QY+3(P,C$P,S,Q+FAT
M;>R]6Y=51;(V?+]_A9_7+YJ'R,P(1[?O0%";WH*VH+YXLT><$A;6@;VJ"L5?
M_^4L* 3;;K$M:JTY:Z)HK5KG^3QQ>"(S(_[R?W\Z/'COF6]/-L='?WT_?A#>
M?^__?OR7_^_&C?_WR==?O'?[6,\._>CTO5M;YU.W]W[<G#Y^[SOSDQ_>Z]OC
MP_>^.][^L'G&-VZ</^?6\=/GV\VCQZ?OI9#BK^[<?N0!L#?.-Q+V? ,"I1M,
ML=X0\V)=W4(/_^?11SE2X!S2C4;3P]3S#0:C&ZPM9&XBH<O_L8^R6BQ1BF%.
M4)E0@@?OP-1=4J7I;1^?CF\WON'1R4>;GTYOG+C^]?W'IZ=//_KPPQ]__/&#
M<?N#1\?//MP<'6R.?/K&'YYN^>BD'V\/^71<D0]3B.5&P!LYOO_J==YXB9]D
M>_#!\?;1],C\V@M=/%R/SXY.M\]?/>?\\1?O^_+.\=P4;H3XVKM,#]O\JS<*
MTQN=G/*1^L7CSTYN/&)^^NH9G4_D_-$O[_BMMSAY\PU^S!<O'S_\?W>_N*^/
M_9!O_/J-QO?[X=]\KNENX9-7#]^<'$.*[=]]DQ>/>/6I_ND-7GZN2$0?GM_[
MZJ,</'_C@0>;\9L/]/AP^K(QY-<Q._WM3_![P*<;J5Z\B/GFMU$<=_S&Y3W9
MGOXS&N.7__S0?_UM)_J^S@C[U2=X>1'KAR_N/'_H1P=\].BO[_O1C6_NOS\L
MP-D^_LNAG_)[TS-O^/^>;9[]]?U;QT>GPZYO/'C^=&"E+V[]]?U3_^GTP_-W
M_?#C__JO__K+Z>;TP#\>E_7&Q27]RX<O?O>7#U^\LAS;\X__8IMG[YV</C_P
MO[YOFY.G!_S\HZ/C(Q_OO_GIH^F!OGWQX\;,C\Y_'/??&[YEN]$7;__3Z=?>
M__K^!G,,+K5 0H7(P^#9M#&:Q#8\AOS/[?./,OZY\0O,+W ;S_[I]",Y/CYP
M/NI\,-'PB ^G#^6;CVX.1V:3,_OL@!^]_][&QL,M?_M<;A\_^R)]_>QAOGMF
M3SY]]OWG].3+)_>>?'_[TWCWNSOQ^]N/?K[[Y!_IX8,?X.&33P[N?O[MX;W/
M/RW?'WZ[N?OD8?DBWSMX^//QSP_3/WZZ]^"SS;WO_@%W?[X3[AU^6K[\_,Z/
MWS_XY.#[)U\__O*[[P\>/KF3OOP6PQ?I^^</O],Z?K_Y\K:&A]]]_^3+VP^?
MW[M]%\;SXL/OOOGYWG=WT_>'#\.]GV_^?/?G1\_L\\\V\ODW]>%W=W^^]^1N
M^?[S?Y2[MP^>W/O\;OS^P<'!W9\_.[CWX$[^_L'X/(</\\,G_WCYG&_'>Y6C
M[Q\\??SPY[OI[L\'/WQ_^X<?O_SN;GCX\[<'7X[WNOO=-_'N$SNXF[[=?/_$
M-O<^P_C%@T]/[]X//WWQX.;_I"(6$LD-FQPKA(8W!J9X XBQ#^_ME>7]CS^[
M^<7]3__RX1O@7C[6OR!Z$9T^VYPH'SQTWGXV?G.R8OM[V*;7L85QJ7-TNM&2
MMQN0TPBWPG)C1.:2C$HWLO<_GJ[_SJ#]:KS^L:W@OA6X^75P3;VT7.U&3+4,
MPRTCV\K>;WA0P.8.9OC^Q_^X2F@_/1H1Y/FM >Z6#^X<F?_TW_Y\A?7W8(77
M88U(K#W1C9[#2)$EV0TJJ=_HW(VY#R-6?O_C,/TI! W?.;RO!V ;2N%PO.)C
MX^>O W_K;+M]PUM_>F2WQV-7['\/^_*&O^X60"O?: #]!A0:RBC$(:4DU.HA
M4N;Z_L<Q?9C_D%4'%*-4,FB@ 3VA-?/>3;5UHHP3[)%B.H=]^N%7L$_BZB,[
MV[X&^L@;/_KB^.1D2C8W1X_\2)_?.N#-X<E]/QTYI-T<^&].#C<G)VY?; XW
M0V#>.=J<;OC@+F]_\--/)W%T_^SITX/G#WQ[N%N>Y+O/Z5 //SOZ\O#[)X,3
M^=Z#@>MW=Y\_?/"/<._VP>9>>OC3PR=_W]Q[\H_X\.>!_9-'^8O\]8'_[>OG
MWW]G3V6HU.\/[SW^_H'&>T]LX/_WQ_=N_R-\^=WTV,\V=P_OI'NWOWTRL#_\
M\K;U>P]NYO]I E2\V\BTT@C.*B/Q:IIOM$@"R:LIZPC._XSTAV]FVUOO/HQ/
M_>0W-,(DJCXZ.==[@POOG8NLCTZ',OCK^R>;PZ<'DYH[_]WC[425U^7 !S^=
MC.3@+Q^^^1(OWOZ7]WSY$4Z.S[;GM\[5[4<OZ?<"U?_$ZUR\D)]'E(M;&YMN
M]XUOWSO_0/Z;DO_6G?]^TT'^^LD?7_SJS5=_>IZ*7-P:VGA[.OFP\_QH4G4A
M7CSOE_M>?4Q[[:'Y1HZ_O,6+>RYN7[S)AV]<J-^\;E)%0Q@!( U^2<OCRQ3K
MH9+6V#CD'5RWEU_?'TT)W(N;-M[LIZ<'&]V<WO5#&6]AFW'OBZ+3RQ+%1_=/
MI\ QGC.<Q,G)E_W^Z;'^</.GS<G['U\\Y-;QX8@LY_???/%"?_GP-U__U;5[
M]3%F@:9FSPVM&\0,L0MY'=@6SP4UC;QM&6A.<>%F_&"\Z[WC4S^Y?>9_/SOR
M-+Y16B*H  ,H]8R9"*S!<&Z"X :]"##4!8':(KX.Z<@64EDBI %'Y V"G% @
M0YYJSSK$,A"4Y-D7!&G\H*;R:SNM2P0U]BZ873,ZPDB I2J.C#A8T4RAA06!
MFCZ(;X*:4\AAB:!V5)?A;*FK@5='KD6J%<:2(WA;$*@7=FIG/M",2T23J%()
M0C9$T!!&@2.R<<$DL6LJBT+S@]9>62@?G?'V^0BG>9&>MZ.YN(H7K!"!*>?>
M6G$N26VXXP7!&C]H+]/><S,%6@B>9T>;%V">/.:A]%_!<^A\<K;UCU^^_?F=
M%R]Q<=_%[>DU?KLXT%KKXA(-$8 ,K89>0^TC-"=M[7_NG-,"4MN#FL"+%?/3
MEU<4;J3VZH5>WO,'K^C9>8GES4OV<M7\HV_NW_[#5]-!/*J&<>D<M($048;N
M*-2'$;XH&80+:PO[6&H);\_J<"FL'AA\Y=O[$WU?70O;/!O?X?6'GE??^/1X
M^Q_"]4_/GWYYVX^.#S='O_6R;VM4;[S$AV]^^M]E2^F8,7+-%B&G3GU$WY%(
MY<(F],KV]H,D;]K>Z[C_,=M[LR@35(*%CL'Z$'A#]E4HVEFQCIR#X/P*A/."
M^%Y=@7 CILNY D74,Z=6ZA"[O67R-E02% Z)H6F?KL#+)8%]#\N?_N_9M/IX
M?/CT^&C<//FM^N)YS+[\N/P+-)$N#9K<NQ9A:3%GR+5BXMYK,G.-GEM=##0W
MS3;3SBP^^(HW=N?H%C_=G/+!3&"BTMAR5M68('@F0*<>(5(=A@3+L:"O_90W
M1VZ?\O9H<_3H9";XM)YCH($+JL#0(CCR32J%L69!-U\,/@^V9R>GGQUO/_$C
M[YO3+_NGAT\/CI^[SP4IJ%Z\%,4F'902%D/I(R#YD /5\F*0NJEZ=GAV,&V[
M_O+TL6^GQVW]\?1JS_S.D1X?^DP@HYQ8G#,D)E"HG$H?"C\JLFH)83&0/=B>
M)]_/YY1 ])$IN)9<.D>P-D2@]PD* .^<*RX&G'O'1],7WQX?'(S =&=<@J&:
M3F>"DC:3:!HI>(*263B&!N3GZ;=)V(%FGWTBL9.*PANH)G>/)0YY&0FX*5E6
MZ]5YF"2%6):'ZE49X>ZQ%>U8!"JU$?+,&QH452Z(:G*Q5+$H;'>2L.P>:.A(
M#%2R6X$<$H?6/74+IN"YRO* ?J=5DMT#6F,HJ?5&I#"D.1%Y:UUK["%X"6EY
M@+[CO'7WD&+MK0_KK%8BI,A80FR-.) 9#G&R/$BOK%RV>W"MI&FI&*92*+#6
M:9- 9:\Q9XV<^XOZ_ (PO:+J]*^A^1.RQ8?2)ZC) "NX C*4GB#DFKS%X(N!
M9@?5Z4N$*7MTH,28,P,VD/%O[A*D=:J=RV)@NLKJ]"7B8[%F8YV.[T4P8 G,
M$J.-I).4&!>#SVZJTY>(5!]"KR<9*B_*P&E<1PU(VIJ%9MUL,4CMN#I]B9 !
M%Z]=&,((4^3&U6H)U+0EL1&U%@/9E56G+Q&<R*D$D.Y8!;IG"H5!H]FTDS='
M7@PX5U^=OD24!, *Y9*]5L"4*4:6/G(\Y<3!]>IVR"PF [^TA0,=.4-+O?00
M002P([(6(-*H07$QT.PF [\LF&HP!/%L4A0,"XO">?8P\H;B%T%H 3!=<09^
M6?B86@_&C5$R<&Z(.4H:3@Y+G5+QQ>"SLPS\LI *!1.W.G(Z G!*. Q+L_34
M1TY7VW)BT>XS\,N"C+FWT*14D0(A9FH]6Q1'\3:R<5X,9%>9@5\:.%B,$"NZ
MRI1Y4\^Y#'4[G1@<,ND*=S\O,0._-*\7AG^#U..0L."),+9)P#8<.3F,8#7'
M$U2[3B1V?R[.@V4<#K$W+I"BLA2A8EE'@*NJL^P<L!]&N ?8UFDMV::#CA7(
ML@#5FD))U,:UMUTTO%EBPK)[H MS,E'G& 6*1-$<RPBH,5A+'GEY0%_=_I#=
MG%9.(PW*-)U2;E#:M(' 6]7AD+.'U!8(Z&XV$^RF U,R-*^&I R2Z]#YG#I;
MZBDZT2P[#.S/YI^=0-IBF^1)RQTZ&!1.M>OX75?O,9=^=2=8Y^QWW\G1VDB]
MBXS\IU*$/C*?$E$!DI5JUDT7 \TNJM.7!Q-3<24(<>I:%I/1 &<Z$A)(IF$-
M=3$P76EU^O+PR;EZ':E'5#/($;&Q0?!$):L@QL7@LZ/J]"5:4L?.9-U+21 4
M*0"F)()DQ0J&Q2"UZ^KT)4)6H#>5.F!RR%RY9BREYP!.69$7 ]G55:<O#QR2
M$,MT,*XS0-&*@5KQKF*::EE09-I!=?H2.ZAXD1 P0.LZTKQ*EAN*!L=>AHB6
M\S.F&&H.>]5!)>*-4&_D< E7P#D,4KJ;=!EY%,HD1X0K%9M:$[:K.V7[QZ[
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M;QAS5; (/.7X5$I,PJ7J'/I9[ M^5][A].AL^N#_HF_OT_'CQ0N\=9_9,)@
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M=>@64X$F%1DU=D9H7%K6N4P7NS[.?S<L43.L);FWX?]3Y<I:*X&'E LNH/'
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M6[:0I%.K!"1"FGKO+51)Y.WE2::51'N'&RO7QMESKATPF/2B-?5D@#B,/\T
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MKLA:\U O2-;,T3-WNQ]C]UOA)W1ST_<[O259AGERSC K(B %QX$ZFFR,B08
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M:WF!S-O_#*!=KSJMDTX;?KV6$6_3^SQ?<P:Z49*^<>[]S7 \&%:"W&G[YB"
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M);*4^^G9UKK83YQTJP^%!!\/.]^ !.;ID!E#N>4QC \ZL6>Q.^G<&#^XDUZ
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MRPE'G*J$+%BU* B!4Y*6\@ 4C1JSSI:/H%6^L14D:!4XS!D<+BE8%$8"#9-
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M")\3"3-DA0+E)8991F+$3*YMJ!=<X"D9[RJ_R.SGWU9,L=N-H=:WWV<0K[*
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MM..YP<X&K1%3V>,GM$/:JXB\C%)X;@7.E!FP0I,I'K]J?V%>X1 PRK,[$[N
MF+,,_*24Q,A;>"&."FSN!#:?)HF) AX.,N,(?GC$@8T@G4,AC Y,&*\\9K2,
MO1)R2NF>A2<FU?;",R0F%4C,!"0N&4G0QG%-&4I@Q2-N<H F"P)Y;0T8]X2&
M&#)(<"6>]<["8Z?HF$Y#?M6[AYV-7[IB]'?N=<7";I<)H$+4.R'J_B3MPIP(
MR<&HXTS /]28G/2((AP 9PV5Q$FVML'E"Q#EE(R,"\^[[CKI'LE;=*^\(RN&
MIP\M<K]D>+H,A+7"T_OAZ01#E49IJG/T?EGXQW.D9?+(..(4L3PXI4L\E8P]
M/*G*8Z';*GC4IO.9MX5U1;/H%Z-TM]EWW#^[T:%VMY12].XII9;S!4MMWY3/
M>5F '5/X6R#V*.]4;4)S[J4NM]TW>LIG/(N*&V7]==2/W58--+_;.866#\%@
M[&6'Q7/0'6)$)]6:G?;A\/80W0]G$1_L2EL08+P]#YO6L6=KNEZ/+W95N:)[
MD:JODT8J98E[EF(^$DD05XHCB[%"( "KHA0XYJH!O#IV,(M]@>4#L(<:DHL'
M8$]H*U8 -C, F\A@)2TU/!G$9'2(2V*1=08C2J(U. C/$U[;T ^OMK9X>Q:+
MS?W&U8]K)_8LUQ>L,DL\6:GZ=T,)5&AS#[0YOI)2DT1.C9<*N9 =^SY7/2&!
MHD UP]1'CI/-]1TE,^MR^2A3%>.Y.FRC0HE'1HG)4YHV$B88<!*5ZR"YB(Q-
M%FE)G<4Z\23+:M$2RZH*[&-/ONW62;-S%B/TL)6K^Y2'C*HPS_EX:<:#_2&6
MY[TF'+L5S-P'9J[DVJ31A2B<1#KEG'HJ<.0XE<A)*GW"..)(US:JI!%55.="
M.3XJ3)@Y)IQ-)+M+%J3C$,4>(TZI1YJI@*P$WA%TE$P!)ABCID1Z5PZ1^6Z&
M@4[W:MWH0.N'FV"AZ VI=^4;>33?2!-Z4TKBPU 0F^VP-19#!3QW IXK63:#
M\59J&I#A0B >!4;6,HD\EH9%F9P,8FU#O-"4+$02B,HS\FSI2(41CXH1E^1$
MJ* 8-01Q4^:-H )9X0)R25J0F*'1D!(C!%O%K)J+34^VBF]%B.WPL V;Q;5_
M%H24G,=N)]C>T0_;P>/AK]RP#X";*VDUE7;:&D8081QL(88)<H)H9%3D-B7#
MM0J9"  EH7\N'R6I/"2K0TDJ+)@+%EQ2#VTTH<DJ9'1.G$DU4 ^ ;A0<MLS;
M&&,V3Y3"4[9M*[_(7"?8,$-LSNL=JV"1.>_'[.5!KE#E :AR)>67=D$R2SE*
M42@P:(S*Y (C3;'2G#MCB054,:0*!JE<'HO#+RH4F $*7'(+8 U<:B\1YC0@
M+O(^;*0&@;",2YI2G=T:W(B9G4JLG!IWRNHU/FS4O,6YLN4T71;$N?'KE#W5
M;N\#D>=*9J^ '?'$$.1<!.3QE""KE 3X"5P#]P@BI+(< )Y6OGGA&4CEX5@=
M!E+!Q&/#Q 1!D=(J'17R'N?<7C0AC1D0E&A=$D!1!"$9)I3 4Q+1++W[8P%Y
MR3"WUZQXR4R2U%2D91H:54#T0""ZDA(KZD")- )I8QSP%6&0C5$BKTP0-$05
M)/ 50EXHPI<Q%>DJI<1:9>19!AY4(<_#D>>2 CD2'2 ,0RXG->4D,:1IB@@+
M[JW51+GRX!Y]P?4T9^V"XL!2)X^Z8W*@H2OGH:F!;FO?/>4SGL6NW]N?IOI9
M<D__4C!;$, >C'_.0U&ET+[G&G-X)=Z()$>4T2@*R1"WP2.M$T<,*R,",90&
M!VN,?$%,=3J\VA!<$AI:P<1,8.*2BC*/.:7$(\JY!Y@@&#G*'0+#.#&G5;#:
ME# AM)P9%5T@MKG8O&33^^X@AEHW]HMNS*6N:BZV8RKZO=IOC4X_UO3OU>;A
MXQ<MC.W>L#9H:0>\Z_3ZEQ+: O&T8_AK**=<JZPW82=4J'5/U+J2*#!Y1YU4
M&$G.<Y'?[+HSS"(9A*3>TT PR?5!C#355F.UU;@4W*8"E2<!E4LJE&P@05&&
M+-A-B&?7G-:6(@<?2: J*(W7-O@+;/BZ6+V-R<5F0I<>FJ**T%X$#C2BIL-X
M^3*&LT*A^Z'0^96D?M@*JQ472&%G$8^$(V.(1IBJF"C-D=RQI#9$34&AA:<V
ME=OF&5*;"BMFB167C(4JF\O/.&25Y(A+:Y#FT2+EK#: 'R+8T@S23$TQ@RK?
MS7R/L,<40<-#9BI5L/>3<I6Q*"X :-)VJFK'WQ&"KJ3]<T!.A& &.8P]XHXQ
MI!GGB$BEL#!.1!)S-"?%TPZS+CQ=J3PQSY"N5' Q8[B8*)O' V&!*^2Y2XAC
MZY'1AN5B\(HH%[S"-,,%-M/RA%8^ED<XG]:^H.:S"@5?0!A:!M9R_>Q)93/=
M$X&NI 94QEH<&$5>D[)P9\[XY32RW&+OE5'4Z9P.78'-M+QUD"O_RG,B+!52
MS XI)J*TDP6I 3GQ*5G$"08CAQ.)J*+<"FE]DD.DP-,\L4OO75E @C(\J-8I
M:<J,/"K+=EAD&8A+A40/1Z(KN0-QB(H*X5&PTN9\I0(9$0420G!IL8E"9B>+
M?H$I7^)XEX4YJ7:7]CS$/[-LX+,,7*@"GYF SR4-\I$%K51 FE.#N+,*:0:L
MR%"NDZ4R$J5+\&%4SNS _N(=5ENDT_QW/*SVJM-J%?T<1C:L]/ *O@%]B&V?
M*YT/XXC-S7'$][#]YD-'OO>*E^VB^=]K_>X@7I_W$YW<;(<K7:SF_"WF_)54
M@B *' 3'*%J-@7"0@&Q2!&DE"'/.:+" \DSZ@6C,PV\P5_V[RXI4Z=]\]6]B
MS4E)Y9/0R"K-$!<J^^>H0,QJKF/T47!UH_XMM?U[1VC?;A:UMT6S>38"]A:T
MY:SV\<AVXU&G"4MHK\PHKOZL;?\S*/IGU3'E9=Z@R1C3R>_J^*_5ALQ\DA(/
MQ_AC'N*_;3/C?&4ZW '&KV3848#BS-N DI("<68<,LY0@/$HI"+T_V?O6YO:
M.K9M_XJ*>^ZM["H:]_N1[$N58YP<YP9(;+Q3]A=7/XT<(7$D$8Q__9V]] 9A
M)"3$$G3.V5@@::U>W3U'CSE[SM$A)+^S+XR9<_!L[8,69:?EZ407"@2L%P*F
M$CY(B"$H,'Q",P1$B8R/"DFL@\%,FNA3A@"]^A&0]=M"J3>;> EMS?UL6XUS
MVPRHV6YX>YZI9TE1W7PYS7@P_H"Q>--^-1B)*2@J*+04"OF9>(9-,=KD '8
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MEHK$6")>6^\%QK=OMI8=U?69^*2,747%@-I&9#P8-I=4(H>%0D)%A@'=371
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M</UA?^>3%HY+H[CG(2H=N/#>"JU]<%2H!1; 6^+_,WHC;RH?'[S]XW1BOY:
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M-@H31/(T5!6\'.NZY+@]B^R3 0^!OD8^EZ1-L9!Q'5K%/$I Y8$9Q2SH3*H
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MXH0P,SE,;KVU"HR?Z<<[T>[I:19]YW2L>:RE8?N-WVS[PG:O!O%'\BS$GY=
M,L PAP-.&H?$#<=.2R[R[-724V'XIS<9P A=H8IV)4@;@]=!LW?>Z=G6KS R
MYUG OMG+#])L7\1P?!Z[MCH-K0#:4H V4T]O8V3$4(PPD13Q9#&R$1SEP#%G
M6 5N%-_99[M2J#WRS!*YBXCU0^P"6IR\BS&XY#@F&CPGEIR51H1@DE<9>X@I
MV/-DL6>*3&$;J6$2!>Q<KB1)2$L2D'%4FF@3S#6QLT]W&5./?$#YT]L^_(X.
M9.94U8O7LYSJL#IWB]U@4POJ<@X>!Q[^>O1MM42(>3WW".SKOQZO5[:<C$:1
M--/$2A8(9S299(*-,C)A@S.J6A#N+@,L"\(V+@A'!R]G]F$=MY$QCCSE0$:C
MU\AJ9E%4 ::5H!%<E4Q&,:9S4LYJ3T;7;?F;%3U?K;W7:? S6S3FSY]GNVBL
M[$68$(B@3MNH'+BH26.<I+!2&<6DU'(0P2B+QI-=-*;J+51224H+;@-CB'/K
MD+&P? AA$Q..687S:7R[TI@YM:9;"N&5"_*B;UTKPK^A^<_^O^''J-UGMONY
MV:YN;V:!S\/DC-U-637-5OTNQD:[TX^]1K^3C;CJ# LFDW\)L5U59@Q2=FT+
MF@1O5>5)>^-!^?[C#1]F_]^N^V)_K=\9/@:G@^I8L.-FGC,_=F,+S/:?^--E
M,_1/1^ U]<7AO,"3KU@'CWW1O_TKCSM&9K8/IG_F-E:0Q#Q +G$B:$:YM$8[
M''%UH'>*V6'_Q/C.Z$NGX]25<_LY(M>-]F]D$SS6C[9U::]Z.R]F1P>&YEIO
M7^^HVT?LQKAMJB]ON#Y57QZ-YOJKZ;G^:CS7?QG/]7?CN7[7M!U.J)P ]%#6
M;!9ZN!].,N3T&N?Y'.YVOQ$ZK9;M]G(6"=RBE=>RW9QZ' '78'5#O5/;C0WH
M ONOF\^XX+12.]^W9SFVY\T-<(/\V!C2E:.+,[B.7T.BR"S_..Y^MNWFMXH@
M3*82_ (LXH]!]U>_'J?QC)I,J$PS6IW>13>>0)M^;E5J%H_*+(ZNALP"K@$K
M^-7AV='?A[^^;1Z>_,DR2S@\^'!U>'(*K,+3XX.?8>7_N04LH17_^^W5Q[_"
MN8/9\1'8QN'!FRNX[^7'7]]\/3KPP!(^7QY]>?/U^-?7[.@;7.=7N,ZO_TF'
M7SPYO/S$DB.)\7Q@5>0(9A5#)CJ+F.=6\D0T,6G +2M*]C(S0\N!3BBN1>2&
M)RI<B%013H)6C"FI=QH1Z-IY1IKN!2S)/]M>LY)]FAZ6QHAJ#.?'-=""]X8W
M'7RZ&IL[;_P=;  K^&DC1C%_!?DK-D[M/S$#PSF8?&CT3V/#>M\Y@R9<Y1++
MB[8%1CQ<]Q<E 1E8\E6Z =Z*C<MF_[2Z<C?O]W;C6 /T%V#U#8+1GSEZN9L_
MTHW ]&/U\@I@*E,0N%AFY="N5@M>#SR!W/DYXIDZG?Z IK1C/C;;=J^JXP!M
M(]EF=P1X@\_##2>-':WQN]"HWD5KT)[.F-KO3O:H4W7 3DZXZU0W;_:O!D^4
MG_"B79TY>-Z%1C;/,\9^CFVX2*MUE=\'0(4N@N_FIW_?KOJQ,O=>XX=?7[[\
MXU][C3?0L(LNW+K9KIJ3/[E,5T./M7+Q2.X=&[Y<]/J#O__0'#DS<,E.+\)/
M"Y_J9EH'/=BJ'K ;_447VO[Y7U-O+]*1@]&<TW'5E_*[YU6"2R_+V%^VJ\<<
M3++<H-OFS/4>SEVTV[B,C3-XK,:9_3LV\DE?9U4'YO;;7N_B['QPX\$##"II
M!LT[[W1S!]JS/$Q5.^'SL0^#VVI:UVP-%4FZ\9\(*))7P//<T</!K_@B?#V,
M0;F*I^=+YX$9]<+<9\G?#Q?=0>>/FE)-E*I7]G+E\@5\9=2%,)%:^4[0^N[@
M+*?!F(V?=B%:O6GT.#F-,P8Y--3AA =P_?/"P@ATP1;>5CV0"YDF-@\S(S^U
MR_UCPW#\OURT!V&$:@)DRY@QAEM[>P:T!H@PW9Q\H9?M=N[S25/N"#VFM.8>
M&Y# $ $8JP[[$5Q4Z)UFI0YD'[D%C=-NYD"G_?YY[\<7+RXO+_=ZT>]][OSS
MXF77GX+CU'L1PV?;?9%YX8MJ1@G#E9YZ"90(_M/L!< ?&B6C[)WVSW;V1\/^
M__[]PFXVYEM-U3$L747;;<1VGA8' '1G+G8'P01&=ANYR7L-6!2;@"NQFC1S
M)YP#; 3X&%CWV61]>Y?AM$*5:DZ.DO@:69T,+CE:M*HE-_YC6Q?5G.Y=N!XL
MC)F89R2"ZU^<9T\D7Q',?PIIJEM6O]UE7'?B13WXQTM8M"8.QQ"H=X%TP$H*
M@)T)P66S-XA$C-?1\9J_6ZU7PZ4)WL_="R":/7: E4SO=@>K0GX!OP\^DB\Q
M:%0,"$:B"[YNHWV19\*T"&AN$33AH@_CWJZ6T?/61:_Z=AR7:S9S_F:>$WE^
M#+Y1H7>>.96,*!K<-F,3+"T#F#SO=CYW[=G=F#X<(_;H''&PO,, P;QN]* O
M6J._Y7[IQ<]GU>1M?X:N' ]37C<[T+U7NXT \[K5.<^?VH5EO'V1+*Q_>7G,
MOW;_COWJ9;:-GFT-Q%C/H3O/K(\753@M=UJX\& ;EYUN*UPV0X1%M/&YU7&#
M9316V]S5NCNY6:,SY8T-E@FPMO-SL!FPS+PLS+S?K3C-.:PW37"7QY"QX(-4
MK1]</#.BB^ZXS7M@H9_A#M#2/+MBM\*3Z7OWAMVPFV_6[S8=3.'A%2.82,6G
MQA?+RZZ[@&'(-@) 8%N]3G7G =T!<!IV"Z#\>:<:.)C#"=CO<&V%:QQ#\T+,
M\ON ;]735X9R.7^L1R/<[%6K,30Q_S:&O0E&3K.!;OQ\T;(9GX!@->/EH&D5
MO3UMQC0U@7(HOP+'S/"Z5;^?7T#3A[*\0Z0<TJ?J!N!5[&;&V_&#O\.P08?[
M# E \*H_@6E"(V'9FC6^/AA210%SYYZW;+M="=15K@2P83LX0SPW(5W R(YY
M[#5C?7'-$[R;DBT6Z9R8_(-^[?G$2 E>1Y"4XYH$26?'VSQ&#(T^> SM[< A
MRZIGK^#2>=/G+\":5^ $=N".-8F-X<-7H]C8>WIX]H%^_.O]U\.#U_SHY.W9
MAY/0/#P)7SY\^\_9AV]_DJ._/I /)V__OA$;._EP]?'+Q];'D]>7AR>?R=&O
M'T^/Z)NO1_3HR]%?'[\<';PG'[_\Y_3HU[?I\-LAS\H>GDC&>3Z06=,LXFR1
M"]8C$2V,DN(D&GD]-A9DH(EPKYR1'!MO)+-1,R-T,-%C<STV-AR!>P3#[K[3
M;,M$")XR:;E.C#,IG, YG\0#QY($)S_>7WZHR7;0[-G/GV&Q&H9EAX]>1<R?
M\4QCQR\_4:,!_JQ"BC"8:8YP!'VJ$#:,:T*3B^G&3-,8_D^K* @SW%D"4*H2
MCS@)2:E4[/I,JU$H(W6 4%Q67ET>?*!49] BN$BO8G/#,%&.F74^ W&;!!9N
M"==-.8PS(;(?%US-Q2SO)X-4G&';1LMQM6/M\W[.>2_^.'KQTTAZN-FNGK7Z
MTO6]:;CH9"G:PX/E:)@@.[S^\.V]ZJUKV^R#]Z384X3>^C;>([>^][W+$K8G
MB%G[9>F>YNI!&DL7[H.G(%-]9YF$N?'1.?E< SKXD G4>J&TUY/3;HR-0_C<
M::_QNHH-C;*F=V\M0MMP3S]0]OE)\PS@[2A>-MYVP*UZB,3*>4F+2R3:U''"
M9"ZQKL=<1!YC^[L+/[@=U4*L_QY2>#6LT<U*(\-PTXCU/)@8X,*)OH]05[-X
MHN_23UU'D;TE$GD)>'?$:.4HH5SSY"R-0D26M#"&&KKD:5#?S>@=.F2UR;:]
MKS<VR+;]\O;L\.RWL\.3MU\^?#GZ^S!_YUOK]/CD\ J^]S?<X]OA7[^<'GW[
M6US/MCWZ]</5A[,/7X]^/6H>YO;^^O'+\5^O!;07O+BW\#R'7S_\]9H=G[32
M87.8:?L.7W["3&GAJ$!"6HQXB H93@W"X(\[G**P3NSLRUU&YYWK4OL"C8?3
M'UWI3*CU%EAL)ZZN6D"Q9;BZ<H$$QI':("F+)O&$C154&)&C:9%QR_0Z3TPO
MN'H_7/TVQE7#F*': :0Z%1"77B!-!$9!VF!)$,%$LK,O=CEF:ZN$?B24>P+<
M?,5R[O$^S89T<G(DSPW3=*K]R2H;8AR%7..J+/?$ DV:LTF8)R%BU;>O]YKM
MQ4%>TP_D6@KY$Y&Q79E".VFD4]0IDT).:K986,(% #[E*0BU (4N>+XZGE]-
M\63K &&]4B@&DQ#/ZOF&$H>,288!B O&V<X^UV)/;A]++D+6=2-[UCB?7(B2
M^\2CU%K ],-2IT \)IK<X]CV@@#W08 )HW,B&>JL1$DSA3AW#MF4=]D]DP9C
M;0V!-8V+>8>TU\T>GP!EVQI5P[<K14DW*)>P15'43<@EU)LBKD&WND0#'G+M
M.'HUQ1XCY5)2P7.BC$><!H$TCPS9X*@/&$M)0HZR:KR5_''=QKG9*.R&9'">
M)JZO-XJ[];A>AR/U"JX_,*Y/? +&I8<A8"A)2A G .[:<((T#CIX'9VV+$=Y
MM3![>KU1WKJA;$U=BD44=7*AV[!C4 ;0B<1.,^=K]G]$:TNF%WMTD5+,6^*I
M=$_?$4]MK#/X>SV#9WYZ[%W1:-OK=7RSRG^MJH+.N\U<Q%.5SC3Z7;AQBMW>
MH&*N'UNY8/UB4-0%G\G5WK;7^*\E$)1E%8C@B57)<TZ53L8GKJ4C07KE4V'&
MZ\P&_W+(/PEG,*8\HA"41MQXAQRU.8<@!$&],HKBG7W.YB00C#1FJGFSU"AK
M%Q3<13/I>2#<.H^C$8)09X7THJR3:QWE/\DG"_X+3DJBP+E$7":"7/0861HI
MMCYJG'T8)N;H>(Y'>4KWH%\EUIX-$FOC)+%VIN*:5/,B#V"EQ7$>\_F_L74U
MI^)NNA2E'G4#?TW5 XS1$- O%PZTKH92#I>=H;1#KIKL7YT/RAK]L+2IMSM.
MMAL4OV;!M6&I4Z_Q0_MF,MZ_!N(DTYC<FP)EV^WFJO.!'%OC[<VRA:I5"WU]
MI*$PJ( 85&GGVMQN)S7[O9%219R]V&ZN';W,=:OP;[=S95L#G8V+<_@\]$"^
M%0Q A$=L0V?9J\&M+JLVQERQ6:D2Y MGV9(;_;77R.)T52T:'VB4P++>']37
MSA:@#@0\<G_"*E/5^Z9AP<9"77?7JC=4!LD2(Z[S3YQTUD#S8_"A<1_]9KNA
MF2M7-[MU^QVJ<<?6+5BIXC^MDVPL:%30T]O21X_0.R==^R4K#FQ+%PVFT6-(
M?N1K-8=J B/Y@('B3E7C/1)JF$&# 7_]N1-/\RH&QOX&?K;@PF>5N5_T>H.Z
MKP'\ !1=N"P0T6\.))\ ],;J2&>V6>%8A5W?1Y)F;P:M1D@WDIB*88!SO:FW
MJG:.UXD:Z@-]3^WFY910%3SP]>V3VCS#C98VAP>VS:L&K!03!O.K&O/AX>TP
M62:B57D8\YP[Z_3ZU;ERS01& XOB-7&P]WOO]OXUY /=V+_HMBNA*F?[(WFJ
M2I6BTK4:B5E=-9QMY05F<)OQE.^=-L_/![/V/$LQ="YZ8W6N2R EC4ILI0_-
M;=Q*S@?Z*->S%8&;<W *L'&!*Q\=B\DKF003"1O-[^#G= %Z#D8UHN9O)DO[
M>S#"D\[!4+\B#C_P=CP4KZJN?]-^.59H>ST<@3]B-U?%C%D^HL^-YI^\%,<G
M<(^3+/O\_NKHST_@2G.1-'AU/.8 ETG(&>&1<4J[O*<A13[0Y2;C/Q]T9I[L
M>;Y.>-&]/8"]1OTPX'LX-I(G:/P^$92KWQ/L[!\/JI0';9T2OQO!5;46SA#_
MRZS%F#EY)58U).9AQ-8K@<?P3Z7NF%?7B2S+A+M/;EC!U:R6XT+(!@Q\@J%S
MFY_]D8G@8H"Y!Q@=F\.U%=I\7LW.*0=AU.JQVS$$Y.\_PO5Y^;"2!/-$+UYF
MY<*7[3"::%?/7:! ''[^9"D6!GN,$B$6<:TDRH"%@J')YQ1ZQM)V"@[<F.V3
MQ?VIR0=P>OO;]Z[(%WM4\7M=]OOO"?9 C94+7?8Y%HMO08'S6"V@L6!E^!+%
MWUOP^",AS5$/S!9[/],BZE=S^$JIHGY*U7Z/>(;>W7QQS!.W?4-KF/CQ!G\\
M\9='WUY"FUYB:-O70_J:?SB![W_QXB/<X^C7]QS^]O5ZXL?AE[<M^!X[//AX
M>GCPY]71P>MO'TY.3X%CTJ-OK3-X'KCV9_C;+VE\JEU5WJ<CMMA@A#DVX!=;
MB8R-!AGM&/&*F^3]SC[C<OO3^>J6KE>*II\/C*Z<3N>Q=SC@I'%(W'#LM.3"
M)^NU]%08/CA5;M[9U 5&'PQ&)_ESU8%_ECE$B2&(X\01#))"SG!.I%(L,+NS
M#Q[0NK/G'@[4YF2=W9V>,'T:U+1?3C<<>3A8*3_CMF2"><&YWF@OS$5XVO98
MO#Y.Y7D,!/ES_E<.#^80?7["2=I"/I/##_?%W'7QQ4I\>B#3_-UF#&XYV%^;
M#O1U' SN* F@FZ.2_68O-?/%!^VY=O=1\ZKP9_NJD?,7<OOO(0Y]]VPH$LXC
M"6=RK7NG?CZ"&O-<V=L[96ROR:0:B1,#RF^C=5P$IB4F''-M=71,<E^3..7W
M]CYFA7.S9<_=QIW;77>KQ%Y3E:6P5# G/%&*.TU=X()3$AC)OE-R<[NK'D=<
MW!'H'2&JNQIG>8W.';@-G1LW@'G1D'". =<_)LS4GN3KEY35>T:O7_O5['&Z
M6.QVN;9*([8D?'W_MCY.ORZF*KRJ "XEU^4[1S:XC0J>"ROD;L,&Q9TE#XOL
M3YB%A_<)J+<N(7:[6C<LH"?]#+I[J?V3#>@(WZ6+]<!NPF+]EC.0[E":>CJ*
MRL<7_5XSQ,;,0S_=QSWI]&UK"P2WBZ'4;>8\>T.IP^X[7.0QU'C^S__2E-"?
M^IU\B'7*IV<.#F@9Y<S_N,B$6.M&5;E!N<&*-UB3[.E@HY/N45'+S<Z#IG6Q
M'^]IHHOJ#I9KU.<:F]:&FV)C,[(0[ 'BP]5U?FS"TMST"TS^D^X%?+#9O]H6
MC=_9"K]93KG,^-4C_6)-66PURK!8/5'-2T*QRX<X1AY]U X[1QSUAD:GZ2):
MQ<].B&&0<''VYMO'L]?X\.27TUR_<'SP]NSX()P>?6F=?3PX/3OZZS7[^.M_
MFD<G[[]=3[CX\.4(KO_GU\._7F-XGQ_]^H$?T=<4VO;W\:_Y/N'OC_#,1R='
MZ6@Z;XTG*9.0"AF/+>+>)*0)U<@)*DB@)N$L6$1V"9F7<K$MF6MK2DXK^/0$
M\(EP2Y+RQFMLN*7<:>-P3J)-EC!%%SF.J(#0.D#H:@Q"R@@1<92(QZRE'@)&
MSFF,M,<L8:8]PVIGGS&QIPH$%0C:?@@*EKBDC(U1<)C?UHD$U(@G[ 07QA>*
M]/CH-,E)U8P8*R6@D\U:O0)39(.*2%A#C &BJYC*%(D+.D?JZIGATWW<\653
M].N'<6O*PJ\1QJV<:*^T,HYX'341/&AJ!$E8!D65DEAZ^\P/K-@<D)$)D$GK
M"*82&1QS!;QQR#HN47!<PTHDF;, 9(::M1U ]FQ)3P&$FV=840I<1PKI+.:<
M:AV9!3?,!:PDX:8 PJ8 @8X!P5/IL< !*2\%  +VV>4"9J.8D\9X+XW?V:?&
M[)D"" 40UJUL+W&(*N_R,,TQQRY8;156+$0IU/!0NZ+8^ZA8P2;G0G-"&-84
M8<F!/%AJD;.:(:9$U$*3+&V?O2 *].&F%_1X:/$(1W_6=:_POR_ ,CJ?MVNG
ML%$.!;U-\5Q$R@6+6BO-"1@C%Y("L9*)4X/9<S\4=%,@V9S:34LB D0JCB)/
M"G%!,+(F)L1T4)%AH7S".9!-MS&0_4"'$#Y3Z[7>I,A@<E@9N6%>)\^<L,([
M2;02MECOAJQWL@WEI$M8>X:,U$!Q3+!(8T&1 Q^)))QHX!3<(<VW,<Q;K'>M
M.S@T>0F&BZO*;8)UL"D8D5@R7$<;B_5NR'HGVS3@(@;-J0./A,+:RTA"CB2)
MF.%@SM@1J=+.OB1JSJDSS]5ZRX'<]U^_$Y.::XXEDYPK987#QDM-)1/<>%S"
MF1M"@,G^AL%!LH %\B2'*(1,R I-LWA0\CPJ+XD ]FWT' VV>MCC,[4E[*.G
M 3Q9HS%7/#B+O0_<69JXBV*1,RZ++:W#EB9; \YI2H@#_Q7G@RR-\\AQK5'B
MPD3+-'$&YZT!M7=3Z[_8TF/NNUM/-'.!""EX@+'2+CEEHD_!.D])L:4-V=(D
M=$X45[0R'@N]SIDD2 <=D. J<$(]-H$#,S5B=5&[-=I2*;*9#IQ?P%^W*W"^
M0M!\T5W4+73<11"<D* U("-WV!OJX"DM20F@D$A>'/>-P./5.&C^[>C+X==/
M4B3#O R(>)]#;Y$ADX1!C%&;MX5Y"@KH!C';Z+P_4(;E,[5@C1TQX.7!?XY+
M2HU)B1/!*57&V;+MM3$+OIJQ8,R4PE83Y%CP0'*H1L82@I0(U@IF$KS8V2=X
M*[>^B@6OTX*=]E%1J6@TF@?/=' Q"L^UHC"!S"('LA<+7H<%?YNQX#S?0HH*
M\< ,XHHIY!*)R((SJ6+2*0FYL\\H*1:\CBJ'+4>!E0,5W 7%DTJ&>,NQDLXX
M3UG@UBOXU>L2J-@0"I 9%%"":*H$1]0QCKA-%EG/' I RJ/7,CCB,A/G>Z1&
M67[%GII1>NN=E%%@QYFE)@)-YM[+K)C-E2CVM"%[HK.\.$AEG=!(4)P03U(@
MAY5 &AP6'+30'HO,BTG=BFZ>NSUIZHR5WE,9'==&6K 9+QP-(D8)+DVQIPW9
M$YNQ)\*C<C#KD)0D(.Z%1,[)B)A,X&]Z1D+V,QF9IQ50LM!K$$S_S79#LSI1
M95OBZ3_0DH$^%R(IL\8X+5E./-=.6299Q-I@CC6P$%(<^0T'TR\_&:F5M!'X
M.I, CX([Y+3S2!,>O"<Q$)R ;@@R9]^^]DY\R118:PZK-QPS$[Q2DE,6C<[<
MAE BG$DXED#ZI@/IEY^PLIA9"7X"5P[(#77("*>15))$EK?%) 7KE7@;M=B*
M]:[3>I,16%'KE6,>AB<?=.6IM5YB$450N%COAH/HEY^L359S19&-N7[$>8DT
M=A$91X3D.@5+679-Z#9N8I<,]+H%*(0*S'D,*X83<+&D\XF EG-AL;1)E:S9
M30?0+S\%':G' A;LH')P@GF4#QA&(EIB%:4ZR5PDSWG)0*^9+7ECG6=""Z(Y
M]D%G 6.CH],\"N-BL:4-!\\O/W%O(_8>(T.Y0ER1A+0U(<O4<(\E4&7/P98H
M75V<IMC2.FU)"HUU,AYKRWBDR3F*0R0B81.DE&5=VG3@_/*3<$&EX!3"T>34
M#F)0K@5 & ?H?0?C8LW./I5J]4VHDH'^$$'SGVW/?F[9[K:$S$L*^G?P47M.
MA4L:*\>C3XZ[7)XH&2',F>'&8O'<'Q@?CZ=/06!,&"$50]KD3469#++*<Z2P
M"]@QJFU./R=*;&/4O*0%K--ZC2$1@Y, :RCEU#DC-;AV4GJ,(]&L*#]LRGHG
M4?/$50R$6A09C8@S+9 EU*"D:.",Q& (W=E79!ME6XKQKG7I95@';&"VR,2%
MPN"HL$2)C"(Z@X>%YL5X']YX)T'SX#Q65 24/-@MYSX@DX)&W!&7(N4,7!1P
M3;B<$S)[KM9;LL[OOWS;P*S(:;'!<NV5M2XD%[B/. 452M;YIA!@$C075(K<
MT<A*P_,19 I92QR*L*Y;Z@1@=%:A9KA6NK+%EII&11U@D:18!!ZTU2'XR)6B
M.%*'0RJVM"%;F@3-&=A+DM(@Z12!-10SY"(XLH0PPF%@O$L.J##;8\64:F5*
M3BAJ8?VA&%S+1)T"_U(EPJW*VU"FF-*&3&DZ9DZCYB(A%KD#4V(6:>D\HE)C
MYQ*'O^9$<\R>8J)Y=6^F'NO0A"6CX\?]T]AMC,X!O_48\.W<CUM=)UQ9DPQ-
MD;G(K3 .UFQP;KEG5'$22KQY(]AR.,"50<SYY2=#I6$T"B0,BX N*B&G*4-4
M$\PIYH%D=)%RSD)=>Z^W;*>OTWRM8THRZX$=1([!B -3 @BW32$!XP[%?#=F
MOLVQ^0J5'!8REUF Y>8S.Y$.-.=MZV""Q(;D,R$-GY.;4LSW69DOULER"@XQ
MPY@GZG70G@5JN+%*.5F.F]Z<^5Z-S5<FI:(EP.V%-8C3$%!.WD;>8)N#440P
MF>LLMG++J&1JU\V[3U@X95)>LQTXDDZ+B(G"L$XH^%>64O*-8<#1A($3:IA6
MF*-<,)/#SAH9QPP245)"5* ,YU 9GU.L40^#?*;&)%@D%H Z$66XELH%CR.A
M6%M*N>"A&-/&C&G"AP/U*5KED-0V2QQ;AYPB&!94$H64T0G"=_9UR=6NF3%%
MP;466@:B!!<D6O ULQ(_XU0%\'&*,6W,F";L-$@.]A(B\H3"RL280#9YBTSR
M5"9P'8+-DD%"/D6]\.K>5.PI4<L3>T\Z?=M:+=0\?&[7Z8;813F;.C]VK]-J
MAL:HV37$FM63KZ0043'IDB=<V&B<),Z[P)D'V%&+Q*'+>;\/"T-OID/4%M,8
MO5)(,L80QYXA+;U!1/O_S][;-K5U+.W"?T7%<^I44N7AGI>>M^RGJ&+'26[O
M>X.3;"<Y]A=7SQO(!L211&S\ZT_/DD ""QN,+"0S^4 PDI;6FIFKY^J>[JNU
MXT%I7=S6CGS"S4:*B=P5ABLZW7YT9L%KU$(4E6O#$IX+%F.5-+3&BA"TQ)I9
M6 >S,*/Z/ 8,$FNFEB!VDHIE: JRE*W75H02@-=&X!S\)D:_FUE8#[.@T!G.
M$1+'# YC5XMMBS7)RA*4;V9A'<S"S&F)7BKH0NKU5!M,-0L9:')HSJ)*VN3B
MMW;4$R'$ N7@9A:^+,W[5O=SGQSP3;,[]P\O)N-45CD%%<!:XZ/B&5/0)0*H
M=)N(2+,[7]ONS(7Q8\D*;,[,21=9[0+#G/*!11&$+%8:KZM,Q!/O%WDI&V %
M&D@7Y,1XB<XFZ0B:8*)S$=%F;Z)%'F4T+6RY,B3.'(,0K;"9&Z:MY Q4+,PG
M#\Q8FE^5I775,?#6+BUAMN'P@7&H4A3"N%1/Y" DYV4!I8S@NF27%+3-<AT@
M.D?2M2@E\,*BU)Y(ND3FO TL<Z(Z0@E'MK2&]+QQ]S^I6Q5(IP</%S<R7<NJ
MH[S+3F!IU_BVKK',0RLAM^5Z'EH]/ZG7/SC_X<;SJF54%+=KK,\U6K^)R\6_
M>]0_'N.C$<Y:WV25^_>-%#GHJ"%G*%!*<N"CY<$":/#*A99*O1I*^<?\*3$$
MGX17EA4@UP]R >:4D2P )N6L(^>\4DJSD5'?EFRV7.DLI05*;XW-$)4*0OD4
M;)6L]S+SV/"[,OS.16TXT(#7-C$5Q*"M8-X9QVBN2M(&15*UWZ.WK>7$8\>O
MBUQI!%0F"; Z.EM 1LUI.\XZ&-/PNS+\SD(Z*'S2%CBS16L&:#,+415:(L"#
ML]$GK[9VM/:MZ40K9;I_Q#>B*44:=$5'(MTA&.N*"RZD)(M.O)V\K,H&S)V!
M%K#!"?",W"'%P*!BWF;!JN8W)"YS<#7W0L+]3T#;CKI<-3H'A"8(21=02;CB
M=3( 1(M+DD(T-*T,33-&'+$8[G5DCO-$.RIRAAHRTZIP9321G=IX0BJ]5N47
M#4U]A4EGDWTTY-20/XD*9:UG*H0MY]-M3B,;FI:#IAD_U2I%3JXDXUD[!L);
MYHT+3%A0GN=8DA'$3PU?$!_:^&*F;R%^_F<>?L@G_<&CB:"OK\S@_;6$R [J
M["#'#*!-\259\N2+4XH'G9L8R>HCZ!]>?GC^VVM3@JB*,"QT$O9<>A:DBBRY
M:+0S/%I72SZMW,0H7),*72:&(10-W$HE>0#T.L3(50[%*P*SY^T4;/51] F&
M2W8R94@LZ5HO*<EEP%C]<7 .T0NP*6WM>+/!Q9(-PDN!L$!R^85%JZP$"\$K
M(ZQ!<-DJI5L/F0<(I$\@+ G#2H3"O$99Y;,C<Y9PG+/4!>BG]-UA]D8&TULS
MBG4+6"01$2 Y[Y* 8 )R0W3/Q^B,T]S8%K!8>3!]8@>(<A<GA&=%JL1 B,P"
M!LN4\9Q,=#;<U7YPTK>6%.N%*,Q1!!!9%A%!>N]YTF"4<B+&H(-LB%IY0'V"
M*&Y#@N BBT(3HFSQS.7L6%1.^NAJ,A\A2KO[-T9O@%KJ>:_B.A '-04SA @A
M&X>^"O@($6C3:H!:>4Q]2E6U)4]!%E:J=CRQ",,\&,\0L*:#%!EUC1@Y=W_]
MRO5K3_$MQ-5_/!_B\8>6F/[P1O+>_GPA*UEEO14'!R84XO,*2X&"2 0DM,2X
M%1G)EU?DRT0&E6)A"3$P<#PP3]2=A2IXJ8R-QI:M'<<W,1S7\@:6*C7$12!W
M6P70!:*UKJ )66DMI2XBM5.QU<%WEH4#4#SW*;*0,CD,*0+S' LS,G/NE"B%
MERK1SUN'G,>.7X/1<:&1O'T$2_\ :PQ!F!M1-+W4\+LR_)[/R>M#--IDQ@O6
MG-22F$^T_6;R)J-VB.BZOLY\6S?\MKST>\<I,B]&9ZU#%% "H L^6I!>.^NC
M;[UH5V8#YO+2 W<I09),QX(,A'(,HZ2-7"KDVL14P!,%]VN5^M? U,?0Z36&
MY',&JX4WX+44PE=!3B^:O-;JP#0CQ%*#M4IS9CT  ]2%<$0SD+#V%'+@LR$P
MB86JNPU-#XBF )68IDS;D@4?=<BQEA#P(JW"8K"A:65HFM'3PK4 31M249RV
MI@*$IFP,2UXY4[+5THM:Y+$HTZ.EI:]!^/RG8>B/S]Y_G?#YG>ZEY:DOW:-/
M4>0H4W!9T.:&Z*W(W$>BDZ! EM;S=D4F\V ^H)Z=EP$S,.P"ZLI9%H@1LF(\
M.E,+>3 1 >%V@V7_6]; <B)RWJ- (JI&$&(KS5&Q<&6CCF@MBH;?E>%WYD#D
M:*6J(DT5KPPTS\Q!YT!$\NJ2<YZ+ZD!L8L_;!M]EPC>&XC3AU!I;()B"H$O(
MZ$ND&W/Y-BUY&GR7 ]^Y0EJ4B5L'3((7K$H&,.^S8KH042+3FE#4 S$I&WY;
M;OHRI"F,CM[PD'D!DXF$!UI;2>?@BLXJMJC%JFS 7$#=166EUHEY+@NKK5N9
MS]*QC$KYX)!FJ6[A8I%8VWH@\I&B*8#@D6NMA?90A4N502^L,,8I23MK0]/*
MT#0G]&*U*RYGE@W6#O Y,B<BX<I;6U+R!@H2FM1:9= V,/5=4J84 ZD8 2E)
M-)!1TIX4!!%6WW+25P>F&3UU/)"K$!6K3@(#ZP-SVEGF7#$Y":/H9P437ZNM
MJ>6CSSI;G_]]/G[$X?3U/8&\?WZZXE)YS$0,#2C@2(93)I,XQB =OTV"ZWR;
MG@]Y.$@X.FQF=,E!]OT7;]\]_^UU2D)%;15#ISSQDE18R$XRX7+B$HR5R=<%
M[Z20_]@\7[]E%RP3VUJC\I&PG+RH2\-''T-)4$7XZW\M5K?J4/L4Q4$45%)8
MIH@8=2(PA&(5F4>OT4;K.F%FP?V"=G@-PX\*PZ+V5(]0:&L6X*)V60'MTR6$
M(E':TC"\ZGC[%,,"/!3G-<LBQ>K46(:>:U:[T""$)(O'AN&6Q+ZLWM.HP&2.
M28( B(C1:IG1%E!:W[V=9N/I7RD23];A_=[!:ZLX!B4X,UW((R5DJ(QG5J>H
MA*4I2OQFGKX>:'VD2%,V&G3<99XE1%%<MMIPFQ4ZJ:1MPNLKC\=/,<6+Y<6#
M(YJ<! ,O:<>%3CA:17*$?1&BMC.Q]Q=>:H!::LF($@0@H8OPM?,;^38Y9DS!
M%*>\AZ:]OO*8_!1047*O@P&6#7F@P*-D*",PD#K&PC4W,:T=H);9EE?9A^K)
M>\< _//Q81[V+GKUWMBJ=S,/_>[O(YMD Q'AJ"1Y9<9B%EJJ'*(VSD-K'K@J
M _/V2DJX(FZ++C.NI20&["/#S"6+8+GE(F=G\M:.W,@:[W9FOU3XHO!2)Q<"
M\JI@CLYAME'37D1>+V^2QZN#[YS&"A*K%BHP+D0M@G.">4]D6P7+B;@5-)(<
M6"TV46*EP7>I!1U:* B^9"P*C*ME0$6;' !,C,JWI@.K@^\LY888D13.!V9H
MTV6@M63!<& ^*HRUXMC4A@-6+-!4?:SP;0GA5V?EN[O8@,"=$RZA%@6XKJ%/
MG0S:X'V)*;A;N/@C>DSZK1F#)1F#N=1PLKI)FQJ"=L4R<-HRIU5DMDK:!1Y$
M+(:H^ );\/U#@_); M1=*BR*2[2;:J=-E0J-P3G)JUHY1,TEM)SPU<%H1HE5
M)(,&,;$B4V*0I6$A0F2E>(_HM="A-O]T]Q=9:6!:)I@,4=$2-0B5$90'5%@@
M>\PN1J]T:Z6Q.C#-""KHD$ 6QXRM$6?./7.!^*KURL@"DAB%K>UT[M^6>OU2
MPKOOEGK;ZH<*/W\ZVWLPQJ/[!9NGSQT&PY2'K.9HU\<>#8[ZJ7=QVVMH:NY?
M'6VB,)X7B8(#:/ Q"6^"3CR!#]C$259C:M[LSD>BDY$IQ.H+JV3(U.3"0E**
M)7)1 JAD10UE&9";&(J^*])6=([]Z)"OB^0>% ?TM<E000/>*7 I>LE#T@WY
M*T/^C+$7Y;FP:)@SA9!?;&TP'AS3$*Q$ZU'*O+5CY2;G:#;D/_2>7[N'!5UJ
MQ@2Y%QE+0JSYV41Q/:3;G#[/9V:>G!VGP7CZ>C,*RS(*,\]#D7$.V4MFG"H,
M4C4*A1NF<\Q.N*IX%+=VQ!-EY0;W_UBI6;B%"W2K^[E/TO>FV9U[AS4*&$25
ME$Z^0/'9%^^B!YXL-ZK(%M98F7&9"[5+;M$1_V,&I6?@563D"M(/$S*7P=/L
M)/(U]"(AQ T >L/AQSB4-A<O5?36>\#$/6JA1%".)CZ7TOJ*K@Z'<^DKK@3A
M36+!%L<@UPY?4B"S(3L;# :T86N'^-K]FXHV'*X)#B76PS$3>"H0N4 0,01?
M:FXHS^FN%5*-AW\5B,Z)%FJ3('C#K%62MLI$/#P'57]H3N:4&ZR-M)](+A8$
MYM84I-,3@HL;F:YEU;':92>;M&M\6]=8YNF2\&MYM/3L^/CLI#M6^N'&<Z5E
M% FW:ZS/-5ICBMG)*AZ-/SR:KL[KFU)R_Y*%;(,S/ F=)023'$($&1')_><V
M^W;:LQI"N3=_SEOKC01PS4KMY0SD@#-G=60IV-I6LH2H:]\>\"WI^;'C-_I$
MWF()5G$!18I06SNYI+T(R+ENI[6KP^\L9E/[@J3,.<O9( /PG 4HA<7H@&,5
M+'.:'$*]*&;3\/NX\.N,%29K45.BK8M>6$*O32'R5'3;?U>(WUE ARB14D8(
MADG5E,Y@F--&LRP)P2%&'C-N[0!7FWBLVHJ.UBW>*W)$6Y07T4?( 4(1(4.2
MA>R!@=)T>E9F ^;./\D=TJ$$SY*OYY]* _,A62822&O!DXWF6SM*VON'=-N.
MNM33$X7<9"A)U&;"P3AT411T8%%;%5-#T\K0-&/$09(IJ\H948K(H I-UEQR
M1I,B X*")%SMZ6):&XHU0U-,R1DM<[9$4:5!@]$8#YE+I9TO#4TK0].,GV(0
MPE7X<&\$H:EXYM!KIJ5S+G*K38S$3T&MU=[4VE#,5+".SH[[>/*5.E&L801]
M?44![^W!![*,W @>HK10"W&,K-G2*FO4Q.>;![\B"_G;? 3=9PW*"6 *-%E(
M*(%YJP*+/"?#LU$I5:$ V.!RB:;IN1SX:N%UD8;+@I"R=85VSY3!613>MP#<
M"N$[E_28G. ITY 771C03Q9B (9.)N=YEARKNV#\MFCX?=SX)<=1! PZ.RY
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M/,1HC<Q>5Q4#: C<? 1&Q,"-)+_9"+ B!8?&BZ0X6M2834/@RA X(]9<::?
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M_GA"SWAV,A[V\ZA%;*Z=72419'(E>UOC-,%[F=%%Y"JZE(5M#&<EEN]JPA&
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MPDK=>JWO+'H4 R8Z):V3E%Q&K1G'5A.K%;Q6M*V,?&CH!$>>[S__!/A(-0D
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M-[\>-W7JTIHVXJG=A1#;':WH?5LZM?.W8G[JKD"YH=3Z22S-MN?<NWE3+)=
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M@^V7O-0.=%H2I"WJ:>&OA;\Y_.E(4[+.:##UN+#8,J>QC H<)4D4%ZV3NS%
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MM$D$;V,+J\W+S7KD$*&#,2J$0&VR@ C6<B9BD,1BS'**>PL1FP,1\UB+Q(J
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M@ G&6V ^"85,HE:D) -Y?\6.)H<G!^7H^/3OG7C63CR[YWO78F2#.@L5M1>
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MZ_1P0WI8N<^*C\4$RZ208FH^-!#8$GXD854AQQQB3QKH#+%&ALB2]Y9U5A4
M=,VO'I5.P9/WNII+3N4[%WP.+AB<MA%O-Y>8"W(PK"I4E46R+HI<T6GKD:S#
MKBIT(EB7S:"#,CY+9R2P?I"TXA^R];9HH"B[JC *>EBI"BK&2#(H40%;">;@
M1$1,0KFL=-0AIHI=5>@,L3:&8"TA*HH8G28(K)]B,A$-VQ8):[:7&!.="SX'
M%PR.V9BL$9FRA4RU,!>PJH#9LJK@K-'2*W)%=U5A'/[6RPY9QNQO74^VPU7K
MGFX@/WXNKVN/1+@A13X;.EZK]#7K' 04E )D":TMCQ0LTQ*;N\E[,EL[)FYB
M(,+XZAY_[5QPMX[7SA W9XB505655Y:J%4JV""5)(*)VI04QRJ)B!E4VV:#J
M)#$ZDOA,OM=.!S>F@Z'[U82B4LA"A693.=0"6Q%&7:P/)6A=L^L*0^>"372_
M=H:X.4.L% ;KC"(F<5&D8H;0VHKHJA=5%U=9^4-99%<8.DF,W@/;Z>#&=#!P
MPMJ<8N-PX3.  ,.6!+KB1/6ZA&BR]MYWA6$<3MA-#7KM;2B^A!]V4 :S'U;=
MA"?ST!/+]JW.1DH1?'0"2!?!"Q1%T5[K5 HDC%L[8+?MF,M@]N/CD;I$.UAO
M#]:!4Q21DM-&!%8Z!13O!8;HA=:!9"K.AI[/W6EBG>)[_5[1S@BW9H2!7U2Y
M7%6-5F1448 GV?K2*$%L_U1,MH:2N_C>#%R.T$'9P7I[L [R222%"*Z(ZD)+
M-\M>!/Y6*$RNU"B;ZM7%=Z>)]8GO]?LH.R/<FA$&7DK'G%TD:A%#*^G8LE"C
M3$[X2(L*;@&J&[_X[C&;=]VX=M..54;C,>R'*S>DK>=#IR'H1%@7T5A9"<C:
MBF 2"1]",<&8F)W?VE%Q6]V"MOJ)Y]BLCB_@-.QXO3E>!]EIQ9:B+9L;JF6G
M.6,$IE2$JU)3, S;C:X<W9EB=$+\L_H-.RG<F!0&KL.":#65+$R47@#Z*)(S
M7LBHG+( -:#M0GPSH#ENUV''Z\WQ.A#BF"@[4UC+SB1 (RO=@%%(BB9G6X.S
MFUR-IC/%Z(3X9_4>=E*X,2D,'(C IGBKQ2^2E%H @1.!-.OXII )+I2BTOB%
M^(CB#>]59=WUM+2\ZB%+'Z./,<JBNO?@P* 7>?BHER%4'Z%(RZHQI!1"S2G'
MH!,HJZA>8LOT%(S/H9N\?'BNR(.M%=&R;E)D9(U$LL$BDQ+*\JK)4D"2W-HQ
MV[(;*]U8N2T5R&"TE\IJ[3RP08PI4&7S.'BKG;2EIVR.A2#./!KO'L/N\]]K
M.WR0GH0D7P2 UR(8QS]JFZ1V"B.X[M7H1+$VHB@)2HK-^1D15*"4-62?7'0Z
MQPR]SL/=4\+@4")J%S4SN2#7*O(G)T5P3HN80H$8BT]$76?H5+ 6*M"E6HC2
MIY@]2.M#0C0QJ:I<209<UQG&0A#G=09/MA9;DI!).P$2C$CHE,B:K;Z<?,U>
M=YVA$\7ZSDR#"]*Y JDZR,XGK5*0U4JT8-BX[3K#G5/"\ Q$%RH6F0XHH0!M
MDD 567'(E'2M/D>7NLXP"D_LIE9Z6&/H]GU.-UF_/[8?&-^>++\[5^]!.Y[^
MS :6=M#\+44$G4%4&ZRI1B$XM[6CW'88<\9)SP0;J7NTXW4M>%U%?2'IK"QI
MD=BR$>!M$BE1$BU'1F:9D<!NL*W3F6)T0GS]#M)."NL@A6'H=BXE*7)"^T8*
MP8*(3E514#*KAZI\3%V(;P8T1^BO['A="UY70MQ%'W.N7C@OBP R3H1@M5")
MM;(8,&>@+L0[4ZPQB7KM'LM."NL@A8';4AG6JZPE$4MR E1L?88K"D4V5DV.
M5\V.7XB/*)1SK*';WQ_-^,?#"?V97^#A\V&X]N'1\860[1:HS6\VF1[.CV<G
M!XRQ&T9M7_5(IX_1QQAEU/:FGA7,*!/+S+3_E1P07,>U8,![0C9AO 6L*FGC
MLU*42P"+(?>FI7>IC>P.SP5,P5(C&1$EM42RW+01"")5HZS350?3M!'XB#;2
M[9-NGUR3"*SU$9PB,M*!JC8X5Z.LOD9O:M9KCM;N]'!#>EAY,'2@1#%I4;/W
M B)*$5VNPA XDB%+E+WR=&>(-1Y89JMUR5", R"70B25)2!Y",F'&_?O[5QP
M,RX8G#YX79 7) C*K1"%2JV_><V"E3HTQ7NH-G95H1/!>H@ )*N>$JA8 U"-
M#P6:M6!"B%EIN(0(NJIPA_2P4A5R4F2"C,)G&9@><FZQ"R@@VUQ4),AFDZ.S
M.T.,C2%<-LD3FZTR$R#ZR#8%V0P0G%'HJ*L*=\L%@S..[(MSH1A!P<>6SE5$
MBSP3KMH:M/.\]JZK"N/PMVYJE8Q>4_M+.%Y['X!;\N2/0^^K3BX8J%+XXG/S
MOBJ1G :15 Y:*T+E<&O'N6T]YC)>/:]LI&[0#M;;@W5EX%".R/Q)(B9RK;6P
M$H@A"EE2E*:F7%TO6=%I8HWB>_W.T,X(MV:$H4>44L*(@>T:[05 !N8&X!^M
MC5K&X*C8+KXW Y<C=$UVL-X>K(.,*D5*JA0$:)\$%# B>FT%LB7$^E>EFGH=
M[4X3:Q3?ZW=0=D:X-2,,N_!YFVN,48!+A17ZJ$2LV0I6YJLL#K26&R"^/ZN[
M\':#]RO'?V7? %_YE6L*T![A.<&W? 4_83LD8+D\GQ::X4)FGQT9O.V%\?L8
M8QBC4WB_LI_Y]E;*Z_(;@PN8K:8L$:2W(2OE5' Y6E>"NG(6\-]/YOP<\_FW
M1P=I>KB0G2N9^NU0I)X9IF^[/7HM>_2/]Z?!>^^>P=Z/OP<HZ$KR(I>4!&/!
M"70ZBQB=MJZ%W[JRM>/5N!L[=5_1-5W*QL?D4RG6) E1 [K8VF4D5ZV)2)<@
M]BHNY8[C.\#QVW,XAIPD8HR"2&L!,4@1:DF"G &0%@'3)I?^Z PR-@:Q4M<B
M30D4$NAJ J!T3"M@,$>M?6>0L3/(WGE-0.6*T7@C+)4B(*4JT%,1-<H24TZ%
M];K.()U!UF<V*-6:\13?:HM!"#IIYI.B#+7RL/JR8J&=+.Z<+,ZK&PD=:X^L
M7["2T6+3K!$A^BPPR1"L"]JTW+QN-MP[R"95LS.1[[1@F^B7!+D6V^Q$JJI#
M=CR0??+O"Y"5&1*;]KH8$%"<$S'D)"J8YJYAHR^8\4-V+8[+LTO.8* 7(!^W
MR[Z/T<<8O4?_BSKR/R[='E&F@T2SB5$/)BR<9*]RU\<8P1@]B.+C9OU/T_D?
MX@ /\3FUJI2W+U"YN93>QQCG&*,0M>.N1?N8;<89S8\G;,0-"]&>+T);<3J;
MO,;]$UK4HZ5>@K:/,8HQ>GQ4O_++:V<;%1^%BUHV]ZP2\<??_1K^TF#L(L B
ME&R 3(F4;'(8@BX.P2Q3]Z32O:/KW;A%W_T\+(?AP6E,/BPZ.@O 8$7(*@GI
M()$"BBZ7K1UEPW;\P"<ZMBH^7ULYKUM#TT8#*B')J@.DY"-Z[U4.KM;@5+T$
MFKTK^]T"=I53:S4JJQ!$RF@$& .M2Z$46E.%(I-!O"2GMD-VPR&KK4FUE.0J
M**ADT 8-Q@?KM-4EQBY-[QR<@^H41I-.*611;$@"5'4B2!=%,91JY*4+8+HT
MO:?0S"4H2\5%%J605$$KI69<ZLR4[$OMTG0L@!T4F.+=&+0CD7W, CQC-2IC
MA<$<?'#>JH!=FMY;R)*)N9BD)&@#J=2461LNB74LUHN5S5V:WCDX!\4BC->L
MY"8I)%E[&J[CBQ2LY:: DNU3XS9%FG9W:K^R;X!^93\RO?61:6;M>%+WC][T
M$],^QHC&Z =F_<!L'49)A*HM0>;_$^B<T=E(E4T4"%(9Q&Z4W+%1\L?PP*S*
MZ*R$*'AU2$"5)&)V01!J4XQ5TH/=VC'A(SD$8[-)NKO@FLA4(1HL+DD*&6HL
M,1/8  %S]I&4[AZ^L>!UT"/+@2L^9X% 14!IQ>0I2Y&4+ID8LB7W\[+["UD+
M"FO2!;TM8)R)U5?*&LEZ",5?XI3OX/Q,X!Q6<P^N.&^,T BV-;"S(M:$HO7
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MFASP0K^83VB1E/.1R-G%9FFK^J"E$+1(>S8W]M\NLP7>T]7_[//RT#G6*KR
MI[EVU_RD%DO_(7$Q]YT;=/4TISD_I]RV">F=RU3#!:M_)(>OY2L<G1S_=>K>
M,O/@Y!7/UUEFXFFBPOM1WZ?)_N?93<M$D#:+RRS&5:+D^1S')G4^DN&XS"TX
M/)\(>I;E.TC1/,UPF#.XEWDHL^W)HZ,WAV]P5D[??_FV%YZG#?T^]W*1G-CV
MU*SMF<'K#BXYESCS09KG*@.X2<Q%0L1BGQVRPCAIT]JR-A8;:7[VR,NG?3!Y
M3H<\ZOY9 LK[^T]3,::'A=]AQGN4[VZIL[PT^?BHI1H]//=ZIT]_"SS\U;[^
MO%D:/Q_R1MQOF#[CX2>'@\2VKSY-HR5'DG>4<RY"AF@%1&U$-+$(R#KQ]%/[
M.M(TC8>GB1EOS_;_^12P]^G @H$OYM@2(5:D/&UH8M7A;(<LI,$B"[S5/SBK
MK['8R8O\J8-%OM(B#_3<+<LDL5,AT@;-^>3@9)FIM,S^;HE0,WK!.F]C_,7P
M]6A__^C-JE7P%>?LZ?2 /V2/WDQ^.CK PT_,7KS2Y%VP>4:47!*LN4ERB7/;
M&N+Z _6!'^AFP_Y55L%GR(3AA[UB"L05P]2O$!NY">&/YPH!7"%N]'Z]_B/*
M=)"8BDYG0/:8SZV=GP<\OJAYLV#S>Q[L^?']<6^]PA]_W1%XA2_D#Z]TAA_:
M5CROM_Z=6'^AI_CGICL13IW#^W_L_?#]/O__8N_IWO3)TY\.=ODSG[W+;_;>
M_2AW]2\O]_1W<O?=+_L7G<-/?OU1/OOU9_Z?WTT_MGL_//OSMT<O7NZ]>VA:
MF>;??MTUSY[^^&[OUU_J^T8_S3E,25MKK.9=U+H39 <"M;8BD-,()9=@6DR
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M7BTF@YW-Z?WA^U9%M49\:A3*B?SF<^)]]M&=9KRRJ[3^K,<[XXSW,.;G81,
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M.8*O9.6(:$-DZ<T78X@WN/BYQ]Y#Y0@<["]9.>+<0)FF($-%HK7*_1!3WU\
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M_O>=W:UHY]-[0(>/] M/<L<TXT0;  :N9$Q$%#E8:I>GN<MT1+%V?7(&$7I
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M=KT.W1I+'+7&$H: :U#Y'NO1O+(@GP&NGA=CC3LCG2O&Z##SH!A<EAOU.AL
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MA(IBD20B%5S!@*-<@QRD0/$LIYPGME.';I9./E)0A[1A(.K2G&0J SH!DX;
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M%%[4WMTF[![8WD1^ZUG?&+WLP00F\-402T1AHW1 S)XG/6MZDU'/2GW@<[1
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MQ)BS,!NWM)3Y/)L)EK[B8=AV.'&QF Z?3,-XQG$Z.$^PNQ46GV#8,L#O\,>
MGO*$UN;#BSWF!"'>=H.!)'@"R(A4FUME"^B&L:8<? <@0@!C -GKP]?7LL.?
M<J/Q/#4).* H3XOXB,(Z6@ :P,V*%0N33-#1R5-<.N#7_#HV*F$86';8U%1@
MS0BT&>H$-PFF$C^GQ$ZHSY#:/K\"73*%6:!>NPS G-$LIF, QZ#[HL*+B'U
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M(/VF36%+*;:'H4X*-'H!&T5QJDY&@4 >[$A[$GMX]XF7%W6N5]U_<CIVC>A
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M/Q$:?QVC?9%G"-*,P*_%IVGNI/P_.3)&]?=I,4!'VTB7E0R_JA'$(_SFV'N
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M<H#HY#Z 5$"MB?A:0=PFRVSUWEO=/<@R:X1F8Z&I&)L$X'( UGW)N9D3$^&
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MGB4/96+.VCD:+?S>X06U:EJ,H3BQT=6)S7L5M9.A05D-E4('(1-7(DXG6 0
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MJ2&BI^C*BGP-IHT2*D$+QI$2["I'%72>)QKJE!YN4;TXI?R3"I5$@K]8$[F
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MD@2UEKR/!800S:HJ89?YAE;%I;6TDGF,-]X8Q?YE+@4-4![ZR<0NNDA!X@;
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M>HVF*]=M;<=ZE@,*Z[G:!N+8I?542LI?8T<[VI_C )^#+4F!*KX?N @ P8H
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M,"^(1[ O8_SY=UB9>CRN#%9J*L-Z>$VUB$ND 2J%76$2^'#$8!I.$C,\8IV
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MU2[XE?8AAI??C\S;S-W9\)5E[+_0Q[OP$Y8LVWI!.*+3K_[ZTR^<9.#][Y/
M=#V]ISL]SS8-J\^&MM/E7>Y;;.ASQ^@/_QX.GCSND=F.+BD1R=XDJ%_/23.V
MM+,XS60$ZA5H9;!":1T1DYBTF( (ERL9!*%1"9IX(C\P.M:=Y9,5BA&'[7>*
M$P!@!6T:!VB-T:JQ9.ZX?7GT54II[>6)AZ7<\D)W6Q.%)B%2' KBPAZ.JANJ
M]@LW<"GG*(]*12G/Y"B)J%2F(EM];0(*O+DZAL@>N$;94B2_>F(&T EF%],A
M 6A#KW!YV"0&<"C/5.D$,8-Q @>GPX4T::1S*3\>+&G&+R?@^<'KDA$\(XY\
MT*#[23S!>0!**EXW6[,D(@Q2#9"I0ETP74K<D!/!CZ8Y;#Q2FXV /PES%"Q+
M]GN$F"HJP,A<IG]YAD#GRW3>-S^ZV(E_XE%KFB6!DXMO@7:8X'$U=QIRC?,X
M#QE7 _.X/(BXFVYZ)-'[P%..TB<]BTL>QE,BM^2-]!' 2XDB:J2CC"+8]?_;
MN];FQ)$K^E=4+B>QJ[",)##&3J:*L6<J3KP[7GMV)YMO AI0+! KB;'97Y_[
MZ)8:$+; /,>JV@<&U/3C]GWUN:<W/R$HE3LT%8>6>79N-"66;#$#QEI6K?!6
MA M5VBLRO]B8R"9(59^:!L26#D$%/1.N ]XXM.VRH1!XY!+DZ<:T<B6_',]#
MI<O==!%? ;K/:Y;T\J@DXY7G1U#]GT3D0KB@^N*E3X.VYT! & ZFH&1$,'YZ
M02&CK/X*&8^8C#GC'&@[NQJV4C775MJA[9^Q [;AK>V5@'Y#)ZL5= ?D,QS:
M];KIZ+K ;?TQ\M!CO[F[_ZO;'UY>)P[88KIH"V*L>8\3B3YYWG7O=85?,NY@
M_%Y$(-R?1#B2\5PC<GL>P4?TZ:G:ZYF=LMY7%WN[0]MJ.D/ZX,7A^'F_O,G)
M=2130IZS%W)Y!%BC. 27G#*$)0TV'@T%I935LL*B']H6^!F)&"SC9BRWA1BD
MNOF-E+H.NI0.M(AM9D:GH[.8(UC:9_@T&D-Y4 V_0\"77YJA>*9$;^HKT/Z*
M4N0FAI9=*8LM3+[@#P>P0+&>4]"?@O6"#8[E >8NF:J5RF.U;M:7$\>RGN'6
M%W<5\WZ-877H[IE!)$@>7:9G70X0K'P$/EG0%\=)4@*=:GZ/9M^!36TMJ0VF
M$F):J^?U91LMFULPM1.Q$T0R+*QR//.B$!D)P"P3ZDTFC[Z#Z),*B41KA'"]
M':W=PB$GQ31&[#Y3!HP&>V[:2Z=1)R7"<DPG=U-&(@%&=N<D*P4L#K;I!6U9
M]\# (3J-QL7 K%4H8GZN*0:BXQ'D'3OD,K0JG/M%K31Q4<M8',E\J-16<21C
ME9UW=";S.3GWOPH&[=1HW7I@CN#O,<O9['_S:)7ZAK4*. 9-X7OB.R/S96$C
ME4Y'G"NA%P*&]MWUN7@S88^A'4J/R5)(Q!,CR!T54S#$_Z-'1BUT_.")_0K\
M/L&+R3'K!6%\@AEQ>:P]Z/)?$ .$E-3&  ET1C3"(B$JE(3'.B/9DGCV(OH1
M?'KHNX,!(0>'7@SK$PH*EPB981J?L1"==,@H4D@) F5D?!O3)\) LVR7+W]R
M!R#*^/[?(N,Z?9[BMH'KCR./'*-[\D'IY1<>?,!U($:&R%#;UB4:KSL\&[BY
M*1DWL>@;-=6OQF P@B?NQ1"F"&W5*W:VTUFQ=# S&+C1,AR[&&&M)_,F_-W=
M<@\,4/(=4-5Q/(PN3D^?GIY,,.!F-_A^V@!=#UHZ.A7MKAN>MMW8/:7=4ZU7
M:N?:2]O"E^?.J>^/3]"06;9CF;VX#YL\ !FTRB?__ONI^V$+#HZR96.!/ ED
MPZY%2R")V)3WE<O=W;1:N9JG/30T"V;]'+-<3K)^+FV='%X*/'9V-O78O-FY
M%QT$([V(Y-+P6X1AENJ*W1=5,TUGBRFP*^ 3LP@,MP>*"8OB(]BU"ILVBH36
MV&)..CZ??VDW[8=J9>0XK:Q!Y]J*)V'T!/$#Q/)P-HJ3F89UM-.D+S9P:)OU
M^NL"0=_-7G&*98?LB/IC#<YWMBR<+UL =G9Q_N4.5 F;1?.?) U=WV> 7J2E
M*7B(Z0$T0_RH>$UR:.&JV&:5,&X2X =&BY;Z")^%=>IV$><8<RA9J]3,BHHE
M2^2XJXV@NG(,IGJ$\1?74,6AVR:GX^JW^_17.*K MV IO!C/Z56?HSAH/?8"
MOXV4B@@[&,H4D;96AQ74+?GZ/'4^!?*D^@\]=<?8MQ*6 OZ/"OL"HR7"&.NF
MT%/A_=Y2=CV2#!%:;@)#-'18^)!<QJ.@"X)1M\=]@B_UJ-@@D59GQ=*ZB\+:
MF*_O65VT13.6U!UGIIT8BFGLSZ%3+RL"6)7"F#(8\/Q9F;^1SVSL!V[UA1E$
MQ>LB/IBGDO)VIEU)="N\,1H0)AS+_KP8Q:OI#AX-F%>0(*1)0I^>4#GPI&:F
MX<FGG@?A/WB]:;R OOQHR*XJ(9V36L*A.^1[[KJAVZ<C#A5QD)9Q^\R(P#$!
M97?5WDB<^YG69%T\A@](1=*$#=<&NT.\ 3(ZT"*+))8 923:.<YT=V-UKQ?'
M#R/3@=<F6H-0I*"BP5@I_E%"UW)XKB\JZTCM&;E>.OM/6G-MG9O&Z[)W:.F_
M )$5J$P<$/<A[GE1*A4_\HH,70^I/[Y[H+O;48:]J=4JYGEJ,4&+'X)"JZ;&
MJZ0\+?I+&K[=]$!R%I\;V=7GV:43H:!\)/G50] %^!X6'K C,\,F\*JQD\)D
MV=N5IH^8&&T'?:0\:5'5"D$UJ!B;!"?A[B!VK0%5?A">+\ 1HS9D-%Y"T@2!
M\@"FIP4"^=T+ \(+7K(;05K]"51B#XFJ(I5D> )A$HC)#'7R*D5JP97"X 32
MP9I$8*90Q!,\,T''LBO %Y&1#UH!4.]A="G1G,I92I&#/>'Z,;H^H')\T?4B
MGU;\,JFQF(1TZMA'ILJ&I\"[AU\@VBL?#ZYDML63>% DGI.4;:K?K5$80C_'
MTQ#2HRBWR'Z635VIICZIINZQJ8-C/CKKN![6B_@C%E ,B.+Q(N<+KPIH5C+T
M?2:PSU>3P#Y[-PGLE[)Z:9[R$U5]\:;:Q033-\$$3J.AC(RDDA%^FLA!_4;9
M@C18ZHX@DL+"8PK2^&%E6^=\-:62GH^^*;UVI#[_1)TUQ@R:/$6=)X?DF8!Y
M#;PPYUR3=.*,"M+A #GJU(Q)/$DZ<?,F39(#TM&<HC#E2D*B'^$:$()JS.(Z
MN41 5A1,/:J5P,GC7*W55Q">>=7NEIW,3VZ(;G*DY2[0->*\5X@9DZ=TT#!#
MS:3.,R131#D8LTP9!'AA._OB77_CL:$<M#STZGC,2EIXJ$T1/PDQ, YM".FG
M<H>U]!W=<8'^*U8Y#DJ2QR3P5 ]MLV4S@1JG)99=""EC#H*3E(L_GEZ9M/!%
M4CI0NQJULJ0O2ID&-!Z.+_ $DG"6TJK43_VNZ_.#X^]C2;2;U*IHV@!^,5_O
MISK\$L&MG)D@O;6>0WC2Q."0Q\H7U_BK=$JLOM<^04(E'Z/4KA>3RIJH*8Z,
MKA\TZ>>Y7MDBWM*T-B4M2(9.(;=3CC9+F6B03#8D#%'C%QB1)/56PH[\$B'P
MJQR.7Z:*=/719<P,M'$%SKM;TOC1F!EM)[-[N:H $\4&@@A;%$1W2APG(^5:
M4LZ+DIP'T+^0UL0B0ETUU$PKU2?2F)%"T7.L$W8VC<S2X@3FMOL3"_M%R#58
M@K,R[>E$ ,QD L+"#E3+$X42*AYLZ[ E%(N,C;YH)<#$9&4N1<9TV1/3=68F
MZ4732'%M]AQ<F[[VF:O38C[,J5^UJI-S9*=_LW-";68@I;)_9G(%+"<5L+4%
M:7ECDOK!S@4(C23?>S-Y%HH.]#?1A*!1[&BXT'<?A9ZOECEFF:P>8H[TB0=0
M B,M2-C8"R]-?*GC^>2=)3#4A]2IYLILF1*XPKPZ(T6.'CY='=-=30&?/*#E
M ?W1!)$;(D^PUZ).49A)5@!531@,9%ZHXU&/19]^E3*$G1%XB5&/WXT#+LZ$
MG^$]$!)H!+V!Z7&KJZ9<1I>H+T*W$LA#R?AC!%8-UGR<]?DO)9E*B6<^/<>'
M<3^-M6,I5)U=J7$PTZQ]P*[\V'#A[[;DG<=C+R0*;0>M$2-W]B2=A_,N)<B
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M4;$+HU(8E5R9UV5QTIO6%(B3T.Z-I1/#Y(@HDM1X,=\>J]4/I,6=277$;%G
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M=:+0816-5@LS0%@".5=/SDV O:,Z8GOJI$C_;S-HC^%_O;CO?_@_4$L#!!0
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M*6?KOYW^*5%ILP%!N,V"2.HX <<T\3&IF$.*--/_>?(GP1P%03DQKGPL)$%
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M9S"]F.3E]Q]2F)R,A_],\74)C(QZR.W^1U<2Z8YSN-5"Q")P ]1HD"D8+VW
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M?K$$$X-R7HA,<,G">6;$X8(!8CA-)@FGI&S2-N$&BJ=,>G^Q;LU5J7>>M%3
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MN(*G+N'$Z\]\VBSM+9T6ULG-]K[:,"LS[J],:-QIA33$1I[P'YD,M8(:V3D
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M=_D&, <AR(!OI5(4K6ZO)7%1H]7-<LQ"<,=-$VMW&Z CTK J,M^@#'N??JR
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MZ/ DL]OZ:%%39AY[=EL26>4H&3%@2MV'@?)"4**C#SEHEWEH&KI^JMEM.^E
MQ^RV7;AXD#RE+@"_9;?MQ^?."4O[D/$@6B.Y#>6.1Y)D*?_/0A'PQA-0047'
MM&"LJ0G_-++;VBK++AP<,KM-\Z1ISI9$J@61/ GBH^,$M' .)!6\T[W$3RV[
M;2<ZNF:W[2++K4?N#5.CKO^@8B+4IL=63WNZ%_M:DA-/!E_:J!F72L9,G:(4
M!"1F,K->I-M)3IM&:)C2Y)0UWJ /9 0O&7DE8N0R$.TA^,"UE, /M"A?@6K?
MR#-J-,NXE&BU,8F++,O$2^/P-;1"1R%X['2G1G___)$W\MQ%.W9OY+D+"PUR
M@W:V]4U4%$)*A'JNRM:,MKZP@JCHI1.6 O??ZLQJJ$Y39AZ[)T[!>U<:9 5E
M+)$:=VX7K".E.;RA";W-T.5&\F?GB>^D QT]\5VX>)B*H0X OWGB^_&Y>^G0
M'F0\C">NG1 ",C%. [XJ@A*P2*Z*E"K&RGT'39M!/ U/O*VR[,)!?4\\#(MH
M7@XGLS!,XY"NN8]<A1"M"(3Y'(@4+A# U92HK+,T&<I]6]U<\>V#/ HSMP\A
MDQ;2K%QJ]FN:GL_>_FT)Q%J<A9-0\D48D5QHXI/7A#L+428GF<X=:+WQT&.B
M<7]I57X[7\S@=/B_89:&[T]A>@:O)M//D\N&A$MP"C0:UBH3%@TGTG!;*A<I
M<4P'F;)G@G5Y0^\=Z)CHK2O5RCW?/PQ/TN@25UA$\V!T;0D!J82VRA,O6(D(
M,T:<38)$E:PM5[[[+#O0?><@QT1U/6E6SE_^.)Q/+_ZX'K3]97@VG*>XJFEE
MC"N)EI/7T2 TKXCUZ,8(QJ4NK2EEZ/)>WS/,,5%=4Z(54WX7"XY_E48C!(9F
MP6AR<AFA7U4O!R53DLP2M"<CD;'$P*3V1+N$YD*R60G3906_8XQCHKF:++=F
MP]8[[G@U&:$F++>6&8R7">G7^J/O<=C1X:%]CSIVQ;U>S:V9==JA2^0R2A\@
MRX0_\]HAMY[:P6Y3J"KPO>_3Z_SH]L+O</=>-."!2Q5<6=<<\]2CAQ%HUIX%
M*4T'"GK=R'?_X_<_[>O^[/94=#GWPW=!>2NCR1)DN?A09"F42HI+8-K2#ES4
M.?R[-LZ7=/WQ+\:+OI!;?KUH?0Z+#OJSKS%]B_JE=4075FDTD4ML!%RFA/(H
M,E6EMU>3N%'-2?39T[?AN+S2!\&\\Z/AR26EES^[]H.!\2$&58I"P2]:*Y>6
M)>6J:YV5=#3XM'YGXL9-OQ>(PUL%#Z: UPV(PQ'7X)SR0_J2QN=I-F VF21
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M2)Z4\P94H/@SK;6A<G ?S)Z"VWO!NN-A+8388=$QT0C*4L"]74@1R^TK7H$
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M8#O-4)A6:GVB-]RQ.FDP(F071&.T@&@RX< XD=HC1.?Q=T)*)Y34&@;HY3T
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M7'"(&6<84S\*A=9V_.''SXVHNA+J?Y<'8#M-5.>!,3)1=84;0%0' -$GJO.
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MO,Y^'+/ 3QCD;AQ!%)$0$D?X,!()8B'QW(@DVE4[7SY_;H11V\2MC 95*P]
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MK?^+.$$<NR2!JN(U1")Q8$P$@C3TL<-QZ&(FAO7WT1-@;BMKUY]I-0!=%2X
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M;+$5C3XZ=JLRG1QUXLI+NBB\K*ZD?>= '^=HQ_%;^<#W^8,<?A'BT!<TB*%
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MEO=I+&Q:1SVC36H?G=9ZWT+2N&-H9D@BY'-X?<3SEGRKSW=]%JM%* +7P4D
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M[W\1_$[\F:29^N%7P=0)TS1)Z\7TK5";<+?DVP*%(7)QB"!GL:,JDQ$8<Y%
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MB/D!Q)0S2'V"7%^5W:7,A+SZ!IL;7QUJ[SF<H'IAUN,D6^"-3$.#<3/F'1U
M;%)-[WB3LHN.YON$HG7/@+-8I"1W2U*T16F#V'-(2& HK1Q5X8A#'(D04I[X
MKB2-,'&TSFZ^?/3L^*&1[@_?NQ'ZD\'!I%W HI@EQ,$.C.*(JRJ^,8PCR;B<
MQ('ONGX4Q&CQ) J:CPM9=XCQ01L,U^D@]7 (QB;&1K AA]EV03 XSC88C*D.
MM&F#8G:V[:#>?:?;=F^8[GS;04%W3K@=OL*,J;E(%Q^R5;IZOGD@RV6[%BP$
M]F@0D  ZD1-!1#F&\B<>=%! _"1VO234,O"./']NG%V+""H9-_W;]3[#8PCV
M$Y(%7$9F)3-(M#_"$XIOS;*RM<M*P7Z\RY]^DG?6)IG\R[XE=NRIDWRN)U1J
MO]E3E]FJB5T5NKS/E_(9Y8=_K.5X7_/E\F->_$X*OL T<I$C?"AP(LV*Q)=.
M&XX"R(,P3 (W<!-B5$/#</RY??A'"CK?W)-"-#K\.ZBU +\J/4"CB*&;9SI-
M>I[?B."/S"['<.^(;XJ[A;+:6NB-6V"[7X17+K6MA<_IHMMZCQD8@,^?R7+U
M?'E7B+KDF\H4: \Y!5Z,"(L@Q@@I'S26W.>&,"(H#HF;)!$51B'WXV/-C><:
M4<%&5E ):QA,[\%6,WQN![&Q ^:'P1KA@)(&'E9CXCW#31L%/ZWWB[BWQBW#
M*&-S(/UG24_KHLX0VOSP+ZDHY"/OG]MB_HD(P@0+F(3(@RAT"22>CY5G%'$W
MCCE!6F6%!HT^-UK95HD &TFK':;/EW\;6/7?;#;T:&<TC$<FHO/@-6:C03#9
MY"<S 29EK$'8['/8L(<,B+TWON4ED]95G>J]J=JXJL:JLN:^BCN5*I47SY>/
MCT7^1);OQ9(\_RPOO5\^?Q5\716[7@18,$$HADBX$41>@F$<BP02ABE!(<'$
MTSJ\9%^TN?'A5A7P5'VV57[J!7BHY09%*[@Z;P18=0SE412@5/ZF0=ZPY0G6
M")Z_VK1-M2O9T>P"=.:QIM^O]3QN]0.M@J#2\ (T.H*-DJ\VFP:[ *\VJU/M
M(AC-[CO5HY-D1^;Y"V/KGL)D9ML0HP#?MXUA=\#IMD%& 6IG&V6<$8:Y(M>%
M>"0I_U"?07W75COPW" )4 @%IR%$KH]@'!('ND)PA_J.PV.C_F$'1YG;4MH(
MV9[';<YXJ#Q/,W_B,*1Z?L/90(V\>+48-0)*!K-=MZ 7 9NF_^&!)C7Q>W7=
M-^7[+QYNLG>R<+YN3JQ?<?GP-$G5,<W+LA2KFJVD-7F9\4YE!/D[N:KR*ANZ
MOJY;-D&L%G$4\C 1#J21(\WYR(^AM.TI="GR,&)4_K_6MNYD$L^-E>IS#*22
MM&*D3JV5"Y )S<+LT\VXOFD_FWF<RN+O*%R=+VG+0W1U!K4RH-6ZFO..:J!1
M_*)I3-9<_J9SR0\7X//\W@MS)V$V[\?4OL,\WI-!_L4D<Z;A=HPKQ^3>R"2P
M'G)2IAG8/(7L4GZ/7'V3'Y?D;B&80Z*$4A@FU(-(8 IIZ 2JW['G8$23*-&J
M>/[BR7.S!C;" 26=?K[8+ES]2_19((R\E&KJ;Y0<=E#7,]+"=I\W64+8036Z
MJ6"'+Q@6-OB[4"$*^;T_B8+<B;8M4Y7%5'Y9K\J57([4<:'V8 GS?228\&""
M7 >B4+H ."$N)&[B!%$2A!0CDXB"J0!S^Y!K0<&ZK*N#,;)D*MK3'$07I,BD
M\)U0_1_-8A#&\Z,7GA@3]9&9HQ4=-+*#;?? 9BXZ\E^ ]^ERK:X>X[304!1M
M1C^,99@T,#(4H?V8R>#GG%O>\:6M)(4X;2GM5=XC"18)=AD,J*O,&G5BV^4.
M#)S8I8@B3@*C&MF6Y9L=IW:J\4F3$Y '5=J\[!9B3/)M+*7K.'6"*NKW2M>A
M]1CM3+T>'[_BA(Y,U]VY/. !*Q[7\W\G*IUH%?]QZB/:$?&5BB!:Q?=XI4.[
MPYR9'5@/W&3N\"_* 5\7ZA#^6U*FY98KPLB)'29"&(>80^1'%)+0"2%E+**Q
M+Z2Q'0U*$-048';KP/KA@13/@(EBI2KZ)"JIK<Z.2;.J.J5^ML3@2=$C\#&A
M'IFAN_VZ&BYNQ5<5M#8*@$J#46EX*(JC9!+JRO ZR82&"!W-)S1]COG^Y.6V
ML%I;0^FS6.W45E(59ILF-M5V*'N^Y/]G7:Y4D.,J8\NULNVOZ_INEZM5D=+U
MJF+J7%5T5T7=\J4<_:YM!MN<+ @(YR%S*4P"$:C6-*J?5^Q#3S@D]'%((D<K
M^^%5M9@;*5=!X&K#LC+/>VJHS>A-.+V7^2\QOV,'93LE$'=*Z'U6=>[WJNR!
M2U7KO.WHU0 "MHBHOMD-)J !!711 ;<YV,5EVVC;O)S!Z[U:^MNA_Q*OV$1;
MI'-YU>QLFK[ZS/9LI+Z>;)-MKKXZ_-T-U]<7QMQ$JXI=MJFK[+D-KUY+);)5
MN>"N&[((4\AC3]I1"'$8^YQ#)A@/:!21D&L=7#L]U-R,G>W>PF,MH/Z*= +3
MTQ:)/:1&-AN4H* CZ46[)?,E =>68=-?;>W!-]&2> Z,1JN5'C(]2\J)!TS&
M^WJ*=,E9\XYA\;Z&YJ^+_"GE@K]]_J44_"K[\BA4.?KL;EMH<Y$(Q_4\'L*8
MJWH"A'H04Y=!P9R(8$ZP[XG%*E^1I5ZD3W]H(X;="# BPTH_LC+W6MD!?08;
MN3MU9LW"? 9SH1?@&P?AD9GY(+AO?JES%7XP@]DXF&>.F,TPGL'HDP;PS%'9
M#]T->,(P/GMWK[IG7&72HE7[K_+1'\I5^B"Y\NWSK7SDY;>T7##'Y\P+!8RI
MH! %K@-Q*'R88,$%"0./ND95H70&G9N56,NLTG^V4H-6;/7)*<'!KTITPY(&
M6E.@1V"V@1V9NJQ@:LQ9)B#99"NM<2?E*1,D]AG*Z-ZA52??"=7+97F5<?'M
M?XKG1>PABI- NJ8.<B"*0ODW56><,3]P.(T]EVFUS#DZPMQ8IRFSV$@)*C&!
ME-.T^.0^D/UT8@6>D;G#&)D!-2B/:']V%<K]YTY<A_*(6B\K41Z[T%K+@,&G
M%+9GL#>=N1>8NY[K27(0TCB1_E:$(,8J%0\)C\8)3;P$#>CZ/K+86I_4]%WC
M/V[3,/($O/O;UTW6G2;W3#7K>H;1'";Q7_K\8J<HQJ>3+X*-E@QC3,_(71VL
MBOS:C2'&P%^CM\0HPPY;KRZ?2+I4HW_,BQNR%#<J:Z8:\KV@J^V_VJ(1?NSZ
ML4,\2*,@ENL/HE M.U N281Y54<&5Z\EPT )3%AHFKX--_=YL8+24'Z03MZ3
MJ'>_R@O I?B@W,AOMJ*8SHO>"C$BUB,SOI(/; 6\ !M58)(7L)3*C%#Z8R!>
M-BG85(1)*74@/OL4.?0QYOO#UX5@::F:':9YR5(AM2RO,M9DP-#(95[@A3#D
MOO2\F7 A\9(0.D$8!903X3"M0[LG1YJ;![X1%G2DK9)1CG>)-L3V]#:Q-<1&
MIJ(>L ;D>_6CIK]+; V]B3:)A[QR1IO#6H#T[ WWWS_9UK"6&MV=8;T;AEF+
M[T61/E4=R:\RU8*Q;DA>_E9%[P/AD4"H\QY$A282%T&"HQC2D*# XP%SA=&A
MC[[!YD:@6UG!5MA!&R6]$.M9>;: &]VD&X"9L0FG X9->ZUWO$F-,QW-]RTQ
MK7N&<<=M0;(RD=^B]&QO1/&4,NG)?DD^2I\X8ZD*P+8#EFIKI3S\JZ;FN204
M&G&/PR@**42Q$T(<\  ZC.'8BP,>"FK"-3:%FQLW;23M?&;EP,KT5B=1C\U>
M:VI&9K^!LV+,?V/ 9Y,OK<HW*;^.@>P^'X\RQE#;+TDSP=^*3/YE=2U?9E7X
MDZT$_RI6ZR+[DJF?U4',A1_2 (?2D^9^5&U.<4AXX,*(18@ZF I"6+M-I6L-
MZ@\_8+MI["WN1E905,*JXZB/\H*F\H.IA6@P$;H6HV5PI[(@*[%!(S=00EZ
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MUP7DZRJO3+/V\J]*)\/NP6?-I9ZY.M4,C4SZXTZ.L>%J U6;YNM9\DQJQ-I
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M&G,W=HSJW>@,.C<3IRMS722\(ZQIRH4&YGK481O)D7FD*^X%V A<5PG7P7-
MUH0^0'9S)#3&G3@C0A^)E_D/!O<.(Z*WZS+-1%F^RQ]HFE5/_+KIW7K%I4F:
M)BG9'$JOW+M"J', G9-:\G?2>N5-%9Y.!9Y%X$0,AR21;I@K[1D><XBQPZ$7
M".2KD%08&'55'U?<N9&?DM",XT:>3CUVG,\DC<RKK:*@H^D%V.H*NLHV%3]
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MTS.23@?-EIZA-O8<C$SP5:"[6_;[\D5&\$4W;4.I :Y/3<* LV##4;1[-FR
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M)J8(#$MD1E42!]*617MGFQN3[@4&C<1W9?G? C(CM#TW]./<SZN#HC<RM_8
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M(U&^73 4A"C" J)4OZY1I%*8Q5$*4QRA-.:41,HJN,Q?A+FQC1$?O%NN_RB
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MF6Y#X#KL(>$&>28^2-R.W/EA8X QW0\D#W0E_V?W1-D^M#M ,DT81#&7$)&
M0Y:R!*9!1 --KBB)K(NQG(P]-XK<BV=O3IZBU6^[WX#!R'RTE\SC2O84!WL[
M^08\)C)\'7!Q,F&O:-YADYX^,9F1>474MM5X[2.>>;[KE9!%_K@RL<1- VR1
MACPB"#(1I1#)6$)"XQ1FA'!&(J$2(9T2><_GF!LC?5QOP9N]C( 6X.]2/%9A
M_DV= ,=,W0O VEE=-\(U,GG9(#5"2D0'*(/FSEZ89MKDV.MZGF6_=GS4OR8N
M7V^>UYN2Z4O7]^NJ*LGKM=[S 8DP12J$,HFY-E'B,L\U@231A$$19RJTZB!M
M.=_<2&)?\K4E\UW=NFV] ;7DP(CN7BVW"_=NWA@!S;%=U0, Z55'UP*> <KI
M=LTR>55="Y4O%=>U><P[8=:,57R17.;?3?J12>.ORT.G6"4!3@0DQ/2H5]KT
M8(()DPF4DD %21:'COFM5R>;&[TTLH+-7M@R(]7$C='E<OT'U8M>F'_]2Q3_
M0L!/QFS]N;S"^)<(U[\(+-TG5JMA9Z\,A?'(I+.']TL+7JJVYNZG0;>L:5A5
MUBUK%-X-5\[;!:V!4S&OSS=UYF2OYA<2'?N?\>2AIL+AN_7F*UU*T[#\4-*P
ME6'Y[Z8&[#]6FU:!PU>F+*)\H'\N*-.'HA"9&FHX@4A@#FD<81A&:2Q4%M)4
M6;5&'E2JN3';0<RC@KJ.3#7(>EE2VM2K,#+W&?F/"K+N%81:6&@*?.K?M?+G
M2[U :]TJ-F2E;D K-R A#HGUH,PYB&#34NR06)YQ\:"#^YY0[X70.Z/XO"ZV
M=/G_Y<_E 4G&-%!)A"!')KHORO29-$XI3 G&"8ZS($*.!]-+T\R-5NMC5"WJ
M':B$!5I:KS/H161MCYZWXC7-B=,9*H]39A<2-Q\N+PX^\9FR2\'SHV3GI]V]
M9J]?GAA=;FE]HQI+CF5$,!2<1!#A*(8D"P,8!U)E 4LX45;%;,^'GMMF;Z3[
MZU_"%/W-WF%T EB_W\P?AI'W<".8A]?L! 1[IYD_&!/YS.Q!<7*97=:[PV-V
M\L!D#K/+@K;]95<^<7.UMU9MG7=:)%.(TI1Z-=X0>4N1+Y8($N.80TEBI6V9
M@$,2F7+='&="T( H;F7+3"?RW*CRK5*RZLC6E/):J[(^K.;.)/B;41E4.GL7
M>QMK\:UOW&:TI./?V^V/I:=%V\JJROLJR_6BSK64V\A+-5+]MK&D_E%%VT9>
MA8Y*;6//[&Y,_YHO]3#KE?Q,7\I."'49)G-JO]<B;?4^S+4 94AKT_,W)8*Q
MA%$8Z?^%2/!0OYK""+(XHIBJ)"."VIK</@+,[6VSUP$T2MR!EAHF0N*@"*@T
ML;=<O9:HW\@?&_B1WPE]F-]?P-SCV. %OOWA8NQ%F.@(XK,8PYQ2;@&PXRSC
M->QD)YY;E&Z?BVX:Q^_T]._KM?@C7VIJ8@+3*.%08!) A"(!:9!D,"4Q352*
MI)1./8B:@>?V;FCD<CMG[&&R.PWX*#\R/_?J[6Q'GRHYI+6['WM2F_14HU/+
M\>SOP[BY#QX;X[_YE6[K?_UGOOV6KSZMY'])NMEW%EJ$@@2Q"# ,B"F;F3 %
M::JPWK,8\42I"&.WVXB;Q)G;_OX@BZ*Z5'CX1E<@!$;:V]S:CNOCY\\>#_4?
MZ\C^6CJR#UW+[D"MV\M=&>3#JYCEE0!?]3E*6R/-G\$;_9>[<OF 5G\\[[8?
M\F.ZM1TE^J'^;#_T^AS9GJ.Z>[#?U ;YPX:NJGS?+_)9G_<7B.NS<V!2+"+&
M-<MF,:3&DQVC(,$Q"5C,K/W7UR:9&W<V<H*#H*"2U-YQ?170?K?U$#"-37;N
M"#GYJ_L@N,%;?77HR7S5?<JU/=6]G_4SO9J#U<.ZS/#?R _KU:/>6D_O5]]E
MU:"A6%#3@54E"B)J @AC22%1,H$11D$6R(02R18K^6C>7 _V=I;-W%9?=5)]
MU<\D&.]K_UD/](T65:CS2J]T%>X)\H/D;B:6U3K8&5*#P3H-@S3B&I]'+3 P
M$D,C,GAO :BSP>."T)!FC=6\DQHO+DB<FBA.S[I?_-\G$?ZXWLI"[&04Q&%]
M=:G" (DP4%"Q4'-1*!'4ED< )0XQB3-]W@L2VZO]RU/,S0@)?M%B_BLH!05:
M4F!$M;\@OH)C__W[[>B,S!R7</&X0;\"D/T=^>U 370+[@>8TW5W-Q8=%]I7
M'ISLRKI;\/:E=,\G/:_ -MJN>RS+"1;W*_%QO:*'WY0V'^7FR]%X<"*>9AB9
MTY@RM]-IFL!,Z-,8EI@(E<:8I4[Y[X[SSXTC7YL*?:Q,!OPN05N9\B9%JP/Y
MM8^ MGJ>=4==E\_R2FR\11F9FJ^N1[D<[7]7E8VVYFKR^*'A:YIZPCGHQ9:C
M"-/>9/GA<W9UY3F,=W&0==-+VZ0$/\FW?S[+52'W+1N40(0'L381XS@VIU=A
M\G4I1!'!7"2,H\@J&,1ZQKF18UM@4$D,?JIE_MF[7T8_\'8D-RB<(]/:S4CZ
MU!2Q0V?@"B,]DTY=;\0.@PO51RP?]..>_7W[^]7S;EM\D-_E,FJ.#VG 6) P
MF*6,F*P/"AF2!$8RUCP4$1&X%7/OF&MN?/,U?USE*N=T_WK_Q JY*5.C024^
M^*E4 $2.I0"Z$+>CFX%P')EHVN[!2M [4",V0@"P!29#TDO7=),2BX7>IY1B
M\XB_T^W_W=&-WJ'+E]I%E 8JX6&"H2 HTJ8+TG02!)I$.$:"4LEH8E5OL6..
MN9''WJ&TE]/;XW:*IKW#[0:,IO*W6</CY6Z[ L  WK;3D2=WMEU1[9*O[=I'
M_:R%DTYR,D92,8P@4Q)!)"(%*<EB?4KA6"5$\"1U,A#FW;?OQN9\7EWX9MMN
M;\2>>N,WS_N17?+LVN$-TO>N&>R-W.3?RQNI,LCXX[HJ<W__9&K^+ 1-$QSK
M=W.<,051ENKMS#F!,@JRB(>2AF'@LHD[9YO;GCX("ZB1]@ZL:GD!+05VV^/=
M2-MM^<'P&_LU?H#NOH*N$17<=T/GS A6D Q)$-T33LH75KJ?TH?=0Y[9!75R
MW:=5RTE^:'F0()G$-$MAF 6:3F(B(&.:4U26()*:DL<I<<HYZ)QN;GQ25[%_
M 1M9I=)NUT /#NA9(2A0[,,A'=,6NO&W(YGA4!V99=IIR.M5*R89_/Y07L:,
MTCG"#IY!DR.Z9YPV9<)*^[-$"KNG?-OH/->A.I_4UV_Z(/,@-T\FC'@1! G)
M!%401TD(41($D 7:? DH3C!.4"*X] CLNSJAU=Z8/IK/I.SS;\9%!?2&*8S$
M5?096V\VZS_RU:-SWYMKB-LQS&T 3M6QII&Q;!I^ ,W(.60?FAXHAFTR<VVR
MB3O(].A\WAZF[X%;#S^FZ9<Y3;5:JM*8*2RUG8*#3!LKC#!MK&048FVQQ +S
ME&5.:5==D\W-5&G9[XVPGI$CG1"['GIN VZZ,X\]9C<<=ZZ#,<YIY\)\/^BP
M<UWSZV>=CF?\N.,_I6D,*,7]=[FAC_+CSOA(/JDW^7*G?UNV!RP^[;;%EJY,
M39%%&BM.,<?ZV),E$ 6$0,H0ABIF/"%"1CQQZM?G./_L&*:2L^P_6_:<+1Q=
MI:[XVW'-B*B.3#^-Y* 6'52R5\:+$1NTY+X#M4;#$9,G<D-RE:L(D]*7)SZG
MC.8[C!O)%9OMXH,^2C^6$=NO:2%;;^T@Y@31.()8*E,=CV0P"U,$$Q0H2D(>
M,FY5.:)KDKG1U4%.4^M,6K:EM\>TFYV&0FID"CH%:3CKQP: #B;1C[=81/_K
ME$$ZQY^$)FPT;+C ZK.>3ERZ69G[@*;#\2M:Y'R!692&(:8PP<(TQPPES'B
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M6880UY;H8KO>TJ4=Y=E/[41T>P'&VYSFY%JVR/O)B STH>%GT*@!F'&WU"J
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M"\3C,!!9"K$,]7DSIA02$>CC)V=9G(A8F5I5#M9(YVQSHZI&6$ /TMY5;=O
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M99"@+(4RB4B8J#!50>;6A,)F6JNO\*0-*?;%)NL>C6!KY/0ND7<=<-O+M(%
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M*^B<;FZ\UD@+62ENRY9VS#/H!MF.K8:#;O3C_7))]?+4IE4C-Z@$;UEE([0
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MJ0$&M=SU;^RWIAWF_80U.)(C4]DYB)].0?0@.CLT[2EP<%0G(D<+=(>A3B>
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M^0G(6F3P1M>\ KYO:4=?QCO@7J2,B "J;4C:)ITJO.,XC>/$]SCQ0XM,I2E
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M+J:G9ZOO!!/\_F\7?T"F7+%!@G!%@F)>0/#<0,RH<TF866'_[^D?)/<L2";
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MRV4,P+0/H% K<%Q$*"B5]"'*R$T'C#SV_KL\W5;ZR2)]URPR+LBZ; D(B_0
M '>1O?G$CY_"@AX$Z6PZR]N_KF:F"WVNFH[E>J5 (OW[[T@"!1<+S+]>Z>]1
M1M=<KLC^XOJ3AV+C8@FG(7R:?""A8V7DU2PLEV_+AU63_GGR9;J<2,>2=UC
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M"=KJ2$1;)H3H<+>I[QPF?]9__+*O.$<"@ZLM<8MC3A$X4]I#UE$0 RQ"T-%
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M9I9[@D\7LA\!A'9PX%)V&7D$9:I4"MG.*)0$$^IM#H]%VEX.VP\$3F_YYYZ
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M7ETL5\TY+J[Q06\*0AN$'#E%IS(A^$CN6TFV)(E9N-1+ZYZ6]!U?N/7D:VX
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MR(!BKNVZ,\0B*#:03!;4#BWKY6RS#7$##V/L=4_J34FC!E[E:+,6C2@6<T[
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MO!)B6+B\4(M^> U8^V<_ATWOLQJL&Y ['S"F.EP^8P(EK(-0*+#*W 0C9<'
MOEVWN/M5.O&<N5A#7I/L.GV7P#FO@*2@N"K"QG[ZO7;/RK=@PO=!=_\F?"]P
M#)@>RSB=_(JG8?;S?#5=7:X+:H2)*7-AH9@Z+A*QD$R9 PI3F.;,^Q)W1(7+
M+;"7F'XX;3[_2(^^PC1]<1_*.UX[EDJV81#0=*..@9%T1?7F="/J8E5R#)*K
M"S(P#3X6#[[8F /WBNUJI;DWC&Z_<Q@,':VTI@,)#GS4]V8^;SZ3C&Z?2&UK
M91*FX(P$R41M42Q(%-$Y*($%;;1WD;4YZ'O\#<-I_7!M-9V+;NBZD88LZ(;L
M(B6%*UJ!C'5*@!<*@F$&;) FV*@2FMQ"X[<>.<RA6V<J/E0X(S@W^TB?>UMN
M;71K\Y:\=H+3WB8,MQ279E7[9#FPJ)DP6:/J)S^TDYJQG,@.ZCETIZ\1@.ZA
M\,)N>6W65/8^,%84(/K*7KTE+^O531<DKR/Z8C^CYO>D<U@7MP-D-,^GIJ$+
MI:<S7*Z:.6Y/J5_C9YPUG^K789YO1D>^"I^FJS"K-X^W37Q>79S77](JW_#-
M3<XQ%@'6ZD@FWWIPLD1:SZZ$Q%.VO,W(Y2YI&A:*O0*G&8$61V!#WS>784;1
MR.D"K\2*B_.M/",/KN08@.1:2(I(B]X;#XHS;1*QX_HYA7B"IF$W\>< 9->*
M&9N%O+6&3I;W:WFVA? ^J5P2>3:B]G1"^JI*$FB7J56+T6C6IC3XD'</>_M@
M,(O7M5;&AKI;%OWDMD7?L*9RXLJ1'$6LTLL!P:'P(,FIMBP(5/X@P#W]VF&O
M,(QA=SU6%V.#V8= /_@I+*_+\ N+/#$KH0[9!152@LB*!)LD:B4\"HR' .O^
MBX:]YC 8E(Z2]^C <Y$2+J_8>; J,J&^F,P@V5(;C:= ;J76(%1!U"Y[GLU!
M0'KBI<->C!@.5%WIX64 C&3[8!D9*5F*V0+SD1S,2#&_=VB@N%IA8FQF3G:'
MMAT4#-MR;V30.U9# ^)PN5A-WBV:?)%6;Q<?</%YFG"=4 HB<([60)(JUV+7
M#)[K0&%R9(EQJ8*^YW'MC"WI^;?B2OKN?DSY& '#^ODCR09WHIUQH*O*:\/!
M<G,,4[)A&9T!-$BF.F9BPI%#0%Y ]2JE%?=/%(^&V$,JALF@=:/8AR@Y4LH#
M;XA_"8L\#?-TG:H+TGA/WB'37)(PG(>HO "4*@FLPY?OCR7>N<O=>^S@&C]6
M24TW$AM8V60A_W<5_$]OME?G.0IA&(,HC"89A  $]@RV)!YIXS9:M1E"=_^Y
MPV0D^U'W43(;6-_D'(7365AL:R($\9F2!J.UJ&EX"@21)PBRCL+.5@G!6VC[
M[E.'<1KZT?41\CI8TY]Q$9L.=/UV=G%.9FFUM4K(O.*T(3NFZP70S FEY DE
M)CWGAHF<? M=WWWJ,,FY?G1]A+P&7M6OWO[]S6ON3^:K:6SR%+<1E\E*,F8B
M8 ZLCM-TX#/S4'0,B)%YX=HD;!]Y_##9M'YTWX4$A][*__/O__EQ0[:W4DI!
MULD44;NHA4@F2CG@I:1<K+9)MLE,W'KD,%FNGC;P R4UM(+#'/]U<1[B-HN+
MOF@KR>-P'D$9*<$'7OL%\$PL*8&>M5'RW<<.DU/J2=%'2&Q@9?^*<3']Y_0V
M]<$(+-8KD,+0AF01ZY@WVI!( ,'('#1KD]Q^^.1A)AOTH_(CY39PFN;Z*LZ?
ML#E=A$]GM;'9.B7A;'#.D6%2@9&=LD1_M(QV(^X-B]D&JSK+!#Y*Q;!'L2-*
M!W:CIZ'!AJ?W6=@L/HO>,RT+9.'K^:!V$+P0D K*VOH@NON]3(\ VV-4#)<A
MZDB[3=>B'GA+HI7UZL]O?CO9]D:S+#.%!12K0YTQ:XJ/I 4OM4].>L-+&Q_S
M[E,'5'HW*FHZD=> FD[-Q7RUH(CH-_*-&>H2R1EFDJRC1 ;.,X12VS)KE;'H
M'96-#RZ=;9YX90HVW]RW!#=O'2Y3V"T"#I3CP&O\[<5J.<WXMP^TD_XE? K;
MIKN$W<22-2#)82+WN4@(64:04BM3- H7V\0:CSQ^N(QA]ZN^"PF.H.*9C-??
MMDD0+HS7F"UDAIYV/6Z!_L" CT(:YH31JI>[^;=H&"[/V"U"CA7O")#QV.@(
M@T87$SP4X6N^5!F(6E.8'6P6UKFH=*^#E X9YM);K=](8I4N=392Z-WM JP+
M.>7D2@&SG-7Y)1YH;7FPM%@E,T6A9L\%PA<P[F4O_>\][F4?90Q=]' Q7YY-
M;TTDV>;_DRJ*883B,NW:=>Q \+9 B;7G+T/G8YO;9H\\?GR@.$*!3;?2'(&Y
MZ<!T_WK=W=?%((S)B8(^0^%?G;$4?"%;(K(L3),H^VEPU"43PY8ZCVQ/'0P=
M0Q\V/\+8^^GIV9KYMW$V/;WJ[7;ULUL_F-B8<M(I@PRU(K=6 D=%7PF*@91G
M*:)H$T@>1<2P9G<XW#1#*'$$=OP]?L;Y!2XGW*%%&<C3X9PB-IUHN6?EP#!D
MV@?/<C^S7K<$#'LO=W#@':6/%V3UWN$BT:\F7(9<D[XDGEA;52L!WA% 4"=M
MM?3&J*YMW>;5P];M#PZTYU#8"\+C^E+\R7Q^$6:_X6I]2>8CX6UYULSR) >5
M6'0(7#I-C-<C+2;(EN<2C'%8>*N.8EW1,^P1\XM#;F>J'<$V_:J9K[N/_F.Z
M.GMUL5PUY[CX=1KB=#9=74Z*",ZBT5!R1MHKK(8HE 19A+0DT<3N5[]T%3\]
M0=6P2<;!T=J]YCHLFNZR\_:ZP\.;\T]ANEBO1%RN%A=I=;&8SD^W_:L_?,+:
M3??565B<'C15X8"7'-^+^UC..FK*?>>]ZWX'L[#"?$(H_3Q=3?&F-;'QSIM:
MD1M]/2T16M8Y1AJ$UUY&B<S=O[+0E0_?DL+CHY5;+[K1S,FV3?KU"W=-+?&)
M,V&8!2,Y!Q55AE#J?125HD'.?.0[^L1V+)T]B1XV'.\'>0]#GF=2ZB@'%^QO
M9 X>37/PJX8PI3V.KFD/:YUM2E(@%$3:GF/,X&.T8),KJ8CLLN@I*?),!O4F
M;_S(*U\UR]7R9KF1--![36$?UBL!640(+C H7L7,K?$E]2*0/>E\*69S'WP]
M/DN@>]5](Y;R\)$OA[]K"%O9YTB8]F"6%,(PS104[6@KEKI.%B\>+,5+'A,+
M&7LYQ7L^8XD42=6[[.N5Q2<N&1:XI27$.3D]/G@(@EP1KR,Y)4XHP?N9L767
MCI=B[/;!QP-C=X3HAQY.?G<Y;Y;L>TP-L53ELW-)3Y(07+D4:^/WVL2.M@;'
MR7"SDASCQ@5I6XTM/^CMPQ[&] NI9]+)")*&=^3X 5>K&6X"JQO6WRV:S]/E
M^N229)F"-0JB8+5F$UUU$! "2IU1!0JP<N_V^ZMD#GM\\SS6KD?%'0[+9A5F
MG<#RAH>WY7ZCV#?DL93I?+K"V?0SYI^_I-E%)B'\J6GR[^0F35STWK"DP*KL
M0*E"\7Z.'F31(4KCR/[UXF0<0_2PYS;/ ]EG4^HH0Y/K>7%OYE78ZX.& Z*.
MG8\Y/J#X.G4=Q0J_$ 3^'F87>).INT%7,*%(L1Y.74>,>BEJ:Q@/:#2/V4LN
M=.ACY3Y%U+&F;->S;R+ND.M 5YVA*,SD+C""M1,&; XA.F>*Z6<.YI-4#1LM
M=(:0^_:G.TV\& -S<![XB8?U8VQZS.4^"2C#G7,E%L@VTX96 @&*9?+7&;,Q
M6Q,XMKFK/2J3<Y/V>TVARN?U ?;REJQO)I;>&F/Z#A>E69S7 )H\@)L?-U>E
M[;_6M])_[PV%UM;$&+P@R=62'Y\MA$#KIWC/:Y]:K7F;O@I')'O[9G'$QG ?
M[#Z>&AX51D80$M](YC=<O9F36%95#G_&?%HE=)+2U30>O(K_7S7G1.D9SI<D
MP3?_I[UO:VXK1])\W_^2L[A?7C;"=MD]M5%E>VU73\R3 I>$S2F9])"4NS2_
M?A,4*<D2)?%RP .Y>SJBIJX\>?F0R 027TXIR.%OL\7=X>DE*:684J"EKL<"
MCE'Z6GG16$3G/8M:[D(3>\0Z&4Z9<4]^3K B1O)[5]A_%19?WIS/_K%1O]9C
MF \U@U(IBY(0,!1-?N$.8JSON+,I/@0F\UVNK:'A/Z@^XQXPG6 %C.?]#A;!
MM7TW@XE"-7%^-_V Z6)>CTA>AL7D5NF@18A!Q]K94@F+O<W@T#IPW'I-JAO!
MFXQ\W%?0<0^9FL&VJ;]ZPN.F)W3%K_F4DD'P)!U/@,RP.N$H@G-60DD)'3(N
M<FP+RGVD';<1N#TRFWFN)WB^O'P9SFMM\/$+XO)O\]G%-U+N1B^&)+GAM>W/
M8&T +!"BJ ?(E O9;$-LDP3L*N"XSW/;@W!(_W2 NU\P+C_6)71U0_$]3,YK
MVO%F-J_O..ZD("$IZS!*8,56ZE)V13I>&_5E5IYKXYJT/>\CY+CCB)KAKYF?
M.L#@'],Y7@VT_%N83&OJ^VYZ4SK>S8,Y"Y@%Y1W!BTH2XC,$0[H6I[CT7DD=
MF]R>[R7E.&RVS5'8SE,=P'"[2C>'$*%PE"O61&=H*5%,CUA3"U%;\JTU,3<)
M?H^+M1/0_+,#VH"^>#;73&_KY+IZ@GQX-^U./]OFZNEQZ4]Q"96ETC(G79F!
M0IVSER!2&0HY%":Y#[C;$+&N+J'N5.4OIOGQ(NCJT>7\QYIHQ3+#O!9EQ?SJ
MO:\L6PBT !T(P9+PR JE"2<X7CE<@XZOD/9!WA/G+B?R< ?;;3T5)05^P<7D
M\S1<L\&YC&AYIBS!2UMG802JVV6 G#TK 35FWZ278[LXG8#NM-B8#>ZH+N&V
MYI>C9*1XB[1D+2FC7*+2O00&B3(*(:WDK TGVD,"C0NY(9S])'X.L'P'"-HH
M@/G%8JW33?ZS&?/!*IM01- 9*1W5J,A.5/R$XA-&%E+@37KO=I"M-UP= H)[
MAR+#>J0+D&WZ2&[EUIMJZ.7E6LM5:W%M2?\R^;9:GTK(8*,.$*1W5^3^/CM:
MGZ;2!]K@4FAR*'*8N)WT/HRZJY[ T1W >8L:&^)RR[(U.0/SE9"E1 6>RPP9
M+>7.2FG2I>&V>U^B<>/C*>"P?5\^TC<=@.QVGP4IM [\@C,K19VNID.FE"5Q
MBODZ@;<VQJA5-%*T -A6:;K8?(_U]%W"I:/-W@%V?IM-/].O?:WW*Y_HOUFM
M*@Q&))DY9%];;9QAX(P14'OF:;%I7MJ\H-@F3"==4J/NE4<[J4.@K1=@#LAY
MM ZR]%4+[L%)6H68B]8:O5>\R:'E=G'&#5/'N_D)W!Q@\Y'?M+^9S9%*G%>T
MG'":+G_!Z>SK9%7Q5)W6(5>FY -:58=$U]9PKZB$B@P*\\S+G*DZOY/\;WW!
MOLNW^@+((?Z<-31N!V%F6Q[Y8;+X<[66N/4\B:Q K/JH2PP0I2YDK1QCR!9Y
MFW=RCPG523ME=[7@04[K"H ;0LY;*]44DM]+#E%77@>5&'A'B:=F2=(_T=&Q
M)I=0CPG57]UWF.L?Q-21?AAY!WQY<?G'XI?*(CO_B.?GKR_FL\TLRUATYEH"
M(NJZ[ QX;QGHP@.IA%[D7<;B//B!7H!QK/]F0QMS?$14P:L"&V4V0^QX\E(&
M!Q:= R7H#U&Z#$E$*;5+1NTTC/[!#XQ[;MD*$0,8<WQ$_/$Q7\-Z-?&2?/.?
MN)E[F2.W+!"Z6;[BO2@0C?80G7):28PIJ!U#Q6/?&;=6;Q8Q!C/M^#!Y6?MG
M%U_>SRZF.4SS"O8?KV"_F0\F;4&><H @= !EG0"70P+KF+4Y^.BLWPTK3W]L
MW.2W%6 &-O+(J/GXC_#MCW_[^&]K!3[-;NV:J+,6(9"1ZH0#A8Z,Y U"R6B,
MIAU5R+(#5A[YQ+AO>IH@9"B#=H"+C_^8+!9O*E\BJ7%+I[4VD7DO(TK(J?(\
M)4JJ@J>_-"87+;R51CS5T;G;E\9]=-,,)0.:MX/*^-<I_18NEA_"$JMV:RUT
MTNAXJ'.;J;Y3Q=;Q?](3#+A1RK&05),GAMO%&??YS.!(&M#V'2!HB-.JWZZ'
MK81<I"[9@[."EH^G/P09'<AL)4I+JRAVVQ'\VU[30-N_>1WU^' \6'2P)FY"
MQO6PG[>SZO]P_N(K9:#+,^8D9Y$4LJHP,JV@XD3S5(\VR. Q&:ECVT/'!R1[
M_LW%!Z+FP:/*(5S8%297MKVKC%3U.7H$S2MQ0F*Z/HLK((5DGBFRG6PR1.Q1
MJ9Y_2][06#S6=1W@\/?PU^3KQ=</6/.GVJ(3*CGM\O)=N7?U><U>QL]*R3D6
M)L';6IMS0I*C1099,ZT#3]:F)O@\2-KGWQXS#&[;N[H#/-?[_T_K^_\S+-IF
M+BQ@$AI45J62@M&>H(I*PABKVLQ1OBW$\[^\'@9]!SNF U"M)E%>-4:^R/]U
M<?76F!;-??XZ^COORJ?PUYF6Z!.F DPA5:(H%00=:-F4:*))E*KH)G2G^XOZ
M_,NC80#:V,D=P/@FKM_)652=#VA)#\ZD(+.MJ&F$@^)%%(4I[MO$R8<$ZH0@
M:'1(#N*PD<_ ?\%%FD^^5?%O4^"N1QY<_GUV?O$5-X/-BPM*AN(@E41ZV4H,
M8J,"8X)V7$C.U2X7:_M\LQ,RH-&PUM1''02]V\>Z/[!M;E[.?)J]1++O>5@L
M)F6"^9?5<(ZW^->2B]]GT^67!<7[,Z48*J?JI;6K5(:&,I:@,@B3C"JH0TY-
M^OV'$;\3KJ'1 ^H(8-A_"?BK)3#%S[7/>-A;@5M4.:^GRY4#/GT)RU?A/*W8
M9DF[E9-6_S*M^(]?R,-_3,M%969Y-?OZ=;*\^J_/C(_(ZP5+ELI5 K$(,=<[
M>IU93LE39M_DR'1X53KA1QI]<8P,DK&?40RH_>H_?A\N5[/!:#N=Y3,ND[1)
M)<#"*D&_21!3G<Q-_T<>2K2E[M)>UE;*W6X;V,^[%#H#0@?IT^O_OJ ,\(96
M\LWWMY/-9GEF@\[):@_,&P4J2P:.)P,H=2A%H.&AR5"2QX3:#</_!%=F@WFN
M Q1>DYF6V7P1SO%&JU^G-X235;/-B)3%_[N@O[F\HIN[YN-:<>FO"YGPN4Z@
MF$V_7<U:J;Y8N>P,B_"6)PZB>,KNE(_@,I797C)I=&7J2DW>6YY2R=U6R3_!
M95ZWR.I@U:U.1.G+MP83K?V54CV&POQF-G^QJ.S"BZN#J5^HNDJSS]-JL[/B
M=7#9:?!%%U"ZD+:!"]"D+9DAI!!]BW5TG-B[K8Q_@NO"$WK_V?"OOBX%TW)6
MZO.[W\.4%GK]V[?^A6%Y67?^7!N^UL.T/06/J^,>!7<9,%9R7RHLP?M,Z0O:
MC#ZHDG(3XI;GP>/JO2W%8(;(%)48FJH+Y^JD 4<UAM,)76Y[-/,3\[CN@[QV
M/*[[>+B#1.(!QDATPF44&G0.GG8GI<"98J'D(+70F<?0)-'^N7E<]\+&;CRN
M^SBJ2[BMGP=(Q109@(%A7(,*0D+@W%+5BZAR85++?_&X[N7L77E<][%\!PC:
MA354:,6Y*.3O1$ZOSU@A,!9 "TNJ>FLM:]0S_EQY7/<"P0$\KOMXI .04?S.
MUUIM7M0'RTNEB3?%1U#,4!A'@9 R9RHF*JC:3*[9(LNX[=Y-0'2LQ3L S>-D
M,!J55%Z"]CK3AE]M(X(!*4NH:2L7JDE"=31Y4]<'C<>G58,YK2L ;GE_R3 K
MR8P S(RJ(Y$U.!$5"%^DS<5$K?Y%WG2@Z_<A;]K'#R/?NZ_:;_*;R5^8:U?.
M+5J]XA/G=7JL$M$"Q>( /EH+WH3HI'<^\EV8$Q[\0"_ .-9_LZ&-V4&4^:%1
M:VV?M29>"87<21 )J3[)%L$582H'D7!2&A=3DR%K#XO4,>?3(4 :V <=H.G5
M?+98;%XW/:)62+J87&VD/0=E@H,H2$'-,BV27-D%FO L["A?Q]Q1Q^"LA7<Z
M -WZ4=WKO]*7,/U\;P6A0U\'Y0A5!U_FS"%Z)<'+6# 9KT.C4?:/2=4QU]0Q
M !O.$QW ZB&:$N:-3)K*6%O+DT"U;$!-]L%2N"[,"]/D"<\1%#'C4%(-M2,>
M:/L.$#1LBX'5E%>Z'$C;7$!QY. 83V!\YL5&2ZE"ZO6R\;>]*&*Z[ODX_I!B
M/%CTTOF]JIZN;WI3<-$X2FJYK@TL608(B17:'(SP-F?G]$Z4^5M__?E?-A[H
MZFV-UH?;O8-H^FJ54]QN%KP93'U5CE<K_3K]45M^QC@ELTDF2%Y0"26X *]H
M,\(LI35*BNRQ2:UQF+SC '8HF-RM.$[@LR[>?3VFZ _*_7"=MN!GR5&MA:Y0
MK56JIHZLR[,"$Y2QG!7$-H.R#Q5XG".8$> YF-=&Q6<UW _O+V_F9&O+DO(&
MK NU8U52>NZ"@42R)TK9N19FAUUWZX\__ZNHXS?=XZW>P9Z[:K9_-?M*W_^"
MT\7J<B7-OF)=(EN?]=X\Z4TK?[^L[?Y8*3PJO1'7WH&F_ZM+QH#/1E-<2FB4
M$"9BDVUX.!7&VYD'P-*L"\=V .E;$?XA,JY;H?[M;/EH0\SBS#E4QM49BQ3X
M007C(5C:B5@1VG%5:&]H<A,[L![/OS _+F3W (_1,X5'!]]^N'ER8I,-E >8
M2@4?0*&N2A4.66:I9:X/K/0.N<..G_N9B-T.S29:>.98N'V:+<-Y\S3C/BO8
M]23FU19T=V,B^]==R9MHM0T:<LEU5Y)D""V0=D@R2A!!V;L#J=JG&X>I\C/1
MQAT3F4<&20>IR]Y)VZ/*EZAEY-J \%F"LB:#3S9!THGSS&V2LLG%Z*!:_$P$
M=JT61UMH/)LGI=?.FI5M_WC8!Z4[?JS-<])#-#W%8U+/A*1BT0,SO#8SU?%D
MJA#*5+:90"]2;$)F_3P>DRI,=;RCAR2MJXV#M.B,$. 0BV)19M_FD=X_PV/2
M?9#7[C'I/A[N(-VX5OSEY5K-&CY6^JR:JB7Z$(/6H&6B[*E4?@V-9-1<C- B
MY1S; G:[7)W \+1H>0BS [BN)R3>K.V:,EV182S6_48QE9Q,U,!$[5K,2#IY
MG<!Y1(9>>5>:$('O(EPGF!P"#0\A;2C7= "W][/YRC7+:^6V:+EY"EF,*<D:
MD%I7ECG*W"-7$2*6XJ11I>@FW#M[R-@)^ 8#R.PTWNH B*_"?'Y)N\('_$9*
M8KXRVL/J2282BTR YH$JR#I'Q-N P'Q,2AGGE&S"UK*GG)U<#[<"9$NO=0#*
MZ_6V.G/X]"5,=UAXV2BMF,JU7S?6.20,G.:" *52"-Y)Y9N4?H<(V\E56/-X
MV<I_'6#T]6(Y^1J6^*[LLBEDS;R2")'5<[> "ARW&D*0CE7&?8M-$L=]A.SD
M#JP5)IOYJP,L;CF"6V7=(FDKI$+('"GK1A:IOBL>M' Z%N:$-TV>5SX@3R>;
M\KAE\P"NZ@!Q&T+):L:/./\^262B=UO/@NM[G<7V?[1>UD%[5)9S,,;3:BN.
M08A&@O%&57,XW^:]TY!*C%P!#8&J!SA#3^[B#N#]Q\>_S;[C?+HRY&<DI7!1
M'^#?, IO9M)K)AG/]1HKT8Y4Z5&C%Z&.<<K,*B%T:E*;[RK@N+ <#T*S$_BS
M YR^FLVI %RS0]Q3QB9DO,[W=)09@4I9@\\R 15[)M>Y8L8W(:!Z5*IQDX!N
M$#F<YSJ X2JC>AG2GYCOJ5('*"OF1=USJ*S3DE-2'13!)NO(F&,V-:'6>T2F
M<:OO;B XE-<Z .#JG&'K2M+*)?2R0-#1@[+*06"60CM2!H\\QYC;O0DX./XU
M*[.[ =\P'NL >K_/YLO/X3,^L)!,UHEG2KXS16U0%+O!US1<9!%]9-F4-B7X
MXV*-V_#9#0@']-W([]Y7R^GNE*"U&BRX(HL.H%$;2B:T)@L%"R@DRPYUYN(.
M!+>VTC_RB7%;)$>'TY .&!E'OX?YG[BLIUSWM/!2IL(I)Q7""<I$@X?@I*N7
M^5%%S!:YV %&#W]AW.F]7:!H(/./#**K9? [+K_,,EESM31N#>#;D/5:95PQ
M5%LK1]&5)=KG%4\@+3IGG/68=PE+.WULW)FY74!K>*<<C++O.(^SX3L(;Y[3
M3W!.8GVY_ V_X_GJ(#13^9S16Y ,R6J*2?#!1$@&!2MH7=9M;D)V$J^3Z^!>
M^@F'<F0'U<&U*K>ZXA;W]5NO[60L5T8E*)'3ZDN,3!="IB*<BSI+U/+2%J6[
M2-E)K]> ,'D(B8/[K"= _CK]=K%<K"S&-\'?N21I<X&")H,*7(*3V0)+L0BT
MQDO=AL?R89DZ =OP2'AX7O=1;ND486)SK,@\T[0P :VJI]FU$DI%0$F46@A*
M/I)M\F3V$9DZ:4H8!6&'N*53A,FU*BG:2+%=@Z$R@1)8(2%*IX$S;9./JK <
M3H4PV<-UP[@(.\0M/2%LD%>WPF63 PO 1+"585V!=]*#X!XQ9DI11+<S''_;
MBU:U:XJ, 6N4D\.B@S51WWB30O7_U;.$[^'\ATARTT-Y1AD)ERQ+L('5<<%:
M@;.8(7&)N8126!N^HITE["2K/#V*[CTC:.'2#K!Z/0G^S6S^\8=)\#]>.5XQ
M+RW/:)_+SC '*5G:G@Q#"$49",)SQ9TM+#9YU;*GG)WDJJ/CMJ5[NSC5W%5!
MLF]:ZQA\8I&3>EHH1ON:H!S>J0C,VF*=4-SJ)HT.^XO:23[\;%!\H).[ /+=
M&]$WW]].SH3*WDJ>(2MC0'&R7)3:T%^ZY'-Q2K$F_=[;A'G^:>TP8#S:41WL
M^G=U^(_)\LOL8OD!0YZ<7_Z"]*6OD^EJQ5W;??6^Z"R):) E254 %[1!I$#I
M#6?@E6:&Q<RB;S+XXF")?R;&MB%AV\;E'6![=5_[VVSZ^1-I=.O>]BR+('.L
MO.3U?D,EQ2%RET&JS H/)6%#CK4M OU,=&G'(',0AW6QAV]30GJ4)JA2;]5\
M'4E#ZRAP!]9&*063P8DF!=.A@&O6-M0/X(YUT^%!;C"2UHT*-?\]*S(*9I2'
M6)"*-JX"1!$"R.*CT\*@"4WNBFX+,6[?4'_8VMLQ1Q, GYC!L8YS_CU,P^?5
M/4DS[L8G/].&M7$_[4[!URADT+;$"(E[42?X,7"9(4A1&!8?Z&\W*06?!U^C
M1)^2KU67JSEJM Z"R!3#-:%+.<ECXX:,GYBO<1_DM>-KW,?#'50ACW+$O[Q<
M#R?X@.<K'R^^3+ZMNK&\QZ1I^P'-E:):2Y""WM5M0V'0PJ82F]"?'"9N)Z ]
M+;9F)W=T!W#>HL:Z#X)[;GVV5)7)K*YN#")5:9 $<N950M&&L.=!B<8%Y2G@
M,&OAFPY =G?*VX:2S4I5%.7.-O-41U5CG?16!P-@H'\BE(A-'N=O%V=<> WD
MZX=VZ<,-WP%\;E/KWRC!>/1>: X:3:'8[C.XRCM-94=,3$7&K&Z!GJW2C'LM
MW08\QYN] ^S<FUERHXGW#)7Q";BKIP%>*O!Z-4F=&XLA")::,&L_+-*XU\)M
M4#20 SJ TE,$SYX61J8=G:S$;26,4+3+.P5%,M+-V^A,$R*D(9C:N^Z8.3Z7
M'])U/2'Q4:;(@,7%B*"5]O659"5@U@8PH:-E9H(LIYH#\LR8VO="PT%,[7NX
MI@.X[</]G:PO6>H W$NRG7$.**YKX#P$)[TK4OR+J7U8@!S!U+Z/MSH XKZ<
MWR$IAE1H@\Z6S.B=@2B% DI8I,$4LQ9MV-]^/J;V(P#9TFL=@'(O5F4F4TG&
M9<@NV3K&68)W+("6CM&FDPUS36YT!V?!'IF9_0@X-O-7!UC<=DA9;SQ7:0UC
M))0+"71)N7(Y(3A5.(AD./V=;"-OTN'WF%"=8*V[BX:#G-85 %_-IJM;QDKG
MLEZU*(.F98I@*FV]\O7HB'$%K@[ ]#IE99MP.SPF5'^7"H>Y_D%,'>F'#C#U
MZY1^"Q?+#Q2T-]IL!F98%M $!L)J,I%EM ]H;<%[FP0ELJ+1K>K#(O6"IV/=
M/FOB@P[0]&I>A_6N'I.DRT?4DJH$J13E%#'7PTE#:GE3.:=T+-:1(1M=+^PF
MW[@U0S.<M?!.!Z![,YOCY//T]5_I2YA^OJM,0%XBU=I@&:L&8U3P<(90<M:*
M2>TMMJ$$>4RJ<3.S9@ ;SA,=P&I]G?(++DBE*]_4Q,$4R57T%ABEGQ21LP*O
MJ)Z.W"=FN,)D6W9NW!'G^3\O.S[%'\!17<)MO2!92M+J@.!-0E#2T(),(8(*
MA<=$%;1+39HT'Q*HBU:.HYS])'X.L'P'"-HH@/G%8JW33>&S86(J.F9%^63A
MLBJ2&(1 ^:3P,6;CBU>LT3'%D[+UAJM#0'"O4!S6(QV C.)WOM9JL[$+6:@:
MD: M*E"".W"V#M K/#"5LQ&Y23:_198N6H6&!=&Q%N\ -#N2:EH?@@H^@HN4
M&U(28"GKC!XT2SQ8XTP232@F!B31[?I)]*"M'D,YLB=X[D1A9Z(M5 @%$,+6
M6PNK(4I:VC+Q: +7EK=AE_CY2'3W@LE1)+K[^*PG0&YA:V49D3D1H!1=1RXB
M);D>23/N8C26!1?:DOT];Q+=O9"P!XGN/F[I%&$;MM84@BQ%%O V>S)14A!R
MDD#Z22ML,$PUH=?[24ATAT;8(6[I%&$;ME;'>$+#$AA15M/?(H2"!(B UB<;
MDN=-FL-_$A+=H1%VB%MZ0M@@] 6YL!)M/3PRE;>5RC/PFM(2*QTM,*9B5&UG
M(YR,1+=K<IP!:Y23PZ*#-7%SM7.E_2UN/Q=Y$JL+9%]('<D".*43H(R,>92I
MB"8780^+U$G>>'J</-A/<I33.H3?AB UR)2U\1[(3+2S"-J[ B<[Y:)5L)FK
M4IJDE _(TTDZV1WP#G%75ZB[9<B-+DP'7CR/4#C59$IG"\$ZA*!#8KE8EW23
M7/,QH3I)-CO"WY&.&YH&:F LW@KH6MLZZ\) $77>>E8"(HL)2HC%VB0RETW.
MN)^0Z_GW$31$Y('NZP>4+R\69)W%XM7L:YQ<74S5WAPR'>E$?[:8D'_7!&!7
M6E^>J904!H,@2BY5TP(Q)0.&4^JAM6>\#=_W ;(^_YN98<#;VLW' OJ$/'N;
MUK.+</Y[6%[3G@_)L??H)]KPZ^VNU2FX];C36LED@8><:I:H()9(6:((3$@E
M4E%M3_$:<.OMRIE_EB03CD5*3*RA=:H]%6;.2V#.!2^MC"XW>?VXJX"=U-;'
MXN;0F09[^:<#9MK'];I9[)5_?#)]-\7_Q#"_MO*9R8'''")8'36H0FF)9Y9#
MJ@S[/F1F8Y.SG>/$[J0,/RU&!_5E!\7WKMJ^*/1-4O;3E_GLXO.7-Y1B5[UO
M;CG.Z@@=:T4&JQCE/R63XC)R")2'I*"E%FT:70?3H).R?BP\#^OAYP;MJNY:
M\T\XO:-X*28G43R$8&3EA OT9W5-8_)2^>B='"%;V$.#3LX'1H7V8!Y^;M"^
MKZVR4CJJCT!2*@4JF0@N\0RE.!4,\S[A"//LGA*[DW."44%\G"\'0V[K^O^/
MZ1S#^>1_,%<6V468YLHD._01P%-?:7,*L)=NIS@(,*B*S3H36E,%;SVDMZ(
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MZCGG#Y]8CY,6CO'@2?>BZN)"!\X@)0T2;?#%.!F;O'_?+LYS"DO[H.9N6!K
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M%G>#&;%#(*P72>V)CT%QT"Z1661&VMPTKZ<9M:5'AICM@5 8LWH;SG-/0.$
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MF/^)R]>5^.'CQ;=OYY>?</[U3+J<I:9U*2DN@V)4?T:K$#P3REF7H]GI!>R
M(O6T-QZ.D-GX[NH+I6\O:KA^5ZZ>#B_./)>%\LL,P>A"NP(JB%XY*$;J* UI
MF0\ WIVO]+0IML#2,4;M&AY7B^1Z:9QQ:Z,B%8";REQK<@3/F0.NBS;*)1-V
M8KS>ZZ.=O6AI#9YC3-XUECY<4*#]8_IM]5>K%")P[NJ<#="\J%J:2/ I(/#"
M"^:D5;;Z:#3=^VQG372M\72<V;M+U2_?XXK'_6J97.EZIKW3-@H-G#$$I90
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M=MD4**(.0I8%20DGP*&)(IA@9,ON@V=TB;67MW>[Q-K#]!W@YP2G4T9Y;YU
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M"OMA3;FR)FM:_%MU(R9FGRR;CS,,W."M1R!^39FBV^$UHY,WS6%W'(!)[CH
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M]NMY%.KF#EW5-E=G[*M+PA8? )IHIHN:%]CWF$ZR>6"?UAU3,< \-\:&+W_
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M$HJ)$40]F)0&1L9EQSM&GV4*VR!O\>,<UE0P]H#G5?(T='@N^H_2#RQZK#
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M?GVT'7\/;B5QEQ :/>8[D4&<U^2/H5N)],]C4X2+:% !V(L^M%/%S4M8JB#
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M,V$OU2X56Q)VK'549?7Y<O@IS\Y14W ](^S218;#I!:<%JAL RRO$!=8Z7
MSV!D*@"\[;'PHJYBIE0(^OH(3&:<;D(ZE^.C*=T(F#FCH2Z,((Q Y/@U:Z,S
M 2FOL:\<[LG;83"FEQQYW E[>P?#ZY(7F+]?6GI-$W4GMENZ!T:*0EW@OD^R
M419N.$49N<W-HK<A*!0: 80$6E:"%R7]9E3&RL%'>65^8^^%;?*[9]-,?=?Z
M[S]P8+&7Z@^S6)S.ORCS"XZ_7![/,27- Y$:+PH2^UC158 7)%$6><4@3!%\
M?1DAWFOK-G U0/6($G).A_,Y'/.[$.N9+L\J-0,NB>JDG&D77JWT6<GI3HGG
MXTES6-="$[MRO3,X7>QQG&)7"$LH8A J&Y"Q@F0I$YQ>8PZ?LP9EMWXB(6D$
M1F8..]$3?$"N=-RX^PW"B9.D?8$M9VX3IUYD%>) DF)?4.&)E<QL)1/?\=X)
M!@$Q+)@KGD%OVMG<H@78MQ'<K:Q:?HG!U>^9_E"#/NYV[B(K<[J]%RJOO.R,
M.TVJS\@*FS>.91EI*ZD3$F%2_)(EM 4=J,V&8 B*LX;@1GVWI,?'401KR>OS
MQJ*N6N,#XLP508#8]^6 \JM:KY%ON30:VSMUGH8P@$]/Q6*8Z<'7S93T5JSD
MEI \SS4W>S58F)O]NPV#Y"J]@,>">166E7,C]:IX2(?5V98>##1>8;WT_I7F
MVKJ2(/YQRR\H64VA\*ILSZ@.G&&!%Z4I?J!<V6-*DUDRU:G N>Y%)\6*6:O+
M9RW548$)1E"C*X)T"A]1:-5?P)9B.SYAB[L$9N]]V,8P"C*(A'9R IQ+(8:U
MUH%+L_G9CF92UMYL T_T]CP>+"&V,T&.3(!3X =L?I+)QU:$&* Z7C95^;?4
MN\2)STOLSE6+,0;(:G[#_;*A,8Q!)S)DGA- WB<Q&*<8G3WS!#Z*MV7;D>U>
MN&/-.M3@QZ!BK8<3SUV%R34J9-E:I;P(.S&->@F9RJBB0;[RRTGMZ=NZ4@[9
ME!'BXRP8)I41&["P!DL,!2?2:@0&T+Y$FE&N:5AW^&U>TFLE26%T(2ID /]#
M.5N/8K^SH&?CU(DU],9<[+G*X,O$6J:6PI8BDZ)@>?>,=4WE:(+G;*#%V\*S
M^.#JMI" <H!8RM<$*&!#335$$BPZ8]_XA -4L<^QUAJ54US0JBN'\=UG,=!C
M!URRV'A(?>_>;^ND^$N4."A<T#TO'2^B$F'\K!5WM#6^Y$/70.<,M#K#76XD
MA]MIBI+:NK+*@"1!M,FPE]2"ZY.I;>Z$7]@8/YA8=>F6"W?"%B4<]>#D;L>"
M)W.NB?Q3[8/&0C6W(&'9N&$T9LI8[TE<.N&'WH<%OQ%:L:S=RRO9N\#+3-6Y
M1AURZ6+O.9_W[%56VX30@)-5>BU?;#CQ  %4\#K5NP0NY^U3#5S9HJ-@2B31
M %WR0*CTM"41&C2NSOV)(ZOT;&W:[KF(?<J%F#0D'.RJG"M)%E[QIC4C46+@
M!S6GK$6&='PZE N61NIEDT$&F'ESG_W@#ALOV^1!='"P31YLDP?;Y$'O0+%^
M/,QWINKM34<<X1&^+RZX'MXW/\Q8%K9O*X0U+<C%&K<YJ?E$5#)I=N[0Z95G
M=CX(PX/==W4WX#ES?8099R/1)JN 5M@49"!%-'P+(Q05N0>D\[+BCY9=(Y_;
MEC068=64A5[8@5[6 ;$EC*8[ =1!IL<.;Y,? >82IEYXO->P3\>K\(:;4':_
MO]YCU]I_@OY*]ITT52,X3F-L=%Q"P=:8K,X8XV".FI%B9<VU!",,<Y1NFIB
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M_DYGPZZ%UBDQ6GU?L;V!E"(U@C];24#0L?%=^24_+IL&DX:WY:HFKVZU\DM
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MI]RQ<SN^@93_*<OL-TBE-NS?,@;VT8"5@O+&4\$NQQ*&[*U,>1JCC^S#$.V
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MH(PCE.-<<:)I#,L[L11A'!$D?;42P5\14$=D4AP/XN[,^000&SU)Q.Y-0AO
MW9^^]L8O8GZ"9S,<RJU..?$TMPAIJOP(J]R(.6X0R9)'4DDW(UG>-BWM(@\Q
MCY[%27U;Y1'DX$L14):;#-%K?1D1Q]H([X"O(4>08G7@CR9Q#!GM#NJ"]7$
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MX8;)W>XAN[YHV_F!8/$W?*[H/YP\^Q]02P,$%     @ [TJ>4DK($-K4!
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M[WPT*J_%)ZS\8]K^%U!+ 0(4 Q0    ( .]*GE(P A9-%I4" !0W'P 0
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M2P$"% ,4    " #O2IY2%*&U:@?J  #==@D %               @ &?+0,
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M>&AI8FET,3 R+FAT;5!+ 0(4 Q0    ( .]*GE*?5W)J&@@  *PI   >
M          "  6\'!0!L;'DM,S,Q,C R,7@Q,'%X97AH:6)I=#,Q,2YH=&U0
M2P$"% ,4    " #O2IY2.Z-L#0@(  "3*0  '@              @ '%#P4
M;&QY+3,S,3(P,C%X,3!Q>&5X:&EB:70S,3(N:'1M4$L! A0#%     @ [TJ>
M4DK($-K4!   IQL  !T              ( !"1@% &QL>2TS,S$R,#(Q>#$P
E<7AE>&AI8FET,S(N:'1M4$L%!@     +  L _P(  !@=!0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
